Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

1 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

TABLE OF CONTENTS

PAGE

ABBREVIATIONS ...... 3

1. BACKGROUND AND OVERVIEW ...... 4 1.1. Conclusions ...... 4 1.2. Formulation Development...... 5 1.3. In Vitro Dissolution Data ...... 10 1.3.1. Comparative of 2 x 25 mg Clinical Tablets and 1 x 50 mg Clinical Tablets, Phase III Formulation...... 10 1.3.2. Comparison of Phase III Clinical Image and Commercial Image Tablets...... 13 1.4. Analytical Methods...... 17 1.4.1. Validation...... 17 1.4.2. Summary of Within Study Quality Control Sample Analysis ...... 18

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES...... 19 2.1. Relative Bioavailability ...... 19 2.1.1. ING111322 Relative bioavailability of DTG 10 mg oral tablet formulation vs oral suspension...... 19 2.1.2. ING113068 Effect of particle size on bioavailability...... 20 2.2. Bioequivalence ...... 22 2.2.1. ING113674 Relative bioavailbility of three DTG tablet formulations and effect of food...... 22 2.3. Effect of Food on Bioavailability ...... 23 2.3.1. ING111322 Effect of food on the DTG 10 mg oral tablet formulation...... 23 2.3.2. ING112941 Effect of food on the DTG 25 mg tablet used in Phase II studies ...... 24 2.3.3. ING113674 Effect of food on the 25 mg tablet formulation selected for Phase III studies...... 25 2.4. Absolute Bioavailability ...... 26

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES ...... 27 3.1. In vitro Dissolution and in vivo Bioavailability ...... 27 3.2. Recommendation for Dosing Dolutegravir Relative to Food...... 28

4. REFERENCES...... 30

2 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

ABBREVIATIONS

API Active Pharmaceutical Ingredient AUC Area under concentration-time curve AUC(0-) Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time AUC(0-) Area under the concentration-time curve over the dosing interval BCS Biopharmaceutics Classification System CI Confidence Interval Cmax Maximum observed concentration Cτ Pre-dose (trough) concentration at the end of the dosing interval CV Coefficient of variance DCS Developability Classification System DTG Dolutegravir FaSSIF Fasted state simulated intestinal fluid GLS Geometric Least-Squares h or hr Hour(s) IC50 50% inhibitory concentration IV Intravenous HIV Human immunodeficiency virus LLQ Lower limit of quantification MICRP Independent (multivariate) confidence region procedure mL milliliter PK Pharmacokinetic t½ Terminal phase half-life τ Dosing interval tmax Time of occurrence of Cmax

Trademark Information

Trademarks of ViiV Healthcare Trademarks not owned by ViiV Healthcare NONE SAS TurboIonSpray

3 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

1. BACKGROUND AND OVERVIEW

Dolutegravir (DTG) is an HIV integrase inhibitor (INI) which has been developed for treatment-naïve and treatment-experienced HIV-infected adults. Limited data on DTG in HIV-infected children ages 12 to < 18 are also included in the initial submission.

This document summarizes the pertinent biopharmaceutical characteristics of DTG immediate release formulations and supports the approval of Dolutegravir Tablets, 50mg, by describing:

 Various formulations developed and used in clinical studies (Section 1.2);  In vitro dissolution profiles for various formulations (Section 1.3)  The relative bioavailability studies completed for the various DTG formulations used throughout the clinical development of the compound (Section 2)  The impact of food on the bioavailability of DTG tablet formulations (Section 2.3) Bioanalytical methods used to determine DTG concentration in the biological samples collected in clinical studies are summarized in this module as well (Section 1.4).

Tablets manufactured at the commercial site were administered in the Phase III studies that demonstrated the safety and efficacy of DTG in HIV-infected subjects.

Data from clinical biopharmaceutics studies ING111322, ING112941, ING113068, and ING113674, along with chemistry, manufacturing and controls (CMC) and bioanalytical methods data, form the basis of the biopharmaceutical evaluation of DTG in this submission.

1.1. Conclusions

The conclusions from the biopharmaceutic evaluations are as follows:

4 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

 For DTG tablets, a 25 mg tablet with the Phase III formulation composition met the bioequivalence criteria with the 25 mg tablet used in the Phase II studies. A higher strength tablet of this formulation (50 mg tablet) was manufactured at the commercial site for use in Phase III clinical trials. This 50 mg tablet has the same % weight/weight composition but made at double the tablet weight of the 25 mg tablets used to establish bioequivalence to the Phase II product. The in-vitro dissolution profiles (3 media used) of the 50 mg tablets (Phase III formulation) compare closely to the profiles of two 25 mg tablets (Phase III composition) tested per dissolution vessel (i.e. total dose level = 50 mg).  Administration with food increases the exposure of DTG. Plasma DTG AUC(0-) increased by 33%, 41%, and 66% when DTG was administered with low fat, moderate fat and high fat food, respectively.  DTG can be taken with or without food based on the accumulated safety data in Phase IIb and III studies which permitted DTG dosing without restriction to food or food content.  DTG 50 mg tablets manufactured at the commercial site were administered in the Phase III studies that demonstrated the safety and efficacy of DTG in HIV-infected patients.  No pivotal bioequivalence study was required because the commercial formulation is identical to the Phase III clinical trial tablet formulation, differing only in the film coat color/level, and the degree of concavity of the tooling used to produce the tablets. 1.2. Formulation Development

DTG sodium, Form 1, is a non-hygroscopic, crystalline solid with suitable solid state stability and oral bioavailability. DTG sodium has a solubility of 3.2 mg/ml in water at 25C. In buffered solutions, across the physiological pH range 1-7, the solubility is significantly lower at, or below, 50 g/ml. The measured permeability is approximately 3 x 10-4 cm/sec. The combination of low solubility with high predicted permeability puts dolutegravir in BCS class II.

Particle size reduction of the DTG sodium (by micronisation) was selected at the start of its development based upon early data pharmacokinetic generated in dogs.

Dosage formulations and strengths administered in each of the clinical studies are provided in Appendix Table 1. A summary of drug substance and drug product is provided in Appendix Table 2.

Initial Phase I studies for DTG sodium utilised a powder for reconstitution consisting of DTG sodium, hypromellose and sodium lauryl sulphate. Doses of up to 250 mg DTG were administered in Phase I studies using this formulation. The composition is shown below in Table 1.

5 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Table 1 Composition of Powder for Reconstitution

Ingredients Quantity Active DTG sodium 2, 5, 10, 20, 25, 50, 100, 250 mg as free acid Vehicle (mL) mL Composition of Vehicle Quantity g g g

Tablet formulations were then developed to provide 1 mg, 10 mg and 25 mg dose strengths for Phase II studies. These tablets contained: and as , as a , as a , and as a . These tablets were used in Phase II studies (ING111521, ING112276 and ING112961). Based on ING112276, a dose ranging study in treatment-naive HIV-infected subjects, a dose of 50 mg dolutegravir was selected for Phase III studies. The composition of these tablets is shown in Table 2.

6 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Table 2 Composition of Dolutegravir Tablets, mg, mg and mg for Phase II Studies ING111521, ING112276/SPRING-1 and ING112961/VIKING-1

Component Quantity [mg] Function Reference to Standard Tablet Strength mg mg mg (mg free acid/tablet)

Dolutegravir sodium a b c Active

q.s. d q.s. d q.s. d USP or Ph Eur () () () USNF or Ph Eur

USP or Ph Eur USNF or Ph Eur Purified Water e q.s. q.s. q.s. Vehicle USP or Ph Eur

USNF or Ph Eur USNF or Ph Eur

Weight of Core Tablet – – Film coating Supplier

Purified Water e q.s. q.s. q.s. Vehicle USP or Ph Eur Total Coated Tablet – – Weight Trace f Trace f Trace f USP or Ph Eur a. Equivalent to mg dolutegravir free acid. Actual amount may vary based on the purity and water content factor for each batch of drug substance. b. Equivalent to mg dolutegravir free acid. Actual amount may vary based on the purity and water content factor for each batch of drug substance. c. Equivalent to mg dolutegravir free acid. Actual amount may vary based on the purity and water content factor for each batch of drug substance d.

e. Purified water is removed during processing. f. The amount of is approximately mg/Tablet. Its use in the manufacturing process is optional.

During Phase II, was identified as a more optimal for long-term stability compared to the used in the Phase II tablet formulation. Consequently, a reformulated tablet was developed for Phase III studies. Two variations of the new formulation (both mg tablets) were assessed against the Phase II tablet formulation ( mg tablet) in a relative bio-availability study (ING113674). The composition of these new formulations is shown in Table 3.

7 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Table 3 Composition of Dolutegravir Tablets, mg for Relative Bio- availability Study (ING113674)

Component Quantity [mg/tablet] Function Reference to Standard

Tablet Strength mg mg (mg free acid/tablet) Formulation 1 Formulation 2 (AW) (AX)

DTG sodiuma Active

b q.s. q.s. USP or Ph Eur ( ) ( ) USNF or Ph Eur USP or Ph Eur USNF or Ph Eur Purified Waterc q.s. q.s. Vehicle USP or Ph Eur

USNF or Ph Eur USNF or Ph Eur Weight of Core Tablet – – Film coating Supplier Purified Waterc q.s. q.s. Vehicle USP or Ph Eur Total Coated Tablet Weight – – a. Equivalent to mg GSK1349572B (free acid). Actual amount may vary based on the purity and water content factor for each batch of drug substance. b. c. Purified water is removed during processing.

In this study, x mg tablets were dosed for each formulation i.e. assessing at a 50 mg total dose. Both new formulations were found to be bioequivalent to the earlier Phase II formulation. The variant with the lower overall tablet weight (Formulation 1) was selected to progress into Phase III with the tablet core compression weight set to deliver 50 mg of dolutegravir in a single tablet.

The composition of the final Phase III tablet is shown in Table 4. API is utilised in dolutegravir tablets, 50 mg. The for this API to be used in the

8 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods commercial formulation is supported by data obtained in study ING113068 Section 2.1.2).

The formulation used in pivotal Phase III studies is identical to the commercial formulation with the following exceptions, which would not be expected to significantly affect product performance:

 The Phase III tablet is and the commercial tablet is

 The Phase III tablet is film coated with a (target coat quantity is % w/w) and the commercial tablet is film coated with a (target coat quantity is % w/w). Table 4 Composition of Dolutegravir Tablets, 50 mg for Phase III Clinical Studies

Component Quantity mg/tablet Strength (as free base) 50 mg

Dolutegravir sodiuma 52.6 d-Mannitol Microcrystalline cellulose Povidone Sodium starch glycolate Purified waterb qs

Sodium starch glycolate Sodium stearyl fumarate Aqueous Film Coatc

Purified waterb q.s. Total (mg/tablet)d a. The amount of dolutegravir sodium salt required to provide the label claim of dolutegravir (free base) is calculated based on the salt conversion factor 1.0524. b. Purified water is removed during drying process. c. Film coat used for commercial tablets are d.

9 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

1.3. In Vitro Dissolution Data

In vitro dissolution data for dolutegravir mg, mg ( and GSK formulations) and mg tablets used in Phase III studies and for the statistical comparisons referred to below are presented in Appendix Table 3, Appendix Table 4, Appendix Table 5, Appendix Table 6, Appendix Table 7, Appendix Table 8, Appendix Table 9, Appendix Table 10, and Appendix Table 11. These data demonstrate comparable performance across batches and consistency of release from tablet batches used to support clinical trials.

A single-point dissolution specification of Q = % at minutes (for tablets used in Phase I/II) and Q = % at minutes (for tablets used in Phase III) has been applied to clinical trial batches.

Comparative dissolution in three media, using appropriate statistical tests, were used to show the equivalence of the 50 mg Phase III tablet to the x mg tablets (same % w/w composition but half the compression weight) used in ING113674.

1.3.1. Comparative of x mg Clinical Tablets and 1 x 50 mg Clinical Tablets, Phase III Formulation

Comparative dissolution data for the Phase III and Commercial tablets using the discriminating method established for Dolutegravir Tablets, 50 mg are shown in Figure 1 and Appendix Table 4. This shows the dissolution profiles of x mg (Batch 101241248) and 1 x 50 mg Phase III tablets (R513665, R513666 and R513667).

The equivalence of the batch dissolution profiles was determined using a ( ). A model independent approach using a similarity factor (F2) was not employed because or dissolution time points were not available, having accounted for relevant criteria (Food and Drug Administration, 1997).

CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

20 to 20,000 ng/mL by , , , , to provide continuing support during Phase III development.

The unbound dolutegravir concentrations were measured in phosphate buffered saline following equilibrium dialysis of plasma collected from hepatically impaired (ING113097) and renally impaired (ING113125) subjects and in plasma from patients who volunteered to participate in cerebrospinal fluid sampling (ING116070). The assay was validated with a calibration range in phosphate buffered saline from 1 to 1000 ng/mL by BST PTS DMPK at GSK, RTP, North Carolina.

The measurement of dolutegravir concentrations in cerebrospinal fluid followed the analytical method used for plasma matrix and was validated over a range of 1 to 1000 ng/mL by , , , .

The bioanalytical method for the measurement of GSK2832500 (the ether glucuronide metabolite of dolutegravir; M3) in plasma samples collected from renally impaired subjects (Study ING113125) was validated with reference standard material by BST PTS DMPK at GSK, RTP, North Carolina. The method was based on protein precipitation, followed by HPLC-MS/MS analysis over a calibration range of 1 to 1000 ng/mL.

In some studies, the concentrations of co-administered drugs were measured by using validated bioanalytical methods. The measurements of atazanavir, darunavir, efavirenz, etravirine, lopinavir, midazolam, ritonavir, and tenofovir were conducted by BST PTS DMPK (GSK). ( , ) conducted the measurement of amprenavir, ( , ) conducted the measurements of R-methadone, S-methadone, ethinyl estradiol, norelgestromin, and telaprevir, ( , UK) conducted the measurements of iohexol and p-aminohippurate, and ( , P.R. China) performed the measurement of rilpivirine.

A summary of the validation data that supported application of the bioanalytical methods to each pharmacokinetic study during the development of dolutegravir is summarized in Appendix Table 12. All of the methods were validated to perform to the same, predefined acceptance criteria for precision and accuracy.

1.4.2. Summary of Within Study Quality Control Sample Analysis

Quality Control samples were analyzed with each batch of study samples. Performance results of the bioanalytical methods used for each study were generated from bioanalytical runs meeting the same run acceptance criteria based upon the predefined requirements for QC performance that no more than one-third of the QC results and 50% from each QC concentration were to deviate from the nominal concentration by more than 15%. The overall precision and accuracy of the assays for each study are shown in Appendix Table 13. Across 34 GSK directed studies, the overall precision (combined within run and between run) for dolutegravir in plasma ranged from 1.5% to 13.9% with a bias that ranged from -8.7% to 12.5%.

18 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES

A powder for oral suspension formulation of DTG was administered in the first time in human study and four other Phase I studies. DTG tablets of 1 mg, 10 mg, and 25 mg strengths were developed and administered in Phase I studies, as well as in the three Phase II studies ING111521, ING112276/SPRING 1 (10 mg and 25 mg strengths), and ING112961/VIKING 1 (25 mg strength). The bioavailability of the 10 mg tablet relative to the powder for oral suspension was assessed in Study ING111322.

Bioequivalence was established between a 25 mg tablet formulation [Formulation Code AW] and the 25 mg tablet formulation administered in Phase II studies [Formulation Code AP] in Study ING113674. Subsequently, a tablet of the same formulation but at a dose strength of 50 mg [Formulation Code BC] was administered in Phase III clinical studies.

The effect of food on the bioavailability of DTG was assessed with the 10 mg tablet (Study ING111322), the 25 mg tablet formulation administered in Phase II studies (Study ING112941), and the 25 mg tablet of the formulation administered in Phase III studies (Study ING113674). The impact of drug substance particle size on the bioavailability of DTG was assessed in Study ING113068.

A tabular summary of the study design, objectives, and treatment arms in each of the biopharmaceutical studies conducted with dolutegravir formulations is provided in Appendix Table 14 and a tabular summary of the pharmacokinetic data is provided in Appendix Table 15. In cases where studies had multiple objectives and study arms (ie, biopharmaceutics in Part A and drug interaction in Part B), only the data relating to the biopharmaceutics are provided in this module; the data from non-biopharmaceutics are provided in m2.7.2.

Narrative descriptions of the individual biopharmaceutical studies for DTG formulations are provided below. In all studies, DTG pharmacokinetic parameters were determined using standard non-compartmental methods. In the clinical study reports the summary statistics were presented in a variety of ways. For consistency within module 2.7.1, unless otherwise stated, the summary statistics for Cmax and AUC(0-) are presented as geometric mean and between subject coefficient of variation (CVb%), where CVb% was calculated as standard deviation / mean. Statistical comparisons are reported ratios of the geometric means and 90% confidence intervals (CI) and were calculated based on log transformed parameters.

2.1. Relative Bioavailability

2.1.1. ING111322 Relative bioavailability of DTG 10 mg oral tablet formulation vs oral suspension

Study title: A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of DTG Followed by A Single Dose, Randomized, 3-Period, Balanced, Crossover Study to Assess the Relative

19 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Bioavailability of Two Formulations and Food Effect on DTG in Healthy Male and Female Subjects

Location of report: m5.3.3.1

Methods: Part 1 of this study was a Phase I, double-blind, randomized, placebo- controlled, repeat dose escalation study of DTG in healthy subjects. One cohort of subjects received the cytochrome P450 3A substrate, midazolam, in addition to DTG. Data from Part 1 are summarized in m2.7.2.

Part 2 study ING111322 was an open-label, randomized, single dose, three-period, six sequence, balanced crossover study to assess the relative bioavailability of the DTG investigational tablet formulation (10 mg tablet x 2) compared to a DTG suspension formulation (20 mg) under fasted conditions and the effect of a moderate fat meal on the pharmacokinetics of the DTG investigational tablet in eligible healthy male or female subjects. There was a washout of at least 5 days between treatments. Serial PK samples were collected over 72 hours in each treatment period. The food effect results are summarized in Section 2.3.1.

Results from Part 2:

Following single dose administration under fasted conditions, the DTG 10 mg oral tablet formulation delivered 30% lower geometric mean plasma DTG AUC(0-) and 42% lower geometric mean Cmax (Table 6). Plasma DTG concentrations were quantifiable within 0.25 hours after oral tablet and suspension dosing, but median tmax was delayed from 0.75 hours with the oral suspension to 2.5 hours for the tablet, suggesting a prolonged absorption time for the tablet. Geometric mean plasma DTG half-life (t½ was similar between treatments, 13.3 hours for tablet and 13.5 hours for oral suspension.

Table 6 Summary of plasma dolutegravir PK parameters and treatment comparisons to assess relative bioavailability in study ING111322.

Plasma DTG PK 20 mg Oral Suspension 20 mg Oral Tablet Tablet/Suspension Parameter Fasted Fasted (Treatment B/Treatment A) (Treatment A) (Treatment B) N=12 N=12 N=12 AUC(0-) 33.5 23.5 0.700 (g.h/mL) (28) (38) (0.642, 0.763) Cmax 2.24 1.30 0.583 (g/mL) (17) (30) (0.529, 0.643) Source Data: Study ING111322, Table 11.19 and Table 11.20 geometric mean (CVb%) for PK summary and GLS mean ratio (90% CI) for treatment comparison Treatment A = 20mg DTG suspension administered under fasted conditions Treatment B = 20mg as DTG 10mg tablet x 2 administered under fasted conditions

2.1.2. ING113068 Effect of particle size on bioavailability

Study title: Phase I, open label, two period, study to evaluate the effects of fosamprenavir/ritonavir (FPV/RTV) on DTG pharmacokinetics and a phase I, randomized, three-way crossover study to evaluate the relative bioavailability of three

20 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods tablet variants made using micronized, un-micronized and intermediate particle sizes of DTG in healthy adult subjects (ING113068).

Location of report: m5.3.3.4

Methods: This was a single-centre, two-part, open-label, study in healthy adult subjects. In Part A, 12 subjects received DTG 50 mg q24 h for 5 days followed by DTG 50 mg q24 h in combination with FPV/RTV 700/100 mg q12 h for 10 days. There was no washout between treatment periods.

Data from Part A are summarized in m2.7.2.

In Part B, 15 subjects received DTG 50 mg using 25 mg tablets with differing particle size drug substance under fasted conditions. Part B was a randomized, open label, 3-way cross over treatment design. Subjects were randomized to a single dose of the reference tablet formulation containing micronized drug substance and 2 new tablet variants, one containing un-micronized drug substance and one containing an intermediate particle size drug substance, in each of three periods. There were six treatment sequences (CDE, CED, DCE, DEC, ECD, EDC). There was a 5 day washout between doses in Part B. Serial PK samples were collected over 48 hours in each treatment period.

The three tablet variants in this study each had been produced to exactly the same formulation and used practically equivalent manufacturing processes. They differed only in the particle size of the DTG drug substance. The reference tablet was produced using micronized drug substance having a particle size X10 =0.73 m, X50 = 2.0 m and X90 = 5.7 m. The first test tablet was produced using non-micronized drug substance having a particle size X10 = 8.3 m, X50 = 25.6 m and X90 = 66.5 m. The second test tablet was produced using micronized drug substance which was processed using conditions specifically set so that the resulting drug substance had a larger particle size. For this material the particle size X10 = 1.1 m, X50 = 8.6 m and the X90 = 26.3 m, which meant that it was positioned approximately mid-way between the particle sizes of the two other drug substances used to produce tablets.

By determining the pharmacokinetic parameters achieved with the two test batches as compared to the reference tablet batch, the study would evaluate whether particle size changes would translate into a difference in bioavailability in humans. The data obtained from all three batches was used to help assign an appropriate particle size specification for the drug substance to be used for producing commercial product.

Results: The results of the statistical comparisons showed that plasma exposure of DTG were similar between un-micronized and the reference tablet (micronized) formulation except a higher Cmax using the un-micronized formulation. Plasma exposure following administration of intermediate particle size DTG formulation was slightly higher compared to those from current tablet formulation: AUC(0-) and Cmax, were 19% and 30%, higher than those from the reference tablet formulation (Table 7).

This study was not powered to demonstrate bioequivalence. The 10% higher Cmax for the larger material is not believed to be attributed to anything other than PK variability in

21 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods the study. These data indicate that particle size and dissolution rate are not the primary determinants of DTG absorption.

Table 7 Summary of Selected Plasma DTG Pharmacokinetic Parametersa (Part B)

Treatment N DTG 50 mg DTG 50 mg DTG 50 mg DTG 50 mg DTG 50 mg Micronized Un- Intermediate Un Micronized Intermediate Micronized vs DTG 50 mg vs DTG 50 mg Micronized Micronized (N=15) (N=15) Cmax 15 1.56 1.72 2.04 1.10 1.30 (g/mL) (56.3) (35.3) (37.9) [0.906, 1.34] [1.07, 1.59] AUC(0-) 15 34.7 34.6 41.0 1.00 1.19 (g/mL) (54.4) (43.7) (43.2) [0.842, 1.19] [0.997, 1.41] Source Data: Study ING113068, Table 11.5 and Table 11.13 a. geometric mean (CVb%) for PK summary and GLS mean ratio (90% CI) for treatment comparison

2.2. Bioequivalence

Bioequivalence was established between a 25 mg tablet formulation [Formulation Code AW] and the 25 mg tablet formulation administered in Phase II studies [Formulation Code AP] in Study ING113674 (Section 2.2.1). Subsequently, a DTG 50 mg tablet of the same formulation [Formulation Code BC] was administered in all Phase III clinical studies.

2.2.1. ING113674 Relative bioavailbility of three DTG tablet formulations and effect of food

Study title: Relative bioavailability study of three different tablet formulations of DTG 50 mg and the dose proportionality of and effect of food on the selected formulation in healthy male and female volunteers

Location of report: m5.3.1.2

Methods: This was a single-centre, randomized, two part, open-label, crossover study in healthy adult subjects to assess the bioavailability of two new tablet formulations relative to the bioavailability of the 25 mg tablet administered in Phase II studies under fasting conditions (Part A) and the effect of food on the bioavailability of the selected formulation from Part A (Part B). The food effect results are summarized in Section 2.3.3.

Part A was an open-label, randomized, single dose, three-period, six-sequence, balanced crossover design conducted in 24 healthy male or female subjects to assess the bioavailability of two new tablet formulations (Formulation Codes AW and AX) relative the bioavailability of the 25 mg tablet administered in Phase II studies (Formulation Code AP). All treatments were administered as single 50 mg (2 x 25 mg tablets) doses of DTG under fasted conditions, with a washout of at least 5 days between treatments. Serial PK

22 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods samples were collected over 48 hours in each treatment period. DTG PK parameters were estimated using non-compartmental methods.

Results: The results of the analysis (Table 8) showed that the 2 test tablet formulations met the criteria for bioequivalence with the reference (Phase IIb) tablet formulation. New formulation 1 (AW) was taken into Part B of the study due to its smaller tablet size and lower inter-subject variability.

Table 8 Summary of Selected Plasma DTG Pharmacokinetic Parametersa (Relative Bioavailability)

Plasma DTG DTG tabletb DTG tabletb DTG tabletb DTG AW vs DTG AX vs PK Parameter 50 mg [AP] 50 mg [AW] 50 mg [AX] DTG 50 mg AP DTG 50 mg AP N=22 N=22 N=22 (n=22) (n=22) AUC(0-) 53.2 50.6 53.7 0.958 1.02 (g.h/mL) (34) (27) (34) [0.871, 1.05] [0.923, 1.12] Cmax 2.67 2.64 2.77 0.995 1.05 (g/mL) (35) (30) (32) [0.905, 1.10] [0.953, 1.15] Source Data: Study ING113674, Table 11.2 and Table 11.4 a. geometric mean (CVb%) for PK summary and GLS mean ratio (90% CI) for treatment comparison b. dose administered as 2 x 25 mg tablet

No bioequivalence studies have been conducted with DTG after the start of Phase III studies. There were no changes in formulation during the conduct of Phase III.

2.3. Effect of Food on Bioavailability

2.3.1. ING111322 Effect of food on the DTG 10 mg oral tablet formulation

Location of report: m5.3.3.1

Part 2 of this study was an open-label, randomized, single dose, three-period, balanced crossover study to assess the relative bioavailability of the DTG investigational tablet (10 mg tablet x 2) compared to a suspension formulation (20 mg) and the effect of a moderate fat meal (30% fat / 669 calories) on pharmacokinetics of DTG investigational tablet in eligible healthy male or female subjects. Serial PK samples were collected over 72 hours in each treatment period. The relative bioavailability results of the tablet to the suspension formulation in the fasting state is summarized in Section 2.1.1.

23 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Results: Administration of the DTG 10 mg oral tablet formulation with a moderate-fat meal delivered equivalent plasma DTG AUC(0-) and Cmax compared to administration fasted (Table 9). Median plasma DTG tmax were similar between fed (3.0 hours) and fasted (2.50 hours) treatments. Geometric mean plasma DTG t1/2 was similar between treatments, 13.6 hours for tablet fed and 13.3 hours for tablet fasted.

Table 9 Summary of Selected Plasma DTG Pharmacokinetic Parametersa Following Single Dose Administration in Part 2 of ING111322

Plasma DTG PK 20 mg Oral Tablet 20 mg Oral Tablet Fed Tablet/Fasted Tablet Parameter Fasted Fed (Treatment B/Treatment A) (Treatment B) (Treatment C) N=12 N=12 N=12 AUC(0-) 23.5 26.0 1.11 (g.h/mL) (38) (33) [1.02, 1.21] Cmax 1.30 1.44 1.11 (g/mL) (30) (16) [1.01, 1.22] Source Data: Study ING111322, Table 11.19 and Table 11.20 geometric mean (CVb%) for PK summary and GLS mean ratio (90% CI) for treatment comparison Treatment B = 10mg as DTG 10mg tablet x 2 administered under fasted conditions Treatment C = 10mg as DTG 10mg tablet x 2 administered under fed conditions

2.3.2. ING112941 Effect of food on the DTG 25 mg tablet used in Phase II studies

Study title: A randomized, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of a supratherapeutic dose of DTG 250 mg and a randomized, open- label study to evaluate the effects of omeprazole 40 mg daily and a high fat meal on the pharmacokinetics of DTG 50 mg in healthy adult subjects

Location of report: m5.3.3.4

Methods: The study was a randomized, two-part study in healthy adult subjects. Part 1 was a randomized, open label, 2-sequence, 3-period, design. In Part 1, Periods 1 and 2 evaluated the food effect of a high-fat meal consisting of 53% fat/869 calories (Treatment B) compared to fasting administration (Treatment A) on the PK of a single 50 mg dose of DTG. Period 3 of Part 1 evaluated the single-dose PK of DTG 50 mg administered on Day 5 in subjects receiving omeprazole 40 mg q24h on days 1-5.

Part 2 was a randomized, double-blind, single dose pharmacokinetic study that evaluated the single-dose safety, tolerability and PK of supratherapeutic 250 mg dose of DTG compared with placebo. Results of Part 2 are reported in m2.7.2.

Serial PK samples were collected over 48 hours in each treatment period.

Results: The results of the comparison showed that plasma exposure of DTG increased with high fat food (Table 10). Plasma DTG AUC(0-) and Cmax increased by 94% and 84%, respectively. Median plasma DTG tmax were similar between fed (4.5 hours) and

24 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods fasted (4.0 hours) treatments. Geometric mean plasma DTG t1/2 was similar between treatments, 13.9 hours for tablet fed and 14.4 hours for tablet fasted.

Table 10 Summary of DTG Pharmacokinetic Parameters and Treatment Comparison for the Effect of Food in ING112941

Plasma DTG PK 50 mg (2x25 mg) 50 mg (2x25 mg) Fed Tablet/Fasted Tablet Parameter Oral Tablet Fasted Oral Tablet Fed (Treatment B/Treatment A) (Treatment A) (Treatment B) N=12 N=12 N=12 AUC(0-) 34.7 67.2 1.94 (g.h/mL) (57) (24) [1.63, 2.30] Cmax 1.84 3.39 1.84 (g/mL) (44) (17) [1.55, 2.19] Source Data: Study ING112941, Table 11.3 and 11.4 geometric mean (CVb%) for PK summary and GLS mean ratio (90% CI) for treatment comparison Treatment A = 10mg as DTG 10mg tablet x 2 administered under fasted conditions Treatment B = 10mg as DTG 10mg tablet x 2 administered under fed conditions

2.3.3. ING113674 Effect of food on the 25 mg tablet formulation selected for Phase III studies

Study title: Relative bioavailability study of three different tablet formulations of DTG 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in healthy male and female volunteers

Location of report: m5.3.1.2

Methods: This was a single-centre, randomized, two part, open-label, crossover study in healthy adult male and female subjects. In Part A, 24 subjects received DTG 50 mg as a single dose in three formulations under fasted conditions with a 5 day washout between formulations (see Section 2.2.1). In Part B, 18 subjects received the selected DTG 50 mg from Part A with either a low, moderate or high fat meal.

Part B was an open-label, randomized, single dose, three-period, six-sequence, balanced crossover design in 18 of the 24 healthy male or female subjects who completed Part A to evaluate the effect of food on the bioavailability of the selected formulation (Formulation Code AW). All treatments were administered as single 50 mg (2 x 25 mg tablets) doses of DTG under fed conditions, including low-fat, moderate-fat, and high-fat meals, with a washout of at least 5 days between treatments. The low-fat meal was comprised of approximately 300 kcal and 7% fat, the moderate fat meal was comprised of approximately 600 kcal and 30% fat, and the high-fat meal was comprised of approximately 870 kcal and 53% fat.

Serial PK samples were collected over 48 hours in each treatment period. The bioequivalence results are summarized in Section 2.3.3.

Results: The selected DTG formulation from Part A (AW) with food resulted in increases in plasma DTG exposures (Table 11). Plasma DTG AUC(0-) increased by

25 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

33%, 41%, and 66% when AW tablets were administered with low fat, moderate fat and high fat food, respectively. Plasma DTG Cmax increased by 46%, 52%, and 67% when the AW tablets were administered with low fat, moderate fat and high fat food, respectively (Table 12). Tmax increased with increasing fat content and median values were 2.0, 3.0, 4.0, and 5.0 hours for fasting, low fat, moderate fat, and high fat meals, respectively. Half-life was similar between treatment groups ranging from 13.4 to 14.1 hours.

Table 11 Summary of DTG Pharmacokinetic Parameters for the Effect of Food in ING113674

Plasma DTG PK 50 mg 50 mg 50 mg 50 mg Parameter (2x25 mg) Oral (2x25 mg) Oral (2x25 mg) Oral (2x25 mg) Oral Tablet Fasted Tablet with Low Tablet with Mod Tablet with High N=18 Fat Meal Fat Meal Fat Meal N=18 N=18 N=18 AUC(0-) 50.3 66.7 71.0 83.6 (27) (35) (31) (35) Cmax 2.65 3.88 4.03 4.44 (28) (21) (19) (24) Data Source: ING113674, Table 11.6 geometric mean (CVb%) for PK summary DTG 50 mg AW = DTG 50 mg using new formulation 1 fasting DTG 50 mg AW + Low Fat = DTG 50 mg using formulation AW with low fat meal DTG 50 mg AW + High Fat = DTG 50 mg using formulation AW with high fat meal DTG 50 mg AW + Mod Fat = DTG 50 mg using formulation AW with moderate fat meal

Table 12 Statistical Comparison of Plasma DTG Pharmacokinetic Parameters with Food Compared to Fasting

Plasma DTG PK Ratio of GLS Means Parameter (90% CI) DTG 50 mg AW + low DTG 50 mg AW + mod DTG 50 mg AW + high fat vs DTG 50 mg AW fat vs DTG 50 mg AW fat vs DTG 50 mg AW (n=18) (n=18) (n=18) AUC(0-) 1.33 1.41 1.66 [1.21, 1.45] [1.29, 1.55] [1.52, 1.82] Cmax 1.46 1.52 1.67 [1.34, 1.60] [1.39, 1.66] [1.53, 1.83] Data Source: ING113674, Table 11.9 GLS mean ratio (90% CI) for treatment comparison DTG 50 mg AW = DTG 50 mg using new formulation 1 fasting DTG 50 mg AW + Low Fat = DTG 50 mg using formulation AW with low fat meal DTG 50 mg AW + High Fat = DTG 50 mg using formulation AW with high fat meal DTG 50 mg AW + Mod Fat = DTG 50 mg using formulation AW with moderate fat meal

2.4. Absolute Bioavailability

The absolute bioavailability of DTG has not been determined. The low solubility of dolutegravir in buffered solutions and its non-specific binding present significant

26 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods challenges to an iv formulation for dolutegravir even at very low doses. However, the majority of the information for which absolute bioavailability is assessed is available through studies that demonstrate that the tablet formulation is well characterized through linear predictable pharmacokinetics and that the clinical trials can serve as a benchmark for product quality and performance. Studies have shown that dolutegravir exhibits high absorptive permeability, low systemic and pre-systemic clearance, unlikely pre-systemic drug interactions with efflux transporters, and linear pharmacokinetics over the clinical dose range with low to moderate variability.

The relative bioavailability of the dolutegravir 50 mg Phase III and commercial tablet product (BC formulation) is estimated to be 75% when compared to a dolutegravir solution/suspension formulation. In addition, in vitro comparative dissolution profiles (Phase II and Phase III 25 mg and 50 mg tablets) and a series of relative bioavailability studies characterizing pertinent biopharmaceutical parameters, such as effects of food and particle size on absorption, have shown that dolutegravir provides consistently predictable systemic exposure. When administered as a suspension, the pharmacokinetics of dolutegravir was linear from 2 to 100 mg. When administered as a tablet, the systemic exposure increased proportionately over the clinical dose range of 25 to 50 mg with low to moderate variability and a predictable dose-response relationship. Dolutegravir exhibits high absorptive permeability that is not affected by efflux transport inhibitors. This is demonstrated by the rapid absorption of dolutegravir from the tablet formulation and the lack of a significant effect on absorption when co-administered with lopinavir and ritonavir (ING111405), potent inhibitors of the efflux transporters P- glycoprotein (Pgp) and breast cancer resistance protein (BCRP). The metabolic and elimination profiles of dolutegravir are well characterized. Unchanged dolutegravir represented >97% of the circulating drug-related material and nearly 100% at Cmax. These data together with the long half-life of 13 to 15 hours indicate that metabolic clearance of dolutegravir is low, with a low first pass effect, and that pre-systemic metabolism does not contribute significantly to exposure or variability.

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES

3.1. In vitro Dissolution and in vivo Bioavailability

As described in section m3.2. P.2.2, dolutegravir sodium is considered a poorly soluble compound, demonstrating low solubility over the physiological pH range (pH 1 to 7.4). Dolutegravir was determined to have high passive membrane permeability (333 nm/s at pH 7.4). The absorptive membrane permeabilities were also high in the presence of FaSSIF at pH 7.4 and pH 5.5 (P7.4[abs] value of 253 nm/s and a P5.5[abs] value of 265 nm/s respectively). Based on solubility and permeability determinations, dolutegravir sodium is classified as a Biopharmaceutics Classification System (BCS) Class 2. However, the Solubility Limited Absorbable Dose (SLAD) concept has been introduced recently (Butler, 2010), and represents the region between Class IIa and IIb for high permeability drugs. The Developability Classification System (DCS) proposed by Butler et al, assigns this drug (up to a dose of 50 mg) in DCS Class I, indicating that the absorption is not expected to be limited by dissolution and/or solubility at that dose level. The

27 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods discriminating dissolution test, discussed in m3.2.P.2.2, is therefore, expected to be more of a quality control test, than an indicator of biopharmaceutical performance.

Furthermore, in Study ING113068, (Section 2.1.2) plasma exposures of DTG were similar between tablets containing the standard micronized drug substance and those containing unmicronised drug substance. This is despite the markedly slower dissolution profile of the tablets containing the unmicronised material compared to that typically observed for the tablets made from the standard micronised material (Appendix Table 3).

Given the observations above, the development of an in-vitro/in-vivo correlation is not considered necessary and has not been progressed.

3.2. Recommendation for Dosing Dolutegravir Relative to Food

The effects of food are dependent upon the calorie and fat content. The dose may also be a factor as a larger food effect was observed with a moderate fat and the 50 mg dose compared to a moderate fat meal with the 20 mg dose (41% vs 11%).

Administration of DTG at a dose of 20mg (10 mg tablet x 2) with a moderate fat meal slightly increased the AUC by 11%. A larger magnitude of effect (33 to 67% increases in DTG AUC or Cmax) was observed when 50mg (25 mg tablet x 2) of the Phase III formulation was dosed with food. At this dose and formulation, increasing exposure was observed with increasing fat and calorie content. The presence of food with the associated increase in gastric residence time would be expected to aid the dispersion and dissolution of DTG from DTG tablets, leading to an overall increase in exposure. This is consistent with the observation that higher exposures were observed from a suspension formulation compared to a tablet formulation.

The increased exposure with food is not considered clinically significant based on the accumulated safety data in Phase IIb and III studies which permitted DTG dosing without restriction to food or food content (refer to m2.7.4). The PK variability for AUC(0-) in the SPRING-1 dose ranging trial was 40-48% across doses, suggesting that dosing without regard to food does not lead to unpredictable high exposures in clinical practice. It is unknown if the increased exposure is beneficial to efficacy in the INI-resistant population where higher C values may be required for subjects with a large fold change in IC50 compared to wild type virus. DTG can be given without regard to meals.

28 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

CONCLUSIONS

The conclusions from the biopharmaceutic evaluations are as follows:

 All strengths and batches of DTG tablets (50 mg and 25 mg) used in clinical studies had consistent in vitro dissolution.  The bioanalytical methods used to measure concentrations of DTG in human plasma were sensitive, selective, accurate and reproducible. Stability of the analyte was demonstrated during sample processing and long-term storage.  The oral bioavailability of the tablet was less than that of a suspension with mean AUC(0-t) decreased by 30% following administration of the tablet compared to the suspension formulation under the fasted condition. The rate of absorption of the drug from tablet was slower than suspension.  Changes in particle size did not have a significant impact on exposure. A formulation of un-micronized particles demonstrated similar exposure to the current tablet formulation (of micronized particles). These data support the particle size specification for the micronized API.  For DTG tablets, a 25 mg tablet with the Phase III formulation composition met the bioequivalence criteria with the 25 mg tablet used in the Phase II studies. A higher strength tablet of this formulation (50 mg tablet) was manufactured at the commercial site for use in Phase III clinical trials. This 50 mg tablet has the same % weight/weight composition but made at double the tablet weight of the 25 mg tablets used to establish bioequivalence to the Phase II product. The in-vitro dissolution profiles of the 50 mg tablets (Phase III formulation) compare closely to the profiles of two 25 mg tablets (Phase III composition) tested per dissolution vessel (i.e. total dose level = 50 mg) in three dissolution media.  Administration with food increases the exposure of DTG. Plasma DTG AUC(0-) increased by 33%, 41%, and 66% when DTG was administered with low fat, moderate fat and high fat food, respectively.  DTG can be taken with or without food based on the accumulated safety data in Phase IIb and III studies which permitted DTG dosing without restriction to food or food content.  DTG 50 mg tablets manufactured at the commercial site were administered in the Phase III studies that demonstrated the safety and efficacy of DTG in HIV-infected patients.  No pivotal bioequivalence study was required because the commercial formulation is identical to the Phase III clinical trial tablet formulation, differing only in the film coat color, a slight difference in the film coat level, and the degree of concavity of the tooling used to produce the tablets.

29 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

4. REFERENCES

Food and Drug Administration. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August 1997. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM070237.pdf

Butler JM, Dressman JB. The developability classification system: application of bipharmaceutics concepts to formulation development. J. Pharm. Sci. 2010; 99, 4940- 4954.

30 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

APPENDIX TABLES Appendix Table 1 Summary of Formulations Used in DTG Clinical Trials Formulation Phase: Study (Description) Powder for Oral Suspension Phase I: (micronized) ING111207 (FTIH) (Table 1) ING111853 (mass balance) ING111322 (repeat dose escalation, midazolam DDI, and RBA) ING111856 (TQTc) ING112941 (evaluation of high [250 mg] dose) Tablet 1 mg Phase II: (micronized) ING111521 (PoC) (Table 2) Tablet 10 mg Phase I: (micronized) ING111322 (RBA) (Table 2) ING111854 (ATV & ATV/RTV DDI) ING111405 (LPV/RTV & DRV/RTV DDI) ING111603 (ETV DDI) ING112934 (ETV + LPV/RTV & ETV + DRV/RTV DDI) ING111604 (TDF DDI) ING111602 (Maalox & MVI DDI) Phase II: ING111521 (PoC) ING112276/SPRING 1 (ART-naive) Tablet 25 mg Phase I: (micronized) ING113674 (RBA) (Table 2 [AP]) ING112941 (FE and omeprazole DDI) ING114819 (Iohexol) ING113096 (TPV/RTV DDI) ING114005 (Efavirenz DDI) ING114819 (Renal Function) Phase II: ING112276/SPRING 1 (ART-naive)

31 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Formulation Phase: Study (Description) ING112961/VIKING 1 (INI-experienced) Tablet 25 mg Phase I: (unmicronized) ING113068 (RBA) Tablet 25 mg Phase I: (intermediate particle size) ING113068 (RBA) Tablet 25 mg Phase I: (micronized) ING113674 (RBA) (Table 3, Formulation 1 [AW]) Tablet 25 mg Phase I: (micronized) ING113674 (RBA) (Table 3, Formulation 2 [AX]) Tablet 50 mg Phase I: (micronized) ING113097 (Hepatic impairment) (Table 4 [BC]) ING115697 (HCV PI DDI) ING111855 (Drug Interaction OC) ING112934 (ETV/LPV/RTV & ETV/DRV/RTV DDI) ING113099(Rifampin DDI) ING113125 (Renal impairment) ING114556 (Pediatric Formulation RBA) ING114581 (FDC RBA) ING115381 (PK, Healthy Japanese Subjects) ING115465 (Female GT CRT) ING115696 (Steroid DDI) ING115697 (BCV & TVR, HCV PI DDI) ING115698 (Methadone DDI) ING116195(Male GT CRT) Phase III: ING113086/SPRING 2 (ART-naive) ING114467/SINGLE (ART-naive) ING111762/SAILING (ART-experienced/INI-naive) ING112574/VIKING 3 (INI-experienced)

32 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 2 Summary of Drug Substance and Drug Product

Study Ref. No. Formula Drug Product Batch No. Dosage Form Input Drug Substance Batch Study Report Code Location ING111322 AA, AB, AC R06001 Powder for Oral Suspension R06001 m5.3.3.1 ING111322 AM 081157297a Dolutegravir Tablet, 10 mg A7Z002 m5.3.3.1 ING112941 AQ 091225017b Powder for Oral Suspension 091225017 m5.3.3.4 ING112941 AP 091212108c Dolutegravir Tablet, 25 mg B87002 m5.3.3.4 ING113068 AW 101241248 Dolutegravir Tablet, 25 mg 091227508 m5.3.3.4 (standard micronised drug substance) ING113068 BM 101255454 Dolutegravir Tablet, 25 mg 091237760 m5.3.3.4 (micronised (intermediate size) drug substance) ING113068 BL 101255473 Dolutegravir Tablet, 25 mg 091237761 m5.3.3.4 (unmicronised drug substance) ING113674 AP 091212108c Dolutegravir Tablet, 25 mg B87002 m5.3.1.2 ING113674 AW 101241248 Dolutegravir Tablet, 25 mg 091227508 m5.3.1.2

ING113674 AX 101243560 Dolutegravir Tablet, 25 mg 091227508 m5.3.1.2 a. GSK tablet batch number. batch number A8302 b. GSK API batch number. batch number B87002 c. GSK tablet batch number. batch number A9105.

33 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 3 Summary of in vitro Dissolution Data Related to PK Study Batches

Study Ref. Product Dosage Form Conditions: No. of Collection times (min) Study No. ID/Batch USP Dosage Mean % Dissolved (range) Report No. Apparatus 2 Units Location (Media, 10 min 15 min 20 min 30 min 45 min Volume, Paddle Speed) ING111322 R06001 Powder for Oral N/A N/A N/A N/A N/A N/A N/A m5.3.3.1 Suspension ING111322 081157297 Dolutegravir Tablet, 0.01M phosphate 6 74 (73-74) N/A 87 (86-88) 92 (91-93) N/A m5.3.3.1 10 mg buffer, pH 6.8, 900 ml, 50 rpm ING112941 091225017c Powder for Oral N/A N/A N/A N/A N/A N/A N/A m5.3.3.4 Suspension ING112941 091212108d Dolutegravir Tablet, 0.01M phosphate 6 79 (72-82) N/A 95 (95-97) 99 (98- 100 m5.3.3.4 d 25 mg buffer, pH 6.8 100) (100-101) with 0.30% SDS, 900 ml, 50 rpm ING113068 101241248 Dolutegravir Tablet, 0.01M phosphate 12b 53 (48-56) 76 (71-79) 85 (83-87) 91 (90-93) 96 (95-97) m5.3.3.4 25 mg (standard buffer, pH 6.8 micronised drug with 0.25% SDS, substance) 900 ml, 50 rpma ING113068 101255454 Dolutegravir Tablet, 0.01M phosphate 12b 59 (53-64) 72 (68-75) 80 (77-82) 89 (86-91) 95 (93-96) m5.3.3.4 25 mg (micronised buffer, pH 6.8 (intermediate size) with 0.25% SDS, drug substance) 900 ml, 50 rpma ING113068 101255473 Dolutegravir Tablet, 0.01M phosphate 12b 48 (44-52) 57 (56-59) 64 (62-66) 73 (69-75) 82 (78-84) m5.3.3.4 25 mg (unmicronised buffer, pH 6.8 drug substance) with 0.25% SDS, 900 ml, 50 rpma

34 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Study Ref. Product Dosage Form Conditions: No. of Collection times (min) Study No. ID/Batch USP Dosage Mean % Dissolved (range) Report No. Apparatus 2 Units Location (Media, 10 min 15 min 20 min 30 min 45 min Volume, Paddle Speed) ING113674 091212108 Dolutegravir Tablet, 0.01M phosphate 12b 64 (55-70) 84 (80-86) 90 (88-91) 94 (92-95) 97 (96-98) m5.3.1.2 25 mg buffer, pH 6.8 with 0.25% SDS, 900 ml, 50 rpma ING113674 101241248 Dolutegravir Tablet, 0.01M phosphate 12b 53 (48-56) 76 (71-79) 85 (83-87) 91 (90-93) 96 (95-97) m5.3.1.2 25 mg buffer, pH 6.8 with 0.25% SDS, 900 ml, 50 rpma ING113674 101243560 Dolutegravir Tablet, 0.01M phosphate 12b 57 (52-60) 79 (74-82) 87 (85-89) 93 (92-94) 97 (96-98) m5.3.1.2 25 mg buffer, pH 6.8 with 0.25% SDS, 900 ml, 50 rpma a. Dissolution conditions used for the Phase III 50 mg tablet and for the proposed commercial dissolution method. At time of release testing the method used was 0.01M phosphate buffer, pH 6.8 with 0.30% SDS, 900 ml, 50 rpm, one tablet per vessel. b. Six vessels, two tablets per vessel i.e. equivalent of 50 mg dose in each vessel. c. GSK API batch number. batch number B87002. d. GSK tablet batch number. batch number A9105.

35 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 4 Summary of in vitro Comparative Dissolution Data for 2 x 25 mg Tablets vs 1 x 50 mg Tablets

Product Dosage Conditions: USP No. of Collection times (min) ID/Batch Form Apparatus 2 Dosage Mean % Dissolved (range) No. (Media, Volume, Units Paddle Speed) 5 min 10 min 15 min 20 min 30 min 45 min 101241248 Dolutegravir 0.01M phosphate buffer, 24a 21 (19-23) 54 (50-58) 77 (73-80) 87 (85-89) 94 (92-96) 99 (98-100) Tablet, 25 mg pH 6.8 with 0.25% SDS, 900 ml, 50 rpma R513665 Dolutegravir 0.01M phosphate buffer, 12 10 (6-19) 42 (34-59) 70 (62-83) 86 (82-90) 94 (93-96) 97 (95-99) Tablet, 50 mg pH 6.8 with 0.25% SDS, 900 ml, 50 rpma R513666 Dolutegravir 0.01M phosphate buffer, 12 12 (9-17) 45 (38-53) 72 (64-77) 87 (83-90) 94 (91-97) 97 (94-100) Tablet, 50 mg pH 6.8 with 0.25% SDS, 900 ml, 50 rpma R513667 Dolutegravir 0.01M phosphate buffer, 12 9 (6-12) 39 (33-45) 67 (59-73) 85 (79-88) 95 (94-97) 98 (96-100) Tablet, 50 mg pH 6.8 with 0.25% SDS, 900 ml, 50 rpma a. 12 vessels, two tablets per vessel i.e. equivalent of 50 mg dose in each vessel.

36 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 5 Summary of in vitro Comparative Dissolution Data for 2 x 25 mg Tablets vs 1 x 50 mg Tablets in 0.1M HCl with 0.25% SDS, 100 rpm Paddle Speed

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 75 90 105 120 101241248 24 a 0 1 4 11 20 27 35 41 45 49 53 56 63 69 74 78 (0-0) (0-2) (1-11) (3-20) (7-29) (11-39) (18-44) (26-50) (32-54) (37-58) (41-61) (45-63) (54-70) (60-75) (65-80) (69-83) R513665 12 0 0 1 2 4 7 15 26 34 39 44 48 56 62 67 70 (0-0) (0-0) (0-2) (1-4) (2-6) (4-13) (9-23) (19-31) (26-37) (32-44) (36-49) (40-53) (48-62) (53-68) (57-71) (61-74) a. 12 vessels, two tablets per vessel i.e. equivalent of 50 mg dose in each vessel.

Appendix Table 6 Summary of in vitro Comparative Dissolution Data for 2 x 25 mg Tablets vs 1 x 50 mg Tablets in USP Acetate Buffer, pH 4.5 50 rpm Paddle Speed

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 101241248 24 a 2 11 21 31 38 44 47 51 53 55 57 59 (1-3) (6-15) (16-26) (25-38) (34-44) (40-49) (45-52) (48-55) (51-57) (53-59) (55-61) (57-62) R513665 12 1 4 12 20 30 38 44 49 52 55 57 59 (1-1) (2-7) (6-14) (17-23) (26-34) (35-41) (42-46) (47-50) (51-53) (54-56) (57-58) (59-60) a. 12 vessels, two tablets per vessel i.e. equivalent of 50 mg dose in each vessel.

37 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 7 Summary of in vitro Comparative Dissolution Data for Dolutegravir Tablets, 50 mg Commercial Image and Phase III Clinical Image Tablets (USP Apparatus 2, 50 rpm, 0.01M Phosphate Buffer, pH 6.8 with 0.25% w/v SDS, 900 mL)

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 30 45 R513665 12 10 42 70 86 94 97 (6-19) (34-59) (62-83) (82-90) (93-96) (96-99) R513666 12 12 45 72 87 94 97 (9-17) (38-53) (64-77) (83-90) (91-97) (94-100) R513667 12 9 40 67 85 95 98 (6-11) (33-45) (59-73) (79-88) (93-97) (96-100) R513668 12 20 54 80 91 96 99 (15-30) (45-63) (72-87) (88-94) (95-99) (98-102) R513669 12 20 54 79 90 96 98 (15-27) (46-62) (73-86) (87-92) (94-97) (96-99) R513670 12 22 58 81 90 95 97 (16-29) (45-69) (69-88) (86-93) (93-97) (96-99)

Appendix Table 8 Summary of in vitro Comparative Dissolution Data for Dolutegravir Tablets, 50 mg Commercial Image and Phase III Clinical Image Tablets (USP Apparatus 2, 100 rpm, 0.1M HCl with 0.25% w/v SDS, 900 mL)

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 75 90 105 120 R513665 12 0 0 1 2 4 7 15 26 34 39 44 48 56 62 67 70 (0-0) (0-0) (1-2) (1-4) (2-6) (4-13) (9-23) (19-31) (26-37) (32-44) (36-49) (40-53) (48-62) (53-68) (57-71) (61-74) R513668 12 0 0 1 3 9 21 31 39 44 49 53 56 64 69 73 76 (0-0) (0-1) (1-2) (2-5) (4-18) (15-28) (27-36) (34-44) (40-50) (45-55) (49-59) (53-62) (61-69) (66-73) (70-76) (74-78)

38 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 9 Summary of in vitro Comparative Dissolution Data for Dolutegravir Tablets, 50 mg Commercial Image and Phase III Clinical Image Tablets (USP Apparatus 2, 50 rpm, USP Acetate Buffer, pH 4.5, 900 mL)

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 R513665 12 1 4 12 20 30 38 44 49 52 55 57 59 (1-1) (2-7) (6-14) (17-23) (26-34) (35-41) (42-46) (47-50) (51-53) (54-56) (57-58) (59-60) R513668 12 1 6 15 25 36 43 48 51 54 57 59 60 (1-2) (2-10) (12-19) (22-31) (33-39) (41-46) (46-51) (50-54) (53-57) (55-59) (57-61) (59-62)

Appendix Table 10 Summary of in vitro Comparative Dissolution Data for Dolutegravir Tablets, 50 mg Commercial Image and Phase III Clinical Image Tablets (USP Apparatus 2, 50 rpm, 0.01M Phosphate Buffer, pH 7.5, 900 mL)

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 R513665 12 14 39 60 68 70 72 74 75 75 76 76 77 (9-19) (33-46) (54-65) (66-70) (68-72) (69-74) (70-75) (71-76) (71-77) (72-78) (72-78) (72-79) R513668 12 22 53 70 74 75 77 77 78 79 79 79 79 (16-25) (45-58) (66-72) (72-75) (74-77) (74-78) (75-79) (75-79) (76-80) (76-80) (76-80) (76-81)

39 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 11 Summary of in vitro Comparative Dissolution Data for Dolutegravir Tablets, 50 mg Commercial Image and Phase III Clinical Image Tablets (USP Apparatus 2, 50 rpm, Water, 900 mL)

Product No. of Collection times (min) ID/Batch Dosage Mean % Dissolved (range) No. Units 5 10 15 20 25 30 35 40 45 50 55 60 R513665 12 24 59 86 100 102 103 103 103 103 103 103 104 (18-28) (48-67) (73-93) (94-103) (101- (101- (101- (100- (101- (101- (101- (101- 105) 105) 105) 106) 106) 106) 106) 106) R513668 12 31 69 94 103 103 103 103 104 105 105 105 105 (25-37) (57-77) (85-100) (101- (103- (94-105) (94-105) (103- (103- (102- (103- (103- 104) 105) 105) 105) 106) 106) 107)

40 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 12 Bioanalytical Methods Summary

Validation Report Clinical Studies Method Description and Performance Supported Dolutegravir is extracted from 25 L human plasma by protein precipitation using Dolutegravir ING111207 2 15 acetonitrile containing [ H7 N]-dolutegravir as an internal standard. Extracts are Human Plasma (EDTA) ING111322 analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction (Original method) ING111405 monitoring. ING111521 GlaxoSmithKline ING111602 Lower limit of quantification (LLQ): 5 ng/mL Five Moore Drive ING111603 Validated Range: 5 to 5000 ng/mL Research Triangle Park, NC, 27709 ING111604 QC levels: 5, 20, 400, 4000, and 5000 ng/mL ING111853 Within-run Precision (%CV): ≤ 14.4% Title: The Validation of a Method for the Between-run Precision (%CV): ≤ 3.8% ING111854 Determination of GSK1349572 in Human Plasma Within-run Accuracy (% Bias): -8.4≤ bias ≤ -0.7% ING111856 (range 5-5000 ng/mL) using HPLC-MS/MS Stability in Human Plasma: 3 freeze-thaw cycles from -30°Ca ING112276 at least 16 months at -30°C Document Number: RD2007/01425 ING112934 at least 24 hours at ambient temperature ING112941 Processed Extract Stability: At least 3 days at ambient temperature Supplemental Report ING112961 (Incorporation of long term stability) Stability in Human Blood: Cross Reference RD2010/00175 Title Supplemental Validation Data to “The Validation of a Method for the Determination of GSK1349572 in Human Plasma (range 5 to 5000 ng/mL) using HPLC- MS/MS” Document Number: 2011N112541

41 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Dolutegravir is extracted from 25 L human plasma by protein precipitation using Dolutegravir ING113068 2 15 acetonitrile containing [ H7 N]-dolutegravir as an internal standard. Extracts are Human Plasma (EDTA) ING113096 analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction ING113097 (Lower limit of quantification raised from original) monitoring. ING113125 GlaxoSmithKline ING113674 Lower limit of quantification (LLQ): 20 ng/mL Five Moore Drive ING114005 Validated Range: 20 to 20000 ng/mL Research Triangle Park, NC 27709 ING114819 QC levels: 20, 60, 1600, 16000, and 20000 ng/mL ING116070 Within-run Precision (%CV): ≤ 4.5% Title: The Validation of a Method for the Between-run Precision (%CV): ≤ 2.7% Determination of GSK1349572 (range 20 to 20000 Within-run Accuracy (% Bias): -0.3≤ bias ≤ 9.6% ng/mL) in Human Plasma using HPLC-MS/MS Stability in Human Plasma: 3 freeze-thaw cycles from -20°C at least 265 days at -20°C Document Number: RD2010/00175 at least 24 hours at ambient temperature Supplemental Report Stability in Human Blood: at least 4 hours at 37°C (Incorporation of long term stability) Processed Extract Stability: At least 3 days at ambient temperature Title: Supplemental Validation Data to “The Validation of a Method for the Determination of GSK1349572 in Human Plasma (range 20 to 20000 ng/mL) using HPLC-MS/MS” Document Number: 2011N112542

42 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Dolutegravir is extracted from 25 L human plasma by protein precipitation using Dolutegravir ING111762 2 15 acetonitrile containing [ H7 N]- dolutegravir as an internal standard. Extracts are Human Plasma (EDTA) ING111855 analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction ING112574 (Transfer of original method – full validation) monitoring. ING113086 ING113099 Lower limit of quantification (LLQ): 20 ng/mL ING114556 Validated Range: 20 to 20000 ng/mL ING114581 QC levels: 20, 60, 1600, 16000, and 20000 ng/mL ING115381 Within-run Precision (%CV): ≤ 8.0% Title: Validation of a Method for the Determination of Between-run Precision (%CV): ≤ 7.5% ING115696 GSK1349572 in Human Plasma by LC-MS/MS Within-run Accuracy (% Bias): -1.7 ≤ bias ≤ 16.9% ING115697 Stability in Human Plasma: 5 freeze-thaw cycles from -20°C and -70°C Document Number: 2011N112453 ING115698 at least 373 days at -20°C LAI116181 at least 26 hours at ambient temperature Processed Extract Stability: At least 147 hours at 4°C Stability in Human Blood: Cross Reference RD2010/00175

43 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Dolutegravir is extracted from 50 L of phosphate buffered saline using acetonitrile Dolutegravir ING113097 2 15 containing [ H7 N]- dolutegravir as an internal standard. Extracts are analyzed by Phosphate Buffered Saline ING113125 HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction monitoring. ING116070 (Support Protein Binding Assessment against Lower limit of quantification (LLQ): 1 ng/mL EDTA plasma) Validated Range: 1 to 1000 ng/mL (Original method validation) QC levels: 1, 3, 80, 800, and 1000 ng/mL Within-run Precision (%CV): ≤ 6.2% GlaxoSmithKline Between-run Precision (%CV): ≤ 2.2% Five Moore Drive Within-run Accuracy (% Bias): -4.4≤ bias ≤ 4.4% Research Triangle Park, NC 27709 Stability in PBS: 3 cycles from 4°C to ambient at least 17 days at 4°C Title: The Validation of a Method for the at least 24 hours at ambient temperature Determination of GSK1349572 (range 1 to 1000 Processed Extract Stability: At least 1 day at ambient temperature ng/mL) in Phosphate Buffered Saline using HPLC- MS/MS Document Number: 2011N112679

44 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Dolutegravir in CSF is mixed 1:1 with blank human plasma and extracted from a 50 Dolutegravir ING116070 2 15 L aliquot of the mixture by protein precipitation using acetonitrile containing [ H7 N]- Human Cerebrospinal Fluid dolutegravir as an internal standard. Extracts are analyzed by HPLC-MS/MS using a ( original method validation) Turbo IonSpray interface and multiple reaction monitoring. Lower limit of quantification (LLQ): 1 ng/mL Validated Range: 1 to 1000 ng/mL QC levels: 1, 3, 30, 150, and 750 ng/mL Within-run Precision (%CV): ≤ 9.0% Between-run Precision (%CV): ≤ 12.7% Title: Validation of a Method for the Determination of Within-run Accuracy (% Bias): -10.0 ≤ bias ≤ 17.8% GSK1349572 in Human Cerebrospinal Fluid (CSF) by Stability in Human CSF: 5 freeze-thaw cycles from -20°C and -70°C LC-MS/MS at least 226 days at -20°C and -70°C in CSF:Plasma (1:1) Document Number 2012N145767 at least 6.5 hours at ambient temperature Processed Extract Stability: At least 109 hours at 4°C

45 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported GSK2832500 is extracted from 50 L human plasma by protein precipitation using GSK2832500 (Glucuronide of Dolutegravir; M3) ING113125 2 15 acetonitrile containing [ H7 N]-GSK2832500 as an internal standard. Extracts are Human Plasma (EDTA) analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction (Original method full validation) monitoring. GlaxoSmithKline Lower limit of quantification (LLQ): 1 ng/mL Five Moore Drive Validated Range: 1 to 1000 ng/mL Research Triangle Park, NC 27709 QC levels: 1, 3, 80, 800, and 1000 ng/mL Within-run Precision (%CV): ≤ 12.6% Title: The Validation of a Method for the Between-run Precision (%CV): ≤ 1.4% Determination of GSK2832500 (range 1 to Within-run Accuracy (% Bias): -3.9≤ bias ≤ 12.8% 1000 ng/mL) in Human Plasma using HPLC-MS/MS Stability in Human Plasma: 3 freeze-thaw cycles from -20°C at least 127 days at -20°C Document Number 2011N122389 at least 24 hours at ambient temperature Processed Extract Stability: At least 48 hours at ambient temperature Stability in Human Blood: At least 2 hours at 37°C At least 2 hours at ambient temperature

46 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Midazolam is extracted from 50 L human plasma by protein precipitation using Midazolam (GI106769) ING111322 13 2 acetonitrile containing [ C3 H3]-Midazolam as an internal standard. Extracts are Human Plasma (EDTA) analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction (original method validation) monitoring. GlaxoSmithKline Lower limit of quantification (LLQ): 0.35 ng/mL The Frythe, Validated Range: 0.35 to 72 ng/mL Welwyn, Hertfordshire, AL6 9AR, UK QC levels: 0.35, 1.4, 7, 58, and 72 ng/mL Within-run Precision (%CV): ≤ 10.6% Title: Validation of a Method for the Determination of Between-run Precision (%CV): ≤ 8.7% Midazolam (Range 0.35 to 72 ng/mL) and Within-run Accuracy (% Bias): -6.7 ≤ bias ≤ 12.0% 1-Hydroxymidazolam (Range 0.5 to 100 ng/mL) in Stability in Human Plasma: 3 freeze-thaw cycles from -20°C Human Plasma using HPLC-MS/MS at least 24 hours at ambient temperature; at least 60 days at -20C Document Number FD2006/00038 Processed Extract Stability: At least 6 days at ambient temperature Supplemental Report (Incorporation of long term stability) Title: Supplemental Validation Data to “The Validation of a Method for the Determination of Midazolam in Human Plasma (range 0.1 to 100 ng/mL) using HPLC-MS/MS” Document Number: 2012N151540

47 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Darunivir, Ritonivir, and Lopinavir are extracted from 50 L human plasma by protein Darunivir (GW832466), Ritonivir (GW278007), ING111405 2 2 13 15 precipitation using acetonitrile containing [ H9]-Darunivir, [ H2 C3 N]-Ritonivir, and Lopinavir 2 13 [ H3 C2]-Lopinavir as internal standards. Extracts are analyzed by HPLC-MS/MS Human Plasma (EDTA) using a Turbo IonSpray interface and multiple reaction monitoring. (Original method validation) Darunivir (GW832466) and Ritonivir (GW278007) GlaxoSmithKline Lower limit of quantification (LLQ): 10 ng/mL Five Moore Drive Validated Range: 10 to 10000 ng/mL Research Triangle Park, NC 27709 QC levels: 10, 40, 800, 8000, and 10000 ng/mL Within-run Precision (%CV): ≤ 8.6% (Darunivir), Title: The Validation of a Method for the ≤ 9.9% (Ritonivir) Determination of GW832466 (Darunavir), Ritonavir, Between-run Precision (%CV): ≤ 2.8% (Darunivir), and Lopinavir in Human Plasma (ranges ≤ 7.7% (Ritonivir) 10 to 10000 ng/mL, 10 to 10000 ng/mL, and 20 to Within-run Accuracy (% Bias): -5.1 ≤ bias ≤ 5.6% (Darunivir) 20000 ng/mL, respectively) Using HPLC-MS/MS -7.0 ≤ bias ≤ 8.9% (Ritonivir) Stability in Human Plasma: 4 freeze-thaw cycles from -30°C, Document Number RD2008/01543 and at least 24 hours at ambient temperature Supplemental Report at least 54 days at -30C (Incorporation of long term stability) Processed Extract Stability: At least 48 hours at ambient temperature Title: Supplemental Validation Data to “The Lopinavir Validation of a Method for the Determination of Lower limit of quantification (LLQ): 20 ng/mL GW832466 (Darunavir), Ritonavir, and Lopinavir in Validated Range: 20 to 20000 ng/mL Human Plasma (ranges 10 to 10000 ng/mL, 10 to QC levels: 20, 80, 1600, 16000, and 20000 ng/mL 10000 ng/mL, and 20 to 20000 ng/mL, respectively) Within-run Precision (%CV): ≤ 14.3% Using HPLC-MS/MS” Between-run Precision (%CV): ≤ 2.8% Document Number: 2012N151539 Within-run Accuracy (% Bias): -7.6 ≤ bias ≤ 5.5% Stability in Human Plasma: 4 freeze-thaw cycles from -30°C, and at least 24 hours at ambient temperature at least 54 days at -30C Processed Extract Stability: At least 48 hours at ambient temperature

48 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Etravirine is extracted from 50 L human plasma by protein precipitation using Etravirine ING111603 13 acetonitrile containing [ C3]-Etravirine as an internal standard. Extracts are analyzed Human Plasma (EDTA) ING112934 by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction monitoring. (original method validation) Lower limit of quantification (LLQ): 5 ng/mL GlaxoSmithKline Validated Range: 5 to 4500 ng/mL Five Moore Drive QC levels: 5, 20, 500, 3600, and 4500 ng/mL Research Triangle Park, NC 27709 Within-run Precision (%CV): ≤ 8.5% Between-run Precision (%CV): ≤ 0.7% Title: The Validation of a Method for the Within-run Accuracy (% Bias): -2.6≤ bias ≤ 8.8% Determination of Etravirine in Human Plasma (range 5 Stability in Human Plasma: 3 freeze-thaw cycles from -30°C to 4500 ng/mL) using UPLC-MS/MS at least 24 hours at ambient temperature at least 159 days at -30°C Document Number RD2008/01746 Processed Extract Stability: At least 96 hours at ambient temperature Supplemental Report (Incorporation of long term stability) Title: Supplemental Validation Data to “The Validation of a Method for the Determination of Etravirine in Human Plasma (range 5 to 4500 ng/mL) using UPLC-MS/MS” Document Number: 2012N151538

49 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Tenofivir is extracted from 80 L human plasma by protein precipitation using Tenofovir (GSK1346957) ING111604 2 methanol containing 1% ammonium hydroxide with [ H6] GSK1019993 as an internal Human Plasma standard. Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray interface (Original method validation) and multiple reaction monitoring. GlaxoSmithKline Lower limit of quantification (LLQ): 1 ng/mL Five Moore Drive Validated Range: 1 to 500 ng/mL Research Triangle Park, NC 27709 QC levels: 1, 3, 75, 400, and 500 ng/mL Within-run Precision (%CV): ≤ 13.7% Title: The Validation of a Method for the Between-run Precision (%CV): ≤ 5.5% Determination of Tenofovir in Human Plasma (range 1 Within-run Accuracy (% Bias): -10.6 ≤ bias ≤ 1.8% to 500 ng/mL) using HPLC-MS/MS Stability in Human Plasma: 3 freeze-thaw cycles from -30°C at least 24 hours at ambient temperature Document Number RD2005/01570 at least 38 days at -30C Supplemental Report Processed Extract Stability: At least 24 hours at ambient temperature (Incorporation of long term stability) Title: Supplemental Validation Data to “The Validation of a Method for the Determination of Tenofovir in Human Plasma (range 1 to 500 ng/mL) using HPLC-MS/MS” Document Number: 2012N151537

50 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Atazanavir is extracted from 50 L human plasma by protein precipitation using Atazanavir (GW573140) ING111854 2 acetonitrile containing [ H5]- atazanavir as an internal standard. Extracts are analyzed Human Plasma (EDTA) by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction monitoring. (Original method validation) Lower limit of quantification (LLQ): 10 ng/mL GlaxoSmithKline Validated Range: 10 to 10000 ng/mL Five Moore Drive QC levels: 10, 40, 400, 8000, and 10000 ng/mL Research Triangle Park, NC 27709 Within-run Precision (%CV): ≤ 12.5% Between-run Precision (%CV): ≤ 4.3% Title: The Validation of a Method for the Within-run Accuracy (% Bias): -11.3 ≤ bias ≤ 6.9% Determination of GW573140 (Atazanavir) and Stability in Human Plasma: 3 freeze-thaw cycles from -30°C Ritonavir in Human Plasma (range at least 53 days at -30°C 10 to 10000 ng/mL) Using HPLC-MS/MS at least 24 hours at ambient temperature Processed Extract Stability: At least 72 hours at ambient temperature Document Number RD2009/00531 Supplemental Report (Incorporation of long term stability) Title: Supplemental Validation Data to “The Validation of a Method for the Determination of GW573140 (Atazanavir) and Ritonavir in Human Plasma (range 10 to 10000 ng/mL) Using HPLC-MS/MS” Document Number: 2012N152554

51 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Amprenavir is extracted from 50 L human plasma by solid phase extraction using Amprenavir (GW141W94) ING113068 13 [ C6]-Amprenavir as an internal standard. Extracts are analyzed by HPLC-MS/MS Human Plasma (EDTA) using a Turbo IonSpray interface and multiple reaction monitoring. ( original proprietary method validation) Lower limit of quantification (LLQ): 10 ng/mL Validated Range: 10 to 10000 ng/mL QC levels: 10, 30, 4000, 7500, and 10000 ng/mL USA Within-run Precision (%CV): ≤ 5.4% Between-run Precision (%CV): ≤ 4.3% Title: Method Validation for the Quantitation of Within-run Accuracy (% Bias): -5.7≤ bias ≤ 5.5% Amprenavir (GW141W94), Fosamprenavir Stability in Human Plasma: 3 freeze-thaw cycles from -20°C (GW433908), and Ritonavir (GW278007A) in at least 836 days at -20°C Tripotassium Ethylenediaminetetraacetic Acid Human at least 24 hours at ambient temperature Plasma (Range 10 to 10000 ng/mL Amprenavir and Processed Extract Stability: At least 58.5 hours at ambient temperature Ritonavir, and 5 to 100 ng/mL Fosamprenavir) by Turbo Ion Spray LC/MS/MS Document Number CD2004/00524

Supplemental Report (Plasma long term stability) Title: Addendum 1 to the Method Validation for the Quantitation of Amprenavir (GW141W94), Fosamprenavir (GW433908), and Ritonavir (GW278007A) in Tripotassium Ethylenediaminetetraacetic Acid Human Plasma (Range 10 to 10000 ng/mL Amprenavir and Ritonavir, and 5 to 100 ng/mL Fosamprenavir) by Turbo Ion Spray LC/MS/MS Document Number: 2012N134430

52 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Efavirenz is extracted from 50 L human plasma by protein precipitation using Efavirenz ING114005 2 acetonitrile containing [ H4]-Efavirenz as an internal standard. Extracts are analyzed Human Plasma (EDTA) by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction monitoring. (Original method validation) Lower limit of quantification (LLQ): 100 ng/mL GlaxoSmithKline Validated Range: 100 to 20000 ng/mL Five Moore Drive QC levels: 100, 300, 4000, 16000, and 20000 ng/mL Research Triangle Park, NC 27709 Within-run Precision (%CV): ≤ 10.5% Title: The Validation of a Method for the Between-run Precision (%CV): ≤ 4.0% Determination of Efavirenz (range 100 to Within-run Accuracy (% Bias): -8.9 ≤ bias ≤ 11.3% Stability in Human Plasma: 3 freeze-thaw cycles from -20°C 20000 ng/mL) in Human Plasma using HPLC-MS/MS at least 96 days at -20°C Document Number RD2010/00300 at least 24 hours at ambient temperature Processed Extract Stability: At least 24 hours at ambient temperature Supplemental Report Stability in Human Blood: at least 4 hours at room temperature (Incorporation of long term stability) Title: Supplemental Validation Data to “The Validation of a Method for the Determination of Efavirenz in Human Plasma (range 100 to 20000 ng/mL) using HPLC-MS/MS” Supplemental Report 2011N112543

53 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Iohexol is extracted from 100 L human plasma by protein precipitation using zinc Iohexol ING114819 sulfate. Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray interface and Human Plasma (sodium heparin) multiple reaction monitoring. ( original proprietary method validation) Lower limit of quantification (LLQ): 1.02 g/mL Validated Range: 1.02 to 100.11 g/mL QC levels: 1.02, 2.89, 48.39, and 99.33 g/mL Within-run Precision (%CV): ≤ 9.6% , UK, Between-run Precision (%CV): ≤ 7.0% Within-run Accuracy (% Bias): -6 ≤ bias ≤ 8% Title: Validation Report for the Determination of Stability in Human Plasma: 3 freeze-thaw cycles from -20°C Iohexol in Human Plasma by LC-MS/MS at least 65 days at -20°C at least 4 hours at ambient temperature Document Number 2010N111226 Processed Extract Stability: At least 31 hours at ambient temperature Supplemental Report (Incorporation of long term stability) Title: Supplemental Validation Data: Long-Term Stability of Iohexol in Human Plasma Sodium Heparin by LC/MS/MS. Supplemental Report 2012N150761

54 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported PAH is extracted from 100 L human plasma by protein precipitation using acetonitrile Para-Amino Hippuric Acid (PAH) ING114819 and methanol containing N-(4-Aminobenzoly-d4)-Glycine as an internal standard. Human Plasma (sodium heparin) Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple ( original proprietary method validation) reaction monitoring. Lower limit of quantification (LLQ): 0.96 g/mL Validated Range: 0.96 to 100.37 g/mL QC levels: 1.02, 2.90, 48.36, and 100.06 g/mL , UK Within-run Precision (%CV): ≤ 4.9% Between-run Precision (%CV): ≤ 7.5% Title: Validation Report for the Determination of PAH Within-run Accuracy (% Bias): -15 ≤ bias ≤ 5% (Para-Amino Hippuric Acid) in Human Plasma by LC- Stability in Human Plasma: 3 freeze-thaw cycles from -20°C MS/MS. at least 90 days at -20°C at least 4 hours at ambient temperature Document Number 2010N111322 Processed Extract Stability: At least 144 hours at ambient temperature

55 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported R-and S-Methadone are extracted from 50 L human plasma and fortified with 25L of R- and S-Methadone ING115698 [2H9]-[(R,S)-Methadone]- as an internal standard through supported liquid extraction with Human Plasma (EDTA) dichloromethane. Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray ( proprietary original method validation) interface and multiple reaction monitoring. R-Methadone Lower limit of quantification (LLQ): 5 ng/mL Validated Range: 5 to 1000 ng/mL QC levels: 5, 10, 25, 70, 200 and 750 ng/mL Title: Quantitation of Methadone Enantiomers in Within-run Precision (%CV): ≤ 5.6% Human Plasma via HPLC with MS/MS Detection Between-run Precision (%CV): ≤ 4.4% Within-run Accuracy (% Bias): -3.2≤ bias ≤ 4.6% Document Number 2012N133617 Stability in Human Plasma: 5 freeze-thaw cycles from -20°C at least 28 hours at ambient temperature at least 365 days at -20°C and 280 days at -70°C Processed Extract Stability: At least 82 hours at 6°C

S-Methadone Lower limit of quantification (LLQ): 5 ng/mL Validated Range: 5 to 1000 ng/mL QC levels: 5, 10, 25, 70, 200 and 750 ng/mL Within-run Precision (%CV): ≤ 6.2% Between-run Precision (%CV): ≤ 3.9% Within-run Accuracy (% Bias): -1.3 ≤ bias ≤ 4.3% Stability in Human Plasma: 5 freeze-thaw cycles from -20°C at least 28 hours at ambient temperature at least 365 days at -20°C and 280 days at -70°C Processed Extract Stability: At least 82 hours at 6°C

56 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported TMC278 is extracted from 100 L human plasma by protein precipitation using Rilpivirine (TMC278) LAI116181 methanol containing isotopically labelled TMC278 as an internal standard. Extracts Human Plasma (heparin) are analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction (Proprietary method validation of ) monitoring. Lower limit of quantification (LLQ): 1 ng/mL , The Netherlands Validated Range: 1 to 2000 ng/mL QC levels: 1, 3, 50, and 1600 ng/mL Title: Validation of a method for the determination of Within-run Precision (%CV): ≤ 5.4% JNJ-16150108 (TMC278) in human plasma samples Between-run Precision (%CV): ≤ 4.7% Within-run Accuracy (% Bias): -3.3≤ bias ≤ 14.1% Document Number 2012N144315 Stability in Human Plasma: 3 freeze-thaw cycles from -18°C at least 1528 days at -18°C Processed Extract Stability: At least 119 hours at 10°C

A 25µL sample aliquot is fortified with isotopically labelled telaprevir and telaprevir is Telaprevir ING115697 isolated through supported liquid extraction using dichloromethane/MtBE (1:2). Human Plasma (EDTA with 5.0 % Phosphoric Acid) Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple ( original proprietary method validation) reaction monitoring. Lower limit of quantification (LLQ): 0.1 µg/mL Validated Range: 0.1 to 20 µg/mL QC levels: 0.10, 0.24, 0.50, 1.5, 4.0, and 16.0 µg/mL Within-run Precision (%CV): ≤ 2.2% Title: Quantitation of (S)-Telaprevir in Human Plasma Between-run Precision (%CV): ≤ 1.7% via HPLC with MS/MS Detection Within-run Accuracy (% Bias): -5.6 ≤ bias ≤ 2.5% Stability in Human Plasma: 5 freeze-thaw cycles from -20°C or -70°C Document Number 2012N150656 at least 24 days at -20°C or -70°C at least 24 hours at room temperature Processed Extract Stability: At least 108 hours at 2 to 8°C

57 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Abacavir is extracted from 200 L human plasma by protein precipitation using Abacavir ING114581 methanol containing 2’,3’-Dideoxyinosine as an internal standard. Extracts are Human Plasma (EDTA) analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction ( original proprietary method validation) monitoring. Lower limit of quantification (LLQ): 5 ng/mL Validated Range: 5 to 5000 ng/mL QC levels: 5, 15, 250, 1000, and 4000 ng/mL Title: Determination of Abacavir in Human Plasma by Within-run Precision (%CV): ≤ 9.6% LC-MS/MS Between-run Precision (%CV): ≤ 7.7% Within-run Accuracy (% Bias): -10.1 ≤ bias ≤ 6.7% Document Number: 2012N133184 Stability in Human Plasma: 3 freeze-thaw cycles from -70°C at least 80 days at -70°C at least 15 hours at room temperature Processed Extract Stability: 110 hours at 4°C

58 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Lamivudine is extracted from 100 L human plasma by protein precipitation using Lamivudine ING114581 methanol containing 3’-Deoxythymidine as an internal standard. Extracts are Human Plasma (EDTA) analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction ( original proprietary method validation) monitoring. Lower limit of quantification (LLQ): 2 ng/mL Validated Range: 2 to 2000 ng/mL QC levels: 2, 5, 15.500, and 1800 ng/mL Title: LC/MS/MS Assay Validation of Zidovudine, Within-run Precision (%CV): ≤ 5.7% Lamivudine, and Stavudine in Human Plasma Between-run Precision (%CV): ≤ 4.5% Within-run Accuracy (% Bias): -13.6 ≤ bias ≤ 1.5% Document Number: 2012N133186 Stability in Human Plasma: 3 freeze-thaw cycles from -70°C at least 310 days at -70°C at least 6.5 hours at ambient temperature Referenced Validation Report Autosampler Stability: At least 278 hours at room temperature (Long Term, Room Temperature, and Freeze-Thaw Stability of Lamivudine in human plasma) Title: LC/MS/MS Assay Validation of Zalcitabine (ddC) and Lamivudine (3TC) in K2 EDTA Human Plasma Document Number: 2012N152558

59 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Validation Report Clinical Studies Method Description and Performance Supported Ethinyl Estradiol is extracted from 500 L human plasma by protein precipitation Ethinyl Estradiol ING111855 followed by a derivitization using (d4)- Ethinyl Estradiol as an internal standard. Human Plasma Extracts are analyzed by HPLC-MS/MS using a Turbo IonSpray interface and multiple (Potassium Oxalate/ Sodium Fluoride) reaction monitoring. ( original proprietary method validation) Lower limit of quantification (LLQ): 2 pg/mL Validated Range: 2 to 500 pg/mL QC levels: 2, 5, 50, and 500 pg/mL Within-run Precision (%CV): ≤ 19.7% Title: Quantitation of 17α-Ethinyl Estradiol and Between-run Precision (%CV): ≤ 15.3% Within-run Accuracy (% Bias): -16.5 ≤ bias ≤ 8.8% Norgestrel in Human Plasma via HPLC with MS/MS Stability in Human Plasma: 5 freeze-thaw cycles from -80°C Detection (LCMSC 256) at least 811 days at -70°C Document Number 2012N151915 at least 28 hours at ambient temperature Processed Extract Stability: At least 434 hours at 2 to 8°C Norelgestromin is extracted from 500 L human plasma by protein precipitation using Norelgestromin ING111855 (d5)-desacetylnorgestimate as an internal standard. Extracts are analyzed by Human Plasma HPLC-MS/MS using a Turbo IonSpray interface and multiple reaction monitoring. (Potassium Oxalate/ Sodium Fluoride) ( proprietary method validation) Lower limit of quantification (LLQ): 0.02 ng/mL Validated Range: 0.02 to 10 ng/mL QC levels: 0.02, 0.05, 0.50, and 7.50 ng/mL Within-run Precision (%CV): ≤ 3.7% Between-run Precision (%CV): ≤ 4.1% Title: Quantitation of Norelgestromin in Human Within-run Accuracy (% Bias): -6.3≤ bias ≤ 2.1% Stability in Human Plasma: 4 freeze-thaw cycles from -70°C Plasma via HPLC with MS/MS Detection (LCMSC at least 515 days at -70°C 372) at least 24 hours at ambient temperature Document Number 2012N151913 Processed Extract Stability: At least 20 days at 2 to 8°C e. For the first freeze/thaw cycle, samples were frozen for a minimum of 12 hours before thawing at room temperature. For subsequent cycles, the samples were frozen for at least 12 hours then completely thawed at room temperature before re-freezing to start another cycle.

60 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 13 Between-run Accuracy and Precision of Quality Control (QC) Samples

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING111322 (DTG plasma) RD2007/01425; (n=60 at each of 3 Repeat dose escalation study in healthy 4.2% to 7.0% -1.8% to -0.8% 2011N126878 Supplemental: levels) subjects 2011N112541 ING113068 (DTG plasma) RD2010/00175; Effects of fosamprenavir on DTG and (n=26 at each of 3 3.0% to 5.3% 5.3% to 6.9% 2011N112681 Supplemental: relative bioavailability of three tablet levels) 2011N112542 variants in healthy subjects ING113674 (DTG plasma) RD2010/00175; (n=44 at each of 3 Relative bioavailability of three tablet 3.5% to 4.4% 0.2% to 3.9% RD2010/00558 Supplemental: levels) formulations in healthy subjects 2011N112542 ING112941 (DTG plasma) RD2007/01425; Supratherapeutic dose and evaluation of (n=24 at each of 3 2.6% to 4.0% -4.7% to 1.0% RD2009/01353 Supplemental: the effects of omeprazole, and a high fat levels) 2011N112541 meal in healthy subjects RD2007/01425; ING111207 (DTG plasma) (n=44 at each of 3 3.0% to 6.7% -3.5% to 0.0% 2011N126877 Supplemental: Single dose escalation in healthy subjects levels) 2011N112541 ING111405 (DTG plasma) RD2007/01425; Effect of darunavir/ritonavir and (n=22 at each of 3 RD2009/00885/0 2.5% to 4.3% -1.1% to 5.2% Supplemental: lopinavir/ritonavir on DTG in healthy levels) 0 2011N112541 subjects ING111521 (DTG plasma) RD2007/01425; (n=36 at each of 3 2011N126879_0 Phase 2a monotherapy study over 10 days 2.3% to 3.7% -0.9% to 1.1% Supplemental: levels) 0 in HIV-1 infected patients 2011N112541 ING111602 (DTG plasma) (n=32 at 20 and RD2007/01425; Evaluation of maalox and multivitamins on 400 ng/mL, and n=31 3.5% to 5.4% -2.5% to -1.7% 2011N126880 Supplemental: DTG in healthy subjects at 4000 ng/mL) 2011N112541

61 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING111603 (DTG plasma) RD2007/01425; (n=12 at each of 3 Effect of etravirine on DTG in healthy adult 1.7% to 4.0% 0.5% to 4.0% 2011N126881 Supplemental: levels) subjects 2011N112541 ING111604 (DTG plasma) RD2007/01425; (n=12 at each of 3 Evaluation of tenofovir and DTG 2.0% to 4.1% -1.5% to 1.8% 2011N126882 Supplemental: levels) pharmacokinetics in healthy subjects 2011N112541 ING111762 (DTG plasma) Population pharmacokinetic analysis of (n=30 at 60, 1600, and 4.5% to 6.5% 2011N117340 2011N112453 dolutegravir in HIV-1 infected treatment- 16000 and n=29 at -4.2% to 3.4% naïve patients (2012N149219_00) 20000 ng/mL) ING111762 (DTG plasma) Population pharmacokinetic analysis of (n=36 at 60, 1600, and dolutegravir in HIV-1 infected treatment- 16000 and n=35 at 4.3% to 7.1% -2.7% to 3.1% 2012N150243 2011N112453 experienced patients (2012N149456_00) 20000 ng/mL)

RD2007/01425; ING111853 (DTG plasma) (n=4 at each of 3 10.3% to 2.0% to 5.1% RD2009/00551 Supplemental: Mass balance study in healthy subjects levels) 17.1% 2011N112541 ING111854 (DTG plasma) RD2007/01425; (n=20 at each of 3 Effects of atazanavir/ritonavir or atazanavir 3.1% to 7.1% -8.2% to -3.5% RD2009/00809 Supplemental: levels) on DTG in healthy subjects 2011N112541 ING111855 (DTG plasma) (n=8 at 60, 16000, and Effects of DTG on an oral contraceptive 20000 and n=7 at 1.7% to 4.8% -1.2% to 6.0% 2012N136662 2011N112453 containing norgestimate and ethinyl 1600 ng/mL) estradiol in healthy women subjects ING111856 (DTG plasma) RD2007/01425; (n=34 at each of 3 Evaluation of a single dose of DTG on 2.5% to 3.2% -6.4% to 4.2% RD2010/00015 Supplemental: levels) cardiac conduction in healthy subjects 2011N112541

62 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) (n=46 at 20, 400, and ING112276 (DTG plasma) RD2007/01425; 4000 ng/mL, n=12 at Phase IIb study of DTG in HIV-1 infected 3.3% to 4.5% -7.5% to -0.1% RD2010/00559 Supplemental: 6000 ng/mL Dilution antiretroviral therapy naïve adult subjects. 2011N112541 QC) ING112574 (DTG plasma) Phase III study in HIV-1 infected adult (n=24 at each of 4 2.8% to 6.4% -1.4% to 3.1% 2011N117341 2011N112453 subjects with treatment failure on an levels) integrase inhibitor containing regimen ING112934 (DTG plasma) RD2007/01425; Effects of darunavir/ritonavir plus etravirine (n=14 at each of 3 1.6% to 3.4% -8.2% to -5.7% RD2009/00762 Supplemental: and lopinavir/ritonavir plus etravirine on levels) 2011N112541 DTG in heathy adult subjects ING112961 (DTG plasma) (n=32 at 20, 400, and RD2007/01425; Phase IIb pilot study of DTG in 4000 ng/mL, n=15 at 5.2% to 6.9% -0.5% to 4.2% 2011N119907 Supplemental: antiretroviral therapy experienced HIV-1 6000 ng/mL Dilution 2011N112541 infected adults with raltegravir resistance QC) ING113086 (DTG plasma) Phase III study comparing DTG to (n=54 at each of 4 4.8% to 7.5% -2.0% to 1.9% 2011N114375 2011N112453 raltegravir in HIV-1 infected antiretroviral levels) therapy naïve adult subjects. ING113096 (DTG plasma) (n=10 at 1600 and RD2010/00175; Effect of Tipranavir/Ritonavir on DTG and 16000 ng/mL, and n=9 3.1% to 4.7% 4.4% to 7.2% RD2010/00364 Supplemental: in healthy adult subjects at 60 ng/mL) 2011N112542 ING113097 (DTG plasma) DTG pharmacokinetics in adult subjects (n=8 at 60 and RD2010/00175; with mild or moderate hepatic impairment 1600 ng/mL, and n=6 1.5% to 4.4% 2.7% to 12.5% 2011N119906 Supplemental: and matched, healthy control subjects. at 16000 ng/mL) 2011N112542

63 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING113099 (DTG plasma) (n=12 at each of 4 Effect of rifampin and rifabutin on DTG in 6.1% to 7.9% 1.3% to 6.1% 2011N117339 2011N112453 levels) healthy volunteers ING113125 (DTG plasma) RD2010/00175; DTG pharmacokinetics in subjects with (n=8 at each of 3 7.3% to 7.7% 0.2% to 3.1% 2012N135064 Supplemental: severe renal impairment and matched levels) 2011N112542 healthy controls. ING114005 (DTG plasma) (n=14 at 60 and 16000 RD2010/00175; Effect of efavirenz on DTG in healthy adult ng/mL, and n=13 at 3.0% to 5.3% 4.7% to 6.6% RD2010/00365 Supplemental: subjects. 1600 ng/mL) 2011N112542 ING114556 (DTG plasma) Relative bioavailability study of a tablet vs. (n=26 at each of 4 pediatric granule formulations and effect of 3.7% to 8.4% 0.7% to 4.2% 2011N123807 2011N112453 levels) water types and infant formula in healthy volunteers ING114581 (DTG plasma) Relative bioavailability of two fixed-dose (n=16 at each of 4 4.8% to 6.4% -3.2% to 0.2% 2011N120851 2011N112453 combination tablets vs single DTG plus levels) Epsicom in healthy adult subjects ING114819 (DTG plasma) RD2010/00175; (n=12 at each of 3 Effect of DTG on Iohexol and PAH 2.6% to 4.5% 9.0% to 10.9% 2011N112682 Supplemental: levels) Clearance in Healthy Subjects 2011N112542 ING115381 (DTG plasma) (n=4 at each of 4 Pharmacokinetics of DTG in healthy 4.0% to 7.7% -4.0% to 6.2% 2012N145039 2011N112453 levels) Japanese subjects ING115696 (DTG plasma) (n=6 at each of 4 Effect of a high prednisone dose on DTG in 1.9% to 13.9% -8.7% to -0.3% 2011N124876 2011N112453 levels) healthy adult subjects

64 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING115697 (DTG plasma) (n=16 at each of 4 Effect of boceprevir and telaprevir on DTG 1.8% to 4.1% -2.2% to 3.9% 2012N136665 2011N112453 levels) pharmacokinetics in healthy adult subjects ING115698 (DTG plasma) (n=4 at each of 4 Effect of DTG on methadone in opiate- 1.5% to 3.3% -5.1% to 4.8% 2012N132253 2011N112453 levels) dependent, HIV seronegative subjects. ING116070 (DTG plasma) RD2010/00175; CNS and plasma exposure to DTG in HIV- (n=2 at each of 3 2.4% to 4.5% Supplemental: 1 infected antiretroviral naive adult subjects -2.8% to 1.8% 2012N150565 levels) 2011N112542 given DTG and abacavir/lamivudine LAI116181 (DTG plasma) (n=6 at each of 4 Evaluation of the pharmacokinetic of DTG 3.1% to 4.8% -5.7% to 3.6% 2012N132345 2011N112453 levels) and RPV in healthy adult subjects. P1093 (GSK No.: ING112578) (DTG plasma) (n=38 at 15 and 450 5.0% to 5.8% Phase I/II DTG in HIV-1 Infected Infants, ng/mL, and n=39 at -6.4% to -3.7% 2012N149534 2012N149534 Children and Adolescents 9000 ng/mL) IRB #11-1733 (GSK No.: ING116195) (DTG-Male Plasma) (n=12 at each of 3 see report see report 2012N149423 2012N149423 DTG distribution to male seminal fluid and levels) rectal tissue in healthy male subjects IRB #11-1011 (GSK No.: ING115465) (DTG-Female Plasma) (n=6 at each of 3 see report see report 2012N149420 2012N149420 DTG distribution to female genitourinary levels) tract in healthy female subjects IRB #11-1733 (GSK No.: ING116195) (DTG-Seminal Plasma) (n=6 at each of 3 see report see report 2012N149428 2012N149428 DTG distribution to male seminal fluid and levels) rectal tissue in healthy male subjects

65 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) IRB #11-1733 (GSK No.: ING116195) (DTG-Rectal Fluid) (n=6 at each of 3 see report see report 2012N149425 2012N149425 DTG distribution to male seminal fluid and levels) rectal tissue in healthy male subjects IRB #11-1733 (GSK No.: ING116195) (DTG-Rectal Tissue) (n=2 at each of 3 see report see report 2012N149427 2012N149427 DTG distribution to male seminal fluid and levels) rectal tissue in healthy male subjects IRB #11-1011 (GSK No.: ING115465) (DTG-Cervicovaginal Fluid) (n=14 at each of 3 see report see report 2012N149418 2012N149418 DTG distribution to female genitourinary levels) tract in healthy female subjects IRB #11-1011 (GSK No.: ING115465) (DTG-Cervical and Vaginal Tissue) (n=2 at each of 3 see report see report 2012N149416 2012N149416 DTG distribution to female genitourinary levels) tract in healthy female subjects ING113097 (DTG-PB) DTG pharmacokinetics in adult subjects (n=6 at each of 3 3.4% to 8.0% 3.7% to 8.6% 2011N124287 2011N112679 with mild or moderate hepatic impairment levels) and matched, healthy control subjects. ING113125 (DTG-PB) DTG pharmacokinetics in subjects with (n=4 at each of 3 1.7% to 7.7%-6.2% to 2.7% 2012N135066 2011N112679 severe renal impairment and matched levels) healthy controls. ING116070 (DTG-PB) CNS and plasma exposure to DTG in HIV- (n=2 at each of 3 1.7% to 2.4% -5.0% to 2.5% 2012N135067 2011N112679 1 infected antiretroviral naive adult subjects levels) given DTG and abacavir/lamivudine

66 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING116070 (DTG-CSF) CNS and plasma exposure to DTG in HIV- (n=4 at each of 4 1.6% to 6.0% -3.5% to 0.7% 2012N136666 2012N145767 1 infected antiretroviral naive adult subjects levels) given DTG and abacavir/lamivudine ING113125 (GSK2832500 plasma) Pharmacokinetic study of DTG in subjects (n=8 at each of 3 2.9% to 7.7% -2.7% to 2.3% 2012N143609 2011N122389 with severe renal impairment and matched levels) healthy controls. ING111322 (MDZ plasma) FD2006/00038 (n=4 at each of 3 Repeat dose escalation study in healthy 4.2% to 6.4% 2.8% to 9.4% 2012N135192 Supplemental: levels) subjects 2012N151540 ING111405 (DRV plasma) RD2008/01543; Effect of darunavir/ritonavir and (n=8 at each of 3 1.8% to 7.8% -6.2% to 0.6% RD2010/00433 Supplemental: lopinavir/ritonavir on DTG in healthy levels) 2012N151539 subjects ING111405 (RTV plasma) RD2008/01543; Effect of darunavir/ritonavir and (n=14 at each of 3 3.2% to 6.1% -8.9% to 0.8% RD2010/00433 Supplemental: lopinavir/ritonavir on DTG in healthy levels) 2012N151539 subjects ING111405 (LPV plasma) RD2008/01543; (n=8 at each of 3 Effect of darunavir/ritonavir and 2.0% to 3.8% -5.9% to -3.4% RD2010/00433 Supplemental: levels) lopinavir/ritonavir on DTG 2012N151539 ING111603 (ETV plasma) RD2008/01746; (n=6 at each of 3 Effect of etravirine on DTG in healthy 2.3% to 6.3% -1.3% to 4.6% 2012N135193 Supplemental: levels) subjects 2012N151538 ING111604 (TFV plasma) RD2005/01570; (n=12 at each of 3 Evaluation of tenofovir and DTG 1.2% to 5.4% 2.2% to 9.3% 2012N135194 Supplemental: levels) pharmacokinetic in healthy subjects 2012N151537

67 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING112934 (ETV plasma) RD2008/01746; Effects of darunavir/ritonavir plus etravirine (n=4 at each of 3 1.6% to 5.5% 2.8% to 5.4% RD2009/00734 Supplemental: and lopinavir/ritonavir plus etravirine on levels) 2012N151538 DTG in healthy adult subjects ING111854 (ATV plasma) RD2009/00531; (n=8 at each of 3 Effects of atazanavir/ritonavir or atazanavir 1.2% to 2.2% 0.5% to 3.9% RD2009/01304 Supplemental: levels) on DTG in healthy subjects 2012N152554 ING111855 (EE plasma) Effects of DTG on an oral contraceptive (n=10 at each of 5 3.5% to 6.6% 0.7% to 4.3% 2012N135878 2012N151915 containing norgestimate and ethinyl levels) estradiol in healthy women subjects ING111855 (NGMN plasma) Effects of DTG on an oral contraceptive (n=12 at each of 5 2.4% to 13.1% -5.8% to 4.2% 2012N135879 2012N151913 containing norgestimate and ethinyl levels) estradiol in healthy women subjects ING113068 (APV) CD2004/00524 Effects of fosamprenavir on DTG and (n=6 at each of 3 1.9% to 16.6% -7.0% to 3.0% 2011N117085 Supplemental: relative bioavailability of three tablet levels) 2012N134430 variants ING115698 (R-MTD plasma) (n=8 at each of 5 Effect of DTG on methadone in opiate- 1.8% to 3.3% -3.3% to -0.9% 2012N132495 2012N133617 levels) dependent, HIV seronegative subjects. ING115698 (S-MTD plasma) (n=8 at each of 5 Effect of DTG on methadone in opiate- 2.0% to 4.9% -4.6% to -1.9% 2012N132495 2012N133617 levels) dependent, HIV seronegative subjects. ING114005 (EFV plasma) RD2010/00300; (n=6 at each of 3 Effect of efavirenz on DTG in healthy 2.4% to 5.8% 1.5% to 12.4% RD2010/00560 Supplemental: levels) subjects. 2011N112543

68 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Total number of QC Overall precision Accuracy Bioanalytical Validation Report Study (Analyte) and Abbreviated Title samples (%CV range) (%bias range) Report Number Number(s) ING114581 (ABC plasma) Relative bioavailability of two fixed-dose (n=22 at each of 4 3.4% to 6.2% -3.2% to 3.5% 2011N120847 2012N133184 combination tablets vs single DTG plus levels) Epsicom in healthy adult subjects ING114581 (3-TC plasma) 2012N133186; Relative bioavailability of two fixed-dose n=20 at each of 4 2.1% to 4.7% -2.8% to 4.7% 2011N120850 Supplemental: combination tablets vs single DTG plus levels) 2012N152558 Epsicom in healthy adult subjects ING114819 (PAH plasma) (n=14 at each of 4 -3.2% to Effect of DTG on Iohexol and PAH 2.1% to 3.4% 2011N115785 2010N111322 levels) 10.9% Clearance in Healthy Subjects ING114819 (IHX plasma) 2010N111226; (n=19 at each of 4 Effect of DTG on Iohexol and PAH 4.8% to 13.3% -8.4% to 5.3% 2011N113437 Supplemental: levels) Clearance in Healthy Subjects 2012N150761 ING115697 (TPV plasma) (n=4 at each of 5 Effect of boceprevir and telaprevir on DTG 2.3% to 8.6% -2.3% to 8.8% 2012N140716 2012N150656 levels) pharmacokinetics in healthy adult subjects LAI116181 (RPV plasma) (n=26 at each of 3 Evaluation of the pharmacokinetic of DTG 3.1% to 5.8% -5.9% to 2.6% 2012N143230 2012N144315 levels) and RPV in healthy adult subjects. Overall Precision = combined within and between run variability. All plasma samples were analyzed within the duration for which long term stability has been established for each analyte . Following blood collection (with EDTA) for DTG, each site for each study was instructed to place the sample on wet ice and isolate plasma within 1 hour. Samples were to be stored at or below -20°C and shipped: i) directly to the bioanalytical laboratory for Phase 1 studies at the end of the study or as interim shipments, or ii) to a Central laboratory facility (Quest) for Phase 2 and Phase 3 studies in real time where they would be stored at or below -20°C then sent to the bioanalytical facility within a month where they were stored at -20C or below until analyzed. DTG = Dolutegravir, DTG-PB = Dolutegravir Protein Binding, GSK2832500 = dolutegravir glucuronide; ABC=Abacavir; APV = Amprenavir; ATV = Atazanavir, DRV = Darunivir, EFV = Efavirenz, EE = Ethinyl Estradiol, ETV, Etravirine, IHX = Iohexol, 3TC=Lamivudine; LPV, Lopinivir, MDZ = Midazolam, R-MTD = R-Methadone, S-MTD = S-Methadone, NGMN = Norelgestromin, PAH = Para-Aminohippurate, RPV = Rilpivirine, RTV = Ritonavir, TPV = Telaprevir, TFV = Tenofivir,

69 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 14 Tabular Listing of all Biopharmaceutic Studies

Protocol Type of Study Study Key No. of Treatment Details Study Location No. Study Objective(s) Design Inclusion Subjects: (Drug/Dose/Form/Route/Frequency/Duration) Status; of Study Criteria Gender M/F: Type of Report of Mean Age Report Subjects (Range) ING111322 PK Part 1: To Part 1: Healthy Part 1: Part 1: Complete; m5.3.3.1 assess safety, DB, Subjects 32: 27/5 DTG/ 10 to 50 mg/ suspension/ oral/ QD/ 10 days Full tolerability and PLC, 31.7 (18-50) PK of repeat DR, PRL Part 2: doses of DTG Part 2: DTG / 20 mg/ suspension, tablet/ oral/ singe-dose 12: 12/0 Part 2: To Part 2: 30.8 (18-50) assess safety, O, UC, tolerability and XO PK of single doses of DTG suspension and single doses of DTG tablets with or without food ING113068 Drug To investigate Part A Healthy Part A Part A Complete; m5.3.3.4 interaction; the effects of O, UC, Subjects 12: 10/2 Period1: DTG/ 50 mg/ tablet/ oral/ QD/ 5 days Full PK fosamprenavir XO 33.4 (24-55) (FPV)/ RTV on Period 2: DTG/ 50 mg/ tablet/ oral/ QD/ 10 days the steady- Part B ), Part B FPV 700 mg / RTV 100 mg/ tablet/ oral/ q12h/ 10 days state PK of UC, XO 15: 4/11 DTG and to 34.7 (20-60) Part B evaluate DTG/ 50 mg/ tablet/ oral/ single dose relative micronized drug substance, unmicronized drug bioavailability substance, intermediate particle size drug substance of tablets with varying particle

70 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Protocol Type of Study Study Key No. of Treatment Details Study Location No. Study Objective(s) Design Inclusion Subjects: (Drug/Dose/Form/Route/Frequency/Duration) Status; of Study Criteria Gender M/F: Type of Report of Mean Age Report Subjects (Range) size INGII3674 PK To evaluate O, UC, Healthy 24: 10/14 Part A Complete; m5.3.1.2 relative XO r Subjects 38.6 (20-61) DTG/ 50 mg/ tablet/ oral/ single dose Full bioavailability study of three Part B different tablet DTG/ 50 mg/ tablet/ oral/ single dose formulations of low fat meal, moderate fat meal, high fat meal DTG 50 mg and and effect of food on the selected formulation ING112941 PK, Drug To evaluate Part 1: Healthy Part 1: Part 1: Complete; m5.3.3.4 interaction the effect of a O,UC, Subjects 14: 12/2 Period 1: DTG/ 50 mg/ tablet/ oral/ single-dose, fasted Full high fat meal R, XO 40.6 (23-55) Period 2: DTG/ 50 mg/ tablet/ oral/ single-dose, high fat and meal omeprazole on Part 2: Part 2: Period 3: DTG/ 50 mg/ tablet/ oral/ single-dose DTG PK and to DB, 10: 9/1 Omeprazole/ 40 mg/ capsule/ oral/ QD/ 5 days evaluate the PLC, R 38.4 (21-54) safety and PK Part 2: of a 250 mg DTG/ 250 mg/ suspension/ oral/ single dose dose of DTG Degree of Blinding Degree of Control Treatment Assignment Treatment Sequence M - Male O = Open UC = Uncontrolled R = Random PRL = Parallel F - Female SB = Single Blind PLC = Placebo NR = Nonrandom XO = Crossover DB = Double Blind AC = Active control DR = Dose Rising

71 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Appendix Table 15 Summary Results of all Biopharmaceutic Studies

Part 2: To assess Part 2: O, DTG/ 25 mg/ suspension/ oral/ 3.09 (26) 1.00 38.4 (23) 15.0 safety, tolerability UC, XO QD/ 10 days (0.50-2.00) (16) and PK of single doses of DTG suspension and 6.16 (15) 1.00 76.8 (19) 15.3 single doses of DTG/ 50 mg/ suspension/ oral/ (0.50-2.00) (8) DTG tablets with or QD/ 10 days without food Part 2: 12: 12/0 Part 2: 2.24 (17) 0.75 33.5 (28) 13.5 30.8 (18-50) DTG / 20 mg/ suspension/ oral/ (0.50-1.50) (18) Healthy subjects singe-dose 1.30 (30) 2.50 23.5 (38) 13.3 (1.50-4.0) (15) DTG / 20 mg/ tablet fasted/ oral/ singe-dose 1.44 (16) 3.00 26.0 (33) 13.6 (0.50-6.0) (17) DTG / 20 mg/ tablet fed/ oral/ singe-dose

72 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

Protocol Study Study No. of Treatment Details Geometric Mean Parameters (CV%) Study No. Objective(s) Design Subjects (Drug/Dose/ Report (M/F) Age Form/Route/ Location Mean(Range) Frequency) Subject type Cmax tmax(hr) AUC(0-)a t1/2 (g/mL) Median (g/mL (hr) (Range) x hr) ING113068 To investigate the Part A O, Part A Part B m5.3.3.4 effects of UC, XO 12: 10/2 DTG/ 50 mg/ tablet/ oral/ single 1.56 (56) 3.0 34.7 (54) 15.9 fosamprenavir 33.4 (24-55) dose/micronized (0.5-6.0) (18) (FPV)/ RTV on the Part B ), Healthy subjects steady-state PK of UC, XO DTG/ 50 mg/ tablet/ oral/ single 1.72 (35) 3.0 34.6 (44) 15.1 DTG and to Part B dose/unmicronized (0.5-4.0) (16) evaluate relative 15: 11/4 bioavailability of 34.7 (20-60) DTG/ 50 mg/ tablet/ oral/ single 2.04 (38) 2.0 41.0 (43) 15.3 tablets with varying Healthy subjects dose/intermediate (0.5-6.0) (15) particle size ING113674 To evaluate relative O, UC, 24: 10/14 Part A m5.3.1.2 bioavailability study XO r 38.6 (20-61) DTG/ 50 mg/ tablet/ oral/ single of three different Healthy subjects dose/ formulation AP 2.67 (35) 3.00 53.2 14.2 tablet formulations (1.0-5.0) (34) (19) of DTG 50 mg and and effect of food DTG/ 50 mg/ tablet/ oral/ single on the selected dose/ formulation AW 2.64 (30) 2.56 50.6 14.1 formulation (1.0-6.0) (27) (21) DTG/ 50 mg/ tablet/ oral/ single dose/ formulation AX 2.77 (32) 2.04 53.7 14.4 (1.0-4.0) (34) (19)

Part B DTG/ 50 mg/ tablet/ oral/ single 2.65 (28) 2.06 50.3 14.1 dose, fasted (1.0-5.0) (27) (22)

73 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods

DTG/ 50 mg/ tablet/ oral/ single 3.88 21) 3.0 66.7 13.4 dose, low fat (2.0-5.1) (35) (19)

DTG/ 50 mg/ tablet/ oral/ single 4.44 (24) 5.0 83.6 13.4 dose, high fat (1.0-8.0) (35) (21)

DTG/ 50 mg/ tablet/ oral/ single 4.03 (19) 4.0 71.0 13.5 dose, mod fat (2.0-6.0) (31) (19) ING112941 To evaluate the Part 1: Part 1: Part 1: m5.3.3.4 effect of a high fat O,UC, R, 14: 12/2 Period 1: DTG/ 50 mg/ tablet/ meal and XO 40.6 (23-55) oral/ single-dose, fasted 1.84 (44) 4.0 34.7 14.4 omeprazole on Healthy subjects Period 2: DTG/ 50 mg/ tablet/ (1.0-5.0) (57) (21) DTG PK and to Part 2: oral/ single-dose, high fat meal evaluate the safety DB, PLC, Part 2: Period 3: DTG/ 50 mg/ tablet/ and PK of a 250 R 10: 9/1 oral/ single-dose fasted with 3.39 (17) 4.50 67.2 13.9 mg dose of DTG 38.4 (21-54) omeprazole/ 40 mg/ capsule/ (2.98-8.0) (24) (19) Healthy subjects oral/ QD/ 5 days

1.69 (19) 3.0 34.8 16.3 (1.0-5.03) (26) (20)

74 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods a. AUC(0-) for ING111322 Part 1 Cmax=maximum concentration tmax=first occurrence of Cmax AUC(0-)=area under the plasma concentration versus time curve from time 0 and extrapolated to infinity t1/2=apparent plasma half-life R&D=research and development

75 m2.7.1

Storage and Stability Data for Clinical Pharmacology Studies a, b

ING111853 ING113099, or ) except ING111854 the longest for the following At least 93 ING111856 duration of studies: days at -70°C ING112934 storage was ING112941 103 days at ING113097 (76 stability ING113068 -70°C) days until At least 26 ING113096 analysis) ING113097 ING113125 hours at ING113125 (137 days until ambient ING113674 analysis) temperature ING114005 ING116070 ING114819 (158 days until ING116070 analysis) ING111855 ING113099 ING114556 ING114581 ING115381 ING115696 ING115697 ING115698 LAI116181

m2.7.1

Analyte and Temp and Temp and Maximum Temp and Temp and Study # duration of duration of duration of duration of duration of sample sample storage prior sample long Term storage at storage at to shipment to storage at stability data clinical site central bioanalytical bioanalytical laboratory site site (site) (DTG in CSF) Samples not not applicable See column 2 Samples stored At least 226 ING116070 stored at at -20°C and days at -20°C clinical site. analyzed within and -70°C in Shipped to 160 days of CSF: Plasma bioanalytical receipt ( ) (1:1) site in real At least 6.5 time - hours at maximum ambient storage < 48 temperature hrs at -20°C (DTG Samples not applicable See column 2 Samples stored At least 127 glucuronide) stored for ≤ 61 at -20°C and days at -20°C ING113125 days at -20°C analyzed within At least 24 (shipped 85 days of hours at monthly) receipt (GSK) ambient temperature (darunavir) Samples not applicable See column 2 Samples stored At least 54 ING111405) stored for < 1 at -30°C and days at -30°C month at analyzed within At least 24 -70°C 1 month of hours at receipt (GSK) ambient temperature

(midazolam) Samples not applicable See column 2 Samples stored At least 60 ING111322 stored for < 1 at -20°C and days at -20°C month at analyzed within At least 24 -20°C or lower 1 month of hours at receipt (GSK) ambient temperature

(lopinavir) Samples not applicable See column 2 Samples stored At least 54 ING111405) stored for < 1 at -30°C and days at -30°C month at analyzed within At least 24 -70°C 1 month of hours at receipt (GSK) ambient temperature

m2.7.1

(etravirine) Samples not applicable See column 2 Samples stored At least 159 ING111603 stored for < 1 at -30°C and days at -30°C ING112934 month at analyzed within At least 24 -70°C 1 month of hours at receipt (GSK) ambient temperature (tenofovir) Samples not applicable See column 2 Samples stored At least 38 ING111604 stored for < 1 at -30°C and days at -30°C month at analyzed within At least 24 -30°C or 1 month of hours at lower receipt (GSK) ambient temperature (atazanavir) Samples not applicable See column 2 Samples stored At least 53 ING111854 stored for < 1 at -30°C and days at -30°C month at analyzed within At least 24 -25°C 1 month of hours at receipt (GSK) ambient temperature ING113068 Samples not applicable See column 2 Samples stored At least 836 (amprenavir) stored for < 1 at -20°C and days at -20°C month at analyzed within At least 24 -20°C or at 42 days of hours at -70°C receipt ( ambient ) temperature (efavirenz) Samples not applicable See column 2 Samples stored At least 96 ING114005 stored for < 1 at -20°C and days at -20°C month at analyzed within At least 24 -20°C or 1 month of hours at lower receipt (GSK) ambient temperature m2.7.1

Analyte and Temp and Temp and Maximum Temp and Temp and Study # duration of duration of duration of duration of duration of sample sample storage prior sample long Term storage at storage at to shipment to storage at stability data clinical site central bioanalytical bioanalytical laboratory site site (site) (iohexol) Samples not applicable See column 2 Samples stored At least 65 ING114819 stored for < 32 at -20°C and days at -20°C days at -20°C analyzed within At least 4 1 month of hours at receipt ( ) ambient temperature (PAH) Samples not applicable See column 2 Samples stored At least 90 ING114819 stored for < 32 at -20°C and days at -20°C days at -20°C analyzed within At least 4 1 month of hours at receipt ( ) ambient temperature (telaprevir) Samples not applicable See column 2 Samples stored At least 24 ING115697 stored for < 1 at -20°C and days at -20°C month at analyzed within or -70°C -70°C 117 days of At least 24 receipt ( ) hours at room temperature

(long term stability data pending; to be submitted within 30 days of file) (R and S Samples not applicable See column 2 Samples stored At least 365 methadone) stored for < 1 at -20°C and days at -20°C ING115698 month at analyzed within and 280 days -20°C 1 month of at -70°C receipt ( ) At least 28 hours at ambient temperature

(rilpivirine) Samples not applicable See column 2 Samples stored At least 1528 LAI116181 stored for < 1 at -20°C and days at -18°C month at analyzed within -20°C or lower 1 month of receipt ( ) m2.7.1

Analyte and Temp and Temp and Maximum Temp and Temp and Study # duration of duration of duration of duration of duration of sample sample storage prior sample long Term storage at storage at to shipment to storage at stability data clinical site central bioanalytical bioanalytical laboratory site site (site) (ethinyl estradiol) Samples not applicable See column 2 Samples stored At least 811 ING111855 stored at at -70°C and days at -70°C -70°C and analyzed within At least 28 shipped 1 month of hours at monthly receipt ( ) ambient temperature (norelgestromin) Samples not applicable See column 2 Samples stored At least 515 ING111855 stored at at -70°C and days at -70°C -70°C and analyzed within At least 24 shipped 73 days of hours at monthly receipt ( ) ambient temperature m2.7.1

sample storage < 14 At least 93 days days at -70°C ING112276 Samples not Samples < 16 days Samples stored (SPRING-1; stored at stored at at -30°C and stability DTG) clinical site. -20°C and analyzed within At least 26 Shipped in real shipped to 1 month of hours at time - bioanalytical receipt ambient maximum lab bi-weekly temperature storage < 48 therefore

hrs at -20°C sample storage < 14 days ING113086 Samples < 32 days Samples stored (SPRING-2; stored at at -20°C and DTG) -20°C and analyzed within shipped to 52 days of bioanalytical receipt lab monthly therefore sample storage < 30 days m2.7.1

hrs at -20°C sample storage < 30 At least 93 days days at -70°C ING112574 Samples < 32 days Samples stored (VIKING-3; DTG) stored at at -20°C and stability -20°C and analyzed At least 26 shipped to between 1 and hours at bioanalytical 6 months of ambient lab monthly receipt temperature with additional

ad hoc shipments toward end of trial therefore sample storage < 30 days ING111762 Samples < 32 days Samples stored (SAILING; DTG) stored at at -20°C and -20°C and analyzed shipped to between 1 and bioanalytical 9 months of lab monthly receipt with additional ad hoc shipments toward end of trial therefore sample storage < 30 days a. All clinical sample and QC anticoagulants were the same as used during the validation procedure. b. For all analytes, samples were analyzed within the stability window. Original Revision CTD2.7.2 p.159 Protocol No. : ING112578 Study Start; Enrolments Status and Date; Total Enrolmrnt/Target Enrolment Start 16 March 2011; Start 16 March 2011 20 April 2011; Ongoing; 22/168 Ongoing; 22/168 CTD2.7.2 p.76（Table 36） Subgroup : Co-administration of Moderate/Strong Metabolic (CYP3A/UGT) Inducers C0_avg (μg/mL) Inducers Not Co-administered (n=103) Inducers Not Co-dministered (n=103102)

CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Module 2.7.2 Summary of Clinical Pharmacology

1 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

TABLE OF CONTENTS

PAGE

ABBREVIATIONS ...... 5

1. BACKGROUND AND OVERVIEW OF CLINICAL PHARMACOLOGY ...... 9 1.1. Overview of Clinical Pharmacology Studies...... 9 1.2. Key Characteristics of Clinical Pharmacology of Dolutegravir ...... 9 1.3. General Design and Analysis Features...... 13 1.3.1. Selection of Study Population ...... 13 1.3.2. Selection of Dose and Dosing Regimen...... 13 1.3.3. PK Sampling Approach...... 14 1.3.4. Drug-Drug Interactions...... 15 1.3.4.1. Drug Interaction at the Level of Absorption...... 15 1.3.4.2. Drug Interaction at the Level of Distribution ...... 16 1.3.4.3. Drug Interaction at the Level of Metabolism...... 17 1.3.4.4. Drug Interaction at the Level of Drug Elimination through Transporters...... 18 1.3.5. Special Populations ...... 18 1.3.5.1. Renal and Hepatic Impairment ...... 18 1.3.5.2. Pediatric Patients ...... 19 1.3.5.3. Gender, Race, and Age (Elderly)...... 19 1.3.5.4. HBV/HCV Co-infection ...... 20 1.3.5.5. UGT1A1 Polymorphism...... 20 1.3.6. Pharmacokinetic-Pharmacodynamic Analysis and Dose Selection...... 20

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES...... 21 2.1. Pharmacokinetics ...... 21 2.1.1. Pharmacokinetics in Healthy Subjects ...... 21 2.1.1.1. Study ING111207 (Single Dose, Suspension/Solution, 2 to 100 mg)...... 21 2.1.1.2. Study ING112941 (Single Dose, Suspension, 250 mg)...... 23 2.1.1.3. Study ING111322 (Repeat Dose, Suspension/Solution, 10 to 50 mg Once Daily)...... 24 2.1.1.4. Study ING114005 (Single Dose, Tablet, 50 mg and 100 mg) ...... 26 2.1.1.5. Study ING111853 (Single Dose, Human Mass Balance) ...... 27 2.1.1.6. Study ING115465 (Female Genital Tract)...... 30 2.1.1.7. Study ING116195 (Male Genital Tract)...... 32 2.1.2. Pharmacokinetics in Special Populations...... 34 2.1.2.1. Study ING115381 (Japanese) ...... 34 2.1.2.2. Study ING113097 (Moderate Hepatic Impairment) ...... 35 2.1.2.3. Study ING113125 (Severe Renal Impairment)...... 37 2.1.2.4. Study ING112578 (Pediatric)...... 39 2.1.3. Pharmacokinetic Interactions...... 42 2.1.3.1. Study ING111322 (Midazolam)...... 42

2 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

2.1.3.2. Study ING111405 (Lopinavir/ritonavir, Darunavir/ritonavir)...... 43 2.1.3.3. Study ING111602 (Antacid, Multivitamins) ...... 44 2.1.3.4. Study ING111603 (Etravirine)...... 45 2.1.3.5. Study ING111604 (Tenofovir)...... 46 2.1.3.6. Study ING111854 (Atazanavir, Atazanavir/ritonavir)...... 47 2.1.3.7. Study ING111855 (Oral Contraceptives) ...... 47 2.1.3.8. Study ING112934 (Etravirine/lopinavir/ritonavir, Etravirine/darunavir/ritonavir)...... 48 2.1.3.9. Study ING112941 (Omeprazole) ...... 49 2.1.3.10. Study ING113068 (Fosamprenavir/Ritonavir) ...... 50 2.1.3.11. Study ING113096 (Tipranavir/Ritonavir) ...... 51 2.1.3.12. Study ING113099 (Rifampin, Rifabutin)...... 51 2.1.3.13. Study ING114005 (Efavirenz)...... 52 2.1.3.14. Study ING115696 (Prednisone)...... 54 2.1.3.15. Study ING115697 (Telaprevir, Boceprevir) ...... 54 2.1.3.16. Study ING115698 (Methadone)...... 55 2.1.3.17. Study LAI116181 (Rilpivirine) ...... 56 2.2. Clinical Pharmacodynamics...... 57 2.2.1. Properties Related to Therapeutic Effect ...... 57 2.2.1.1. Mechanism of Action of Dolutegravir ...... 57 2.2.1.2. Therapeutic Endpoints Used in Clinical Trials for HIV Treatment...... 57 2.2.2. Other Pharmacological Properties ...... 58 2.2.2.1. Study ING111856 (Definitive QT) ...... 58 2.2.2.2. Study ING114819 (Effect of DTG on Renal Functions) ...... 60 2.3. Pharmacokinetics and Pharmacokinetic-pharmacodynamic Relationship in Target Patient Population ...... 62 2.3.1. PK Sampling and Analysis Strategy...... 62 2.3.2. Overall Strategy of PK/PD Analyses ...... 62 2.3.3. Study ING111521 (10-day Monotherapy, 2-50 mg Once Daily) ...... 63 2.3.4. Study ING112276 (HIV-infected Treatment-Naïve, 10- 50 mg Once Daily) ...... 67 2.3.5. Study ING113086 (HIV-infected Treatment-naïve, 50 mg Once Daily)...... 70 2.3.6. Study ING112961 (HIV-infected Treatment-experienced Integrase-inhibitor-resistant, 50 mg Once Daily and 50 mg Twice Daily) ...... 72 2.3.7. Study ING112574 (HIV-infected Treatment-experienced Integrase-inhibitor-resistant, 50 mg Twice Daily)...... 75 2.3.8. Study ING111762 (HIV-infected Treatment-experienced Integrase Inhibitor-naïve, 50 mg Once Daily) ...... 77 2.3.9. Study ING116070 (Cerebrospinal Fluid) ...... 83

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES ...... 85 3.1. Clinical Pharmacokinetics ...... 85 3.1.1. Summary of Pharmacokinetic Parameters in Healthy Subjects and HIV-infected Subjects...... 85 3.1.2. PK Variability ...... 86

3 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

3.1.3. Absorption ...... 87 3.1.4. Plasma Protein Binding and Distribution ...... 88 3.1.5. Metabolism ...... 89 3.1.6. Excretion...... 91 3.2. PK/PD Relationships and Definition of No Effect Boundaries...... 91 3.2.1. PK/PD Relationship for Efficacy Endpoints ...... 91 3.2.2. PK/PD Relationship for Safety Endpoints...... 93 3.2.3. Definition of No Effect Boundaries of Alteration in DTG Exposure ...... 95 3.2.3.1. Lower Boundary Based on Efficacy ...... 95 3.2.3.2. Upper Boundary Based on Safety ...... 96 3.3. Effect of Intrinsic and Extrinsic Factors on Pharmacokinetics...... 97 3.3.1. Population Pharmacokinetic Analysis in Treatment-Naïve Subjects...... 97 3.3.2. Population Pharmacokinetic Analysis in Treatment- Experienced Subjects ...... 104 3.3.3. Study ING116265 (PGx Analysis)...... 113 3.3.4. Summary ...... 116 3.4. Drug-Drug Interactions...... 117 3.4.1. Supporting Non-clinical Data...... 118 3.4.2. Effect of DTG on the Pharmacokinetics of Co- administered Drug ...... 118 3.4.3. Effect of Co-administered Drug on Pharmacokinetics of DTG...... 121 3.4.3.1. UGT/CYP3A Inhibitors...... 125 3.4.3.2. UGT/CYP3A Inducers ...... 126 3.4.3.3. Metal Cation-Containing Products ...... 127 3.4.4. Summary of Predicted Drug Interaction ...... 128

4. SPECIAL STUDIES...... 130

5. CONCLUSIONS...... 130

6. REFERENCES...... 131

7. APPENDIX...... 134

4 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

ABBREVIATIONS

Ci Microcurie g Microgram M Micromolar z Terminal phase rate constant 3TC Lamivudine AAG 1-acid glycoprotein AIC Akaike’s information criterion AE Adverse event ALT Alanine aminotransferase APV Amprenavir ART Antiretroviral therapy ARV Antiretroviral AST Aspartate aminotransferase ATV Atazanavir AUC Area under the concentration-time curve AUC(0-) Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time AUC(0-24) Area under the concentration-time curve from time zero (pre-dose) to 24 hours post dose or over 24 hours AUC(0-t) Area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration AUC(0-) Area under the concentration-time curve over the dosing interval BCRP Breast cancer resistance protein BCS Biopharmaceutical Classification System BCV Boceprevir BID Twice daily BP Blood plasma BSA Body surface area c Copies (of HIV RNA) CI Confidence interval CL Systemic clearance of parent drug CLIA Clinical Laboratory Improvement Amendments CL/F Apparent clearance following oral dosing C0 Observed pre-dose concentration C0_avg Average pre-dose concentration over time cm Centimeters Cmax Maximum observed concentration Cmin Minimum observed concentration COPD Chronic obstructive pulmonary disease CrCL Creatinine clearance CSF Cerebrospinal fluid Cτ Trough concentration at the end of the dosing interval Cτ,avg Average trough concentration Ct Last observed quantifiable concentration

5 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

CT Cervical biopsy/tissue CV Coefficient of variance CVb Between-subject variability (or coefficient of variation) CVF Cervicovaginal fluid CVw Within-subject variability(or coefficient of variation) CYP Cytochrome P450 CYP3A4 Cytochrome P450 isozyme 3A4 DNA Deoxyribonucleic acid DRV darunavir ECG Electrocardiogram EC90 Concentration at which 90% of the maximal effect is achieved EE Ethinyl estradiol EFV Efavirenz ERDF Efficacy-related discontinuation = failure ERPF Effective Renal Plasma Flow ETR Etravirine EVG Elvitegravir F Bioavailability FC Fold change FPV Fosamprenavir FTC Emtricitabine GFR Glomerular filtration rate GI Gastrointestinal GLS Geometric least-squares GMR Geometric mean ratio h or hr(s) Hour(s) HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus HIV-1 Human immunodeficiency virus, type 1 IC50 Concentration at which 50% of the maximum inhibitory effect is achieved IC90 Concentration at which 90% of the maximum inhibitory effect is achieved IIV Inter-individual variability IMPAACT International Maternal Pediatric Adolescent AIDS Clinical Trials Group IN Integrase INI Integrase inhibitor IOVInter-occasion variability IQ Inhibitory quotient IQR Inter-quartile range KA Absorption rate constant kg Kilogram L Liter LPV Lopinavir MDZ Midazolam

6 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology mg Milligram min Minute mL Milliliter mm3 Cubic millimeter mRNA Messanger ribonucleic acid MRP2 Multidrug resistance-associated protein 2 MSD=F Missing, switch, discontinuation = failure msec Millisecond mSv Millisievert NAG N-acetyl-beta-D-glucosaminidase NGMN Norelgestromin NRTI Nucleoside/nucleotide reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OATP Organic anion-transporting polypeptide OBR Optimized background regimen OC Oral contraceptive OCT2 Organic anion transporter 2 OMP Omeprazole PA Protein-adjusted PAH Para-aminohippurate PBMC Peripheral blood mononuclear cell PD Pharmacodynamic PDVF Protocol-defined virologic failure Pgp P-glycoprotein PGx Pharmacogenetics PI Protease inhibitor PIQ Phenotypic inhibitory quotient PK Pharmacokinetic PoC Proof of concept PSS Phenotypic susceptibility score PSSf PSS with full sensitivity only PXR Pregnane X receptor QTcB QT duration corrected for heart rate by Bazett’s formula QTcF QT duration corrected for heart rate by Fridericia’s formula R Accumulation ratio RAL Raltegravir RF Rectal mucosal fluid RBT Rifabutin RIF Rifampin RNA Ribonucleic acid RPV Rilpivirine RT Rectal mucosal tissue RTV Ritonavir s Second SD Standard deviation SF Seminal fluid

7 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology t Time of last observed quantifiable concentration t½ Terminal phase half-life τ Dosing interval TB Tuberculosis TDF Tenofovir disoproxil fumarate tlag Lag time before observation of drug concentrations in sampled matrix TLOVR Time to Loss of Virologic Response tmax Time of occurrence of Cmax TPV Tipranivir TVR Telaprevir UGT Uridine diphosphate glucuronosyltransferase UGT1A1 Uridine diphosphate glucuronosyltransferase isozyme 1A1 VT Vaginal biopsy/tissue V/F Apparent volume of distribution Vz/F Apparent volume of distribution after extravascular (e.g., oral) administration at terminal phase

Trademark Information

Trademarks of ViiV Healthcare Trademarks not owned by ViiV Healthcare NONE Affymetrix Glucophage Incivek Maalox One A Day Sustiva

8 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

1. BACKGROUND AND OVERVIEW OF CLINICAL PHARMACOLOGY

Dolutegravir (DTG, S/GSK1349572) is a human immunodeficiency virus (HIV) integrase inhibitor (INI) developed for the treatment of HIV infections. This module provides a summary of human pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of DTG to support the following recommended doses of DTG, in combination with other antiretroviral therapy (ART) agents, for the treatment of HIV infection in adults and children 12 years of age (weighing at least 40 kg), based on prior treatment experience:

 Treatment-naïve adults: DTG 50 milligrams (mg) once daily;  Treatment-experienced, integrase inhibitor-naïve adults: DTG 50 mg once daily;  Integrase inhibitor-resistant adults: DTG 50 mg twice daily;  Integrase inhibitor-naïve children of 12 - <18 years of age and weighing 40 kg: DTG 50 mg once daily.

Section 1 of this module gives an overview of clinical pharmacology evaluations and key clinical pharmacology characteristics of DTG, as well as provides a summary of the general design and analysis features of the clinical pharmacology studies. Section 2 of this module presents a summary of results from individual studies. Section 3 of this module provides cross-study comparisons and analyses. Section 4 of this module presents a summary of special studies (Summary of Microbiology/Virology) which is provided as a stand-alone module 2.7.2.4. Clinical pharmacology conclusions are provided in Section 5. A summary of safety data from clinical pharmacology studies is included in m2.7.4 Clinical Summary of Safety.

1.1. Overview of Clinical Pharmacology Studies

The summary of PK, PD, and PK/PD relationships of DTG provided in this module is based on clinical pharmacology studies conducted in healthy subjects (26 studies) and HIV-negative subjects with hepatic or renal impairment (2 studies), as well as clinical Phase II/III studies in HIV-infected subjects (8 studies).

A tabular list of all clinical pharmacology studies is provided in Appendix Table 1. Summaries of single- and repeat-dose DTG PK parameters from all clinical pharmacology studies and clinical studies in HIV-infected subjects are presented in Appendix Table 2 and Appendix Table 3, respectively. Summary of PK parameters of co- administerd drugs from clinical pharmacology studies are presented in Appendix Table 4.

1.2. Key Characteristics of Clinical Pharmacology of Dolutegravir

Based on comprehensive, clinical pharmacology evaluations, DTG can be described with the following characteristics:

9 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Pharmacokinetics (PK):

 DTG is rapidly absorbed following oral administration of the tablet formulation, with tmax observed at 2-4 hours post dose, and a terminal t1/2 of approximately 14 hours; the estimated CL/F and V/F are 0.56L/h and 12.5L for suspension formulations and 0.90 L/h and 17.4 L for tablet formulations;  DTG PK exposure from the tablet formulation increased less than proportionally with doses from 10 mg to 100 mg; however exposure from 25 mg to 50 mg is proportional to increases in dose;  Following repeat dosing, steady state was achieved after approximately 5 days of dosing, and DTG showed time-invariant PK; accumulation ratios after 50 mg once daily dosing were 1.43, 1.36, and 1.42 for AUC(0-), Cmax, and C, respectively;  DTG PK is similar between healthy and HIV-infected subjects;  DTG has low to moderate between-subject and within-subject PK variability, and variability is higher in HIV-infected subjects than healthy subjects: the between- subject variability in HIV-infected subjects were estimated at 30-50% for AUC and Cmax, and at 55-140% for trough concentration;  There is no clinically-significant food effect and DTG can be taken without regard to meals (m2.7.1, Section 3);  DTG is highly bound to plasma protein with estimated percentage bound in human plasma of 98.9-99.7% in healthy subjects and 99.5% in HIV-1 infected subjects;  DTG is present in cerebrospinal fluid (CSF) at levels similar to the unbound concentration in plasma and demonstrates potent antiviral activity in CSF as part of a combination regimen with abacavir and lamivudine; DTG is present in the female and male genital tract; AUC in cervicovaginal fluid, cervical tissue, and vaginal tissue were 6 to 10% of that in corresponding plasma at steady-state; AUC was 7% in semen and 17% in rectal tissue of the plasma AUC at steady-state;  Unchanged DTG is eliminated primarily through hepatic metabolism with minimal renal excretion (<1% of dose administered orally); uridine diphosphate (UDP) glucuronosyltransferase isozyme 1A1 (UGT1A1) is the primary route of metabolism with cytochrome P450 (CYP) 3A4 as a notable secondary metabolic pathway;  DTG demonstrates minimal or no direct inhibition of CYP isozymes, UGT1A1, UGT2B7, and many transporters (Pgp, BCRP, OATP1B1, OATP1B3, MRP2, and OCT1), and is not an inducer of CYP1A2, CYP2B6, or CYP3A4;  Drug interactions:  No clinically significant drug interactions were observed between DTG and midazolam (MDZ), oral contraceptives containing norgestimate and ethinyl estradiol (EE), methadone, multivitamins, omeprazole (OMP), prednisone, rifabutin (RBT), tenofovir (TDF), rilpivirine (RPV), darunavir/ritonavir (DRV/RTV), lopinavir (LPV)/RTV, etravirine (ETR)/LPV/RTV, ETR/DRV/RTV, fosamprenavir (FPV)/RTV, boceprevir (BCV), and telaprevir (TVR);

10 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 DTG should be administered at least 2 hours before or 6 hours after polyvalent metal cation-containing antacids; plasma DTG exposure was reduced 74% when co-administered with the antacid Maalox (aluminium hydroxide/magnesium hydroxide/simethicone);  Due to more than 80% reduction in DTG C by ETR, DTG should not be dosed with ETR alone; the co-administration of DTG with ETR is only permitted if the subject is also receiving concomitant RTV-boosted protease inhibitors (PIs) including LPV/RTV, DRV/RTV, and atazanavir (ATV)/RTV;  Plasma DTG C was reduced by about 75% when co-administered with the moderate/strong UGT1A1/CYP3A4 inducers rifampin (RIF), efavirenz (EFV), and tipranivir (TPV)/RTV; a DTG 50 mg twice daily dose should be given when co-administered with these inducers; caution should be given in INI-resistant patients;  Plasma DTG AUC(0-) was increased by 62% and 91% when co-administered with the potent UGT1A1 inhibitor ATV/RTV and ATV, respectively; no DTG dose adjustment is required based on accumulated safety data;  DTG inhibits the renal organic anion transporter 2 (OCT2); DTG should not be administered with OCT2 substrates having narrow therapeutic indices; DTG is contraindicated in combination with dofetilide; metformin concentrations may be increased by DTG; subjects should be monitored during therapy and a dose adjustment of metformin may be required;  No dose adjustment for DTG is needed in subjects with mild to moderate hepatic impairment (Child-Pugh grade A or B); Data in severe hepatic impairment has not been generated;  No dose adjustment for DTG is needed in subjects with mild, moderate, or severe (CrCL <30 mL/min, not on dialysis) renal impairment;  No dose adjustment for DTG is needed in subjects with genotypes conferring poor metabolizer status of UGT1A1 (*28/*28; *28/*37; *37/*37);  PK in adolescents of 12 - <18 years of age and at least 40 kg of body weight is similar to adults, and therefore, INI-naïve paediatric subjects can take the adult dose of 50 mg once daily;  DTG can be used in hepatitis B virus (HBV) or hepatitis C virus (HCV) co-infected subjects:  HCV co-infection has no effect on DTG PK based on population PK modelling; PK data on HBV co-infected subjects are limited;  There was no drug interaction or no drug interaction is anticipated between DTG and commonly used drugs for the treatment of HBV and HCV infections;  There is no clinically significant effect of age, weight, gender, race, ethnicity, smoking, and disease status (CDC classification of HIV infection) on DTG PK, and therefore, no dose adjustment of DTG is needed in subjects based on these characteristics; PK data on subjects of 65 years of age are limited.

11 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Pharmacodynamics:

 DTG has no effect on cardiac repolarization at a supratherapeutic dose of 250 mg (suspension);  DTG demonstrated a nonpathological effect of increasing creatinine levels due to inhibition of secretion by OCT2 transporter with no effect on glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).

Pharmacokinetic-Pharmacodynamic Relationship:

 In a 10-day monotherapy study in HIV-infected, INI-naïve subjects, a significant correlation between DTG plasma exposure and plasma HIV ribonucleic acid (RNA) measures (log10 reduction in plasma HIV-1 RNA to Day 11 from Baseline) was observed. Greater antiviral activity was associated with higher DTG plasma exposure. Such relationship was best described by an Emax model and DTG trough concentration, C, was identified as the best predictor for antiviral activity; DTG exposure from 10 mg once daily dose is around EC90 of this model and DTG exposure from 50 mg once daily is at the plateau of curve;  In HIV-infected, ART-naïve subjects where DTG was given in combination with dual nucleos(t)ide reverse transcriptase inhibitors (NRTIs), no relationship between DTG dose/exposure and virological response was observed at doses ranging from 10 to 50 mg once daily. The lack of PK-PD relationship is due to the potency of combination therapy resulting in more than 78% of subjects on DTG treatments achieving HIV-1 RNA values <50 copies (c)/mL at Week 96 in the Phase IIb study ING112276 and an 88% response rate at Week 48 in the Phase III study ING113086;  In HIV-infected, ART-experienced, INI-naïve subjects taking DTG in combination with at least 1 active agent in their background regimen, DTG trough concentration (i.e., the observed pre-dose concentration [C0]) was a statistically significant predictor of virological response at Week 24 when using all available data, but was not a predictor of virological response when subjects with moderate/strong inducers in their background therapy (e.g., TPV/RTV, EFV, and ETR without RTV-boosted PIs) and noncompliant subjects were excluded;  In HIV-infected, INI-resistant subjects in the Phase III study, DTG exposure, (i.e., C0), was not statistically significantly correlated with virological response observed (Day 8 and Week24);  Plasma DTG exposure was not correlated with the presence of the most frequent adverse events (AEs), including diarrhea, nausea, and headache, or with most clinical laboratory tests of interest. There was a statistically significant correlation between DTG exposure and increase from Baseline in total bilirubin (likely due to competition with UGT1A1) and serum creatinine (due to known OCT2 inhibition); however, such relationships are not considered clinically significant as the changes in total bilirubin and creatinine were small and non-progressive.

12 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

1.3. General Design and Analysis Features

This section discusses the overall design features of the DTG clinical pharmacology program, including selection of study populations, selection of dose, the PK sampling and analysis strategy, evaluations of drug interactions, assessments in special populations, and PK/PD analyses.

1.3.1. Selection of Study Population

Evaluation of DTG PK was conducted in both HIV-negative subjects (healthy subjects and subjects with hepatic or renal impairment) as well as HIV-positive subjects. Evaluation of food effects, formulations, drug-drug interactions, and enzyme polymorphisms were primarily performed in HIV-negative, healthy subjects. Evaluations of the effects of hepatic and renal impairment were conducted in HIV-negative subjects. Effects of intrinsic factors, including age, gender, body size, and race/ethnicity, and extrinsic factors, including HBV/HCV co-infection, were primarily evaluated in HIV- positive subjects using a population PK modelling approach. As DTG PK is similar between HIV-negative and HIV-positive subjects (see Section 3.1.1 for details), findings from HIV-negative subjects can be applied to HIV-positive subjects.

1.3.2. Selection of Dose and Dosing Regimen

Since DTG 50 mg is the clinical dose evaluated in Phase III, this dose was used in most Phase I studies. For studies requiring repeat doses of DTG, DTG 50 mg once daily was typically used as it is the recommended dose for INI-naïve patients, which represent the majority of the HIV-infected population to be treated by this compound. Studies that used DTG 50 mg once daily include drug interaction studies that focus on evaluating the effect of co-administered drugs on DTG PK, as well as tissue compartment studies that evaluate tissue penetration of DTG (e.g., cerebrospinal fluid, male genital tract, and female genital tract). DTG 50 mg twice daily (BID) is only recommended for INI-resistant patients, which represent a very small portion of the HIV-infected patient population to be treated by this compound. For drug interaction studies that focus on evaluating the effect of DTG on co-administered drugs (e.g., oral contraceptives, methadone), DTG 50 mg twice daily dose was selected. As DTG PK is dose proportional from 50 mg once daily to 50 mg twice daily (Section 3.3.2; Table 45), the effects of interacting drugs on DTG PK observed at DTG 50 mg once daily dosing can be applied to DTG 50 mg twice daily dosing. The effects of metabolic inducers/inhibitors on DTG PK parameters from DTG 50mg twice daily were estimated using the population PK model developed based on pooled PK data from treatment-experienced subjects in Phase IIb/III studies (m5.3.3.5, Population PK in ART-experienced, Section 4).

Exceptions to dosing with 50 mg occurred within the following studies, with reasons for selection of a DTG dose other than 50 mg listed below:

 A single supratherapeutic dose of DTG 250 mg, using a suspension formulation, was selected for the definitive QT study in order to achieve supratherapeutic exposure (Study ING111856; Section 2.2.2.1).

13 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 A single oral dose of DTG 20 mg, using a suspension formulation, was selected for the human mass balance study (Study ING111835; Section 2.1.1.5). This study was conducted prior to Phase IIb when the therapeutic dose of DTG had yet to be established. A DTG dose of 20 mg was selected because it fell within the dose range evaluated in healthy subjects and in the Phase IIa study. In addition, the DTG exposure from this dose was predicted to be within the toxicity coverage based on the 28-day monkey and rat studies.  A once daily dose of DTG 25 mg, using a suspension formulation, was selected for the evaluation of DTG on CYP3A enzyme activity using MDZ as the probe (Study ING111322; Section 2.1.1.3). Study ING111322 was the first human study evaluating repeat doses of DTG, and therefore, the therapeutic dose of DTG had yet to be established. DTG PK exposure observed from 25 mg once daily (in suspension) in this study was close to that observed for DTG 50 mg once daily using the tablet formulation. Thus, results from this study can be applied to DTG therapeutic dose of 50 mg.  A conservative 30 mg once daily dose of DTG (tablet formulation) was selected for two drug interaction studies with concomitant medications expected to increase plasma DTG exposure, including Study ING111405 (LPV/RTV & DRV/RTV) and Study ING111854 (ATV/RTV & ATV). DTG PK parameters were dose- proportional from 25 mg once daily to 50 mg once daily (Section 2.3.4), and from 50 mg once daily to 50 mg twice daily using tablet formulation (Section 3.1.1), therefore the effects of interacting drugs on DTG PK observed at 30 mg once daily can be applied to 50 mg once daily and twice daily.This is supported by the DTG PK data from a Phase III study (ING111762; Section 2.3.8) which demonstrated the magnitude of the effects of DRV/RTV and ATV or ATV/RTV on DTG trough concentrations (at 50 mg once daily) was similar to those estimated in ING111405 and ING111854 using DTG 30 mg once daily.

For co-administered drugs evaluated in drug interaction studies, in general, the highest clinical dose or the dose with the highest potential for enzyme inhibition or induction was used.

1.3.3. PK Sampling Approach

The parent form of DTG is the active moiety, and it is primarily eliminated through metabolism. DTG metabolites are not expected to have pharmacological effects (m2.4, Section 3.4.2.2). Most importantly, unchanged DTG is the predominant species in the plasma (>97% on average, based on a human mass balance study; see Section 2.1.1.5 for details). Therefore, only DTG were measured in clinical studies, except for the human mass balance study (ING111853), EFV drug interaction study (ING114005), and renal impairment study (ING113125), where metabolites were evaluated as well. Total DTG concentration in plasma was measured in most studies, while unbound DTG concentration in plasma was also measured in the studies for hepatic impairment (ING113097), renal impairment (ING113125), and CNS penetration (ING116070).

14 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

In tissue compartment studies, including male genital tract (ING116915), female genital tract (ING115465), and CNS penetration (ING116070), total DTG concentration in the body fluids or tissues of interest was measured in addition to total DTG plasma concentration.

DTG concentration in various sample matrixes (total DTG in plasma, body fluids, or tissues, and unbound DTG in plasma) was quantified by validated assays (see m2.7.1 for details).

1.3.4. Drug-Drug Interactions

A total of 17 Phase I studies in healthy subjects have been performed to assess the interaction between DTG and various drugs, including antiretrovirals for HIV treatment and non-ART medications expected to be used concomitantly with DTG. Consistent with regulatory guidance document [EMA, 2008], priority was given to ART drugs, drugs for the treatment of concomitant infections (e.g., HCV, HBV, tuberculosis), hormonal contraceptives, drugs for the treatment of metabolic abnormalities, such as hyperlipidemia and gastroesophageal reflux, and therapies used in the management of substance abuse. In general, the development strategy and study design of drug interaction evaluations followed regulatory authority guidance [EMA, 2012; FDA, 2012].

Drug interactions were only evaluated on a pharmacokinetic basis as there is no known mechanistic basis for any pharmacodynamic drug-drug interactions for DTG. Results of drug interaction studies were reported as the geometric least squared mean ratio (GMR) of the PK parameters of the drug of interest, with and without the interacting drug, and its 90% confidence interval (CI). The clinical significance of any alteration in DTG exposure caused by co-administered drugs was judged against the “no effect boundaries” (Section 3.2.3) and dosing recommendations are provided in Section 3.4.

Results from in vitro metabolism and transporter experiments (Section 3.4.1), the finding that DTG has no effect on CYP3A enzyme activity using MDZ as a probe (ING111322), and results from the human mass balance study (ING111853) guided the overall strategy and study design of drug interaction evaluations.

Most drug interaction studies were designed to evaluate the one-way interaction-the effect of the co-administered drug on DTG PK, not vice versa--as data had suggested that DTG is unlikely to be a perpetrator of drug interaction, but possibly a victim (Section 3.4.1).

Consideration was given for drug interaction potential at the levels of absorption, distribution, metabolism, and elimination via transporters.

1.3.4.1. Drug Interaction at the Level of Absorption

DTG is considered a Biopharmaceutical Classification System (BCS) Class II compound (i.e., low water solubility and high permeability, see m2.7.1 for details). Such classification of DTG is consistent with the observations of solubility-limited absorption, less than dose-proportional increases in DTG exposure following tablet dosing (Section 3.1.3), and positive food effect (i.e., food increased DTG exposure; m2.7.1 for

15 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

details). DTG is a substrate of efflux transporters Pgp and BCRP. Currently there is no data on DTG as substrate of other active uptake transporters and efflux transporters such as OATP and MRP2.

Drugs affecting solubility of DTG may affect DTG absorption and overall drug exposure. DTG is a 2-metal-binding integrase inhibitor. The mechanism of action involves binding to magnesium in the active site of the integrase enzyme, preventing insertion of HIV viral DNA into the host cell DNA. As such, DTG is susceptible to chelation-type drug interactions with divalent and trivalent metal cations that lead to reduced water solubility. Therefore a clinical study was conducted to evaluate the effect of widely used antacid and multivitamins products on DTG PK, and to provide guidance for concomitant use. A study evaluating the effect of the proton pump inhibitor OMP was also performed as OMP has been showed to alter exposure of drugs with pH-dependent solubility, including the integrase inhibitor raltegravir (RAL)[Iwamoto, 2009].

Drugs that modulate (inhibit or induce) efflux transporters are unlikely to affect the absorption of DTG due to its high passive and absorptive permeability (estimated at 3x10-4 cm/s across the absorptive pH range of 5.5 to 7.4, m2.4, Section 3.3.2). The EMA guidance document on drug interaction [EMA, 2012] suggests that PK indications of clinically relevant transporter involvement in drug absorption include low bioavailability, erratic or dose-dependent absorption, or CYP3A catalysed intestinal drug metabolism, as well as unexpected in vivo interactions, with effects on intestinal absorption as a possible mechanism. DTG in general does not fit this profile: DTG has a moderate oral bioavailability (at least 47% based on the mass balance study, see Section 2.1.1.5 for details), low to moderate PK variability (Section 3.1.2), no observation of erratic absorption, and low first-pass metabolism (Section 3.1.5). Phase I studies with Pgp/BCRP inhibitors, LPV/RTV (Section 2.1.3.2) and TVR (Section 2.1.3.15), showed no change in DTG PK exposure by these agents. Therefore, drug interactions with other Pgp/BCRP modulators are not expected and additional studies are not needed.

1.3.4.2. Drug Interaction at the Level of Distribution

Interactions affecting distribution include displacement interactions and interactions through modulation of active uptake or efflux transport of the drug [EMA, 2012].

DTG has a relative low volume of distribution. Vd/F is estimated at ~12 L (Section 2.1.1.5) or 0.17 L/kg, which is close to the volume of total water in the extracellular space, and intracellular tissue distribution is expected to be low. Therefore, the involvement of transporters and the effect of transporter modulators on DTG distribution are unlikely to be significant. Although DTG is highly bound to plasma proteins (>99% bound in plasma), the risk of clinically relevant interactions via displacement from plasma protein binding sites is expected to be low. EMA guidance [EMA, 2012] suggests that possible displacement interactions be evaluated for highly bound drugs that have narrow therapeutic windows, high hepatic extraction ratios, high renal extraction ratios, and are administered intravenously. DTG does not meet any of these criteria. Therefore, the potential for drug interactions at the level of distribution is considered low, and thus, studies to evaluate this were not performed.

16 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

1.3.4.3. Drug Interaction at the Level of Metabolism

Interaction at the level of metabolism is the primary focus of drug-drug interaction evaluations for DTG, with studies targeted mainly to drugs that are inhibitors or inducers of UGT1A1 and/or CYP3A4, given that unchanged DTG was primarily eliminated through metabolism (see Section 2.1.1.5), and that DTG is primarily metabolized by UGT1A1 with a notable contribution from CYP3A4 (Section 3.1.5).

For antiretroviral (ARV) drugs, consideration was primarily given to the drugs in the non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) class, as most NNRTIs induce CYP3A (and possibly UGT1A1), most PIs are moderate or strong inhibitors or inducers of CYP3A4, and the RTV component of boosted PI regimens is an inducer of CYP3A and UGT1A1 and an inhibitor of Pgp. The following ARV drugs were evalutated for drug-interaction potential with DTG: NNRTIs including ETR and EFV; PIs including LPV/RTV, DRV/RTV, LPV/RTV/ETR, DRV/RTV/ETR, FPV/RTV, TPV/RTV. A drug interaction study to evaluate the effect of ATV and ATV/RTV was performed as ATV is a potent inhibitor of UGT1A1. Drugs in other ART classes (e.g., NRTIs and entry inhibitors) were not evaluated as they do not affect UGT and CYP3A4 except for TDF, which was studied because it has demonstrated unpredictable interactions.

For non-ART drugs, the following were evaluated in clinical pharmacology studies:

 RIF: a strong inducer of CYP3A, Pgp, and likely UGT1A1; most commonly used anti-tuberculosis (TB) agent; co-administration may be needed in TB co- infected subjects;  RBT: a weaker inducer of CYP3A than RIF; first-line therapy for TB; co- administration may be needed in TB co-infected subjects;  Prednisone: a weak inducer of CYP3A and likely UGT1A1; a corticosteroid frequently used in HIV-infected subjects for various indications including asthma, chronic obstructive pulmonary disease (COPD), immune reconstitution inflammatory syndrome, and severe Pneumocystis pneumonia, etc;  BCV: a strong inhibitor of CYP3A; recently approved HCV therapy; co- administration may be needed in HCV co-infected subjects;  TVR: strong inhibitor of CYP3A and Pgp; recently approved HCV therapy; co- administration may be needed in HCV co-infected subjects;  Methadone: no drug interaction was expected, however, a confirmatory study was conducted as methadone is commonly used in HIV-infected subjects with substance abuse;  Oral contraceptives (OC): no drug interaction was expected, however a confirmatory study was conducted given the widespread use of oral contraceptives in HIV-infected women.

17 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

No drug interaction studies with HMG CoA reductase inhibitors (“statins”), drugs widely used for the treatment of hyperlipidaemia, were performed as statins are mostly substrates of CYP3A4, OATP, and BCRP, which are not affected by DTG. No drug interactions are expected between DTG and statins.

1.3.4.4. Drug Interaction at the Level of Drug Elimination through Transporters

DTG is primarily eliminated through hepatic metabolism with minimal renal excretion (Section 3.1.6), and therefore, drugs affecting transporters involved in drug elimination are unlikely to affect DTG PK.

In vitro, DTG demonstrated little or no direct inhibition (IC50 values >50 M) on most transporters, except for OCT2 (Section 3.4.1). This suggests that DTG has low propensity to cause drug interactions at the transporter level except for OCT2. Therefore, in vivo drug interaction evaluations of the effect of DTG on other drugs at the level of elimination through specific transporters have not been performed. Caution is given to drugs that are OCT2 substrates and have narrow therapeutic windows (see Section 3.4.2 for details). The potential effect of DTG on 3TC and FTC PK through OCT2 inhibition is discussed in Section 3.4.2.

1.3.5. Special Populations

1.3.5.1. Renal and Hepatic Impairment

Evaluation of hepatic and renal impairment on DTG PK were performed using HIV- negative subjects in 2 separate studies in order to provide dosing guidance for HIV- infected subjects with hepatic or renal impairment. A reduced PK study design was used in both studies, and DTG PK from a single dose of 50 mg was evaluated, consistent with recommendations by the FDA and the EMA [FDA, 2003b; FDA, 2010; EMA, 2004; EMA, 2005]. A single dose of DTG was studied, rather than multiple doses, since DTG exhibits time-invariant PK over the dose range of 2-50 mg and there are low concentrations of circulating DTG metabolites, the kinetics of which appear to be formation rate limited. Together, these attributes of DTG allow reliable prediction of multiple-dose PK from single dose PK data. Both total and unbound plasma DTG concentrations were measured in these studies.

As DTG is primarily eliminated through metabolism with minimal renal excretion (<1% of total dose administered), the renal impairment study was performed only in subjects with severely impaired renal function (CrCL <30 mL/min based on 24 hour urine creatinine clearance), and not in subjects on renal replacement therapy (i.e., the worst case scenario), in comparison to a matched group of healthy subjects with normal renal function. Evaluation of DTG PK in subjects with mild or moderate renal impairment was not performed in the Phase I study as severe renal impairment does not affect DTG PK to a clinically significant degree (Section 2.1.2.3). Evaluation of dialysis on DTG PK was not performed. Due to high protein binding in plasma (>99%, Section 3.1.4), it is not expected that dialysis would significantly affect DTG PK.

18 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

The hepatic impairment study used an adaptive design with two parts planned. Part 1 evaluated DTG PK in subjects with moderate hepatic impairment (Child-Pugh grade B) in comparison to a matched group of healthy subjects with normal liver function. PK results from Part 1 were reviewed to determine the need for Part 2, assessing subjects with mild hepatic impairment (Child-Pugh grade A). Given that DTG PK was not anticipated to be altered to a significant extent in moderate hepatic insufficiency and its favorable safety profile to date, evaluation of a reduced dose of DTG (<50 mg) was not necessary in this study. In Phase III studies of DTG, HIV-infected subjects with moderate to severe hepatic impairment were excluded based on Child-Pugh grade B for moderate and grade C for severe impairment. There were no specific inclusion/exclusion criteria related to renal function for Phase III studies; however, any verified Grade 4 laboratory abnormality (with a single repeat test allowed during the Screening period to verify a Grade 4 result) at Screening precluded the subject’s enrolment. Thus, subjects with severe renal impairment were excluded from the Phase III studies. Renal impairment (mild to moderate), liver chemistry including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, and albumin, were evaluated as covariates in the population PK analyses, using pooled PK data from HIV-infected subjects.

1.3.5.2. Pediatric Patients DTG PK, as the primary objective, was evaluated in INI-naïve, HIV-infected pediatric subjects in the on-going, dose-finding, Phase II study ING112578/P1093 conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group. A strategy of fixed doses by weight band was used in this study. DTG PK was evaluated in real time to select the optimal dose for each age cohort by matching AUC(0- ) (primary) and C (secondary) to the predefined target exposure range, based on observed adult PK data at the clinical dose (50 mg once daily). Stage 1 of Cohort 1 (12-18 years of age) was completed with intensive DTG PK data collected in 10 subjects; results are included in this module (see Section 2.1.2.4 for study details).

1.3.5.3. Gender, Race, and Age (Elderly) Gender, race, and age were evaluated as covariates using the population PK analyses, based on pooled DTG PK data obtained from HIV-infected subjects in Phase II and III studies (n=563 for treatment-naïve subjects and n=574 for treatment-experienced subjects) (see Section 3.3 for details). Female subjects accounted for ~20% of total subjects included in the population PK analyses; Caucasians, African Americans, and Asians represent ~60-80%, 10-30%, and ~1%, respectively. There was only 1 subject aged >65 in the population PK analysis in treatment-naïve subjects, and only 11 subjects aged 65yr (~2%) in the population PK analysis in treatment-experienced subjects. A Phase I study was conducted to evaluate the single dose DTG PK in Japanese subjects (ING115381), and data were compared to accumulated single dose DTG PK parameters generated in studies conducted in the US. The effect of gender on DTG PK was evaluated in the definitive QT study (ING111856) in healthy subjects as ~60% of subjects enrolled were female.

19 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

1.3.5.4. HBV/HCV Co-infection

Patients who are HIV-positive are commonly co-infected with HBV or HCV due to shared routes of transmission. HCV co-infection represents about 15-30% of the HIV- infected population. Pegylated interferon alpha and the antiviral drug ribavirin are components of the first-line therapy for HCV. No drug interactions with DTG are expected for either drug due to the lack of overlap in their elimination pathways, and because neither are enzyme inducers or inhibitors. While there are some reports of interferon therapy inhibiting metabolism of CYP3A4, this is not a major pathway for DTG and more potent CYP3A4 inhibitors (i.e., LPV/RTV) have not shown a significant interaction (Section 2.1.3.2). BCV and TVR are recently approved protease inhibitors for HCV treatment. A drug interaction study between these drugs and DTG was conducted (Study ING115697; Section 2.1.3.15).

There is low propensity for drug interactions between DTG and drugs for HBV treatment. HBV drugs, including NRTIs (TDF, lamivudine [3TC], emtricitabine [FTC], adefovir, telbivudine, and entecavir), do not inhibit or induce CYP or UGT enzymes, and therefore, DTG PK is not expected to be affected by HBV drugs. A drug interaction study with tenofovir disproxil fumarate (TDF) was conducted (Study ING111604; Section 2.1.3.5). The potential effect of DTG on 3TC and FTC PK due to OCT2 inhibition by DTG is discussed in Section 3.4.2. 3TC, FTC, and TDF have been used with DTG in Phase III trials. PK data from treatment-naïve trials (where DTG was given together with TDF/FTC or 3TC/abacavir [ABC]) did not demonstrate differences in DTG PK in HIV-1 infected subjects compared to PK data from healthy subject studies (where DTG was given alone) (Table 45), which suggests these antiretroviral drugs did not affect DTG PK. While 3TC and TDF/FTC concentrations were not determined, efficacy/safety data suggests no clinically significant alteration in exposure of either of these NRTIs.

Population PK analyses also evaluated HBV/HCV co-infection as a covariate for DTG PK (see Section 3.3.1 and Section 3.3.2 for details). Effect of HBV and HCV co-infection on safety based on data from Phase IIb/III is summarized in m2.7.4 Section 3.1.1.

1.3.5.5. UGT1A1 Polymorphism

A pharmacogenetics (PGx) meta-analysis was performed to evaluate the effect of UGT1A1 polymorphisms on DTG PK, using pooled DTG PK data from 7 Phase I studies (see Section 3.3.3 for details). Based on this meta-analysis, a prospective clinical study enrolling subjects with UGT1A1 polymorphisms is not needed.

1.3.6. Pharmacokinetic-Pharmacodynamic Analysis and Dose Selection

Evaluations of the relationship between DTG dose, exposure and efficacy, and safety were performed throughout the clinical development program.

 Phase I studies performed in healthy subjects evaluated safety/tolerability with DTG doses ranging from 2 to 100 mg single doses, and repeat doses of 10 mg once daily up to 50 mg twice daily. Safety/tolerability by DTG dose was evaluated, however no DTG exposure (PK parameters)-response analyses were performed for Phase I data.

20 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 A dose-ranging, Phase IIa study in HIV-infected subjects evaluated DTG monotherapy at 2 to 50 mg once daily (Study ING111521); PK/PD analyses for efficacy endpoints were performed, and the results were used to define the optimal and suboptimal DTG exposures for antiviral activity as well as to support the Phase IIb dose selection.  Two dose-ranging, Phase IIb studies were performed to evaluate DTG in combination with other drugs at 10 to 50 mg once daily in treatment-naïve subjects (Study ING112276), and at 50 mg once daily and twice daily in INI-resistant subjects (Study ING112961). PK/PD analysis for both efficacy and safety were performed in these studies. Results from these Phase IIb studies supported the dose selection of DTG 50 mg once daily in Phase III studies in INI-naïve subjects (ING113086, ING114467, and ING111762) and 50 mg twice daily in the Phase III study in INI-resistant subjects (ING112574).  PK/PD analyses for both efficacy and safety were performed at the study level for each of the Phase III studies (except for ING114467 which did not collect PK data).  PK and PK/PD results from Phase II and III studies were used for the following purposes:  To define the “no effect boundaries” (see Section 3.2.3) of changes in DTG PK parameters. The PK/PD relationship for safety defines the upper bound and the PK/PD relationship for efficacy defines the lower bound; these “no effect boundaries” were used as the justification for dose adjustment (or no dose adjustment) recommendations due to drug interactions, or the impact of other intrinsic or extrinsic factors on DTG PK;  To support or provide primary evidence for the recommended optimal DTG doses for the treatment of HIV infection in various populations and subpopulations (see m2.7.3 Section 4 for details).

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES

2.1. Pharmacokinetics

2.1.1. Pharmacokinetics in Healthy Subjects

2.1.1.1. Study ING111207 (Single Dose, Suspension/Solution, 2 to 100 mg)

Study Title: A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects

Location of Report: m5.3.3.1, Study ING111207

Study Design: This was the first administration of DTG to investigate the safety, tolerability, and pharmacokinetics of DTG after single doses in healthy subjects. Two cohorts of 10 subjects (8 active, 2 placebo) received doses of 2, 5, 10, 25, 50 and 100 mg as suspension in an alternating panel design. Subjects randomized to placebo received placebo on all dosing occasions. Subjects were fasted overnight for 10 hours before until

21 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

4 hours after receiving investigational product. Plasma PK samples were collected over 72 hours after single dose administration.

Results: Following a single oral dose administration of suspension, DTG was readily absorbed (tlag=0) with the maximum concentration achieved between 0.50 to 1.25 hours post dose across the 2 to 100 mg dose levels. Plasma exposures [AUC(0-24), AUC(0-), AUC(0-t), Cmax, and C24) of DTG increased proportionally as doses increased from 2 mg to 100 mg. The terminal half-life (t1/2) for all subjects was estimated to be approximately 13 to 15 hours. Plasma DTG C24 exceeded the in vitro protein-adjusted (PA) concentration at which 90% of the maximal inhibitory effect is achieved (IC90) (0.064 g/mL) at doses higher than 5 mg. Low to moderate between-subject variability was observed in single dose DTG PK parameters with between-subject %CVb ranging from 9% to 41%. A summary of selected plasma DTG PK parameters following a single dose is presented in Table 1. A summary of dose proportionality assessments is presented in presented inTable 2.

Table 1 Summary of Selected Plasma DTG Pharmacokinetic Parameters Following Single Dose in Suspensiona

Treatment N Cmax tmaxb AUC(0-∞) t1/2 C24 (g/mL) (h) (g.h/mL) (h) (g/mL) 2 mg 8 0.231 0.63 2.78 12.7 0.0382 (20) (0.25-1.00) (26) (20) (41) 5 mg 7 0.661 0.50 8.87 14.3 0.126 (20) (0.50-1.50) (27) (25) (28) 10 mg 8 1.23 0.63 14.6 12.7 0.196 (9) (0.25-1.50) (21) (9) (34) 25 mg 8 2.76 0.75 35.2 12.7 0.469 (12) (0.50-1.50) (30) (21) (41) 50 mg 6 4.56 1.25 73.2 14.2 1.06 (21) (0.50-3.00) (19) (19) (27) 100 mg 5 8.14 1.00 136 14.7 1.80 (12) (0.75-3.00) (24) (23) (33) Source Data: m5.3.3.1, Study ING111207. Table 11.4. a. PK parameters are presented as geometric mean (%CVb) unless noted otherwise b. Presented as median (range)

Table 2 Summary of Dose Proportionality of Single Dose DTG PK Parameters Using Power Model

Parameter Slope 90% Confidence Interval AUC(0-∞) 0.996 [0.941, 1.05] C24 0.970 [0.861, 1.08] Cmax 0.948 [0.864, 1.03] Source Data: Study ING111207,Table 11.5

22 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions:

 DTG was absorbed rapidly following oral administration and its exposure increased proportionally with dose up to 100 mg when DTG was given as a suspension formulation.  DTG demonstrated low to moderate PK variability.  Observed DTG PK following single dose administration supports once daily dosing.

2.1.1.2. Study ING112941 (Single Dose, Suspension, 250 mg)

Study Title: A randomized, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of a supratherapeutic dose of GSK1349572 250 mg and a randomized, open-label study to evaluate the effects of omeprazole 40 mg daily and a high fat meal on the pharmacokinetics of GSK1349572 50 mg in healthy adult subjects (ING112941)

Location of Report: m5.3.3.4, Study ING112941

Study Design: Part 2 of ING112941 was a randomized, double-blind, single dose pharmacokinetic study that evaluated the safety, tolerability, and PK of a single supratherapeutic dose of DTG (250 mg) compared with placebo. The planned enrollment was ten subjects (8 on DTG and 2 on placebo). Plasma PK samples for DTG were collected pre-dose and over 48 hours post dose on Day 5.

Results: Summary of selected DTG PK parameters following a single dose of 250 mg DTG in suspension is presented in Table 3.

Table 3 Summary of Selected Plasma DTG Pharmacokinetic Parameters Following Single Dose Administration

Treatment N Cmax tmax AUC(0-∞) C24 CL/F (L/hr) Vz/F t½ Regimen (g/mL) (h) (g.h/mL) (g/mL) (L) (hr)

Part 2 DTG 250 mg 8 14.1 2.50 278 4.08 0.90 18.8 14.5 (10) (1.50-4.00) (15) (17) (15) (11) (10) Data Source: m5.3.3.4, Study ING112941, Table 11.3. Data presented are geometric mean (%CVb) except for tmax where median (range) is presented.

The single 250 mg dose as suspension achieved supratherapeutic exposure, which is at least 4-fold of that observed at 50 mg once daily, therefore supporting the use of a 250 mg dose in suspension in the QTc study (Study ING111856). The higher CL/F estimates, but similar t1/2, in the current study compared to single dose PK data in ING111207 up to 100 mg, indicates solubility-limited absorption at doses higher than 100 mg using suspension.

Conclusions: The observed DTG PK of a single 250 mg dose as suspension demonstrated supratherapeutic exposure and supports this dose/formulation in the thorough QTc study (Study ING111856) to be conducted separately.

23 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

2.1.1.3. Study ING111322 (Repeat Dose, Suspension/Solution, 10 to 50 mg Once Daily)

Study Title: A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 Followed by A Single Dose, Randomized, 3-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1349572 in Healthy Male and Female Subjects

Location of Report: m5.3.3.1, Study ING111322

Study Design: This was a Phase I, double-blind, randomized, placebo-controlled, repeat– dose, escalation study to investigate the safety, tolerability and PK of DTG in healthy subjects. Three cohorts of 10-12 subjects (8 or 10 active, 2 placebo) received suspension doses of 10, 25 and 50 mg once daily for 10 days. Subjects were fasted overnight from 10 hours before until 4 hours after receiving investigational product. PK samples were collected over 24 hours after the 1st dose on Day 1, at pre-dose on Days 5 through 10, and over 72 hours after the last dose on Day 10.

Results: Following once daily administration, plasma concentrations of DTG reached steady state by approximately 5 days of dosing and accumulation was observed in AUC, Cmax, and C, with accumulation ratios across the different dose levels estimated to be 1.24-1.42, 1.16-1.36, and 1.29-1.53, respectively, consistent with the observed half-life of DTG, estimated to be approximately 14 hours. DTG demonstrated time-invariant pharmacokinetics based on geometric mean ratios of Day 10 AUC(0-) over Day 1 AUC(0-), which was estimated to be close to 1 at all dose levels. DTG AUC(0-) and C increased proportionally with dose, while the increase in DTG Cmax was slightly less than dose-proportional. Low to moderate between-subject variability, %CVb, was observed in both single- and repeat-dose DTG PK, ranging from 8% to 33%.

A summary of selected Day 1 and Day 10 plasma DTG PK parameters following the repeated doses is presented in Table 4 and Table 5, respectively. A summary of dose proportionality analyses is presented in Table 6. A summary of steady state assessments is presented in Table 7.

Table 4 Summary of Selected Day 1 Plasma DTG Pharmacokinetic Parameters Following Day 1 Suspension Dose Administrationa

Dose N Cmax tmaxb CLF AUC(0-∞) AUC(0-24) t1/2 C24 (g/mL) (h) (L/hr) (g.h/mL) (g.h/mL) (h) (g/mL) 10 mg 8 1.24 0.50 0.63 15.8 11.8 11.8 0.23 (12) (0.50-1.00) (12) (12) (7) (19) (19) 25 mg 1 2.66 1.00 0.58 43.1 31.0 12.6 0.65 0 (21) (0.50-2.00) (28) (28) (21) (17) (33) 50 mg 8 4.52 0.75 0.66 75.8 53.9 12.6 1.18 (20) (0.50-1.00) (28) (28) (23) (14) (32) Source Data: m5.3.3.1, Study ING111322, Table 11.6 a. PK parameters are presented as geometric mean (%CVb) unless noted otherwise. All values of tlag were zero, and therefore, not included in this table. b. Presented as median (range).

24 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 5 Summary of Selected Day 10 Plasma DTG Pharmacokinetic Parameters Following Once Daily Repeat Doses in Suspension

Dose N Cmax tmax AUC(0-) C Rc Rc Rc Time- (g/mL) (h) (g.h/mL) (g/mL) (Cmax) (AUC) (C) invariance 10 mg 8 1.47 0.50 16.7 0.35 1.18 1.41 1.53 1.06 (24) (0.25-2.00) (15) (20) (20) (10) (14) [0.961, 1.16] 25 mg 10 3.09 1.00 38.4 0.84 1.16 1.24 1.29 0.892 (26) (0.50-2.00) (23) (33) (17) (9) (8) [0.841, 0.946] 50 mg 8 6.16 1.00 76.8 1.64 1.36 1.42 1.38 1.01 (15) (0.50-2.00) (19) (25) (15) (12) (14) [0.920, 1.12] Data Source: Study ING111322, Table 11.8. Data presented are geometric mean (%CVb) except for tmax where median (range) is presented and for time- invariance where GLS mean ratio and (90%CI) of Day 10 AUC(0-) vs Day 1 AUC(0-) is presented.

Table 6 Summary of Dose Proportionality of Single and Repeat Suspension Dose DTG PK Parameters Using the Power Model

Plasma DTG PK Slope in dose range of 10 mg-50 mg [90% CI] Parameter Day 1 Day 10 Slope 90 %CI Slope 90 %CI AUC (g.hr/mL) 0.98 (0.85-1.11) NA NA AUC (µg.hr/mL)a 0.95 (0.85-1.05) 0.95 (0.86-1.04) C0 (µg/mL) NA NA 1.07 (0.93-1.20) Cmax (µg/mL) 0.80 (0.71-0.90) 0.89 (0.79-0.999) Cmin (µg/mL) NA NA 1.06 (0.92-1.19) C (µg/mL) NA NA 0.97 (0.84-1.09) Source Data: Study ING111322. Table 11.11 NA = Not applicable. A slope estimate of close to 1 with 90% CI including 1 represents dose proportionality. a. AUC(0-t) for Day 1 and AUC(0-) for Day 10

Table 7 Summary of DTG Steady State Assessment

Days Treatment Slope 90% CI 5, 6, 7, 8, 9, and 10 10 mg 0.000 [-0.013, 0.014] 25 mg -0.014 [-0.029, 0.001] 50 mg 0.025 [0.010, 0.040] 6, 7, 8, 9, and 10 10 mg 0.011 [-0.006, 0.028] 25 mg -0.012 [-0.036, 0.012] 50 mg 0.003 [-0.015, 0.021] Source Data: Study ING111322. Table 11.10 A slope estimate of close to 0 with 90% CI including 0 represents achievement of steady state.

Conclusions:

 Following repeat-dose administration, plasma concentrations of DTG reached steady state by approximately 5 days of dosing.  DTG AUC and C increased proportionally between 10 and 50 mg once daily. The increase in DTG Cmax was slightly less than dose-proportional.

25 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 Accumulation was observed in AUC, Cmax and C following repeat-dose administration of DTG once daily, with accumulation ratios estimated to be 1.24- 1.42, 1.16-1.36, and 1.29-1.53, respectively, across 10 to 50 mg once daily dose levels.  DTG showed time-invariant pharmacokinetics.

2.1.1.4. Study ING114005 (Single Dose, Tablet, 50 mg and 100 mg)

Study Title: A Phase I, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100 mg versus 50 mg and the Effect of Efavirenz 600 mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50 mg Once Daily in Healthy Adult Subjects (ING114005)

Location of Report: m5.3.3.4, Study ING114005

Study Design: Period 1 and Period 2 of this study compared DTG PK parameters from a single 100 mg dose (tablet) to a single 50 mg dose (tablet) to evaluate the dose proportionality. A total of approximately 12 subjects were enrolled, in order to obtain approximately 10 evaluable subjects. In Period 1, all subjects received a single dose of DTG 100 mg in the fasted state on the morning of Day 1 followed by a washout of 6 days. In Period 2, subjects received DTG 50 mg once daily in the morning for 5 days. All doses were administered in the fasted state in the morning. Plasma PK samples for DTG were collected pre-dose and over 24 hours post morning dose on Day 1 of Period 1, as well as Day 1 of Period 2.

Results:

Table 8 Summary of Selected Plasma DTG Pharmacokinetic Parameters Following Single Dose Administrationa

Treatment N Cmax AUC(0-24) C24 tlagb tmaxb (g/mL) (g.h/mL) (g/mL) (h) (h) 100 mg 12 2.77 34.3 0.80 0.00 2.00 (35) (41) (53) (0.00-0.00) (1.0-4.0) 50 mg 12 1.83 24.3 0.53 0.00 2.00 (35) (44) (59) (0.00-0.00) (1.0-4.0) Data Source: m5.3.3.4, Study ING114005, Table 11.6 a. Parameters presented as geometric mean (%CVb) unless noted otherwise. b. Presented as median (range).

26 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 9 Summary of DTG Dose Proportionality Analysis Using ANOVA

Plasma DTG PK GLS Mean Ratio [90% CI] Parameter DTG 100 mg SD vs DTG 50 mg SD Dose-normalized AUC(0-24) 0.705 [0.597, 0.833] Dose-normalized Cmax 0.756 [0.648, 0.883] Dose-normalized C24 0.750 [0.639, 0.881] Source Data: Study ING114005, Table 11.12 GLS = geometric least-squares

Conclusions: Plasma exposures of DTG increased less than dose proportionally as dose increased from 50 mg to 100 mg with relative oral bioavailability of 100 mg is 70.5% to that of 50 mg.

2.1.1.5. Study ING111853 (Single Dose, Human Mass Balance)

Study Title: An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853)

Location of Report: m5.3.3.1, Study ING 111853; m5.3.2.2, Study 09DMR014 [GlaxoSmithKline Document Number RD2009/00356/00]

Study Design: Six subjects received a single oral suspension dose of DTG 20 mg containing [14C]-GSK1349572 of approximately 80 Ci (0.96 mSv) of radioactivity after an overnight fast of at least 10 hours.Serial whole blood and plasma samples were collected for a minimum of 72 hours post dose. Urine and fecal samples were collected for a minimum of 120 hours post dose. Total radiocarbon in individual samples (whole blood, plasma, urine, and feces), as well as DTG concentration in plasma, were determined. Plasma, urine, and fecal samples were also analyzed for metabolite profiles.

Results:

The mean total recovery of the administered dose was 95.6%, with a mean recovery of 64% in feces and 31.6% in urine; most of the dose (94.5%) was recovered in the feces and urine by 144 hours post dose. A summary of the percent of the administered dose recovered in feces, in urine, and in total is presented in Table 10.

27 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 10 Summary of Percent Radioactivity Recovered in Feces and Urine Following a Single Oral Dose Administration of [14C]-GSK1349572

Percent of Administered Dose Subject Feces Urine Total 531001 72.0 24.0 96.1 531002 65.2 30.6 95.8 531003 61.0 34.8 95.8 531004 59.4 33.8 93.2 531005 65.7 29.4 95.1 531006a 60.8 36.7 97.6 Mean 64.0 31.6 95.6 SD 4.7 4.6 1.4 Source Data: m5.3.3.1, Study ING111853, Table 6. a. Subject 531006 withdrew from the study after 144 hours post dose. The subject was excluded from descriptive statistics after this time point.

Plasma DTG exposure was similar to that of plasma radiocarbon. The individual ratio of plasma DTG AUC(0-)/ total plasma radiocarbon AUC(0-) has a mean of 0.97 with range of 0.95-0.99, meaning the plasma DTG AUC(0-) accounted for an average of 97% of the total plasma radiocarbon AUC(0-). This demonstrates that DTG is the predominant circulating compound in plasma. The estimated terminal half-lives were similar among plasma DTG, plasma radiocarbon and blood radiocarbon, implying no metabolite(s) with prolonged half-life. The mean blood: plasma concentration ratios between 0.5 hour to 72 hours post dose ranged from 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components. Mean concentration-time profiles for plasma DTG, plasma radiocarbon, and blood radiocarbon are presented in Figure 1. The summaries of PK parameters of plasma DTG, plasma and blood radiocarbon are presented in the Table 11.

28 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 1 Mean Concentration-Time Profiles for Plasma DTG, Plasma Radiocarbon, and Blood Radiocarbon

3 Analyte 572 (ug/mL) Radioactivity Blood (ug/g) Radioactivity Plasma (ug/g)

Concentration 1

0 0 30 60 90 120 150 180 210 240 Planned Relative Time (Hrs)

Source Data: Study ING111853. Figure 11.4

Table 11 Summary of Selected Pharmacokinetic Parameters for Plasma DTG, Plasma Radiocarbon, and Blood Radiocarbon Following a Single Oral Dose Administration of [14C]-GSK1349572a

Analyte n Cmaxb Tmaxc AUC(0-t)d AUC(0-)d CL/F Vz/F T1/2 (g/mL) (h) (g.h/mL) (g.h/mL) (L/hr) (L) (hr) Plasma DTG 6 2.57 0.50 35.7 35.9 0.56 12.5 15.6 (24) (0.50-2.00) (12) (12) (12) (9) (16) Plasma 6 2.46 0.50 35.9 36.1 nr nr 15.7 Radiocarbon (24) (0.50-1.50) (11) (11) (14) Blood 6 1.13 1.25 17.7 18.4 nr nr 14.6 Radiocarbon (25) (0.50-2.00) (13) (13) (12) Source Data: Study ING111853,Table 11.2. nr = not reported a. Data are presented as geometric mean (%CVb) unless otherwise noted. b. Cmax is reported in units of g/mL for plasma DTG, and g/g for plasma and blood radiocarbon. c. Presented as median (range). d. AUC is reported in units of g.h/mL for plasma DTG and g.h/g for plasma and blood radiocarbon.

Analyses of metabolite profiles using plasma, urine, and fecal samples revealed the following:

The principal radiolabeled component in plasma pooled from all subjects at 6, 24, and 48 hours post dosing was DTG, representing 95.2%, 96.8% and 99.8% of the plasma radiocarbon, respectively. An ether glucuronide conjugate of DTG (M3) represented ≤2.4% of plasma radiocarbon at 6 and 24 hours post dose, but was not detected at 48 hours post dose.

29 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

M3 was the major biotransformation product observed in the urine, accounting for 62.5% of the radiocarbon (18.9% of the dose). Two other notable metabolites were also observed in human urine; these resulted from oxidation at the benzylic carbon (M7), representing 10.1% of the urinary radiocarbon (3.0% of the dose), and N-dealkylation (M1), representing 11.8% of the urinary radiocarbon (3.6% of the dose). Renal elimination of unchanged DTG was low (≤2.6% of the sample radiocarbon or ≤0.8% of the dose).

An average of 89.1% of the fecal radiocarbon (53.1% of the dose) was recovered as DTG. Other notable components in feces included a metabolite resulting from the loss of fluorine and the addition of cysteine and oxygen (M13), representing 3.1% of the fecal radiocarbon (1.8% of the dose), and M1 accounting for 2.2% of the fecal radiocarbon (1.3% of the dose). It was unclear how much of the unchanged DTG recovered in feces was due to unabsorbed dose and how much may be due to biliary secretion of M3 with subsequent conversion of the conjugate to the parent drug in feces. However based on such data, the oral bioavailability of DTG (from suspension formulation) is at least 47% assuming unchanged DTG recovered in feces was completely due to unabsorbed dose and no metabolite(s) observed in feces were generated from degradation of DTG by gut lumen bacteria.

The total radioactivity of the glucuronide conjugate metabolite, M3, recovered in urine and feces represented at least 18.9% of total dose administered (possibly higher if accounting for M3 converted to parent drug in feces). The total radioactivity of metabolites formed through oxidation (M1, M7, and M13) that were recovered in urine and feces accounted for approximately 9.7% (mean) of the total dose administered.

Conclusions:

 Following oral administration, the total mean recovery of DTG was 95.6% of the administered dose, with a mean recovery of 64.0% in feces and 31.6% in urine.  Unchanged DTG is primarily eliminated through metabolism, with renal elimination of unchanged DTG comprising less than 1% of the total dose administered.  DTG was the predominant circulating compound in plasma.  Low mean blood:plasma concentration ratios indicated minimal association of radioactivity with the blood cellular components.  The observed metabolites included ether glucuronide of DTG (M3), an N- dealkylation metabolite (M1), a metabolite from oxidation at the benzylic carbon (M7), and a metabolite resulting from the loss of fluorine and the addition of cysteine and oxygen (M13).  DTG is mainly metabolized through glucuronidation with oxidation as a minor route.

2.1.1.6. Study ING115465 (Female Genital Tract)

Study Title: A Phase I, open-label, study in healthy female subjects to describe GSK1349572 exposure in blood, cervicovaginal fluid, cervical tissue, and vaginal tissue following single and multiple dosing of GSK1349572

30 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Location of Report: m5.3.3.1, Study ING115465

Study Design: Eight healthy, adult female subjects were enrolled to take one 50 mg tablet of DTG orally each day for 5-7 days, and provided evaluable PK data. DTG in cervicovaginal fluid (CVF) and blood plasma (BP) were measured over 24 hours after both the initial dose and at steady state (on Days 5-7). Cervical and vaginal biopsies (CT and VT) were collected once at 3, 6, 12, or 24 hours after the initial dose, and again at steady state at the same single time points. Samples were collected from 2 subjects per time point; the specific tissue sample collection time for each subject was assigned sequentially as enrolled. BP and CVF samples were obtained at 48 and 72 hours following the final DTG dose. Individual PK parameters in BP and CVF, and composite PK parameters in CT and VT, were estimated based on non-compartmental approach.

Results:

Figure 2 Median (IQR) DTG Concentration-over-time Profiles in BP, CVF, VT, and CT at Steady State

Data Source: m5.3.3.1, Study ING115465, Supplementary Figure 36.

Table 12 Summary of DTG PK Parameters in BP, CVF, VT, and CT

PK Parameter BP CVF CT VT Day 1 AUC(0-24), g.h/mL 37.4 (28) 3.06 (119) 2.75 2.73 Steady State AUC(0-24), g.h/mL 51.8 (24) 3.25 (72) 5.30 4.74 Accumulation Ratio of AUC(0-24) 1.39 (9.8) 0.86 (25) 1.93 1.74 Tissue-to-Plasma Ratio of AUC(0- n.a. 0.06 (median) 0.10 0.09 24) at Steady State Data Source: Study ING115465, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, and Table 15. Data presented are geometric mean (%CVb) for BP and CVF, and composite for CT and VT.

31 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions:

 DTG exposure in CVF was 6% of plasma exposure at steady-state. There was no accumulation after repeat dosing. Delayed tmax is observed in CVF (tmax=6hr) compared to plasma (tmax=2hr).  DTG exposure in CT was 10% of plasma exposure at steady state. There was a higher accumulation in CT after repeat dosing than in plasma (R=1.9 in CT vs 1.4 in plasma).  DTG exposure in VT was similar to CT, representing 9% of plasma exposure. The accumulation in VT after repeat dosing is higher than in plasma (R=1.7 in VT vs 1.4 in plasma).  CT and VT exposures were highly correlated, and had concentrations above the PA- IC90 (0.064 g/mL) of DTG for wild-type HIV-1 virus at steady state in CT in all women, and in VT in 7/8 women.

2.1.1.7. Study ING116195 (Male Genital Tract)

Study Title: Phase I, open-label study in healthy male subjects describing GSK1349572 exposure in blood plasma, seminal fluid and rectal mucosal tissue following single and multiple dosing (ING116195)

Location of Report: m5.3.3.1, Study ING116195

Study Design: Twelve healthy male subjects were enrolled. A 50 mg oral dose of DTG was administered once daily for 8 days, and drug concentrations after a single dose (Day 1) and at steady state (Day 7 or Day 8) were measured in blood plasma (BP), seminal fluid (SF), rectal mucosal fluid (RF), and rectal mucosal tissue (RT). At each visit, samples for BP, SF, RF, and RT were collected over 24 hours. At the Day 1 visit, SF and RF samples were collected from 4 patients per time point, and RT samples were collected from 2 patients per time point. At the steady state PK visit, the 1, 6, and 18 hour SF and RF samples were collected from each subject on Day 7, and the 3, 12, and 24 hour SF and RF samples were collected from each subject on Day 8; RT samples were collected from 2 patients per time point. Individual PK parameters in BP and composite PK parameters in SF, RF, and RT were estimated based on a non-compartmental approach.

Results:

32 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 3 Median (IQR) DTG Concentration-over-time Profiles in BP, SF, RF, and RT at Steady State following DTG 50 mg Once Daily

Data Source: m5.3.3.1, Study ING116195, Supplementary Figure 25.

Table 13 Summary of DTG PK Parameters in BP, SF, RF, and RT

PK Parameter BP SF RF RT Day 1 AUC(0-24), g.h/mL 30.8 (32) 2.01 0.092 5.28 (median) Day 1 C24, g/mL 0.706 (36) 0.047 (46) 0.017 0.115 (22) (median) Steady State (Day 7) AUC(0-24), 50.4 (30) 3.18 (42) 0.356 (581) 7.60 g.h/mL Steady State (Day 7) C24, g/mL 1.07 (41) 0.061 (58) 0.0093 0.139 (2164) Accumulation Ratio of AUC(0-24) 1.64 (23) 1.57 (42) n.a. 1.44 Tissue-to-Plasma Ratio of AUC(0- 0.07 (33) n.a. 0.17 24) at Steady State Data Source: Study ING116195, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, and Table 15. n.a. = not applicable Data presented are geometric mean (%CVb) for BP and SF, and composite for RF and RT.

Conclusions:

 Penetration of DTG into SF was ≤7% BP, with SF C24h below the PA-IC90 (0.064 g/mL) of DTG for wild-type HIV-1 virus.  Although the AUC of DTG in RT was <20% BP, RT C24h was approximately 2-fold higher than the PA IC90.  RF was not a strong surrogate for RT concentrations, and demonstrated high intra- and between-subject variability.

33 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

2.1.2. Pharmacokinetics in Special Populations

2.1.2.1. Study ING115381 (Japanese)

Study Title: An Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Location of Report: m5.3.3.3, Study ING115381

Study Design: The purpose of this study was to evaluate the PK of DTG following single oral administration in healthy Japanese subjects to support the development of the drug globally, including in North East Asia. A single 50 mg oral dose of DTG was administered to 10 healthy Japanese subjects resident in the US. Serial plasma samples were to be collected for PK analysis from pre-dose (within 15 minutes of dosing) up to 72 hours post dose.

Results: DTG PK parameters observed in this study in healthy Japanese subjects are summarized in Table 14. PK parameters of DTG reported in previous studies conducted in US in healthy Western subjects (predominantly Caucasian) following a single 50 mg oral dose are also provided in Table 14.

Table 14 Summary of Selected DTG PK Parameters Following a Single 50 mg Dose in Healthy Japanese Subjects and healthy Western, Predominantly Caucasian, Subjects

Clinical Trials N Body Cmax Tmax AUC(0-∞) T1/2 C24 /(Study Location) Weight (g/mL) (hours) (g.h/mL) (hours) g/mL (kg) Healthy Japanese Subjects ING115381 /(US) 10 66.4 (7.72) 2.14 (47) 3.0 (2.0-4.0) 43.4 (46) 14.6 (10) 0.67 (45) Historical Data from Healthy Western Data primarily from Caucasian Subjects ING114005 /(US) 12 83.3 (12.6) 1.83 (35) 2.0 (1.0-4.0) NR 13.6 (24) 0.53 (59) ING113674 (AP 22 68.8 (9.9) 2.67 (35) 3.00 (1.0-5.0) 53.2 (34) 14.2 (19) 0.82 (38) formulation) /(US) ING113674 (AW 22 68.8 (9.9) 2.64 (30) 2.56 (1.0-6.0) 50.6 (27) 14.1 (21) 0.76 (33) formulation) /US ING111602 /US 16 79.6 (11.3) 2.03 (25) 2.5 (0.5-8.0) 35.6 (33) 13.7 (15) 0.51 (38) ING112941 /US 12 84.7 (13.4) 1.84 (44) 4.0 (1.0-5.0) 34.7 (57) 14.4 (21) 0.56 (63) ING113097 /US 8 97.2 (22.7) 1.80 (49) 3.0 (1.0-4.0) 37.3 (47) 14.9 (24) 0.57 (44) ING113125 /US 8 86.6 (17.1) 1.86 (45) 2.00 (1.0-4.0) 37.1 (58) 15.4 (15) NR Data Source: m5.3.3.3, Study ING115381, Table 6; Table 9; m5.3.3.4, Study ING111602, Table 9.5, Table 11.3; Study ING112941, Table 9.5, Table 11.3; m5.3.3.3, Study ING113097, Table 9.5, Table 11.3; m5.3.3.3, Study ING113125, Table 9.5, Table 11.3; m5.3.1.2, .Study ING113674 Table 9.5, Table 11.2; m5.3.3.4, Study ING114005, Table 9.5, Table 11.6. Data presented are geometric mean (%CVb) except for tmax where median (range) is presented and body weight where mean (SD) are presented. NR: not reported.

34 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions: The pharmacokinetics of DTG following single dose oral administration to healthy Japanese subjects studied in the US were consistent with the DTG PK parameters reported in healthy subjects in the US who were predominantly Caucasian. DTG has low to moderate between-subject PK variability in both the healthy Japanese (%CVb: 11- 47%) and Western (15-63%) subjects. Dose adjustment of DTG in Japanese subjects solely based on pharmacokinetic principles would not be necessary.

2.1.2.2. Study ING113097 (Moderate Hepatic Impairment)

Study Title: A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects with Hepatic Impairment and Healthy Matched Control Subjects (ING113097)

Location of Report: m5.3.3.3, Study ING113097

Study Design: In Part 1, 8 subjects with moderate hepatic impairment, defined by a Child-Pugh grade B (score of 7 to 9), and 8 matched control subjects (matched for gender, age, and body mass index) received a single oral dose of DTG 50 mg in the morning followed by 72-hour serial PK sampling to determine total DTG concentration in plasma. Plasma samples at 3 hours and 24 hours post dose were also collected for the determination of unbound DTG concentration in plasma. PK samples obtained in Part 1 were evaluated. If the geometric mean total plasma AUC of DTG among subjects with moderate hepatic impairment was >2-fold above that among matched control subjects, Part 2 of the study would have been conducted, in which subjects with mild hepatic impairment defined by a Child-Pugh grade A (score of 5 to 6) and matched control subjects would have received a single oral dose of DTG 50 mg in the morning followed by 72-hour serial PK sampling. See Section 1.3.5.1 for more details on study design discussion.

Results: Selected DTG PK parameters in Part 1 are summarized in Table 15.

35 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 15 Summary and Comparison of Selected Plasma DTG Pharmacokinetic Parametersa

Cohort Moderately Healthy Ratio of GLS Means Hepatic (n=8) (90% CI) Impaired Hepatic Impaired vs Healthy (n=8) (n=8) Cmax 1.78 1.80 1.02 (g/mL) (17) (49) [0.754, 1.37] C24 0.59 0.57 1.04 (g/mL) (36) (44) [0.727, 1.48] AUC(0-∞) 38.5 37.3 1.05 ( g.h/mL) (30) (47) [0.745, 1.49] AUC(0-t) 36.7 35.5 1.06 ( g.h/mL) (27) (48) [0.753, 1.48] CL/F 1.30 1.34 0.950 (L/hr) (30) (47) [0.673, 1.34] Vz/F 29.1 28.7 0.986 (L) (18) (50) [0.737, 1.32] t1/2 15.5 14.9 1.04 (h) (19) (24) [0.845, 1.27] tmax 4.00 3.00 1.00 (h) b (2.0-5.0) (1.0-4.0) [-0.500, 2.50] Fraction Unbound at 3 0.58 0.23 2.20 hours post dose, FU3, (0.2, 0.8) (0.2, 0.3) [1.62, 2.99] (%)b Fraction Unbound at 24 0.48 0.23 1.76 hours post dose, FU24, (0.2, 0.6) (0.2, 0.3) [1.23, 2.51] (%)b Source Data: m5.3.3.3, Study ING113097, Table 11.3, Table 11.5, and Table 11.6 a. PK parameters are presented as geometric mean (%CVb) unless otherwise noted. b. Presented as median (range).

Total DTG exposure on plasma was similar between subjects with moderate hepatic impairment and matched healthy subjects, while unbound DTG concentration and fraction unbound were higher in subjects with hepatic impairment. Part 2 of the study was not performed. The higher unbound DTG concentration in moderate hepatically impaired subjects is not considered a safety concern at the single digit ng/mL level (a mean value of 8.38 ng/mL at 3h post dose and 2.49 ng/mL at 24h post dose).

Results from Pearson correlation and regression analyses between DTG PK parameters and hepatic function variables revealed that unbound DTG fractions were statistically higher in subjects with higher albumin score (lower serum albumin concentration), higher bilirubin score (higher serum bilirubin concentration), and higher Child-Pugh score. There was no apparent relationship between DTG unbound fraction and total protein concentration.

Data on the PK, safety, or efficacy of DTG in HIV-infected subjects with moderate hepatic impairment have not been generated as these subjects were excluded from Phase IIb and III clinical studies of DTG. However, based on similar DTG PK observed between HIV-negative and HIV-infected subjects without hepatic impairment (Section 3.1.1), data generated in HIV-negative subjects can be applied to HIV-infected subjects.

36 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions:

 The pharmacokinetics of total plasma DTG was not affected by moderate hepatic impairment.  The unbound concentration and unbound fraction of DTG in moderately hepatically impaired subjects was 48-106% and 76-120%, respectively, higher than those in healthy subjects, primarily due to lower albumin concentrations and possibly reduced intrinsic clearance.  DTG can be taken without dose adjustment in subjects with mild to moderate hepatic impairment.

2.1.2.3. Study ING113125 (Severe Renal Impairment)

Study Title: A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects with Renal Impairment and Healthy Matched Control Subjects (ING113125)

Location of Report: m5.3.3.3, Study ING113125

Study Design: Eight subjects with severe renal impairment (creatinine clearance [CrCL] <30 mL/min, not on dialysis) and 8 healthy controls (matched for gender, age, and body mass index) received a single dose of DTG 50 mg under fasted conditions. Creatinine clearance was determined after a 24-hour urine collection. Serial plasma samples over 72 hours post dose were collected for the determination of total DTG and DTG ether glucuronide conjugate. Plasma samples at 3 hours and 24 hours post dose were also collected for the determination of unbound DTG concentration. See Section 1.3.5.1 for more details on study design discussion.

Results:

Plasma DTG AUC and Cmax were approximately 40% and 23% lower, respectively, in subjects with severe renal impairment than in healthy subjects. However, there was considerable overlap in DTG concentrations between the groups. Plasma DTG glucuronide AUC and Cmax in the subjects with severe renal impairment were approximately 4-fold and 3-fold higher, respectively, than in the healthy subjects, however, there was no difference in t1/2. DTG unbound plasma concentration was 14% and 49% lower in subjects with severe renal impairment than in healthy subjects at 3 hours and 24 hours post dose, respectively. Unbound fraction (%) of DTG in subjects with severe renal impairment was similar to those in healthy subjects.

37 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 16 Summary and Statistical Comparison of Plasma DTG and DTG Glucuronide Pharmacokinetic Parameters

PK Parameter Renal Healthy Ratio of GLS Means Impaired (n=8)a (90% CI) (n=8)a Renal Impaired vs Healthy (n=8) DTG AUC(0-∞) (g.h/mL) 23.5 (48) 37.1 (58) 0.601 (0.370, 0.975) AUC(0-t) (g.h/mL) 22.6 (47) 35.3 (58) 0.606 (0.375, 0.978) Cmax (g/mL) 1.50 (34) 1.86 (45) 0.774 (0.532, 1.13) CL/F (L/hr) 2.12 (48) 1.35 (58) 1.67 (1.03, 2.70) t1/2 (hr) 12.7 (31) 15.4 (15) 0.818 (0.639, 1.05) Vz/F (L) 38.8 (43) 29.9 (44) 1.36 (0.918, 2.02) DTG Glucuronide AUC(0-∞) (g.h/mL) 2.48 (78) 0.54 (98) 4.30 (2.11, 8.76) AUC(0-t) (g.h/mL) 2.40 (79) 0.49 (107) 4.53 (2.16, 9.49) Cmax (g/mL) 0.12 (68) 0.04 (83) 3.07 (1.60, 5.89) t1/2 (hr) 12.9 (30) 13.0 (31) 0.989 (0.724, 1.35) Source Data: m5.3.3.3, Study ING113125, Table 11.3, Table 11.5 a. Presented as geometric mean (%CVb).

Table 17 Summary of Unbound Plasma DTG Concentration Data by Cohorta

Cohort DTG unbound concentration DTG unbound fraction (fu%) (g/mL) 3 hr 24 hr 3 hr 24 hr Renal Impaired 12.3 2.87 0.84 1.01 (n=8) (9.3-16.7) (2.11-7.11) (0.6, 1.4) (0.7, 1.7) Healthy 17.7 7.83 0.87 1.10 (n=8) (5.66-25.1) (2.40-10.8) (0.8, 0.9) (1.0, 1.3) Comparison of Renal 0.857 0.510 1.051 0.957 Impairment to Healthyb (0.587, 1.251) (0.306, 0.851) (0.915, 1.208) (0.801, 1.144) Source Data: Study ING113125, Table 11.2, Table 11.3, Table 11. 5, Table 11.9 a. Data are presented as median (range) unless noted otherwise. b. GLS mean ratio (90% CI).

The median molar DTG glucuronide/DTG AUC ratio increased from 0.010 in healthy subjects to 0.055 in subjects with severe renal impairment, and the median molar DTG glucuronide/DTG Cmax ratio increased from 0.015 in healthy subjects to 0.045 in subjects with severe renal impairment. The low DTG glucuronide/DTG ratio (~0.01 for healthy subjects and ~0.05 for severe renal impairment) indicated that DTG is the predominating species in plasma in both healthy subjects and subjects with severe renal impairment.

No statistically significant correlation or relationship was identified between DTG PK parameters and the renal function variable (creatinine clearance), consistent with previous findings that DTG is primarily eliminated through metabolism, while renal excretion of unchanged DTG only accounts for <1% of the total dose administered.

38 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

There was a statistically significant negative correlation between DTG glucuronide PK parameters, including AUC(0-t), AUC(0-) and Cmax, and the renal function variable (creatinine clearance). This implied that renal excretion is an important route of elimination for DTG glucuronide. However the t1/2 of DTG glucuronide was similar between healthy subjects and subjects with severe renal impairment, and was not correlated with creatinine clearance, which is consistent with formation rate-limited kinetics for DTG glucuronide.

The moderate reduction in DTG exposure (total and unbound in plasma) in subjects with severe renal impairment was not considered clinically significant. The increase in DTG glucuronide exposure in subjects with severe renal impairment is not expected to be a safety concern as the glucuronide is still <10% of the exposure of parent DTG, based on molar ratios, and also because glucuronide is a Phase II metabolite, which is considered generally more water soluble, is less pharmacologically active, and does not require safety/toxicity testing. The DTG glucuronide metabolite has no antiviral activity and would not contribute to efficacy in HIV-infected subjects.

Conclusions:

 DTG exposure was lower in subjects with severe renal impairment (CrCL< 30mL/min) than in healthy, matched subjects: AUC(0-) and Cmax were 40% and 23% lower, respectively.  The moderate reduction in DTG exposure in subjects with severe renal impairment was not considered clinically significant; no dose adjustment of DTG is needed in subjects with mild to severe renal impairment (not on renal replacement therapy).

2.1.2.4. Study ING112578 (Pediatric)

Study Title: IMPAACT P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Location of Report: m5.3.5.2, Study ING112578 (Cohort 1, 12-18yr olds)

Study Design: The primary endpoints are toxicity through Week 24 and DTG PK, AUC0-24, based on intensive PK sampling. Secondary endpoints include toxicity through Week 48 and beyond, antiviral activity, and additional PK parameters. Eligible subjects were treatment-experienced (but no prior treatment with an integrase inhibitor), HIV-1 infected, male and female subjects, 6 weeks to <18 years old, with a screening plasma HIV-1 RNA ≥1000 copies/milliliter (c/mL), and at least one available fully active drug for the planned optimized background regimen. Pediatric doses were selected based on comparable PK exposure to that observed at 50 mg once daily in adults, as well as safety/tolerability in children. AUC(0-) was the primary PK endpoint and C was a secondary PK endpoint. Subjects were enrolled sequentially by pre-defined age cohorts as well as by Stage within each cohort. Ten subjects of 12 to <18 years old enrolled in Stage I Cohort I and received DTG once daily at approximately 1.0 mg/kg according to weight-based fixed doses, using 10 mg, 25 mg, and 50 mg tablets.

39 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 18 Initial DTG Dosing Table for Subjects Enrolled in P1093

Weight Dose Tablets taken Dose in mg/kg Dose in mg/kg Range (kg) (mg) for lower for upper weight subject weight subject 15 - <20 20 Two 10 mg tablets 1.33 1.00 20 - <30 25 One 25 mg tablet 1.25 0.83 30 - <40 35 One 10 mg tablet AND one 1.17 0.88 25 mg tablet 40 50 One 50 mg tablet 1.25 1.25

An intensive PK evaluation was performed over 24 hours following an observed dose between Days 5-10, after DTG was added to a stable, failing antiretroviral (ARV) regimen, or started as monotherapy for those not taking ARVs. Background therapies were optimized the day after intensive PK. Assessment for safety, tolerability, and plasma HIV RNA were performed throughout the study. The target PK exposures were predefined based on adult data from ING111521 and ING112276: geometric mean for AUC(0-) at 46 g.h/mL and for C at 0.96 g/mL. However, variability around these targets was considered acceptable, and the target range was defined as follows: the lower limits are 80% of the geometric means (37 µg.h/mL for AUC(0-) and 0.77 µg/mL for C); the upper limits are the 90th percentiles of the AUC(0-) (67 µg.h/mL) and C (2.26 µg/mL) observed in adult subjects in ING112276. Therefore, the target exposure for the geometric mean of AUC(0-) was 46, with an acceptable range of 37-67µg.h/mL; the target exposure for the geometric mean of C was 0.96µg/mL, with an acceptable range of 0.77-2.26µg/mL.

Results:

Among the 10 subjects enrolled in Stage I Cohort I, 9 subjects received DTG 50 mg once daily, and 1 subject received DTG 35 mg once daily based on weight. The median (range) age was 13.5 (12-17) years. There were 3 males and 7 females. Six subjects were African American/African heritage and 4 subjects were White/Caucasian/European Heritage. These 10 subjects have completed 24 weeks of treatment and this study is ongoing.

Pharmacokinetics

The geometric mean AUC(0-24) for the Stage I Cohort I was 46 g.h/mL, and the C24h was 0.902 g/mL, meeting the pre-defined targeted PK exposure for AUC0-24 and C24h. This supports DTG 50 mg once daily in subjects 12 - <18 years of age weighing at least 40 kg.

40 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 19 Summary of DTG PK Parameters for Stage I Cohort I

Cohort Subject ID Sex Age Weight Dose AUC(0-) C Cmax CL/F Vz/F (yr) (kg) (mg) (g.hr/mL) (g/mL) (g/mL) (L/hr) (L) 1 (n=10) Stage I 8503351J F 12.23 37.1 35.0 38.9 0.642 2.71 0.90 10.7 8503340A F 12.41 48.9 50.0 61.3 1.18 4.11 0.82 11.7 290207H F 12.94 56.8 50.0 13.1 0.208 1.15 3.83 48.8 400412G F 13.19 91.4 50.0 78.3 2.10 4.48 0.64 15.6 8503342I F 13.55 51.7 50.0 85.0 2.13 6.08 0.59 15.3 450364B M 14.67 45.7 50.0 45.5 0.656 3.79 1.10 13.8 450367G F 15.80 46.0 50.0 62.3 1.22 4.96 0.80 12.8 8500394C M 16.57 50.0 50.0 60.4 1.11 4.90 0.83 13.1 400535I F 16.98 56.6 50.0 27.2 0.455 2.12 1.84 25.8 450527G M 17.86 87.4 50.0 44.0 1.26 3.93 1.14 40.7 Geometric 46.0 0.902 3.49 1.05 18.0 mean Mean 51.6 1.10 3.82 1.25 20.8 %CVb 43 59 38 78 64 Median 52.9 1.14 4.02 0.87 14.5 Min 13.1 0.208 1.15 0.59 10.7 Max 85.0 2.13 6.08 3.83 48.8 Data Source: m5.3.5.2, Study ING112578, Table 13.

Figure 4 Mean (SD) DTG Concentration-time Profiles

Ref: [Hazra, 2012]

41 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Efficacy

Eight of 10 subjects achieved virologic suppression (HIV-1 RNA <400 c/mL) at Week 24 based on the FDA Snapshot analysis, with 7 of 10 subjects achieving HIV-1 RNA <50 c/mL. The 2 subjects who failed to achieve HIV-1 RNA <400 c/mL had documented adherence problems.

Safety

Overall, DTG was demonstrated to be safe and well-tolerated in children 12 to <18 years of age (m2.7.4, Section 5.5).

Although only treatment-experienced children were enrolled in this age cohort of ING112578 (Cohort I), the primary objective of this study was the assessment of PK and safety, which would be expected to be similar in treatment-naïve patients.

Conclusions:

 The PK/safety/tolerability/efficacy data support dose selection of 50 mg in children 12 to <18 years older weighing  40kg.

2.1.3. Pharmacokinetic Interactions

2.1.3.1. Study ING111322 (Midazolam)

Location of Report: m5.3.3.1, Study ING111322

Study Design: In Part 1 of this study, the potential of DTG to inhibit or induce CYP3A activity was examined using MDZ (probe for CYP3A) in a cohort of subjects. Subjects received DTG 25 mg or placebo once daily on Day 1 through Day 10 and a single oral dose of MDZ 3 mg alone on Day -1 and co-administered with the DTG/placebo dose on Day 10. All doses were administered under fasted conditions. Plasma PK samples for MDZ were collected pre-dose and over 12 hours post dose on Day -1 and Day 10. PK samples for plasma DTG concentration were collected pre-dose and over 24 hours post dose on Day 1, and were collected pre-dose and over 72 hours post dose on Day 10. Single pre-dose samples for DTG were collected on the mornings of Days 3 through Day 9.

Results: MDZ PK was not changed when co-administered with DTG; therefore, DTG does not affect CYP3A enzyme activity.

42 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 20 Summary of MDZ Treatment Comparison

Plasma MDZ PK GLS Mean Ratio [90% CI] Parameter DTG 25 mg + MDZa/MDZb (N=10/10) AUC(0-∞) 0.953 [0.790, 1.15] AUC(0-t) 0.945 [0.815, 1.10] AUC(0-6) 0.923 [0.806, 1.06] AUC(0-8) 0.927 [0.798, 1.08] Source Data: m5.3.3.1, Study ING111322, Table 11.15 a. DTG 25 mg + MDZ = 25 mg DTG suspension once daily x 10 days + 3 mg MDZ single dose on Day 10 b. MDZ = 3 mg MDZ single dose

Although the dose used in this study was lower than the Phase III clinical dose, DTG was given as a suspension, which gave a higher drug exposure than the tablet formulation, and provided a DTG exposure only slightly lower than that observed for DTG 50 mg once daily given as a tablet formulation in Phase III trials. Geometric means (%CVb) of DTG AUC(0-) and Cmax were estimated at 38.4 g.h/mL (23%) and 3.09 g/mL(26%), respectively, for DTG 25 mg once daily given as a suspension formulation in this study, verses 53.6 g.hr/mL (26.9%) and 3.67 g/mL (19.7%), respectively, for DTG 50 mg once daily using tablets in the Phase III trials (Section 3.3.1). Therefore, result from this study is applicable to the DTG therapeutic dose.

Conclusions: Co-administration of repeat doses of DTG 25 mg once daily with a single dose of 3 mg MDZ resulted in no significant change in MDZ plasma AUC, indicating no induction or inhibition effect of DTG on CYP3A activity. Thus, DTG will not affect exposure of CYP3A substrates following co-administration.

2.1.3.2. Study ING111405 (Lopinavir/ritonavir, Darunavir/ritonavir)

Study Title: A Phase I, open label, randomized, two period, one-way two sequence crossover study to evaluate the effect of darunavir/ritonavir and lopinavir/ritonavir on GSK1349572 pharmacokinetics in healthy adult subjects (ING111405) Location of Report: m5.3.3.4, Study ING111405

Study Design: A total of approximately 30 subjects were enrolled in order to obtain 24 evaluable subjects (12 per treatment sequence). All subjects received DTG 30 mg once daily for 5 days in Period 1, followed by DTG 30 mg once daily in combination with either LPV/RTV 400/100 mg twice daily or DRV/RTV 600/100 mg twice daily for 14 days in Period 2. There was no washout between treatment periods. All doses were administered with a moderate fat meal. PK samples for plasma DTG concentration were collected over 24 hours on Day 5 in Period 1 and after the last dose on Day 14 in Period 2. PK samples for plasma LPV, DRV, and RTV concentrations were collected over 24 hours on Day 14 in Period 2.

43 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results: Co-administration of LPV/RTV had no effect on steady state pharmacokinetics of DTG (Table 56). Co-administration of DRV/RTV decreased plasma DTG exposures: plasma DTG AUC(0-), Cmax, and C were decreased by 22%, 11%, and 38%, respectively (Table 56). Co-administration of DTG with DRV/RTV resulted in a 28% increase in CL/F and a 20% shorter t1/2 for DTG. There was no correlation between the treatment ratio of DTG PK parameters [AUC(0-), Cmax, and C] and DRV/RTV exposure. The effect of DRV/RTV on DTG was not considered to be clinically significant (Section 3.2.3). DTG PK parameter values obtained in this study can be found in Appendix Table 3.

LPV, DRV, and RTV PK parameter values observed in this study were consistent with historical data. RTV PK parameters values were similar between LPV/RTV and DRV/RTV treatments.

The disparate effects of DRV/RTV and LPV/RTV on DTG PK were not due to RTV (as the RTV daily dose was the same, and a similar RTV exposure was observed between the treatment groups); rather, this was likely due to the differential effects of LPV and DRV on UGT1A1, the enzyme governing the primary metabolism of DTG (Section 3.1.5).

Conclusions:

 Co-administration of LPV/RTV had no effect on plasma DTG pharmacokinetics.  Co-administration of DRV/RTV resulted in decreased plasma DTG exposures; however, these decreases are not considered to be clinically significant (see Section 3.4.3 for rationle). DTG can be co-administered with DRV/RTV or LPV/RTV with no dose adjustment.

2.1.3.3. Study ING111602 (Antacid, Multivitamins)

Study Title: A Phase I, open label, randomized, four-period crossover study to evaluate the effects of Maalox Advanced Maximum Strength and One A Day Maximum on pharmacokinetics of GSK1349572 in healthy adult subjects (ING111602)

Location of Report: m5.3.3.4, Study ING111602

Study Design: A total of 16 subjects were enrolled and each subject 4 different treatments (Table 21) in a crossover manner and treatments were separated by at least 7 days. All doses were administered under fasted conditions. PK samples for plasma DTG concentrations were collected pre-dose and over 72 hours post dose on Days 1, 2, 3, and 4 of all treatment periods.

44 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 21 Study Treatment and Description in ING111602

Treatment Description A A single dose of DTG 50 mg (five 10 mg tablets) B A single dose of DTG 50 mg co-administered with a single dose of a One A Day Maximum multivitamin C A single dose of DTG 50 mg co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength D A single dose of DTG 50 mg administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength

Results: Concurrent administration of a multivitamin decreased DTG AUC, Cmax, and C24 by 33%, 35%, and 32%, respectively, on average (Table 56). Concurrent administration of Maalox decreased DTG AUC, Cmax, and C24 by 74%, 72%, and 74%, respectively, on average (Table 56). Administration of Maalox 2 hr after DTG decreased DTG AUC, Cmax, and C24 by 26%, 18%, and 30%, respectively, on average (Table 56). DTG PK parameter values obtained in this study can be found in Appendix Table 3.

One A Day Maximum contains the most metal cations including iron, magnesium, zinc, and copper, compared to other widely used multivitamin supplements. Maalox Advanced Maximum Strength contains the most metal cations including magnesium and aluminium, compared to other widely used antacids. Therefore, the results from this study represent the worst case and can be applied to other multivitamin and antacid products.

Conclusions:

 Concurrent administration of a multivitamin decreased DTG exposure; however, the decrease is not considered clinically relevant. DTG may be taken concomitantly with a multivitamin without dose adjustment.  Concurrent administration of Maalox decreased DTG exposure by more than 70%, and separation by 2 hours attenuated the effect of Maalox. Concomitant administration of DTG and antacids should be avoided. It is recommended that DTG should be administered 2 hours before or 6 hours after antacids similar (similar to quinolones, see Section 3.4.3.3 for details).

2.1.3.4. Study ING111603 (Etravirine)

Study Title: A Phase I, open label, two period, fixed-sequence crossover study to evaluate the effect of etravirine on GSK1349572 pharmacokinetics in healthy adult subjects (ING111603)

Location of Report: m5.3.3.4, Study ING111603

Study Design: Sixteen subjects were enrolled in the study. In Period 1, subjects received DTG 50 mg once daily from Day 1 to Day 5. In Period 2, subjects received DTG 50 mg once daily and ETR 200 mg twice daily from Day 1 to Day 14. There was no washout between treatment periods. All doses were administered following a moderate fat meal.

45 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Serial PK samples for plasma DTG concentrations were collected over 24 hours on Day 5 in Period 1, as well as on Day 14 in Period 2. Serial PK samples for plasma ETR concentrations were collected over 12 hours post the morning dose on Day 14 of Period 2. Results: Co-administration of ETR decreased steady-state plasma DTG exposures. Plasma DTG AUC(0-), Cmax, and C decreased by 71%, 52%, and 88%, respectively (Table 56). Co-administration of DTG with ETR resulted in a 3.4-fold increase in CL/F and a 48% reduction in t1/2 for DTG. DTG PK parameter values obtained in this study can be found in Appendix Table 3. ETR PK parameters values were consistent to historical data in healthy subjects. The reduction in DTG exposure by ETR is likely due to the combined inductive effect on UGT1A1 and CYP3A4 activity by ETR. The inductive effect on UGT1A1 by ETR is consistent with the modest decreases in plasma raltegravir AUC of 20 to 40% seen with co-administration [Kassahun, 2007; Anderson, 2008]. Support for this hypothesis was demonstrated by the amelioration of the decrease in DTG concentrations following co- administration of the combination product LPV/RTV, which are inhibitors of CYP3A4 and UGT1A1. In addition, ETR is an inhibitor of the multidrug resistance protein 2 (MRP2) with an IC50 of 7.8 M [Zembruski, 2011]. Thus, there is a potential for ETR to interfere with the biliary secretion of DTG glucuronide and disrupt enterohepatic recirculation. This has been reported as an explanation for the reduced exposure of mycophenolate mofetil when co-administered with cyclosporine-A [Hesselink, 2005]. Conclusions: Co-administration of DTG and ETR resulted in decreased steady-state plasma DTG AUC(0-), Cmax, and C by 71%, 52%, and 88%, respectively. Co- administration of DTG and ETR is not recommended.

2.1.3.5. Study ING111604 (Tenofovir)

Study Title: A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604) Location of Report: m5.3.3.4, Study ING111604 Study Design: Sixteen healthy subjects were enrolled in this study. Subjects received DTG 50 mg once daily for 5 days in Period 1, TDF 300 mg once daily for 7 days in Period 2, and DTG 50 mg once daily and TDF 300 mg once daily for 5 days in Period 3. Serial PK samples over 24 hours were collected on last day of dosing in each period. There was a 6-day washout between the first and second periods, and no washout between Period 2 and Period 3. All doses were administered in the fasting state. Results: Co-administration of TDF 300 mg once daily and DTG 50 mg once dialy had no effect on DTG pharmacokinetics, with GLS mean ratios for PK parameters ranging from 0.920 to 1.01, and confidence intervals within the bounds of 0.8-1.25 (Table 56). Co- administration of DTG 50 mg once daily and TDF 300 mg once daily resulted in an equivalence in tenofovir AUC(0-) and Cmax, and a slight increase in tenofovir trough plasma exposures (Table 55); however, the small effect is not considered clinically significant. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

46 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions: PK parameters of DTG and tenofovir during combination therapy were similar to those when either drug was given alone, demonstrating no drug interaction. Therefore, these two drugs can be taken together without dose adjustment.

2.1.3.6. Study ING111854 (Atazanavir, Atazanavir/ritonavir)

Study Title: Phase I, open-label, randomized, drug-drug interaction study in healthy subjects to investigate the effects of co-administered atazanavir/ritonavir (300 mg/100 mg) or atazanavir 400 mg administered once daily on the steady-state plasma pharmacokinetics of GSK1349572 30 mg administered once daily (ING111854)

Location of Report: m5.3.3.4, Study ING111854

Study Design: A total of approximately 24 subjects were enrolled, in order to obtain 20 evaluable subjects (10 per treatment sequence). Subjects received DTG 30 mg once daily for 5 days in Period 1, and DTG 30 mg once daily in combination with either ATV/RTV 300/100 mg once daily or ATV 400 mg once daily for 14 days in Period 2. There was no washout between treatment periods. All doses were administered following a moderate fat meal. Plasma PK samples for DTG were collected pre-dose and over 24 hours post morning dose on Day 5 in Period 1 and Day 14 in Period 2. Plasma PK samples for ATV were collected pre-dose and over 24 hours post morning dose on Day 14 in Period 2.

Results: Co-administration with ATV/RTV resulted in an increase in plasma DTG exposures; plasma DTG AUC(0-), Cmax, and C increased by 62%, 34%, and 121%, respectively (Table 56). Co-administration with ATV resulted in an increase in plasma DTG exposures; plasma DTG AUC(0-), Cmax, and C increased by 91%, 50%, and 180%, respectively (Table 56). There was no correlation between ATV exposure and treatment ratio of DTG exposure. ATV PK parameter values were consistent with historical data. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: Although co-administration of ATV/RTV or ATV with DTG resulted in increased DTG plasma exposure, this effect is not considered clinically significant based on accumulated toxicity data in animals, and safety and tolerability data in humans receiving DTG to date. Therefore it is recommended that no dose adjustment is necessary when DTG is co-administered with ATV/RTV or ATV.

2.1.3.7. Study ING111855 (Oral Contraceptives)

Study Title: A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol when Co-administered with Dolutegravir in Healthy Adult Female Subjects

Location of Report: m5.3.3.4, Study ING111855

Study Design: The treatment phase was divided into a Run-in Period and two treatment periods (Treatment Period 1 and Treatment Period 2), which were conducted successively. In the Run-in Period, subjects who were not already on a stable regimen of Ortho-Cyclen received Ortho Cyclen for one cycle of 21 days followed by washout

47 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

period of 7 days before continuing to Treatment Period 1 and 2. Subjects who were already on a stable dose of Ortho-Cyclen were permitted to skip the Run-in Period. Following the Run-in Period, subjects either received Ortho-Cyclen once daily with DTG twice daily on Days 1-11 (Period 1) and then Ortho-Cyclen with placebo on Days 12 to 21 (Period 2), or the reverse order of treatments in Period 1 and Period 2. On Days 10 and 21, subjects underwent 24-hour serial PK collection for norelgestromin (NGMN) and EE, and 12-hour serial PK collection for DTG. Study drugs were administered with a moderate fat meal on Days 10 and 21.

Results: NGMN and EE PK parameters, AUC, Cmax, and Cmin were similar between the treatment of Ortho-Cyclen with DTG and the treatment of Ortho-Cyclen with placebo (Table 55). Exposure of DTG when administered with Ortho-Cyclen was similar to historical data, suggesting Ortho-Cyclen had no effect on DTG PK. Ortho-Cyclen is an example of a combination estrogen-progestin OC. While it was selected in this study for its widespread use and fixed dose throughout the cycle, there are a wide variety of similar products. Most combination OCs use EE for the estrogen component while the progestin component may include norethindrone, drospirenone, desogestrel, or norgestimate. While there are some differences in metabolism of these drugs, the lack of an effect by DTG on either the estrogen or progestin component in this study support the use of DTG with OC brands other than Ortho-Cyclen. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: Co-administration with DTG had no effect on the pharmacokinetics of norelgestromin (NGMN) and EE in healthy female subjects receiving Ortho-Cyclen. DTG and common oral contraceptives can be co-administered without dose adjustment.

2.1.3.8. Study ING112934 (Etravirine/lopinavir/ritonavir, Etravirine/darunavir/ritonavir)

Study Title: A Phase I, open-label, randomized, three-period, one-way, two-cohort, adaptive crossover study to evaluate the effect of darunavir/ritonavir plus etravirine and lopinavir/ritonavir plus etravirine on GSK 1349572 pharmacokinetics in healthy adult subjects (ING112934)

Location of Report: m5.3.3.4, Study ING112934

Study Design:A sample size of approximately 18 subjects was targeted for enrollment to obtain approximately 12 subjects who would complete dosing and all critical assessments. Periods 1 and 2 evaluated the effect of ETR/LPV/RTV (Cohort 1) and ETR/DRV/RTV (Cohort 2) on the PK of a 50 mg once daily dose of DTG. After completion of Period 2, PK data were analyzed and a decision was made whether to conduct Period 3. The dose of DTG for Period 3 was to be determined based on the results. If a significant drug interaction was observed in Period 2, the dose regimen of DTG in Period 3 would have been adjusted to 50 mg twice daily. As no significant drug interaction was observed, Period 3 was not conducted. In Period 1, all subjects received DTG 50 mg once daily from Day 1 to Day 5. All doses were administered following a moderate fat meal in the morning. In Period 2, subjects received DTG 50 mg once daily and either ETR/LPV/RTV 200/400/100 mg twice daily (Cohort 1) or ETR/DRV/RTV 200/600/100 mg twice daily (Cohort 2) from Day 1 to Day 14. There was no washout

48 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

between treatment periods. Plasma PK samples for DTG were collected pre-dose and over 24 hours post morning dose on Day 5 in Period 1 and Day 14 in Period 2. Plasma PK samples for ETR were collected pre-dose and over 12 hours post morning dose on Day 14 in Period 2. Trough PK samples for DTG were collected on Days 5, 9, 12, and 13 in Period 2.

Results: Co-administration with ETR/LPV/RTV had no effect on DTG AUC(0-) and Cmax, while increasing C by 28% and t1/2 by 36% (Table 56). Co-administration with ETR/DRV/RTV resulted in decreased plasma DTG exposures, plasma DTG AUC(0-), Cmax, and C were on average 25%, 12%, and 37% lower when co-administered with ETR/DRV/RTV compared to DTG given alone (Table 56). Such effects of ETR/LPV/RTV and ETR/DRV/RTV on DTG exposures are not considered clinically relevant. DTG PK parameter values obtained in this study can be found in Appendix Table 3. ETR PK parameters values obtained in this study were consistent with historical data in healthy subjects.

Conclusions: Co-administration of LPV/RTV and DRV/RTV attenuated the effect of ETR on DTG exposure. DTG may be co-administered with ETR without a dosage adjustment if the subject is receiving concomitant LPV/RTV or DRV/RTV.

2.1.3.9. Study ING112941 (Omeprazole)

Location of Report: m5.3.3.4, Study ING112941

Study Design: In Part 1, Periods 1 and 2 evaluated the food effect of a high-fat meal consisting of 53% fat/869 calories on the PK of a single 50 mg dose of DTG (results are presented in m2.7.1, Section 2.3.2). Period 3 of Part 1 evaluated the effect of OMP on the single-dose DTG PK. Approximately 14 subjects were to be randomized into Part 1 of the study. In Period 1 and Period 2, enrolled subjects received a single dose DTG 50 mg under fasted conditions and with a high-fat meal in a crossover fashion. In Period 3, subjects received OMP 40 mg once daily on Days 1 to 5 after a 10-hour fast and 2 hours before a moderate fat meal. On Day 5, subjects received a single dose DTG 50 mg administered 2 hours after OMP followed by a moderate-fat meal 4 hours after receiving DTG. Plasma PK samples for DTG concentration were collected pre-dose and over 48 hours post dose on Day 5 of each period. The effect of food of Part 1 of this study is presented in module 2.7.1, Section 2.4.2.

49 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results: Co-administration with OMP had no significant effect on plasma DTG AUC(0- ), AUC(0-), Cmax, and C24 (Table 56). This result is expected as in vitro solubility evaluation did not show pH-dependent solubility of DTG over the physiological pH range. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: Co-administration with OMP had no effect on DTG plasma PK. DTG can be co-administered with OMP without dose adjustment.

2.1.3.10. Study ING113068 (Fosamprenavir/Ritonavir)

Study Title: Phase I, open label, two period, study to evaluate the effects of fosamprenavir/ritonavir (FPV/RTV) on GSK1349572 pharmacokinetics and a Phase I, randomized, three-way crossover study to evaluate the relative bioavailability of three tablet variants made using micronized, un-micronized and intermediate particle sizes of GSK1349572 in healthy adult subjects (ING113068)

Location of Report: m5.3.3.4, Study ING113068

Study Design: A total of approximately 12 subjects were enrolled in order to obtain 10 evaluable subjects. In Period 1, all subjects received DTG 50 mg once daily for 5 days. In Period 2, subjects received DTG 50 mg once daily in combination with FPV/RTV 700/100 mg twice daily for 10 days. There was no washout between treatment periods. All morning doses of study drugs were administered after a 10-hour overnight fast on PK days. Blood PK samples for plasma DTG concentrations were collected pre-dose and over 24 hours post DTG morning dose on Day 5 in Period 1 and Day 10 in Period 2. Pre- dose PK samples for DTG were collected on Days 8 and 9 in Period 2. Blood PK samples for plasma amprenavir (APV) concentration were collected pre-dose and over 12 hours post FPV/RTV morning dose on Day 10 in Period 2. Part 2 of this study evaluated the relative bioavailability of three tablet variants (micronized, un-micronized, and intermediate particle sizes) of DTG and is summarized in m2.7.1, Section 2.1.2.

Results:

APV exposure following co-administration of FPV/RTV and DTG is similar to historical data of APV; therefore, these data suggest that DTG did not affect APV exposure.

The results of the statistical comparisons showed that co-administration of FPV/RTV decreased DTG SSAUC(0-), Cmax, and C by 35%, 24%, and 49% (Table 56), respectively, resulting from increased CL/F and decreased t1/2 for DTG. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions:

 APV concentrations in combination with DTG were similar to literature values suggesting that DTG does not have a significant effect on APV exposure.

50 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 Co-administration of FPV/RTV decreased DTG plasma exposures: AUC(0-), Cmax, and C decreased by 35%, 24%, and 49% , respectively. The effect of FPV/RTV on DTG exposure is not considered clinically significant, therefore no DTG dose adjustment is necessary when co-administered with FPV/RTV (see Section 2.3.8 for details). However caution should be given to INI-resistant subjects.

2.1.3.11. Study ING113096 (Tipranavir/Ritonavir)

Study Title: An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)

Location of Report: m5.3.3.4, Study ING113096

Study Design: A total of approximately 18 subjects received DTG 50 mg once daily for 5 days in Period 1. Subjects were administered TPV/RTV 500/200 mg twice daily for 7 days in Period 2, followed by the combination of DTG 50 mg once daily and TPV/RTV 500/200 mg twice daily for 5 days in Period 3. There was no washout period between treatments. DTG doses were administered following a moderate fat meal in the morning. TPV/RTV doses were administered following a moderate fat meal in the morning and evening. Plasma PK serial samples for DTG were collected over 24 hours on Day 5 in Period 1 and over 24 hrs on Day 5 in Period 3. Plasma PK trough samples for DTG were also collected on Days 3 and 4 in Period 3.

Results: Co-administration of TPV/RTV resulted in decreased plasma DTG exposures: plasma DTG AUC(0-), Cmax, and C, were decreased 59%, 46%, and 76% (Table 56), respectively, resulting from 144% increase in CL/F and 47% decrease in t1/2. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: Co-administration with TPV/RTV resulted in a 59%, 46%, and 76% decrease in plasma DTG AUC(0-), Cmax, and C, respectively. DTG 50mg twice daily dosing is recommended when co-administered with TPV/RTV based on clinical efficacy data (see Section 2.3.8 and Section 3.4.3.2 for details)

2.1.3.12. Study ING113099 (Rifampin, Rifabutin)

Study Title: Phase I, open label, two arm, and fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers (ING113099)

Location of Report: m5.3.3.4, Study ING113099

Study Design: In all arms of the study, study drugs were administered in a fasted state.

Arm 1: In Period 1, all subjects received DTG 50 mg once daily from Day 1 to Day 7. Serial PK samples were collected over 24 hours on Day 7. Subjects received the first dose in Period 2 after the last PK sample from Period 1 was collected. Day 1 of Period 2 was the day after Day 7 of Period 1. In Period 2, all subjects received DTG 50 mg twice daily from Day 1 to Day 7. Serial PK samples were collected over 12 hours on Day 7. Day 1 of Period 3 was the day after Day 7 of Period 2. Subjects received DTG 50 mg twice daily

51 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

and RIF 600 mg once daily from Day 1 to Day 14. No evening dose of DTG were given on Day 14. Serial PK samples for DTG concentrations were collected over 12 hours on Day 14.

Arm 2: All subjects received DTG 50 mg once daily from Day 1 to Day 7. Serial PK samples were collected over 24 hours on Day 7. Subjects received the first dose in Period 2 after the last PK sample from Period 1 was collected. Day 1 of Period 2 was the day after Day 7 of Period 1. Subjects received DTG 50 mg once daily and RBT 300 mg once daily from Day 1 to Day 14. Serial PK samples for DTG concentrations were collected over 24 hours on Day 14. Subjects were discharged from the unit after the last PK sample was collected on the morning of Day 15.

Results: Co-administration of DTG 50 mg twice daily with RIF 600 mg once daily significantly reduced plasma DTG concentrations relative to DTG 50 mg twice daily alone, but resulted in 18 to 33% higher plasma DTG Cmax, AUC(0-24), and C than DTG 50 mg once daily alone.

Co-administration of DTG 50 mg once daily with RBT 300 mg once daily resulted in a 16% increase in DTG Cmax, no change in AUC(0-), and a 30% reduction in C compared DTG 50 mg once daily alone. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Table 22 Statistical Comparison of Plasma DTG Pharmacokinetic Parameters

Comparison Ratio of GLS Means (90% CI) DTG 50 mg twice daily + DTG 50 mg twice daily + DTG 50 mg once daily + RIF vs DTG 50 mg twice RIF vs DTG 50 mg once RBT vs DTG 50 mg once daily daily daily (Arm 1) (Arm 1) (Arm 2) AUC(0-) 0.460 (0.384, 0.552) ND1 0.947 (0.816, 1.10) AUC(0-24) ND 1.33 (1.15, 1.53) 0.947 (0.816, 1.10) Cmax 0.565 (0.489, 0.652) 1.18 (1.03, 1.37) 1.16 (0.978, 1.37) C0 0.282 (0.164, 0.484) 0.971 (0.566, 1.67) 0.702 (0.531, 0.928) Cmin 0.306 (0.204, 0.460) 1.15 (0.763, 1.72) 0.633 (0.541, 0.742) C 0.277 (0.228, 0.336) 1.22 (1.01, 1.48) 0.700 (0.566, 0.866) CL/F 2.17 (1.87, 2.53) 1.51 (1.30, 1.75) 1.06 (0.910, 1.22) t1/2 0.445 (0.383, 0.516) 0.396 (0.342, 0.460) 0.724 (0.642, 0.816) Source Data: m5.3.3.4, ING113099, Table 11.5 (Arm 1) and Table 11.6 (Arm 2) ND: not determined

Conclusions: DTG 50 mg twice daily is recommended when co-administered with RIF. No dose adjustment is needed when DTG is co-administered with RBT.

2.1.3.13. Study ING114005 (Efavirenz)

52 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Location of Report: m5.3.3.4, Study ING114005

Study Design: A total of 12 subjects were enrolled in order to obtain 10 evaluable subjects. In Period 2, subjects received DTG 50 mg once daily in the morning, in the fasted state, for 5 days. In Period 3, subjects received DTG 50 mg once daily in the morning plus EFV 600 mg once daily in the evening for 14 days. All DTG doses were administered in the fasted state, and all EFV doses were administered on an empty stomach. There was no washout between Treatment Periods 2 and 3. Serial plasma PK samples for DTG and its metabolites, as well as pooled urine samples for DTG and metabolite profiling, were collected over 24 hours post morning dose on Day 5 in Period 2 and on Day 14 in Period 3. Trough PK samples for plasma DTG were collected on Days 12 and 13 in Period 3. Serial plasma PK samples for EFV concentrations were collected on Day 13 in Period 3.

Results: Co-administration of DTG with EFV resulted in 57%, 39%, and 75% decreases in plasma DTG AUC(0-), Cmax, and C (Table 56), respectively, resulting from a 132% increase in CL/F and a 44% decrease in t1/2. This is likely due to the net inductive effect of EFV on CYP enzymes, and UGT enzymes as well. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Subjects who are CYP2B6 *1/*1 or *1/*6 show EFV PK exposure similar to those in the EFV product label, which shows a mean AUC(0-) of 184 M.h (58.1 g.h/mL), a mean Cmax of 12.9 M (4.07 g/mL), and a mean Cmin of 5.6 M (1.77 g/mL). [Sustiva, 2009]. Subjects who are CYP2B6*6 homozygous have 2-4 fold higher EFV exposure than CYP2B6 *1/*1 or *1/*6, consistent with other reports [Tozzi, 2010]. Therefore it is concluded that DTG did not affect EFV exposure.

Plasma and urine were analyzed by mass spectrometry to evaluate the comparative metabolic profile of DTG to understand which metabolic pathway of DTG is more affected by EFV as DTG is a substrate for UGT1A1 and CYP3A4. Plasma metabolic profiles of DTG were similar between DTG alone and in combination with EFV, with DTG being the major component, while M3 (glucuronidation) and M11 (oxidation, sulfation) were each present at mean values of <2% of DTG. These results are consistent with the plasma metabolic profile from the human mass balance study (ING111853). The urine from subjects receiving DTG in combination with EFV displayed an increase of M3 (glucuronidation), and a concomitant decrease in M1 (N-dealkylation) as compared to the metabolic profile of DTG alone. No other significant urinary metabolite differences between the two dose groups were noted (m5.3.2.2, GlaxoSmithKline Document Number RD2010/00413/00 [Study 10DMR012]).

Conclusions: Co-administration with DTG did not affect EFV exposure. Co- administration with EFV resulted in a 57%, 39%, and 75% decreased plasma DTG AUC(0-), Cmax, and C, respectively. DTG 50mg twice daily is recommended when co-administered with EFV based on clinical efficacy data (see Section 2.3.8 and Section 3.4.3.2 for details)

53 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

2.1.3.14. Study ING115696 (Prednisone)

Study Title: An Adaptive, Two part, Two period, Single Sequence, Drug Interaction Study between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers (ING115696)

Location of Report: m5.3.3.4, Study ING115696

Study Design: In Part 1, approximately 12 subjects received DTG 50 mg once daily for 5 days in Period 1. Subjects were administered DTG 50 mg once daily in combination with prednisone 60 mg for 5 days followed by a 5 day taper (total duration of 10 days) in Period 2. A formal pharmacokinetic and statistical analysis was performed at the end of Part 1 to inform the decision of whether to conduct of Part 2. If the analysis in Part 1 showed that DTG C on Day 5 or Day 10 (whichever demonstrated the bigger effect on DTG exposure) in Period 2 was reduced by more than 50% compared to C on Day 5 in Period 1, Part 2 would have been carried out. Since prednisone increased DTG PK parameters by about 20% in Part 1, Part 2 was not conducted. All doses of study drug were taken following a moderate fat meal (approximately 30% fat content). Plasma PK samples for DTG were collected pre-dose and over 24 hours post dose on Day 5 in Period 1 and Days 5 and 10 in Period 2. Pre-dose PK samples for DTG were collected on Days 8 and 9 in Period 2.

Results: DTG PK parameters were similar between Day 5 and Day 10 in Period 2. Co-administration of prednisone 60 mg once daily x 5 days + 5 days of taper with DTG (Day 10 in Period 2) resulted in an increase in the mean DTG AUC, Cmax and C by 11%, 6%, and 17% (Table 55), respectively. Steady state was reached for DTG following 5 days co-administration of DTG with prednisone. DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: No dose adjustment is needed for DTG when co-administered with prednisone.

2.1.3.15. Study ING115697 (Telaprevir, Boceprevir)

Study Title: A Phase I, Open-Label, Randomized, Two Cohort, Two Period, One-Way Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Location of Report: m5.3.3.4, Study ING115697

Study Design: A total of approximately 32 subjects were planned to be enrolled, in order to obtain 24 evaluable subjects (12 per cohort). In Period 1, all subjects received DTG 50 mg once daily for 5 days. In Period 2, subjects received DTG 50 mg once daily with either BCV 800 mg three times daily for 10 days or teleprevir (TVR) 750 mg three times daily for 10 days. There was no washout between treatment periods. All doses of study medications were taken with a moderate-fat meal or snack. Plasma PK samples for DTG were collected pre-dose and over 24 hours post dose on Day 5 in Period 1 and Day 10 in Period 2. Plasma PK samples for TVR and BCV were collected pre-dose and 1, 2, 3, 4, and 8 hours post the first morning dose of BCV and TVR on Day 10 in Period 2.

54 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results: Co-administration with BCV had no effect on plasma exposure of DTG. Co- administration with TVR resulted in increased DTG plasma exposures: AUC(0-), Cmax, C, increased by 25%, 19%, 37%, respectively (Table 56). DTG PK parameter values obtained in this study can be found in Appendix Table 3.

TVR PK parameters when co-administered with DTG were similar to historical data. BCV PK parameters were not available at this time and will be included in a subsequent amended report.

Conclusions:

 Co-administration of BCV or TVR with DTG had no clinically significant effect on DTG pharmacokinetics.  Steady-state Day 10 TVR PK data were very similar to those reported in the Incivek label, indicating no effect of DTG on TVR [Incivek, 2012].

2.1.3.16. Study ING115698 (Methadone)

Study Title: A Phase I, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone once daily with Dolutegravir (GSK1349572) 50 mg twice daily in Opiate- Dependent, HIV Seronegative Adult Subjects

Location of Report: m5.3.3.4, Study ING115698

Study Design: This was an open label, two-period study in adult male and female opiate- dependent, HIV-seronegative subjects. Twelve subjects receiving individual once daily doses of methadone were admitted to the clinical site for 3 days (Period 1) then received DTG 50 mg twice daily for 5 days while continuing on their stable methadone therapy (Period 2). Serial PK samples for measurement of plasma concentration of R-methadone and S-methadone were collected on Day 3 in Period 1, and on Day 5 in Period 2. Serial PK samples for plasma DTG were collected on Day 5 in Period 2. Study drugs were taken under fasted conditions on these PK sampling days.

Results: Plasma exposures of total, R-, and S-methadone were similar between methadone alone and when co-administered with 50 mg DTG twice daily.

55 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 23 Statistical Comparison of Plasma Methadone PK Parameters

Plasma Ratio of GLS Means Methadone PK (90% CI) Parameter Total Methadone R-Methadone S-Methadone B vs A B vs A B vs A AUC(0-) 0.98 0.95 1.01 (0.91, 1.06) (0.89, 1.02) (0.93, 1.09) Cmax 1.00 0.97 1.03 (0.94, 1.06) (0.91, 1.03) (0.97, 1.10) C 0.99 0.95 1.02 (0.91, 1.07) (0.89, 1.02) (0.93, 1.12) CL/F 1.02 1.05 0.99 (0.95, 1.09) (0.98, 1.12) (0.92, 1.07) R/S Methadone NA 0.94 NA AUC Ratio (0.92, 0.97) Source Data: m5.3.3.4, Study ING115698, Table 11.8 Treatment A: Stable individual once daily methadone dose Treatment B: DTG 50 mg twice daily x 5 days + stable individual methadone dose

DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: Co-administration of methadone with repeat doses of 50 mg DTG had no effect on total, R-, and S-methadone pharmacokinetics. No dose adjustment in methadone is required when given in combination with DTG.

2.1.3.17. Study LAI116181 (Rilpivirine)

Study Title: A Phase I, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Location of Report: m5.3.3.4. Study LAI116181.

Study Design: Cohort 1 of the study was to evaluate the drug interaction between DTG and RPV. Cohort 2 was to evaluate the drug interaction between GSK1265744 and RPV. Twelve subjects enrolled in Cohort 1 and received DTG 50 mg once daily for 5 days in Period 1, RPV 25 mg once daily for 11 days in Period 2, and DTG 50 mg once daily in combination with RPV 25 mg once daily for 5 days in Period 3. There was a 7-day washout between Period 1 and Period 2, and no washout between Period 2 and Period 3. Study drugs were taken with a moderate-fat meal. Serial PK samples were collected on the last day of each period for the measurement of plasma DTG and RPV concentrations.

Results: Co-administration of DTG with RPV resulted in no change in DTG AUC(0-), and Cmax, and a 22% increase in C [Table 56]. Co-administration of DTG with RPV resulted in no change in RPV AUC(0-) and Cmax, and a 21% increase in C (Table 55). DTG PK parameter values obtained in this study can be found in Appendix Table 3.

Conclusions: There was no significant drug interaction between DTG and RPV. DTV and RPV can be co-administered without dose adjustment.

56 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

2.2. Clinical Pharmacodynamics

2.2.1. Properties Related to Therapeutic Effect

2.2.1.1. Mechanism of Action of Dolutegravir

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration, which is essential for the HIV replication cycle.

The antiviral activity of DTG was evaluated using various HIV-1 strains and cell culture- based assays (see m2.7.2.4 for details). Peripheral blood mononuclear cells infected with HIV-1 strain BaL or HIV-1 strain NL432 gave DTG IC50s of 0.51 nM and 0.53 nM, respectively. In a viral integrase susceptibility assay using the integrase coding region from 13 clinically diverse clade B isolates, dolutegravir demonstrated antiviral potency for these isolates that was similar to that against laboratory strains, with a mean IC50 of 0.52 nM (= 0.2 ng/mL). The effect of human serum albumin (20 or 40 mg/mL), 1-acid glycoprotein (AAG) (2 mg/mL), and human serum (extrapolated up to 100%) on the antiviral activity of dolutegravir was evaluated in the PHIV or MT-4 assay systems. In vitro studies suggested a 75-fold shift in IC50 of DTG in the presence of 100% human serum (by method of extrapolation), and the PA IC90 in PBMCs was estimated to be ~150 nM (= 0.064 g/mL).

2.2.1.2. Therapeutic Endpoints Used in Clinical Trials for HIV Treatment

Plasma HIV-1 RNA (viral load) is an accepted surrogate marker for efficacy in clinical trials for antiretroviral agents [EMA, 2008; FDA, 2002], and this efficacy variable has been measured in all clinical studies of DTG in HIV-infected subjects.

In all Phase III trials in treatment-naïve (ING113086 and ING114467) and treatment- experienced/INI-naive (ING111762) subjects, as well as the Phase IIb trial in treatment- naïve subjects (ING112276), the primary efficacy endpoint was the proportion of subjects achieving HIV-1 RNA <50 c/mL at a pre-defined time point (Week 24 or Week 48). The secondary efficacy endpoints include the proportion of subjects achieving HIV-1 RNA <400 c/mL at a pre-defined time point (Week 24 or Week 48), the mean HIV-1 RNA change from Baseline (log10 c/mL), and protocol-defined virologic failures (PDVF).

In the Phase IIb and III trials in subjects with INI-resistant virus (ING112961 and ING112574), the primary efficacy endpoint is the HIV-1 RNA change from Baseline (log10 c/mL) to Day 8 or Day 11 upon DTG treatment. The secondary efficacy endpoints include the proportion of subjects achieving HIV-1 RNA <50 c/mL or <400 c/mL at Week 24, and the mean HIV-1 RNA change from Baseline (log10 c/mL) over time.

In the Phase IIa dose-ranging monotherapy trial (ING111521), the primary efficacy endpoint is the HIV-1 RNA change from Baseline (log10 c/mL) to Day 11 upon DTG treatment. The secondary efficacy endpoints include the proportion of subjects achieving HIV-1 RNA <50 c/mL or <400 c/mL at Day 10.

57 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Refer to individual clinical studies in patients in m2.7.3 for the results on HIV-1 RNA. All these efficacy endpoints were evaluated for PK/PD relationship (see Section 2.3 for summary of the PK/PD analysis results from individual studies).

2.2.2. Other Pharmacological Properties

2.2.2.1. Study ING111856 (Definitive QT)

Study Title: A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856)

Location of Report: m5.3.4.1, Study ING111856

Study Design: This was a randomized, partial-blind, placebo-controlled, single dose, cross-over trial investigating the effect of DTG on cardiac repolarisation as compared to placebo in healthy, adult males and females. Forty-two subjects were enrolled in this study and admitted to the clinic for three separate dosing sessions with a washout period of at least 10-14 days between doses (Table 24). Subjects and the investigator were only blind for DTG and placebo treatments; moxifloxacin was open label. Subjects received single dose administrations of placebo, a supratherapeutic dose of DTG (250 mg, suspension), and moxifloxacin (400 mg) in random sequence.

Table 24 Treatment Assignment

Sequence Period 1 Period 2 Period 3 1 A B C 2 A C B 3 B A C 4 B C A 5 C A B 6 C B A Note: There was a washout of 10 to 14 days between treatments and the follow-up visit. Treatment A = DTG 250 mg suspension single dose Treatment B = DTG Placebo suspension single dose Treatment C = Moxifloxacin 400 mg single dose

Safety of the subjects was monitored by clinical observation, measures of vital signs, 12- lead ECGs, and clinical laboratory measurements. Twelve-lead continuous digital data were obtained from two hours prior to dose on Day 1 until 24 hrs post dose of each treatment period using a Mortara H12 plus, 1000 Hz Holter monitor. The primary comparison of interest was the time-matched change from Baseline in QTcF between each active treatment relative to placebo (QTcF). Forty-two subjects (approximately 60% female) were enrolled to ensure that a minimum of 34 subjects completed all treatment periods. Serial pharmacokinetic samples were collected for up to 24 hours following each dose of study drug.

58 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results: DTG had no significant effect on cardiac repolarization. For the primary endpoint, QTcF, all time-matched values and their corresponding upper bounds of the 90% CI were below 10 msec for DTG. The maximum observed time-matched change from Baseline in QTcF for DTG 250 mg was at 4 hours (1.99 msec, 90% CI: -0.55, 4.53 msec). The maximum observed time-matched change from Baseline in QTcF for moxifloxacin was at 4 hours (9.58 msec, 90% CI: 7.05, 12.11 msec). Since the study had adequate sensitivity to detect a positive QT effect with moxifloxacin, it is concluded that this study was valid to assess the effects of DTG on cardiac repolarization.

Figure 5 Plot of Least Squares Mean of Treatment Difference from Placebo for QTcF Change from Baseline (90% CIs)

Source Data: m5.3.4.1, Study ING111856, Figure 12.1 Treatment: 572 = A single dose of DTG 250 mg (suspension) PBO = A single dose of DTG placebo (suspension) Moxi = A single dose of moxifloxacin 400 mg (one 400 mg tablet)

Selected DTG PK parameters after the 250 mg single dose using suspension are presented in Table 25 overall, as well as by gender. Plasma DTG exposure was similar between males and females. The DTG exposure presented in this study was at a supratherapeutic level: the geometric mean AUC(0-24) of 167 g.h/mL was about 3-fold the value estimated for DTG 50 mg once daily (53.6 g.h/mL in Table 45) and 2-fold the value estimated for DTG 50 mg twice daily in patients (75.1 g.h/mL in Table 45); the geometric mean Cmax of 12.4 g/mL was about 3.4-fold the value estimated for DTG 50 mg once daily (3.67 g/mL in Table 45) and 3-fold the value estimated for DTG 50 mg twice daily in patients (4.15 g/mL in Table 45).

59 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 25 Summary of Plasma DTG Pharmacokinetic Parameters Following a Single Dose Administrationa

Treatment Sex n Cmax AUC(0-t) AUC(0-24) tmaxb C24 (g/mL) (g.h/mL) (g.h/mL) (h) (g/mL)

DTG F 24 13.5 180 179 3.08 3.96 250 mg (22) (31) (31) (1.52-4.12) (52) M 17 10.9 151 150 3.05 3.71 (28) (35) (35) (2.05-6.05) (42) Overall 41 12.4 167 167 3.08 3.86 (27) (33) (33) (1.52-6.05) (48) Source Data: Study ING111856, Table 11.2 a. PK parameters are presented as geometric mean (%CVb) unless otherwise noted. b. Presented as median (range).

Conclusions: DTG had no effect on cardiac repolarization at a supratherapeutic dose of 250 mg suspension. The study was sensitive enough to detect the effect of moxifloxacin, the positive control, on QTcF, which confirms that this study is valid for assessing the effects of DTG on cardiac repolarization.

2.2.2.2. Study ING114819 (Effect of DTG on Renal Functions)

Study Title: A Phase I, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects (ING114819)

Location of Report: m5.3.4.1, Study ING114819

Study Design: This study was designed to confirm the mechanism behind the increase in serum creatinine observed during DTG therapy; specifically, the study was intended to determine whether DTG had any effect on glomerular filtration rate (GFR) or effective renal plasma flow (ERPF). Other biomarkers for renal function, including cystatin-C, β2- microglobulin, N-acetyl-beta-D-glucosaminidase (NAG), and retinol binding protein, were evaluated as well. Thirty-four healthy adult subjects received DTG 50 mg (twice daily or once daily) or placebo for 14 days. Subjects received iohexol and para- aminohippurate (PAH) infusions on Days -1, 7, and 14. GFR was measured by iohexol plasma clearance. ERPF was assessed by PAH plasma clearance; CrCL was measured by 24-hour urine collection. Plasma samples of iohexol were collected at predose, 0.5, 1, 1.5, 2, 3, 4, and 5 hours after the start of iohexol dose on Days -1, 7, and 14. Plasma samples of PAH were collected at 30, 90, 150, and 180 minutes after the start of the PAH loading dose on Days -1, 7, and 14. On Days -1, 4, and 10 serum and urine creatinine was collected. Serial plasma samples for DTG PK were collected on Day 14. Samples for cystatin-C, β2-microglobulin, NAG, and retinol binding protein were collected on Days - 1, 7, and 14.

60 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results: DTG decreased creatinine clearance (by 10% at 50 mg once daily and 14% at 50 mg twice daily, respectively after 14 days of dosing, after adjusted by placebo) but had no effect on GFR (as measured by iohexol plasma clearance) or ERPF, as measured by PAH plasma clearance. These data support in vitro studies that suggest the increases in creatinine observed in clinical studies are due to inhibition of OCT2 in the proximal renal tubules, which mediates the tubular secretion of creatinine.

Table 26 Statistical Analysis Summary of Iohexol Clearance, PAH Clearance, and Creatinine Clearance-Comparison of Day 14 (7)/Day -1 DTG to Day 14 (7)/Day -1 Placebo

PD Parameter Ratio of GLS Means (90% CI) DTG Once Daily vs DTG Twice Daily vs Placebo Placebo BSA-adjusted Ratio Day 7/Day -1 1.02 1.01 Iohexol Clearance [0.939, 1.11] [0.926, 1.10] (mL/min/1.73m2) Ratio Day 14/Day -1 0.993 1.05 [0.915, 1.08] [0.963, 1.14] BSA-adjusted PAH Ratio Day 7/Day -1 0.912 0.953 Clearance [0.822, 1.01] [0.857, 1.06] (mL/min/1.73m2) Ratio Day 14/Day -1 1.03 0.969 [0.921, 1.15] [0.866, 1.08] BSA-adjusted Ratio Day 7/Day -1 0.814 0.922 Creatinine Clearance [0.735, 0.901] [0.831, 1.02] (mL/min/1.73m2) Ratio Day 14/Day -1 0.900 0.861 [0.808, 1.00] [0.772, 0.960] Source Data: m5.3.4.1, Study ING114819, Table 12.6

Selected DTG PK parameters are also summarized in Table 27.

Table 27 Summary of Selected Plasma DTG Pharmacokinetic Parameters Following Repeat Dose Administrationa

Treatment N AUC(0-) AUC(0-24) Cmax C0 C (g.h/mL) g.h/mL) (g/mL) (g/mL) (g/mL) DTG 50 mg 11 39.1 39.1 2.83 0.91 0.84 once daily (38) (38) (27) (142) (61) DTG 50 mg 11 51.6 103 5.50 4.18 3.02 twice daily (36) (36) (34) (44) (40) Source Data: Study ING114819, Table 11.4 a. Data are presented as geometric mean (%CVb).

There were no correlation between DTG PK parameters [AUC(0-24), Cmax, and C] and change from Baseline in PD endpoints including iohexol clearance, PAH clearance, CrCL, cystatin-C, β2-microglobulin, NAG, and retinol binding protein.

61 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions: Administration of DTG causes a 10-14% reduction in plasma creatinine clearance, which is consistent with previous clinical studies. DTG had no effect on GFR or ERPF.

2.3. Pharmacokinetics and Pharmacokinetic-pharmacodynamic Relationship in Target Patient Population

2.3.1. PK Sampling and Analysis Strategy

In the Phase IIa and IIb studies in adults and children [ING111521, ING112961, ING112276, and ING112578 (P1093)], intensive PK samples for determination of plasma DTG concentrations were collected in all or a subgroup of subjects enrolled. DTG PK parameters were estimated using a non-compartmental approach based on intensive PK sampling. Sparse PK samples at more than one visit were also collected in as many subjects enrolled as possible.

In the Phase III studies in adults, sparse PK samples for plasma DTG concentrations were collected in 3 studies including ING113086 (treatment-naïve), ING111762 (treatment- experienced, INI-naïve), and ING112574 (treatment-experienced, INI-resistant). No DTG PK samples were collected in ING114467 (treatment-naïve). PK samples were collected in as many subjects as possible in these studies. Sparse PK samples (1 or 2 at each visit) were collected at 3 different visits over the course of the study up to the primary analysis time point (Week 48 for ING113086, and Week 24 for ING111762 and ING112574). Since C was identified as the best predictor for antiviral activity for INI (see Section 3.2.1 for details), pre-dose samples (C0) were collected at all PK visits to estimate C in all Phase III studies. An average of these C0 values collected at different visits, C0_avg, was estimated for each subject and used in PK/PD analyses.

In addition, two population PK analyses were performed using both intensive and sparse PK data collected in Phase II and III studies:

 Population PK 1: this analysis included PK data from ING111521, ING112276, and ING113086, with the purpose of developing a Population PK model that can best describe DTG PK data obtained in an HIV-positive treatment-naïve patient population (see Section 3.3.1).  Population PK 2: this analysis included PK data from ING111762, ING112961, and ING112574, with the purpose of developing a Population PK model that can best describe DTG PK data obtained in an HIV-positive treatment-experienced patient population (see Section 3.3.2).

2.3.2. Overall Strategy of PK/PD Analyses

Results from PK/PD analyse for each individual Phase II/III study are presented in this module. No PK/PD analyse using pooled data across studies has been performed due to study population difference except for the treatment-naive studies. PK/PD analyses based on pooled data from Study ING112276 and ING113086 and post-hoc estimates of DTG PK parameters were performed and results are presented in Section 3.3.1.

62 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

PK/PD Analyses for Efficacy

To be in line with the objectives of the Phase II/III studies, the primary efficacy endpoint of plasma HIV RNA and the secondary efficacy endpoint of CD4+ cell count were evaluated for PK/PD relationship.

PK/PD Analyses for Safety

To be in line with the objectives of the Phase2/3 studies, the following safety measures were evaluated for PK/PD relationship:

Phase IIb studies included:

 Change from Baseline in serum creatinine level, creatinine clearance at various time points;  Occurrence of any AEs, maximum intensity of AE per subject, key clinical laboratory parameters at various time points (including ALT, total bilirubin, creatine kinase, triglycerides, lipase, and total cholesterol);  Presence of AEs of special interest from the gastrointestinal (GI) system organ class (any GI AEs, abdominal pain, diarrhea, nausea, and vomiting) at various time points.

Phase III studies included:

 Dose-limiting AEs or SAEs likely driven by drug exposure (this was intended, but not performed due to lack of significant findings in clinical studies of DTG);  Presence of the top three most common AEs, including diarrhoea, nausea, and headache;  Lab abnormality: change from Baseline in serum creatinine, creatinine clearance, ALT, total bilirubin, albumin/creatinine ratio at the time point of primary evaluation only (e.g., only Week 48 for the treatment-naïve population, and Weeks 24 and 48 for the treatment-experienced population).

2.3.3. Study ING111521 (10-day Monotherapy, 2-50 mg Once Daily)

Study Title: A Phase IIa, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)

Location of Report: Module 5.3.4.2, Study ING111521

Study Design: This was a Phase IIa dose-ranging study to evaluate DTG monotherapy versus placebo over 10 days in ART-naïve and ART-experienced (INI-naïve) HIV-1- infected adults who were not currently receiving antiretroviral therapy. Among the primary objectives were the characterization of DTG PK in HIV-1-infected patients, and exploring the relationship between DTG PK exposure and change in plasma HIV-1 RNA.

63 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Secondary objectives included estimating DTG accumulation and time invariance, and assessing attainment of steady state following repeat administration of DTG in HIV- infected subjects, as well as examining dose proportionality of DTG PK parameters after repeat dose administration. Subjects with HIV RNA > 5000 c/ml and CD4+ cell count >100 cells/mm3 were randomized to once daily doses of DTG 2 mg ,10 mg, or 50 mg, or placebo, using a tablet formulation. Each active treatment (~8 subjects) with matching placebo (~2 subjects) was dosed in the same frequency and with a matching number of tablets to achieve the double-blind. HIV-1 RNA, genotypes/phenotypes, safety labs, vital signs, and ECGs were performed at regular intervals. Subjects were fasted overnight from 10 hours before until 4 hours after receiving investigational product on Days 1 and 10. PK samples for plasma DTG were collected over 24 hours after the first dose on Day 1, at pre-dose on Days 1-4 and 7-10, and over 24 hours after the last dose on Day 10.

Results:

Pharmacokinetics:

Following oral dose administration of the tablet formulation in HIV-infected subjects, DTG was readily absorbed (tlag=0 for the first dose on Day 1) with themaximum concentration achieved between 0.50 to 2 hours post dose across the 2 to 50 mg dose levels. With regard to DTG exposure, Day 1 AUC(0-24) and Cmax, and Day 10 AUC(0- ) and Cmax, increased less than proportionally to the increase in dose (Table 29). Following repeat-dose administration, plasma concentrations of DTG reached steady state by 7 days of dosing (Table 30) and moderate accumulation was observed in AUC, Cmax, and C, with accumulation ratios estimated to be 1.25-1.43, 1.23-1.40, and 1.27- 1.42, respectively, across the different dose levels. DTG showed time-invariant pharmacokinetics and low to moderate between-subject variability, with %CVb ranging from 16 to 51%. A summary of selected plasma DTG Day 10 PK parameters is presented in Table 28.

Table 28 Summary of Selected Plasma DTG Pharmacokinetic Parameters Following Day 10 Dose Administrationa

Dose N Cmax tmaxb AUC(0-) C Rc Rc Rc Time (g/mL) (h) (g.h/mL) (g/mL) (Cmax) (AUC) (C) Invarianced 2 mg 9 0.22 1.00 2.56 0.04 1.23 1.25 1.27 0.973 (25) (0.42-3.0) (29) (50) (28) (26) (34) [0.851, 1.11] 10 m 7 0.80 1.48 10.1 0.19 1.40 1.37 1.28 1.00 g (23) (0.50-3.0) (20) (25) (20) (15) (16) [0.898, 1.12] 50 m 10 3.34 2.00 43.4 0.83 1.36 1.43 1.42 1.07 g (16) (0.97-4.0) (20) (26) (24) (30) (33) [0.903, 1.27] Source Data: m5.3.4.2, Study ING111521. Table 11.5 a. Data are presented as geometric mean (%CVb) unless otherwise noted. b. Data are presented as median (range). c. R: Accumulation ratio d. Data are presented as GLS mean ratio [90%CI] of Day 10 AUC(0-) vs Day 1 AUC(0-).

64 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 29 Summary of Dose Proportionality of Day 1 and Day10 DTG PK Parameters Using Power Model

GLS Mean Ratio [90% CI] Plasma DTG PK Day 1 Day 10 Parameter Slope 90%CI Slope 90%CI

AUC(0-∞) or AUC(0-)a 0.849 [0.771, 0.928] 0.880 [0.824, 0.935] Cmax 0.811 [0.733, 0.888] 0.841 [0.790, 0.892] C24 0.881 [0.792, 0.969] ND ND C0 NDb ND 0.917 [0.819, 1.02] C ND ND 0.915 [0.832, 0.997] Cmin ND ND 0.915 [0.878, 1.01] Source Data: Study ING111521. Table 11.6 a. Data presented as AUC(0-∞) for Day 1 and AUC(0-) for Day 10. b. ND: Not determined

Table 30 Summary of DTG Steady State Assessment

Days Treatment Slope 90% CI 7, 8, 9, and 10 2 mg -0.054 [-0.096, -0.011] 10 mg -0.010 [-0.067, 0.048] 50 mg 0.008 [-0.046, 0.062] 8, 9, and 10 2 mg -0.037 [-0.103, 0.029] 10 mg 0.001 [-0.093, 0.095] 50 mg 0.009 [-0.089, 0.107] 9, and 10 2 mg 0.077 [-0.075, 0.229] 10 mg 0.063 [-0.190, 0.315] 50 mg -0.015 [-0.268, 0.237] Source Data: Study ING111521. Table 11.9

PK/PD Relationship:

The relationships between various PK parameters [AUC(0-τ), Cmax, Cmin, C0, Cτ, and Cτ,avg] and inhibitory quotient (IQ) and PD measures [reduction in log10 c/mL plasma HIV-1 RNA to Day 11 from Baseline, and reduction in log10 c/mL plasma HIV-1 RNA from Baseline to the on-treatment nadir (maximum change)] were explored with linear and Emax models. An Emax model (Emax fixed to 2.6,  (hill factor) fixed to 1, and PK parameter on the original scale) was selected, based on the lowest Akaike’s Information Criterion (AIC) value. Among PK parameters, the order of goodness of fit is: Cτ > Cτ,avg > Cmin > C0 > AUC(0-τ) > Cmax. The best model selected in this study is described in the equation below and presented as a graph of observed data in Figure 6.

PD Response = Emax * C/(EC50 +C) where Emax = 2.60log, EC50 = 35.68 ng/mL. where PD Response is reduction in log10 c/mL plasma HIV-1 RNA from Baseline to Day 11.

65 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 6 Relationship between Reduction in Log10 Plasma HIV-1 RNA from Baseline to Day 11 and Day 10 C with Emax model

3.0

2.5

2.0

1.5

1.0

0.5 Emax = 2.60 log10 EC50 = 35.68 ng/mL

0.0 Plasma HIV-1 RNA from Copies/mL) Baseline (log10 to Day Change 11 0 200 400 600 800 1000 1200

Ctau on Day 10 (ng/mL)

Note: Lines represent the best fitted line (solid) and 95% CI (dashed). EC90 is estimated at 320 ng/mL based on the Emax model. Data source: Study ING111521, Figure 1.

In the 50-mg dose group, seven of the 10 subjects achieved an HIV-1 RNA level less than 50 c/mL during the study and more importantly, a sustained virologic response was observed from day 11 to day 14 when DTG dose was stopped. The likely explanation is that DTG exposures remained above the protein-adjusted IC50 (0.016mg/ml) through day 14 based on the basis of the observed half-life of DTG and modelled DTG concentrations between day 11 and day 14 [Min, 2011].

Conclusions:

Pharmacokinetics:

 Following oral dosing using the tablet formulation, DTG was rapidly absorbed with maximal concentration observed at 1.5 to 2 hours post dose.  Following repeat-dose administration, plasma concentrations of DTG reached steady state by 7 days of dosing, and accumulation ratios ranged from 1.25 to 1.42 across doses.

66 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 The increase in DTG exposure (AUC and Cmax) was less than dose proportional following both single- and repeat-dose administration.  DTG showed time-invariant pharmacokinetics and moderate between-subject variability with %CVb ranging from 16 to 51%.

PK/PD Relationship:

 A mean decrease from Baseline on Day 11 in plasma HIV-1 RNA of 1.51 to 2.46 log10 c/mL was observed across the DTG doses tested (2 mg, 10 mg, 50 mg once daily) compared with placebo (0.05 log10 c/mL increase). A dose response relationship was observed.  Greater antiviral activity was associated with higher DTG plasma exposure by an Emax model. C was the PK parameter that best predicted antiviral activity. DTG exposure from 10 mg once daily dose is around EC90 and DTG exposure from 50 mg once daily is at the plateau of curve.

2.3.4. Study ING112276 (HIV-infected Treatment-Naïve, 10-50 mg Once Daily)

Study Title: A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretorviral therapy naïve adult subjects

Location of Report: m5.3.5.1, Study ING112276 (96 week analysis)

Study Design: This is a Phase IIb, randomized, multicenter, parallel group, dose-ranging study conducted in HIV-1 infected, ART-naïve adults. The trial was partially blinded( i.e., subjects and their investigators were blinded to the dose of DTG). Subjects received DTG at one of three doses (10 mg, 25 mg, or 50 mg, all given once daily), or EFV once daily, both co-administered with either abacavir sulfate (abacavir, ABC) and lamivudine (3TC), ABC/3TC fixed dose combination (FDC), or TDF/FTC FDC as background therapy. A total of 208 subjects were randomized (1:1:1:1) to one of the four treatment regimens. The primary objective of this study was to select a DTG once daily dose for further evaluation in Phase III based on a comparison of the Week 16 antiviral activity and tolerability of a range of oral doses of DTG in HIV-1 infected therapy-naïve adult subjects. One of the secondary objectives was to characterize the PK parameters of DTG, using intensive and sparse PK sampling strategies, and to explore exposure-response relationships. Serial PK samples at Week 2 were collected in a subgroup of subjects receiving DTG treatment (n=~15 per DTG dose arm). Sparse PK at Week 2, Week 12, and Week 24 were collected in most subjects receiving DTG with one pre-dose sample and one post-dose sample collected at each visit. DTG was taken with or without food.

67 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Results:

Pharmacokinetics:

DTG PK parameters estimated using a non-compartmental analysis approach, based on data from subjects providing intensive and sparse PK at Weeks 2, 12, and 24, are summarized by dose in Table 31.

Table 31 Summary of Selected DTG PK Parameters by Dose

DTG Dose AUC(0-) Cmax tmax C0 C Cmin C0_avg g.hr/mL g/mL hr g/mL g/mL g/mL 10 mg 16.0 1.10 2.0 0.31 0.30 0.33 0.34 (n=15) (40) (37) (2.0-4.0) (61) (71) (64) (49) [n=47] [n=47] [n=48] 25 mg 23.1 1.71 2.0 0.57 0.54 0.44 0.56 (n=15) (48) (43) (2.0-8.0) (62) (67) (68) (61) [n=44] [n=44] [n=46] 50 mg 48.1 3.40 2.0 1.20 1.20 0.94 1.25 (n=15) (40) (27) (1.9-4.0) (61) (62) (74) (55) [n=43] [n=44] [n=46] Data Source: m5.3.5.1, Study 112276, Table 9.3 Data presented are geometric mean (%CVb), except for tmax, which is presented as median (minimum, maximum). All PK parameters are for Week 2 except for C0_avg, which is the average pre-dose concentration at Weeks 2, 12, and 24.

DTG demonstrated moderate PK variability with %CVb ranging from 40-50% for AUC(0-), 30-40% for Cmax, and 60-70% for C in HIV-infected subjects.

All 3 DTG doses achieved DTG exposure above the in vitro PA IC90 (0.064 g/mL): geometric means of C at 10, 25, and 50 mg once daily doses were ~4-, ~8-, and ~18-fold the in vitro PA IC90. Such data supports the antiviral response observed in the DTG treatment groups.

Assessments of dose proportionality using the power model showed that Week 2 DTG PK parameters, AUC(0-), Cmax, and C, increased less than proportionally as dose increased from 10 mg to 50 mg. A dose proportionality assessment using pair wise ANOVA based on dose-normalized PK parameters showed that DTG PK exposure increased in a dose proportional manner between 25 mg and 50 mg, and less than proportionally from 10 mg to 25 mg.

PK/PD Relationship:

All three DTG doses showed rapid and sustained antiviral response and no apparent dose- response relationship was observed. An overall response rate of 82% of subjects achieving the primary endpoint of <50 c/mL plasma HIV-1 RNA through Week 96 was observed in subjects receiving DTG. A good safety and tolerability profile was observed across all the DTG doses (m2.7.4).

68 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Exposure-Antiviral Activity and Exposure-Immunologic Response Relationships

There was no apparent relationship between plasma DTG exposure and Week 2 virologic response. Plasma DTG exposure, C0_avg, was not correlated with time to virological failure at Week 96, as obtained from the TLOVR algorithm, nor with change from Baseline up to Week 96 in CD4+ cell counts. The lack of exposure-antiviral activity and exposure-immunologic response relationship is consistent with the observation of no dose-response relationship in this study.

Three subjects met protocol-defined virological failure (rebound 400 c/mL) at Week 96. Two subjects in the 10 mg DTG treatment (#77 and #808), 1 subject in the 25 mg DTG treatment (#99), and no subject in the 50 mg DTG treatment met protocol-defined virological failure. DTG PK parameters observed in these subjects were similar to the rest of the subjects in the same DTG dose group. However one subject (#99) has documented noncompliance, which likely explains virological failure at Week 24.

Exposure-Toxicity Relationship

There was a small (~10%) and non-progressive increase in serum creatinine levels upon DTG treatment, consistent with known inhibition of OCT2 by DTG. A statistically significant correlation (p<0.05) was found between DTG C0_avg values and change from Baseline in serum creatinine and creatinine clearance at all visits up to Week 96, with correlation coefficients ranging from 0.201 to 0.317 across the Week 4 to Week 96 assessments. The positive correlation coefficients suggest that serum creatinine change from Baseline was higher in subjects with higher DTG exposure. This is consistent with the observed dose-dependent increase in serum creatinine.

Statistically significant correlations (p<0.05) were found between DTG exposure and total bilirubin (positive correlation), as well as and change from Baseline in ALT (negative correlation), however these correlations were not considered clinically relevant due the small magnitude in changes of these clinical chemistries. No correlation (p >0.05) was found between DTG PK exposure and presence of abdominal pain, diarrhea, nausea, and vomiting.

Conclusions:

Pharmacokinetics:

 DTG exposure, including AUC(0-), Cmax, and C, increased as dose increased from 10 mg to 50 mg; the increase in DTG exposure is dose proportional from 25 mg to 50 mg, but less than dose proportional from 10 mg to 25 mg.  DTG PK parameters demonstrated moderate variability with %CVb estimated at 30- 50% for AUC(0-) and Cmax and 60-70% for C.  DTG 50 mg once daily dose achieved C of 1.2 g/mL (geometric mean), which is ~18-fold higher than the in vitro PA IC90 of 0.064 g/mL, supporting the dose selection of DTG 50 mg once daily in Phase III studies in INI-naïve subjects.

69 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

PK/PD Relationship:

 No dose or exposure-response relationship was found for DTG antiviral activity due to combination therapy.  There was a positive correlation between DTG dose/exposure and increase in serum creatinine from Baseline.

2.3.5. Study ING113086 (HIV-infected Treatment-naïve, 50 mg Once Daily)

Study Title: A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily compared to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects.

Location of Report: m5.3.5.1, Study ING113086 (48 week analysis)

Study Design: This is a multicenter, pivotal Phase III study. The primary objective is to compare the antiviral activity of DTG 50 mg once daily to raltegravir 400 mg twice daily over 48 weeks in HIV-1 infected therapy-naïve subjects. A total of 827 subjects were randomized (1:1) to DTG (N=413) or RAL (n=414). One of the secondary objectives is to characterize the pharmacokinetics (PK) of DTG using a sparse PK sampling strategy, and to explore exposure-response relationships of DTG [e.g., the relationship between DTG plasma exposure and virologic response or occurrence of adverse events (AEs)]. Sparse PK samples at Week 4, Week 24, and Week 48 were collected in most subjects receiving DTG. One pre-dose sample was collected at each PK visit and one post-dose sample was collected at the Week 4 and Week 48 visits. DTG was taken with or without food. The DTG pre-dose concentration (C0) was determined and used in PK/PD analyses for efficacy and safety. All DTG PK concentration data were included in a population PK analysis (Section 3.3.1).

Results:

Pharmacokinetics:

A summary of DTG C0 is provided below.

70 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 32 Summary of DTG C0

Treatment Week 4 Week 24 Week 48 C0_avg (g/mL) C0 C0 C0 Overall by Response by Background (g/mL) (g/mL) (g/mL) Therapy

Non- Responders ABC/3TC TDF/FTC responders

DTG 1.05 1.17 1.13 1.18 1.20 1.17 1.16 1.19 50 mg (69)[379] (71) [365] (72)[351] (60)[399] (74)[41] (58)[358] (61)[165] (59)[234] once daily Data Source: m5.3.5.1, Study 113086, Table 9.3 Data presented are geometric mean (%CVb) [n]. C0_avg is average of C0 at Week 4, Week 24, and Week 48.

PK/PD Relationship:

No correlation was observed between plasma DTG exposure (C0_avg) and virologic response (Snapshot response or PDVF) based on box-plots and logistic regression analysis. The lack of PK/PD relationship for efficacy is due to the potency of combination therapy resulting in more than 88% subjects on DTG treatment achieving HIV-1 RNA values <50 c/mL at Week 48.

There was no statistically significant correlation (p>0.05) between DTG C0_avg and the occurrence of the top three most common AEs: diarrhea, headache, or nausea based on graphic exploration and logistic regression.

No statistically significant correlation was found between DTG C0_avg and safety variables including change from Baseline in ALT. There was a statistically significant correlation (p<0.05) between DTG C0_avg and maximum change in total bilirubin, creatinine, and creatinine clearance. The higher the DTG C0_avg, the greater the increase from Baseline in total bilirubin and serum creatinine, and the lower the change in creatinine clearance. However, due to the small magnitude of changes in these clinical lab measures, these PK/PD relationships are not considered clinically relevant.

Conclusions:

Pharmacokinetics:

 DTG pre-dose concentrations (C0) and moderate variability are consistent with prior studies, with average C0 well above the in vitro PA IC90, supporting the antiviral response observed in the DTG treatment group.

71 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

PK/PD Relationship:

 DTG pre-dose concentrations were similar between PDVF and non-PDVF subjects. There was no correlation between DTG pre-dose concentratins and virologic response (Snapshot).  No clinically relevant relationship was observed between concentrations and predefined safety assessments/endpoints.

2.3.6. Study ING112961 (HIV-infected Treatment-experienced Integrase- inhibitor-resistant, 50 mg Once Daily and 50 mg Twice Daily)

Title: A Phase IIb pilot study to assess the antiviral activity of dolutegravir containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance

Location of Report: m5.3.5.2, Study ING112961 (Cohort II Week 48 analysis)

Study Design: This is Phase IIb dose-ranging study to assess the antiviral activity, safety, and PK of DTG with failing background regimen (short-term, 10 days only), as well as optimized background therapy from Day 11 to Week 96 in subjects with demonstrated INI resistance. Among the secondary objectives were an assessment of steady-state plasma DTG PK at Day 10, Week 4, and Week 24, and an evaluation of the PK/PD relationship. A total of 51 subjects enrolled in study: 27 subjects enrolled in Cohort I (DTG 50 mg once daily) and 24 subjects in Cohort II (50 mg twice daily). Cohort II was enrolled upon data review of Day 11 response in Cohort I. Subjects received DTG with failing background regimens on Day 1-10, and with optimized background regimens from Day 11 and onward. Serial DTG PK samples were collected on Day 10 and sparse PK samples were collected at Week 4 and Week 24 in all subjects with one pre-dose sample and one post-dose sample collected at each of the PK visits. DTG was taken with or without food.

Results:

Pharmacokinetics:

The DTG PK data from Cohort I (50 mg once daily) and Cohort II (50 mg twice daily) are summarized below.

72 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 33 Summary of Selected PK Parameters of DTG

Treatment Day 10 Week 4 Week 24 Cmax tmax AUC(0-24) C C0 Cmin C0 C0 (g/mL) (h) (g.h/mL) (g/mL) (g/mL) (g/mL) (g/mL) (g/mL) Cohort I 3.04 2.97 36.5 0.69 0.51 0.48 0.57 0.38 (50 mg (38) (1.97-7.92) (53) (91) (139) (136) (100) (114) once daily) (n=24) (n=20) (n=17) n=25 Cohort II 5.41 2.00 93.4 2.72 3.20 2.61 2.55 2.38 (50 mg (40) (0-7.87) (50) (70) (69) (67) (63) (69) twice daily) (n=24) (n=21) n=23 Data Source: m5.3.5.2, Study 112961, Table 9.2. Data presented are geometric mean (%CVb) except for tmax where median (range) is presented.

Values for the phenotypic inhibitory quotient (PIQ), a parameter representing the DTG exposure fold coverage above the viral PA-IC90 and Baseline fold change, are provided in Table 34.

Table 34 Summary of PIQ Values of DTG

Treatment Day 10 Week Week 4 24 PIQ_Cavg PIQ_Cmax PIQ_C PIQ_C0 PIQ_Cmin PIQ_C0 PIQ_C0 Cohort I (50 mg once 10.2 20.4 5.16 3.33 3.20 3.64 3.13 daily) (237) (202) (283) (311) (327) (211) (130) n=25 (n=24) (n=20) (n=17) Cohort II 21.64 30.1 15.1 17.8 14.5 14.4 13.8 (50 mg twice daily) (107) (108) (125) (129) (116) (113) (103) n=23 (n=24) (n=21) Data Source: Study 112961, Table 9.2. Data presented are geometric mean (%CVb).

DTG PK exposures and PIQ values were similar at Day 10, Week 4, and Week 24 within each cohort but higher in Cohort II.

PK/PD Relationship Between DTG Exposure and Plasma HIV-1 RNA Change from Baseline to Day 11 (as a continuous variable)

 Univariate Analysis

Among all the PK parameters examined, including Day 10 plasma DTG AUC(0-24), Cmax, Cmin, C0, and C, and PIQs [PIQ_C0, PIQ_Cavg, PIQ_Cmax, PIQ_Cmin, and PIQ_C], only PIQ, a parameter incorporating Baseline susceptibility to DTG was found to be statistically significantly (p<0.001) correlated with plasma HIV-1 RNA change from Baseline at Day 11. Among the PIQs evaluated, PIQ_Cavg and PIQ_Cmax were found to be the best predictors for plasma HIV-1 RNA change from Baseline at Day 11, based on the lowest Akaike’s Information Criterion (AIC) values. PIQ_Cavg was used in the subsequent multivariate analysis.

73 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

The relationship between PIQ_Cavg and reduction in plasma HIV RNA at Day 11 is best described by an Emax model as detailed in the previous ING112961 clinical study report [Study ING112961, Table 7.9 and Figure 7.12).

 Multivariate Analysis

The final best model included: phenotypic susceptibility score (PSS) of the Day 1-10 regimen, IN mutation pathway, and PIQ_Cavg (based on AIC reduction), but only PIQ_Cavg and PSS were statistically significant predictors (p<0.05) of the virological response at Day 11.

PK/PD Relationship Between DTG Exposure and Plasma HIV-1 RNA Change from Baseline at Day 11 >0.7 log10 c/mL (as a categorical variable)

Based on univariate logistic regression, PIQs were identified as statistically significant predictors for this Day 11 antiviral activity endpoint (p<0.05). As PIQ increases, the possibility of achieving plasma HIV-1 RNA change from Baseline at Day 11 >0.7 log10 c/mL increases.

Relationship between DTG Exposure and Long-term Virological Response (Week 48)

Based on univariate logistic regression using pooled data from both cohorts, C0, Cmin, and C (on log scale), and PIQ_C0 and PIQ_Cmin (on both linear and log scale) were determined to be the statistically significant predictors for virological response (plasma HIV RNA <50 c/mL based on TLOVR) at Week 48 (p<0.05).

Relationship between DTG Exposure and Safety Parameters

No statistically significant correlation was found between examined DTG PK parameters and safety measures, except for the following: there was a statistically significant correlation (p<0.05) between DTG PK [AUC(0-24), Cmax, Cmin, and C0] and creatinine change from Baseline at Day 11. The higher the DTG exposure, the greater the increase from Baseline in serum creatinine. Such correlation diminished over time and became statistically insignificant at Day 21 and beyond.

Conclusions:

Pharmacokinetics:

 The PK parameters estimated at Day 10, Week 4, and Week 24 were similar within cohorts, with higher exposures observed in Cohort II compared to Cohort I, consistent with the increased dose administered.

PK/PD Relationship:

 Based on multivariate analysis assessing DTG PK measures and other covariates on antiviral activity, PIQ and PSS of failing regimens at Days 1-10 were statistically significant predictors of change from Baseline in plasma HIV-1 RNA at Day11.

74 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 A significant positive correlation (p<0.05) between DTG PK exposure (AUC, Cmax, and C0) and serum creatinine increase from Baseline was observed, but such correlation diminished over time becoming insignificant at Day 21 and beyond.

2.3.7. Study ING112574 (HIV-infected Treatment-experienced Integrase- inhibitor-resistant, 50 mg Twice Daily)

Study Title: A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen

Location of Report: m5.3.5.2, Study ING112574 (Week 24 analysis)

Study Design: This is a multicenter, single arm, open-label study to assess the antiviral activity and safety of a DTG-containing regimen in HIV-1 infected, ART-experienced adults who experienced virological failure on an INI containing regimen with historical or current evidence of genotypic and/or phenotypic resistance to RAL or elvitegravir (EVG). Among the secondary objectives was the characterization of the pharmacokinetics (PK) of DTG using a sparse PK sampling strategy and a population modelling approach, an evaluation of the effect of patient characteristics (e.g. demographic factors) and concurrent medications (as covariates) on PK parameters of DTG, and an assessment of the PK/PD relationship. All subjects received 50 mg DTG twice daily along with their current failing background therapy for 7 days before switching to DTG 50 mg twice daily with an optimized background regimen (OBR) from Day 8 onward (the OBR included at least one active drug). A total of 183 subjects were enrolled and provided Day 8 data; 114 subjects provided Week 24 data on efficacy and safety. Sparse PK samples were collected at Day8, Week 4, and Week 24 in the majority of subjects, with one pre-dose sample and one post-dose sample collected at each visit. DTG was taken with or without food. The DTG pre-dose concentration (C0) was determined from PK samples collected. Average C0 (C0_avg) was estimated for each subject as the average of C0 observed at Day 8, Week 4, and Week 24, and used in study- level PK/PD analyses for efficacy and safety. All DTG PK concentration data were included in a population PK analysis (Section 3.3.2).

Results:

Pharmacokinetics:

Plasma DTG C0 and PIQ_C0 were consistent across visits (Table 35). The overall geometric mean plasma DTG pre-dose concentration (C0_avg) was 2.35 g/mL, with high variability (between-subject coefficient of variation [%CVb] of 70%). The geometric mean PIQ_C0_avg was 19.7, and PIQs ranged from 0 to 204.

75 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 35 Summary of DTG C0 and PIQ_C0 by Visit

Treatment Plasma DTG C0 (g/mL) PIQ_C0 DTG 50 mg Day 8 Week 4 Week 24 Average Day 8 Week 4 Week 24 Average twice daily (N=148) (N=160) (N=81) (N=178) (N=142) (N=154) (N=77) (N=171) 2.36 1.94 2.18 2.35 19.4 17.1 22.4 19.7 (91) (106) (98) (70) (202) (206) (204) (177) Data Source: m5.3.5.2, Study ING112574, Table 9.3 Data are presented as geometric mean (%CVb).

In the Week 24 ITT-E population (n=114). plasma DTG C0_avg was similar between virology responders and non-responders (where response was defined as <50 c/mL at Week 24), Baseline HIV-1 RNA categories (>100,000 vs 100,000 c/mL), hepatitis infected and non-infected subjects, and subjects who did and did not receive concomitant moderate to strong metabolic (CYP3A4/UGT) inducers (TPVr/ and EFV) in their OBR (Table 36). A small number of subjects (n=3) received ATV/RTV, a UGT1A1 inhibitor, and showed higher DTG exposure.

Table 36 Summary of DTG C0 and PIQ_C0 by Subgroup

Treatment Subgroup DTG Week 24 Virological Response 50 mg (Snapshot algorithm for Week 24 ITT(E) Population) twice daily C0_avg (g/mL) PIQ_C0_avg Non-responders Responders Non-responders Responders N=41 (N=72) N=41 N=68 2.33 2.44 12.7 26.7 (77) (63) (183) (143) Baseline Viral Load Category C0_avg (g/mL) PIQ_C0_avg 100,000 c/mL >100,000 c/mL 100,000 c/mL >100,000 c/mL (N=138) (N=40) (N=131) (N=40) 2.33 2.45 19.2 21.4 (67) (80) (177) (179) HBV/HCV Status C0_avg (g/mL) PIQ_C0_avg HBV HCV Hepatitis HBV HCV Hepatitis (N=10) (N=25) Negative (N=10) (N=24) Negative (N=141) (N=135) 2.97 2.06 2.41 32.3 20.1 19.1 (89) (57) (67) (135) (161) (182) Co-administration of Moderate/Strong Metabolic (CYP3A/UGT) Inducers C0_avg (g/mL) PIQ_C0_avg Inducers Not Co- Inducers Co- Inducers Not Co- Inducers Co- administered (n=103) administered (n=8) administered (n=98) administered (n=8) 2.34 2.21 20.0 14.0 (68) (30) (168) (181) Data Source: Study ING112574, Table 9.3 Data are presented as geometric mean (%CVb). C0_avg is the average of C0 at Day 8, Week 4, and Week 24.

76 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

PK/PD Relationship:

Day 8 plasma DTG C0 was not a significant predictor of change from Baseline to Day 8 in plasma HIV-1 RNA in the multivariate linear regression analyses that included either Baseline fold-change in DTG IC50, or Baseline number of INI resistance mutations as a measure of viral susceptibility. Plasma DTG C0 at Day 8 was, however, a significant predictor when INI mutational pathway was included. The estimated effect in all three models was small at -0.04 to 0.05 log10 change from Baseline to Day 8 in plasma HIV-1 RNA for each 1 g/mL increase in Day 8 plasma DTG C0.

Plasma DTG C0_avg was not a significant predictor of Week 24 virological response in multivariate logistic regression analyses.

There was no correlation between DTG C0_avg and occurrence of the top three most common AEs (i.e., diarrhoea, headache, or nausea), nor with change from Baseline in clinical laboratory measures including ALT, total bilirubin, serum creatinine, creatinine clearance, and the urine albumin/serum creatinine ratio.

Conclusions:

Pharmacokinetics:

 Subjects receiving DTG 50 mg twice daily achieved an average C0 approximately 2- fold higher than previously reported with 50 mg once daily in treatment-naïve subjects in ING113086. Similar exposures were observed in eight subjects receiving inducers of CYP3A4/UGT1A1 compared to those not receiving these agents.

PK/PD Relationship:

 Plasma DTG C0_avg was not statistically predictive of Day 8 or Week 24 antiviral response.  Plasma DTG C0_avg was not correlated with the three most frequently reported AEs or with clinical laboratory tests of interest.

2.3.8. Study ING111762 (HIV-infected Treatment-experienced Integrase Inhibitor-naïve, 50 mg Once Daily)

Study Title: A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV- 1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults

Location of Report: m5.3.5.1, Study ING111762 (Week 24 analysis)

Study Design: This is a multicenter pivotal Phase III study in treatment-experienced, INI-naïve subjects. The primary objective of the study is to assess the non-inferiority (NI margin=12%) of DTG 50 mg once daily to RAL 400 mg twice daily, using the proportion of subjects with HIV-1 RNA <50 c/mL (MSD=F, Snapshot algorithm) through Week 48 as the primary endpoint. A total of 724 subjects were randomized (1:1) to DTG (N=362)

77 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

or RAL (n=362). One of the secondary objectives is to characterize the pharmacokinetics (PK) of DTG using a sparse PK sampling strategy, and to explore exposure-response relationships of DTG (e.g., the relationship between DTG plasma exposure and efficacy response or occurrence of adverse events). Sparse PK samples at Week 4, Week 24, and Week 48 were collected in most subjects receiving DTG. One pre-dose sample was collected at every PK visit, and one post-dose sample was collected at the Week 4 and Week 48 visits. DTG was taken with or without food. DTG concentrations in pre-dose samples, C0, were obtained. C0_avg, the average C0 at Week 4 and Week24, was calculated for each subject and used in study-level PK/PD analyses for efficacy and safety. All DTG PK concentration data available by a cut-off of were included in a population PK analysis (Section 3.3.2).

Results: This report presents all PK data obtained at Week 4 and partial data at Week 24 and Week 48.

Pharmacokinetics:

Table 37 Summary of DTG C0 by Visit

Treatment Plasma DTG C0 (g/mL) DTG Week 4 Week 24 Week 48 C0_avg of Week 4 and 50 mg (N=329) (N=262) (N=106) Week 24 (N=337) once daily 0.786 (143) 0.956 (129) 0.907 (147) 0.856 (140) Data Source: m5.3.5.1, ING111762, Table 9.3 Data presented as geometric mean (%CVb)

Based on the subgroup analysis (Table 38), plasma DTG C0_avg:

 Was lower in non-responders than responders (<50 c/mL at Week 24 based on Snapshot);  Was lower in protocol-defined virologic failure (PDVF) subjects than non-PDVF subjects;  Was similar by Baseline HIV-1 RNA categories (>50,000 vs 50,000 c/mL);  Was similar between HCV co-infected subjects and subjects with no HBV or HCV co-infection, but seems to be higher in HBV co-infected subjects.

78 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 38 Summary of DTG C0_avg (g/mL) by Subgroup

Treatment Subgroup (Week 24 mITT(E) population) DTG Week 24 Snapshot Virological Response 50 mg Non-responders Responders once daily (N=60) (N=275) 0.673 (259) 0.897 (120) Week 24 PDVF PDVF Non-PDVF (N=14) (N=321) 0.369 (1091) 0.884 (124) Baseline Viral Load Category 50,000 c/mL >50,000 c/mL (N=237) (N=100) 0.862 (146) 0.843 (129) HBV/HCV Co-infection Status HBV only HCV only Hepatitis Negative (N=15) (N=28) (N=277) 1.30 (65) 0.777 (87) 0.857 (140) Data Source: ING111762, Table 9.3 Data are presented as geometric mean (%CVb).

Effect of Metabolic Inducers:

TPV/RTV and EFV

Subjects on TPV/RTV and EFV showed lower DTG C0_avg (78% lower) and lower virologic response rate (based on Snapshot analysis) than subjects not on these inducer or inhibitors (Table 39). All 5 non-responders on these inducers had virologic failures due to viral load not being suppressed <50 c/mL through Week 24 rather than other reasons (e.g., early withdraw due to safety reasons). DTG 50 mg twice daily is recommended when co-administered with TPV/RTV and EFV (see Section 3.4.3.2 for rationale).

Table 39 Summary of DTG C0_avg and Snapshot Response Rate by Use of TPV/RTV, EFV, and ETR

N DTG C0_avg Snapshot Responders (g/mL) (<50 c/mL) On inducera 16 0.169 (209) 11/16 (68.8%) Not on inducer or 268 0.774 (119) 222/268 (82.8%) inhibitorb Data source: ING111762, Table 9.5 Data presented are geometric mean (%CVb) for DTG C0_avg and number of responder over total number of subjects (percentage of responders, %). a. Including 1 subject on ETR without RTV-boosted protease inhibitors. b. Inhibitors are ATV and ATV/RTV.

79 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

FPV/RTV

DTG C0_avg in subjects on FPV/RTV had a geometric mean (%CVb) of 0.266 g/mL (149%), which is similar to that observed in the Phase I drug interaction study (0.31 g/mL, Study ING113068). Despite the reduced DTG exposure, the virologic response rate (Snapshot analysis) was 80% (8 out of these 10 subjects) (data source: ING111762, Table 9.5), comparable to the response rate in subjects not on inducers (82.9%). Based on the Phase I study (ING113068), the geometric mean ratio (90% CI) of DTG C0 for DTG + FPV/RTV vs DTG alone is 0.51 (0.41-0.63). The lower bound of the 90% CI remains higher than 0.25, which is the lower bound of the “no effect boundary” defined based on the cumulative understanding of the PK/PD relationship of DTG (3.2.3.1). It is recommended that no DTG dose adjustment is necessary when co-administered with FPV/RTV.

Once Daily Dosing of DRV/RTV

Effect of twice daily dosing of DRV/RTV (600/100 mg) on DTG PK was evaluated in Phase 1 studies (ING111405, Section 2.1.3.2; ING112934, Section 2.1.3.8) which showed no clinically significant impact on DTG PK. The impact of once daily dose of DRV/RTV (800/100mg) was evaluated in this study. Subjects on once daily DRV/RTVas part of their background therapy (N=43) demonstrated (Table 40):

 Slightly higher DTG C0_avg than subjects on twice daily DRV/RTV;  Slightly lower DTG C0_avg than subjects on LPV/RTV;  Similar or higher virologic response rate (Snapshot analysis) as those in subjects on twice daily DRV/RTVor LPV/RTV.

Table 40 Summary of DTG C0_avg and Snapshot Response Rate by Use of RTV-boosted Protease Inhibitors

N DTG C0_avg Snapshot Responder (g/mL) (<50c/mL) DRV/RTVOnce 43 0.760 (105) 38/43 (88.4%) Daily DRV/RTVTwice 92 0.645 (110) 77/92 (83.7) Daily LPV/RTV Twice 86 0.890 (138) 68/86 (79.1%) Daily Others 114 1.093 (174) 92/114 (80.7%)

Data source: ING111762, Table 9.5 Data presented are geometric mean (%CVb) for DTG C0_avg and number of responder over total number of subjects (percentage of responders).

It is recommended that no DTG dose adjustment is necessary when co-administered with once daily dosing of DRV/RTV.

80 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG C0_avg in subjects on DTG and twice daily DRV/RTV (geometric mean of 0.645 g/mL) observed in this study was about 45% lower than those observed in the Phase III treatment-naïve study ING113086 (1.18 g/mL as the geometric mean, Section 2.3.5), which was similar to that observed in Phase I studies, about 38% reduction on DTG C by twice daily DRV/RTV (ING111405 and ING112934; Table 56).

ATV and ATV/RTV

DTG C0_avg in subjects on UGT1A1/CYP3A inhibitors ATV (n=5) or ATV/RTV (n=46) was estimated at 2.34 g/mL, which is about 98% higher than DTG C0_avg observed in ING113086 (1.18 g/mL as the geometric mean, Section 2.3.5). The magnitude of the effect of ATV or ATV/RTV on DTG C0 observed in this study was similar to that observed in the Phase I drug interaction study (Study ING111854; Table 56). Despite higher DTG concentration, similar Snapshot response rate was observed in subjects on ATV or ATV/RTV compared to subjects not on these inhibitors.

PK/PD Relationship for Virological Response:

When using all available data, DTG exposure [C0_avg (log2 transformed)] was a statistically significant predictor of efficacy response [Snapshot response, PDVF, and Efficacy Related Discontinuation = Failure (ERDF) response] based on univariate logistic regression analyses, as well as a multivariate analysis (Table 41). This multivariate regression model also evaluated Baseline HIV-1 RNA, DRV/RTV use in background regimen without primary PI mutations, and Baseline PSSf (i.e., PSS with full sensitivity only) score of background ART, and identified Baseline HIV-1 RNA as a significant predictor of Snapshot response in addition to DTG C0_avg.

Table 41 Summary of Multivariate Logistic Regression of Snapshot Response at Week 24

Factor Effect of Odds Ratio 95% CI p-value DTG C0_avg 2-fold increase 1.273 (1.095, 1.480) 0.002 (g/mL) Baseline HIV-1 >50,000 vs 0.482 (0.267, 0.869) 0.015 RNA (c/mL) 50,000 DRV/RTV use in Yes vs no 1.105 (0.536, 2.274) 0.787 background therapy without primary PI mutations Baseline PSSf of 2 vs <2 1.031 (0.542, 1.960) 0.926 background therapy Data Source: ING111762, Table 7.37.

As the results from the above analysis (using all subjects) was confounded by the use of moderate-strong inducers (TPV/RTV, EFV, and ETR without RTV-boosted protease inhibitors) in the background therapy and noncompliance, additional analysis was

81 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

performed by excluding subjects on these inducers and of noncompliance (defined as with at least one non-detectable DTG concentration at Week 4 or Week 24). The analysis using censored data demonstrated that DTG drug exposure, C0, was no longer a statistically significant predictor of efficacy response (Table 42). This finding implies that DTG doses higher than the studied dose of 50 mg once daily (therefore higher DTG exposure) may not be beneficial (from an efficacy standpoint) in the study population evaluated, except for subjects using moderate to strong inducers in their background therapy. Therefore, the PK/PD results for efficacy supported the dose recommendation of DTG 50 mg once daily in the treatment-experienced, INI-naïve population, and a DTG dose adjustment to 50 mg twice daily is necessary for subjects who require co- administration with TPV/RTV and EFV.

Table 42 Summary of Multivariate Logistic Regression of Snapshot Response at Week 24 (Data Censored on Use of Inducersa in Background Therapy and Noncomplianceb)

Factor Effect of Odds Ratio 95% CI p-value DTG C0_avg 2-fold increase 1.047 (0.816, 1.344) 0.718 (g/mL) Baseline HIV-1 >50,000 vs 0.510 (0.269, 0.965) 0.038 RNA (c/mL) 50,000 DRV/RTV use in Yes vs no 0.989 (0.450, 2.171) 0.978 background therapy without primary PI mutations Baseline PSSf of 2 vs <2 1.150 (0.579, 2.284) 0.690 background therapy Data Source: ING111762, Table 7.50 a. Inducers include TPV/RTV, EFV, and ETR without RTV-boosted protease inhibitors. b. Noncompliance is defined as having at least one non-detectable DTG concentration at Week 4 or Week 24.

PK/PD Relationship for Safety

 There was no statistically significant correlation (p>0.05) between DTG C0_avg and occurrence of the top four most common AEs: headache, upper respiratory tract infection, diarrhea, and nausea  There was no statistically significant correlation (p>0.05) between DTG C0_avg and change from Baseline in clinical laboratory measures that included ALT and the urine albumin/serum creatinine ratio.  There was a statistically (p<0.05) significant correlation between DTG C0_avg and change from Baseline of clinical laboratory measures that included total bilirubin, serum creatinine, and creatinine clearance. The higher the DTG C0_avg, the greater increase from Baseline in total bilirubin and serum creatinine, and the greater the decline in creatinine clearance.

82 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions:

Pharmacokinetics:

 Trough DTG concentrations observed in treatment-experienced subjects were lower than that observed in treatment-naïve subjects, likely due to drug interactions with concomitant medications, including antiretrovirals, and less optimal compliance.  DTG should be given at 50 mg twice daily when co-administered with TPV/RTV and EFV.  DTG can be co-administered with FPV/RTV without dose adjustment.  DTG can be co-administered with once or twice daily DRV/RTVwithout dose adjustment.

PK/PD Relationship:

 DTG drug exposure, C0, was a statistically significant predictor of Week 24 efficacy response using data from all subjects, but was not a predictor once subjects with evidence of non-compliance or on moderate/strong inducers were excluded.  The only PK/PD relationship observed between DTG and safety measureswas a correlation wtih total bilirubin and serum creatinine, likely due to benign competition between DTG and unconjugated bilirubin for UGT1A1 and an expected effect of DTG on OCT2, respectively.

2.3.9. Study ING116070 (Cerebrospinal Fluid)

Study Title: A single-arm study of the safety, efficacy and central nervous system and plasma PK of GSK1349572 (dolutegravir, DTG) 50 mg once daily in combination with the abacavir/lamivudine fixed dose combination tablet over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects. Location of Report: m5.3.4.2, Study ING116070 (Week 2 interim analysis) Study Design: This study in approximately 14 HIV-1 infected, ART-naïve adult subjects assessed the cerebral spinal fluid (CSF) penetration of DTG dosed at 50 mg once daily in combination with the abacavir/lamivudine (ABC/3TC) fixed dose combination (FDC) tablet at Weeks 2 and 16. One pair of PK samples, in plasma and CSF (matching time) for determination of DTG concentration (total and unbound concentration in plasma and total concentration in CSF), were collected at Week 2 and Week 16 from each subject. Samples for plasma HIV-1 RNA were collected at Baseline and various time points throughout the study, and samples for HIV-1 RNA levels in the CSF were collected at Baseline, Week 2, and Week 16. Results: The study is currently ongoing; results presented are based on the last subject completing the Week 2 visit. A total of 13 subjects enrolled in this study. Twelve subjects were ongoing at the time of analysis and one subject withdrew early due to an adverse event. All (100%) subjects were white males, 23% were of Hispanic ethnicity, and the mean age was 40 years. Twelve subjects provided evaluable PK data, and eleven subjects provided paired plasma/CSF samples.

83 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Efficacy Results:

At Week 2, 4/13 (31%) and 8/13 (62%) of subjects had plasma HIV-1 RNA <50 c/mL and <400 c/mL, respectively, using the FDA snapshot MSDF algorithm. This increased to 46% and 92%, respectively, by Week 4. The median change from Baseline in plasma HIV-1 RNA at Week 2 was -2.53 log10 c/mL, and at Week 4 was -3.04 log10 c/mL.

At Week 2, 7/12 (58%) and11/12 (92%) of subjects had CSF HIV-1 RNA <50 c/mL and <400 c/mL, respectively, using an Observed Dataset. The median change from Baseline to Week 2 in CSF HIV-1 RNA was -2.18 log10 c/mL.

At Week 2, there was no statistically significant correlation between CSF and plasma change from Baseline in HIV-1 RNA levels (Pearson Correlation Coefficient [P-value] = 0.237 [0.458]).

Pharmacokinetic and PK/PD Results:

DTG CSF concentrations exceeded in vitro IC50 of DTG (0.51nM = 0.00021 g/mL). The ratio of DTG CSF to plasma concentration was similar to the unbound fraction of DTG.

Table 43 Summary of DTG Concentration in CSF and Plasma at Week 2

Week 2 Result PK Variable, n median (range) CSF (g/mL), n=11 0.0182 (0.0040 – 0.0232) Total Plasma (g/mL), n=12 3.36 (2.09 – 5.28) Unbound Plasma (g/mL),n=12 0.0171 (0.0103 – 0.0240) Unbound Fraction (%), N=12 0.49 (0.33 – 0.65) CSF/Plasma Ratio (%) 0.52 (0.11 – 0.66) Source Data:m5.3.4.2, ING116070, Table 9.3, Table 9.4 and Table 9.6

At Week 2, there was no significant correlation between CSF and total plasma DTG concentrations (Pearson Correlation Coefficient [P-value] = 0.267 [0.427]) or between CSF and unbound plasma DTG concentrations (Pearson Correlation Coefficient [P-value] = 0.434 [0.183]). There was no statistically significant correlation between CSF DTG concentration and absolute CSF HIV-1 RNA levels (Pearson Correlation Coefficient [P- value] = 0.567 [0.069]) ,or between CSF DTG concentration and change from Baseline in CSF HIV-1 RNA (Pearson Correlation Coefficient [P-value] = 0.007 [0.983]).

Conclusions:

 DTG was detected in the CSF with median (range) concentrations of 0.0181 (0.0040- 0.0232) g/mL. DTG concentrations in CSF were similar to the unbound DTG concentrations in plasma. However, no correlation of DTG concentrations in the plasma and CSF was observed.

84 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 DTG concentrations observed in CSF exceed in vitro IC50 against wild-type viruses (0.0002 g/mL) suggesting that DTG is able to reach sanctuary sites within the CNS at therapeutic concentrations.  A regimen of DTG + ABC/3TC was effective in decreasing CSF HIV-1 RNA levels with a median decrease of -2.18 log10 c/mL at Week 2.  No direct correlation of DTG CSF concentrations and change from Baseline in CSF HIV-1 RNA levels was observed likely due to combination therapy and the potent antiviral activity across subjects at Week 2 (decreases in CSF HIV-1 RNA from Baseline ranged from -1.29 to -3.11 log10 c/mL).  Median decreases in CSF HIV-1 RNA levels at Week 2 were similar to those observed in plasma (-2.53 log10 c/mL). 3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES

3.1. Clinical Pharmacokinetics

3.1.1. Summary of Pharmacokinetic Parameters in Healthy Subjects and HIV-infected Subjects

A meta-analysis of DTG PK parameters from DTG 50 mg once daily and twice daily dosing observed in Phase I studies was conducted (m5.3.5.3 CPM). In general, plasma DTG PK parameter values following single- and repeat-dose DTG 50 mg tablet administration are similar between healthy and HIV-infected subjects (Table 44; Table 45). DTG PK exposure from 50 mg twice daily dosing seems to be lower in HIV-1- infected subjects (treatment-experienced) than in healthy subjects, and this is due to wide use of inducers (e.g. DRV/RTV) in the background regimen in the treatment-experienced HIV-1-infected subjects.

Table 44 Summary of Key DTG Pharmacokinetic Parameters following Single Dose 50 mg Tablet Administration in Healthy and HIV-infected Subjects

Population DTG Data Source Cmax AUC(0-) C24 CL/F Vz/F t½ /N Dose (g/ml) (g.h/mL) (g/mL) (L/h) (L/h) (h) Healthy/ 50 mg Phase I Meta- 2.20 43.7 0.65 1.14 23.3 14.4 analysis (43) (45) (49) (45) (45) (19) HIV-1 50 mg ING111521 2.46 40.5 0.59 1.23 ND 11.2 infected/10 (32) (33) (31) (33) (29)a Data Source: m5.3.5.3 CPM Table 3.3; m5.3.4.2, Study ING111521, Table 11.3. Data presented are geometric mean (%CVb) except for tmax where median (range) is presented. ND: not determined. a. Likely underestimated as based on 24-hour sampling window

85 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 45 Summary of Key DTG Pharmacokinetic Parameters following 50 mg Once and Twice Daily Dosing in Healthy and HIV-infected Subjects

Population DTG Dosing Data Source Cmax AUC(0-) AUC(0-24) C Regimen (g/ml) (g.h/mL) (g.h/mL) (g/mL) Healthy 50 mg once Phase I Meta- 3.62 49.1 49.1 1.05 daily analysis (35) (41) (41) (56) (overall) (m5.3.5.3) 50 mg once Phase I Meta- 2.90 38.4 38.4 0.79 daily analysis (34) (40) (40) (59) (fasted) (m5.3.5.3) 50 mg once Phase I Meta- 4.21 58.2 58.2 1.28 daily analysis (27) (30) (30) (41) (fed) (m5.3.5.3) Healthy 50 mg twice Phase I Meta- 6.00 53.0 106 3.02 daily analysis (39) (42) (42) (52) (overall) (m5.3.5.3)

50 mg twice Phase I Meta- 5.33 47.1 94.3 2.66 daily analysis (38) (42) (42) (53) (fasted) (m5.3.5.3)

50 mg twice Phase I Meta- 7.77 68.6 137 4.00 daily analysis (23) (27) (27) (36) (fed) (m5.3.5.3)

HIV-1 50 mg once Population PK in 3.67 53.6 53.6 1.11 infected daily Treatment-naivea (20) (27) (27) (46) (no food (m5.3.3.5) restriction) HIV-1 50 mg twice Population PK in 4.15 37.5 75.1 2.12 infected daily Treatment- (29) (35) (35) (47) (no food experiencedb restriction) (m5.3.3.5) Data Source: m5.3.5.3, CPM, Table 3.2; m5.3.3.5, Population PK in ART-naive, Table 4-5; m5.3.3.5, Population PK in ART-experienced, Table 4-5. Data presented are geometric mean (%CVb) a. Population PK analysis using pooled data from Phase II/III studies in treatment-naive subjects including ING111521, ING112276, and ING113086. b. Population PK analysis using pooled data from Phase II/III studies in treatment-experienced subjects including ING112961, ING112574, and ING111762.

3.1.2. PK Variability

In Phase I studies in healthy subjects, between-subject (%CVb) for AUC and Cmax ranged from ~20 to 40%, and C from 30 to 65%, across studies (m5.3.5.3, CPM, Table 3.8). The %CVb of DTG was higher in HIV-infected subjects than healthy subjects (see Table 46): 30-50% for AUC and Cmax, and 55-140% for trough concentration (C0 or C). DTG PK variability was higher in ING111762 (140% for C0_avg) than in ING113086 (60%) due to use of metabolic inhibitors or inducers in the background therapy, as well as less optimal compliance.

86 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 46 Summary of Between-subject Variability (%CVb and N) of Selected DTG PK Parameters in HIV-infected Subjects in Phase IIb/III Studies

Study DTG Dose PK Parameter Data Source AUC(0-) Cmax C C0_avg %CVb N %CVb N %CVb N %CVb N ING112276 50 mg 40% 15 27% 15 72% 15 55% 46 Table 31 once daily ING113086 50 mg ND ND ND 60% 399 Table 32 once daily ING112961 50 mg 50% 23 40% 23 70% 23 ND Table 33 twice daily ING112574 50 mg ND ND ND 70% 178 Table 35 twice daily ING111762 50 mg ND ND ND 140% 337 Table 37 once daily Data presented are %CVb and N (number of subjects); ND: not determined.

Between-subject variability (%CVb) accounts for the majority of PK variability while within-subject variability (%CVw) is lower than between-subject variability. In Phase I studies, the estimated within-subject variability (%CVw) ranged from 8 to 20% for DTG PK parameters including AUC, Cmax, and C24/C. In HIV-infected patients, based on the population PK modelling using pooled data from Studies ING111521, ING112276, and ING113086 in treatment-naïve HIV-infected subjects, inter-occasional variability (a parameter roughly estimating %CVw) was estimated at 17.2% on CL/F, which was lower than the estimated between-subject variability of 23% for CL/F. In the population PK modelling, using pooled data from studies ING111762, ING112961, and ING112574 in treatment-experienced subjects, inter-occasional variability was estimated at 28.9% for CL/F compared to between-subject variability of 28.7% for CL/F.

As DTG shows a moderate between-subject PK variability and a relatively wide therapeutic window (see Section 3.2.3 for details), individualized dose or clinical drug monitoring is not needed for DTG therapy.

3.1.3. Absorption

Following oral administration of tablet formulations, DTG absorption is rapid with no absorption lag time and a median tmax of 2 to 3 hours post dose. DTG concentration declines mono-exponentially with an average terminal half-life of approximately 14 hours.

DTG absorption is increased with co-administration of food (m2.7.1, Section 3.2) and decreased when co-administered with polyvalent metal cation-containing products (Section 2.1.3.3). The linearity of DTG PK is dependent on dose and formulation. Following oral administration of suspension formulation, DTG exhibits linear PK from 2 to 100 mg (dose-proportional increases in plasma exposure; Section 2.1.1.1) and nonlinear PK between 100 mg and 250 mg (less than dose-proportional increases in

87 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

plasma exposure; Section 2.1.1.2). Following oral administration of tablet formulations, in general, DTG exhibits nonlinear PK with less than dose-proportional increases in plasma exposure from 2 to 100 mg (Section 2.3.3 and Section 2.1.1.4), likely due to different dispersion rates of various tablet strengths and solubility-limited absorption at higher doses; however, increase in DTG exposure appears dose proportional from 25 mg to 50 mg (as observed in ING112276; Section 2.3.4).

3.1.4. Plasma Protein Binding and Distribution

The apparent volume of distribution (following oral administration of suspension formulation, Vd/F) was estimated at 12.5 L (Section 2.1.1.5). Vd/F was estimated at 17.4 L following oral tablet dosing based on a population PK analysis (Section 3.3.1). The estimated Vd/F is greater than the total plasma volume (~3 L for a 70-kg person), but similar to the volume of total water in the extracellular space (~15 L for a 70-kg person). Total blood and plasma drug-related radioactivity concentration ratios, as measured in the human mass balance study ING111853, were averaged at 0.441 to 0.535, indicating minimal association of DTG with blood cellular components (Section 2.1.1.5).

In vitro, the protein binding of DTG in human serum and plasma is high (approximately 99.3%). A summary of unbound fraction of DTG in plasma estimated in clinical studies is provided in Table 47.

Table 47 Summary of Unbound Fraction(%) of DTG in Plasma Estimated in Clinical Studies

Study ING113097 ING113125 ING116070

Subject Healthy match Moderate Hepatic Healthy match Severe Renal HIV-1 infected Population Impairment Impairment n 8 8 8 8 12

Unbound 3hr: 3hr: 3hr: 3hr: 2-6hr: fraction,% 0.23 (0.2, 0.3) 0.58 (0.2, 0.8) 0.87 (0.8, 0.9) 0.84 (0.6, 1.4) 0.49 (0.33, 24hr: 24hr: 24hr: 24hr: 0.65) 0.23 (0.2, 0.3) 0.48 (0.2, 0.6) 1.10 (1.0, 1.3) 1.01(0.7, 1.7) Data source: ING113097, Table 11.3; ING113125, Table 11.3; ING116070, Table 9.3. Data presented are median (range).

Binding of DTG to plasma proteins (unbound fraction) is independent of total DTG plasma concentration at therapeutic levels. The specific types of proteins to which DTG is bound has not been directly characterized, however, DTG appears to primarily bind to albumin other than 1-acid glycoprotein (AAG) based on the following observations:

 The DTG unbound fraction appeared to be better correlated with albumin than AAG in Study ING113097 (Section 2.1.2.2);  A in vitro virology study evaluated the protein binding effect of both human serum albumin (HSA) and AAG on the antiviral activity of DTG using the PHIV assay system and the results suggested that DTG binding to AAG is minimal in comparison with its binding to HSA (m4.2.1.1, GlaxoSmithKline Document Number RH2007/00071/00, Section 5).

88 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG is present in cerebrospinal fluid (CSF) at levels similar to the unbound concentration in plasma. DTG is present in the female and male genital tract: AUC in cervicovaginal fluid, cervical tissue, and vaginal tissue were 6 to 10% of that in corresponding plasma at steady-state; AUC in semen and rectal tissue were 7% and 17%, respectively of that in corresponding plasma at steady-state.

3.1.5. Metabolism

Following oral administration in humans, unchanged DTG is primarily eliminated through metabolism, and renal elimination of unchanged DTG represents less than 1% of the total dose administered. The quantified metabolites in human include an ether glucuronide of DTG (M3), an N-dealkylation metabolite (M1), a product from oxidation at the benzylic carbon (M7), and a product of oxidative defluorination with cysteine addition (M13). M3 is the major metabolite observed in urine, and represents 18.9% of the total dose administered. The total radioactivity of the metabolites formed through oxidation (M1, M7, and M13) that are recovered in urine and feces accounts for approximately 9.7% (mean) of total dose administered. The enzymes responsible for the formation of M3 are UDP glucuronosyl transferase (UGT) 1A1 (major), and UGT1A3 and UGT1A9 (minor) [GlaxoSmithKline Document Number RD2008/01339/00/Study 08DMR067]. The enzyme responsible for forming M7 is CYP3A4 [GlaxoSmithKline Document Number RD2008/00373/00], while the enzyme responsible for forming for M13 is unknown. M1 is formed by hydrolysis of M7. Therefore, UGT1A1 is the primary route of metabolism, with CYP3A4 as a secondary metabolic pathway in humans. DTG is the predominant circulating compound in plasma, representing 97% of plasma total radiocarbon, while M3 represents <2.4% (Section 2.1.1.5). These human metabolites were observed in animals (see m2.4, Section 3.4.2.2).

The proposed metabolic scheme for DTG in human as well as in various animal species is provided in Figure 7.

89 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 7 Metabolic Scheme of DTG in Human Compared to Nonclinical Species

OH O OH

OH OH OH OH OOH CH3 O O OH OH F O N O O CH O O CH 3 3 NH N F O F O O H N N OH F O M7 NH N NH N Human, Mouse, Rat O O OOH CH H H 3 F O M3 F O O Human, Mouse, Rat, Monkey M2 N Human, Mouse, Rat, Monkey 2NH N O H O M1 Human, Mouse, Rat, Monkey

OOH CH - CO 3 OOH CH3 +glutathione +Gluc F O F O +O N OOH CH -F 3 N NH N F O NH N O N O H H F O NH N F O O M16 M9 M15 H Human, Mouse Mouse, Rat Mouse F O GSK1349572 Human, Mouse, Rat, Monkey OOH CH3 -F F O +2O N +cysteine

OOH CH3 NH N -F O F O H +SO4H N F O M14 NH N O Human, Mouse H F O OH

M10 2NH Human, Rat O

+C6H11O5 OOH CH 3 -F S OOH CH3 OOH CH +SO4 3 +O F O F O F O N N N NH N NH N NH N O O H O H H F O F O F O M11 M12 Human, Mouse, Rat Human, Rat M13 Human, Monkey

Data source: m2.4, Figure 1. Bolded arrows indicate the primary metabolic products in humans (M3 is the predominant product; M7 is a notable metabolite)

The primary metabolite, ether glucuronide of DTG (M3), in plasma shows formation rate-limited elimination following oral administration of DTG (Section 2.1.2.3). Apparent half-life of the ether glucuronide in plasma is similar to the parent compound, DTG, and renal excretion is a primary route of elimination of this metabolite (Section 2.1.2.3). In subjects with severe renal impairment (Section 2.1.2.3), exposure (AUC) of this metabolite is approximately 3-fold higher than that observed in healthy matching subjects, likely due to impaired renal elimination of the metabolite in subjects with renal impairment. However the apparent half-life of the metabolite is unchanged.

Co-administration of EFV decreases DTG systemic exposure, AUC, by 57% (Section 2.1.3.13). The plasma and urine metabolite profiling data suggests that EFV induces both UGT1A1 and CYP3A pathways. With presence of EFV, DTG is still the major component in plasma, while M3 is present at a mean value of <2% of DTG, similar to that observed from the treatment of DTG alone. DTG and 11 metabolites were identified in pooled human urine.The urine from subjects receiving DTG in combination with EFV displays an increase in the ratio of M3 relative to parent DTG, and a concomitant decrease in the ratio of M1 to DTG, when compared to the metabolic profile of DTG alone. No other significant urinary metabolite differences between the two treatments are noted.

90 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG has a terminal half-life of ~14 hours and a low apparent oral clearance (CL/F) of 0.56 L/hr (Section 2.1.1.5), which represents <2% of liver plasma flow; therefore, the hepatic extraction ratio is low (lower than 2%). As CYP3A4 is a secondary route of elimination of DTG, the first-pass metabolism of DTG following oral dosing is expected to be very low.

3.1.6. Excretion

Renal elimination of unchanged drug is low (<1% of the dose). Following oral administration of a suspension formulation, 31% of the total oral dose is excreted in the urine, represented by M3 (18.9% of total dose), M1 (3.6% of total dose), M7 (3.0% of total dose), and other minor metabolites. Sixty-four percent of the total oral dose is recovered in the feces, represented mainly by DTG (53% of total dose). It is unknown if all or part of the parent compound in feces is due to unabsorbed drug or biliary excretion of the glucuronide conjugate, which can be converted back to the parent compound in the gut lumen. In bile duct-cannulated animals, 7% of the administered dose was recovered as DTG in rat bile, and 12% in monkey bile; the percentage of administered drug recovered as DTG in feces was similar for humans (64%) and monkeys (59%), and higher in rats (88%) (m2.6.4). Other notable components in feces include M13 (1.8% of total dose) and M1 (1.3% of total dose) (Section 2.1.1.5).

3.2. PK/PD Relationships and Definition of No Effect Boundaries

3.2.1. PK/PD Relationship for Efficacy Endpoints

Overall, the results from PK/PD analyses for efficacy support the recommended DTG doses in various patient populations.

Response from Monotherapy

In treatment-naïve subjects who received DTG monotherapy for 10 days (ING111521), a strong dose-response relationship and an exposure-response relationship were observed. A mean decrease from Baseline on Day 11 in plasma HIV-1 RNA of 1.51 to 2.46 log10 c/mL was observed with DTG doses of 2 to 50 mg compared with placebo (0.05 log10 c/mL increase). Greater antiviral activity was associated with higher DTG plasma exposure by an Emax model. C was the PK parameter that best predicted antiviral activity. DTG exposure from 10 mg once daily dose is around EC90 (0.32 g/mL) and DTG exposure from 50 mg once daily is at the plateau of curve (see Section 2.3.3 for details).

Response from Combination Therapy in Treatment-Naïve Subjects

In treatment-naïve subjects who received DTG in combination with two NRTIs as background therapy, no dose-response and exposure-response relationship for antiviral activity was observed in the Phase IIb study (ING112276; Section 2.3.4) with DTG doses ranging from 10 to 50 mg once daily, and no exposure-response relationship for antiviral activity was observed in the pivotal Phase III study( ING113086; Section 2.3.5). The lack of dose-response or exposure-response relationship in Phase IIb and III studies is due to the potency of combination therapy, which resulted in more than 78% of subjects on

91 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG treatments achieving HIV RNA values <50 c/mL at Week 96 in the Phase IIb study ING112276, and an 88% response rate at Week 48 in the Phase III study ING113086. Such findings indicate a drug effect at DTG doses of 10 to 50 mg once daily in combination with dual NRTIs background therapy, achieved maximum virological suppression in this population. These data support the selection of DTG 50 mg once daily for the treatment-naïve subjects.

Response from Combination Therapy in Treatment-Experienced, Integrase Inhibitor- Naïve Subjects

In ART treatment-experienced, INI-naïve subjects where DTG was given in combination with at least 1 active agent in the optimized background regimen (Study ING111762; Section 2.3.8), plasma DTG drug exposure, C0_avg, was associated with virologic response based on all available data.

For subjects receiving moderate/strong inducers as part of their background therapy such as EFV and TPV/RTV, lower DTG exposures and lower virologic responses (11/16, 69%) were observed compared to the rest of the population receiving DTG (222/268, 83%) (Section 2.3.8), supporting the use of a higher DTG dose in this limited sub- population. DTG 50 mg twice daily is the recommended dose for treatment-experienced, INI-naïve patients receiving EFV or TPV/RTV (see Section 3.4.3.2 for rationale).

As the use of moderate-strong inducers (TPV/RTV and EFV) in the background therapy and noncompliance were confounding factors in the PK/PD evaluation, additional PK/PD analysis was performed by excluding subjects on these inducers and with evidence of noncompliance (defined as non-detectable DTG concentration observed at one or more PK visits). The results from this additional analysis showed that DTG C0_avg was no longer a predictor of virological response, suggesting that a sufficiently high DTG exposure was achieved for robust virologic responses for the rest of the population. Subjects on UGT1A1 inhibitor, ATV or ATV/RTV, as part of their background regimens (n=51) demonstrated two folds higher DTG exposure however similar virologic response (Section 2.3.8). Thess findings imply that DTG dose higher than 50 mg once daily (therefore higher DTG exposure) may not be beneficial (from an efficacy standpoint) in the study population evaluated, except for subjects using moderate-strong inducers in their background therapy. Therefore, these PK/PD results for efficacy supported the selection of DTG 50 mg once daily for the treatment-experienced, INI-naïve subjects and DTG dose adjustment to 50 mg BID is neccessary for subjects who require co- administration with TPV/RTV and EFV.

Response from Combination Therapy in Integrase Inhibitor-Resistant Subjects

In the dosing-ranging Phase IIb study (ING112961; Section 2.3.6), which evaluated DTG 50 mg once daily (n=27) and 50 mg twice daily doses (n=24), the univariate logistic regression using pooled data from both cohorts identified C0 and C as statistically significant predictors for virological response (i.e., plasma HIV RNA <50 c/mL based on TLOVR) at Week 48 (p<0.05). However, multivariate analysis performed at Week 24 showed that PSS to Day11 OBR and Baseline CD4+ cell count are statistically significant predictors of Week 24 response, while the effect of DTG C0 was not statistically

92 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology significant (m5.3.5.2, Study ING112961 Week 24 CSR). These data suggested that DTG 50 mg twice daily may be at the plateau of the dose-response curve for the drug effect in INI-resistant subjects.Due to many confounding factors and the small sample size, the results from such analyses should be interpreted with caution.

In the Phase III study (ING112574) evaluating DTG 50 mg twice daily, plasma DTG C0 was not predictive of Day 8 (n=183) or Week 24 (n=114) antiviral response, based on multivariate analyses that included either Baseline fold change (FC) in DTG IC50, or Baseline number of INI resistance mutations as a measure of viral susceptibility. Plasma DTG C0 at Day 8 was, however, a statistically significant predictor when INI mutational pathway was included, but the estimated effect size was small. Plasma DTG C0_avg was similar between virologic responders and non-responders.

The DTG 50 mg twice daily dose achieved therapeutic concentrations in most INI- resistant subjects. DTG C0 was estimated at 2.36 g/mL, which was 37 fold the in vitro PA IC90 (0.064g/mL) against wild-type viruses. As the FC in IC50 to DTG of less than 10 represented ~94% of the population in ING112574 [m5.3.5.2, ING112574 CSR, Table 92 and Table 93], the exposures from DTG 50 mg twice daily would be expected to cover the majority of INI-resistant viruses. In a separate analysis of approximately 700 isolates with raltegravir resistance, viruses with Q148+ 2 secondary integrase inhibitor resistance mutations (the viral population with the most variable and highest FC to DTG) represented 13% of the population, and those with DTG FC >10 represented 6% of the population [m2.7.2.4, Section 4.1.12.3.2].

Baseline resistance to INI is found to be the strongest predictor of Day 8 and Week24 response, based on multivariate analysis, followed by Baseline viral load (m5.3.5.2, ING112574 Week 24 CSR), suggesting that any further increase of DTG dose (e.g., 100 mg twice daily) is unlikely to further improve the response rate in all except a small minority of subjects. Furthermore, increasing the dose from 50 mg to 100 mg produced a less-than-proportional increase in DTG exposure [Section 2.1.1.4]. This suggests that doses above 50 mg twice daily (e.g. 100 mg twice daily) may not provide additional benefit.

These data support the selection of DTG 50 mg twice daily in the INI-resistant population.

3.2.2. PK/PD Relationship for Safety Endpoints

DTG is well tolerated in all patient populations evaluated. No dose-limiting toxicity has been reported for DTG treatment (m2.7.4):

 The most frequently observed adverse events (AEs) across patient populations were diarrhea, nausea, and headache, which were typically Grade 1 or 2 in severity and typically did not lead to discontinuation from studies. The AE profile of DTG 50 mg twice daily in the treatment-experienced, INI-resistant subjects (who tended to have advanced HIV disease) was similar to that reported for treatment-naïve and treatment-experienced (INI-naïve) subjects receiving DTG 50 mg once daily.

93 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 Treatment emergent liver chemistry elevations (Grade 3 or 4 per Division of AIDS criteria) for DTG-containing regimens was low, in general, related to alternative causes in most cases (e.g., HCV or HBV acute or chronic co-infection, co- administered medications), comparable between DTG 50 mg once daily and DTG 50 mg twice daily dosing regimens, and comparable (RAL) or lower (EFV- containing regimens) than observed for the comparators.  A modest (approximately 10%), non-progressive increase in serum creatinine levels was observed upon DTG treatment in Phase I/II/III clinical studies, which is related to a benign effect of DTG on creatinine secretion with blockade of OCT2 transporter (Section 3.4.1), with no effect on renal functions such as GFR and ERPF (Section 2.2.2.2).  A small percentage of subjects not receiving co-administered ATV or ATV/RTV were noted to have modest total bilirubin elevations, likely related to competitive use of a common metabolic pathway (UGT1A1) by unconjugated bilirubin and DTG.

PK/PD analysis for safety measures performed in Phase IIb/III revealed the following results:

In treatment-naïve populations (ING112276 and ING113086):

 There was no statistically significant correlation (p>0.05) between DTG exposure and occurrence of the most common AEs: diarrhea, headache, nausea, abdominal pain, and vomiting.  There was a positive correlation between DTG dose/exposure and increase in serum creatinine from Baseline.  There was a positive correlation between DTG exposure and increase from Baseline in total bilirubin.  There was a negative correlation between DTG exposure and increase from Baseline in ALT found in ING112276, however such correlation was not found in ING113086.

In treatment-experienced populations (ING112961, ING112574, and ING111762):

 In all three studies, there was no correlation between DTG C0_avg and occurrence of the top three most common AEs: diarrhoea, headache, or nausea.  In the treatment-experienced and INI-naïve study (ING111762),  There was no statistically significant correlation between DTG C0_avg and change from Baseline in clinical laboratory measures including ALT and the urine albumin/serum creatinine ratio.  There was a positive correlation between DTG C0_avg and increase from Baseline in total bilirubin for subjects not receiving ATV or ATV/RTV.  There was a positive correlation between DTG C0_avg and increase from Baseline in serum creatinine.

94 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 In the treatment-experienced and INI-resistant studies (ING112961 and ING112574), there was no correlation between DTG C0_avg and change from Baseline in clinical laboratory measures including ALT, total bilirubin, serum creatinine, creatinine clearance, and the urine albumin/serum creatinine ratio.

Overall, there was no relationship found between DTG dose or exposure and the most common AEs and clinical laboratory measures, except for change from Baseline in total bilirubin and serum creatinine, which would be anticipated based on the likely mechanisms of action. The lack of association between DTG exposure and the most commons AEs including diarrhea, nausea, and headache, suggested that these AEs were not related to the systemic exposure of DTG. The correlation between DTG exposure and the increase in serum creatinine is consistent with the known inhibition of OCT2 transporter by DTG. The correlation between DTG exposure and change from Baseline in total bilirubin is likely due to competition for the UGT1A1 enzyme due to a shared metabolic pathway with unconjugated bilirubin. However, due to the small magnitude of changes in these clinical lab measures and the lack of progression in the creatinine or bilirubin increases, these PK/PD relationships are not considered clinically relevant.

The results from the PK/PD analysis for safety support the recommended DTG doses in various patient populations.

3.2.3. Definition of No Effect Boundaries of Alteration in DTG Exposure

PK/PD relationships for efficacy and safety of DTG not only support the dose recommendation in various patient populations but also help to define the “no effect boundaries” of alteration in DTG exposure due to effect of various intrinsic or extrinsic factors (e.g., drug interaction, special population, age, race). The PK/PD relationship for efficacy defines the lower bound, and the PK/PD relationship for safety defines the upper bound. These “no effect boundaries” were used as justification for recommendations on whether dose adjustment was needed because of drug interactions or the impact of other intrinsic or extrinsic factors on DTG PK. The lower boundary is proposed to be 75% reduction in DTG C based on efficacy, and currently the upper boundary cannot be determined due to good safety and tolerability profiles of DTG. The rationale for defining these boundaries are presented in this section.

3.2.3.1. Lower Boundary Based on Efficacy

For the INI class, available data suggest that C is the primary PK parameter associated with efficacy. This is further supported by a PK/PD analysis using pooled data from 10- day monotherapy with several INIs including raltegravir, elvitegravir, GSK1265744, and GSK1364735 [Song, 2010]. In addition, the long-term clinical data on raltegravir 800 mg once daily compared to 400 mg twice daily support Ctrough as the driver for antiviral activity for raltegravir. Study QDMRK showed raltegravir 800 mg once daily was inferior to 400 mg twice daily in combination with NRTIs in treatment-naïve subjects, based on Week 48 analyses, suggesting C is the primary driver for long-term efficacy for raltegravir [Eron, 2011]. As C is likely the driver for DTG antiviral activity, the lower boundary was targeted at C.

95 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

After 10-day monotherapy with DTG, Day11 antiviral response was found best associated with DTG C using an Emax model (Figure 6). Based on this model, EC90 is estimated at 0.32 g/mL.

No PK/PD relationship was observed for DTG doses from 10 to 50 mg once daily in combination with NRTI backbones in treatment-naïve trials (ING112276 and ING113086). In ING112276, the 10 mg once daily dose of DTG demonstrated similar efficacy as the 50 mg once daily dose at 48 and 96 weeks. These data suggested that the drug effect of DTG doses from 10 mg to 50 mg once daily in combination with other active drugs are on the plateau of the dose-response curve for INI-naïve subjects.

DTG exposure observed at 10 mg once daily (0.30 g/mL for C) is considered as the lower boundary (for INI-naïve population). This value is also equivalent to the EC90 estimate (0.32 g/mL), based on the Emax model from the PK/PD analysis using 10-day monotherapy data. As DTG C at 10 mg (0.30 g/mL) is 25% of that observed at 50 mg once daily (1.20 g/mL) in ING112276 (Section 2.3.4), a reduction of <75% in DTG exposure (from 50 mg once daily) is not considered clinically significant (“no effect”) when considering whether the presence of a factor (e.g., covariate, drug interaction, etc) requires a dose adjustment. Therefore, the lower “no effect boundary” is defined as 25% of DTG C at 50 mg once daily or 0.30 g/mL. Taking into the account of variability, if 90% confidence intervals of the effect (GMR) on DTG C caused by any intrinsic or extrinsic factor is completely above 0.25, the effect of that factor is not considered clinically significant, and DTG dose adjustment by that factor is not necessary.

3.2.3.2. Upper Boundary Based on Safety

DTG is well tolerated in HIV-infected subjects, no dose-limiting toxicity has been observed, and there was no apparent difference in safety profiles across DTG doses evaluated in Phase III studies (m2.5, Section 5). Therefore, an upper limit of exposure that has been associated with an increase incidence of AEs or significant clinical chemistry toxicity has not been identified. A wide range of exposures was observed with 50 mg once daily and twice daily dosing in various Phase II/III studies; however, PK/PD analyses did not identify an association between plasma exposure and any safety parameter.

The only drug known to significantly increase DTG plasma concentration by up to 2-fold is ATV, an inhibitor of UGT1A1. ATV or ATV/RTV has been used with DTG in ING111762 (n=51 out of 362 DTG subjects included in the Week 24 analysis), and in a small number of subjects in ING112574 (n=3 out of 114 subjects included in the Week 24 analysis). DTG exposures in subjects on ATV or ATV/RTV in these Phase III studies was about 2-fold higher than those observed in subjects who were not on inducers, ATV, or ATV/RTV. No increased toxicity has been observed in these subjects. Based on these data, no dosage reduction in DTG is required due to drug interactions or covariates that increase DTG exposure.

96 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

3.3. Effect of Intrinsic and Extrinsic Factors on Pharmacokinetics

3.3.1. Population Pharmacokinetic Analysis in Treatment-Naïve Subjects

Study Title: Population Pharmacokinetic Analysis of Dolutegravir in HIV-Infected Treatment-Naïve Patients.

Location of Report: m5.3.3.5, GlaxoSmithKline Document Number 2012N149219_00, Population PK in ART-naive CSR

Methodology: DTG concentration-time, dosing, demographic, and covariate data from the following studies were combined: proof of concept (PoC: ING111521), Phase IIb (SPRING-1: ING112276), and Phase III (SPRING-2: ING113086). PK data from the 2 mg treatment group in ING111521 were not included in the analysis. The Population PK model was developed using a non linear mixed-effect modelling approach; the NONMEM VII software with the first order conditional estimation method with interaction (FOCEI) was used. The final Population PK model was used to simulate plasma PK profiles of DTG in HIV-1-infected, treatment-naive adults to evaluate the influence of covariates.

Exploratory graphical analysis of potential exposure-response relationships was performed using individual measures of DTG exposure obtained from the final Pop PK model with studied doses.

Results: The Population PK analysis included 563 subjects from 3 studies that contributed 3357 concentrations.

97 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 48 Covariate Distributions (Treatment-naive)

Covariate Statistic or All Subjects (n=563) category Age (yrs) at baseline Median [Min-Max] 37 [18-68] Weight (kg) at baseline Median [Min-Max] 74.5 [39.0-135] Body mass index (kg/m2) at Median [Min-Max] 24.2 [14.7-47.9] baseline Body surface area (m2) at Median [Min-Max] 1.92 [1.27-2.69] baseline Total bilirubin (µmol/L) at Median [Min-Max] 9.00 [3.00-38.0] baseline Albumin (g/L) at baseline Median [Min-Max] 45.0 [30.0-54.0] Aspartate aminotransferase Median [Min-Max] 24.0 [11.0-180] (IU/L) at baseline Alanine aminotransferase Median [Min-Max] 21.0 [5.00-260] (IU/L) at baseline Creatinine clearance Median [Min-Max] 121 [54.6-239] (mL/min) at baseline Gender N (%) Male 481 (85) Female 82 (15) Race N (%) Caucasian 470 (83) Black 66 (12) Asian 6 (1) Other 21 (4) Ethnicity N (%) Non-Hispanic or 497 (88) Latino 66 (12) Hispanic or Latino Smoking N (%) Never 235 (42) Current 236 (42) Former 73 (13) Unknown 19 (3) CDC classification of HIV A 490 (87) infection N (%) at baseline B 62 (11) C 11 (2) Formulation N (%) AL 68 (12) AP 92 (16) AW 403 (72) Dose (mg) N (%) 10 58 (10) 25 46 (8) 50 459 (82) Data Source: m5.3.3.5, Population PK in ART-naive, Table 4-1.

The PK of DTG following oral administration was adequately described by a linear one- compartment model with first-order absorption and absorption lag-time and first-order elimination, with inter-individual variability (IIV) in apparent clearance (CL/F), apparent volume of distribution (V/F) and first-order absorption (KA) and inter-occasion variability (IOV) in CL/F.

CL/F=0.901·(WT/70)0438·(AGE/40)0.193·(BILI/9)-0.211 for non-smoking subjects

CL/F=0.901·(WT/70)0.438·(AGE/40)0.193·(BILI/9)-0.211·1.16 for smoking subjects

98 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

V/F=17.4·(WT/70)0.768

Bioavailability (F) =1 for males and =1.21 for females

Table 49 Parameter Estimates of Final DTG Population PK Model (Treatment- Naïve)

Parameter NONMEM Estimates Bootstrap Estimatesa [Units] Point Estimate %RSE 95% CI Median 95% CI CL/F [L/h] 0.901 2.11 0.864-0.938 0.901 0.866-0.940 V/F [L] 17.4 2.49 16.5-18.3 17.4 16.6-18.2 KA [h-1] 2.24 15.4 1.56-2.92 2.21 1.73-3.10 ALAG [h] 0.263 32.7 0.0942-0.432 0.262 0.0833-0.393 CL/F~PoC 1.35 4.83 1.22-1.48 1.35 1.24-1.51 F~10 mg 1.24 2.92 1.17-1.31 1.24 1.17-1.31 CL/F~WT 0.438 16.9 0.293-0.583 0.440 0.290-0.582 V/F~WT 0.768 10.8 0.605-0.931 0.774 0.616-0.944 F~GEND 1.21 3.27 1.13-1.29 1.21 1.13-1.30 CL~SMOK 1.16 2.45 1.10-1.22 1.16 1.10-1.22 CL~AGE 0.193 23.7 0.103-0.283 0.195 0.105-0.283 CL~BILI -0.211 14.0 -0.269- -0.153 -0.212 -0.267- -0.152 Inter-individual or inter-occasion variability CV%* 2CL 0.0551 9.27 0.0451-0.0651 23.5 0.0539 0.0449-0.0652 2V 0.0188 29.5 0.00794-0.0297 13.7 0.0182 0.00714-0.0295 2KA 0.224 38.8 0.0535-0.395 50.1 0.217 0.0613-1.11 2IOV-CL 0.0296 15.6 0.0205-0.0387 17.2 0.0300 0.0184-0.0407 Residual variability CV% Median 95% CI 2prop 0.0704 7.41 0.0602-0.0806 31.3 0.0698 0.0555-0.0830 a. From 1000 completed bootstrap runs. Abbreviations: %RSE: percent relative standard error of the estimate = SE/parameter estimate * 100, 95% CI= 95% confidence interval on the parameter, CL/F = apparent clearance, V/F = volume of central compartment, KA = absorption rate constant, ALAG = absorption lag-time, 2CL, 2V, and 2KA = variance of random effect of CL/F, V/F, and KA, respectively, CV = Coefficient of variation of proportional error (=[2prop]0.5*100), 2prop = proportional component of the residual error model, IOV = Inter-occasion variability. The reference population for PK parameters CL/F and V/F are 40 year old, 70 kg male, non-current smoker, with total bilirubin of 9 µmol/L.

2 CV eP 1 * TVP when 2P exceeds 0.15 Data source: Population PK in ART-naive, Table 4-3.

Weight, smoking status, age, and total bilirubin were predictors of CL/F, and gender was a predictor of bioavailability (F). Following the same dosing regimen, females would have 21% (95% CI: 13-29%) higher F compared to males, and current smokers would have 16% (95% CI: 10-22%) higher CL/F compared to non-current smokers. CL/F and V/F increased with body weight.For the range of weights in the analysis (39-135 kg), CL/F ranged from 23% lower to 33% higher and V/F ranged from 36% lower to 66% higher than for 70-kg individuals. CL/F increased with age.For the range of age in the analysis (18-68 yrs), CL/F ranged from 14% lower to 11% higher compared to a 40 yr old subject. Only one subject was >65 years old. CL/F decreased with total bilirubin.For the range of total bilirubin in the analysis (3-38 µmol/L), CL/F ranged from 26% higher to 26% lower compared to a subject with total bilirubin of 9 µmol/L.

99 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

There was a 24% increase in bioavailability for the 10 mg dose compared to the 25 and 50 mg doses. The reason for a higher oral bioavailability at the lower dose is possibly due to better dispersion of the tablet at lower tablet strength.

The PoC study (ING111521) differed from the SPRING studies (ING112276 and ING113086), with a 35% higher CL/F for the ING111521. Although ING111521was a DTG monotherapy study, and both ING112276 and ING113086 were combination studies (DTG was administered in combination with ABC/3TC or TDF/FTC FDCs), no difference in DTG PK was expected between subjects receiving monotherapy versus combination therapy with ABC/3TC or TDF/FTC, as these NRTIs do not share, and have no effect on, the elimination pathways of DTG (UGT1A1 and CYP3A). The sample size of ING111521 is much smaller than for either ING112276 or ING113086, which both also had a more diversified patient population. These factors may potentially account for the difference in the estimated CL/F for ING111521 compared with ING112276 and ING113086. Inter-occasion variability was estimated to be 17% on CL/F.

Table 50 Summary of Steady State DTG PK Exposure Parameters Following 50 mg Once Daily Based on Post-hoc Estimates using the Final Model (Pooled Data from ING112276 and ING113086)

Dose Statistic AUC0- Cmax C (mg) (µg·h/mL) (µg/mL) (µg/mL) 50 N 449 449 449 once Geomean (95% CI) 53.6 (52.3-55.0) 3.67 (3.61-3.74) 1.11 (1.06-1.15) daily %CVb 26.9 19.7 46.3 Median (Min-Max) 53.2 (24.1-142) 3.61 (2.15-7.92) 1.15 (0.290-4.07) Percentiles 5% 35.1 2.74 0.532 10% 38.5 2.94 0.625 25% 45.4 3.22 0.842 50% 53.2 3.61 1.15 75% 63.6 4.17 1.49 90% 74.9 4.75 1.90 95% 84.9 5.19 2.24 Data source: Population PK in ART-naive CSR, Table 4-5

100 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 8 Predicted Fold Change in Steady-State Cmax to Reference Covariate Category (Fold Change in Median and 90% Confidence Interval)

SS Cmax

Gender-Females Current Smoker HBV/HCV Non-Caucasian Hispanic/Latino CDC B/C TDF/FTC Weight <66 kg 66-75 kg 75-84 kg >84 kg Age <55 yrs >55 yrs Bilrubin <7 umol/L 7-9 umol/L 9-12 umol/L >12 umol/L

0.8 0.9 1.0 1.1 1.2 1.3 1.4 Changes Relative to Reference

Data source:Population PK in ART-naive, Figure 4-3 Reference categories: male, non-current smoker, no HBV/HCV co-infection, Caucasian, non Hispanic/Latino, CDC A, ABC/3TC for gender, smoking status, HCV/HBV co-infection, race, ethnicity, CDC, and background therapy, respectively. For continuous covariates, the overall median was used to normalize the Cmax of each category (i.e., 4.43 µg/mL).

101 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 9 Predicted Fold Change in Steady-State AUC to Reference Covariate Category (Fold Change in Median and 90% Confidence Interval)

AUCss

Gender-Females Current Smoker HBV/HCV Non-Caucasian Hispanic/Latino CDC B/C TDF/FTC Weight <66 kg 66-75 kg 75-84 kg >84 kg Age <55 yrs >55 yrs Bilrubin <7 umol/L 7-9 umol/L 9-12 umol/L >12 umol/L

0.8 0.9 1.0 1.1 1.2 1.3 1.4 Changes Relative to Reference

Data source: Population PK in ART-naive, Figure 4-3 Reference categories: male, non-current smoker, no HBV/HCV co-infection, Caucasian, non Hispanic/Latino, CDC A, ABC/3TC for gender, smoking status, HCV/HBV co-infection, race, ethnicity, CDC, and background therapy, respectively. For continuous covariates, the overall median was used to normalize AUC0- of each category (i.e., 52.8 µg·h/mL).

102 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 10 Predicted Fold Change in Steady-State C to Reference Covariate Category (Fold Change in Median and 90% Confidence Interval)

SS C

Gender-Females Current Smoker HBV/HCV Non-Caucasian Hispanic/Latino CDC B/C TDF/FTC Weight <66 kg 66-75 kg 75-84 kg >84 kg Age <55 yrs >55 yrs Bilrubin <7 umol/L 7-9 umol/L 9-12 umol/L >12 umol/L

0.8 0.9 1.0 1.1 1.2 1.3 1.4 Changes Relative to Reference

Data source: Population PK in ART-naive, Figure 4-3. Reference categories: male, non-current smoker, no HBV/HCV co-infection, Caucasian, non Hispanic/Latino, CDC A, ABC/3TC for gender, smoking status, HCV/HBV co-infection, race, ethnicity, CDC, and background therapy, respectively. For continuous covariates, the overall median was used to normalize the C of each category (i.e., 1.12 µg/mL).

The magnitude of effect of weight, age, gender, total bilirubin, and smoking status on CL/F, V/F, or F was relatively small (all less than 30%), and magnitude of effect on steady-state AUC0-, Cmax, and C of DTG was <32% (Figure 8). Based on the known safety profile and PK/PD relationship for antiviral activity of DTG, the likely range of DTG therapeutic effect encompasses these changes. Subgroup analysis on Week 48 antiviral response in ING113086 demonstrated that there were no effects of gender and age on response (m2.7.3). Thus, the effects of these covariates are not considered clinically significant.

103 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Conclusions:

Population Pharmacokinetic Modelling:

 The PK of DTG in subjects with HIV following repeat-oral administration were adequately described by a one-compartment model with first-order absorption and absorption lag-time and first-order elimination.  Weight, smoking status, age, and total bilirubin were predictors of CL/F; weight was a predictor of V/F, and gender was a predictor of F. The effect of these covariates were not considered clinically significant, therefore, no DTG dose adjustment by these covariates is necessary.  For a typical 40 year old male, non-current smoker subject that weighed 70 kg with total bilirubin of 9 µmol/L, the estimated mean (95% CI) parameter values were: CL/F=0.901 (0.864, 0.938) L/h, V/F=17.4 (16.5, 18.3) L, KA=2.24 (1.56-2.92) h-1, and ALAG=0.263 (0.0942, 0.432) h.  Race/ethnicity, HCV co-infection, CDC classification, albumin, CrCL, ALT, or AST did not influence the PK of DTG in this analysis. There were limited PK data on subjects with HBV co-infection (n=8, 1%) and subjects of 65 years of age (n=1).  The PK of DTG were dose proportional for the range of doses between 25 and 50 mg, but a greater than dose-proportional PK was found at the 10 mg dose due to its 24% higher oral bioavailability compared to the 25 and 50 mg doses.  Inter-individual variability for CL/F and V/F was relatively low (23.5% and 13.7%), but was high for KA (50.1%).  Inter-occasion variability on CL/F was 17% over the course of studies.

Pharmacokinetic-Pharmacodynamic Relationship:

 There was no correlation between DTG exposure (AUC0-, Cmax, and Cmin) and antiviral response and CD4+ cell count change from Baseline.  There was no correlation between DTG exposure (AUC0-, Cmax, and Cmin) and safety measures except for change from Baseline in serum creatinine and creatinine clearance. Change from Baseline in serum creatinine and creatinine clearance appeared correlated with DTG exposure, however, was not clinically significant due to the small magnitude.

3.3.2. Population Pharmacokinetic Analysis in Treatment-Experienced Subjects

Study Title: Population Pharmacokinetic Analysis of Dolutegravir in HIV-1 Infected Treatment-Experienced Adults

Location of Report: m5.3.3.5, GlaxoSmithKline Document Number 2012N149456_00, Population PK in ART-experienced CSR

104 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Methodology:DTG concentration-time, dosing, demographic, and covariate data from the following studies were combined: ING112961 (VIKING, Phase IIb raltegravir- resistant), ING112574 (VIKING-3, Phase III integrase inhibitor-resistant) and ING111762 (SAILING, Phase III, treatment-experienced and integrase inhibitor-naïve). The Population PK model was developed using a non-linear mixed-effect modelling approach; the NONMEM VII software with the first-order conditional estimation method with interaction (FOCEI) was used.

A Population PK model for DTG has been developed in HIV-1-infected, treatment-naïve adult subjects. The predictive performance of this previous model was evaluated by applying the final model to the current analysis population and re-estimating all model parameters. Backward deletion was performed to retain covariates that were significant in the current population. Structural model was also refined to ensure parameter identifiability in the current population. Investigation of additional covariate-parameter relationships was based on range of covariate values in the dataset, scientific interest, mechanistic plausibility, and exploratory graphics. The full model approach was implemented in stages, where time-varying concomitant medications considered to be potentially important from the exploratory graphics were entered in the model first. A backward deletion was once again implemented. The resultant semi-full model was subjected to further covariate screening where covariate-parameter relationship deemed potentially influential, based on the exploratory graphics, were entered into the model followed by backward deletion. Insignificant, or poorly estimated covariates (less than 10.83 points increase of objective function value upon covariate removal, and/or confidence interval includes the null value of the parameter, and/or the parameter is estimated with high % relative standard error), were eliminated from the model.

Once the final Population PK model was developed, the ability of the model to describe the observed data was investigated using a predictive check procedure. Precision of the parameter estimates were evaluated using a nonparametric bootstrap procedure.

The final Population PK model was used to simulate plasma PK profiles of DTG in HIV- 1-infected, treatment-experienced adults to evaluate the influence of covariates and different dosing schedules.

Results: The population PK analysis included 574 subjects from 3 studies that contributed 2289 DTG concentrations.

Table 51 Covariate Distribution (Treatment-experienced)

Covariate Statistic or category All Subjects (N=574) Age (yrs) at baseline Median [Min-Max] 45 [19-69] Weight (kg) at baseline Median [Min-Max] 72.0 [32.0-163] Body mass index (kg/m2) Median [Min-Max] 24.4 at baseline [12.7-53.6] Body surface area (m2) at Median [Min-Max] 1.87 baseline [1.17-3.01]

105 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Covariate Statistic or category All Subjects (N=574) Total bilirubin (µmol/L) at Median [Min-Max] 8.00 baseline [3.00-100] Albumin (g/L) at baseline Median [Min-Max] 43.0 [29.0-55.0] Aspartate Median [Min-Max] 27.0 aminotransferase (IU/L) [9.00-382] at baseline Alanine aminotransferase Median [Min-Max] 24.0 (IU/L) at baseline [5.00-363] Serum creatinine (mg/dL) Median [Min-Max] 0.820 at baseline [0.420-2.86] Creatinine clearance Median [Min-Max] 111 (mL/min) at baseline [23.0-285] Gender N (%) Male 422 (74) Female 152 (26) Race N (%) Caucasian 345 (60) Black 196 (34) Asian 8 (1) Other 24 (4) Unknown 1 (<1) Ethnicity N (%) Non-Hispanic or 417 (73) Latino Hispanic or Latino 157 (27) Smoking N (%) Never 276 (48) Current 203 (35) Former 95 (17) Hepatitis co-infection at None 458 (80) baseline N (%) Hepatitis B only 26 (5) Hepatitis C only 62 (11) Hepatitis B and C 3 (1) Unknown 25 (4) CDC classification of HIV A 162 (28) infection at baseline B 117 (20) N (%) C 295 (51) Renal impairment Normal (CRCL≥90) 439 (76) classification at baseline Mild (60≤CRCL<90) 116 (20) N (%) Moderate to Severe 19 (3) (CRCL<60) Dosing regimen N (%) 50 mg QD 367 (64) 50 mg BID 207 (36) Metal-cation containing Present, visit 1 57 (10) products N (%) Present, visit 2 36 (8) Present, visit 3 18 (10) CYP3A inhibitors N Present, visit 1 477 (85) (%) Present, visit 2 373 (88) Present, visit 3 163 (88) CYP3A inducers N Present, visit 1 168 (30) (%) Present, visit 2 130 (31) Present, visit 3 65 (35) P-gp inhibitors N (%) Present, visit 1 183 (32) Present, visit 2 132 (31) Present, visit 3 44 (24) UGT1A1 inhibitors Present, visit 1 248 (44) N (%) Present, visit 2 178 (42) Present, visit 3 61 (33)

106 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Covariate Statistic or category All Subjects (N=574) UGT1A3 inhibitors Present, visit 1 192 (34) N (%) Present, visit 2 124 (29) Present, visit 3 33 (18) Background ART as Present, visit 1 60 (11) inhibitorsa N (%) Present, visit 2 37 (9) Present, visit 3 12 (6) Background ART as Mild, visit 1 305 (54) inducersb N (%) Mild, visit 2 246 (58) Mild, visit 3 132 (71) Moderate, visit 1 31 (5) Moderate, visit 2 21 (5) Moderate, visit 3 9 (5) Data Source: m5.3.3.5, Population PK in ART-experienced, Table 4-1. a. Background ART as inhibitors include atazanavir and atazanavir-ritonavir. b. Background ART as mild inducers represent any combination therapy containing darunavir-ritonavir or fosamprenavir-ritonavir. Background ART as moderate inducers represent any combination therapy containing etravirine without ritonavir-boosted protease inhibitors, efavirenz without ritonavir-boosted protease inhibitors, or tipranavir-ritonavir.

The PK of DTG following oral administration was adequately described by a linear one- compartment model with first-order absorption, absorption lag-time and first-order elimination, with inter-individual variability (IIV) and inter-occasion variability (IOV) in apparent clearance (CL/F).

CL/F = 1.05  1.16SMOKC  1.26INDMI  1.73INDMO  0.576INH  (WT/70)0.395  (ALBU/43)-0.592 where SMOKC=1 for current smokers and =0 for non-current smokers; INDMI=1 for mild inducers (DRV/r or FPV/r) as part of background ART and =0 for none; INDMO=1 for moderate inducers (TPV/r, ETR without PI/r, and EFV without PI/r) as part of background ART and =0 for none; INH=1 for inhibitors (ATV or ATV/r) as part of background ART and =0 for none;

V/F=19.9  (WT/70)0.697  (ALBU/43)-0.592

F=1.18GEND  0.846MCAT where GEND=1 for females and =0 for males; MCAT=1 for metal-cation containing products and =0 for none.

107 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 52 Parameter Estimates of Final DTG Population PK Model (Treatment- Experienced)

Parameter NONMEM Estimates Bootstrap Estimatesa [Units] Point Estimate %RSE 95% CI Median 95% CI CL/F [L/hr] 1.05 3.25 0.983-1.12 1.04 0.974-1.12 V/F [L] 19.9 2.60 18.9-20.9 19.8 18.3-21.2 Ka [hr-1] 2.35 11.2 1.83-2.87 2.30 1.81-3.16 ALAG [hr] 0.333 FIX - - - - CL/F~WT 0.395 20.1 0.240-0.550 0.398 0.236-0.567 V/F~WT 0.697 12.3 0.530-0.864 0.716 0.496-0.953 CL/F~SMOKC 1.16 3.35 1.08-1.24 1.16 1.08-1.24 F~GEND 1.18 3.67 1.10-1.26 1.17 1.09-1.27 F~MCAT 0.846 6.57 0.737-0.955 0.841 0.752-0.955 CL/F~INDMI 1.26 3.16 1.18-1.34 1.26 1.18-1.34 CL/F~INDMO 1.73 7.46 1.48-1.98 1.73 1.50-2.01 CL/F~INH 0.576 4.64 0.524-0.628 0.578 0.521-0.630 CL/F, V/F~ALBU -0.592 29.2 -0.931 - -0.253 -0.596 -0.944 - -0.249 Inter-individual or inter-occasion variability CV% 2CL 0.0823 11.8 0.0632-0.101 28.7 0.0798 0.0609-0.100 2IOV-CL 0.0838 10.8 0.0661-0.101 28.9 0.0843 0.0642-0.105 Residual variability CV% Median 95% CI 2prop 0.0992 5.64 0.0882-0.110 31.5 0.0981 0.0881-0.110 a. From 1000 bootstrap runs. Abbreviations: %RSE: percent relative standard error of the estimate = SE/parameter estimate * 100, 95% CI= 95% confidence interval on the parameter, CL/F = apparent clearance, V/F = apparent volume of central compartment, Ka = absorption rate constant, ALAG = absorption lag time, 2CL= variance of random effect of CL/F, CV = Coefficient of variation of proportional error (=[2prop]0.5*100), 2prop = proportional component of the residual error model, IOV = Inter-occasion variability, WT = Baseline weight (kg), ALBU = Baseline albumin (g/L). The reference population for PK parameters CL/F and V/F is 70 kg male, non-current smoker, not currently taking metal-cation containing medications, not receiving metabolic inducers as part of background ART, not receiving metabolic inhibitors as part of or background ART, with albumin of 43 g/L. Data Source:Population PK in ART-experienced, Table 4-3

Weight, smoking status, concomitant use of metabolic inducers as part of background ART classified by their level of induction, use of metabolic inhibitors as part of background ART, and albumin level were predictors of CL/F; weight and albumin were predictors of V/F; and gender and concomitant use of metal cation-containing products were predictors of F. CL/F of DTG was, on average, 16% (95% CI: 8-24%) higher in current smokers than non-current smokers. Subjects who were currently taking, or had taken, mild inducers as part of background ART within the previous two weeks would have 26% (95% CI: 18-34%) higher CL/F compared to those without inducers in their background ART. This increase in CL/F was more pronounced for moderate inducers, at 73% (95% CI: 48-98%) higher than non-users. On the contrary, subjects who were currently taking metabolic inhibitors as part of background ART would have 42% (95% CI: 37-48%) lower CL/F compared to non-users. CL/F and V/F increased with body weight. For the range of weights in the analysis (32-163 kg), CL/F ranged from 27% lower to 40% higher, and V/F ranged from 42% lower to 80% higher, than for 70 kg individuals. CL/F and V/F decreased with albumin to the same extent. For the range of albumin in the analysis (29-55 g/L), CL/F and V/F ranged from 14% lower to 26% higher compared to subjects with albumin of 43 g/L. Subjects who were concurrently taking

108 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

metal cation-containing medications would have 15% (95% CI: 4-26%) lower F compared to those who were not on those medications. Females would have 18% (95% CI: 10-26%) higher F than males. IOV was estimated to be 29% on CL/F.

Table 53 Summary of Steady-State Cmax, C, AUC0- and AUC0-24 following Actual Dose of DTG Administered by Dose Based on Post-hoc Estimates using the Final Model

Dose Statistic Cmax C AUC0- AUC0-24 (µg/mL) (µg/mL) (µg·h/mL) (µg·h/mL) 50 mg N 367 367 367 367 once Geomean (95% 3.18 (3.10- 0.826 (0.770- 44.0 (42.3- 44.0 (42.3- daily CI) 3.26) 0.885) 45.8) 45.8) %CVb 26.4 76.5 40.3 40.3 Median (Min- 3.13 (1.53- 0.867 43.5 (15.6- 43.5 (15.6- Max) 7.20) (0.0807-3.82) 130) 130) Percentiles 5% 2.14 0.254 23.6 23.6 10% 2.33 0.323 26.7 26.7 25% 2.68 0.550 33.5 33.5 50% 3.13 0.867 43.5 43.5 75% 3.79 1.26 56.4 56.4 90% 4.42 2.07 75.1 75.1 95% 4.95 2.58 88.0 88.0 50 mg N 207 207 207 207 twice Geomean (95% 4.15 (4.00- 2.12 (1.99- 37.5 (35.8- 75.1 (71.6- daily CI) 4.32) 2.25) 39.3) 78.6) %CVb 29.2 47.1 35.1 35.1 Median (Min- 4.14 (2.19- 2.13 (0.455- 37.3 (15.6- 74.7 (31.2- Max) 10.3) 7.39) 107) 213) Percentiles 5% 2.61 0.954 20.1 40.2 10% 2.98 1.18 25.0 50.0 25% 3.34 1.63 29.1 58.3 50% 4.14 2.13 37.3 74.7 75% 5.00 2.87 47.3 94.5 90% 5.93 3.68 57.3 115 95% 6.69 4.19 65.4 131 Data Source: Population PK in ART-experienced, Table 4-5

109 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 11 Predicted Fold-Change in Steady-State Cmax Relative to Reference Covariate Category (Fold-Change in Median and 90% Confidence Interval) – 50 mg Once Daily

50mg QD Cmax

Female Current Smoker Metal-Cation Medication Background ART Mild Inducers Moderate Inducers Inhibitors Weight <62 kg 62-72 kg 72-82 kg >82 kg Albumin <41 g/L 41-43 g/L 43-46 g/L >46 g/L

0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Changes Relative to Reference

Data Source: Population PK in ART-experienced, Figure 4-3 Reference categories: male, non-current smoker, not currently taking metal cation-containing products or metabolic inducers or inhibitors as part of background ART for gender, smoking status, and concomitant medications, respectively. For continuous covariates, the overall median was used to normalize the Cmax (median=3.81 µg/mL of each category.

110 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 12 Predicted Fold-Change in Steady-State C Relative to Reference Covariate Category (Fold-Change in Median and 90% Confidence Interval) – 50 mg Once Daily

50mg QD C

Female Current Smoker Metal-Cation Medication Background ART Mild Inducers Moderate Inducers Inhibitors Weight <62 kg 62-72 kg 72-82 kg >82 kg Albumin <41 g/L 41-43 g/L 43-46 g/L >46 g/L

0.2 0.6 1.0 1.4 1.8 2.2 2.6 3.0 3.4 Changes Relative to Reference

Data source: Population PK in ART-experienced, Figure 4-3 Reference categories: male, non-current smoker, not currently taking metal cation-containing products or metabolic inducers or inhibitors as part of background ART for gender, smoking status, and concomitant medications, respectively. For continuous covariates, the overall median was used to normalize the C (median=0.738 µg/mL) of each category.

111 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 13 Predicted Fold-Change in Steady-State AUC0- Relative to Reference Covariate Category (Fold-Change in Median and 90% Confidence Interval) – 50 mg Once Daily

50mg QD AUC0-

Female Current Smoker Metal-Cation Medication Background ART Mild Inducers Moderate Inducers Inhibitors Weight <62 kg 62-72 kg 72-82 kg >82 kg Albumin <41 g/L 41-43 g/L 43-46 g/L >46 g/L

0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 Changes Relative to Reference

Conclusions:

 The PK of DTG following repeat oral administration in HIV-1-infected, treatment- experienced adults were adequately described by a one-compartment model with first-order absorption, absorption lag-time and first-order elimination. The structural model resembled PK in HIV-1-infected, treatment-naïve adults.  Weight, smoking status, concomitant use of metabolic inducers as part of background ART classified by their level of induction, concomitant use of metabolic inhibitors as part of background ART, and albumin level were predictors of CL/F; weight and albumin level were predictors of V/F; and gender and concomitant use of metal cation-containing products were predictors of F.

112 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 The effect of weight, gender, smoking status, albumin, and concomitant use of mild metabolic inducers as part of background ART, and concomitant use of metal cation- containing products are unlikely to be clinically significant due to the small magnitude of effects.  Moderate/strong metabolic inducers (TPV/RTV and EFV) increased and metabolic inhibitors (ATV or ATV/RTV) decreased DTG clearance significantly and the estimated effect size in the final model is similar to observed in Phase 1 studies.  For a typical 70-kg male, non-current smoker, not currently receiving metabolic inducers or inhibitors as part of background ART, not taking any metal cation- containing medications, with albumin of 43 g/L, the estimated mean (95% CI) parameter values were CL/F=1.05 (0.983, 1.12) L/hr, V/F=19.9 (18.9, 20.9) L, Ka=2.35 (1.83, 2.87) hr-1, and ALAG=0.333 (fixed) hr.  Race/ethnicity, HCV co-infection, CDC classification, mild to moderate renal impairment, CrCL, ALT, or AST did not influence the PK of DTG in this analysis. There were limited PK data on subjects with HBV co-infection (n=29, 5%) and subjects of 65 years of age (n=11, 2%).  The PK of DTG appeared to be dose proportional between 50 mg once daily and 50 mg twice daily regimens.  Inter-individual variability (IIV) for CL/F was relatively low (CV=28.7%). IIV for V/F and KA could not be estimated due to lack of PK samples during the absorption phase.  Inter-occasion variability on CL/F was moderate, at 29% over the course of studies in treatment-experienced subjects; however, it was higher than that estimated in treatment-naïve subjects (17%).

3.3.3. Study ING116265 (PGx Analysis)

Study Title: PGx432 Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir PK: meta-analysis of Phase I studies ING111521, ING111603, ING111604, ING112934, ING113068, ING113096, ING114005, ING114819, ING113099

Location of Report: m5.3.5.3, Study ING116265

Study Design: The objective of this meta-analysis was to determine the effect of UGT1A1 genotypes on DTG PK and to explore the influence of CYP3A4, CYP3A5 and pregnane X receptor variants (NR1I2) in relation to DTG PK. Nine clinical pharmacology studies with DTG steady state PK data from 50 mg once daily, administered as a tablet formulation, were selected for inclusion in the analysis, and only data from subjects consented to PGx analyses were used.

DNA was extracted from venous blood collected from each consented subject for genotyping of the UGT1A1, CYP3A4, CYP3A5, and NR1I2 variants. UGT1A1 TA repeat genotyping was performed in a CLIA-certified laboratory (LabCorp, Durham, NC, USA). Control DNA samples known to carry specific UGT1A1 TA repeat genotypes were included to control for the detection of all four repeat alleles. Genotyping of the CYP3A4,

113 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

CYP3A5, and NR1I2 variants was performed using the Affymetrix DMET-Plus array under research conditions (Gen-Probe, Manchester, UK). Control DNA samples known to carry CYP3A4, CYP3A5, and NR1I2 functional alleles were included to control for the detection of the various functional alleles.

DTG PK parameters, including CL/F, AUC(0-), and Cmax, were retrieved from each study and combined. Associations of DTG PK parameters with UGT1A1 star alleles and with known functional variants in genes from the CYP3A pathway were evaluated by analysis of covariance using a mixed effect model with covariates, study, and genetic marker as fixed effects, and subject as a random effect. Covariates evaluated included age, gender, and fasting status. UGT1A1 genotype was categorized into three groups; low, reduced, and normal UGT1A1 activity as predicted from the genotypes for the two UGT1A1 genetic markers evaluated. CYP3A4 and CYP3A5 genotype was categorized into two predicted functional enzyme activity groups: low/reduced activity vs. normal activity.

Results: A total of 89 unique individuals were included in the Genetic analysis population with both genetic and PK data: 37 with African American/African heritage, 5 were Asian, and 46 were White; 7 were Hispanic, while 82 were not Hispanic; and 11 were female and 78 were male.

CL/F decreased 23%, while AUC(0-) and Cmax increased 31% and 22%, respectively, in subjects with low and reduced UGT1A1 activity compared to subjects with normal UGT1A1 activity.

CL/F decreased 32%, while AUC(0-) and Cmax increased 46% and 32%, respectively, in subjects with low UGT1A1 activity (*28/*28; *28/*37; *37/*37) compared to subjects with normal UGT1A1 activity(*1/*1, *1/*36).

114 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 54 Summary of PK Parameter Comparisons between UGT1A1 Predicted Enzyme Activity

Geometric LS Mean

PK Parameter Normal Reduced Low Activity Activity Activity Geometric Mean Ratio (N=41) (N=40) (N=7) Comparison (92% CI) CL/F (L/hr) 1.094 0.936 0.749 Low+Reduced vs 0.765 (0.659-0.889) Normal Low vs Normal 0.684 (0.543-0.862) AUC(0-) 45.7 53.4 66.8 Low+Reduced vs 1.307 (1.125-1.518) (g*h/mL) Normal Low vs Normal 1.462 (1.160-1.842)

Cmax (g/mL) 3.45 3.89 4.57 Low+Reduced vs 1.221 (1.063-1.402) Normal Low vs Normal 1.323 (1.068-1.638) Source Data: m5.3.5.3, Study ING116265, Table 1.10 From mixed effect model includes Predicted enzyme activity, Sex, and Study as fixed effect, and Subject as random effect. One subject had a genotype with metabolizer status as unknown.

DTG PK parameters were similar between CYP3A4 and CYP3A5 functional groups (low, reduced, and normal metabolizers). There were no statistically significant differences in PK parameters (CL/F, AUC, and Cmax) among the number of low activity or risk allele markers for UGT1A1, CYP3A4/5, and NR1I2.

It was also found that gender was a significant covariate in the analysis, with female subjects demonstrating ~30% lower CL/F than male subjects. Such a finding is consistent with historical DTG PK data.

The increased DTG exposure in UGT1A1 poor metabolizer is not considered clinically significant. This position is supported by the observation of no dose-limiting toxicities in dose-ranging Phase IIb studies as well as on-going Phase III studies. In addition, subjects receiving concomitant ATV or ATV/RTV have higher exposures but have not demonstrated an increase in toxicity to DTG.

Conclusions:

 Subjects with genotypes conferring poor metabolizer status of UGT1A1 (*28/*28; *28/*37; *37/*37) had a 32% lower clearance, 46% higher AUC, and 32% higher Cmax of DTG compared to subjects with genotypes associated with normal UGT1A1 activity (*1/*1, *1/*36).  Subjects with genotypes conferring intermediate and poor metabolizer status of UGT1A1 had a 23% lower clearance of DTG and 31% higher AUC compared to subjects with genotypes associated with normal UGT1A1 activity.

115 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

 Polymorphisms in CYP3A4, CYP3A5 and NR1I2 were not associated with differences in the PK of DTG.  Increases in DTG exposure due to UGT1A1 polymorphisms are not considered clinically significant based on the accumulated safety data for DTG.

3.3.4. Summary

Effects of intrinsic and extrinsic factors on DTG PK were evaluated in either Phase I studies or through population PK modelling, and findings are summarized here as well as in Figure 14:

 Body size, age, gender, and smoking: these are statistically significant covariates of DTG CL/F, Vd/F, and/or F, but the effects are not considered clinically significant; no DTG dose adjustment according to these covariates is needed. Pharmacokinetic data of DTG in subjects of >65 years old are very limited;  Race: race (Caucasian, African American, and Japanese ancestry) or ethnicity(Hispanic/Latino or Not-Hispanic/Latino) has no effect on DTG PK parameters; no DTG dose adjustment according to race or ethnicity is needed;  Hepatic impairment: DTG PK are similar between healthy subjects and subjects with moderate hepatic impairment (Child-Pugh grade B) (Section 2.1.2.2); no DTG dose adjustment is needed in subjects with mild to moderate hepatic impairment (Child- Pugh grade A or B); the effect of severe hepatic impairment on the pharmacokinetics of DTG has not been studied;  Renal impairment: There is no clinically relavant difference in DTG PK in subjects with mild/moderate renal impairment (Section 3.3.2) or severe renal impairment (CrCL <30mL/min) (Section 2.1.2.3); no DTG dosage adjustment is needed for subjects with mild, moderate, and severe (CrCL<30mL /min, not on dialysis) renal impairment; currently there is no data on DTG PK in subjects on hemodialysis although no effect of hemodialysis on DTG PK is expected due to high protein binding of DTG in plasma;  UGT1A1 polymorphism: subjects with genotypes conferring poor metabolizer status of UGT1A1 (*28/*28; *28/*37; *37/*37) had a 32% lower clearance, 46% higher AUC, and 32% higher Cmax of DTG compared to subjects with genotypes associated with normal UGT1A1 activity (*1/*1, *1/*36). Increases in DTG exposure due to UGT1A1 polymorphisms are not considered clinically significant. No DTG dose adjustment according to UGT1A1 polymorphism is needed;  HBV/HCV Co-infection: HCV co-infection has no effect on DTG PK exposure. There were limited PK data for subjects with HBV co-infection. There is no drug interaction between DTG and commonly/recently approved drugs for the treatment of HBV or HCV (Section 3.4). DTG can be used in HBV or HCV co-infected subjects.

116 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 14 Forrest Plot of Effect of Intrinsic Factors on DTG Pharmacokinetic PK Parameters based on Phase I Studies

Results from subgroup analysis of integrated efficacy (m2.7.3) and integrated safety (m2.7.4) indicated that there was no apparent or consistent difference in efficacy and safety by age, gender, or race, supporting the conclusions of no dose adjustment for DTG by these intrinsic and extrinsic factors. Differences in the safety profile of DTG for HBV and HCV co-infected subjects is likely due to the intrinsic nature of these diseases and to the more robust virologic and immunologic activity of DTG, especially in treatment- experienced subjects, rather than direct toxicity of DTG. Therefore, dose adjustment is also unnecessary due to this intrinsic factor.

3.4. Drug-Drug Interactions

In addition to background antiretroviral drugs, DTG is expected to be co-administered with drugs that are used to treat opportunistic infections or the side effects associated with taking other antiretrovirals, and with other medications commonly used in HIV- infected subjects. A total of 17 Phase I studies in healthy subjects have been performed to assess the interaction between DTG and various drugs, including ART for HIV treatment and non-ART medications expected to be used concomitantly with DTG (Section 1.3.4).

117 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

3.4.1. Supporting Non-clinical Data

DTG is primarily metabolized by UGT1A1 with a notable contribution from CYP3A4. UGT1A3 and 1A9 were minor pathways. Therefore, drugs that are strong inducers of UGT1A1 or CYP3A4 may decrease DTG plasma concentrations and reduce the therapeutic effect of DTG. Drugs that inhibit UGT1A1 and CYP3A4 may increase DTG plasma concentrations (m2.6.5). In vitro, DTG was a substrate for the human efflux transporters P-glycoprotein (Pgp) and human breast cancer resistance protein (BCRP). DTG was determined to have high passive and absorptive membrane permeability (3 x 10-4 cm/s) across the absorptive pH range of 5.5 to 7.4 and provided support for classification as a BCS Class II drug (m2.7.1). High permeability and rapid absorption has the potential to attenuate any impact of efflux inhibitors. In clinical studies, no notable effect on DTG pharmacokinetics was observed following co-administration with the efflux transport inhibitors LPV/RTV and TVR (Section 3.4.3).

In vitro, DTG was noted to have little or no inductive effects on the human Pregnane X Receptor (PXR), on CYP1A2, 2B6 or 3A4 mRNA. DTG demonstrated little or no direct inhibition (IC50 values >50 M) in vitro on the transporters BCRP, multi-drug resistance protein (MRP) 2, organic anion transporting polypeptide (OATP) 1B1, 1B3, organic cation transporter (OCT) 1, and Pgp, or the enzymes CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, UGT1A1 or 2B7. Therefore DTG has a low propensity to cause drug interaction. DTG glucuronide, GSK2832500, did not inhibit MRP2, thus inhibition of biliary clearance of bilirubin glucuronides or glucuronide conjugates of co-administered drugs is not expected (m2.6.5).

In vitro, DTG was an inhibitor of the renal organic cation transporter 2 (OCT2). In vitro incubation with DTG concentrations that were observed in vivo after a 50 mg oral dose produced a 90% inhibition of OCT2. These in vitro results indicate the potential for a drug interaction in vivo with cationic compounds that are renally cleared by this transporter, such as the endogenous substrate, creatinine, and the antiarrhythmic drug, dofetilide. Caution should be used when considering co-administration of narrow therapeutic index drugs in which a significant part of their clearance is by renal proximal tubule secretion by OCT2 (see Section 3.4.2 for details).

3.4.2. Effect of DTG on the Pharmacokinetics of Co-administered Drug

In vivo drug interaction studies with sensitive substrates for CYP3A4 (MDZ) and CYP2B6 (EFV) confirmed the low propensity of DTG to alter the pharmacokinetics of agents metabolized by either CYP3A4 or CYP2B6 in vivo, by demonstrating a lack of effect of DTG on the pharmacokinetics of MDZ and EFV. Drug interaction studies also indicated no clinically meaningful effect of DTG on tenofovir (a renal OAT1, OAT3, MRP2, and MRP4 substrate), RPV (a CYP3A substrate), methadone (primarily metabolized by CYP2B6 and CYP2C19 with CYP3A as a minor route), and oral contraceptive (OC) containing norgestimate and EE, which have complex metabolism, including oxidation, reduction, and conjugation.

118 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 55 Summary of Effects of DTG on PK of Co-administered Drugs

Concomitant Concomitant DTG dose N GM Ratio (90% CI) Study Conclusion drug drug dose Co-ad drug +DTG / co-ad drug alone

C24/C AUC Cmax MDZ (CYP 3A4 3 mg SD 25 mg once 10 NA 0.945 NA ING111322 No effect on MDZ substrate) daily (0.815, 1.095) (suspension) TDF 300 mg once 50 mg once 15 1.186 1.119 1.094 ING111604 No TDF dose adjustment daily daily (1.042-1.350) (1.012-1.238) (0.974-1.228)

Methadone Individualized 50 mg twice 11 Total methadone ING115698 No methadone dose adjustment dose daily 0.99 0.98 1.00 (0.91, 1.07) (0.91, 1.06) (0.94, 1.06)

R-methadone 0.95 0.95 0.97 (0.89, 1.02) (0.89, 1.02) (0.91, 1.03)

S-methadone 1.02 1.01 1.03 (0.93, 1.12) (0.93, 1.09) (0.97, 1.10) Oral norgestimate 50 mg twice 15 0.932 0.975 0.890 ING111855 No OC dose adjustment Contraceptive 0.25 mg and daily (0.846, 1.027) (0.910, 1.044) (0.815, 0.973) (Ortho-Cyclen) EE 0.035 mg 1.019 1.032 0.988 (0.934, 1.112] (0.964, 1.105) (0.907, 1.077) RPV 25 mg once 50 mg once 16 1.214 1.063 1.102 LAI116181 No RPV dose adjustment daily daily (1.070, 1.378) (0.976, 1.158) (0.992, 1.224)

Data source:ING111322, Table 11.15; ING111604, Table 11.10; ING115698, Table 11.8; ING111855, Table 3.6, Table 3.10; LAI116181, Table 11.12

119 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 15 Forrest Plot of Effect of DTG on Co-administered Drugs PK

In vivo drug interaction studies also demonstrated that DTG did not affect the PK of EFV, LPV/RTV, DRV/RTV, ATV, ETR, FPV, RPV, and TVR, by comparing PK data of these agents observed when co-administered with DTG to historical data. Most of these drugs are primarily metabolized by CYP3A. Based on consistent in vitro and in vivo data, DTG is not expected to affect the pharmacokinetics of drugs that are substrates of CYP isoenzymes, UGT isoenzymes, or major drug transporters (except for OCT2), including abacavir, nevirapine, nelfinavir, maraviroc, digoxin, opioid analgesics, statins, azole antifungals, proton pump inhibitors, antierectile dysfunction agents, acyclovir, valcyclovir, sitagliptin, and adefovir. OCT2 affects cation transport into the renal tubule. OAT1 (oganic anion transporter) and OAT3 are responsible for anion (e.g., tenofovir) transport into the renal tubule. As serum tenofovir concentrations are not increased with co-administration with DTG, OAT inhibition by DTG is highly unlikely. Additionally, MRP2 and MRP4 are anion transporters responsible for the transport of anions (e.g., tenofovir) from the renal tubule to the urine, and DTG has been shown not to inhibit MRP2, which also makes inhibition of MRP4 by DTG unlikely. Additionally, polymorphic MRP4 that decreases tenofovir renal clearance by 15% also increases plasma tenofovir concentrations by 32% [Kiser, 2008], which was not observed in the drug interaction study assessing the impact of DTG on tenofovir PK. Based on this data, an interaction with tenofovir at the renal tubule is considered unlikely and DTG is unlikely to potentiate nephrotoxicity observed with tenofovir.

120 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG may increase the exposure of 3TC and FTC through the inhibition of OCT2, which may be involved in active secretion of these agents in the urine [Moore, 1996]. Abacavir and zidovudine are not substrates of OCT2 and their metabolism through UGT2B7 (abacavir and zidovudine) and alcohol dehydrogenase (abacavir) are not expected to be affected by DTG. A clinically significant drug-drug interaction between DTG and 3TC or FTC is unlikely, given the safety profile observed across the treatment-naive studies, where subjects have received DTG in combination with 3TC or FTC for up to 96 weeks (ING112276) or up to 48 weeks and beyond (ING113086 and ING114467) (m2.7.4).

DTG inhibited the renal transporter OCT2, a mechanism that is consistent with a benign increase in serum creatinine. Based on this observation, DTG may reduce the excretion of dofetilide, thereby increasing plasma concentrations to toxic levels. Co-administration of DTG and dofetilide is contra-indicated. The concentration of metformin may be increased by the same mechanism and dose adjustment of metformin may be considered [Somogyi, 1987]. Metformin should be titrated against its effect on blood glucose and should be started at a low dose, with gradual dose escalation up to a maximum of 2,550 mg in adults, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient [Glucophage, 2008]. It does not cause hypoglycemia under normal conditions of use. Although theoretically, increases in metformin concentration may increase the risk of lactic acidosis, it would be expected that any effect of DTG on metformin concentration would be reflected by a lower dose being required to achieve the desired therapeutic effect, rather than a clinically significant increase in exposure.

3.4.3. Effect of Co-administered Drug on Pharmacokinetics of DTG

A summary of the effects of co-administered drugs on DTG PK can be found in Table 56.

121 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 56 Summary of Effects of Co-administered Drugs on DTG PK

Co-administered Co-administered DTG Dose N Geometric Mean Ratio (90% CI) of DTG PK Data DTG Dose Drug Drug Dose Parameters with/without Co-administered Drugs Source Recommendation No Effect = 1.00 C or C24 AUC Cmax TDF 300 mg once daily 50 mg once daily 15 0.920 1.005 0.969 ING111604 No dose adjustment (0.816-1.036) (0.908-1.113) (0.867-1.083) Table 11.6 DRV/RTV 600/100 mg twice 30 mg once daily 15 0.620 0.782 0.892 ING111405 No dose adjustment daily (0.555-0.694) (0.722-0.848) (0.825-0.965) Table 11.6 LPV/RTV 400/100 mg twice 30 mg once daily 15 0.944 0.973 1.000 ING111405 No dose adjustment daily (0.848-1.052) (0.911-1.039) (0.937-1.066) Table 11.6 ETR 200 mg twice daily 50 mg once daily 15 0.121 0.294 0.484 ING111603 Not recommended (0.093-0.157) (0.257-0.337) (0.433-0.542) Table 11.6 ETR/LPV/RTV 200/400/ 50 mg once daily 8 1.278 1.105 1.072 ING112934 No dose adjustment 100 mg twice daily (1.130-1.445) (1.017-1.201) (1.020-1.128) Table 11.6 ETR/DRV/RTV 200/600/ 50 mg once daily 9 0.629 0.750 0.882 ING112934 No dose adjustment 100 mg twice daily (0.523-0.758) (0.691-0.814) (0.781-0.997) Table 11.6 Multivitamins One-a-Day 50 mg SD 16 0.679 0.668 0.646 ING111602 No dose adjustment (0.560-0.824) (0.553-0.806) (0.540-0.774) Table 11.4 Maalox 20 mL 50 mg SD 16 0.256 0.264 0.276 ING111602 DTG should be taken 2 (0.211-0.311) (0.218-0.318) (0.231-0.331) Table 11.4 hours before or 6 hours Maalox 2 hrs after 20 mL 50 mg SD 16 0.703 0.743 0.821 ING111602 after antacid (0.579-0.853) (0.615-0.897) (0.686-0.984) Table 11.4 ATV/RTV 300/100 mg once 30 mg once daily 12 2.206 1.617 1.336 ING111854 No dose adjustment daily (1.972-2.468) (1.500-1.743) (1.254-1.423) Table 11.6 ATV 400 mg once daily 30 mg once daily 12 2.802 1.911 1.495 ING111854 No dose adjustment (2.523-3.113) (1.802-2.026) (1.404-1.591) Table 11.6 OMP 40 mg once daily 50 mg SD 12 0.954 0.971 0.915 ING112941 No dose adjustment (0.752-1.209) (0.783-1.203) (0.754-1.111) Table 11.4 TPV/RTV 500/200 mg twice 50 mg once daily 14 0.239 0.409 0.535 ING113096 DTG 50 mg twice dailyc daily (0.212-0.270) (0.379-0.443) (0.500-0.572) Table 11.6 EFV 600 mg once daily 50 mg once daily 12 0.245 0.431 0.608 ING114005 DTG 50 mg twice dailyc (0.179-0.336) (0.346-0.536) (0.506-0.730) Table 11.10 FPV/RTV 700/100 mg twice 50 mg once daily 12 0.510 0.651 0.763 ING113068 No dose adjustment daily (0.413-0.629) (0.542-0.782) (0.632-0.921) Table 11.12

122 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

123 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 16 Forrest Plot of Effect of Co-administered Drugs (Non-inducers) on DTG PK

Dashed line represents 0.25 or 75% reduction in DTG exposure, the lower end of the “no effect boundaries”.

124 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Figure 17 Forrest Plot of Effect of Co-administered Drugs (Inducers) on DTG PK

Dashed line represents 0.25 or 75% reduction in DTG exposure, the lower end of the “no effect boundaries”.

3.4.3.1. UGT/CYP3A Inhibitors

LPV/RTV, LPV/ RTV +ETR, ATV, ATV/ RTV, BCV, and TVR were evaluated in Phase I clinical drug interaction studies and showed no clinically significant effect on DTG PK as GMRs all fell within the “no effect boundaries” defined in Section 3.2.3.

LPV/RTV, BCV, and TVR are strong inhibitors of CYP3A4 as well as Pgp, but had no or minimal effect on DTG exposure. Therefore, other unstudied CYP3A4/Pgp inhibitors, (e.g., ketoconzaole) are not expected to affect DTG exposure either. No DTG dose adjustment is necessary when co-administered with CYP3A4 inhibitors. Nelfinavir is a weak CYP3A inhibitor, and therefore not expected to affect DTG PK significantly, so no DTG dose adjustment is needed. Use of UGT/CYP3A inhibitors as either background ART or concurrent medications were allowed in Phase II/III studies.

125 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

ATV is a strong inhibitor of UGT1A1, and ATV and ATV/RTV both increased DTG AUC by 62-91%. DTG exposure may be affected by other UGT1A1 inhibitors. However, since the effects of ATV and ATV/RTV are not considered clinically significant, the effects of other UGT1A1 inhibitors are expected to be not clinically significant either. No DTG dose adjustment is necessary when co-administered with UGT1A1 inhibitors.

3.4.3.2. UGT/CYP3A Inducers

DRV/RTV, FPV/RTV, TPV/RTV, DRV/RTV + ETR, RIF, RBT, prednisone, ETR, EFV, and RPV were evaluated in clinical studies and showed varied effect on DTG PK. Based on the observed effects and regulatory guidance [FDA, 2012; EMA, 2012], these inducers are classified into 3 groups:

 No net inductive effect (reducing DTG AUC by <20%): including RBT, prednisone, RPV, and LPV/RTV/ETR.  Weak inducers (reducing DTG AUC by 20 to 50%): including DRV/RTV, ETR + DRV/RTV, FPV/RTV.  Moderate inducers (reducing DTG AUC by 50-80%): including ETR (without a boosted PIs), EFV, TPV/RTV, and RIF.

A 75% reduction in DTG C or the geometric mean ratio on DTG C of 0.25 is defined as the lower bound of the “no effect boundaries” (Section 3.2.3). Based on such criteria, no DTG dose adjustment is needed when co-administered with these drugs, except for ETR, TPV/RTV, EFV, and RIF. The 90% CI of geometric mean ratio of ETR effect on DTG C was (0.093-0.157), which is completely outside the lower bound of the “no effect boundaries”, 0.25 (see Figure 16). Therefore ETR is recommended to be contraindicated with DTG. The 90% CIs of geometric mean ratios of the effects of TPV/RTV, EFV, and RIF on DTG C, at (0.212-0.270), (0.179-0.336), (0.23, 0.34), respectively, overlap with the lower bound of the “no effect boundaries”, 0.25 (see Figure 16); therefore DTG dose adjustment is needed when co-administered with TPV/RTV, EFV, and RIF.

Limited clinical data on the combination of DTG with TPV/RTV or EFV are available in ING111762 (SAILING). Significantly reduced DTG C0 by co-administration with TPV/RTV or EFV was confirmed in this study: DTG C0 in subjects on these inducers (n=16) was estimated at 0.169 g/mL (%CVb of 209%;Table 39), and is much lower than the lower bound of the “no effect boundaries” (0.3 g/mL as defined in Section 3.2.3.1). The observed antiviral response rate (Snapshot) in subjects on these inducers was consequently 14% lower than that in the subjects not on these inducers (Table 39). The lack of response in subjects on these inducers was driven by virologic failure rather than other causes (e.g., adverse events, lost to follow up, etc). Such data, even though limited, suggested the necessity of DTG dose adjustment when co- administered with TPV/RTV or EFV.

DTG 50 mg twice daily is recommended when co-administered with TPV/RTV or EFV. DTG C0 from 50 mg twice daily dosing co-administered with these moderate/strong inducers is estimated at 1.20 g/mL (m5.3.3.5, Population PK in ART-experienced,

126 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 4-9), which is 40% higher than the geometric mean of C0 observed in ING111762 (0.856 g/mL). It is expected that DTG 50 mg twice daily with TPV/RTV or EFV would demonstrate comparable antiviral response as observed in ING111762.

In the INI-resistant population in ING112574 (VIKING-3), a small number of subjects (n=8) received EFV and TPV/RTV in OBR with DTG 50mg twice daily. These subjects showed similar DTG C to other subjects not on these inducers, and showed higher Week 24 response rate (6/8: 75%) than the overall population (63%). These data support that DTG may be used without dose adjustment in combination with moderate inducers such as EFV and TPV/RTV in an INI-resistant population, however data are limited. Therefore caution is advised when DTG is co-administered with EFV and TPV/RTV in INI- resistant subjects.

DTG 50 mg twice daily should be used in subjects who require RIF therapy for treatment of TB infection. DTG 50 mg twice daily with RIF demonstrated DTG exposure at 18- 30% higher than that observed with DTG 50 mg once daily alone, supporting the recommendation of DTG 50 mg twice daily with RIF. Caution is advised when DTG is co-administered with RIF in INI-resistant subjects.

However, DTG can be dosed with ETR without dose adjustment if ETR is also co- administered with boosted PIs, including LPV/RTV, DRV/RTV, and ATV/RTV. The ability of LPV/RTV and DRV/RTV to attenuate the induction of ETR was demonstrated in ING112934, and this combination has been used in Phase III trials. ATV/RTV, as a strong UGT1A1 inhibitor, is likely to have the ability to attenuate the induction of ETR as well, although a drug interaction study evaluating the combination of ATV/RTV and ETR on DTG exposure has not been performed. Previous studies have demonstrated that RTV-boosted PIs can counteract the induction effect of EFV [Abel, 2008; Duval, 2000; Morse, 2005].

The effect of DRV/RTV on DTG PK was evaluated in a Phase I drug interaction study using DRV/RTV 600 mg/100 mg twice daily (Section 2.1.3.2). Twice daily dosing of DRV/RTV reduced DTG exposure without clinical significance; DTG AUC was reduced by 22% and C was reduced by 38%. There were a significant number of subjects on DRV/RTV twice daily dosing (N=92) as well as once daily dosing (800 mg/100 mg DRV/RTV, N=43) in the Phase III study ING111762. Clinical data in this study supports that DTG can be dosed with once daily DRV/RTV without dose adjustment (Section 2.3.8). No drug interaction study with once daily dosing of DRV/RTV is needed.

3.4.3.3. Metal Cation-Containing Products

Metal cation-containing antacids and multivitamins are used frequently in the HIV- infected populations. Chelation with metal cations has the potential to reduce DTG absorption. The effects of the antacid Maalox and multivitamins on DTG PK were evaluated in a clinical study (See Section 2.1.3.3). Due to a significant reduction in DTG exposure by antacid (>70% on AUC) and attenuation with separated dosing by 2 hours (Section 2.1.3.3), dosing separation is needed when DTG is given together with antacids. The antacid product selected for this study had the largest amount of metal cations to demonstrate the worst case scenario that might occur in clinical use. It is well known that

127 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

quinolones are recommended to be given at least 6 hours [Cipro, 2011] after antacids due to reduced absorption resulting from chelation with metal cations; therefore it is recommended that DTG should be administered 2 hours before or 6 hours after antacids. DTG should be taken 2 hours before or 6 hours after antacid dose. The effect of antacids on DTG PK is not a pH effect as OMP has shown no effect on DTG PK (See Section 2.1.3.9). DTG can be dosed with multivitamins without dosing separation. Other multivitamin products, althoughnot evaluated in a clinical study, are not expected to have significant effects on DTG PK since the multivitamin product (One A Day Maximum) that was evaluated represents a worse case scenario as it contains the highest level of metal cations: 162 mg calcium, 18 mg iron, 100 mg magnesium, 15 mg zinc, and 2 mg copper) (Section 2.1.3.3).

Reduction in DTG exposure by high-dose replacement therapy with metal cations (Ca, Fe, Mg, Al) is expected, although the magnitude is unknown. Dosing principles similar to antacids should apply to other high-dose metal cation supplements (Ca, Fe, Mg, Al) until further data are available. A specific study to evaluate the effect of calcium supplements on DTG PK has not been conducted. Calcium carbonate and citrate are the two most commonly used calcium supplements, and contain 40% and 21% of elemental calcium, respectively. The effect of a common calcium supplement dose of 1000 to 1200 mg (calcium carbonate or calcium citrate), containing about 200 to 480 mg elemental calcium, on DTG PK, is likely to be similar to that observed from One A Day Maximum due to similar elemental cations contained.

Milk also contains calcium. A specific study to assess a possible interaction of dolutegravir with milk alone has not be conducted; however, a Phase I study performed to assess the effects of food with varying fat/calories (m2.7.1, Section 2.3.3) evaluated dosing with meals that included milk. Milk was administered in both the moderate fat meal (2% milk, containing ~300 mg calcium per cup) and high fat meal (whole milk, containing ~250 mg calcium per cup) dosing arms. Increases in DTG exposure were observed in both arms. The amount of calcium in a glass of milk appears to have no impact on absorption. The effect of fat in food and milk increases solubilization of DTG and leads to improved absorption and higher plasma concentrations.

3.4.4. Summary of Predicted Drug Interaction

By extrapolating observed drug interaction results to drugs that have not been evaluated in clinical studies, but have similar metabolic properties, or by extrapolating based on in vitro data, the following can be anticipated:

128 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Table 57 Recommendations Based on Predicted Drug Interactions

Concomitant Drug Class: Anticipated Effect on Clinical Comment Drug Name Concentration of Dolutegravir or Concomitant Drug HIV-1 Antiviral Agents NNRTI: Co-administration with DTG dose adjustment to 50 mg twice daily Nevirapine nevirapine has the potential to is recommended when co-administration decrease dolutegravir plasma with nevirapine is needed. Caution is concentration to the extent warranted and clinical monitoring is similar to or less than EFV due recommended when the combination is to enzyme induction. given in INI-resistant patients. PI: Although an inhibitor of No dose adjustment is necessary. Nelfinavir CYP3A4, based on data from other inhibitors, an increase is not expected. CCR5 Antagonist: Maraviroc A CYP3A4 substrate. No drug No dose adjustment is necessary interaction expected NRTIs: abacavir, lamivudine, No drug interaction expected No dose adjustment is necessary emtricitabine, zidovudine Other Agents Antacids containing divalent Co-administration of antacids DTG is recommended to be administered cations (e.g., Mg, Al or Ca) other containing divalent cations has 2 hours before or 6 hours after taking than Maalox the potential to decrease DTG antacid products containing divalent exposure. cations. Proton Pump Inhibitors other No drug interaction expected No dose adjustment necessary than omeprazole (e.g lansoprazole, esomethrazole, and pantoprazole) Histamine-2 receptor No drug interaction expected No dose adjustment necessary antagonists (cimetidine, ranitidine, famotidine, nizatidine), Dofetilide Co-administration of DTG has DTG and dofetilide co-administration is the potential to increase contraindicated due to potential life- dofetilide plasma concentration threatening toxicity caused by high via inhibition of OCT2 dofetilide concentration. transporter. Metformin Co-administration of DTG has Clinical monitoring of blood sugar and for the potential to increase symptoms of lactic acidosis is metformin plasma concentration recommended. via inhibition of OCT2 transporter Weak metabolic inducers: No drug interaction expected No dose adjustment necessary glucocorticoids (<30 days of use), modafinil, pioglitazone, troglitazone Moderate/strong metabolic Co-administration with these Co-administration with these metabolic inducers: oxcarbazepine, metabolic inducers may inducers should be avoided. rifapentine, phenytoin, decrease DTG exposure phenobarbital, carbamazepine, St. John’s wort

Statins Statins are mostly substrates of No dose adjustment necessary CYP3A4 and OATP. No drug interaction with DTG is expected.

129 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Concomitant Drug Class: Anticipated Effect on Clinical Comment Drug Name Concentration of Dolutegravir or Concomitant Drug Digoxin, opioid analgesics, azole No drug interaction expected No dose adjustment necessary antifungals, antierectile dysfunction agents, acyclovir, valcyclovir, sitagliptin, adefovir, telbivudine, and entecavir Buprenorphine, naltrexone No drug interaction expected No dose adjustment necessary

4. SPECIAL STUDIES

Please note that m2.7.2.4, Special Studies (Summary of Microbiology/Virology), is provided as a standalone module.

5. CONCLUSIONS

Summary of characteristics of clinical pharmacology of DTG is presented in Section 1.2. Overall, pharmacokinetics, pharmacodynamics, PK/PD relationship in various patient population, and drug interaction profiles of DTG support the following dose recommendation:

Treatment-naïve adults: DTG 50 mg once daily.

Treatment-experienced but integrase inhibitor-naïve adults: DTG 50 mg once daily.

Integrase inhibitor resistant adults: DTG 50 mg twice daily.

Integrase inhibitor-naïve children of 12-<18 years of age and weighing greater than or equal to 40 kg: DTG 50 mg once daily.

No DTG dose adjustment is necessary based on age, gender, race/ethnicity, weight, smoking, CDC classification of HIV infection, HBV/HCV co-infection, UGT1A1 polymorphisms, in subjects with mild to moderate hepatic impairment (Child Pugh grade A or B), and in subjects with mild, moderate, or severe (CrCL<30 mL /min, not on dialysis) renal impairment. DTG can be co-administered with most ART or non-ART drugs without dose adjustment except for the following:

 Moderate/strong metabolic inducers: DTG 50mg twice daily dose is recommended when co-administered with TPV/RTV, EFV, and RIF; DTG should not be co- administered with ETR if the subject is not receiving concomitant RTV-boosted protease inhibitors (PIs) including LPV/RTV, DRV/RTV, and ATV/RTV.  Ployvalent metal cation-containing antacids: DTG should be dose 2 hours prior to or 6 hours after antacids.

130 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

6. REFERENCES

Abel, S., T.M. Jenkins, L.A. Whitlock, C.E. Ridgway, and G.J. Muirhead. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 2008;65(Suppl. 1):38-46.

Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RW, Wagner JA, and Iwamoto M. Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects. Antimicrob Agents Chemother. 2008. 52(12): 4228–4232.

Cipro (ciprofloxacin) Product Information, 2011. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.p df. Date accessed: November 1, 2012.

Duval, X., V. Le Moing, C. Longuet, C. Leport, J.L. Vildé, C. Lamotte, G. Peytavin, and R. Farinotti. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob. Agents Chemother. 2000;44:2593.

Eron, JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non- inferiority trial. Lancet Infec Dis. 2011;11:907-15.

European Medicine Agency (EMA). Guideline On The Clinical Development Of Medicinal Products For The Treatment Of HIV Infection. CHMP, London, UK; 2008. Doc. Ref. EMEA/CPMP/EWP/633/02 Revision 2. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003460.pdf. Date accessed: March 6, 2012.

European Medicine Agency (EMA). Guideline On The Evaluation Of The Pharmacokinetics Of Medicinal Products In Patients With Impaired Hepatic Function. CHMP, London, UK; 2005. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003122.pdf. Date accessed: October 31, 2012.

European Medicine Agency (EMA).Note for Guidance On The Evaluation Of The Pharmacokinetics Of Medicinal Products In Patients With Impaired Renal Function. CHMP, London, UK; 2004. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003123.pdf. Date accessed: October 31, 2012.

European Medicines Agency (EMA). Guideline on the Investigation of Drug Interactions (final). CHMP, London, UK; 2012. CPMP/EWP/560/95/Rev. 1. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/ WC500129606.pdf. Date accessed: Oct 03, 2012.

131 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Food and Drug Administration (FDA). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements — Clinical Considerations for Accelerated and Traditional Approval. CDER, Rockville, MD; 2002. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM070968.pdf. Date accessed: March 6, 2012.

Food and Drug Administration (FDA). Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance. CDER. Rockville, MD; 2012. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM292362.pdf. Date accessed: March 6, 2012.

Food and Drug Administration (FDA). Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. Draft Guidance. CDER. Rockville, MD; 2010. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM204959.pdf. Date accessed: March 6, 2012.

Food and Drug Administration (FDA). Guidance for Industry. Pharmacokinetics in Patients with Impaired Hepatic Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. CDER. Rockville, MD; 2003. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM072123.pdf. Date accessed: March 6, 2012.

Glucophage prescribing information. 08/27/2008. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.p df. Date accessed: November 1, 2012.

Hazra R, Viani R, Acosta E, et al., Pharmacokinetics, safety and efficacy of dolutegravir (DTG; S/GSK1349572) in HIV-1-positive adolescents: preliminary analysis from IMPAACT P1093. Abstract TUAB0203. Presented at: 19th International AIDS Conference; July 22-27, 2012; Washington, DC. Available online at http://www.iasociety.org/Abstracts/A200745155.aspx. Date accessed: November 12, 2012.

Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RWF, and van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005. 5:987-994.

Incivek prescribing information. Revised October 2012. Available online at: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Date accessed: November 7, 2012.

Iwamoto M, Wenning LA, Nguyen B-Y, etc. Effects of Omeprazole on Plasma Levels of Raltegravir. Clinical Infectious Diseases. 2009. 48:489-492.

Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner J, and Wenning L. Metabolism and Disposition in Humans of Raltegravir (MK-0518),an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1Integrase Enzyme. Drug Metabolism and Disposition. 2007. 35(9): 1657-1663.

132 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, and Fletcher CV. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients. Clinical Pharmacology & Therapeutics. 2008. 83(2): 265-272.

Min S, Sloan L, DeJesus E, etc. Antiviral Activity, Safety, and Pharmacokinetics/ pharmacodynamics of Dolutegravir as 10-day Monotherapy in HIV-1-infected Adults. AIDS. 2011;25:1737-1745.

Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, Hussey EK. Pharmacokinetics of lamivudine administered alone and with trimethoprim- sulfamethoxazole. Clin Pharmacol Ther. 1996 May;59(5):550-8.

Morse, G.D., S. Rosenkranz, M.F. Para, Y. Segal, R. Difrancesco, E. Adams, B. Brizz, K.E. Yarasheski, and R.C. Reichman. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob. Agents Chemother. 2005;49:3373-3381.

Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F. Reduction of metformin Renal Tubular Secretion by Cimetidine in Man. Br. J.Clin. Pharm. 1987; 23:545-551.

SongI, Chen S, and Piscitelli S. Meta-analysis of Pharmacokinetic-Pharmacodynamic Relationship of Integrase Inhibitors following Short-term Monotherapy. 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento, Italy. April 7-9, 2010. Abstract 50.

Sustiva (efavirenz) Product Information. March 2009. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020972s042,021360s030lbl.p df. Date accessed: November 7, 2012.

Tozzi V. Pharmacogenetics of antiretovirals. Antiviral Res. 2010; 85:190-200.

Zembruski N, Haefeli WE, and Weiss J. Interaction Potential of Etravirine with Drug Transporters Assessed In Vitro. Antimicrobial Agents Chemotherapy. 2011. 55(3):1282- 1284.

133 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

7. APPENDIX

Appendix Table 1 Tabular Listing of All Clinical Pharmacology Studies

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report Pharmacokinetic Studies in HIV-Negative Subjects ING111207 1 US Start 13 Nov To assess Double- 18-55yrs, DTG 2 to 25 Enrolled, 20/5; DTG safety Completed (Dose 2007; safety, Blind, Healthy 100 mg; oral 13 Completed 31.8yrs parameters CPSR Linearity) Completed tolerability and Randomized subjects, suspension; (19-54) 5.3.3.1 GSK 18 Feb 2008; PK of single , Placebo- male/ female single dose; AUC(0-t), AUC(0-), 25/20 doses of DTG Controlled fasted Cmax, tmax, C24, and t½ following single dose administration ING111322 1 US Start 27 Feb Part 1: Part 1: 18-50yrs, Part 1: Part 1: Part 1: Part 1: Completed (Dose 2008; To assess Double- Healthy DTG 10 to 32* (includes 27/5; DTG safety CPSR Linearity) Completed safety, Blind, subjects, 50 mg; oral 5 placebo) 31.7yrs parameters from 5.3.3.1 GSK 12 Jun 2008; tolerability and Randomized male/ suspension; Enrolled, 31 (18-50) predose values Part 1: 32/32, Pharmacokine , Placebo- female once daily; 10 Completed Part 2: 12/12 tics (PK) of Controlled days; fasted Part 2: DTG PK parameters repeat doses Part 2: 12/0; following single dose of DTG Part 2: Part 2: 12 Enrolled, 30.8yrs administration on Randomized DTG 20 mg; 12 Completed (18-50) Day 1: AUC(0-) and Part 2: , 3-Period, oral AUC(0-24), Cmax, To assess Balanced, suspension; *1 subject tmax, C24, t1/2, tlag, safety, Crossover singe dose; assigned to and CL/F; and tolerability and fasted placebo (AUC(0-t), C0, Ct, PK of single received a Cmin, Cmax, tmax, doses of DTG DTG 10 mg single dose of t1/2, and CL/F on suspension x2 (20 mg); DTG in error Day 10 and single tablet; oral;

134 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

AUC(0-t), AUC(0-∞), Cmax, tmax, λz, tlag, CL/F, Vz/F, and t½ of DTG in plasma following oral suspension [14C]- DTG dosing

Collection of samples for use in a separate

135 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Accumulation ratio of DTG in BP, CVF, CT, and VT

CVF:BP, CT:BP, VT:BP, CT:CVF, and VT:CVF DTG AUC ratios

136 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Accumulation of ratio of DTG in BP, SF, RF, and RT

SF: BP, RT:BP, and RF: RT DTG AUC ratios ING113125 1 US Start 28 Jun To evaluate Single dose, 18-70yrs, DTG 50 mg; Renal: Renal: Plasma DTG tlag, Completed (PK) 2011; the single open-label, Severe renal tablet; oral; 8 Enrolled, 8 5/3; tmax, Cmax, AUC(0- CPSR ViiV Completed dose PK and parallel impairment single dose Completed 56.8yrs t), 5.3.3.3 Healthcare 20 April 2012; safety of DTG group, two- subjects and (47-65) AUC(0-∞), %AUCex, 16/16 in healthy part study matched, Healthy: t½, CL/F and Vz/F subjects and healthy 8 Enrolled, 8 Healthy: in subjects control Completed 5/3; with severe subjects with 56.1yrs renal normal renal (43-68)

137 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report impairment function, male / female ING113097 1 US Start 19 Nov To evaluate Single dose, 18-70yrs, DTG 50 mg; Hepatic Hepatic Plasma DTG AUC(0- Completed (PK) 2010; the single open-label, Subjects tablet; oral; Impaired: Impaired: t), AUC(0-∞), Cmax, CPSR ViiV Completed dose PK and parallel with mild or single dose 8 Enrolled, 8 5/3; C24, apparent 5.3.3.3 Healthcare 04 Jun 2011; safety of DTG group, two- moderate Completed 55.5yrs t½, apparent 16/16 in healthy part, hepatic (50-61) clearance (CL/F), and subjects and adaptive impairment Healthy Vz/F in subjects study and Controls: Healthy with mild or matched, 8 Enrolled, 8 Controls: moderate healthy Completed 5/3; hepatic control 57.0yrs impairment subjects with (42-67) based on normal Child-Pugh hepatic category function, male / female ING115381 1 US Start 20 Apr To assess Open label, 20-55yrs, DTG 50 mg; 10 Enrolled, 6/4; Plasma DTG Completed (PK) 2011; safety, single dose Healthy tablet; oral; 10 Completed 33.4yrs following single dose CPSR ViiV Completed tolerability and study Japanese single dose (22-52) administration: 5.3.3.3 Healthcare 27 May 2011; PK of single subjects, AUC(0-t), AUC(0-∞), 10/10 doses of DTG male / Cmax, and C24 in healthy female Japanese subjects ING113099 1 US Start 13 May To assess the Randomized 18-65yrs, DTG 50 mg; Arm 1: ITT-E: Plasma DTG Cτ, Completed (Drug 2011; potential for a , open-label, Healthy tablet; oral; 12 Enrolled, 19/7; Cmax, and AUC(0-τ), CPSR Interaction) Completed drug two-period, subjects, once daily; 7 11 Completed 44.7yrs and AUC(0-24) for 5.3.3.4

138 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 50 mg; tablet; oral; once daily for 7 days then DTG 50 mg; tablet; oral BID+ RIFABUT 300 mg; capsule; oral; once daily; 14 days

139 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING115696 1 US Start 01 Sep To investigate Open-label, 18-65yrs, DTG 50 mg; 12 Enrolled, 5/7; DTG PK parameters Completed (Drug 2011; the effects of repeat dose, Healthy tablet; oral; 12 Completed 28.5yrs on Day 5 and Day 10: CPSR Interaction) Completed prednisone on two-period, subjects, once daily; 5 (23-38) AUC(0-), Cmax, C0, 5.3.3.4 ViiV 17 Oct 2011; the steady- single- male / days C, Cmin, CL/F, and Healthcare 12/12 state PK of sequence female t½ DTG DTG 50 mg; tablet; oral; once daily; Days 1-10 + prednisone; tablet; oral; once daily (60 mg Days 1-5; 50 mg Day 6; 40 mg Day 7; 30 mg Day 8; 20 mg Day 9; 10 mg Day 10) ING115697 1 US Start 13 Mar To assess the Randomized 18-65yrs, DTG 50 mg; DTG + BCV 19/13; Plasma steady-state Completed (Drug 2012; potential for a , open-label, Healthy tablet; oral; 16 enrolled, 42.5yrs DTG AUC(0-), CPSR Interaction) Completed drug two-period, subjects, once daily; 5 13 completed (19-65) Cmax, Cmin, C, 5.3.3.4 ViiV 23 May 2012; interaction single- male / days following Healthcare 32/32 between DTG sequence, female DTG + TLV administration of DTG and telaprevir two cohort DTG 50 mg; 16 enrolled, 50 mg once daily (TLV) and study tablet; oral; 15 completed (q24h) for 5 days and between DTG once daily + following co- and TLV 750 mg; administration with bocepravir tablet; oral; BCV 800 mg q8h for (BCV) q8h; 10 days 10 days or TVR 750

140 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report mg q8h for 10 days DTG 50 mg; tablet; oral; once daily + BCV 800 mg; capsule; oral; q8h; 10 days ING115698 1 Canada Start 02 Dec To assess the Open-label, 18-65yrs, Stable 11 Enrolled, 6/5; Steady-state total and Completed (Drug 2011; potential for a repeat dose, Healthy methadone 10 Completed 34.5yrs R-Methadone PK CPSR Interaction) Completed drug two-period, subjects dose; oral (24-44) parameters: AUC(0-τ), 5.3.3.4 ViiV 30 Dec 2011; interaction single- enrolled in a solution; once Cmax, and Cτ Healthcare 11/12 between DTG sequence methadone daily; 3 days and maintenance methadone program, Stable male / methadone female dose; oral solution + DTG 50 mg; tablet; oral; BID; 5 days ING111405 1 US Start 09 Oct To assess the Randomized 18-50yrs, DTG 30 mg; 31 Enrolled, 31/0; Plasma DTG steady- Completed (Drug 2008; potential for a , open-label, Healthy tablet; oral; 30 Completed 29.4yrs state AUC(0-τ), Cmax, CPSR Interaction) Completed drug two-period, subjects, once daily; 5 (18-50) Cτ, Cmin, CL/F, t½ 5.3.3.4 GSK 12 Dec 2008; interaction single- male / days and t1/2 following 31/30 between DTG sequence, female administration of DTG and lopinavir two cohort DTG 30 mg; 30mg q24h for 5 days (LPV)/ study tablet; oral; and following co- ritonavir (RTV) once daily + administration with and between LPV/RTV LPV/RTV 400/100 mg DTG and 400/100 mg; q12h or DRV/RTV

141 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 30 mg; tablet; oral; once daily + DRV (tablet) /RTV (capsule) 600/100 mg; oral; q12h; 14 days ING111602 1 US Start 07 Jan To assess the Open-label, 18-65yrs, DTG 50 mg; 16 Enrolled, 16/0; Single dose plasma Completed (Drug 2009; potential for a single dose, Healthy tablet; oral; 16 Completed 30.8yrs DTG AUC(0-∞), CPSR Interaction) Completed drug randomized, subjects, single dose (18-53) Cmax, and C24 5.3.3.4 GSK 05 Mar 2009; interaction four-period male/ female 16/16 between DTG crossover DTG 50 mg; and study tablet; oral; multivitamin single dose + and between multivitamin; DTG and tablet; oral; Maalox single dose

DTG 50 mg; tablet; oral; single dose + Maalox Advanced Maximum Strength;

142 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 50 mg; tablet; oral; single dose 2 hrs prior to Maalox Advanced Maximum Strength 20mL; suspension; single dose ING111603 1 US Start 16 Oct To assess the Open-label, 18-65yrs, DTG 50 mg; 16 Enrolled, 16/0; Plasma DTG steady- Completed (Drug 2008; potential for a repeat dose, Healthy tablet; oral; 15 Completed 41.5yrs state AUC(0-τ), Cmax, CPSR Interaction) Completed drug two-period, subjects, once daily; 5 (19-64) Cτ, Cmin, CL/F, t½ 5.3.3.4 GSK 12 Dec 2008; interaction single- male/ female days following 16/16 between DTG sequence administration of DTG and etravirine study DTG 50 mg; 50mg q24h for 5 days (ETV) tablet; oral; and following co- once daily + administration with ETV 200 mg; ETV 200mg q12h for tablet; oral; 14 days q12h; 14 days

143 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 50 mg; tablet; oral; once daily + TDF 300 mg; tablet; oral; once daily; 5 days ING111854 1 US Start 07 Apr To assess the Randomized 18-65yrs, Period 1: 24 Enrolled, 21/3; Plasma DTG steady- Completed (Drug 2009; potential for a , open-label, Healthy DTG 30 mg; 24 Completed 37.2yrs state AUC(0-τ), Cmax, CPSR Interaction) Completed drug repeat dose, subjects, tablet; oral; (18-61) C0, Cτ, and Cmin 5.3.3.4 GSK 09 Jun 2009; interaction two-period, male / once daily; 5 following 24/24 between DTG single- female days; fed administration of DTG and sequence, 30mg q24h for 5 days atazanavir two-cohort Period 2: and following co- (ATV) and study DTG 30 mg; administration with between DTG tablet; oral; ATV/RTV 300/100mg and ATV/RTV once daily + q24h or ATV 400mg ATV/RTV q24h for 14 days 300/100 mg; capsule; once

144 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 30 mg; tablet; oral; once daily + ATV 400mg; capsule; oral; once daily; 14 days ING111855 1 US Start 13 Dec To assess the Randomized 18-40yrs, DTG 50 mg or 16 Enrolled, 0/16; AUC[0-τ] of Completed (Drug 2011; potential for a , two-period, Healthy placebo; oral; 15 Completed 31.1yrs Norelgestromin and CPSR Interaction) Completed drug double-blind subjects, tablet; once (20-40) EE after Ortho-Cyclen 5.3.3.4 ViiV 28 Mar 2012; interaction study female daily days 1- alone and after Healthcare 16/16 between DTG 11 and DTG Ortho-Cyclen with and oral 50 mg or DTG contraceptives placebo; (ethinyl tablet; oral; estradiol (EE) once daily /norgestimate days 12-21 [NGM]) EE / NGM; tablet; oral; once daily days 1-21

145 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

146 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING112941 1 US Start 23 Jul To evaluate Part 1: 18-65yrs, Part 1: Part 1: Part 1: Plasma DTG Completed (Drug 2009; the effect of a Randomized healthy DTG 50 mg; 14 Enrolled, 12/2; following a single CPSR Interaction) Completed high fat meal , open-label, subjects, tablet; oral; 12 Completed 40.6yrs dose administration of 5.3.3.4 GSK 28 Sep 2009; and two male / single dose; (23-55) 50 mg under fasted Part 1: 14/14, omeprazole sequence, female fasted Part 2: conditions with and Part 2: 10/10 on DTG PK three 10 Enrolled Part 2: without OMP 40 mg: and to treatment DTG 50 mg; (includes 2 9/1; AUC(0-t), AUC(0-∞), evaluate the crossover tablet; oral; placebo), 38.4yrs Cmax, tmax, C24, tlag safety and PK single dose; 10 Completed (21-54) of a 250 mg Part 2: within 30 Plasma DTG dose of DTG Randomized minutes after following a single , double- the start of a dose administration of blind, single high fat meal 50 mg under fasted dose PK conditions and with a study DTG 50 mg; high-fat meal: AUC(0- tablet; oral; t), AUC(0-∞), Cmax, single dose + tmax, C24, and tlag omeprazole 40 mg; Plasma DTG following capsule; oral; a single dose once daily; 5 administration of days 250 mg under fasted conditions: AUC(0-t), Part 2: AUC(0-∞), Cmax, DTG 250 mg tmax, C24, and tlag or placebo; Safety and tolerability oral parameters following suspension, a single single dose; supratherapeutic dose fasted of DTG 250 mg

147 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING113068 1 US Start 09 Sep To investigate Part A: 18-65yrs, Part A: Part A: Part A: Part A: Completed (Drug 2010; the effects of Open-label, Healthy DTG 50 mg; 12 Enrolled 10/2; Plasma DTG steady- CPSR Interaction) Completed fosamprenavir repeat dose, subjects, tablet; oral; 12, 33.4yrs state AUC(0-), 5.3.3.4 ViiV 04 Nov 2010; (FPV)/ RTV two-period, male / once daily; 5 Completed (24-55) Cmax, C0, C, and Healthcare Part A: 12/12, on the steady- single- female days Cmin following Part B: 15/15 state PK of sequence Part B: Part B: administration of DTG DTG and to DTG 50 mg; 15 Enrolled, 4/11; 50 mg q24h for 5 days evaluate Part B: tablet; oral; 15 Completed 34.7yrs and following relative Open-label, once daily + (20-60) co-administration with bioavailability single dose, FPV 700 mg; FPV/RTV 700/100 mg of tablets with randomized, tablet / RTV q12h for 10 days varying three-period, 100 mg; particle size cross over capsule; oral; Part B: study q12h; 10 days Plasma DTG AUC(0- ), AUC(0-t), and Part B: Cmax following a DTG 50 mg single dose of DTG using 25 mg 50 mg tablets with micronized drug substance; oral; single dose

DTG 50 mg using 25 mg tablets with unmicronized drug

148 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

DTG 50 mg using 25 mg tablets with intermediate particle size drug substance; oral; single dose

149 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING113096 1 US Start 15 Feb To assess the Randomized 18-55yrs, DTG 50 mg; 18 Enrolled, 14/4; Plasma DTG steady- Completed (Drug 2010; safety, , open-label, Healthy tablet; oral; 13 Completed 29.3yrs state AUC(0-), CPSR Interaction) Completed tolerability and repeat dose, subjects, once daily; 5 (19-45) Cmax, C0, C, and 5.3.3.4 GSK 05 Apr 2010; PK of repeat three-period male / days Cmin following 18/18 dose co- single- female administration of DTG administration sequence, TPV / RTV 50 mg once daily for 5 of DTG alone, study 500/200 mg; days and following co- tipranavir capsule; oral; administration with (TPV)/RTV BID; 7 days TPV/RTV 500/200 mg alone, and BID for 5 days DTG in DTG 50 mg; combination tablet; oral; with TPV/RTV once daily and TPV / RTV 500/200 mg; capsule; oral; BID; 5 days ING114005 1 US Start 16 Mar To evaluate Open label, 18-65yrs, DTG 100 mg; 12 Enrolled, 12/0; Plasma DTG AUC(0- Completed (Drug 2010; PK of DTG repeat dose, Healthy tablet; oral; 12 Completed 38.7yrs 24), Cmax, and C24, CPSR Interaction) Completed 100 mg three period subjects, single dose (20-65) and dose-normalized 5.3.3.4 ViiV 26 May 2010; versus 50 mg single- male / AUC(0-24), Cmax, Healthcare 12/12 and the effect sequence female DTG 50 mg; and C24 following of efavirenz tablet; oral; single dose (EFV) on the once daily; 5 administration of PK, safety and days 100 mg and 50 mg tolerability of DTG 50 mg DTG 50 mg; Plasma DTG steady- tablet; oral; state AUC(0-), once daily in Cmax, C0, C, and

150 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

LAI116181 1 US Start 07 Nov To assess the Open label, 18-55yrs Cohort 1: Cohort 1: 16 24/4; Plasma DTG Completed (Drug 2011; potential for a repeat dose, Healthy Treatment A = Enrolled, 16 31.4yrs AUC(0-τ), Cmax, and CPSR Interaction) Completed drug single- subjects, DTG 50 mg; Completed (18-50) tmax, and Cτ, 5.3.4.4 ViiV 20 Feb 2012; interaction sequence, 3- male / tablet; oral; following 50 mg q24h Healthcare Cohort 1: between DTG period study female q24h; 5 days Cohort 2: 12 administration with 16/16, and rilpivirine Enrolled, 11 and without RPV 25 Cohort 2: (RPV) Treatment B = Completed mg 12/12 RPV 25 mg; q24h tablet; oral; q24h; 11 days Plasma GSK1265744 steady-state AUC(0- Treatment C τ), Cmax, tmax, and = RPV 25 mg; Cτ following tablet; oral; GSK1265744 30 mg q24h + DTG q24h administration 50 mg; tablet; with and without RPV oral; q24h; 5 25 mg q24h days Plasma RPV steady- state AUC(0-τ), Cmax,

151 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Treatment B = RPV 25 mg; tablet; oral; q24h; 12 days

Treatment E = RPV 25 mg; tablet; oral; q24h + GSK1265744 30 mg; tablet; oral; q24h; 12 days ING116265 NA NA To evaluate Meta- Healthy DTG 50 mg; 89 subjects 78/11; NA Completed: (PGx) the effects of analysis of adult tablet; oral; included in 36.9yrs Meta- ViiV UGT and CYP PGx and PK subjects once daily; 5 the analysis (19-64) analysis Healthcare polymorphism data from 9 days Report s on the PK of Phase II 5.3.5.3 DTG studies

152 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report Human Pharmacodynamic Studies ING111856 1 US Start 28 Sep To evaluate Randomized 18-55yrs, DTG 250 mg; 42 Enrolled, 17/25; Change from Baseline Completed (PD) 2009; the effect of , partial- Healthy oral 38 Completed 34.5yrs in QTcF for DTG CPSR GSK Completed DTG on blind, single subjects, suspension; (18-55) 5.3.4.1 29 Dec 2009; cardiac dose, three- male / single dose 42/42 conduction as period, female assessed by cross-over Placebo; oral 12-lead study suspension; electrocardiog single dose ram compared to placebo Moxifloxacin and 400 mg; moxifloxacin tablet; oral; (Thorough single dose QTc study of DTG) ING114819 1 US Start 05 Oct To evaluate Open-label, 18-65yrs, DTG 50 mg; 38 Enrolled, 28/10; GFR as measured by Completed (PD) 2010; the effect of randomized, Healthy tablet; oral; 34 Completed 31.8yrs iohexol plasma CPSR ViiV Completed DTG on three-arm, subjects, once daily; 14 (19-59) clearance at Days -1, 5.3.4.1 Healthcare 03 Dec 2010; glomerular parallel, male / days 7, and 14 38/36 filtration rate placebo- female as measured controlled DTG 50 mg; by iohexol and tablet; oral; to evaluate q12h; 14 days creatinine clearance, Placebo; extra- tablet; oral; glomerular once daily; 14 creatinine days excretion, and

153 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Aminohippura te Sodium 2 g/10ml (20%) of Loading Dose : 8 mg/kg, Maintenance Dose: 12 mg/min; solution; IV Pharmacokinetic and PK/PD Studies in Target Patient Population ING111521 14 US Start 25 Jun To assess the Dose- 18-65yrs, DTG 2, 10, 35 Enrolled 35/0; Change from baseline Completed (PK and 2008; safety, ranging, 10- HIV-infected 50 mg tablet; (including 7 38.4yrs in plasma HIV-1 RNA CPSR PK/PD) Completed tolerability and day, repeat subjects, oral; once placebo) (20-55) to Day 11 5.3.4.2 GSK 26 Aug 2008; efficacy of dose, male/ daily; 10 35, DTG following dose 35/30 repeat dose placebo- female days; fasted Completed administration on DTG controlled Day 1: AUC(0-), monotherap AUC(0-24), Cmax, y study tmax, C24, t½, tlag, and CL/F; and following last repeat administration on Day 10: AUC(0-), C0, C, Cmin, Cmax,

154 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Safety and tolerability parameters ING116070 3 US Start 24 Jan To determine Phase IIIb 18yrs, HIV- DTG 50 mg; 13 Enrolled, ITT-E: Proportion of subjects Completed (PK) 2012; plasma (total single-arm, infected, tablet; oral; 12 Ongoing 13/0; with plasma HIV-1 Week 2 ViiV Ongoing; and unbound) open-label, ART-naïve once daily + 40.2yrs RNA <50 c/mL over Synoptic Healthcare 13/14 DTG multicenter subjects, ABC/3TC (28-52) time; Clinical concentration study male / 600/300 mg; Study and evaluate female tablet; oral; Absolute values and Report the once daily; 96 change from Baseline (CSR) relationship weeks in plasma HIV-1 RNA 5.3.4.2 between DTG over time; concentration Absolute values and in plasma and changes from CSF Baseline in CD4+ and CD8+ T cell counts over time

Incidence of disease progression HIV- associated conditions, acquired immunodeficiency syndrome [AIDS] and death

155 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING112276 34 centres: Start 30 Jul To select a Phase IIb, 18yrs, HIV- DTG 10 mg; DTG 10 mg: 177/28; Proportion of subjects Completed: (PK and 6 France, 4 2009; once daily oral Randomized infected, tablet; oral + 53 37.2yrs with HIV-1 RNA PK/PD) Germany, 3 Ongoing; dose of DTG , multicentre, ART-naïve ABC/3TC Randomized, (20-79) <50 c/mL (c/mL) (Week 16 ViiV Russia, 4 205/200 administered parallel subjects, 600mg/300 47 Completed through Week 16 Synoptic Healthcare Italy, 5 with either group, dose- male / mg or using the Time to CSR) Spain, 12 ABC/3TC or ranging female TDF/FTC DTG 25 mg: Loss of Virological US TDF/ 300mg/200m 51 Response (TLOVR) (Week 24 emtricitabine g; tablet; oral; Randomized, algorithm. Dose Full CSR) (FTC) and to once daily; 96 45 Completed selection will be based evaluate weeks primarily on antiviral (Week 48 antiviral DTG 50 mg: activity and tolerability Abbreviate activity, safety DTG 25 mg; 51 in conjunction with d CSR) and PK over tablet; oral + Randomized, immunologic, safety time ABC/3TC 46 Completed and PK measures will (Week 96 600mg/300m also be considered Full CSR) g or TDF/FTC EFV 600 mg: 300mg/200m 50 5.3.5.1 g; oral; once Randomized, daily; 96 39 Completed weeks DTG 50 mg DTG 50 mg; Open label: tablet; oral + 138 Enrolled, ABC/3TC 127 Ongoing 600mg/300m g or TDF/FTC 300mg/200m g; oral; once daily; 96 weeks

156 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

EFV 600 mg + ABC/3TC 600mg/300m g or TDF/FTC 300mg/200 mg; oral; once daily; 96 weeks ING113086 100 centres: Start 19 Oct To assess Phase III, 18yrs, HIV- DTG 50 mg; DTG: 411 703/119; The proportion of Completed: (PK and 27 Spain 2010; safety and multicentre infected, tablet; oral; Randomized, 37.0yrs subjects with HIV-1 Week 48 PK/PD) 19 US,12 Ongoing; efficacy of randomized, ART-naïve once daily or 359 Ongoing. (18-75) RNA <50 c/mL Full CSR ViiV France, 822/788 DTG 50 mg double blind, subjects, RAL 400 mg; RAL: 411 through Week 48 5.3.5.1 Healthcare 11 Russia, once daily to double- male / tablet; oral; Randomized, using a Missing, 10 Germany, RAL 400 mg dummy, female once daily + 345 Ongoing Switch or 7 Canada, BID both active- ABC/3TC Discontinuation = 7 Italy, administered controlled, 600mg/300m Failure (MSDF) 4 Australia, with fixed- parallel g algorithm 3 UK dose dual group, fully- or TDF/ FTC nucleoside powered 300mg/200m reverse non- g; tablet; oral; transcriptase inferiority once daily; 96 inhibitor study weeks therapy ING111762 185 centres: Start 26 Oct To evaluate Phase 3, 18yrs, HIV- DTG 50 mg; DTG: 362 487/232; The proportion of Completed: (PK and 4 Belgium, 2010; safety and multicentre infected, tablet; oral; Randomized, 42.5yrs subjects with HIV-1 Week 24 PK/PD) 12 France, Ongoing; efficacy of randomized, ART- once daily or 48 (18-73) RNA <50 c/mL Full CSR ViiV 4 Greece, 719/688 DTG 50 mg double-blind, experienced RAL 400 mg; Completed, through Week 48 5.3.5.1 Healthcare 1 Hungary, once daily vs. active- subjects, tablet; oral; 263 Ongoing using MSDF algorithm 7 Italy, raltegravir controlled, integrase BID + as codified by the

157 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report 2 (RAL) 400 mg parallel inhibitor Investigator- RAL: 357 FDA’s “snapshot Netherlands, BID, both group, non- naïve selected Randomized, algorithm. The 3 Romania, administered inferiority regimen, background 57 proportion of subjects 24 Spain, with an study male / regimen; 48 Completed, with plasma HIV-1 4 UK, investigator- female weeks 242 Ongoing RNA <50 c/mL will 6 Canada, selected also be assessed at 72 USA, background Week 24 6 Argentina, regimen 2 Australia, 9 Brazil, 5 Chile, 4 Mexico, 12 Russia, 3 South Africa, 5 Taiwan ING112961 16 centres: Start 31 Aug To assess the Phase IIb, 18yrs, HIV- Cohort I: Cohort I: Cohort I: The proportion of Completed: (PK and 7 France, 2009; antiviral multicentre, infected, DTG 50 mg; 27 25/2; subjects with Day 11 PK/PD) 1 Italy, Ongoing; activity of open-label, ART- tablet; oral; Randomized, 46.7yrs plasma HIV-1 RNA (Week 24 ViiV 2 Spain, Cohort I: DTG single-arm, experienced once daily; 96 12 Ongoing (19-61) <400 c/mL or at least Cohort 1 Healthcare 6 US 27/30, containing sequential subjects, weeks 0.7 log10 c/mL below Full CSR) Cohort II: regimen cohort, pilot raltegravir Cohort II: Cohort II: their Baseline value 24/50 study resistance, Cohort II: 24 18/6; (sample for evaluation (Week 72 male / DTG 50 mg; Randomized, 47.4yrs of plasma HIV-1 RNA Cohort I/ female tablet; oral; 17 Ongoing (33-68) to be taken prior to Week 24 BID; 48 Day 11 background Cohort II weeks treatment Full CSR) optimization) (Week 96 Cohort I/

158 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

5.3.5.2 ING112574 78 centres: 1 Start 6 May To assess the Phase III, 18yrs, HIV- DTG 50 mg; 183 141/42; Mean change from Completed: (PK and Belgium, 3 2011; antiviral multicentre, infected, tablet; oral; Randomized, 47.0yrs baseline in plasma Week 24 PK/PD) Canada, 15 Ongoing; activity of single-arm, ART- BID; 24 155 Ongoing (19- 67) HIV-1 RNA (log10 Full CSR ViiV France, 6 183/175 DTG open-label experienced weeks c/mL) at Day 8 5.3.5.2 Healthcare Italy, 4 administered study subjects, Portugal, 8 with failing integrase Spain, 41 background inhibitor US therapy to Day regimen, 8 and male / thereafter with female optimised background ART ING112578 1 US Start 16 March To select a Phase I/II, 6wks- DTG once-a- Cohort 1 Cohort 1: Toxicity through week Completed: (PK) 2011; DTG dose for multicenter, <18yrs, HIV- day doses (Stage 1): 10 (Stage 1) 24 Week 24 Ongoing; chronic dosing open-label, 1 infected with target Enrolled, 10 3/7; Full CSR All AEs or lab 22/168 in infants, non- subjects, dose of ~1 Ongoing 14.0yrs toxicities of grade 3 or children and comparative male / mg/kg and (12–17) (10 higher severity adolescents intensive PK female with 4 weight Cohort 1 subjects that achieves and safety bands, and (Stage 2): 12 Cohort 1 [Stage 1] Adverse events or lab similar study maximum Enrolled, 12 (Stage 2): from toxicities of grade 3 or exposure to dose of 50 Ongoing no data Cohort 1 higher severity judged the DTG adult mg; 48 weeks available through 24 to be at least possibly dose selected weeks)

159 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

160 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Protocol No. Study Study Start; Study Study Diagnosis; Treatment No. of Gender Primary Endpoint(S) Study No. Centres Enrolments Objectives Design Key Details Subjects by M/F; Reporting (Study Location(s) Status and Inclusion (Drug; Dose; Group Mean Status Type) Date; Total Criteria Form; Route; Entered/ Age (Type of Sponsor Enrolment Frequency; Completeda (Range) Report) / /Target Duration) Location Enrolment of Report ING116529 26 US Start 18 Apr To quantify Phase III, 18yrs, HIV- DTG 50 mg; 4 No data The mean change Completed: (PK and 2012; the antiviral randomized, infected, tablet; oral; Randomized; available from baseline in Brief Study PK/PD) Ongoing; 4/30 activity of multicentre, ART- BID or 4 Ongoing plasma HIV-1 RNA Summary ViiV DTG placebo- experienced Placebo; (log10 c/mL) at Day 8, 5.3.5.4 Healthcare compared to controlled, subjects, tablet oral; using a last placebo (PCB) double-blind integrase BID + current observation carried when followed by inhibitor failing forward with administered an open regimen, regimen; 7 discontinuation equals with failing label phase male / days baseline background female therapy for 7 days a. For ongoing studies, the number of ongoing subjects reported as of data cut off date (~ or data cut off date in respective CSR) 3TC = lamivudine; ABC = abacavir; ART = antiretroviral therapy; ATV = atazanavir; BA = bioavailability ; BCV = boceprevir; BID = twice daily; CPSR = clinical pharmacology study report ; CSR = clinical study report; DRV = darunavir; DTG = dolutegravir ; EE= ethinyl estradiol; EFV = efavirenz; ETR = etravirine; FPV = fosamprenavir; FTC = emtricitabine; IV = intravenous; LPV= lopinavir; NGM = norgestimate; OL = open label ; OMP = omeprazole ; PD = pharmacodynamics; PD = pharmacodynamics; PK = pharmacokinetics; PK = pharmacokinetics; QD = once daily; RAL = raltegravir; RBT = rifabutin; RIF = rifampin; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil fumarate; TLV = telaprevir; TPV = tipranavir

161 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Appendix Table 2 Summary of Single Dose DTG Pharmacokinetic Parameters

Study/ Location of Population/ No. of Route of Dose/ No. of Subjects Parametera,c Study Report Subjects Administration/ Cmax (g/ml) Tmax AUC (0-) T1/2 C24 completed Dosage Form (h) (g.h/mL) (h) (g/ml) ING111207/ m5.3.3.1 Healthy adult/ 13 Oral Suspension 2 mg/ 8 0.23 (20) 0.63 (0.25-1.00) 2.78 (26) 12.7 (20) 0.038 (41) 5 mg/ 7 0.66 (20) 0.5 (0.50-1.50) 8.87 (27) 14.3 (25) 0.126 (28) 10 mg/ 8 1.23 (9) 0.63 (0.25-1.50) 14.6 (21) 12.7 (9) 0.196 (34) 25 mg/ 8 2.76 (12) 0.75 (0.50-1.50) 35.1 (30) 12.7 (21) 0.469 (41) 50 mg/ 6 4.56 (21) 1.25 (0.50-3.00) 73.2 (19) 14.2 (19) 1.06 (27) 100 mg/ 5 8.14 (12) 1.00 (0.75-3.00) 136 (24) 14.7 (23) 1.80 (33) ING111322/ m5.3.3.1 Healthy adult/32 Oral Suspension 10mg/ 8 1.24 (12) 0.50 (0.50-1.00) 15.8(12) 11.8 (19) 0.23 (19) 25mg/ 10 2.66 (21) 1.00 (0.50-2.00) 43.1(28) 12.6 (17) 0.65 (33) 50mg/ 8 4.52 (20) 0.75 (0.50-1.00) 75.8(28) 12.6 (14) 1.18 (32) ING111521/ m5.3.4.2 HIV-infected/ 35 Oral Tablet 2 mg (fasted)/ 9 0.18 (35) 1.5 (0.5-3.0) 2.63 (39) 10.7 (30) 0.03 (49) 10 mg (fasted)/ 7 0.57 (28) 2.0(1.0-6.0) 10.1 (26) 11.8 (22) 0.15 (30) 50 mg (fasted)/ 10 2.46 (32) 2.1 (1.0-3.97) 40.5 (33) 11.2 (29) 0.59 (31) ING111602/ m5.3.3.4 Healthy adult/ 16 Oral Tablet 50 mg (alone)/ 16 2.03 (25) 2.5 (0.5-8.0) 35.6 (33) NR 0.51 (38) 50 mg (+ multi-vitamin)/ 1.31 (25) 2.5 (0.5-8.0) 23.74 (30) NR 0.34 (33) 16 50 mg (+ Maalox)/ 16 0.56 (29) 2.5 (0.5-8.0) 9.40 (36) NR 0.13 (41) 50 mg (+ Maalox 2 hrs 1.67 (51) 2.5 (0.5-8.0) 26.33 (45) NR 0.36 (42) post dose)/ 16 ING111853/ m5.3.3.1 Healthy adult/ 6 Oral Suspension 20 mg (fasted)/ 6 2.57 (24) 0.50 (0.50-2.00) 35.9 (12) 15.6 (16) N/A ING111856/ m5.3.4.1 Healthy adult/ 42 Oral Suspension 250 mg (fasted)/ 41 12.4 (27) 3.08 (1.52-6.05) 167 (33) NR 3.86 (48) ING112941/ m5.3.3.4 Healthy adult/ 14 Oral Tablet 50 mg (fasted)/ 12 1.84 (44) 4.00 (1.00-5.00) 34.7 (57) 14.4 (21) 0.56 (63) 50 mg (fasted + OMP)/ 12 1.69 (19) 3.00 (1.00-5.03) 34.8 (26) 16.3 (20) 0.53 (27) Oral Suspension 250 mg/ 8 14.1 (10) 2.50 (1.50-4.00) 278 (15) 14.5 (10) 4.08 (17) ING113097/ m5.3.3.3 Healthy and Oral Tablet 50 mg (fasted)/ 8 healthy 1.80 (49) 3.0 (1.0-4.0) 37.3 (47) 14.9 (24) 0.57 (44) moderate hepatic matches impairment adult/ 16 50 mg (fasted)/ 8 with 1.78 (17) 4.0 (2.0-5.0) 38.5 (30) 15.5 (19) 0.59 (36) moderate hepatic impairment

162 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Study/ Location of Population/ No. of Route of Dose/ No. of Subjects Parametera,c Study Report Subjects Administration/ Cmax (g/ml) Tmax AUC (0-) T1/2 C24 completed Dosage Form (h) (g.h/mL) (h) (g/ml) ING113125/ m5.3.3.3 Healthy and Oral Tablet 50 mg (fasted)/ 8 healthy 1.86 (45) 2.00 (1.0, 4.0) 37.1 (58) 15.4 (15) NR severe renal matches impairment adult/ 16 50 mg (fasted)/ 8 with 1.50 (34) 2.00 (1.0, 3.0) 23.5 (48) 12.7 (31) NR severe renal impairment ING114005/ m5.3.3.4 Healthy adult/ 12 Oral Tablet 50 mg (fasted)/ 12 1.83 (35) 2 (1-4) 24.3 (44)b 13.6 (24) 0.53 (59) 100 mg (fasted)/ 12 2.77 (35) 2 (1-4) 34.3 (41) NR 0.80 (53) ING115381/ Healthy adult Oral Tablet 50 mg(fasted)/ 10 2.14 (47) NR(2.0-4.0) 43.4 (46) 14.6 (10) 0.67 (45) m5.3.3.3 (Japanese)/ 10 a. Data presented are geometric mean (%CVb) except for tmax where median (range) are presented. b. AUC(0-24) is reported. c. NR: not reported.

163 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Appendix Table 3 Summary of Repeat Dose DTG Pharmacokinetic Parameters

Study/ Population/ Route of Dose/ No. of Regimen Parametera Location of No. of Subjects Administration/ Subjects Cmax Tmax AUC (0-) T1/2 C Study Dosage Form (g/ml) (h) (g.h/mL) (h) (g.mL) Report ING111322/ Healthy adult/ Oral Suspension 10 mg/ 8 QD x 10 days 1.47 (24) 0.50 (0.25-2.00) 16.7 (15) 13.7 (15) 0.35 (20) m5.3.3.1 32 25 mg (+MDZ)/ 10 3.09 (26) 1.00 (0.50-2.00) 38.4 (23) 15.0 (16) 0.84 (33) 50 mg/ 8 6.16 (15) 1.00 (0.50-2.00) 76.8 (19) 15.3 (8) 1.64 (25) ING111405/ Healthy adult/ Oral Tablet 30 mg/ 30 QD x 5 days 2.80 (15) NR 36.9 (19) 12.1 (15) 0.77 (29) m5.3.3.4 31 30 mg (+LPV/RTV QD (+LPV/RTV 2.94 (21) NR 38.0 (25) 12.2 (22) 0.77 (36) 400/100 mg)/ 15 q12h) x 14 days 30 mg (+DRV/RTV QD (+DRV/RTV 2.38 (20) NR 27.3 (23) 9.78 (17) 0.45 (37) 600/100 mg)/ 15 q12h) x 14 days ING111521/ HIV-infected Oral Tablet 2 mg/ 9 QD x 10 days 0.22 (25) 1.00 (0.42-3.00) 2.56 (29) 11.1 (24) 0.04 (50) m5.3.4.2 adult/ 35 10 mg/ 7 QD x 10 days 0.80 (23) 1.48 (0.50-3.00) 10.1 (20) 11.6 (21) 0.19 (25) 50 mg/ 10 QD x 10 days 3.34 (16) 2.00 (0.97-4.00) 43.4 (20) 12.0 (22) 0.83 (26) ING111603/ Healthy adult/ Oral Tablet 50 mg/ 15 QD x 5 days 4.34 (19) 3.00 (1.00-4.07) 60.4 (22) 12.4 (21) 1.29 (29) m5.3.3.4 16 50 mg QD (+ETR q12h) 2.10 (24) 2.00 (1.00-3.00) 17.8 (39) 6.39 (22) 0.16 (84) (+ETR 200 mg)/ 15 x 14 days ING111604/ Healthy adult/ Oral Tablet 50 mg/ 15 QD x 5 days 3.45 (30) 3.00 (1.00-4.00) 46.6 (32) N/A 1.08 (39) m5.3.3.4 16 50 mg (+300 mg QD x 5 days 3.34 (26) 3.00 (1.00-4.03) 46.9 (28) N/A 0.99 (32) TDF)/ 15 ING111762/ HIV-infected Oral Tablet 50mg/337 (average) QD NR NR NR NR 0.856 (140)b m5.3.5.1 adult/ 354 50mg/329 (Wk 4) 0.786 (143)c 50mg/262 (Wk 24) 0.956 (129)c 50mg/106 (Wk 48) 0.907 (147)c ING111854/ Healthy adult/ Oral Tablet 30 mg/ 12 QD x 5 days 3.21 (19) 3.00 (1.00-4.00) 45.3 (21) 13.3 (19) 1.00 (30) m5.3.3.4 24 30 mg (+ATV/RTV QD x 14 days 4.29 (19) 4.00 (2.00-4.00) 73.3 (16) 24.1 (11) 2.21 (16) 300/100 mg)/ 12 30 mg/ 12 QD x 5 days 3.42 (13) 4.00 (1.00-4.00) 45.8 (17) 12.6 (20) 0.95 (29) 30 mg (+ATV QD x 14 days 5.11 (20) 4.00 (2.00-4.00) 87.4 (17) 23.8 (21) 2.67 (21) 400 mg)/ 12 ING111855/ Healthy adult Oral Tablet 50 mg (+OC)/ 15 BID (+ OC QD) x 7.77 (23) 1.00 (1.0-6.0) 68.6 (27) NR 4.00 (36) m5.3.3.4 female/ 16 10 days

164 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Study/ Population/ Route of Dose/ No. of Regimen Parametera Location of No. of Subjects Administration/ Subjects Cmax Tmax AUC (0-) T1/2 C Study Dosage Form (g/ml) (h) (g.h/mL) (h) (g.mL) Report ING112276/ HIV-infected Oral Tablet 10 mg/ 15 QD x 10 days 1.10 (37) 2.0 (2.0-4.0) 16.0 (40) NR 0.30 (71) m5.3.5.1 adult/ 155 25 mg/ 15 QD x 10 days 1.71 (43) 2.0 (2.0-8.0) 23.1 (48) NR 0.54 (67) 50 mg/ 15 QD x 10 days 3.40 (27) 2.0 (2.0-4.0) 48.1 (40) NR 1.20 (62) ING112574/ HIV-infected Oral Tablet 50 mg/ 178 (Average) QD NR NR NR NR 2.35 (70)b m5.3.5.2 adult/ 178 50 mg/ 148 (Day 8) 2.36 (91)c 50 mg/ 160 (Wk 4) 1.94 (106)c 50 mg/ 81 (Wk 24) 2.18 (98)c ING112578/ HIV-infected Oral Tablet 50 mg (~1mg/kg)/ 10 QD 3.49 (1.15- 2.74 (3.00-6.00) 46.0 (13.1-85.0d) 11.9 (8.4- 0.53 (0.002- m5.3.5.2 adolescent (12 6.08d) 24.8d) 2.22d)c to <18 years)/ 10 ING112934/ Healthy adult/ Oral Tablet 50 mg/ 8 (Cohort 1) QD x 5 days 3.52 (12) 3.50 (2.00-4.00) 47.8 (19) 11.3 (18) 0.97 (33) m5.3.3.4 17 50 mg/ 8 (Cohort 2) QD x 5 days 3.38 (26) 3.02 (1.00-12.00) 45.2 (22) 10.4 (17) 0.94 (40) 50 mg (+ ETR 200 QD (+ETR and 3.78 (12) 3.50 (1.00-4.00) 52.8 (18) 15.4 (25) 1.23 (32) mg and LPV/RTV LPV/RTV q12h) 400/100 mg)/ 8 x 14 days 50 mg (+ ETR 200 QD (+ETR and 2.98 (18) 4.00 (1.00-4.00) 33.9 (22) 10.2 (16) 0.59 (33) mg and DRV/RTV DRV/RTV q12h) 600/100 mg)/ 9 x 14 days ING112961/ HIV-infected Oral Tablet 50 mg/ 25 (Day 10) QD 3.04 (38) 2.97 (1.97-7.92) 36.5 (53) NR 0.69 (91) m5.3.5.2 adult/ 48 50 mg/ 23 (Day 10) BID 5.41 (40) 2.0 (0-7.87) 46.7 (50) NR 2.72 (70) ING113068/ Healthy adult/ Oral Tablet 50 mg/ 12 QD x 5 days 2.38 (38) 2.0 (1.0-4.0) 30.6 (39) 12.1 (19) 0.61 (45) m5.3.3.4 12 50 mg (+FPV/RTV QD x 10 days 1.82 (57) 2.0 (1.0-4.0) 19.9 (57) 9.54 (26) 0.31 (64) 700/100 BID)/ 12 ING113086/ HIV-infected Oral Tablet 50 mg/ 399 (average) QD NR NR NR NR 1.18 (60)b m5.3.5.1 adult/ 404 50 mg/ 379 (Wk 4) 1.05 (69)c 50 mg/ 365 (Wk 24) 1.17 (71)c 50 mg/ 351 (Wk 48) 1.13 (72)c

165 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

50 mg (+ RBT QD x 14 days 3.41 (23) 3.0 (1.0-4.0) 37.0 (32) 8.64 (22) 0.53 (56) 300 mg)/ 9 ING114005/ Healthy adult/ Oral Tablet 50 mg/ 12 QD x 5 days 3.08 (30) 2.0 (1.0-4.0) 42.3 (39) 13.9 (23) 0.91 (53) m5.3.3.4 12 50 mg (+EFV 600 mg QD x 14 days 1.87 (42) 1.0 (1.0-4.0) 18.2 (50) 7.82 (21) 0.22 (76) QD)/ 12 ING114819/ Healthy adult/ Oral Tablet 50 mg (+iohexol and QD x 14 days 2.83 (27) NR 39.1 (38) NR 0.84 (61) m5.3.4.1 38 PAH infusion)/ 11 50 mg (+iohexol and BID x 14 days 5.50 (34) NR 51.6 (36) NR 3.02 (40) PAH infusion)/ 11 ING115696/ Healthy adult/ Oral Tablet 50 mg/ 12 QD x 5 days 4.27 (25) 4.0 (1.0-4.0) 58.6 (32) 13.8 (21) 1.32 (40) m5.3.3.4 12 50 mg (+prednisone)/ QD x 10 days 4.47 (31) 3.5 (1.0-4.0) 65.9 (37) 15.2 (17) 1.59 (47) 12 (Day 5) 50 mg (+prednisone)/ QD x 10 days 4.54 (29) 3.5 (1.0-4.0) 65.0 (37) 14.6 (24) 1.53 (50) 12 (Day 10) ING115697/ Healthy adult/ Oral Tablet 50 mg/ 16 (Cohort 1) QD x 5 days 4.62 (21) 2.50 (1.0, 4.0) 61.5 (27) 13.2 (18) 1.31 (38) m5.3.3.4 32 50 mg/ 16 (Cohort 2) QD x 5 days 4.99 (23) 3.00 (1.0, 4.0) 68.9 (25) 14.5 (19) 1.59 (35) 50 mg (+BCV 800 QD (+q8h BCV) 4.82 (17) 3.00 (1.0, 4.0) 65.3 (22) 13.8 (19) 1.40 (36) mg)/ 13 x 10 days 50 mg (+TLV 750 QD (+ q8h TVR) 5.81 (15) 4.00 (1.1, 4.0) 84.2 (21) 16.7 (18)3 2.09 (28) mg)/ 15 x 10 days ING115698/ Healthy adult/ Oral Tablet 50 mg (+methadone)/ BID x 5 days 4.88 (35) NR 44.3 (37) NR 2.63 (41) m5.3.3.4 11 11

166 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

167 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Appendix Table 4 Summary of PK Parameters of Co-administered Drugs

3 mg Single dose NR NR 0.0154 (41)b NR NR (+25 mg DTG)/ 10 (DTG once daily x 10 days) ING111405/ Healthy adult/ LPV/ Oral Tablet 400 mg BID 11.5 (22) NR 95.8 (25) NR 4.52 (43) m5.3.3.4 31 (+100 mg RTV (RTV BID, DGT + 30 mg DTG)/ 15 once daily) x 14 days DRV/ Oral Tablet 600 mg BID 5.811 (23) NR 46.5 (29) NR 2.190 (47) (+100 mg RTV (RTV BID, DGT + 30 mg DTG)/ 15 once daily) x 14 days RTV/ Oral Tablet 100 mg BID 0.884 (36) NR 4.59 (33) NR 0.115 (50) (+400 mg LPV (LPV BID, DGT + 30 mg DTG)/ 15 once daily) x 14 days RTV/ Oral Tablet 100 mg BID 0.815 (32) NR 5.42 (25) NR 0.202 (34) (+600 mg DRV (DRV BID, DGT + 30 mg DTG)/ 15 once daily) x 14 days ING111603/ Healthy adult/ ETR/Oral Tablet 200 mg BID 1.12 (28) NR 10.3 (24) NR 0.638 (24) m5.3.3.4 16 (+50 mg DTG)/ 15 (DTG once daily) x 14 days

ING111604/ Healthy adult/ TDF/Oral Tablet 300 mg/ 15 Once daily x 7 0.274 (34) 1.00 (1.00-2.00) 2.45 (41) NR 0.0472 (49) m5.3.3.4 16 days

168 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Study/ Population/ Co-administered Dose/ No. of Regimen Parametera of Co-administered Drug Location of No. of Subjects Drug/Route of Subjects Cmax Tmax AUC (0-) T1/2 C Study Administration/ (g/ml) (h) (g.h/mL) (h) (g.mL) Report Dosage Form 300 mg Once daily x 5 0.300 (34) 1.00 (1.00-4.03) 2.74 (39) NR 0.0560 (46) (+DTG 50 mg)/ 15 days

ING111854/ Healthy adult/ ATV/Oral Tablet 400 mg Once daily x 14 5.39 (26) NR 53.08 (31) NR 1.08 (42) m5.3.3.4 24 (+100 mg RTV days + 30 mg DTG)/ 12 400 mg Once daily x 14 4.85 (42) NR 27.49 (45) NR 0.19 (84) (+ 30 mg DTG)/ 12 days ING111855/ Healthy adult NGM (as Ortho- 0.25 mg Once daily 0.00142 (18) 1.50 (1.0-2.5) 0.0138 (16) 22.02 (19) NR m5.3.3.4 female/ 16 Cyclen)/ Oral (+ 0.035 mg EE (DTG BID) x 10 Tablet +50 mg DTG)/ 15 days Analyte: NGMN NGM (as Ortho- 0.25 mg Once daily x 10 0.00159 (30) 1.00 (1.0-3.0) 0.0141 (25) 22.29 (32) NR Cyclen)/ Oral (+ 0.035 mg EE)/ 15 days Tablet Analyte: NGMN EE (as Ortho- 0.035 mg Once daily 0.000100 (22) 1.00 (0.5-2.5) 0.000952 (19) 14.39 (19) NR Cyclen)/ Oral (+0.25 mg NGM (DTG BID) x 10 (n=14) (n=14) Tablet +50 mg DTG)/ 15 days EE (as Ortho- 0.035 mg Once daily x 10 0.000101 (25) 1.00 (0.5-2.0) 0.000916 (27) 13.60 (24) NR Cyclen)/ Oral (+0.25 mg NGM)/ 15 days Tablet ING112934/ Healthy adult/ ETR/Oral Tablet 200 mg BID 0.974 (73) 4.00 (2.00-4.00) 8.834 (79) NR 0.585 (93) m5.3.3.4 17 (+400 mg LPV (LPV, RTV BID; +100 mg RTV DTG once daily) + 50 mg DTG)/ 8 x 14 days 200 mg BID 0.886 (32) 4.00 (3.00-4.00) 7.691 (34) NR 0.495 (42) (+ 600 mg DRV (DRV, RTV BID; +100 mg RTV DTG once daily) + 50 mg DTG)/ 9 x 14 days

169 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Study/ Population/ Co-administered Dose/ No. of Regimen Parametera of Co-administered Drug Location of No. of Subjects Drug/Route of Subjects Cmax Tmax AUC (0-) T1/2 C Study Administration/ (g/ml) (h) (g.h/mL) (h) (g.mL) Report Dosage Form ING113068/ Healthy adult/ FPV/Oral Tablet 700 mg BID 6.34 (28.1) 1.00 (0.50-2.00) 40.9 (35.8) 8.35 (45.9) 1.91 (59.4) m5.3.3.4 12 (+100 mg RTV (RTV BID, DTG +50 mg DTG)/ 12 QD) x 10 days Analyte: amprenavir ING114005/ Healthy adult/ EFV/Oral Tablet 600 mg Once daily x 14 6.02 (40) NR 84.18 (62) 22.17 (54) 2.41 (80) m5.3.3.4 12 (+50 mg DTG)/ 12 days 600 mg Once daily x 14 9.50 (27) NR 173.78 (26) 39.09 (34) 5.85 (25) (+50 mg DTG; days CYP2B6*6 subjects)/ 3 600 mg Once daily x 14 4.52 (17) NR 55.69 (28) 15.61 (24) 1.45 (40) (+50 mg DTG; days CYP2B6*1/*6 subjects)/ 6 ING115697/ Healthy adult/ TVR/Oral Tablet 750 mg q8h 3.21 (17) 3.00 (2.0-4.0) 19.22 (19) 5.14 (27) 1.75 (26) m5.3.3.4 32 (+50 mg DTG)/ 15 (DTG once daily) (except n=10 for x 10 days T1/2) ING115698/ Healthy adult/ Methadone/Oral Individualized doses/ Once daily x 3 0.150 (81.4) NR 2.51 (77.9) NR 0.082 (79.9) m5.3.3.4 11 Tablet 11 days Analyte: R-methadone Individualized doses Once daily 0.145 (78.5) NR 2.39 (77.7) NR 0.078 (80.6) (+50 mg DTG) / 11 (DTG BID) x 5 Analyte: days R-methadone Individualized doses/ Once daily x 3 0.188 (91.4) NR 2.79 (90.3) NR 0.0838 (97.3) 11 days Analyte: S-methadone

170 CONFIDENTIAL Module 2.7.2 Summary of Clinical Pharmacology

Study/ Population/ Co-administered Dose/ No. of Regimen Parametera of Co-administered Drug Location of No. of Subjects Drug/Route of Subjects Cmax Tmax AUC (0-) T1/2 C Study Administration/ (g/ml) (h) (g.h/mL) (h) (g.mL) Report Dosage Form Individualized doses Once daily 0.195 (82.3) NR 2.81 (85.4) NR 0.0847 (92.7) (+50 mg DTG) / 11 (DTG BID) x 5 Analyte: days S-methadone Individualized doses/ Once daily x 3 0.337 (86.5) NR 5.32 (83.2) NR 0.166 (86.9) 11 days Analyte: total methadone Individualized doses Once daily 0.337 (80.1) NR 5.23 (80.6) NR 0.164 (84.9) (+50 mg DTG) / 11 (DTG BID) x 5 Analyte: days total methadone LAI116181/ Healthy adult/ RPV/Oral Tablet 25 mg/ 16 Once daily x 11 0.148 (29) 4.00 (4.0-6.0) 2.23 (33) 0.0745 (41) m5.3.3.4 28 (Cohort 1, Period 2) days

25 mg Once daily x 5 0.164 (36) 4.00 (2.0-5.0) 2.37 (34) NR 0.0905 (48) (+50 mg DTG)/ 16 days (Cohort 1, Period 3) a. Data are presented are geometric mean (%CVb) except for tmax where median (range) is presented. b. Presented as AUC(0-t). ATV = atazanavir; BID = twice daily; DRV = darunavir; EE = ethinyl estradiol; EFV = efavirenz; ETR = etravirine; FPV=fosamprenavir; LPV= lopinavir; NGM = norgestimate; NGMN = norelgestromin; MDZ = midazolam; NR = not reported; OC = oral contraceptive; PAH = para-aminohippurate; q8h = dosed every 8 hours (three times daily); RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil fumarate; TVR = telaprevir; TPV = tipranavir.

171 CONFIDENTIAL Module 2.7.2.4 Special Studies

Module 2.7.2.4 Special Studies

1 CONFIDENTIAL Module 2.7.2.4 Special Studies

TABLE OF CONTENTS

PAGE

ABBREVIATIONS ...... 4

1. BACKGROUND AND OVERVIEW OF CLINICAL PHARMACOLOGY ...... 7

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES...... 7

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES ...... 7

4. SPECIAL STUDIES...... 7 4.1. Nonclinical Virology ...... 8 4.1.1. Listing of in vitro Virology Non-Clinical Studies ...... 9 4.1.2. Mechanism of Action ...... 13 4.1.3. Cell Based Antiviral Assays ...... 13 4.1.4. Effect of Human Serum and Serum Proteins ...... 14 4.1.5. Antiviral Activity in Combination with other Antiviral Agents ...... 14 4.1.6. Evaluation of Cytotoxicity in Antiviral Assays ...... 15 4.1.7. Evaluation of Cytotoxicity in Human Cell Lines and Peripheral Blood Mononuclear Cells...... 15 4.1.8. Susceptibility of Multiple Clade B Clinical Isolates of HIV-1...... 16 4.1.9. Susceptibility of a Panel of HIV-1 and HIV-2 Isolates in PBMCs and Monocyte Derived Macrophages...... 17 4.1.10. Activity against non-HIV Viruses ...... 19 4.1.11. Isolation of DTG Resistant HIV-1 Mutants...... 20 4.1.11.1. Isolation from Wild type HIV-1 Strain IIIB...... 21 4.1.11.2. Isolation from Wild Type and Site Directed Mutant INI Resistant HIV-1 Strain NL432 ...... 22 4.1.11.3. Selection of R263K in Passage Experiments using HIV-1 with Subtype B, C, and A/G...... 24 4.1.12. Assessment of Resistance...... 25 4.1.12.1. Sixty Integrase Inhibitor Resistant HIV-1 Strains...... 25 4.1.12.2. Integrase Inhibitor Resistant HIV-2 Strains ...... 30 4.1.12.3. Clinical Isolates from RAL Therapy Virologic Failure Subjects...... 30 4.1.12.3.1. Activity against Thirty-nine Clinical Isolates...... 30 4.1.12.3.2. Activity against 705 RAL Resistant Clinical Isolates...... 32 4.1.12.3.3. Characterization of DTG resistance in the Raltegravir Resistant Clinical Isolate Population ...... 34 4.1.13. Evaluation of DTG Dissociation from Wild Type and Integrase Inhibitor Resistant Integrase-DNA Complexes ...... 38 4.1.14. Minority Species Analysis from Antiretroviral Therapy, Raltegravir Resistant Experienced Adults in Phase 2b Study ING112961 ...... 41

2 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.15. Integrase Polymorphism Effects on DTG Resistance and Clinical Response ...... 46 4.2. Clinical Virology ...... 48 4.2.1. Phase III Clinical Studies ...... 50 4.2.1.1. Studies of Treatment-Naive Subjects ...... 50 4.2.1.1.1. ING113086 ...... 50 4.2.1.1.2. ING114467 ...... 54 4.2.1.2. Studies of Treatment-Experienced (INI-naive) Subjects ...... 59 4.2.1.2.1. ING111762...... 59 4.2.1.3. Studies of Treatment-Experienced (Integrase Inhibitor Resistant) Subjects ...... 75 4.2.1.3.1. ING112574 ...... 75 4.2.1.3.2. An Exploratory Analysis of Minor Variants in HIV-1 Integrase for Subjects Enrolled in ING112574 Having Only Historic Evidence of Primary IN Resistance (Appendix 5)...... 99 4.2.1.3.3. Antiviral Activity of DTG in ING112574 by Baseline Resistance...... 104 4.2.2. Phase IIb Clinical Studies ...... 120 4.2.2.1. ING112276...... 121 4.2.2.2. ING112961...... 122 4.2.3. Conclusions ...... 137 4.3. References ...... 139

3 CONFIDENTIAL Module 2.7.2.4 Special Studies

ABBREVIATIONS

3TC Lamivudine AAG 1-acid glycoprotein ABC Abacavir AIDS Acquired immunodeficiency syndrome APV Amprenavir BID Twice daily (bis in die) BVDV Bovine Viral Diarrhea Virus CBMC Umbilical cord blood mononuclear cells CCR5 Chemokine receptor 5 CDC Centers for Disease and Prevention Control CI Confidence Interval CIP4 Cell line derived from 293T cells Cmax Maximal drug concentration Cmin Minimal drug concentration CSR Clinical study report D4T Stavudine DAIDS Division of Acquired Immunodeficiency Syndrome DTG Dolutegravir DRV/r Darunavir + ritonavir EBV Epstein-Barr virus EFV Efavirenz EVG Elvitegravir ETR Etravirine FC Fold Change FDA Food and Drug Administration FPV Fosamprenavir FTC Emtricitabine g Gram GSK GlaxoSmithKline GSS Genotypic susceptibility score HBV Hepatitis B Virus HCV Hepatitis C Virus HCMV Human Cytomegalovirus HeLa CD4 Human cell line HIV-1 Human Immunodeficiency Virus type 1 IC50 50% Inhibitory Concentration IM9 Human B cell lymphocytic leukemia cell line IN Integrase INI Integrase Inhibitor IP Investigational product IQR Interquartile range ITT-E Intent to treat exposed LANL Los Alamos National Laboratory HIV Sequence Database LOCFDB Last observation carried forward, discontinuation=Baseline

4 CONFIDENTIAL Module 2.7.2.4 Special Studies

LPV Lopinavir g Microgram Magi CCR5 Cells obtained through the NIH AIDS Research and Reference Reagent Program MDF Missing or discontinuation=failure MSDF Missing, Switch or Discontinuation = Failure mg Milligrams mL Millilitre Molt-4 Human T cell lymphocytic leukemia cell line MT2 Human T cell lymphocytic leukemia cell line MT4 Human T cell lymphocytic leukemia cell line M8166 Human T cell lymphocytic leukemia cell line NNRTI Non-nucleoside reverse transcriptase inhibitor NRTI Nucleoside reverse transcriptase inhibitor N(t)RTI Nucleoside/nucleotide reverse transcriptase inhibitor NVP Nevirapine OBR Optimised background regimen OSS Overall susceptibility score PBMC Peripheral Blood Mononuclear Cells PDVF Protocol Defined Virologic Failure PHIV Pseudotyped HIV PI Protease Inhibitor PIQ Phenotypic inhibitory quotient PSS Phenotypic susceptibility score RAP Reporting and analysis plan RAL Raltegravir, Isentress RNA Ribonucleic acid ROC Receiver operating characteristic RTV, /r Ritonavir SDM Site Directed Mutant SPA Scintillation Proximity Assay T-20 Enfuvirtide TZM-bl Cells obtained through the NIH AIDS Research and Reference Reagent Program LANL Los Alamos National Laboratory HIV Sequence Database TDF Tenofovir TLOVR Time to Loss of Virological Response TPV Tipranavir UDPS Ultra-deep pyrosequencing USA United States of America U937 Human monocytic lymphoma cell line VZV Varicella Zoster Virus VO Virologic Outcomes Population

5 CONFIDENTIAL Module 2.7.2.4 Special Studies

Trademark Information

Trademarks of ViiV Healthcare Trademarks not owned ViiV Healthcare NONE GenSeq PhenoSense

6 CONFIDENTIAL Module 2.7.2.4 Special Studies

1. BACKGROUND AND OVERVIEW OF CLINICAL PHARMACOLOGY

Refer to m2.7.2 as these headings are not relevant to m2.7.2.4.

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES

Refer to m2.7.2 as these headings are not relevant to m2.7.2.4.

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES

Refer to m2.7.2 as these headings are not relevant to m2.7.2.4.

4. SPECIAL STUDIES

Dolutegravir (DTG) inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for the HIV replication cycle. In vitro data are supportive of DTG’s high barrier to resistance. DTG retained activity against a vast majority of 60 RAL resistant site-directed HIV-1 mutants and 6 site directed HIV-2 mutants. Additionally, susceptibilities to DTG and RAL were determined for over 700 RAL resistance clinical isolates with DTG retaining activity <10 FC against >90% of them. DTG was slower to select for resistant mutants during in vitro passage than RAL; the level of DTG fold change in these mutants was less than for RAL. DTG demonstrated slower dissociation from all IN-DNA complexes tested as compared to RAL and elvitegravir, including those with single, double, and up to four residue clinically relevant IN substitutions.

Dolutegravir 50 mg once daily has a higher barrier to resistance in INI-naive patients, as demonstrated in the treatment-experienced (INI-naive) study ING111762 where significantly fewer virologic failures and significantly fewer subjects with INI resistance (in addition to less treatment-emergent resistance to the background regimens) were observed when compared with RAL. Data from two studies (ING1133086 and ING114467) including over 1600 treatment-naive patients are also supportive of DTG’s higher barrier to resistance, given that no subjects on the DTG regimen developed resistance to either the INI or the background NRTIs, whereas resistance to both the third agent and the background NRTIs was observed in both the RAL and EFV-based comparator arms.

In a study of treatment experienced (INI-resistant) subjects (ING112574) three IN mutation groups derived from Day 8 antiviral responses also provided good prediction for Week 24 responses. The vast majority of subjects with virus in the “No Q148” group achieved <400 c/mL HIV-1 RNA at Week 24 (85%) lower response rates were seen with Q148+1 secondary mutation and Q148 +2 secondary mutations, (50% and 22 % respectively). Those with Q148 +2 secondary mutations, however, represent a minority of the INI-resistant population (~11-12% overall). This analysis suggests that a regimen of DTG 50 mg twice daily will provide benefit to the majority of subjects and that the

7 CONFIDENTIAL Module 2.7.2.4 Special Studies

derived IN mutation groups can further aid prescribers who would use DTG in INI- resistant patients.

4.1. Nonclinical Virology

Dolutegravir (DTG) inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for the HIV replication cycle.

Dolutegravir has low nM activity against wild type HIV-1 and HIV-2 in a variety of cells lines, regardless of subtype. DTG has little activity against non-HIV viruses. Human serum causes approximately 75-fold increase in DTG IC50 against HIV-1. DTG is additive or synergistic when assayed in combination with other antiretroviral agents.

When HIV-1 Strain IIIB was passaged in the presence of DTG for 112 days, viruses with a 4.1-fold maximum increase in IC50 and S153Y or S153F substitutions in the integrase gene were observed. Passage of the wild type HIV-1 NL432 in the presence of 6.4 nM DTG selected for E92Q (FC=3.1) and G193E (FC=3.2) substitutions in the IN region on Day 56. Passage of HIV-1 NL432 with Q148H, Q148K, or Q148R RAL resistant mutations resulted in selection of additional mutations and an increase in DTG FC. Passage of HIV-1 NL432 with E92Q, Y143C, Y143R or N155H RAL resistant mutations did not lead to additional substitutions. Passage of HIV-1 subtypes B, and A/G in TZM-bl cells selected for integrase mutation R263K.

Comparative susceptibilities to DTG and raltegravir (RAL) were obtained from 60 RAL resistant site directed HIV-1 mutants and 6 site directed HIV-2 mutants. DTG retained activity against a vast majority of these mutants, and had similar activity for equivalent mutants for both HIV-1 and HIV-2. Additionally, susceptibilities to DTG and RAL were determined for over 700 RAL resistant clinical isolates, with DTG retaining activity <10 FC against >90% of them.

Evaluation of ~1000 RAL- resistant isolates from Aug 2008 to Mar 2012 demonstrated a decreasing proportion of Q148+≥2 pathway isolates over time. The derived mutational group Q148+≥2 (i.e., with L74I, E138A/K/T, G140A/C/S) associated with decreased response in ING112574 was 54% of 115 isolates with more inclusive RAL-associated secondary resistance mutations.

The dissociation of DTG, RAL, and EVG from wild type and mutant IN proteins complexed with DNA was investigated to obtain a better understanding of INI dissociation kinetics. DTG demonstrated slower dissociation from all IN-DNA complexes test, including those with single, double, and up to four residue clinically relevant IN substitutions; these studies provide a mechanism-based explanation for DTG’s different in vitro and clinical profile.

Clonal analyses provided information that the INI-associated resistance mutations reside on the same subset of viral genomes and that this accumulation of INI-associated resistance mutations results in the reduction of DTG susceptibility. Polymorphisms at the most variable positions in wild type IN do not reduce susceptibility to DTG

8 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.1. Listing of in vitro Virology Non-Clinical Studies

A series of in vitro studies have been conducted to investigate the virology of DTG. A listing of these studies is provided in Table 1.

9 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 1 List of Virology (Primary Pharmacodynamic) Non-Clinical Studies Performed with DTG

Type of Study Species (Strain)/ Method of Form GLP Testing Report No. Location in Test System Administration Facility (Study No.) CTD

Antiviral mechanistic study using quantitative MT-4 cells In vitro B No RH2010/00018/00 m5.3.5.4 PCR Anti-HIV activity in peripheral blood Human PBMCs In vitro B No GSK and RH2007/00071/00 and m5.3.5.4 mononuclear cells (PBMCs) RH2007/00116/00 Antiviral activity in tissue culture cells Human MT-4 and CIP- In vitro B No GSK and RH2007/00071/00 and m5.3.5.4 4 cells RH2007/00116/00 Integrase inhibition in strand transfer assays Recombinant In vitro B No GSK and RH2007/00071/00 and m5.3.5.4 HIV integrase RH2007/00116/00 Anti-HIV activity in the presence of human Human MT-4 and CIP- In vitro B No GSK and RH2007/00071/00 and m5.3.5.4 serum and purified human serum proteins 4 cells RH2007/00116/00 Anti-HIV activity in combination with other MT-4 cells In vitro A No GSK RH2009/00002/00 m5.3.5.4 antiviral agentsa Anti-HIV activity in combination with maraviroc Magi-CCR5 cells In vitro A No RH2009/00009/00 m5.3.5.4

Evaluation of cytotoxicity in antiviral assays Human MT-4 and CIP- In vitro B No GSK and RH2007/00071/00 and m5.3.5.4 4 cells RH2007/00116/00 Evaluation of cytotoxicity in human cell lines Human leukemic B- In vitro B No GSK RH2007/00036/00 m5.3.5.4 and peripheral blood lymphocytes (PBLs) and T-cells lines and PBLs Dissociation from integrase-DNA complexes Wildtype and mutant In vitro B No GSK 2011N114191_00 m5.3.5.4 integrase protein Integrase inhibitor susceptibility of multiple 293 cells In vitro A No RH2007/00090/00 m5.3.5.4 clinical isolates of HIV-1 Anti-HIV activity against a panel of HIV-1 and Human PBMC and In vitro A No RH2008/00134/00 m5.3.5.4 HIV-2 isolates MDM cells

10 CONFIDENTIAL Module 2.7.2.4 Special Studies

Type of Study Species (Strain)/ Method of Form GLP Testing Report No. Location in Test System Administration Facility (Study No.) CTD

Anti-HIV activity against protease inhibitor MT-4 cells In vitro A No RH2008/00141/00 m5.3.5.4 (PRI)-resistant strains Anti-HIV activity against reverse transcriptase HeLa-CD4 cells In vitro A No RH2008/00142/00 m5.3.5.4 inhibitor (RTI)-resistant strains Anti-HIV activity against integrase inhibitor HeLa-CD4 cells In vitro A No RH2007/00115/00 m5.3.5.4 resistant HIV-1 strains Anti-HIV activity of RSC-364735 against HeLa-CD4 cells In vitro A No RH2005/00088/00 m5.3.5.4 integrase inhibitor resistant HIV-1 strains Anti-HIV activity against raltegravir-resistant HeLa-CD4 cells In vitro A No RH2008/00143/00 m5.3.5.4 strains Anti-HIV activity against integrase site directed 293 cells In vitro A No RH2009/00010/00 m5.3.5.4 mutant strains and resistant clinical isolates Isolation of GSK1349572-resistant HIV-1 MT-2 cells In vitro A No RH2007/00119/00 m5.3.5.4 mutants Isolation of GSK1349572-resistant mutants MT-2 cells In vitro A No RH2008/00144/00 m5.3.5.4 from integrase inhibitor resistant HIV-1 strains Isolation of GSK1349572-resistant mutants HeLa-CD4 cells In vitro A No RH2010/00017/00 m5.3.5.4 Activity against 700 raltegravir resistant clinical 293 cells In vitro A No 2012N146158_00 m5.3.5.4 isolates Characterization of DTG resistance in the 293 cells In vitro A No 2012N152930_00 m5.3.5.4 raltegravir resistance clinical isolation population Dissociation from integrase-DNA complexes Wildtype and mutant In vitro B No GSK 2012N145179_00 m5.3.5.4 with various substitutions including integrase protein combinations observed during Viking

11 CONFIDENTIAL Module 2.7.2.4 Special Studies

Type of Study Species (Strain)/ Method of Form GLP Testing Report No. Location in Test System Administration Facility (Study No.) CTD

Minority species analysis of samples from Ultradeep In vitro No GSK 2012N151522_00 m5.3.5.4 antiretroviral experienced, raltegravir resistant pyrosequencing, clonal subjects in ING112961 analysis Isolation of GSK1349572 Resistant Mutants MT-2 cells In vitro A No 2012N141510_00 m5.3.5.4 from Integrase Inhibitor-Resistant HIV-1 Strains (2) Key: Testing Facility: a = Other antiviral agents including anti-HBV and anti-HCV drugs. A = GSK1349572A (sodium salt of GSK = GlaxoSmithKline. dolutegravir). B = GSK1349572B (dolutegravir parent form). HeLa-CD4 = Human epithelial cell line expressing = CD4. MDM = Monocyte-derived macrophage cells. MT-4 = Human T-cell lymphotropic virus transformed cell = line. PBMC = Peripheral blood mononuclear cells. Magi-CCR5 cells = HeLa CD4 LTR -gal cells expressing = high levels of CD4 and CCR5

12 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.2. Mechanism of Action

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.

The antiviral mechanism of DTG on HIV replication was investigated (m5.3.5.4, RH2010/00018/00, RH2007/00119/00, RH2010/00017/00, 2011N114191_00) using quantitative PCR. A dose dependent decrease in integrated HIV-1 DNA (Alu PCR) and an increase of 2 LTR circles was observed with DTG treatment suggesting that the antiviral activity is a direct consequence of its effect on viral integration. Dolutegravir demonstrated equivalent potency against two nonnucleoside inhibitor resistant, three nucleoside inhibitor resistant and two protease inhibitor resistant HIV-1 mutant clones (one with three and one with six mutations) compared with the wild type strain (m5.3.5.4, RH2008/00141/00, RH2008/00142/00). In addition, passage studies with DTG selected mutations within the integrase enzyme; some of those mutations recreated as site-direct mutant HIV virus conferred moderate but greater than wild-type levels of DTG resistance. Direct and prolonged DTG binding to integrase protein was demonstrated with purified integrase in cDNA:Mg2+ complexes in bead based assays. These data are also consistent with direct targeting of the HIV-1 integrase in cells.

4.1.3. Cell Based Antiviral Assays

Dolutegravir activity against Ba-L HIV-1 in PBMCs, HIV-1 strain IIIB in MT4 cells and pseudotyped HIV-1 in CIP4 cells was examined (m5.3.5.4, RH2007/0071/00, RH2007/00116/00).

For peripheral blood mononuclear cell (PBMC) assays, cells were stimulated with phytohemagglutinin and interleukin-2 and infected with HIV-1 strain BaL or HIV-1 strain NL432. Following incubation with DTG for 4 or 7 days, the antiviral activity was assayed by reverse transcriptase (RT) resulting in IC50s of 0.51 nM (BaL) and 0.51 nM (NL432). For MT-4 assays, cells were infected with HIV-1 strain IIIB and incubated with DTG for 4 or 5 days followed by cell viability analyses with CellTiter-Glo or MTT resulting in IC50s of 0.71 and 2.1 nM, respectively Table 2). For pseudotyped HIV (PHIV) assays, the infected cells were incubated with DTG for 2 days and when assayed for cell viability by Steady Glo gave an IC50 of 2.2 nM. In vitro strand transfer biochemical assays using purified HIV-1 integrase, which measure the inhibition of the amount of donor DNA covalently attached to target DNA by DTG using either [3H] target DNA or a sandwich ELISA resulted in IC50s of 2.7 nM and 12.6 nM, respectively.

13 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 2 Antiviral Activity of DTG in PBMC, MT4, or CIP4 cells

Virus DTG Geometric N Cell lines mean IC50 (nM) 95% CI PBMC Ba-L 0.51 0.34-0.77 12 PBMC NL432 0.53 SD = 0.21 5 MT4 HIV-1IIIB 0.71 0.40-1.3 9 MT4 HIV-1IIIB 2.1 SD = 0.82 3 CIP4 PHIV vector 2.2 0.96-5.2 2

4.1.4. Effect of Human Serum and Serum Proteins

The effect of human serum albumin (HSA)(20 or 40 mg/mL), 1-acid glycoprotein (AAG) (2 mg/mL) (Table 3) and human serum (extrapolated up to 100%) on the antiviral activity of DTG was evaluated in the PHIV or MT-4 assay systems. HSA was the predominant DTG binding component compared with AAG. Maximum fold shift observed with MT-4 assays performed at GSK (m5.3.5.4, RH2007/00071/00) and (m5.3.5.4, RH2007/00116/00) and extrapolated to 100% human serum provided a mean consensus 75-fold shift in the IC50 values for DTG and a resulting PA-IC50 of 38 nM for PBMCs in 100% serum.

Table 3 The Effect of Serum Proteins on Antiviral Activity of DTG in HIV-1 IIIB-Infected MT4 Cells

Serum Protein Geometric Mean 95% Confidence Potency N IC50 Interval Shift 40 mg/mL HSA 18 nM 16 – 21 nM 12-fold 10 2 mg/mL AAG 3 nM 2.6 – 3.5 nM 2-fold 4

4.1.5. Antiviral Activity in Combination with other Antiviral Agents

Dolutegravir was tested for antiviral activity in combination with currently approved antiviral drugs (m5.3.5.4, RH2009/00002/00, RH2009/00009/00). The greatest value of the in vitro combination studies is to identify antagonism of antiviral activity indicating that certain drugs should not be used clinically in combination. In this regard, the in vitro combination data support the conclusion that the antiviral activity of DTG is compatible with other approved antiretrovirals.

The in vitro anti-HIV-1 activity of DTG was studied in checkerboard format in combination with representative anti-HIV drugs (stavudine, abacavir, efavirenz, nevirapine, lopinavir, amprenavir, enfuvirtide, and RAL) and anti-HBV (adefovir) and anti-HCV (ribavirin) drugs in MT-4 cells with HIV-1 strain IIIB (Table 4), and in combination with the anti-HIV drug maraviroc in Magi-CCR5 cell line with HIV-1 strain BaL (Table 5). All drugs with inherent anti-HIV activity were additive or synergistic with DTG, or if without inherent anti-HIV activity (ribavirin) had no apparent effect on DTG activity.

14 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 4 Inhibition of HIV-1IIIB by DTG in Combination with Other Marketed Anti-HIV Agents in MT-4 cells

Deviation from Additivity Interaction Compound Average S.E. p-value with DTG DTG 0.031 0.151 0.423 Additive D4T -0.473 0.083 0.001 Synergy ABC -0.605 0.150 0.002 Synergy EFV -0.356 0.102 0.005 Synergy NVP -0.246 0.087 0.015 Synergy LPV -0.310 0.082 0.005 Synergy APV -0.332 0.085 0.003 Synergy T-20 -0.245 0.110 0.034 Synergy PMEA -0.179 0.168 0.168 Additive RAL -0.05 0.16 0.39 Additive

Table 5 Antiviral Efficacy and Cytotoxicity Results for DTG in Combination with Maraviroc vs HIV-1 BA-L in MAGI-CCR5 Cells

Seetup Antiviral Cytotoxicity Interpretation 1 44.6 / -0.08 3.41 / -2.15 Antiviral: Additive 2 38.7 / -0.73 0 / -93.8 (Nonantagonistic) 3A 28.4 / 0 0 / -132 3B 33.4 / -0.08 2.52 / -35.7 Cytotoxicity: Mean 36.3 / -0.21 0.18 / -64.6 Additive to Slightly Antagonistic

4.1.6. Evaluation of Cytotoxicity in Antiviral Assays

Cytotoxicity assays with DTG were conducted in parallel with the antiviral assays (m5.3.5.4, RH2007/0071/00, RH2007/00116/00). Overall the cytotoxicities measured in these assays were distinct from the antiviral potencies and provided selectivity ratios from >350-fold to 6800-fold indicating that the observed antiviral activity of DTG was not due to cytotoxicity.

4.1.7. Evaluation of Cytotoxicity in Human Cell Lines and Peripheral Blood Mononuclear Cells

Cytotoxicity assays were conducted in proliferating human leukemic and lymphomic cell lines and PHA stimulated and unstimulated human PBMCs from the same donors, with resulting cell cytotoxicity (CC) IC50s for DTG in proliferating IM-9, U-937, MT-4 and Molt-4 cells of 4.8, 7.0, 14 and 15 µM, respectively and in unstimulated and stimulated PBMCs of 189 µM and 52 µM, respectively (m5.3.5.4, RH2007/00036/00)(Table 6). When compared to the antiviral activity of DTG IC50 of 0.51 nM in PBMCs the selectivity index for antiviral activity was >9400.

15 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 6 Cytotoxicity Assay Results in PBLs and B and T Cells

Cell lines DTG CC50 95% CI Flavopiridol 95% CI (M) CC50 (M) IM-9 (n=4) 4.8 3.0-7.7 0.019 0.012-0.030 U-937 (n=4) 7.0 4.8-10 0.035 0.024-0.050 MT-4 (n=4) 14 7.0-29 0.13 0.062-0.26 Molt-4 (n=4) 15 12-19 0.16 0.13-0.21 Stimulated PBLs (n=8) 52 36-76 0.36 0.25-0.53 Unstimulated PBLs (n=8) 189 58-620 0.29 0.15-0.56

4.1.8. Susceptibility of Multiple Clade B Clinical Isolates of HIV-1

Dolutegravir activity against site directed mutant strains and clinical isolates with integrase resistance mutations was evaluated at Monogram Biosciences using the Integrase PhenoSense assay (m5.3.5.4, RH2007/00090/00).

The susceptibility of 13 clinically diverse HIV-1 clade B isolates to integrase inhibition by DTG was tested with Monogram Bioscience’s PhenoSense assay. The mean IC50 for viral replication of the clinical isolate based viruses was 0.52 nM (range 0.41 to 0.60 nM) (Table 7).

16 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 7 Activity of DTG against a Panel of HIV-1 Clinical Isolates

Virus IC50 (nM) ASJM 108 0.54 ASM 34 0.54 ASM 42 0.59 NIH 57 0.60 NIH 660 0.41 NIH 657 0.54 NIH 714 0.54 NIH 727 0.50 CV 110 0.49 CV 154 0.49 CV 163 0.55 CV 243 0.43 CV 281 0.49 HIV-1 IIIB 0.46 HXB2 0.65 NL4-3 0.60

Isolate mean 0.52 Isolate Median 0.54 Isolate standard deviation 0.06 Isolate range 0.41 - 0.60 Laboratory virus mean 0.57 Laboratory virus median 0.60 Laboratory virus standard deviation 0.10 Laboratory virus range 0.46 - 0.65

4.1.9. Susceptibility of a Panel of HIV-1 and HIV-2 Isolates in PBMCs and Monocyte Derived Macrophages

The antiviral activity of DTG was tested against a panel of HIV-1 isolates (3 in each group of M clades A, B, C, D, E, F and G, and 3 group O isolates) (Table 8) and 3 HIV-2 isolates, in PBMC assays (m5.3.5.4, RH2008/00134/00) (Table 9). The antiviral activity of DTG against four clade B HIV-1 isolates was also evaluated in cell based monocyte- derived macrophage assays (Table 10). DTG was highly active with broad activity against all HIV-1 (geometric mean IC50 of 0.20 nM and range of 0.02 to 2.14 nM) and HIV-2 (geometric mean IC50 of 0.18 nM and range of 0.09 to 0.61 nM) isolates tested. In the monocyte-derived macrophage assays using 4 clade B isolates, the geometric mean IC50 was 0.87 nM and values ranged from 0.37 to 1.98 nM. Mean IC50s for each of these categories are listed in Table 11.

17 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 8 Activity of DTG against HIV-1 in PBMCs

HIV-1 Isolate Envelope Subtype IC50 (nM) 92RW009 A 0.18 92UG037 A 0.09 92UG029 A 0.50 92BR014 B 2.14 JR-CSF B 0.05 92TH026 B 0.08 Ba-L B <0.10 Ba-L B 0.20 92BR025 C 0.14 93IN101 C <0.10 93IN101 C 0.51 93MW959 C 0.05 92UG001 D 0.17 92UG024 D 0.35 92UG046 D 0.16 93TH073 E 0.09 CMU08 E 0.24 CMU06 E 0.32 93BR019 F 0.44 93BR020 F 0.23 93BR029 F <0.10 93BR029 F 0.07 JV1083 G 0.87 RU132 G 0.20 G3 G 0.02 BCF01 O 0.41 BCF02 O 0.42 BCF03 O 1.79

Table 9 Activity of DTG against HIV-2 Isolates in PBMCs

HIV-2 Isolate IC50 (nM) CDC 310319 0.61 CDC 310342 <0.10 CEC 310342 0.18 CBL 20 0.09

18 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 10 Activity of DTG against Subtype B Isolates in Macrophages

HIV-1 Isolate IC50 (nM) Ada 1.33 Ba-L 1.98 92BR014 0.58 92TH026 0.37

Table 11 Mean Activity of DTG against Broad Subtypes and HIV-2 in PBMCs, and Subtype B Isolates in Macrophages

Virus Mean IC50 (nM) Subtype A 0.26 Subtype B 0.62 Subtype C 0.23 Subtype D 0.23 Subtype E 0.22 Subtype F 0.25 Subtype G 0.36 Group O 0.87 HIV-2 0.29 Subtype B in Macrophages 1.07

4.1.10. Activity against non-HIV Viruses

Dolutegravir was evaluated for antiviral activity against a panel of 19 non-HIV viruses. In general, DTG did not exhibit significant antiviral activity in this panel (m5.3.5.4, 2011N113854_00). Some activity was observed against BVDV (IC50 = 66 M), DENV (IC50 = 69.5 M), measles (IC50 = 30.3 M), HCV (IC50 = 11.2 M), and VZV (IC50 = 88.1M) (Table 12, Table 13, Table 14). DTG displayed the highest antiviral activity against HCV. DTG caused a mild cytotoxic effect at the high test concentration.

19 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 12 Activity of DTG against a Range of Viruses in Cytoprotection Assays

High TC50 (M) Concentration Virus (M) IC50 (M) Adenovirus 100 >100 >100 Bovine Viral Diarrhea 100 66 >100 Virus Dengue Virus (serotype 100 69.5 >100 2) Yellow Fever Virus 100 >100 >100 HSV-1 100 >100 >100 HSV-2 100 >100 >100 Influenza A 100 >100 64.9 Influenza B 100 >100 75.7 Human Parainfluenza 100 >100 >100 Measles Virus (Morilli 100 30.3 >100 virus) Respiratory Syncytial 100 >100 >100 Virus Coxsackie A Virus 100 >100 97.6 Coxsackie B Virus 100 >100 >100 Enterovirus 100 >100 >100 Polio Virus 100 >100 >100 Rhinovirus 100 >100 >100

Table 13 Activity of DTG against Hepatitis C Virus (Replicon Assay)

High TC50 (M) Concentration Virus (M) IC50 (M) HCV 100 11.2 96.7

Table 14 Activity of DTG in a Plaque Reduction Assay

High TC50 (M) Concentration Virus (M) IC50 (M) HCMV 100 >100 >100 VZV 100 88.1 >100

4.1.11. Isolation of DTG Resistant HIV-1 Mutants

Selection of resistant mutants during in vitro passage of virus in the presence of drug may provide insight into the resistance mutations selected in vivo. Resistant mutants were

20 CONFIDENTIAL Module 2.7.2.4 Special Studies

isolated during passage of wild type virus, virus with RAL resistant mutants, and during simultaneous passage of HIV-1 subtypes B, A/G, and C.

4.1.11.1. Isolation from Wild type HIV-1 Strain IIIB

Virus cultures were derived by co-culturing MT-2 cells with Molt-4 cells persistently infected with HIV-1 strain IIIB (m5.3.5.4, RH2007/00119/00). This strain has ~40% T124A polymorphism in integrase in viral stocks used for passage (Kobayashi, 2011). The culture media from the co-cultures including resuspended co-cultured cells was used for initiating passage of resistant variants. Every 3 or 4 days the cells were examined for apparent cytopathic effects and supernatants were used to infect new MT-2 cells in the presence of increasing DTG concentrations (up to 5-fold). Infected cell DNA was prepared and HIV proviral DNA sequence was determined.

At selected intervals (14, 28, 42, 56, 70, 84, 98 and 112 days), susceptibility to DTG was measured using the supernatant from passaged cells (briefly expanded in fresh M8166 cells) in assays using HeLa-CD4 cells carrying a reporter -galactosidase gene. Viruses highly resistant to DTG were not observed during the 112 day passage, with a 4.1-fold maximum fold resistance observed for the passaged resistant virus with substitutions at the conserved IN positions S153Y and S153F. These data are consistent with direct targeting of the HIV-1 integrase in cells and provide a relative fold resistance level for virus with these substitutions (Table 15).

Table 15 Passage with HIV IIIB

Days of Culture Amino Acid Substitution DTG Fold Change 14 T124A 1.2-2.5 28 T124A 0.57-1.0 T124A, S153F 1.9 42 T124A 0.48-1.7 T124A, S153F 1.7 56 T124A 0.95-2.9 T124A, S153F 2.7 70 T124A 1.1-3.1 T124A, S153Y 2.9 L101I, T124A, S153F 2.4 84 T124A 0.82-3.1 S153Y 3.7 T124A, S153Y 3.3 L101I, T124A, S153F 2.4 98 T124A 1.3-3.1 T124A, S153Y 4.1 L101I, T124A, S153F 3.0 112 T124A 1.2-4.1 S153Y 2.1 T124A, S153Y 1.8-2.6 L101I, T124A/, 153F 2.0

21 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.11.2. Isolation from Wild Type and Site Directed Mutant INI Resistant HIV-1 Strain NL432

Wild type HIV-1 NL432 and molecular clones with single amino acid substitutions (E92Q, Q148H, Q148K, Q148R, and N155H) within the IN open reading frame were passaged sequentially under increasing concentration of DTG for up to 56 days (m5.3.5.4, RH2008/00144/00). Passaged virus populations were analyzed for genotypic changes on Days 14, 28, 42 and 56, and for phenotypic fold change (FC) on Day 56 samples (Table 16).

22 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 16 Passage of NL-432 and Single Mutants with DTG.

Initial Virus DTG Initial Amino Acid Substitution DTG Fold Change of Conc. / Passaged Virus Final Conc Days of Pools (nM) Culture NL-432 6.4 / 6.4 56 E92Q 3.1 G193E 3.2 Q148K 6.4 / 32 14 E138K, Q148K - 28 E138K, Q148K - 42 E138K, Q148K - 56 E138K, Q148K 47 - 190 Q148R 6.4 / 6.4 or 14 Q148R - 32 28 G140S, Q148R - 42 G140S, Q148R - 56 G140S, Q148R 16 (6.4 final conc.) G140S, Q148R, V201I 39 (32 final conc.) Q148R 6.4 / 6.4 14 E138K, Q148R - 28 E138K, Q148R - 42 E138K, Q148R - 56 E138K, G140S, Q148R 13 Q148H 6.4 / 6.4 or 14 G140S, Q148H - 32 28 G140S, Q148H - 42 G140S, Q148H - 56 G140S, Q148H 4.8 – 8.0 (6.4 final conc.) T97A, G140S, Q148H 44 (32 final conc) V75I, E138K, G140S, 46 (32 final conc) Q148H, M154I N155H 6.4 / 32 14 N155H - 28 N155H - 42 N155H - 56 N155H 2.0 – 3.9 E92Q 6.4 / 6.4 14 E92Q - 28 E92Q - 42 E92Q - 56 E92Q 2.9 – 4.1

Passage of the wild type HIV-1 NL432 in the presence of 6.4 nM DTG selected for E92Q (FC=3.1) and G193E (FC=3.2) substitutions in the IN region on Day 56. Passage of the Q148K mutant selected E138K/Q148K (FC=47 to190) on Day 14 and was present throughout the remaining passages up to 32 nM DTG with no additional substitutions selected up to Day 56. Passage of the Q148R mutant selected E138K/Q148R and G140S/Q148R (FR=16) on Days 14 and 28, respectively, in the presence of 6.4 nM DTG. Further passage at 32 nM DTG selected E138K/G140S/Q148R (FC=13) and

23 CONFIDENTIAL Module 2.7.2.4 Special Studies

G140S/Q148R/V201I (FC=39) by Day 56. Passage of Q148H selected G140S/Q148H (FC=4.8 to 8) on Day 14 in the presence of 6.4 nM DTG, and selected T97A/G140S/Q148H (FC=44) and V75I/E138K/G140S/Q148H/M154I (FC=46) on Day 56 in the presence of 32 nM DTG. Passage of the E92Q or N155H mutant viruses in the presence of DTG did not lead to additional substitutions. Passage of site directed mutant virus with polymorphic substitutions L101I, L101I/T124A, and RAL resistance mutations Y143C and Y143R in the presence of DTG did not lead to additional substitutions (m5.3.5.4, 2012N141510)

Passage of site direct double mutant virus G140S/Q148R at 6.4 nM selected V113L at Day 56 (FC not determined). Passage of G140S/Q148H at 6.4 nM dolutegravir selected the addition of N155H at Day 28 (FC = 85 to >120) and E92Q (FC >120), and of E92Q/E138K by Day 56 (FC >120). Passage at 32 nM DTG selected for addition of F139S at day 28 (FC not determined), L74M at Day 42 (FC = 15 to 95), or L74M/T123S/V113L (FC >120). All FCs were determined at Day 56 (Table 17).

Table 17 Passage of Double Mutants with DTG

Initial Virus DTG Initial Amino Acid Substitution DTG Fold Change of Conc. (nM) Days of Added Passaged Virus Culture Pools G140S, 6.4 28 N155H - Q148H 42 N155H - 56 N155H 85 - >120 G140S, 6.4 28 E92Q - Q148H 42 E92Q - 56 E92Q >120 G140S, 32 28 F139S - Q148H 42 F139S - 56 F139S - G140S, 32 42 L74M - Q148H 56 L74M 15 - 95 56 L74M, T112S, V113L >120

4.1.11.3. Selection of R263K in Passage Experiments using HIV-1 with Subtype B, C, and A/G

Serial passage experiments were performed with DTG using healthy donor primary human cord blood mononuclear cells (CBMCs) infected with various subtype B, C, and A/G viruses [Quashie, 2012]. After 20 weeks, the R263K mutation was observed in all five subtype B selections and one of two subtype A/G selections. During the selections, neither L101I nor T124A appeared. However, the S153Y substitution was observed in combination with R263K for one subtype B virus and S153T was partially detected in one subtype C virus. Importantly, the only subtype B or A/G virus that did not bear the R263K mutation carried the G118R mutation, which was characterized as a resistance mutation to MK-2048, another second generation integrase inhibitor. The same mutation

24 CONFIDENTIAL Module 2.7.2.4 Special Studies

(G118R) was observed in one subtype C virus. The R263K mutation was detected alone or in combination with other substitutions that varied among virus strains. R263K emerged early in culture in both subtype B and A/G viruses (Table 18).

Table 18 Serial Passage Experiments with CBMCs infected with Subtype B, A/G, and C HIV-1 Viruses in the Presence of Increasing Concentrations of DTG

Week 20 Week 37 Subtype Virus DTG Acquired DTG Acquired Concentration Mutations Concentration Mutations (M) (M) B 5331 0.05 R263K B BK-132 0.05 R263K, 0.05 R263K, W243G/W E138E/K B 5326 0.05 R263K/R, 0.05 S153Y S153Y, R166K/R B PNL4.3 0.05 R263K, M50I/M, 0.05 R263K, M50I, V151I V151I B 12197 RAL 0.01 R263K, D288E 0.025 R263K, TI D288E (week 34) A/G 6399 0.025 G118R, E69E/K 0.05 G118R A/G 96USSN20 0.1 R263K 0.1 R263K, H51H/Y C 4742 0.05 G118R 0.05 G118R, H51Y C 96USNG31 0.01 S153S/T 0.025 H51Y, G193E/G

4.1.12. Assessment of Resistance

Comparative susceptibilities to DTG and RAL were obtained from 60 RAL resistant site directed HIV-1 mutants and 6 site directed HIV-2 mutants.

4.1.12.1. Sixty Integrase Inhibitor Resistant HIV-1 Strains

HIV-1 viruses (28 with single mutations, Table 19) and 32 with two or more mutations, (Table 20) were produced from wildtype virus NL-432 using site directed mutagenesis DTG and other INI susceptibilities were tested in HeLa-CD4 cell assay carrying a reporter -galactosidase gene driven by HIV-1 LTR (m5.3.5.4, RH2007/00088/00, RH2007/00115/00, RH2008/00148/00, RH2010/00017/00). DTG showed anti-HIV activity (susceptibility) with fold change (FC) <5 against 27 of 28 INI-resistant mutant viruses with single mutations including T66A/I/K, E92Q/V, Y143C/H/R, Q148H/K/R, Q148R, and N155H, while for RAL there were 17/28 mutant viruses with FC <5. EVG (compound 3927 in m5.3.5.4, RH2005/00088/00) FC was obtained for 21 of these 28

25 CONFIDENTIAL Module 2.7.2.4 Special Studies viruses; 11 of 21 had FC <5. In addition, of the 32 INI-resistant mutant viruses with two or more mutations, 23 of 32 showed FC <5 to DTG compared with FC < 5 for 4 of 32 for RAL. EVG FC was obtained for 25 of these 32 viruses; 2 of 25 had FC <5.

Overall against the 60 site directed mutant viruses (single and 2 mutations), DTG showed a fold change (FC) of <2 for 39 of 60, while RAL showed a FC of <2 for 16 of 60. DTG showed a FC of 10 for 3 of 60, while RAL showed a FC of 10 for 32 of 60. Of the 46 mutant viruses with data for EVG, 7 of 46 showed a FC of <2, and 30 of 46 showed a FC of 10.

26 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 19 Fold Change (FC) of DTG and RAL against INI-Resistance Single Mutant Viruses by HeLa-CD4 Assay

virus DTG FC (SD) RAL FC (SD) EVG FC (SD) Wild type (NL432) 1.0 (IC50=2.1 nM, SD=0.36) 1.0 (IC50=6.1 nM, SD=0.89) - Wild type (NL432) 1.0 (IC50=2.0 nM, SD=0.34) 1.0 (IC50=8.6 nM, SD=1.3) 1.0 (IC50=1.3 nM, SD=0.24) T66A 0.26 (0.01) 0.61 (0.09) - T66I 0.26 (0.09) 0.51 (0.10 8 (1.7) T66K 2.3 (0.35) 9.6 (1.3) 84 (29) E92I 1.5 (0.19) 2.1 (0.62) - E92Q 1.6 (0.12) 3.5 (1.4) 19 (8.1) E92V 1.3 (0.20) 1.4 (0.18) - G118R 10 (4.7) 7.2 (1.5) - G118S 1.1 (0.21) 1.2 (0.30) - F121Y 0.81 (0.12) 6.1 (1.3) 36 (23) T124A 0.95 (0.19) 0.82 (0.08) 1.2 (0.29) E138K 0.97(0.029) 1.0 (0.30) 0.93 (0.12) G140S 0.86 (0.30) 1.1 (0.22) 2.7 (0.63) Y143C 0.95 (0.26 3.2 (0.57) 1.5 (0.46) Y143R 1.4 (0.29) 16 (3.9) 1.8 (0.16) Y143H 0.89 (0.11) 1.8 (0.38) 1.5 (0.047) P145S 0.49 (0.08) 0.87 (0.20) >345 Q146R 1.6 (0.17) 1.2 (0.26) 2.8 (0.72) Q148H 0.97 (0.67) 13 (5.0) 7.3 (2.3) Q148K 1.1 (0.19) 83 (6.6) >1726 Q148R 1.2 (0.21) 47 (9.3) 244 (91) +I151L 3.6 (3.6) 8.4 (4.7) - S153F 1.6 (0.20) 1.3 (0.14) 2.8 (0.93) S153Y 2.5 (1.1) 1.3 (0.19) 2.3 (0.49) M154I 0.93 (0.27) 0.82 (0.18) 1.1 (0.18) N155H 0.99 (0.094) 8.4 (1.8) 25 (7.8) N155S 1.4 (0.36) 6.2 (1.9) 68 (2.6) N155T 1.9 (0.32) 5.2 (2.0) - G193E 1.3 (0.25) 1.3 (0.35) 1.3 (0.40)

27 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 20 Fold Change (FC) of DTG and RAL against INI-Resistance Multiple Mutant Viruses by HeLa-CD4 Assay

virus DTG FC (SD) RAL FC (SD) EVG FC (SD) Wild type (NL432) 1.0 (IC50=2.1 nM, SD=0.36) 1.0 (IC50=6.1 nM, SD=0.89) - Wild type (NL432) 1.0 (IC50=2.0 nM, SD=0.34) 1.0 (IC50=8.6 nM, SD=1.3 1.0 (IC50=1.3 nM, SD=0.24) T66I, I74M 0.35 (0.08) 2.0 (0.81) - T66I, E92Q 1.2 (0.19) 18 (3.6) 185 (103) T66K, L74M 3.5 (0.94) 40 (13) 117 (33) V72I, F121Y, T125K 1.3 (0.54) 13 (7.1) - V72I, F121Y, T125K, I151V 1.2 (0.32) 7.0 (2.8) - L74M, N155H 0.91 (0.17) 28 (12) 42 (8.6) V75I, E138K, G140S, Q148H, 21 (6.6) >660 2600 (450) M154I E92Q, N155H 2.5 (1.2) >130 320 (39) T97A, N155H 1.1 (0.46) 26 (7.9) 37 (6.9) T97A, G140S, Q148H 13 (2.1) >660 3900 (630) L101I, S153F 2.0 (0.11) 1.3 (0.54) 2.6 (0.23) L101I, T124A, S153F 1.9 (0.24) 1.4 (0.14) 2.0 (0.40) F121Y, T125K 0.98 (0.35) 11 (0.49) - E138K, Q148H 0.89 (0.24) 17 (5.9) 6.7 (1.5) E138K, Q148K 19 (8.0) 330 (75) - E138K, Q148R 4.0 (1.1) 110 (37) 461 (229) E138A, Q148R 2.6 (0.47) 110 260 (12) E138K, G140S, Q148H 4.5 (1.1) 500 (210) 1600 (370) E138K, G140S, Q148R 8.3 (1.1) >660 190 (43) E138K, G140S, Q148H, M154I 8.4 (1.5) >660 2400 (670) E138A, S147G, Q148R 1.9 (0.89) 27 (3.7) 130 (8.8) G140C, Q148R 4.9 (1.8) 200 (42) - G140S, Q148H 2.6 (1.4) >130 >890 G140S, Q148K 1.5 (0.10 3.7 (1.3) 94 (53)

28 CONFIDENTIAL Module 2.7.2.4 Special Studies

virus DTG FC (SD) RAL FC (SD) EVG FC (SD) G140S, Q148R 8.4 (4.0) 200 (5.3) - G140S, Q148H, M154I 7.0 (0.98) >660 3000 (780) G140S, Q148R, V201I 10 (3.0) >660 420 (80) Y143H, N155H 1.7 (0.27) 38 16 (4.6) Q148R, N155H 10 (1.4) >140 390 N155H, G163R 1.1 (0.18) 17 (5.9) 35 (12) N155H, G163K 1.4 (0.40) 23 (7.2) 35 (4.4) N155H, D232N 1.4 (0.25 20 (3.9) 36 (7.1)

29 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.12.2. Integrase Inhibitor Resistant HIV-2 Strains

Site directed mutant HIV-2 viruses were constructed based on subjects infected with HIV-2 and treated with RAL who showed virologic failure (m5.3.5.4, 2012N141511). DTG FC resistance was <5 against 4 HIV-2 virus; S163D, G140A/Q148R, A153G/N155H/S163G and E92Q/T97A/N155H/S163D; for E92Q/N155H DTG FC = 8.5, and for G140S/Q148R DTG FC = 17. DTG, RAL and EVG all had the same activity against site directed mutant HIV-2 with S163D as wild type, and for the remaining mutant HIV-2 virus RAL and EVG FC ranges were respectively 6.4 to 420 and 22 to 640 (Table 21).

Table 21 Fold Change (FC) of DTG against RAL Resistant HIV-2 Viruses

Compound DTG RAL EVG AZT Viruses Mean FC (SD) Wild type (ROD) 1.0 1.0 1.0 1.0 S163D 0.87 (0.070) 0.86 (0.093) 1.1 (0.40) 1.2 (0.26) E92Q, N155H 8.5 (0.57) 110 (24) 340 (49) 2.8 (0.67) G140A, Q148R 0.60 (0.35) 6.4 (0.38) 110 (5.7) 0.21 (0.087) G140S, Q148R 17 (1.5) 420 (100) 640 (190) 0.43 (0.11) A153G, N155H, S163G 3.8 (0.12) 16 (2.6) 22 (3.2) 4.5 (0.99) E92Q, T97A, N155H, S163D 3.9 (0.35) 57 (8.0) 200 (82) 0.43 (0.049)

4.1.12.3. Clinical Isolates from RAL Therapy Virologic Failure Subjects

Susceptibility to DTG and RAL was obtained with over 700 RAL resistant clinical isolates from subjects not enrolled in ViiV Healthcare sponsored studies. DTG retained activity against a vast majority of these viruses.

4.1.12.3.1. Activity against Thirty-nine Clinical Isolates

Thirty-nine clinical isolate samples with genotypic and phenotypic resistance to RAL (median FC >81) were examined for susceptibility to DTG (median FC 1.5) using Monogram Biosciences PhenoSense assay (m5.3.5.4, RH2009/00010/00) (Table 22). The median FC to DTG for isolates containing changes at G140S + Q148H; G140S + Q148R, T97A + Y143R and N155H were 3.75, 13.3, 1.05 and 1.37, respectively (Table 23).

30 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 22 Genotypes and FCs to DTG and RAL for Clinical Isolates in Subjects Failing RAL Therapy

Sample RAL FC Months on RAL Number Genotype DTG FC 3242 N155H 1.37 34 5.7 3242 N155H 1.22 36 7.5 3251 N155H 1.45 14 6.7 3246 T97A, Y143R 1.04 >81 6.4 3246 T97A, Y143R 1.06 >81 11.6 3249 T97A, Y143Y/C 1.09 49 5.6 3249 T97T/A, Y143Y/C 1.05 7.08 9.6 3249 T97T/A, Y143Y/C 0.91 >81 14.4 3261 T97T/A, N155N/H 1.11 3.74 13.7 3508 E92E/Q, T97T/A, Y143R 0.87 59 6.6 3501 G140G/S, Q148Q/H 1.38 3.9 5.6 3180 G140S, Q148H 4.96 >87 5.9 3180 G140S, Q148H 3.75 >87 7.8 3223 G140S, Q148H 3.16 >87 10.5 3240 G140S, Q148H 15.0 >87 3.3 3501 G140S, Q148H 2.05 58 1.8 3501 E138E/A, G140G/S, 2.96 >81 7.5 Q148Q/H 3501 E138E/A, G140G/S, 1.94 19 8.9 Q148Q/H 3501 E138E/A, G140G/S, 2.64 >81 11.3 Q148Q/H 3501 E138E/A, G140G/S, 1.58 12 3.8 Q148Q/H 3508 E92Q, N155N/H, 4.07 >81 2.8 G140G/S, Q148Q/R 3501 E138E/K, G140G/S, 2.16 25 6.3 Q148Q/H, N155N/D 3180 Wild type 1.11 1.18 -0.7 3223 Wild type 0.69 0.9 -2.2 3223 Wild type 0.65 0.85 6.2 3240 Wild type 0.64 1.02 0 3242 Wild type 0.59 0.45 0 3242 Wild type 0.54 0.45 8.7 3261 Wild type 0.84 0.79 6.7 3501 Wild type 0.79 0.58 0 3508 Wild type 0.63 0.83 -0.2 Library 44 N155H 1.45 18 NA Library 45 G140S, Q148R 7.57 >87 NA Library 46 G140S, Q148R 19 >87 NA Library 47 N155H 1.33 19 NA Library 48 T97A, E138E/K, Y143R 1.32 >87 NA

31 CONFIDENTIAL Module 2.7.2.4 Special Studies

Sample RAL FC Months on RAL Number Genotype DTG FC Library 49 G140S, Q148H 7.32 >87 NA Lib 50 T97A, Y143C 1.21 >87 NA Lib 51 G140S, Q148H 3 >87 NA

Table 23 Representative Isolate Susceptibilities to DTG and RAL

Genotype n DTG FC RAL FC Median Range Median Range N155H 5 1.37 1.22 to 1.45 19.0 14.0 to 36.0 G140S, Q148H 7 3.75 2.05 to 15.0 >87 58.0 to >87 G140s, Q148R 2 13.3 7.57 to 19.0 >87 >87 to >87 T97A, Y143R 2 1.05 1.04 to 1.06 >81 >81 to >81

4.1.12.3.2. Activity against 705 RAL Resistant Clinical Isolates

Seven hundred and five clinical isolates from RAL-experienced patients in Monogram Bioscience’s isolate library through were analyzed for susceptibility to DTG using the Monogram Biosciences PhenoSense assay (m5.3.5.4, 2012N146158_00). The 705 isolates were selected based upon a RAL FC >1.5, and had diverse RAL-associated IN resistance patterns and proportions (Table 24) which were consistent with what has been observed previously (Clotet, 2010). Overall 662 (93.9%) of the 705 RAL resistant isolates had a DTG FC of ≤10, and 13 (1.8%) had a DTG FC of >25 (Table 25). The two Q148 categories Q148+1 and Q148+≥2 IN mutation consisted of 92 and 184 isolates respectively, and contain the majority (41 of 43) of the isolates which had a DTG FC>10. Of the 705 isolates 332 (47.1%) had RAL FC > max measurable and were found within all categories, while only three of 705 isolates (which were within the Q148+≥2 category) had DTG FC > max measurable (Table 25).

Table 24 Proportion of Samples for IN Mutation Categories

Mutation Categorya Percent (N=705) Q148+2 13.0 Q148+1 26.1 Y143 13.9 N155 28.9 2 Primary 6.0 Primary not detected 12.1 a. INI mutations list, primary mutations are bolded: Q148H, Q148K, Q148R, Y143C, Y143H, Y143R, N155H, H51Y, G118R, S147G, S153F, S153Y, G193E, R263K, L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R

32 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 25 DTG and RAL Susceptibility by Fold Change Range and IN Mutation Category

Number of viruses with FC to DTG (%) or RAL (%) in each Mutation Categorya FC Primary not Range All Q148+2 Q148+1 Y143 N155 2 Primary detected DTG RAL DTG RAL DTG RAL DTG RAL DTG RAL DTG RAL DTG RAL 0 to 282 15 1 0 13 0 72 0 102 2 18 0 76 13 1.5 (40.0) (2.1) (1.1) (7.1) (73.5) (50.0) (1.0) (42.9) (89.4) (15.3) >1.5 to 147 23 4 0 12 2 26 0 86 3 13 0 6 18 2.5 (20.9) (3.3) (4.3) (6.5) (1.1) (26.5) (42.2) (1.5) (31.0) (7.1) (21.2) >2.5 to 77 23 19 0 37 3 0 0 13 5 6 2 2 (2.4) 13 4 (10.9) (3.3) (20.7) (20.1) (1.6) (6.4) (2.5) (14.3) (4.8) (15.3) >4 to 137 21 34 0 96 3 0 3 3 11 3 0 1 (1.2) 4 8 (19.4) (3.0) (37.0) (52.2) (1.6) (3.1) (1.5) (5.4) (7.1) (4.7) >8 to 19 20 9 0 10 1 0 1 0 12 0 3 0 3 10 (2.7) (2.8) (9.8) (5.4) (0.5) (1.0) (5.9) (7.1) (3.5) >10 to 20 40 13 1 7 3 0 5 0 23 0 1 0 7 15 (2.8) (5.7) (14.1) (1.1) (3.8) (1.6) (5.1) (11.3) (2.4) (8.2) >15 to 7 36 4 1 3 1 0 4 0 26 0 4 0 0 20 (1.0) (5.1) (4.3) (1.1) (1.6) (0.5) (4.1) (12.7) (9.5) >20 to 3 35 0 0 3 3 0 7 0 22 0 1 0 2 25 (0.4) (5.0) (1.6) (1.6) (7.1) (10.8) (2.4) (2.4) >25 13 492 8 90 3 168 0 78 0 100 2 31 0 25 (1.8) (69.8) (8.7) (97.8) (1.6) (91.3) (79.6) (49.0) (4.8) (73.8) (29.4) N 705 705 92 92 184 184 98 98 204 204 42 42 85 85 Median 1.76 89 5.98 115.92 4.84 115.92 1.24 100.24 1.5 25 1.81 79 0.88 3.98 Range 0.19- 0.81- 1.46- 11- 0.49- 2.24- 0.45- 4.24- 0.75- 0.9- 0.91- 2.61- 0.19- 0.81- 58 >max 58 >max 44 >max 2.16 >max 6.78 137.3 37 135.9 4.34 >max >max N 3 332 3 84 0 153 0 47 0 17 0 19 0 12 (%)b (0.43) (47.1) (3.26) (91.3) (83.2) (48.0) (8.3) (45.2) (14.1) a. INI mutations list, primary mutations are bolded: Q148H, Q148K, Q148R, Y143C, Y143H, Y143R, N155H, H51Y, G118R, S147G, S153F, S153Y, G193E, R263K, L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R b. >max is the maximum measureable FC within assay and ranged from >42.8 to >49.8 FC DTG and from >100.24 to >170.6 FC RAL

33 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.1.12.3.3. Characterization of DTG resistance in the Raltegravir Resistant Clinical Isolate Population

To better understand the extent and evolving characteristics of DTG resistance in broad clinical practice for subjects experiencing virologic failure on RAL, queries into RAL resistant pathway frequencies was carried out on 1079 patient samples with an aim to detecting genotypic changes over time, and the proportion of isolates with potential increased DTG fold change resistance (m5.3.5.4, 2010N152930_00).

Query analysis

The query was in two parts and compared samples received and tested at Monogram Biosciences over two time periods encompassing collection dates between through inclusive (N=273) compared with through inclusive (N=806). Monogram Biosciences carried out the Queries into their dataset and provided proportions within the defined groups.

Query One compared proportions of specific primary and secondary mutations and also samples without the defined mutations:

 Primary mutations: Y143C; Y143H; Y143R; Q148H; Q148K; Q148R; N155H. Secondary mutations: L74I,M; T97A; E92Q,V; E138A,K,T; G140A,C,S; V151I; G163K,R; None of above mutations.

 Query parameters: Mixtures at a specific position will be counted as one mutation (example: both E92Q/V and E92Q will be counted as one E92Q mutation).

Query Two compared Q148H/K/R in combination with increasing number of other RAL associated secondary resistance mutations, or with other primary resistance mutations:

 Primary RAL Resistance Associated Mutations: Y143C, Y143H, Y143R, N155H. Secondary RAL Resistance Associated Mutations: L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R

 Parameters: Proportions of five groups were determined: Q148H or Q148K or Q148R + 1 secondary; Q148H or Q148K or Q148R + 2 secondary; Q148H or Q148K or Q148R + 3 secondary; Q148H or Q148K or Q148R + 4 secondary; or Q148H or Q148K or Q148R + other primaries. Mixtures at a specific position were counted as one mutation (example: both E92Q/V and E92Q be counted as one E92Q mutation). Prevalence for categories 1, 2, 3, and 4 were calculated within samples with no other primary RAL resistance associated mutations.

Enumeration of key RAL associated resistance mutations in virus samples with Q148+≥2

Data for the frequencies of RAL primary and secondary mutations (and associated DTG susceptibilities) for a set of 705 isolates randomly selected from the 806 isolates in the through window is found in m5.3.5.4, 2012N146158_00. The

34 CONFIDENTIAL Module 2.7.2.4 Special Studies different IN mutation categories evaluated within that report were Q148 + ≥2 mutation category, Q148+1 mutation category, Y143 mutation category, N155 mutation category, ≥2 Primary IN mutations category, and Primary not detected category.

Isolates from the ≥2 Primary IN mutations category with genotypes demonstrating presence of Q148 + at least two secondary mutations were included within the Q148 + ≥2 mutation category for this enumeration. This supergroup category called Q148 + ≥2 +P allows for evaluating proportions of key resistance mutations (L74I, E138A/K/T, and G140A/C/S) in all available virus possessing Q148 + ≥2 RAL associated resistance mutations.

Phenotypic data was provided with listed defined INI-associated resistance mutations within the integrase open reading frame. The defined list of mutations is provided, primary mutations are in bold: Q148H, Q148K, Q148R, Y143C, Y143H, Y143R, N155H, H51Y, G118R, S147G, S153F, S153Y, G193E, R263K, L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R.

Table 26 provides the proportions of isolate samples for IN single mutation categories. There were decreases in the proportion of Q148 pathway virus, including the tightly associated G140 secondary mutation, from the early to late window. N155H increased during this time.

35 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 26 Proportion of samples for IN single mutation categories

- - N=273 N=806 Change in Mutationa Prevalence (%) Prevalence (%) Prevalence (%) Primaryb Y143C 9.52 9.18 -0.34 Y143H 2.93 3.23 0.3 Y143R 7.69 11.04 3.35 Q148H 41.76 31.39 -10.37 Q148K 2.20 0.50 -1.7 Q148R 10.99 9.68 -1.31 N155H 31.50 34.49 2.99 Secondaryc L74I,M 14.65 15.76 1.11 T97A 19.78 24.07 4.29 E92Q,V 3.66 4.47 0.81 E138A,K,T 10.62 10.17 -0.45 G140A,C,S 50.55 37.47 -13.08 V151I 19.05 21.22 2.17 G163K,R 11.72 12.41 0.69 None of above 0.73 2.11 1.38 a. Mixtures at a specific position are counted as one mutation b. Primary RAL Resistance Associated Mutations: Y143C, Y143H, Y143R, N155H. c. Secondary RAL Resistance Associated Mutations: L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R.

Table 27 provides the proportions of isolate samples for IN Q148 plus multiple mutation categories. Similar toTable 26, there was a decrease in the number of Q148 isolate samples from the early to late window, including those which had Q148 plus additional primary mutations present at Y143 and N155.

36 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 27 Proportion of samples for IN Q148 plus multiple mutation categories

Mutation Profile - - Difference in N=273 N=806 Prevalence (%) Prevalence (%) Prevalence (%)

Q148H/K/R + 1a 33.33 26.67 -6.66 Q148H/K/R + ≥2 15.75 10.3 -5.45 Q148H/K/R + 2 13.55 9.06 -4.49 Q148H/K/R + 3 2.2 1.24 -0.96 Q148H/K/R + other primary(s)b 4.4 3.23 -1.17 a. Q148H or Q148K or Q148R + 1, 2, 3, or 4 secondaries were evaluated. Secondaries: H51Y, G118R, S147G, S153F, S153Y, G193E, R263K, L74I, L74M, T97A, E92Q, E92V, E138A, E138K, E138T, G140A, G140C, G140S, V151I, G163K, G163R. Mixtures at a specific position were counted as one mutation. b. Primaries: Q148H, Q148K, Q148R, Y143C, Y143H, Y143R, N155H

Table 28 is for 115 isolates of a total of 705 random isolates from the through time frame (m5.3.5.4, 2012N146158_00). The 115 isolate samples include 92 isolates from the Q148 + ≥2 mutations category + 23 isolates from the ≥2 Primary IN mutations category with (in addition to a second primary mutation at Y143 or N155) a Q148 signature mutation plus at least two RAL-associated secondary mutations. There were overall 62 subjects with at least two derived key mutations within the 115 subjects. The majority of those 62 subjects with the derived mutations were in the set Q148 + G140 + E138 (n=46) followed by Q148 + G140 + L74 (n=14) and then all 3 Q148 + G140 + E138 + L74 (n=2).

37 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 28 Proportion of Samples with Key Mutations in the Q148+>=2 + P Group

Mutationsa from Q148 derived mutation group Total present number per Group All three mutations: Q148 + G140 + E138 + L74 2

Two of three Mutations: Q148 + G140 + E138 46 Q148 + G140 + L74 14 Q148 + L74 + E138 0

One of three mutations: Q148 + L74 0 Q148 + E138 9 Q148 + G140 41

Zero of three mutations: Not L74 or E138 or G140 3

Total 115 a. Key mutations L74I, E138A/K/T, G140A/C/S.

4.1.13. Evaluation of DTG Dissociation from Wild Type and Integrase Inhibitor Resistant Integrase-DNA Complexes

The dissociation of DTG, RAL, and EVG from wild type and mutant IN proteins complexed with DNA was investigated to obtain a better understanding of INI dissociation kinetics. DTG demonstrated slower dissociation from all IN-DNA complexes tested, including those with single and double residue IN substitutions, compared to RAL and EVG.

The dissociation rate of [3H]-labeled INIs, including DTG was determined at 37°C against a panel of integrase proteins, including wild type and signature RAL and EVG resistant mutations (WT, E92Q, G140S, Y143C, Y143H, Y143R, Q148H, Q148K, Q148R, N155H, E92Q/N155H, E138K/Q148R, G140S/Q148H) (m5.3.5.4, 2011N114191_00). Integrase:DNA duplexes attached to Scintillation Proximity Assay (SPA) imaging beads were incubated with [3H]-labeled DTG, RAL, or EVG overnight to achieve maximum binding. Excess unlabeled INI was added to block re-binding of the released 3H-INI which results in a decrease in signal measured via a ViewLux™ CCD imager for up to 2.5 weeks.

For wild type integrase, the half-life of dissociation for DTG was approximately 71 hours at 37°C, substantially longer than the half-life for RAL (8.8 hours) or EVG (2.7 hours). Prolonged binding (t1/2 of at least 7 hours) was observed for DTG with E92, Y143, Q148,

38 CONFIDENTIAL Module 2.7.2.4 Special Studies

and N155 integrase mutants. For all of the integrase mutants tested, the off-rate of DTG was significantly slower (from 6 to 60 times slower) than the off-rate of RAL or EVG. The addition of a second mutant to either a Q148 or N155 mutant resulted in an increase in the dissociation rate compared to the single mutant but DTG retained significant binding (Table 29).

Table 29 Dissociation of INIs from IN-DNA Complexes at 37C

Koff(s-1)a (10-6) t1/2(h) IN DTG RAL EVG DTG RAL EVG Wild type 2.7  0.4 22  2 71  4 71 8.8 2.7 E92Q 11.4  0.3 59  9 430  20 17 3.3 0.4 E138K 2.3  0.2 17  0.3 52  1 84 11 3.7 G140S 9.6  0.8 44  3 180  20 20 4.4 1.1 Y143C 3.2  0.1 96 4 91  2 60 2.0 2.1 Y143H 4.4  0.2 78 2 120  6 44 2.5 1.6 Y143R 4.6  0.3 176  4 116  5 42 1.1 1.7 Q148H 37  3 1160  120 1130 140 5.2 0.2 0.2 Q148K 18  5 730  130 ND 11 0.3 ND Q148R 21  2 480  80 ND 9.2 0.4 ND N155H 20  2 300  80 500  140 9.6 0.6 0.4 E92Q/N155H 49  3 770  70 ND 3.9 0.3 ND E138K/Q148H 53  10 900  340 ND 3.6 0.2 ND G140S/Q148H 58  8 1130  210 ND 3.3 0.2 ND a. koff values represent mean and SD for 3 to 8 independent experiments. ND denotes not determined due to low signal with [3H]EVG.

In addition to specific RAL and EVG resistance-based mutant integrase proteins, the binding of DTG, RAL, and EVG was determined for integrase proteins based on treatment emergent resistance mutations observed with RAL resistant viruses in the clinical study ING112961 and for substitutions and combinations of substitutions identified during passage studies and their related control proteins (m5.3.5.4, 2012N145179_00). G118R and G118R/E138K were observed during passage with MK- 2048, P145S was observed during passage with EVG, R263K was observed during passage with DTG, and the V75I/E138K/G140S/Q148H/M154I combination was observed during passage of Q148H virus with DTG. Under the conditions used in these 3 3 experiments the signal with [ H]RAL and [ H]EVG was not sufficient to determine koff for some of the IN substitutions.

Prolonged binding (t1/2>1 h) was observed for DTG with all of the combinations of IN substitutions derived from the ING112961 study genotypes (Table 30), except for proteins with the combinations of E92Q/G140S/Q148H (t1/2 = 0.4 – 0.6 h) and G140S/Q148H/N155H (t1/2 = 0.3 – 0.5 h).

39 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 30 Dissociation of INIs from IN-DNA Complexes at 37C: IN Substitutions Observed during VIKING

k . (s-1)a (x10-6) t 1/2 (h)b IN DTG RAL EVG DTG RAL EVG T97A/Y143R/N155H 84  10 ND ND 2.3 0.1 ND L74M/T97A/Y143R 20  2 760  50 280  40 9.6 0.3 0.7 L74M/T97A/Y143R/N155H 80  11 ND ND 2.4 ND ND L74M/T97A/E138A/Y143R/ 2550  620 2.2 0.1 0.1 N155H 89  16 2619 L74M/G140S/Q148H 58  6 1430  350 ND 3.3 0.1 ND L74M/E138A/G140S/Q148H 81  15 2482 ND 2.4 0.1 ND L74M/T97A/G140S/Q148H 170  50 2275 ND 1.1 0.1 ND G140S/Y143H/Q148H 50  9 ND ND 3.9 ND ND E92Q/G140S/Q148H 300  40 ND ND 0.6 ND ND E92Q/E138T/G140S/Q148H 450  50 ND ND 0.4 ND ND E138K/G140S/Q148H 64  11 1140  300 ND 3.0 0.2 ND G140S/Q148H/N155H 380  8 ND ND 0.5 ND ND E138K/G140S/Q148H/ 560  20 ND ND 0.3 ND ND N155H a. koff values represent mean and SD for 3 to 7 independent experiments except where noted with * (“n = 1 or 2). ND denotes not determined due to low signal with [3H]EVG b. For reference, t1/2 values for DTG, RAL, and EVG with a wild type IN-DNA complex with IN protein from BH10 virus are 71 h, 8.8 h, and 2.7 h, respectively..

The addition of multiple RAL secondary substitutions to IN with Q148H generally resulted in faster DTG dissociation. Dissociative half-lives of 2.1 h and 1.0 h were obtained for DTG with IN-DNA complexes containing the E138K/G140S/Q148H/M154I and V75I/E138K/G140S/Q148H/M154I substitution, respectively. The dissociative half- life for DTG was greater than 10 h (10.3 to 15.5 h) for IN-DNA complexes containing the IN substitutions from DTG passage studies G118R, G118R/E138K, P145S, or R263K Table 31).

40 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 31 Dissociation of INIs from IN-DNA Complexes at 37C: IN Substitutions Observed during Passage Studies

k . (s-1)a (x10-6) t 1/2 (h)b IN DTG RAL EVG DTG RAL EVG E138K/G140S/Q148H/M154I 90  17 1630  60 ND 2.1 0.1 ND V75I/E138K/G140S/Q148H/ ND 1.0 ND ND M154I 200  40 ND G118R 18  1 71  12 215  11 10.7 2.7 0.9 G118R/E138K 19  1 61  3 168  6 10.1 3.2 1.1 P145S 11.1  0.5 57  4 ND 17.3 3.4 ND

WT (B) 7.5  0.4 40  1 88  3 25.7 4.8 2.2 WT(C) 5  0.1 23  1 73  3 38.5 8.4 2.6 R263K(B) 12.4  0.4 52  2 164  8 15.5 3.7 1.2 R263K(C) 8.6  1.1 31  1 ND 22.4 6.2 ND a. koff values represent mean and SD for 3 to 7 independent experiments except where noted with * (“n = 1 or 2). ND denotes not determined due to low signal with [3H]EVG b. For reference, t1/2 values for DTG, RAL, and EVG with a wild type IN-DNA complex with IN protein from BH10 virus are 71 h, 8.8 h, and 2.7 h, respectively.

4.1.14. Minority Species Analysis from Antiretroviral Therapy, Raltegravir Resistant Experienced Adults in Phase 2b Study ING112961

Plasma samples from subjects representing an array of raltegravir therapy (days on RAL and days off RAL) were selected for ultradeep pyrosequencing (UDPS) at both Screen and Day 1 of ING112961 and are summarized in Table 32 (m5.3.5.4, 2012N151522_00). A total of 40 viruses (16 Screen, 24 Day 1) were analyzed by UDPS. Not all subjects analyzed by UDPS were enrolled in ING112961 (i.e, Screen). Included in Table 32 are the visit type, HIV RNA levels, the length of time (days) the subject had taken raltegravir, as one component of antiretroviral therapy, the length of time (days) that the subject was off of raltegravir before initiating DTG therapy, and a summary of UDPS results. Also, shown in Table 32 the unique mutations/substitutions detected by UDPS but not detected by population genotyping.

41 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 32 UDPS Summary INI-Associated Resistance Mutations Detected in Screen or Day 1 virus but Not Detected by Population Genotyping

1171 Day 1 674 0 G140S, Q148H none 815 1610 Day 1 48736 1176 0 V151I, N155H none L74M, E92A, 1611 Day 1 13350 802 0 none Y143R 1612 Day 1 52935 816 287 L74I, T97A, Y143R none L74M, T97A, 1621 Day 1 57497 1254 0 none E138A, Y143R L74L/M, T97A, 1622 Day 1 7385 810 20 E138K/T/Q/P, none Y143R L74I, G140S, 1630 Day 1 7434 944 0 none Q148H L74M, T97A, 1640 Day 1 173080 103 0 none Y143R N155H (22.30%), T97A 1662 Day 1 5587 1078 169 E92Q (1.76%), G193E (2.38%) G140S, Y143H, L74I (2.63%), L74M 1680 Day 1 240221 743 0 Q148H (1.0%), E138A (6.32%) 1681 Day 1 9771 754 0 G140S, Q148H none E138A, G140S, 1703 Day 1 10255 731 71 none Y143H, Q148H G140S (4.52%), 1811 Day 1 45907 1078 96 none Q148 (4.4%) 2000c. Screen 42263 1178 0 NAa. E92Q (8.28%) 2100 Screen 234337 762 41 NA none 2101 Screen 2971 728 67 G163E G163K (23.78%) T97A (1.76%), N155H 2102 Screen 2261 1076 0 none (33.24%), G193E (2.38%) 2103 Screen 16278 147 579 none T97A (7.29%),

42 CONFIDENTIAL Module 2.7.2.4 Special Studies

Screen/Day1 UDPS Screen/Day1 Summary INI- Population Time Time Associated Resistance Visit Viral Genotyping Subject On Off Mutations not Detected Type RNA INI-Associated RAL RAL by Population Resistance Genotyping Mutations (Frequency 1%) 2104 Screen 160576 818 55 none none 2122 Screen 14151 363 572 NA none 2201 Screen 75422 174 103 none none E138E/K, G140G/S, 2202 Day 1 18621 1901 0 none Q148Q/H 2310 Day 1 68652 1174 0 G140S, Q148H none T97A, V151I, 2340 Day 1 60256 1505 0 none N155H 2360 Screen 1291 490 561 none L74I (15.22%) 2369 Screen 4508 984 287 none none L74L/M, E138E/K, L74M (2.56%), Q148R 2410 Day 1 12841 836 0 Y143R (3.60%), T97A (56.6%) L74L/M, T97T/A, 2415 Day 1 147851 941 312 none Y143Y/C 2430 Day 1 28875 310 664 E138A, Q148H E138T (3.98%) G140S, 2432 Day 1 51505 NA NA Y143Y/H/R/C, G163R (2.47%) Q148H 2460 Day 1 12378 316 0 G140S, Q148H none 2461 Screen 210935 930 0 E138E/D, V151I G193E (1.11%) 2462 Day 1 16306 868 0 G140S, Q148H none 2464 Screen 16522 1123 0 none none 2480 Screen 75938 247 3 L74M, E92Q, T97A none a. NA- Data not available b. Subjects enrolled in Cohort I are Day 1 and numbered in the 1000 range c. Subjects enrolled in Cohort II are Day 1 and numbered in the 2000 range

Clonal analyses were performed on virus from subjects experiencing virologic failure by week 24 at both the Day 1 and protocol defined virologic failure (PDVF) time points. A summary of the results for detection and frequency of INI-associated resistance mutations seen by clonal analyses but not by population genotyping are shown in Table 33.

43 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 33 Summary of INI-Associated Resistance Mutations Detected and Frequency at Day 1 and VF by Clonal Analyses but Not by Population Genotyping

IN Virologic INI-Associated Resistance Mutations Subject Mutational Failure Day 1 Day 1 Additional VF Population VF Additional Group Visit Population Mutations Mutations detected by detected by Clonala Clonala 1680d Mixture Day 11 G140S, Y143H, L74M (3.2%) L74I/M, T124Ab, Y143H (17.2%) Q148H L74I (2.4%) E138E/A, G140S, E138A (96.8%) Q148H 1630 Q148+2 Day 11 L74I, G140S, T97A (0.8%) L74I, T124A, NAc Q148H G140S, Q148H 1624 Q148+2 Day 11 E138K/T, G140S, T97A (27.4%), E138K, G140S, T97A (2.0%) Q148H Y143C (0.5%), Q148H 1625 Q148+2 Day 11 L74I, G140S, T66I (3.9%), L74I , G140S, Nonef. Q148R,G163R T97A (0.7%) Q148R, G163R 1681 Q148+1 Day 11 G140S,Q148H T97A (0.7%) G140S, Q148H None 1703 Mixture Day 11 E138A,G140S, R263K (0.5%) E138A, G140S, G193E (0.6%) Y143H, Q148H Y143H, Q148H 1811 Other Week 8 None T97A (0.6%), L74L/M/I, T97A, N155H (5.4%) G140S (1.8%), G140S, Q148H Y143H (0.6%), Q148H (1.8%) 1610 N155 Week 12 V151I, N155H T97A (0.4%), V151V/I, N155H Y143H (0.9%) G193E (0.4%) 1623 Y143 Week 12 L74I, T97T/A, T66A (0.6%), L74I, T97A, NA E138E/K.Y143R L74V (4.0%), E138K, Y143R E138A (65.2%). 1700 Y143 Week 16 L74L/M, Y143R E138K (1.2%) Y143R T97A (0.5%) 1621 Y143 Week 24 L74M, T97A, G140S (0.3%), L74M, T97A, Y143C (0.9%) E138A, Y143R Q148H (0.3%) E138A, Y143R, N155H 1640 Y143 Week 24 L74M, T97A, Y143C (0.7%) L74M, T97A, None Y143R Y143R, N155H 2310e Q148+1 Week 16 G140S, Q148H None T97T/A,E138E/K, T66A (0.8%) G140S, Q148H, N155H 2340 N155H Day 11 T97A, V151I, None T97A, V151I, NA N155H N155H 2462 Q148+1 Week 8 G140S, Q148H None E92E/V, E138E/K, None G140S, Q148H, N155H a. INI-associated resistance mutations not detected by population genotyping (frequency) b. T124A is a well characterized polymorphism that has no impact on integrase resistance c. NA – Amplicon could not be generated d. Subjects enrolled in Cohort I are numbered in the 1000 range e. Subjects enrolled in Cohort II are numbered in the 2000 range f. None- no mutations detected

44 CONFIDENTIAL Module 2.7.2.4 Special Studies

Clonal analyses afford, in addition to the frequency of mutations, the frequency of primary and/or secondary INI- associated mutations residing on a subset of genomes. Table 34 represents the frequency of primary and/or secondary mutations residing on the most prevalent subset of genomes within a specified virus population. Clonal analyses have shown that the INI-associated resistance mutations detected by population genotyping accumulate and reside on a subset of genomes.

Table 34 Prevalent Frequencies of INI-Associated Resistance Mutations Residing on a Subset of Viral Genomes for Day 1 and VF Timepoints as Determined by Clonal Analyses

IN Prevalent Frequency of INI-Associated Resistance Mutations Virologic Subject Mutational Failure Visit Day 1 VF Group 1680c Mixture Day 11 E138A, G140S, Y143H, L74I, E138A, G140S, Q148H (51.7%) Q148H (91.2%) 1630 Q148+2 Day 11 L74I, G140S, Q148H (98.3%) NDb 1624 Q148+2 Day 11 E138K, G140S, Q148H E138K, G140S, Q148H (93.1%) (34.1%); none (31.3%); T97A (25.4%) 1625 Q148+2 Day 11 L74I, G140S, Q148R, G163R L74I, G140S, Q148R, G163R (98.9%) (95.4%) 1681 Q148+1 Day 11 G140S, Q148H (97.3%) G140S, Q148H (100%) 1703 Mixture Day 11 E138A, G140S, Y143H, E138A, G140S, Y143H, Q148H (97.7%) Q148H (97.4%) 1811 Other Week 8 G140S, Q148H (1.8%); nonea T97A, G140S, Q148H (92.4%) (97.0%) 1610 N155 Week 12 V151I, N155H (84.1%) V151I, N155H (45.5%); N155H (99.1%) 1623 Y143 Week 12 L74I, T97A, E138A, Y143R ND (61.1%); L74I, T97A, E138K, Y143R (33.7%) 1700 Y143 Week 16 Y143R (98.2%) Y143 (100% ) 1621 Y143 Week 24 L74M, T97A, E138A, Y143R L74M, T97A, Y143R, N155H (94.4 %) (97.7%) 1640 Y143 Week 24 L74M, T97A, Y143R (89.3%) L74M, T97A, Y143R, N155H (100%) 2310d Q148+1 Week 16 G140S, Q148H (98.6%) G140S, Q148H, N155H (100%) 2340 N155H Day 11 T97A, V151I, N155H (95.5%) ND 2430 Q148+2 Week 8 E138A, G140S, Q148H E92E, T97A, E138T, G140S, Q148H (92.6%); E138T, G140S, (55.4%), E92Q, T97T, E138T, G140S, Q148H (6.0%); E138K, Q148H (41.4%), E92Q, T97A, E138T, G140S, Q148H (0.9%) G140S, Q148H (1.3%) 2462 Q148+1 Week 8 G140S, Q148H (97.9%) G140S, Q148H, N155H (99.4%) a. None- wild-type, no INI-associated mutations detected b. ND-analysis not performed due to inability to obtain amplicon c. Subjects enrolled in Cohort I d. Subjects enrolled in Cohort II

Genetic analyses of subjects with PDVF could not identify any de novo mutations within the viral integrase gene that are associated with resistance to DTG. UDPS identified additional INI-associated resistance mutations in minority quasispecies at screen or Day 1 in 10% of samples tested. Clonal analyses on paired Day 1 and PDVF virus provided

45 CONFIDENTIAL Module 2.7.2.4 Special Studies

additional information that the INI-associated resistance mutation that emerged at PDVF were added to pre-existing Day 1 INI associated resistance mutation profiles and that this accumulation of INI-associated resistance mutations results in the reduction of DTG susceptibility.

4.1.15. Integrase Polymorphism Effects on DTG Resistance and Clinical Response

A total of 2997 IN sequences were identified and aligned from integrase inhibitor naive sequences obtained from LANL and SRD. The major genomic subtypes represented in this data set included B (55%), CRF02_AG (13%), C (13%), and CRF01_AE (6%). The analysis revealed a high degree of conservation across the 288 amino acid residues. The majority of positions (59% were found to vary by <1 % at the amino acid level (ie. >99% conservation). These highly conserved positions spanned long regions across the IN protein. However a total of 34 positions met the criteria for a polymorphic site (>10% amino acid diversity) and were found to be distributed across IN (Vavro, 2012).

To characterize any impact on DTG susceptibility of polymorphisms seen in the integrase enzyme, a panel of site-directed molecular clones (SDMs) was constructed from pNL- 432 with single, double, and triple mutants (Vavro, 2012). This panel comprised IN substitutions identified during in vitro passage with DTG as well as IN polymorphic sites. Baseline viruses from a study in INI naive, HIV-infected patients were evaluated for DTG and RAL susceptibility and differences in HIV-1 RNA decline with DTG monotherapy were evaluated. Fold change susceptibility to DTG and RAL was measured using HeLa CD4 cells.

The SDMs with polymorphic amino acid changes T124A and L101I had DTG FC values below the assay cutoff for reduced susceptibility. Fold change for SDMs ranged from 0.91 for the L101I/T124A double substitution to 2.5 for the non-polymorphic substitution S153Y, which arose during in vitro passage of DTG (Table 35). The mean FC for L101I was 1.4 for DTG and 1.2 for RAL, each of which is within the assay’s variability. The addition of polymorphisms L101I and T124A to the S153F mutation had FC within the assay’s variability of 2. DTG trough concentrations are 19-fold above the protein- adjusted inhibitory concentration at 90% (IC90) of 152 nM that was observed at the once- daily, 50 mg dose; this is well above the maximum FC for all SDMs tested in this study.

46 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 35 In vitro drug susceptibilitya for site-directed mutants with polymorphisms and substitutions observed during DTG passage

Amino acid substitution in Where observed DTG FC, mean RAL FC, mean NL-432 L101I Polymorphism/Passage 1.40 1.20 T124A Polymorphism/Passage 0.95 0.82 L101I/T124A Polymorphism 0.91 0.77 S153F Passage 1.60 1.30 S153Y Passage 2.50 1.30 L101I/S153F Polymorphism/Passage 2.00 1.30 L101I/T124A/S153F Polymorphism/Passage 1.90 1.40 E92Q Passage 1.60 3.50 G193E Passage 1.30 1.30 a. Assay variability of 2-fold changes

47 CONFIDENTIAL Module 2.7.2.4 Special Studies

In the phase IIa dose-ranging study of DTG monotherapy, HIV-infected subjects were randomized to receive DTG (2, 10, or 15 mg) as a monotherapy or placebo every 24 hours for 10 days (Min, 2011). IN genotypes and phenotypes were determined at Day 1 by Monogram Biosciences. Differences in the group median FC were calculated for DTG and RAL at sites 101 and 124 (Table 36). All 101 and 124 genotypes had similar IC50 values and overlapping variance ranges for DTG and RAL. The average FC to DTG was 0.79, and the average FC to RAL was 0.89. No polymorphism showed an average shift in susceptibility >2-fold to either DTG or RAS, and no median FC observed was greater than the FC assay variability.

Table 36 Fold Change Response to DTG and RAL for Day 1 Isolate Samples (N = 36) with variation at amino acids 101 and 124

Site DTG FC RAL FC 101 124 Subjects, n Median (range) Median (range) L101L T124T 6 0.64 (0.47 – 0.89) 0.72 (0.5 – 0.95) L101L T124A 5 0.97 (0.63 – 1.17) 0.91 (0.58 – 1.05) L101L T124N 7 0.78 (0.66 – 0.82) 0.92 (0.83 – 1.41) L101L T124S 2 0.825 (0.79 – 0.86) 0.965 (0.96 – 0.97) L101L T124T/N 1 0.89 0.82 L101L T124T/N/D/A 1 0.89 1.15 L101I T124T 5 0.79 (0.72 – 0.88) 0.86 (0.84 – 1.16) L101I T124A 3 0.81 (0.78 – 0.89) 0.79 (0.76 – 0.97) L101I T124N 3 0.85 (0.46 – 0.86) 0.97 (0.89 – 0.98) L101I T124S 1 0.74 0.64 L101I T124T/N 1 0.8 1.16

Two additional analyses for the phase IIa dose-ranging study evaluated polymorphism effects. Dose-adjusted differences in viral load response at Day 11 were compared across the 34 polymorphic positions. The residuals (ie, differences in change from baseline in log10 HIV-1 RNA at day 11 after adjusting for the effect of dose in a linear model) at positions of polymorphic substitutions were consistent with random variation about a mean of zero and a small variance (<0.3 log10 c/mL). This indicated no apparent difference in viral load decline with any polymorphism. In addition, the effect of substitutions at each position was tested using a multivariate linear model that adjusted for dose and the presence or absence of substitutions at each position. The distribution of P values ranged from 0.035 to 0.99, a pattern consistent with no position examined having an effect on day 11 response to DTG.

Baseline clinical samples taken from participants in the phase IIa study showed no differences in HIV-1 RNA decline with any polymorphism, including those involving sites 101 and 124.

4.2. Clinical Virology

Treatment-naive (ING112276, ING113086, ING114467): No virologic resistance was observed on DTG (50mg once daily)-containing regimens in the treatment-naive

48 CONFIDENTIAL Module 2.7.2.4 Special Studies

population to either integrase or the background regimen (NRTI), whereas virologic resistance to the 3rd agent (RAL or EFV) and/or the background regimen (NRTI) has been observed on the comparator arms.

Treatment-experienced, INI-naive (ING111762): Results from this Week 24 interim analysis show DTG has a higher barrier to resistance in this patient population. A statistically significant difference in favour of DTG was demonstrated by planned virologic analyses for emergent integrase resistance. In a pre-specified analysis, there was a statistically significant difference in favor of DTG for the proportion of mITT-E subjects harboring virus with evidence of INI Resistance by Week 24 (DTG: 2/354 (0.6%); RAL: 10/361(2.8%); p=0.016). An additional prespecified analysis using a common FC cutoff to determine phenotypic resistance to RAL and DTG also confirmed a statistically significant difference in favour of DTG.

Of the PDVF subjects with matched baseline and PDVF resistance testing there were 2/9 (22%) in the DTG arm and 9/27 (33%) in the RAL arm with emergent integrase genotypic and/or phenotypic resistance. The observed mutations in the RAL arm were clinically relevant INI resistance mutations commonly observed during RAL therapy and included the primary resistance mutations at Y143, Q148, and N155 and associated secondary mutations. In the DTG arm no primary or secondary resistance mutations commonly selected during RAL therapy emerged. In both cases of emergent resistance in the DTG arm the IN substitution observed were at position R263.

Treatment-experienced, INI-resistant (ING112961, ING112574): DTG is efficacious (sustained viral load suppression) in patients with current or historic integrase mutations and DTG FC in INI-resistant population (ING112574). ING112574 enrolled sufficient range and diversity with respect to DTG FC and IN resistance patterns (respectively) allowing for an appropriate evaluation of DTG in the HIV-1 INI-resistant population. At Baseline, the viral population of enrolled subjects showed minimal cross-resistance between RAL and DTG: median FC to RAL was: 47.5 [0.49, 127.0], (n=176) and median FC to DTG was: 1.29 [0.45, 37.0], (n=176). Eight percent (15/183) of subjects had DTG FC >10 and 28% (53/183) had Q148+ additional mutations which is consistent with the INI-resistant viruses in the general HIV population (4.1.12.3.2). Good short term and long term responses to DTG were seen in subjects harbouring 143/155/66 historic integrase mutations; lower responses were observed in 148 pathways. Secondary IN mutations influenced response in 148 pathway but not in 143/155/66 pathway. Including all subjects (N=111) with data at Day 1 and Day 8, treatment emergent IN resistance was detected in few subjects (12%) under functional monotherapy; the only mutations that were identified have been previously described for the integrase class. From the 35 subjects with PDVF in the ITT-E population (N=183), 31 subjects had paired Baseline and time of virological failure samples. Of these, 15/31 had treatment-emergent mutations detected at virological failure. Treatment-emergent resistance was detected in virus harbouring a mutation at Q148 (at Baseline or historic) for 13/15 (87%) subjects.

Increasing Baseline DTG FC was significantly associated with decreasing antiviral activity, however, no precise phenotypic FC cut-off could be defined to effectively predict antiviral activity at both Day 8 and Week 24. For genotypic resistance groups, three baseline groups (No Q148, Q148+1, and Q148+2) were identified based on their

49 CONFIDENTIAL Module 2.7.2.4 Special Studies

differential impact on DTG antiviral response. The best antiviral responses were seen in the No Q148 group. The derived genotypic groups provide a robust and predictive genotypic guidance for response in this INI resistant population.

4.2.1. Phase III Clinical Studies

4.2.1.1. Studies of Treatment-Naive Subjects

Of the 825 treatment-naive subjects in ING113086 and ING114467 randomized to receive DTG 50 mg once daily, 38 had PDVF. None of these subjects had treatment emergent INI or NRTI primary resistance mutations through 48 Weeks of treatment, whereas subjects receiving comparator drugs (RAL or Atripla) were noted to have NRTI, INI and/or NNRTI resistance.

4.2.1.1.1. ING113086

Study Title: A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily compared to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naive adult subjects.

Location of Report: 5.3.5.1

Study Design: ING113086 is a Phase III randomized, double-blind, double dummy, active-controlled, multicenter, parallel group, fully-powered non-inferiority study. Subjects were randomized to DTG 50 mg once daily or 400 mg RAL twice daily, both in combination with either abacavir/lamivudine (ABC/3TC), or tenofovir/emtricitabine (TDF/FTC). Protocol defined virologic failure (PDVF) required two consecutive HIV-1 RNA values 50 c/mL HIV-1 RNA on or after Week 24. At the Week 96 visit, subjects randomized to RAL are discontinued from the study, while subjects randomized to DTG are given the opportunity to remain on the study while receiving DTG 50 mg once daily during the Open-label Phase of the study.

Viral genotyping and phenotyping study population

High response rates in study ING113086 were observed despite the application of a strict PDVF criterion – namely, two consecutive HIV-1 RNA values 50c/mL HIV-1 RNA on or after Week 24, which mandated withdrawal from the trial (if confirmed before Week 48) and testing for resistance. The majority of subjects who met PDVF in study ING113086 had low-level viremia: 75% of subjects in both arms with PDVF failed with <200 c/mL HIV-1 RNA (Table 37). All 20 subjects with PDVF on DTG had <1000 c/mL HIV-1 RNA at confirmed failure, while 3 (11%) of subjects with PDVF on RAL had >10,000 c/mL HIV-1 RNA at the time of confirmed failure (Table 37).

50 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 37 Distribution of HIV-1 RNA at Time of PDVF

DTG RAL 50 mg once daily 400 mg BID (N=411) (N=411) n (%) n (%) Subjects with PDVF 20 (5%) 28 (7%) Suspected PDVF HIV-1 RNA (c/mL) 50 to <200 13 (65) 23 (82) 200 to <400 2 (10) 1 (4) 400 to <1000 2 (10) 0 1000 to <10,000 2 (10) 1 (4) 10,000 to <50,000 1 (5) 0 50,000 to 100,000 0 3 (11) >100,000 0 0 Confirmed PDVF HIV-1 RNA (c/mL) 50 to <200 15 (75) 21 (75) 200 to <400 4 (20) 2 (7) 400 to <1000 1 (5) 2 (7) 1000 to <10,000 0 0 10,000 to <50,000 0 2 (7) 50,000 to 100,000 0 0 >100,000 0 1 (4) Data Source m5.3.5.1 ING113086 Week 48 CSR Table 7.23

As seen in Table 37, 20 subjects (5%) in the DTG treatment group met the definition of PDVF while 28 (7%) subjects in the RAL treatment group met the definition of PDVF. While subtypes were not obtained on all subjects, subjects predominantly had HIV-1 subtype B, with A1 being the next most common. In other subjects, a variety of subtypes were seen in small numbers, including AG, BF, C, F1, and G). Integrase, reverse transcriptase (RT) and protease (PR) genotypes and phenotypes were attempted at Baseline and time of PDVF for all subjects with PDVF.

Integrase genotyping and phenotyping results

In a secondary analysis, superiority of DTG vs. RAL was not concluded with respect to the proportion of subjects with genotypic or phenotypic evidence of INI resistance at time of PDVF by Week 48.

Eight subjects of the 20 with PDVF in the DTG treatment arm had IN genotype at both Baseline and at the time of PDVF, while 18 subjects of the 28 with PDVF in the RAL treatment arm had IN genotype at both Baseline and time of PDVF. None of the eight subjects in the DTG treatment arm had treatment emergent INI resistance mutations while 1/18 (6%) of the subjects on the RAL treatment arm had treatment emergent INI resistance mutations (Table 38).

Three subjects (3617, 3909, and 3713) had genotypic or phenotypic indication of treatment emergent integrase resistance and are discussed below.

51 CONFIDENTIAL Module 2.7.2.4 Special Studies

Subject 3617 was randomized to the RAL treatment group and received TDF/FTC as the nucleoside backbone. This subject had 3,346,333 c/mL HIV-1 RNA at Baseline, reached a nadir of 11,959 c/mL HIV-1 RNA at Week 2, and increased to 88,126 c/mL HIV-1 RNA at Week 24.

Of note in Subject 3617:

 Treatment emergent INI resistance mutations at Week 24 were T97T/A, E138E/D, V151V/I, and N155H.  Week 24 virus had a 34 fold change (FC) to RAL and 2.02 FC to DTG, as compared to 1.15 FC to RAL and 1.48 FC to DTG at Baseline.  Week 24 virus also had treatment emergent NRTI mutations A62A/V, K65K/R, K70K/E, and M184V with accompanying 1.44 FC to TDF and MAX FC to FTC. Two additional subjects (3909 and 3713) had treatment emergent elevated FC to RAL (Table 38). Subject 3909, who was randomized to the DTG group and received TDF/FTC, had 2.01 FC to RAL (0.96 FC to DTG) at PDVF (Week 32). As there were no treatment emergent INI resistance mutations at Week 32, all IN substitutions at Baseline and Week 32 were compared.

Of note in Subject 3909:

 Baseline virus had IN substitutions K14R, V32I, E48E/K, V72I, Y99F, L101I, V113I, S119P, T122I, T124A, T125A, G134N, K136T, K188R, V201I, T206S, Y227F, S255N, D256E, and S283G.  IN substitutions at Week 32 were identical to those observed at Baseline with the exception that E48K was a full substitution at Week 32. Subject 3713, who received RAL and TDF/FTC as the nucleoside backbone, had 1.62 FC to RAL (1.40 FC to DTG) at PDVF (Week 24). As there were no treatment emergent INI resistance mutations at Week 24, all IN substitutions at Baseline and Week 24 were compared.

Of note in Subject 3713:

 Baseline virus had IN substitutions E11E/D, V31I, V72I, L101I, V113I, V201I, T206S, K215T, Q216Q/K, T218I, I220L, V234L, and D256E.  IN substitutions at Week 24 were identical to those observed at Baseline with the exceptions that E11D was a full substitution at Week 24 and Q216 was fully Q at Week 24.

52 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 38 Treatment Emergent Phenotypic or Genotypic Evidence of Integrase Inhibitor Resistance

DTG RAL Subjects with PDVF N=20 N=28 IN Genotypic Results at Baseline and PDVF N=8 N=18 INI resistance mutations 0 1/18 (6%)a Phenotypic evidence of INI resistance Subject 3617 RAL FC = 34a Subject 3909 RAL FC = 2.01 Subject 3713 RAL FC = 1.62 a. T97T/A, E138E/D, V151V/I, N155H Data Source: ING113086 Week 48 CSR Table 7.10, Listing 44

Reverse transcriptase genotyping and phenotyping results

Twelve of the 20 subjects with PDVF in the DTG treatment group had PR/RT genotype at both Baseline and time of PDVF, while 19 of the 28 with PDVF in the RAL treatment group had PR/RT genotype at both Baseline and time of PDVF (Table 39). None of the twelve subjects with Baseline and PDVF RT and PR genotypic data in the DTG treatment arm had treatment emergent NRTI resistance mutations while 4/19 (21%) of the subjects on the RAL treatment arm had treatment emergent NRTI resistance mutations (Table 39). In addition to Subject 3617 (NRTI treatment emergent mutations A62A/V, K65K/R, K70K/E, and M184V) described above, subjects 3173, 3294, and 4424 had treatment emergent NRTI resistance mutations at PDVF.

 Subject 3173, who was in the RAL treatment group and received TDF/FTC as the NRTI backbone, had treatment emergent mutation M184M/I at PDVF (Week 24) with no accompanying phenotypic change to TDF or FTC.  Subject 3294, who was randomized to RAL and received TDF/FTC as the NRTI backbone, had treatment emergent mutation A62A/V at PDVF (Week 24) with no phenotypic change to TDF or FTC.  Subject 4424, who was randomized to RAL and received ABC/3TC as the NRTI backbone, had treatment emergent mutation M184M/V with 2.56 FC to ABC and MAX FC to 3TC.

Table 39 Treatment Emergent Genotypic Evidence of NRTI Resistance

DTG RAL Subjects with PDVF N=20 N=28 RT/PR Genotype Results at BL and PDVF 12 19 Subjects with NRTI resistance mutations 0 4/19 (21%) Genotypic Evidence of NRTI resistance 3617 A62A/V, K65K/R, K70K/E, M184V 3173 M184M/I 3294 A62A/V 4424 M184M/V Data Source: ING113086 Week 48 CSR Table 7.22, Listing 43

53 CONFIDENTIAL Module 2.7.2.4 Special Studies

If subjects with PDVF with <400 c/mL HIV-1 RNA are censored from this analysis, there were only 5 subjects with PDVF in the DTG treatment group, none of whom had any treatment emergent resistance mutations, and only 4 subjects with PDVF in the RAL treatment group, including the one subject with RAL resistance mutations T97T/A, E138E/D, V151V/I, and N155H and NRTI resistance mutations A62A/V, K65K/R, K70K/E, and M184V. 4.2.1.1.2. ING114467

Study Title: A Phase III, randomized, double-blind study of the safety and efficacy of DTG plus abacavir-lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects

Location of Report: 5.3.5.1

Study Design: ING114467 is a Phase 3 randomized, stratified, double-blind, double- placebo, active-controlled, multicentre, parallel group, fully-powered non-inferiority study. Subjects were randomized 1:1 to receive DTG 50 mg plus ABC/3TC FDC therapy once daily or Atripla once daily. Subjects were stratified by screening HIV-1 RNA and CD4 cell count. PDVF required two consecutive HIV-1 RNA values 50 c/mL HIV-1 RNA on or after Week 24. The primary analysis took place after the last subject completed 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 and Week 144 on study.

Viral Genotyping and Phenotyping Study Population

High response rates were observed despite the application of a strict PDVF criterion – namely, two consecutive HIV-1 RNA values 50 c/mL HIV-1 RNA on or after Week 24, which mandated withdrawal from the trial (if confirmed before Week 48) and testing for resistance. The majority of subjects who met PDVF in study ING114467 had low-level viremia (23/35, or 66% of subjects in both treatment groups with PDVF failed with <200 c/mL HIV-1 RNA). At confirmed failure 16/18 (89%) subjects with PDVF on DTG + ABC/3TC had <200 c/mL HIV-1 RNA, while 11/17 (65%) of subjects with PDVF on Atripla had <200 c/mL HIV-1 RNA (Table 40).

54 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 40 Distribution of HIV-1 RNA Results at Suspected and Confirmation of PDVF

DTG Atripla 50 mg + ABC/3TC QD QD N=414 N=419 n (%) n (%) Subjects with PDVF 18 (4) 17 (4) Suspected PDVF HIV-1 RNA (c/mL) 50 to <200 12 (67) 11 (65) 200 to <400 3 (17) 0 400 to <1000 1 (6) 1 (6) 1000 to <10,000 2 (11) 2 (12) 10,000 to <50,000 0 2 (12) 50,000 to 100,000 0 1 (6) >100,000 0 0 Confirmed PDVF HIV-1RNA (c/mL) 50 to <200 16 (89) 11 (65) 200 to <400 0 3 (18) 400 to <1000 0 1 (6) 1000 to <10,000 1 (6) 1 (6) 10,000 to <50,000 1 (6) 0 50,000 to 100,000 0 0 >100,000 0 1 (6) Data Source: m5.3.5.1 ING114467 Week 48 CSR Table 7.29

As seen in Table 40, 18/414 subjects (4%) in the DTG + ABC/3TC treatment group met the definition of PDVF and 17/419 (4%) subjects in the Atripla treatment group met the definition of PDVF. While subtype was not obtained for every subject, the vast majority of subjects had HIV-1 subtype B, with subtypes C, G, BF, and AG being represented by just one or (in the case of Subtype C) two subjects). Integrase, reverse transcriptase (RT) and protease (PR) genotypes and phenotypes were attempted at Baseline and time of PVDF for subjects with PDVF and obtained for 11 in the DTG + ABC/3TC treatment group and 9 subjects in the Atripla treatment group.

Integrase Genotyping and Phenotyping Results

Seven subjects in the DTG + ABC/3TC treatment arm had IN genotype and phenotype at both Baseline and at the time of PDVF, while 7 subjects in the Atripla treatment arm had IN genotype at and phenotype at both Baseline and time of PDVF.

None of the 7 subjects in either the DTG + ABC/3TC treatment group or the Atripla treatment group had treatment emergent INI resistance mutations. One subject (7912) in the DTG + ABC/3TC treatment group had a treatment emergent substitution E157Q/P at Week 24, without accompanying DTG phenotypic resistance (Table 41).

55 CONFIDENTIAL Module 2.7.2.4 Special Studies

Of note in Subject 7912:

 Treatment emergent IN substitution at Week 24 was E157Q/P. Replicative capacity could not be determined.  Week 24 virus had a 1.13 fold change (FC) to DTG and 1.26 FC to RAL, as compared to 1.02 FC to DTG and 1.22 FC to RAL at Baseline.  HIV-1 RNA at Baseline was 330,641 c/mL, reached a nadir of 79 c/mL at Week 12, and increased to 275 c/mL at Week 24.

Table 41 Treatment Emergent Genotypic or Phenotypic Evidence of Integrase Inhibitor Resistance

DTG + ABC/3TC Atripla Subjects with PDVF N=18 N=17 IN Genotypic Results at PDVF N=7 N=7 IN substitution E157Q/P 1a None IN Phenotypic Results at PDVF N=7 N=7 Increase in DTG FC None a None a. Subject 7912; IN E157Q/P at Week 24. DTG FC = 1.13; RAL FC = 1.26 Data Source: ING114467 Week 48 CSR Table 12.2 and Table 12.5

Non-Nucleoside Genotyping and Phenotyping Results

Nine subjects in the DTG + ABC/3TC treatment group had NNRTI genotypic and phenotypic data at both Baseline and time of PDVF. There were no treatment emergent NNRTI resistance mutations or treatment emergent NNRTI phenotypic changes in any of the subjects with PDVF in the DTG + ABC/3TC treatment group.

Nine in the Atripla treatment group had NNRTI genotypic and phenotypic data at both Baseline and time of PDVF. Four subjects (5506, 5576, 6033, and 6856) in the Atripla treatment group had treatment emergent NNRTI resistance mutations. Phenotypic changes to EFV were observed in three of these subjects (Table 42).

Of note in Subject 5506:

 Treatment emergent NNRTI resistance mutation at Week 48 was K101E.  Week 48 virus had a 1.9 FC to EFV, as compared to 0.75 FC at Baseline.  HIV-1 RNA at Baseline was 2212 c/mL, reached <50 c/mL at Week 16. Suspected Virologic Failure at Week 24 was not confirmed. HIV-1 RNA was 992 c/mL at Week 48. Of note in Subject 5576:

 Treatment emergent NNRTI resistance mutation at Week 32 was K103K/N.  Week 48 virus had a 14 FC to EFV, as compared to 1.66 FC at Baseline.

56 CONFIDENTIAL Module 2.7.2.4 Special Studies

 HIV-1 RNA at Baseline was 53,961 c/mL, reached a nadir of <50 c/mL at Week 16, and increased to 6882 c/mL at Week 32. Of note in Subject 6033:

 Treatment emergent NNRTI resistance mutations at Week 24 were K103N and G190G/A.  Week 24 virus had a 22 fold change (FC) to EFV, as compared to 1.03 FC to at Baseline.  HIV-1 RNA at Baseline was 112,284 c/mL, reached a nadir of <50 c/mL at Week 16, and increased to 40,751 c/mL at Week 24. Of note in Subject 6856:

 Treatment emergent NNRTI resistance mutation at Week 24 was G190G/A. Additional treatment emergent NNRTI mutations were K103R and V179V/D.  Week 24 virus had a 20 fold change (FC) to EFV, as compared to 1.05 FC to at Baseline.  HIV-1 RNA at Baseline was 5218 c/mL, reached a nadir of 89 c/mL at Week 16, and increased to 29.777 c/mL at Week 24.

Table 42 Treatment Emergent Genotypic or Phenotypic Evidence of NNRTI Resistance

Mutation NNRTI Phenotype Treatment Subjects with PDVF N=17 Group NNRTI Genotype and 9 9 Phenotype Results at PDVF 5506 K101E 1.9 FC to EFV Atripla 5576 K103K/N 14 FC to EFV Atripla 6033 K103N, 22 FC to EFV Atripla G190G/A 6856 G190G/A 20 FC to EFV Atripla Data Source: ING114467 Week 48 CSR Table 12.4 and Table 12.5

Nucleoside Reverse Transcriptase Genotyping and Phenotyping Results

Nine with PDVF in the DTG + ABC/3TC treatment group had NRTI and PI genotypic and phenotypic data at both Baseline and time of PDVF, while 9 in the Atripla treatment group had NRTI and PI genotypic and phenotypic data at both Baseline and time of PDVF.

There were no treatment emergent PI resistance mutations in either treatment group.

57 CONFIDENTIAL Module 2.7.2.4 Special Studies

There were no treatment emergent NRTI resistance mutations in any of the subjects with PDVF in the DTG + ABC/3TC treatment group. One subject (7762) in the DTG + ABC/3TC treatment group had a treatment emergent phenotypic change to DDI without accompanying genotypic changes (Table 43).

One subject in the Atripla treatment group (6707) had the treatment emergent NRTI resistance mutation K65K/R. This subject did not have treatment emergent phenotypic changes, although the Monogram Net Assessment predicted resistance to all NRTIs with the exception of AZT and d4T (Table 43).

Of note in Subject 6707:

 Treatment emergent NRTI resistance mutation at Week 24 was K65K/R.  Week 24 virus had a 0.69 FC to TDF and 1.27 FC to FTC, although the Monogram Biosciences Net Assessment predicted resistance to FC to ABC, DDI, FTC, 3TC, and TDF.  HIV-1 RNA at Baseline was 376,229 c/mL. HIV-1 RNA was 131 c/mL at Week 24. Of note in Subject 7762:

 Week 32 virus had a 1.39 FC to DDI (clinical cut off = 1.3), without treatment emergent NRTI resistance mutations.  HIV-1 RNA at Baseline was 564,854 c/mL, was <50 c/mL at Week 12 and Week 24, and increased to 66 c/mL at Week 32.

Table 43 Treatment Emergent Genotypic Evidence of NRTI Resistance

Mutation NRTI Phenotype Treatment Subjects with PDVF N=17 Group NRTI Genotype and 9 9 Phenotype Results at PDVF 6707 K65K/R No change Atripla 7762 0 1.39 FC to DDI DTG + ABC/3TC Data Source: ING114467 Week 48 CSR Table 12.4 and Table 12.5

If subjects with PDVF with <400 c/mL HIV-1 RNA are censored from this analysis, there were only 3 subjects with PDVF in the DTG + ABC/3TC treatment group, none of whom had any treatment emergent resistance mutations, and only 6 subjects with PDVF in the Atripla treatment group, including the four subjects with NNRTI resistance mutations.

58 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.2.1.2. Studies of Treatment-Experienced (INI-naive) Subjects

Results from this Week 24 interim analysis of ING111762 show DTG has a higher barrier to resistance in this patient population. A statistically significant difference in favor of DTG was demonstrated by planned virologic analyses for emergent integrase resistance. In a pre-specified analysis, there was a statistically significant difference in favor of DTG for the proportion of mITT-E subjects harbouring virus with evidence of INI Resistance by Week 24 (DTG: 2/354 (0.6%); RAL: 10/361(2.8%); p=0.016). An additional prespecified analysis using a common FC cutoff to determine phenotypic resistance to RAL and DTG also confirmed a statistically significant difference in favor of DTG.

4.2.1.2.1. ING111762

Study Title: A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral Therapy-Experienced Adults - Week 24 Results

Location of Report: 5.3.5.1

Study Design: ING111762 is a Phase III randomized, double-blind, active-controlled, multicenter, parallel group, fully-powered non-inferiority study. Subjects were randomized to DTG 50 mg once daily or RAL 400 mg twice daily (BID), both in combination with investigator selected background therapy based on Screening and historic resistance results. The background therapy was limited to no more than two antiretroviral agents. At the Week 48 visit, subjects randomized to RAL will be discontinued from the study (if RAL is approved and commercially available in the country), while subjects randomized to DTG will be given the opportunity to remain on the study while receiving DTG 50 mg once daily during the Open-label Phase of the study.

Protocol-defined virologic failure (PDVF) was defined as the following:

Virologic Non-response

 A decrease in plasma HIV-1 RNA of less than 1 log10 c/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is <400 c/mL.  Confirmed plasma HIV-1 RNA levels ≥400 c/mL on or after Week 24. Virologic Rebound

 Confirmed rebound in plasma HIV-1 RNA levels to ≥400 c/mL after prior confirmed suppression to <400 c/mL.

 Confirmed plasma HIV-1 RNA levels >1 log10 c/mL above the nadir value where nadir is the lowest HIV-1 RNA value ≥400 c/mL.

59 CONFIDENTIAL Module 2.7.2.4 Special Studies

Results:

PDVF Frequency

Virologic failure through Week 24 occurred earlier and more frequently in the RAL arm (Table 44). At Week 16 there were 10 (3%) confirmed virologic failures for the DTG arm and 21 (6%) for the RAL arm. At Week 24 there were respectively 14 (4%) and 34 (9%) virologic failures for DTG and RAL. The difference through Week 24 was driven by a greater proportion of virologic non-response in the RAL arm 5% versus <1% in the DTG arm, with a similar proportion of virologic rebound in both arms (4%). In terms focused on subjects experiencing virologic failure, through Week24 there was a greater proportion of virologic non-response in the RAL arm with 19 non-responders of 34 PDVFs, compared with greater proportion of virologic rebounders with 13 rebounders of 14 PDVFs in the DTG arm.

Table 44 Cumulative Summary of Protocol-Defined Virologic Failures by Visit (mITT-E) Through Week 24

Week DTG 50 mg Once Daily RAL 400 mg BID N=354 N=361 n/N (%) n/N (%) Week 8 1 (<1) 1 (<1) Rebound 1 (<1) 1 (<1) Week 12 4 (1) 6 (2) Rebound 4 (1) 6 (2) Week 16 10 (3) 21 (6) Virologic non-response 0 13(4) Rebound 10 (3) 8(2) Week 24 14 (4) 34 (9) Virologic non-response 1 (<1) 19 (5) Rebound 13 (4) 15 (4) Data Source: m5.3.5.1 ING111762 Week 24 CSR Table 7.10.

Genotypic and Phenotypic Accountability

Integrase PhenoSense and PhenoSense GT assay was performed at Monogram BioSciences (MBI) as well as PhenoSense Entry and Trofile (the latter two only when requested by investigator) to assess resistance to other ARTs for eligibility purposes and to aid in the selection of the background regimen. All Baseline and On-treatment genotypic (Table 45) and phenotypic testing (Table 46) were conducted at MBI.

Due to integrase assay failure, paired data (baseline and time of PDVF) for IN resistance was not available for 5/14 DTG PDVF samples and 7/34 RAL samples (Data Source: ING111762 Week 24 Clinical Study ReportTable 7.10, Table 12.2 for genotypic and Table 12.40 for phenotypic). This is typically due to viral load < 500 copies/mL, reduced viral fitness, or compromised sample collection/handling. One exception is Subject 2785,

60 CONFIDENTIAL Module 2.7.2.4 Special Studies who does not have paired data because a sample was not available at the suspected PDVF timepoint..

Table 45 Genotypes Available in PDVF Genotypic Population through Week 24

Genotype DTG 50 mg Once Daily RAL 400 mg BID Assessment N=11 N=31 n (%) n (%) Integrase Screen 0 2 (6) Baseline Sample 11 (100) 30 (97) On-Treatment PDVF Sample 9 (82) 27 (87) On-Treatment Non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 9 (82) 27 (87) Baseline and On-Treatment Non-PDVF 0 1 (3)

Reverse Transcriptase Screen 11 (100) 31 (100) Baseline Sample 11 (100) 31 (100) On-Treatment PDVF Sample 11 (100) 31 (100) On-Treatment Non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 11 (100) 31 (100) Baseline and On-Treatment Non-PDVF 0 1 (3)

Protease Screen 11 (100) 31 (100) Baseline Sample 11 (100) 31 (100) On-Treatment PDVF Sample 11 (100) 31 (100) On-Treatment Non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 11 (100) 31 (100) Baseline and On-Treatment Non-PDVF 0 1 (3) Data Source: ING111762 Week 24 CSR Table 12.1

61 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 46 Phenotypes Available in PDVF Phenotypic Population through Week 24

Phenotype DTG 50 mg Once Daily RAL 400 mg BID Assessment N=11 N=30 n (%) n (%) Integrase Screen 0 2 (7) Baseline Sample 11 (100) 29 (97) On-Treatment PDVF Sample 9 (82) 27 (90) On-Treatment non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 9 (82) 27 (90) Baseline and On-Treatment non-PDVF 0 1 (3) Reverse Transcriptase Screen 11 (100) 30 (100) Baseline Sample 11 (100) 30 (100) On-Treatment PDVF Sample 11 (100) 30 (100) On-Treatment non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 11 (100) 30 (100) Baseline and On-Treatment non-PDVF 0 1 (3) Non Reverse Transcriptase Screen 11 (100) 30 (100) Baseline Sample 11 (100) 30 (100) On-Treatment PDVF Sample 11 (100) 30 (100) On-Treatment non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 11 (100) 30 (100) Baseline and On-Treatment non-PDVF 0 1 (3) Protease Screen 11 (100) 30 (100) Baseline Sample 11 (100) 30 (100) On-Treatment PDVF Sample 11 (100) 30 (100) On-Treatment non-PDVF Sample 0 1 (3) Baseline and On-Treatment PDVF 11 (100) 30 (100) Baseline and On-Treatment non-PDVF 0 1 (3) CCR5 Inhibitor Screen 10 (91) 27 (90) Baseline Sample 10 (91) 27 (90) On-Treatment PDVF Sample 1 (9) 3 (10) On-Treatment non-PDVF Sample 0 0 Baseline and On-Treatment PDVF 1 (9) 3 (10) Baseline and On-Treatment non-PDVF 0 0

62 CONFIDENTIAL Module 2.7.2.4 Special Studies

Phenotype DTG 50 mg Once Daily RAL 400 mg BID Assessment N=11 N=30 n (%) n (%) Fusion Screen 7 (64) 23 (77) Baseline Sample 7 (64) 23 (77) On-Treatment PDVF Sample 1 (9) 1 (3) On-Treatment non-PDVF Sample 0 0 Baseline and On-Treatment PDVF 0 1 (3) Baseline and On-Treatment non-PDVF 0 0 Data Source: ING111762 CSR Table 12.37

Proportion of Subjects with Detectable Virus with Evidence of INI Resistance by Week 24 (mITT-E population)

For the mITT-E population, 0.6% of subjects receiving DTG and 2.8% of subjects receiving RAL had evidence of treatment emergent genotypic or phenotypic INI resistance at the time of protocol defined virologic failure by Week 24 (Table 47). The treatment difference was statistically significant in favor of DTG (p=0.016, less than the pre-specified two-sided 5% type I error cutoff) based on a pre-specified analysis of this key secondary endpoint.

Genotypic evidence of INI resistance was determined according to the presence of IN substitutions associated with development of resistance to RAL or DTG (as specified in the RAP) that were not present at Baseline.

Phenotypic evidence of INI resistance was determined as FC in IC50 relative to wildtype, as provided by the PhenoSense HIV assays from Monogram Biosciences Inc., above the 1.5 cutoff for RAL or 2.5 cutoff for DTG (standard cut-off used by Monogram Biosciences Inc. until clinical or biological cut-off has been determined), if not above the cutoff at Baseline.

63 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 47 Summary of Analysis for Proportion of Subjects with Detectable Virus that has Treatment Emergent Genotypic or Phenotypic Evidence of INI Resistance by Week 24 (mITT-E Population)

Treatment Number of Adjusted Difference in P-Valuea Responders / Proportionb (95% CI) Total Assessed (DTG - RAL)

DTG 50 mg Once Daily 2 / 354 (0.6%)

RAL 400 mg BID 10 / 361 (2.8%) -2.3 (-4.2, -0.4) 0.016 Data Source: ING111762 Week 24 CSR Table 7.14 a. Difference: Proportion on DTG - Proportion on RAL. b. Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: baseline HIV-1 RNA, (<=50,000 vs. >50,000 c/mL), DRV/r use without primary PI mutations (yes vs. no), and baseline PSS (2 vs. <2) to background regimen. PSS based on full susceptibility, category ‘2’ includes two subjects with PSS=3. Proportion of Subjects with Phenotypic Resistance to RAL and DTG using a Common Fold Change Cutoff

A statistically significant difference in favor of DTG was observed with the planned sensitivity analysis in Table 48 using a common FC cutoff of 2.5 to assess phenotypic resistance to DTG and RAL.

Table 48 Summary of Sensitivity Analysis for Proportion of Subjects with Detectable Virus that has Treatment Emergent Phenotypic Evidence of INI Resistance by Week 24

Treatment Number Meeting Difference in Adjusted Difference in Criteria / Number Proportiona (95% Proportionb (%) (95% CI) Assessed CI) DTG 50 mg 2 / 354 (<1%) Once Daily RAL 400 mg 9 / 361 (2%) -1.9 (-3.7, -0.1) -2.0 (-3.8, -0.2) BID Data Source: ING111762 Week 24 CSR Table 7.16 a. Difference: Proportion on DTG - Proportion on RAL. b. Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: baseline HIV-1 RNA, (<=50,000 vs. >50,000 c/mL), DRV/r use without primary PI mutations (yes vs. no), and baseline PSS (2 vs. <2) to background regimen. PSS based on full susceptibility, category ‘2’ includes two subjects with PSS=3.

Treatment Emergent INI Genotypic Resistance

There were 9 subjects experiencing PDVF in the DTG arm and 27 in the RAL arm with matched baseline and PDVF resistance testing available. Overall, 2 of the 9 (22%) subjects with confirmed virologic failure in the DTG treatment arm had treatment emergent INI resistance mutations which were both at position R263 in the IN open reading frame (Table 49). No primary or secondary resistance mutations commonly

64 CONFIDENTIAL Module 2.7.2.4 Special Studies

selected during RAL therapy were observed. Of 27 subjects with confirmed virologic failure on the RAL treatment arm, 9 (33%) had treatment emergent INI resistance mutations commonly observed during RAL therapy including the primary resistance mutations at Y143, Q148, and N155 as well as associated secondary mutations.

Table 49 Treatment Emergent Integrase Substitutions from Baseline (Week 24 PDVF Genotypic Population - IN results at Baseline and time of PDVF)

Codona Treatment Emergent IN DTG 50 mg Once Daily RAL 400 mg BID Genotype N=9 N=27 n (%) n (%) Any 2 (22) 9 (33) 68 L68L/V 0 1 (4) 74 L74L/M 0 1 (4) 92 E92E/Q 0 1 (4) 97 T97A, T97T/A 0 3 (11) 140 G140A, G140S 0 2 (7) Y143Y/C, Y143R, 143 Y143Y/R/H/C 0 3 (11) 148 Q148H, Q148Q/R 0 3 (11) 151 V151I, V151V/I 0 2 (7) 155 N155H, N155N/H 0 5 (19) 157 E157E/Q 0 1 (4) 163 G163K 0 1 (4) 263 R263K, R263R/K* 2 (22) 0 Data Source: ING111762 Week 24 CSR Table 12.2 a. Per RAP definition RAL or DTG associated resistance mutations: H51Y, T66A, T66I, T66K, L68V, L68I, L74I, L74M, L74R4, E92Q, E92V, Q95K, T97A, G118R, E138A, E138K, E138T, G140A, G140C, G140S, Y143C, Y143H, Y143R, P145S, S147G, Q148H, Q148K, Q148R, V151I, V151L, S153F, S153Y, N155H, E157Q, G163R, G163K, G193E, R263K. IN substitutions listed above in bold were defined from the Stanford database (http://hivdb6.stanford.edu) with a score of >45. Other mutations are secondary IN resistance mutations from the Stanford database detected during INI clinical investigation, or were observed during other clinical investigation or in vitro studies with DTG.

Treatment Emergent INI Phenotypic Resistance

Within the DTG arm all nine subject samples had a DTG fold change of below the Mongram Biosciences FC cutoff <2.5; all nine RAL subject samples had RAL fold change of <1.5 (Monogram Biosciences RAL cutoff). Within the RAL arm three of the subject samples had a DTG fold change of ≥2.5 and nine had RAL fold changes of ≥1.5 (Table 50).

65 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 50 Summary of Fold Change to DTG and RAL at Time of PDVF (Week 24 PDVF Phenotypic Population)

Investigational Product Fold-Change Compared DTG 50 mg RAL 400 mg to Wildtype Virus Once Daily Twice Daily N=11 N=30 n (%) n (%) DTG n 9 27 0 to 2.5 9 (82) 24 (80) >2.5 to 4 0 1 (3) >4 to 8 0 1 (3) >8 to 10 0 0 >10 to 15 0 0 >15 to 20 0 1 (3) >20 to 25 0 0 >25 0 0 Median (Range) 0.92 (0.71 – 1.93) 1.04 (0.67 – 18.00) RAL n 9 27 0 to 1.5 9 (82) 18 (60) >1.5 to 4 0 2 (7) >4 to 8 0 0 >8 to 10 0 0 >10 to 20 0 0 >20 to maximum of assay 0 4 (13) limit >maximum of assay limit 0 3 (10) Median (Range) 0.93 (0.80 – 1.12) 1.11 (0.59 – 117.00) Data Source: ING111762 Week 24 CSR Table 12.39

Paired Analysis of Day 1 and Virologic Failure Integrase Genotypic and Phenotypic Results

Table 51 includes subjects on DTG or RAL with emergent integrase genotypic or phenotypic resistance. Additional details are found in case narrative sections, Subjects With Treatment Emergent Resistance and Subjects Without Treatment Emergent Resistance.

There were two subjects in the DTG arm (Subjects 672 and 2568) with emergent integrase-defined substitutions. Both had experienced virologic rebound instead of non- response, had no defined integrase resistance substitutions at Baseline, and acquired a substitution at R263 in the integrase open reading frame. In each case the DTG fold change was < 2, as was the maximum RAL fold change. Neither of these subjects with emergent substitutions at R263 had RAL-associated secondary mutations at Baseline.

66 CONFIDENTIAL Module 2.7.2.4 Special Studies

Subject 672 was a virologic rebound PDVF at Week16 and had treatment emergent R263R/K in integrase with no change in DTG susceptibility with fold change from Baseline 0.96 to PDVF 1.12. This subject had an initial HIV-1 RNA response from Day 1: 41179 c/mL to Week 4: <50 c/mL, followed by HIV-1 RNA >50 c/mL with sequential HIV-1 RNA values of 57, 1305, 308, and Week 16 PDVF timepoint of 6446 c/mL, followed by confirmation timepoint of 903 c/mL (Data Source: ING111762 Week 24 CSR ICH Listing 9). The BL PSSf score was 2 and GSS score was 2 on a regimen of Tenofovir and Darunavir/r. The Week4 C0 value was 0.5706 g/mL. The fluctuating RNA between Day 1 and PDVF confirmation suggests adherence may have been incomplete.

Subject 2568 was a virologic rebound PDVF at Week 24 and had treatment emergent R263K in integrase with change in DTG susceptibility fold change from Baseline 0.92 to PDVF 1.93. For Subject 2568 a novel additional and conserved IN substitution V260I proximal to R263 was also present. This subject had an initial HIV-1 RNA response from Day 1: 876610 c/mL to Week 4: 1461 c/mL, followed by HIV-1 RNA 684 c/mL with sequential HIV-1 RNA values of 1852, 900, and at Week 24 PDVF timepoint 9367 c/mL followed by confirmation timepoint of 59400 c/mL (Data Source: ING111762 Week 24 CSR ICH Listing 9). The BL PSSf score was 1 and GSS score was 0.75 on a regimen of tenofovir (inactive) and efavirenz. The Week4 C0 value was 0 and Week 24 C0 was 0.2525. The Week 4 C0 value of 0 suggests adherence may have been incomplete.

There were nine subjects in the RAL arm with emergent clinically relevant RAL associated genotypic integrase resistance, seven of which were virologic non-responders, and two were rebounders. Five of these nine subjects in the RAL arm had emergent DTG fold change >2 (Subjects 2427, 2769, 963, 785, and 260). Four of these five experienced PDVF as virologic non-response, two at Week 16 and two at Week 24, and one experienced PDVF as virologic rebound. One of the five (Subject 260) with >19 years ART experience (but no reported RAL experience) showed at Baseline the RAL primary resistance mutation Y143R (plus secondary L74I/M) and at PDVF had Y143Y/C, Q148Q/R (plus secondaries L68L/V, L74L/M/I, G140A, and E157E/Q). This subject also had greater than maximum RAL fold change at Baseline and at PDVF. All five subjects with DTG FC >2 acquired (new) RAL associated primary resistance mutations at Y143 and/or Q148, or N155 at PDVF, plus additional secondary resistance mutations.

67 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 51 Summary of Subjects with Paired Day 1 and PDVF IN Genotype and Phenotype Exhibiting Genotypic or Phenotypic Changes Through Week 24

Arm / PDVF PSSf / Virologic HIV-1 RNA c/mL DTG FC RAL FC IN Genotype Subj Visit GSS Failure Baseline PDVF Baseline PDVF Baseline PDVF Baseline PDVF DTG / Week 2 / 2 Rebound 41179 6446 0.96 1.12 1.02 0.94 None R263R/K 672 16 DTG / Week 1 / 0.75 Rebound 876610 9367 0.92 1.93 1.11 1.12 None R263K 2568 24 RAL / Week 2 / 1.25 Virologic non- 98571 10725 0.71 18 >Maxa >Max L74I/M, L68L/V, L74L/M/I, G140A, 260 16 response Y143Rb Y143Y/C, Q148Q/R, E157E/Q RAL / Week 1 / 1 Virologic non- 641416 84973 1.3 3.73 1.18 117 None E92E/Q, T97T/A, V151V/I, 2769 16 response N155H RAL / Week 0 / 0 Virologic non- 63449 58433 1.04 1.27 1.46 114 None T97A, Y143R 1146 16 response RAL / Week 1 / 1 Virologic non- 18441 2300 0.83 0.92 1.04 98 L74I L74I, Y143Y/R/H/C, Q148Q/R 2472 16 response RAL / Week 1 / 1 Virologic non- 131377 7203 1.28 1.89 1.01 >Max None L74L/M, T97T/A, V151I, N155H, 419 24 response G163K RAL / Week 2 / 1 Virologic non- 856849 28931 1.13 4.12 1.23 >Max E157Q G140S, Q148H, E157Q 963 24 response RAL / Week 1 / 1 Rebound 936821 10472 1 2.12 0.96 22 L74I L74I, N155H 2427 24 RAL / Week 2 / 2 Virologic non- 28814 2734 1.14 0.89 1.14 1.44 None N155N/H 2688 24 response RAL / Week 1 / 1 Rebound 535742 3007185 0.92 1.38 1.09 3.78 L74I L74I, N155N/H 9088 24 Data Source: ING111762 Week 24 CSR Table 12.59 and Other Listing 52 a Greater than maximum measureable in assay fold change resistance = >114.82. b Per RAP definition RAL or DTG associated resistance mutations: L74M, L74I, T97A, E92Q, E138A, E138K, G140S, Y143C, Y143H, Y143R, Q148H, Q148K, Q148R, V151I, N155H, S153Y, S153F, G163K, G163R, G193E, R263K.

68 CONFIDENTIAL Module 2.7.2.4 Special Studies

Treatment Emergent Non-INI Resistance

There were numerically more examples of emergent resistance to the background regimen in the RAL arm (6/351 versus 3/354 in the DTG arm), but the treatment difference was not statistically significant owing to the small number of cases (Table 52).

There were 3 subjects on DTG with emergent resistance to BR at PDVF are summarized herein; one also had emergent INI resistance. Subject 2568: received tenofovir and efavirenz and had a PSSf of 1 and GSS of 0.75. At Week 24 PDVF the PSSf and GSS score both changed to zero as NNRTI mutation G190S emerged, and integrase substitution R263K emerged.

Subject 1067: received tenofovir and darunavir/r and had aPSSf of 2 and GSS of 1.75. At Week 16 PDVF the PSSf score remained 2 while GSS score changed to 1.50 according to Stanford HIV/db guidance, but no primary resistance mutation emerged, and no integrase substitutions emerged.

Subject 941: received tenofovir and atazanavir/r and had a PSSf score of 2 and GSS of 2.0. At Week 12 PDVF the PSSf score remained 2 while GSS score changed to 1.25 and the NNRTI mutation K101P/Q emerged, and no integrase substitutions emerged.

In the RAL arm, four subjects (Subjects 260, 977, 2427, and 963) had treatment emergent background regimen resistance and emergent INI resistance (Data Source: ING111762 Week 24 CSR Other Listing 50). As mentioned previously, Subject 260 showed at Baseline the RAL primary resistance mutation Y143R plus secondary L74I/M. Three other PDVF subjects in the RAL arm (Subjects 2201 and 2360) with treatment emergent background resistance did not have emergent integrase resistance at PDVF.

Table 52 Summary of Emergence of Genotypic and/or Phenotypic Resistance to the Background Regimen at Time of PDVF (mITT-E Population)

Treatment Number meeting Difference in Adjusted Difference Criteria / Total Proportion (95% CI) in Proportiona (95% Assessed (DTG - RAL) CI) (DTG - RAL) DTG 50 mg Once Daily 3 / 354 (<1%) RAL 400 mg BID 6 / 361 (2%) -0.8 (-2.48, 0.8) -0.8 (-2.48, 0.8) Data Source: ING111762 Week 24 CSR Table 7.30. a. Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: baseline HIV-1 RNA (<=50,000 vs. >50,000 c/mL), DRV/r use without primary PI mutations (yes vs. no), and baseline PSS (2 vs. <2) to background regimen. PSS based on full susceptibility, category ‘2’ includes two subjects with PSS=3.

69 CONFIDENTIAL Module 2.7.2.4 Special Studies

Week 48 Analysis Based on Data to Date

The Week 48 PDVF Genotypic and Phenotypic populations were used to assess the occurrence of PDVF and the development of genotypic and/or phenotypic INI resistance between Week 24 and Week 48 (based on data through Week 48 to date).

Additional summaries of genotypic and phenotypic analysis through Week 48 are provided in the source tables.

Comparison of PDVF Protocol Defined Virologic Failure by Visit (mITT-E Population): Week 24 Through Week 48

Data was also available for subjects through Week 48 during which time an additional 4 subjects experienced virologic rebound on DTG for total of 18 (5%) PDVFs, and for RAL an additional 8 subjects experienced virologic rebound for a total of 42 (12%) PDVFs (Table 53).

Table 53 Cumulative Summary of Protocol-Defined Virologic Failures by Visit (mITT-E Population): Week 24 Through Week 48

Week DTG 50 mg Once Daily RAL 400 mg BID N=354 N=361 n/N (%) n/N (%) Week 24 14 (4) 34 (9) Virologic non-response 1 (<1) 19 (5) Rebound 13 (4) 15 (4) Week 32 18 (5) 37 (10) Virologic non-response 2 (<1) 19 (5) Rebound 13 (4) 15 (4) Week 40 18 (5) 41 (11) Virologic non-response 2 (<1) 19 (5) Rebound 16 (5) 22 (6) Week 48 18 (5) 42 (12) Virologic non-response 2 (<1) 19 (5) Rebound 16 (5) 23 (6) Data Source: ING111762 Week 24 CSR Table 7.10

Distribution of HIV-1 RNA Levels at PDVF

Proportions of subjects experiencing virologic failure through Week 48 were distributed across the varying RNA ranges in each arm, and overall were proportionally similar between DTG versus RAL (Table 54). Although there were more PDVFs proportionally within the ≥100,000 c/mL range for the RAL arm there was a low absolute number within the DTG arm in this range.

70 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 54 Distribution of HIV-1 RNA at Time of PDVF through Week 48

DTG 50 mg Once Daily RAL 400 mg BID N=354 N=361 n/N (%) n/N (%) Subjects with PDVF 18 (5) 42 (12) PDVF HIV-1 RNA (c/mL)a <1000 1 (6) 6 (14) 1000 to <10,000 9 (50) 15 (36) 10,000 to <50,000 4 (22) 7 (17) 50,000 to <100,000 3 (17) 6 (14) 100,000 1 (6) 8 (19) Data Source: ING111762 Week 24 CSR Table 7.33 a. HIV-1 RNA at time point of suspected PDVF

Treatment emergent INI Genotypic Resistance by Week 48

From Week 24 to Week 48, the proportion of subjects having genotypic IN resistance decreased for the DTG arm and increased for the RAL arm (Table 55).

Table 55 Week 24 and Week 48 PDVF Genotypic (IN results at Baseline and time of PDVF)

DTG RAL 50 mg Once Daily 400 mg BID Cumulative Proportion with Pre-specified Treatment Emergent IN substitutions by: Week 24 2/9 (22%) 9/27 (33%) Week 48 2 /12 (17%) 13/32 (41%) Data Source: ING111762 Week 24 CSR Table 12.2 and Table 12.12

Treatment Emergent INI Phenotypic Resistance by Week 48

There continued to be no subjects with DTG or RAL phenotypic resistance on the DTG arm from Week 24 to Week48, and the proportion of subjects with phenotypic resistance on RAL for both DTG and RAL increased (Table 56).

71 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 56 Week 24 and Week 48 PDVF Phenotypic (IN results at Baseline and time of PDVF)

DTG RAL 50 mg Once Daily 400 mg Twice Daily Cumulative Proportion with Phenotypic Resistance by: Week 24 DTG FC>2.5 0 3/27 (11%) RAL FC>1.5 0 9/27 (33%)

Week 48 DTG FC>2.5 0 4/32 (12%) RAL FC>1.5 0 11/32 (34%) Data Source: ING111762 Week 24 CSR Table 12.39 and Table 12.48

Additional Virology Results

IN Viral Genotypic and Phenotypic Data for the Last Timepoint on Study for Selected Subjects

To further monitor the development of resistance to INIs, the genotypic and phenotypic susceptibilities were determined at the last time point on study meeting the following criteria: unconfirmed suspected protocol-defined virologic failure HIV-1, RNA ≥400 c/mL. Eight subjects in the DTG arm and seven subjects in the RAL arm met these criteria for testing. Table 57 below provides a summary of these results for the subjects meeting these criteria.

72 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 57 Summary of Subjects with Elevated HIV-1 RNA who Withdrew Without Confirmation

IN Genotype DTG Fold RAL Fold Arm / Visit HIV-1 HIV-1 RNA Change Change Subject (Week) RNA Resistance Baseline Testing Day 1 Final Day 1 Final Day 1 Final (c/mL) (c/mL) DTG / 16 66035 19896 none none 0.90 0.81 0.87 1.03 262 DTG / 4 4155 1929 none L74L/ 0.88 0.88 0.73 0.75 351 M/I DTG / 8 371109 668 L74I L74I 1.03 0.96 1.05 1.07 2467 DTG / 16 71412 67722 NA none NA 0.91 NA 0.84 2618 DTG / 16 171984 126925 none V151 0.94 0.92 0.83 0.91 2785 V/I DTG / 16 15447 2202 none none 1.25 1.27 0.9 0.98 2920 DTG / 12 433019 1486 L74I L74I 0.91 0.94 1.02 1.06 9068 DTG / 2 4695 2007 T97A none 0.70 0.87 1.85 1.01 9983 RAL / 48 64707 458 None None 0.97 0.81 0.8 0.77 2600 RAL / 8 663584 1375311 None None 1.41 1.07 1.09 1.2 655 RAL / 4 381204 105809 L74I L74I 1.00 0.95 1.22 1.06 2430 RAL / 16 233573 44202 L74I L74I 0.93 0.86 0.97 0.87 2425 RAL / 16 120085 17972 None None 0.68 0.83 0.56 0.9 2766 RAL / 16 33112 30725 L74I L74I 0.91 0.75 1.33 1.33 2851 RAL / 8 624823 247888 None None 0.73 0.72 0.94 0.89 2513 Data Source: ING111762 Week 24 CSR Table 12.60 and Other Listing 51

Discussion:

Results from this Week 24 interim analysis show DTG has a higher barrier to resistance in this patient population and a distinct resistance profile from RAL. A statistically significant difference in favor of DTG was demonstrated by planned virologic analyses for emergent integrase resistance. The proportion of subjects harboring virus with evidence of INI resistance by Week 24 was statistically greater for DTG vs RAL, with 0.6% (2/354) of subjects receiving DTG and 2.8% (10/361) of subjects receiving RAL harboring treatment emergent genotypic or phenotypic INI resistance at the time of

73 CONFIDENTIAL Module 2.7.2.4 Special Studies protocol-defined virologic failure. An additional prespecified analysis using a common FC cutoff to determine phenotypic resistance to RAL and DTG also confirmed a statistically significant difference in favor of DTG.

Dolutegravir exhibits a higher barrier to treatment failure than RAL. PDVF occurred earlier and more frequently in the RAL arm compared with the DTG arm, which reflects the greater suppressive effect in this ART-experienced patient population for DTG versus RAL.

Two PDVF subjects on DTG and 9 on RAL with matched Baseline and PDVF resistance testing developed treatment emergent integrase genotypic and/or phenotypic resistance. The observed mutations in the RAL arm were as expected clinically relevant INI resistance mutations commonly observed during RAL therapy, and including the primary resistance mutations at Y143, Q148, and N155 and associated secondary mutations. In the DTG arm no primary or secondary resistance mutations commonly selected during RAL therapy emerged. In both cases of emergent substitutions in IN for the DTG arm the IN mutations observed were at position R263.

The R263K mutation has been selected during passage with EVG [Jones, 2007], has been infrequently observed during RAL therapy [Brenner, 2011], and most recently was selected during in vitro passage with DTG [Quashie, 2012; Oliveira, 2012]. Position 263 is in the C-terminal domain of the IN protein, resides within a posited integrase nuclear localization motif [De Houwer, 2012], and is distal from the typical location of strand transfer integrase inhibitor mutations which usually are positioned at or near component residues of the catalytic pocket or its sublayers. Based on a set of 2997 aligned integrase sequences selected from integrase inhibitor naive subjects, R263 was highly conserved at a 99.77% level, with 263K present at 0.11% frequency. Of note, binding of DTG with R263K mutant protein: DNA complexes revealed prolonged binding with a dissociation half life t1/2 of 15.5 hours for subtype B based R263K in comparison with a t1/2 of 25.7 hours for parental wildtype subtype B protein, and similarly a t1/2 of 22.4 hours with subtype C based R263K in comparison with t1/2 of 38.5 hours for parental wildtype subtype C protein [m5.3.5.4, 2011N114191_00]. Finally, the change in DTG or RAL susceptibility observed in two subjects upon acquisition of R263K was minimal with these integrase substitutions, suggesting that they did not confer high level resistance to either DTG or RAL.

Overall, RAL and EVG have strongly overlapping resistance profiles while DTG has been demonstrated to have a distinct resistance profile based on in vitro [Kobayashi, 2011] and now in vivo evaluations from this study.

Genotypic and/or phenotypic resistance to the background regimen was observed infrequently in both treatment arms. Overall there were not enough cases to determine whether a statistically significant difference existed in emergence of resistance to back ground regimens across arms.

While low levels of HIV-1 RNA were observed at PDVF for the ART-naive DTG studies ING113086 [m5.3.5.1 ING113086 Week 48 CSR] and [m5.3.5.1 [ING114467 Week 48 CSR], subjects experiencing virologic failure through Week 48 in this study typically had higher HIV-1 RNA levels that were more broadly distributed across HIV-1 RNA ranges.

74 CONFIDENTIAL Module 2.7.2.4 Special Studies

Most HIV-1 RNA levels were above 1000 c/mL and >40% were above 10,000 c/mL. Thus, the virologic failures in this study had sufficient viral replication for a robust assessment of integrase resistance. Despite these higher viral loads at failure, clinically relevant resistance to DTG was not observed, while clinically relevant RAL resistance was observed.

The virologic results of this study combined with the supporting 48-week results in treatment-naïve patients, as well as accumulating in vitro data [Kobayashi, 2011; m5.3.5.4, 2011N114191_00] show that DTG possesses a higher barrier to resistance than other INIs and RTIs.

Conclusions:

 DTG exhibits a higher barrier to treatment failure than RAL.  In a prespecified analysis, there was a statistically significant difference in favor of DTG for the proportion of subjects who failed therapy with evidence of INI Resistance through Week 24.  A unique IN substitution was observed (R263K or R263R/K mixture) in the 2 subjects with treatment emergent resistance on DTG that conferred little change in susceptibility to DTG and to RAL.

4.2.1.3. Studies of Treatment-Experienced (Integrase Inhibitor Resistant) Subjects

Protocol-defined virologic failure (PDVF) was observed in 19% of subjects enrolled in ING112574, the majority of whom harboured Q148 pathway virus at Baseline. Highest DTG FC was observed in virus harbouring Q148+2 additional IN mutations however this subgroup was represented in only 11% of the enrolled population. Good short term and long term responses were seen in subjects with 143/155/66 mutations or historic evidence of IN resistance which make up the majority of RAL resistant virual isolates lower response rates were observed in virus harbouring Q148/G140 dual mutations. 4.2.1.3.1. ING112574

Study Title: A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen (ING112574 – Week 24 results)

Location of Report: 5.3.5.2

Study Design: Study ING112574 is a multicenter, single arm, open-label study to assess the antiviral activity and safety of a DTG containing regimen in HIV-1 infected, ART- experienced adults who experienced virologic failure on an INI containing regimen with historical or current evidence of genotypic and/or phenotypic resistance to RAL or EVG. All subjects received 50 mg DTG twice daily alongside their current failing background therapy for 7 days then transferred to DTG with an optimised background therapy (OBR) from Day 8 (OBR included at least one active drug). Subjects who completed 24 weeks

75 CONFIDENTIAL Module 2.7.2.4 Special Studies

on the optimised treatment phase continue to have access to DTG, where feasible as per protocol. Antiviral activity, safety and tolerability of DTG were evaluated at Day 8 and over time. 200 subjects were planned and 183 subjects were enrolled. 155 subjects remained ongoing at the time of this analysis. This report will focus on efficacy data through Day 8 for all subjects enrolled and through 24 weeks for the initial 114 subjects enrolled to address the primary objective.

Virologic failure at Day 8 was based on a single plasma HIV-1 RNA evaluation at Day 8 and did not require confirmation. During the Optimised Phase, virologic non-response was defined as a decrease in plasma HIV-1 RNA of less than 1 log10 c/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is <400 c/mL.or confirmed plasma HIV-1 RNA levels 400 c/mL on or after Week 24. Virologic rebound was defined as confirmed rebound in plasma HIV-1 RNA levels to 400 c/mL after prior confirmed suppression to <400 c/mL or confirmed plasma HIV-1 RNA levels >1 log10 c/mL above the nadir value where nadir is 400 c/mL.

All subjects had genotypic and phenotypic resistance testing at Baseline to conduct analyses of response by Baseline resistance. Subjects with confirmed virologic failure had genotypic and phenotypic testing performed on the sample collected at time of suspected virologic failure. Additional genotypic and phenotypic testing was conducted on subjects at Day 8 (virus with HIV-1 RNA 150c/mL), at last timepoint on treatment (for subjects with HIV-1 RNA >400 and >12 weeks form last resistance testing), and for patient management during the optimized phase of the study.

Results:

Prevalence of IN substitutions

The ITT-E population of ING112574 (N=183) showed diverse IN resistance patterns with proportions of each IN mutational pathway similar to those detected in earlier studies evaluating raltegravir [Garrido, 2012].

Of the 183 subjects enrolled, 57/183 (31%) harboured virus with a mutation at Q148 at Baseline. Virus with mutations at position148 has shown moderate to high DTG FC and as such is important for the evaluation of DTG. At position 148 mutations Q148H (n=46), Q148R (n=11), Q148K (n=1) and Q148N (n=2) were detected as full mutations or as mixtures. The Q148N substitution is not a recognized IN resistance mutation. In this study the Q148N was only seen as a minor variant in a population of virus with Q148H present suggesting it may have only a small contribution to the phenotype of the virus.

In the study 15% of subjects harboured Y143 mutations at Day 1. At position Y143 mutations Y143C (n=7), Y143R (n=23) and Y143H (n=1). The virus harbouring Y143H also had Q148H present. This mutational profile was seen in previous studies investigating DTG (m5.3.5.1 ING112961 Week 48 CSR) and in general was associated with a good antiviral response.

As well as those mutations noted above, the study also enrolled 18% of subjects with N155H. Both the N155H and Q148 mutations are clinically relevant resistance

76 CONFIDENTIAL Module 2.7.2.4 Special Studies associated mutations for EVG and therefore the population enrolled allowed adequate evaluation of DTG in virus with reduced susceptibility to EVG. Two additional EVG associated mutations T66A/I/K and E92Q were detected in few subjects. E92Q was detected in only 2 Baseline viruses and in each case seen with another IN primary mutation. The T66 mutations were noted in 4 subjects but only one subject (Subject 481) had this mutation detected with no other IN primary mutation and this subject had no prior exposure to EVG. All subjects with the detection of either E92Q or T66A/I/K had prior exposure to only RAL.

Table 58 Summary of Number of Subjects Per IN Mutation Category

Number of subjects with IN mutation ITT-E Week 24 ITT-E category 50 mg DTG BID 50 mg DTG BID N = 183, n (%) N = 114, n/N (%) Q148+1 32 (17) 20 (18) Q148+2 21 (11) 12 (11) N155 33 (18) 21 (18) Y143 28 (15) 15 (13) T66 1 (<1) 1 (<1) 2 Primary mutations 8 (4) 5 (4) Primary not detected 60 (33) 40 (35) Data Source: m5.3.5.2 ING112574 Week 24 CSR Table 12.9 and Table 12.64

In vitro and prior clinical investigations of DTG have shown specific IN primary mutations (specifically Q148 mutations) impact DTG FC. The numbers of IN resistance- associated mutations when present with Q148 mutations are also associated with elevated DTG FC and protocol-defined virologic failure (Kobayashi, 2011; Vavro, 2012, m5.3.5.4, 2011N114191_00, m5.3.5.2, 2012N145179_00). The table below (Table 59) provides the proportion of subjects enrolled in ING112574 by the number of IN resistance-associated mutations. Of the 183 subjects enrolled, 62/183 (34%) have 3 or more IN resistance-associated mutations.

Table 59 Summary of Number of Baseline Pre-specified IN Mutations

Number of subjects with 0, 1, 2, 3,4 and ITT-E Week 24 ITT-E 5 pre-specified primary or secondary 50 mg DTG BID 50 mg DTG BID mutations N = 183, n (%) N = 114, n (%) 0 mutations 47 (26) 33 (29) 1 17 (9) 10 (9) 2 57 (31) 31 (27) 3 34 (19) 23 (20) 4 20 (11) 12 (11) 5 8 (4) 5(4) Data Source: ING112574 Week 24 CSR Table 12.8 and Table 12.63

77 CONFIDENTIAL Module 2.7.2.4 Special Studies

Phenotypic susceptibilities to INIs at Day 1

Limited cross resistance to RAL was seen in the study population with the median DTG FC of 1.29 (0.45, 37) vs. RAL with a median FC of 47 (0.49, 127) and only 9% of subjects had virus with DTG FC of >10 (Table 60). Thirty-one percent of subjects enrolled have a RAL FC of <1.5 as determined by the population-based phenotypic measure of susceptibility. This result is associated with virus that has documented historic evidence of INI resistance only. At the time this study was conducted, EVG was not approved and thus no measure of EVG FC could be produced. IN genotype and IN phenotype are correlated in that Y143 and N155 mutants have lower DTG FC and the highest DTG FC was seen in subjects with Q148 +2 (Table 78).

Table 60 Fold Change in IC50 to DTG and RAL

Drug FC compared to ITT-E Week 24 ITT-E wild type virus 50 mg DTG BID 50 mg DTG BID N=183 N=114 n (%) n (%) DTG n 176 110 0 to 2.5 122 (67) 78 (68) >2.5 to 4 13 (7) 8 (7) >4 to 8 22 (12) 11 (10) >8 to 10 4 (2) 4 (4) >10 to 15 8 (4) 5 (4) >15 to 20 3 (2) 3 (3) >20 to 25 1 (<1) 0 >25 3 (2) 1 (<1) DTG Median (range) [IQR] 1.29 (0.45, 37.00) 1.29 (0.47, 37.00) RAL n 176 110 0 to 1.5 56 (31) 38 (33) >1.5 to 4 6 (3) 3 (3) >4 to 8 2 (1) 1 (<1) >8 to 10 0 0 >10 to 20 10 (5) 7 (6) >20 to maximum 26 (14) 15 (13) of assay limit >maximum of 76 (42) 46 (40) assay limit RAL Median (range) [IQR] 47.50 (0.49, 127.00) 40.50 (0.68, 127.00) Data Source: ING112574 Week 24 CSR Table 12.42 and Table 12.60

78 CONFIDENTIAL Module 2.7.2.4 Special Studies

Change from baseline in plasma HIV-1 RNA at Day 8 by presence of IN resistance mutations

Day 8 response for the virologic outcome (VO) population (N=177, which consisted of all subjects in the ITT-E population excluding subjects who received incorrect IP, had IP interruption, received a prohibited medication, or discontinued IP prior to the analysis timepoint for a reason other than lack of efficacy) was good with a median change from Baseline in HIV-1 RNA of 1.4 log10 c/mL (95% CO 1.3 -1.5 log10 c/mL). . In Table 61 below, short term responses are provided by predefined primary mutations in IN and compared to wildtype for a given codon. IN mutations at codon 143 or 155 had no impact on short term antiviral activity of DTG. However, mutations at codon 148 demonstrated a statistically significantly reduced short term response (p-value <0.001). With regards to specific substitutions at codon 148, Q148H had the greatest impact on response followed by Q148R as was predicted by in vitro characterization of DTG.

Few subjects harboured mutations at positions T66 and E92 and in all but one subject they were seen with other IN primary mutations. As such no conclusions can be drawn with respect to mutations at these two sites and short term antiviral response, although most viruses with these mutations showed a strong response at Day 8, except for one subject harbouring virus mutation T66A, which also had the 148 mutation.

79 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 61 Summary of Change from Baseline in Plasma HIV-1 RNA log10 c/mL at Day 8 by Baseline Primary IN Resistance Mutation (LOCFDB, VO)

Codon Mutation Total P-value N=177 n Mean (SE) Q148 Wild type or non-resistance mutation 122 -1.591 (0.0461) - Any resistance mutation 55 -1.086 (0.0870) <0.001 AnyQ148H 46 -1.065 (0.0912) <0.001 AnyQ148R 9 -1.194 (0.2678) 0.033 Q148H 42 -1.041 (0.0969) <0.001 Q148N/H 1 -1.678 (0) 0.865 Q148Q/H 2 -1.071 (0.5061) 0.156 Q148Q/N/K/H 1 -1.443 (0) 0.772 Q148Q/R 2 -1.150 (0.3699) 0.226 Q148R 7 -1.207 (0.3410) 0.067 Y143 Wild type or non-resistance mutation 146 -1.386 (0.0510) - Any resistance mutation 31 -1.661 (0.0834) 0.020 Y143C 7 -1.586 (0.1281) 0.397 Y143H 1 -2.108 (0) 0.246 Y143R 23 -1.664 (0.1046) 0.042 E92 Wild type or non-resistance mutation 175 -1.426 (0.0452) - Any resistance mutation 2 -2.175 (0.2760) 0.079 Any E92Q 2 -2.175 (0.2760) 0.079 E92E/Q 1 -1.899 (0) 0.431

E92Q 1 -2.451 (0) 0.089

T66 Wild type or non-resistance mutation 173 -1.438 (0.0456) - Any resistance mutation 4 -1.260 (0.3527) 0.558 Any T66A 2 -0.879 (0.6408) 0.193 T66A 1 -0.238 (0) 0.048 T66K 1 -1.428 (0) 0.986 T66T/A 1 -1.520 (0) 0.893 T66T/I 1 -1.854 (0) 0.491 N155 Wild type or non-resistance mutation 144 -1.422 (0.0513) -

Any resistance mutation 33 -1.489 (0.0936) 0.563 AnyN155H 33 -1.489 (0.0936) 0.563 N155H 28 -1.519 (0.1056) 0.441 N155N/H 5 -1.324 (0.1810) 0.725

Note: p-values at each mutation are from a t-test of the difference between all subjects with that mutation and all subjects with wild type or non-resistance mutation Data Source: ING112574 Week 24 CSR Table 12.15

The table below provides results to address the impact of additional IN resistance mutations seen with the Q148 on short term response. When additional IN resistance-

80 CONFIDENTIAL Module 2.7.2.4 Special Studies

associated mutations are detected with a Q148 mutation, a lower change from Baseline in HIV-1 RNA was achieved. Additional IN mutations with either N155H or Y143 mutations (not highlighted in Table 62) did not impact short term responses in these mutational pathways.

Table 62 Statistics Analysis of Change from Baseline in Plasma HIV-1 RNA log10 c/mL at Day 8 by Baseline IN Mutation Category (LOCFDB, VO)

IN resistant mutation type n 50 mg DTG BID N=177 Mean (SD) Plasma HIV- 1 RNA log10 c/mL Q148+ 2 20 -0.978 (0.8130) Q148+1 31 -1.156 (0.4917) N155 31 -1.445 (0.5195) Y143 28 -1.695 (0.4218) T66 1 -1.854 (0) 2 Primary mutations 7 -1.447 (0.8205) Primary not detected 59 -1.598 (0.5347) Data Source: ING112574 Week 24 CSR Table 7.7

Change from baseline in plasma HIV RNA through Day 8 by baseline DTG FC

With the caveat of differing sample sizes, as DTG FC increased the short term response decreased. Short term response in the DTG FC category of >4-8 (n=22) provided slightly lower responses than the category >8-10 (n=4) although both are lower than the FC<4 categories (n=131). For the subjects in the FC>4-8 subcategory, 21/22 harboured virus with Q148 mutations, 14 with Q148 +1 and 7 with Q148+ 2. As noted above, both the presence of the Q148 mutation and presence of additional IN resistance mutations with Q148 have strong associations to reduced antiviral responses to DTG. In this study virus with DTG FC>10 had the lowest short term responses (<1.0 log10 c/mL with one subject exception) when compared to other DTG FC categories. All virus with DTG FC >10 had mutations at Q148 and additional IN resistance-associated mutations. Given the results below, the reduced response noted in the >4-8 subgroup could be a result of minor variants in the IN genotype not detected at the population level for these viruses.

81 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 63 Statistics Analysis of Change from Baseline in Plasma HIV-1 RNA log10 c/mL at Day 8 by Baseline DTG FC Category (LOCFDB, VO)

Baseline DTG FC subcategories n 50 mg DTG BID N=114 Mean (SD) Plasma HIV-1 RNA log10 c/mL 0 to 2.5, 119 -1.598 (0.5123) >2.5 to 4, 12 -1.438 (0.5547) >4 to 8, 22 -1.042 (0.5700) >8 to 10, 4 -1.235 (0.6648) >10 to 15, 7 -0.858 (0.7094) >15 to 20, 3 -0.902 (1.0613) >20 to 25 1 -1.405 (0) >25 3 -0.152 (0.2637) Missing 6 -1.333 (0.3808) Data Source: ING112574 Week 24 CSR Table 7.7

Proportion of subjects with less than 50 c/mL HIV-1 RNA at Week 24 by presence of IN resistance mutations

Through Week 24 the proportion of subjects with <50 c/mL in the Virologic Outcome population was 63%. Subjects harbouring virus with mutations at codon 143 or 155 had greater proportions of subjects with <50 c/mL at Week 24 as compared with the full population, however, mutations at codon 148 demonstrate a statistically significant reduced long term response (p-value <0.001). With regards to specific substitutions at codon 148, Q148H had the greatest impact on response. Other mutations at codon 148 were detected in too few subjects to provide a meaningful conclusion.

82 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 64 Proportion of Subjects with Plasma HIV-1 RNA below 50 c/mL at Week 24 by Baseline IN Resistance Mutation (MSDF, VO)

DTG 50 mg BID Codon N Mutation % <50 c/mL at P-value Week 24 (N=101) n/N (%) Q148 101 Wild type or non-resistance 57/72 (79) - mutation Any resistance mutation 10/29 (34) <0.001 Any Q148H 8/25 (32) <0.001 Any Q148R 2/4 (50) 0.214 Q148H 7/23 (30) <0.001 Q148N/H 1/1 (100) >0.999 Q148Q/H 0/1 0.219 Q148Q/R 1/2 (50) 0.388 Q148R 1/2 (50) 0.388 N155 101 Wild type or non-resistance 50/81 (62) - mutation Any resistance mutation 17/20 (85) 0.064 Any N155H 17/20 (85) 0.064 N155H 16/19 (84) 0.104 N155N/H 1/1 (100) >0.999 T66 101 Wild type or non-resistance 64/98 (65) - mutation Any resistance mutation 3/3 (100) 0.549 T66K 1/1 (100) >0.999 T66T/A 1/1 (100) >0.999 T66T/I 1/1 (100) >0.999 Y143 101 Wild type or non-resistance 56/85 (66) >0.999 mutation Any resistance mutation 11/16 (69) >0.999 Y143C 4/4 (100) 0.299 Y143R 7/12 (58) 0.748 Note: p-values at each mutation are from a Fisher's exact test comparing the proportion of responders with that mutation and the proportion of responders with wild type or non-resistance mutation. Data Source: ING112574 Week 24 CSR Table 12.16

IN genotypic and phenotypic correlates to antiviral response at Week 24 were similar to those identified in short term responses at Day 8 (Table 61 and Table 63). Virus with the presence of mutation at Q148 and virus with additional IN resistance-associated mutations with Q148 had lower Week 24 responses than those harbouring N155 or Y143 mutations. As DTG FC increased, Week 24 responses decreased and no subject with DTG FC >10 achieved <50 c/mL by Week 24 (as per VO population analysis).

83 CONFIDENTIAL Module 2.7.2.4 Special Studies

Paired analysis of Day 1 and Day 8 IN genotype and phenotype results

Of the 183 subjects enrolled in ING112574, 124/183(%) had HIV-1 RNA 150 c/mL at Day 8 and were sent for IN genotypic and phenotypic testing. Of these, 111 had paired Day 1 and Day 8 samples to examine IN treatment emergent genotypic and/or phenotypic changes. In only 13/111 (12%) subjects was treatment emergent IN genotypic resistance identified and only two viruses (Subjects 10 and 1844) had a 2-fold increase in DTG FC from Day 1 to Day 8. In all but 2 of the 13 subjects with treatment emergent IN genotypic resistance, IN resistance associated mutations detected were mixtures of wildtype and mutant. All treatment-emergent mutations detected were well characterized RAL and/or EVG IN resistance associated mutations. One subject (Subject 1844) had phenotypic but no genotypic evidence of resistance evolution. These data demonstrate minimal evolution in IN during the eight-day functional monotherapy phase of DTG clinical investigation.

84 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 65 Summary of Subjects with Paired Day 1 and Day 8 IN Genotype and Phenotype Exhibiting Genotypic and/or Phenotypic Changes

OSS for failing HIV-1 RAL-associated Resistance Mutation DTG FCa INI HIV-1 RNA background ART RNA Day 1 Day 8 Day 8 Treatment Day 1 Day 8 Subject Mutational Change at Day 1 Emergent Group from Day 1 (c/mL) Mutations 10 Q148+1 1 9224 -0.78 L74L/I/M, Q148Q/R L74I, G140A, Q148R G140A 0.72 23.00 15 Q148+2 1 25488 -0.41 E138E/T/K/A, E138E/T/K/A, E157E/Q 13.00 16.00 G140S, Q148H G140S, Q148H, E157E/Q 221 Q148+1 2 56686 -0.49 G140S, Q148H T97T/A, G140S, T97T/A 9.15 9.86 Q148H 231 Q148+1 0 11817 -0.69 G140S, Q148H T97T/A, G140S, T97T/A 5.28 8.59 Q148H 565 Y143 0 40741 -1.30 L74I, T97A, Y143R L74I, T97A, Y143R, G163G/R 1.05 1.07 G163G/R 566 Q148+2 1 195737 -2.08 E138T, G140S, E138K/T, G140S, E138K/T 10.00 7.43 Q148H Q148H 582 Y143 0 13152 -1.69 L74M, T97A, Y143R L74I, T97A, Y143R L74I 1.15 0.91 1001 Primary not 0 170395 -1.86 None G140G/S, Q148Q/H G140G/S, Q148Q/H 1.05 1.21 detected 1004 Q148+1 0 17547 -1.11 G140S, Q148H E138E/K, G140S, E138E/K 5.24 5.29 Q148H 1065 Primary not 1 282206 -1.89 L74I L74I, E157E/Q E157E/Q 1.30 1.36 detected 1243 Primary not 1 171547 -1.40 G140G/S G140G/S, Q148Q/H Q148Q/H 1.05 1.79 detected 1264 Q148+2 1 74097 -0.56 E138E/A, G140G/S, E138E/T/K/A, E138E/T/K/A 4.35 6.43 Q148Q/H, G193E G140G/S, Q148Q/H, G193E 1273 Primary not 0 50738 -1.21 T97A T97A, G163G/R G163G/R 0.66 0.65 detected 1844 Q148+1 0 716 -0.73 G140S, Q148H G140S, Q148H None 3.44 7.58 Data Source: ING112574 Week 24 CSR Table 12.56

85 CONFIDENTIAL Module 2.7.2.4 Special Studies

Genotype and phenotype analysis of virus at PDVF

At the interim data reporting, 35/183 (19%) subjects enrolled met the criteria for protocol-defined virologic failure. Of the 35 subjects with protocol-defined virologic failure, 31/35 had paired Baseline and time point of virologic failure samples for evaluation of treatment-emergent resistance.

IN genotypic and phenotypic results at time of virologic failure

Table 66 provides the summary by visit of protocol defined virologic failure for the Week 24 ITT-E population (n=114) through Week 24 (n=26). Table 68 describes specific IN genotypic and phenotypic results for each of the 26 subjects with PDVF in the Week 24 ITT-E population. For the ITT-E population (N=183), 35 subjects met PDVF on study, 9 of whom were identified either post Week 24 (from the ITT-E Week 24 population) or from the full study population (not yet reaching Week 24 at time of data cut-off). Treatment-emergent IN resistance was detected at PDVF for two subjects and each had a mutation at Q148 at Baseline. These subjects are summarised in Table 69 below.

Table 66 Summary (cumulative) of Protocol-Defined Virologic Failures by Visit (Week 24 ITT-E)

Visit 50 mg DTG BID N=114 n (%) Day 8 9 (8) Virologic non-response 9 (8) Week 4 10 (9) Virologic non-response 9 (8) Virologic rebound 1 (<1) Week 8 14 (12) Virologic non-response 9 (8) Virologic rebound 5 (4) Week 12 17 (15) Virologic non-response 9 (8) Virologic rebound 8 (7) Week 16 21 (18) Virologic non-response 11 (10) Virologic rebound 10 (9) Week 24 26 (23) Virologic non-response 13 (11) Virologic rebound 13 (11) Data Source: ING112574 Week 24 CSR Table 7.9

For the 31 subjects with PDVF and paired samples for analysis, 22/31 had virus with Q148 mutations and 2 or more additional IN resistance-associated mutations present at Baseline. The proportion of subjects with this IN genotype was higher for PDVF when compared with the full study population (Table 67).

86 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 67 Summary of Virus with Q148+ Additional IN Secondary Mutations in PDVF

ING112574 ING112574 DTG 50 mg BID DTG 50 mg BID (N=183) (N=31) IN Mutation Category Baseline PDVF Q148+2 21 (11%) 16 (52%) 2 Primary mutations 8 (4%)a 7 (23%)b a. 4 subjects with Q148+≥ 2 with T66 or Y143 mutations b. 6 subjects with Q148+≥ 2 with N155, E92, Y143, or T66 mutations Data Source: ING112574 Week 24 CSR Table 12.9 and Table 12.23

For the 26/114 (23%) subjects of the Week 24 ITT-E population who met protocol- defined virologic failure through Week 24, 16 had a Q148 mutation detected in the Baseline IN genotype. Of the remaining 10 subjects, 2 subjects had N155H and 8 subjects had no primary detected at Baseline. Of the 26 subjects with PDVF, 25 had paired Baseline and PDVF resistance data for analysis and 13 (52%) had treatment- emergent IN resistance at the time point of virologic failure. For 11/13 subjects with treatment-emergent IN resistance detected at PDVF, a mutation at Q148 was seen at Baseline or historic.

87 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 68 Plasma HIV-1 RNA log10 c/mL, Genotype and Phenotype for Subjects with Protocol-defined Virologic Failure in Week 24 ITT-E population (N=114)

IN Genotype Phenotype Subj. VF visit OSSa HIV-1 Day 8 C0 Virologic Day 1 At VF Treatment Day 1 PDVF of background RNA (g/mL) Non- Emergent DTG DTG at Day 1 response or FC FC (c/mL) rebound 181 Day 8 0 26859 1.89 Virologic non- E138K, G140S, E138K, G140S, None 6.52 7.53 response Q148H Q148H 221 Day 8 2 56686 2.09 Virologic non- G140S, Q148H T97T/A, G140S, T97T/A 9.15 9.86 response Q148H 504 Day 8 1 28685 3.16 Virologic non- L74I, G140S, L74I, G140S, None 14.00 24.00 response Q148H Q148H 545 Day 8 >2 52623 1.25 Virologic non- G140A, Q148R G140A, Q148R None 11.00 17.00 response 1067 Day 8 1 13068 - Virologic non- E138A, G140S, E138A, G140S, None 37.00 46.00 response Q148H Q148H 1203 Day 8 2 23390390 6.49 Virologic non- G140S, Q148H G140S, Q148H None 4.40 4.28 response 1842 Day 8 1 396681 0.67 Virologic non- E138A, G140S, E138A, G140S, None 16.00 20.00 response Q148H Q148H 1901 Day 8 1 304380 4.45 Virologic non- E138K, G140S, E138K, G140S, None 17.00 14.00 response Y143R, Q148H, Y143R, Q148H, E157Q, G193E E157Q, G193E 2001 Day 8 2 3470 3.65 Virologic non- G140S, Q148H, G140G/S, None 4.19 2.01 response G193E Q148Q/H, G193E 1843 Week 4 2 29840 - Rebound G140S, Q148H, G140S, Q148H, N155H 4.31 49.00 E157Q N155H, E157Q 228 Week 8 2 8347 0.04 Rebound None None None 0.95 1.02 569 Week 8 2 395106 3.95 Rebound G140G/S, E138K, G140S, E138K 1.57 12.00 Q148Q/H Q148H 1206 Week 8 2 2118674 - Rebound Noneb E92E/Q, T97T/A, E92E/Q, 0.88 5.29

88 CONFIDENTIAL Module 2.7.2.4 Special Studies

IN Genotype Phenotype Subj. VF visit OSSa HIV-1 Day 8 C0 Virologic Day 1 At VF Treatment Day 1 PDVF of background RNA (g/mL) Non- Emergent DTG DTG at Day 1 response or FC FC (c/mL) rebound E138E/K, T97T/A, G140G/S, E138E/K, Q148Q/H G140G/S, Q148Q/H 1241 Week 8 1 47143 2.87 Rebound Noneb T97T/A, E138A, T97T/A, 1.38 21.00 G140S, Q148H E138A, G140S, Q148H 227 Week 1 9623 2.71 Rebound E138A, G140A, E138A, G140A, Q148Q/R/K 8.11 46.00 12 Q148R, G193E Q148Q/R/K, G193E 1821 Week 2 94164 1.08 Rebound L74I, V151I, L74I, S147G, S147G 3.89 15.00 12 N155H, E157Q, V151I, N155H, G163K E157Q, G163K 2021 Week 1 8938 2.88 Rebound G140S, Q148H T97A, G140S, T97A 5.00 94.00 12 Q148H 8 Week 1 125369 1.78 Rebound G140S, Q148H T97A, G140S, T97A 6.12 88.96 16 Q148H 1012 Week 1 45010 6.26 Virologic non- E138T, G140S, T97A, E138T, T97A 11.00 99.16 16 response Q148H G140S, Q148H 1056 Week 1 664390 1.60 Rebound None None None 0.89 0.87 16 1242 Week 2 407487 2.33 Virologic non- G140G/S, Q148H E92E/Q, E138K, E92E/Q, 3.39 98.23 16 response G140S, Q148H E138K 1008 Week 2 2936633 5.78 Virologic non- V151I, N155H, Y143Y/H, V151I, Y143Y/H 1.46 1.79 24 response E157Q, G163K N155H, E157Q, G163K 1201 Week 2 154899 - Rebound None - - 1.00 24

89 CONFIDENTIAL Module 2.7.2.4 Special Studies

IN Genotype Phenotype Subj. VF visit OSSa HIV-1 Day 8 C0 Virologic Day 1 At VF Treatment Day 1 PDVF of background RNA (g/mL) Non- Emergent DTG DTG at Day 1 response or FC FC (c/mL) rebound 1214 Week 2 14830 0.65 Rebound None None None 0.84 0.90 24 1243 Week 1 171547 3.67 Rebound G140G/Sb E138E/K, E138E/K, 1.05 4.27 24 G140G/S, Q148Q/H Q148Q/H 1274 Week >2 633135 3.60 Virologic non- None None None 0.91 1.04 24 response a. OSS at time of protocol defined virologic failure (VF) b. Historic evidence of Q148 mutation for this virus Data Source: ING112574 Week 24 CSR Table 12.55

90 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 69 Plasma HIV-1 RNA log10 c/mL, Genotype and Phenotype for 9 Additional Subjects with Protocol-Defined Virologic Failure from ITT-E Population (N=183)

IN Genotype Phenotype Subj. VF visit OSSa HIV-1 Day 8 C0 Virologic Day 1 At VF Treatment Day 1 PDVF of background RNA (g/mL) Non- Emergent DTG DTG at Day 1 response or FC FC (c/mL) rebound 15 Day 8 2 25488 - Virologica E138E/T/K/A, E138E/T/K/A, E157E/Q 13.00 16.00 non- G140S, Q148H G140S, Q148H, response E157E/Q 585 Day 8 1 10426 3.62 Virologic L74I/M, T97T/A, L74M, G140A, None 34.00 64.00 non- E138E/K, Q148R response G140G/A, S147S/G, Q148R, V151V/I/M 1806 Day 8 2 13130 2.38 Virologic E138A, G140S, E138A, G140S, None 11.00 15.00 non- Q148H Q148H response 1964 Day 8 2 7430 4.34 Virologic T66A, L74I, T66A, L74I, None 27.00 36.00 non- E138K, S147G, E138K, S147G, response Q148R, G163R Q148R, G163R 1090 Week 0 293311 0.91 Rebound L74I, T97A, - - 1.43 4 E138E/T/K/A, Y143R, E157E/Q 1219 Week >2 1218 5.12 Rebound T97A, Y143R - - 0.81 8

91 CONFIDENTIAL Module 2.7.2.4 Special Studies

IN Genotype Phenotype Subj. VF visit OSSa HIV-1 Day 8 C0 Virologic Day 1 At VF Treatment Day 1 PDVF of background RNA (g/mL) Non- Emergent DTG DTG at Day 1 response or FC FC (c/mL) rebound 1264 Week 1 74097 0.17 Virologic E138E/A, - - 4.35 16 non- G140G/S, response Q148Q/H, G193E 566 Week 1 195737 2.95 Rebound E138T, G140S, E138T, G140S, N155H 10.00 209.0 32 Q148H Q148H, N155H 2 Week 1 9905 1.70 Rebound T97A, Y143R T97A, Y143R None 0.92 1.08 40 a. For PDVFs at Day 8: OSS to failing regimen; for other PDVFs, OSS to OBR Data Source: ING112574 Week 24 CSR Table 12.55

92 CONFIDENTIAL Module 2.7.2.4 Special Studies

Summary of treatment emergent resistance detected at PDVF

From the 35 subjects with PDVF in the ITT-E population (N=183), 31 subjects had paired Baseline and time of virologic failure samples. Of these, 15/31 had treatment- emergent mutations detected at virologic failure (Table 70). Treatment-emergent resistance was detected in virus harbouring a mutation at Q148 (at Baseline or historic) for 13/15 (87%) subjects. The most prevalent treatment- emergent mutations detected were IN resistance-associated secondary mutations that were added to a viral genotype with IN primary mutations present. All treatment-emergent mutations detected were well characterized RAL and/or EVG resistance associated mutations. Of note, 4 subjects had virus with treatment emergent mutations at position 148. Three of these subjects entered the study with only historic evidence of IN resistance and for all 3; the historic IN resistance provided was Q148H. A fourth subject with Q148R at Day 1 had a treatment emergent mixture of Q148Q/R/K at the time point of PDVF.

Table 70 Summary of Treatment- Emergent IN Genotypic Resistance Detected at PDVF

Codon Baseline IN Treatment Emergent Mutation 50 mg DTG BID Genotype Detected PDVF genotypic Pop N=31 n (%)

Any - - 15 (48%) 97 T97 T97A, T97T/A 6 (19%) 138 E138 E138A, E138E/K, E138K 5 (16%) 148 Q148 Q148H, Q148Q/H, Q148Q/R/K 4 (13%) 92 E92 E92E/Q 2 (6%) 140 G140 G140G/S, G140S 2 (6%) 155 N155 N155H 2 (6%) 157 E157 E157E/Q 1 (3%) 147 S147 S147G 1 (3%) 143 Y143 Y143Y/H 1 (3%) Data Source: ING112574 Week 24 CSR Table 12.27

For subjects meeting PDVF while on study, only 12/31(39%) had increases in DTG FC more than 2-fold of that detected at Baseline (Table 71). For all 12 subjects there was additional IN resistance associated mutations detected with the increased DTG FC.

93 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 71 Summary of Treatment Emergent Increases in DTG FC in Subjects with PDVF (N=31)

50DTG FC Ratio of Baseline and PDVF time 50 mg DTG BID point PDVF phenotypic Pop N=31 n (%) N 31 <1 4 (13) 1-<2 15 (48) 2-<4 1 (3) 4-<8 4 (13) 8 7 (23) Data Source: ING112574 Week 24 CSR 12.53

Summary of the IN genotype for the screening population

The screening population provides a good evaluation of the INI-resistant population during enrolment of this study. From these results we conclude that ~25% of subject experiencing virologic failure on a prior RAL or EVG treatment with IN resistance will have a Q148H mutation while the remaining 75% of subjects will harbour virus with Y143, N155, T66 or E92 mutations. Only 10% of subjects in the screening population harbour Q148 +2 additional mutations.

Table 72 Summary of Subjects Screened by IN Primary Mutation Categories

IN Primary mutation Category Screening Population with Genotypic Data at Screening (N=323) n (%) n 269 N155 42 (16) Q148+1 36 (13) Y143 36 (13) Q148+2 26 (10) T66 1 (<1) E92 1 (<1) 2 primary mutations 9 (3) Primary not detected 118 (44) Data Source: ING112574 Week 24 CSR Table 12.10

Summary of DTG and RAL FC for the screening population

The study screening population showed a low proportion of subjects with DTG FC>10 (~5%) however 76% of subjects potentially available for the study had DTG FC at <2.5. In this study, 80%of subjects with virus having DTG FC <2.5 achieved <50 c/mL

94 CONFIDENTIAL Module 2.7.2.4 Special Studies

at Week 24 suggesting that the majority of subjects failing prior RAL or EVG treatment could benefit from a regimen containing DTG 50 mg BID.

Table 73 Summary of DTG and RAL FC for the Screening Population

Drug FC compared to wild type virus Screening Population N=323 n (%) DTG n 274 0 to 2.5 209 (76) >2.5 to 4 18 (7) >4 to 8 26 (9) >8 to 10 6 (2) >10 to 15 9 (3) >15 to 20 1 (<1) >20 to 25 1 (<1) >25 4 (1) DTG Median (range) 1.18 (0.45, 47) RAL n 274 0 to 1.5 117 (43) >1.5 to 4 9 (3) >4 to 8 2 (<1) >8 to 10 1 (<1) >10 to 20 10 (4) >20 to maximum of assay limit 44 (16) >maximum of assay limit 91 (33) RAL Median (range) 17.50 (0.46, 149.0) Data Source: ING112574 Week 24 CSR Table 12.43

IN viral genotype and phenotype data for subjects with elevated HIV-1 RNA at last time point of IP

To further monitor the development of resistance to DTG, both IN genotype and phenotype were determined at the last timepoint on study meeting the following criteria: unconfirmed suspected protocol-defined virologic failure, HIV-1 RNA 400 c/mL or >12 weeks from the previous virologic failure testing. Nine subjects met one of these criteria for testing. Table 74 below provides a summary of these results.

95 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 74 Plasma HIV-1 RNA log10 c/mL, Genotype and Phenotype for Subjects at Last Assessment Other than Time of Virologic Failure

Subj. Test OSS Baseline Day 8 c0 HIV-1 RNA c/mL DTG FC Prespecified IN Genotype Week24 visit OBR mutation (ug/mL) Baseline Last Baseline Last Baseline Last ITT-E Group 41 Follow-up 1 Y143 - 121533 49864 0.84 0.92 T97T/A, Y143R T97A, Y143R, Y G163K/N/Q/H 221 Week 8 2 Q148+1 2.09 56686 44155 9.15 78.00 G140S, Q148H T97A, G140S, Y Q148H 226 Follow-up 2 Q148+1 11.01 36340 34483 2.54 1.82 G140S, Q148H G140G/S, Y Q148Q/H 461 Follow-up >2 Q148+2 1.28 120055 80427 13.00 100.05 E138T, G140S, T97A, E138T, Y Q148H G140S, Q148H 504 Week 16 1 Q148+2 3.16 28685 35549 14.00 103.24 L74I, G140S, L74I, T97A, Y Q148H G140S, Q148H 1203 Follow-up 2 Q148+1 6.49 23390390 17722840 4.40 17.00 G140S, Q148H T97T/A, G140S, Y Q148H 1206 Week 24 2 Primary - 2118674 511569 0.88 104.45 None L74L/M, T97T/A, Y not E138E/K, G140S, detected Q148H 1241 Week 12 1 Primary 2.87 47143 94263 1.38 88.00 None T97A, E138A, Y not G140S, Q148H detected 1901 Week 16 1 2 4.45 304380 31960 17.00 66.00 E138K, G140S, T97T/A, E138K, Y primary Y143R, Q148H, G140S, Y143R/C, mutations E157Q, G193E Q148H, E157Q, G193E Data Source: ING112574 Week 24 CSR Table 12.57

96 CONFIDENTIAL Module 2.7.2.4 Special Studies

Discussion

The population of ING112574 reflects the diversity of INI resistant virus in the general population in that the proportion of virus with Y143 and N155 and Q148 mutations was similar to that seen in treatment failures from previous RAL clinical studies and in earlier phase clinical investigation of DTG [Cooper, 2008; Hatano 2010; Clotet, 2010]. IN mutational patterns seen in the ING112574 also provide a good representation of those that can arise on EVG treatment and therefore provide for appropriate investigation of DTG for EVG associated resistance as well. The broad range of DTG FC and diverse resistance patterns observed allowed an appropriate test of DTG in this HIV-1 INI resistant population.

Thirty-two percent of subjects enrolled had received RAL or EVG as a component of an earlier regimen and had only historic evidence of IN resistance at Screening. In a minor variant analysis of subjects with no primary IN resistance at Baseline, the documented IN resistance was confirmed in only 9.6% of subjects. These results were not unexpected given the long duration post last dose of RAL or EVG at the time of testing. Earlier studies have suggested that minor variants of IN primary resistance diminish as early as 6 months post RAL interruption [Codoner, 2011; Canducci, 2011.

A broad range of DTG FC was seen at Baseline with minimal cross resistance to RAL/EVG. This result is a striking contrast to RAL and EVG which had broad cross resistance detected in both in vitro and clinical investigation [Garrido, 2012; Blanco, 2011; Kobayashi, 2011; Molina, 2012; Sax, 2012; Margot, 2012]. As noted in earlier clinical investigation, DTG FC was highly correlated to IN resistance pathways in that low DTG FC’s were seen with 143/155/66 plus secondary mutations and moderate to high DTG FC was seen with the Q148 mutation pathway. The highest DTG FC was detected in virus with Q148+2 additional IN resistance mutations. The broad diversity in DTG FC seen with 148 pathway virus may be due to the presence of secondary mutations in disparate number and combinations, or due to wildtype virus masking mutant virus resistance when present as a positional mixture (e.g. as Q148Q/H G140G/S [Underwood, 2009]).

Results from ING112574 show good short term and long term antiviral responses with virus harbouring 143/155/66 primary mutations as well as virus with only historic IN primary resistance, regardless of additional IN secondary mutations being present. However, virus having Q148/G140 dual mutations had reduced short term and long term responses as compared to the full population. Furthermore, virus harbouring the Q148/G140 dual mutations with additional IN secondary mutations (Q148+2) showed further reductions in short term responses. Further, no subject with this mutational profile achieved <50 c/mL at Week 24 although 2 subjects did achieve <400 c/mL. In vitro characterization of DTG and recent clinical reports support both the reduced antiviral activity of DTG on virus harbouring Q148 mutations as well as the expected good DTG antiviral activity that was achieved in virus harbouring Y143 and N155 mutations (Kobayashi, 2011; m5.3.5.4, 2011N127961_00) As previously noted, Q148 mutations are present in approximately 30% of subjects failing prior RAL or EVG treatment with IN resistance however only 11% of subjects harbour virus with Q148+2 suggesting a

97 CONFIDENTIAL Module 2.7.2.4 Special Studies

HAART regimen that contains DTG 50 mg BID could provide good efficacy in at least 89% of IN resistant virus.

A separate analysis was conducted specifically to provide potential IN phenotypic and/or genotypic guidance for use of DTG in this INI-resistant population, based on correlation between baseline resistance and antiviral response (GlaxoSmithKline Document Number m5.3.5.4, 2012N148111_00).This analysis showed that no robust phenotypic FC cut off could be defined, however, 3 baseline genotypic resistance groups were identified based on their differential impact on DTG antiviral response. These 3 distinct IN genotypic groups were: the No Q148 mutation group (includes Y143, N155H, T66, E92 mutations or historical evidence of resistance); the Q148+1 group (Q148_HKR with one mutation [G140_ACS, L74I, E138_AKT]); and the Q148+2 group (Q148_HKR with two or more mutations [G140_ACS, L74I, E138_AKT]). The best antiviral responses were seen with the IN mutational group “No Q148” and lowest responses with “Q148+2” group and confirm the conclusions presented in this study report. A strong statistically significant association, in presence at Baseline, was seen between the Q148_HKR mutation and G140_ACS mutation such that their individual impact on antiviral response could not be determined. (The G140 was detected in 53/57 [93%] genotypes with the Q148 mutation at baseline.)

Viral evolution during functional monotherapy of DTG was assessed at Day 8 and showed only few subjects (12%) had treatment-emergent IN resistance. The treatment- emergent IN resistance that was detected for the majority was mixtures of IN secondary mutations suggesting their presence as minor variants in the Baseline population. All treatment-emergent mutations detected were well characterised INI resistance-associated mutations [Stanford database, Stanford].

Conclusions

 ING112574 enrolled a broad range of DTG FC and diverse IN resistance patterns allowing for appropriate evaluation of DTG in the HIV-1 INI resistant population.  Low DTG FC was observed in subjects harbouring 143/155/66 or historic evidence of IN resistance while moderate to high DTG FC was observed with virus harbouring Q148 virus. Highest DTG FC was observed in virus harbouring Q148+2 additional IN mutations however this subgroup was represented in only 11% of the enrolled population.  Good short term and long term responses were seen in subjects with 143/155/66 mutations or historic evidence of IN resistance which make up the majority of RAL resistant virus; lower response rates were observed in virus harbouring Q148/G140 dual mutations. Protocol-defined virologic failure (PDVF) was observed in 19% of subjects the majority of whom harboured Q148 pathway virus at Baseline.  Limited viral evolution was detected at PDVF consisting of previously identified, INI secondary mutations which lead to an increase in DTG FC; the majority of which were identified in virus harbouring Q148 mutations.

98 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.2.1.3.2. An Exploratory Analysis of Minor Variants in HIV-1 Integrase for Subjects Enrolled in ING112574 Having Only Historic Evidence of Primary IN Resistance (Appendix 5)

Minor variant analyses have been used to explore viral evolution and to elucidate further antiviral resistance that can occur at virologic failure while receiving antiviral treatment [Mukherjee, 2011; Codoner, 2010]. These analyses have utilised a variety of molecular techniques including molecular cloning, allelic-specific PCR and ultra deep pyrosequencing [Canducci, 2011; Paredes, 2010; Dalmau, 2012].

Study ING112574 allowed enrolment of subjects with current or historic evidence of IN resistance. In this exploratory analysis the technology of ultra deep pyrosequencing (454 sequencing) is used to identify minor variants of IN primary resistance associated mutations in HIV integrase in subjects with only historic evidence of IN resistance at the time of enrolment to ING112574. Minor variants at 0.5% of total population will be summarised.

For the 52 Baseline samples tested for minor variants in integrase to confirm the provided historic IN resistance, only 5/52 (9.6%) samples tested had minor variants of IN primary resistance associated mutations (at a 0.5% detection threshold). All five viral samples had HIV-1 RNA >10,000 c/mL at the time of testing. All five subjects had been on prior RAL treatment for more than one year. The minor variants of IN primary resistance mutations detected in these samples were identified at <11%.

For these 5 subjects the average number of days off RAL treatment to Baseline testing was 163 days compared to 504 days for all subjects tested. Indeed, only 2/40 samples tested for subjects who had been off RAL treatment for >6 months had evidence of IN primary resistance associated mutations at the 0.5% detection threshold. For the 5 samples with minor variants of IN primary resistance detected the average number of days on prior RAL treatment was 806 days compared to 676 for the 52 samples tested. No samples with <356 days of prior RAL treatment had evidence of minor variants of IN primary resistance mutations although in each case the short duration of prior RAL treatment was followed by a longer duration off drug prior to testing (Table 76).

Only 10/52 subjects tested were on prior RAL treatment near (within 33 days) the timepoint of minor variant testing (Baseline). For these subjects 2/10 had evidence of minor variants of IN primary resistance associated mutations. For the remaining eight subjects, 6/8 subjects had historic evidence of INI phenotypic resistance only and 2/8 had historic evidence of IN primary resistance associated mutations that were not detected during minor variant testing (Table 76).

In this analysis only 5 samples had evidence of minor variants of IN primary resistance mutations, but 25/52 samples had evidence of minor variants of IN secondary resistance associated mutations to a 0.5% detection level Table 76). For 10/25 of these samples only historic RAL or EVG FC >1.5 or 2.5, respectively, was provided to qualify for study enrollment.

Eight subjects with no IN primary resistance mutations at Day 1 met protocol-defined virologic failure while on study, subjects 228, 1056, 1201, 1206, 1214, 1241, 1243, and

99 CONFIDENTIAL Module 2.7.2.4 Special Studies

1274. Results from population IN genotyping performed at the timepoint of virologic failure showed only three of these eight subjects had treatment-emergent IN resistance (subjects 1206, 1241 and 1243). In each case the virus at virologic failure had treatment emergent Q148H. For these three subjects the historic IN resistance that was provided was Q148H but only subject 1243 had minor variants of Q148H detected at Day 1(at 4%).

Table 75 Summary of Confirmed Historic Primary INI Mutations at Baseline by Minor Variant Detection

Subject Historic IN Baseline Duration Time to Baseline Baseline Minority Variants ID resistance HIV-1 of prior INI IP since IN detected and (proportion) provided RNA treatment INI Genotype (days) stopped (days)

381 Q148H 373747 1247 119 G140S(.0487), Q148H(.049) E138A(.0099), G140S(.1081), 1001 Q148H 170395 477 483 Q148H(.1063)

1243 Q148H 171547 357 2 G140G/S G140S(.0399), Q148H(.0406) RAL FC = T66A(.0085), T97A(.9899), 1273 2.86 50738 717 2 T97A V151I(.0286), G163R(.0754) V151I, G140S(.008), V151I(.9967), 1402 N155H 34035 1232 211 G163R N155H(.0062), G163R(.9875) 0.5% detection threshold Note: Bolded mutations are primary IN resistance associated mutations Data Source: ING112574 Week 24 CSR: NON-ICH Listing 13, NON-ICH Listing 45 and NON–ICH Listing 47

100 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 76 Summary of Minor Variant Detection for 53 Samples Tested

Subject Historic IN Baseline Duration Time to Baseline IN Baseline Minority Comments ID resistance HIV-1 of prior IP since Genotype Variants detecteda provided RNA INI INI and (proportion) treatment stopped (days) (days) RAL FC= 1 84 72577 580 380 V151V/I V151I(.2889) Q95K(.9975), RAL FC T97A(.9986), 24 MAX 644 1162 33 Q95K,T97A/V V151I(.0182) RAL FC 102 MAX 366 1400 263 107 N155H 132039 1078 278 RAL FC = 143 33 32489 1064 322 V151I(.0304) all amplicons did not RAL FC provide b 228 MAX 8347 542 662 sequence 262 Q148H 9464 911 562 T97A(.0136) all amplicons did not G140S(.0487), provide b 381 Q148H 373747 1247 119 Q148H(.049) sequence 387 N155H 12352 NA 483 all amplicons Q95K(.9804), did not RAL FC = L74M, Q95K, T97A(.9955), provide b 463 48 14281 2115 2 T97A, S147G S147G(.9924) sequence RAL FC = 663 1.98 95255 896 2 E138A E138A(.9815) E138A(.0099), G140S(.1081), 1001 Q148H 170395 477 483 Q148H(.1063) all amplicons did not provide b 1002 N155H 3208 118 513 V151I(.0303) sequence 1006 N155H 535 708 604 E157Q(.0776) 1011 N155H 102008 1078 860 L68V, L68V(.9981), 1022 N155H 1955 923 848 V151V/I V151I(.6265) 1026 E92Q 10065 575 657 E138K(.0157), S147G(.0147), 1036 N155H 7034 782 309 V151I(.1928) 1041 Q148H 320949 611 1090 all amplicons 1051 N155H 24207 226 799 did not

101 CONFIDENTIAL Module 2.7.2.4 Special Studies

Subject Historic IN Baseline Duration Time to Baseline IN Baseline Minority Comments ID resistance HIV-1 of prior IP since Genotype Variants detecteda provided RNA INI INI and (proportion) treatment stopped (days) (days) provide sequenceb 1056 Q148R 664390 1428 2 V151I(.0099) 1057 N155H 57974 1289 331 L74M(.1259) RAL FC = L74I(.9971), 1065 65 282206 1863 1 L74I E157Q(.0835) 1076 Y143R 34759 722 785 b b 1088 Q148H 9572 594 1137 NR 1202 Q148R 104203 525 946 Results removed from analysis due G140S(.9804), to sample 1205 Q148H 10312 607 681 Q148H(.9838) ID error 1206 Q148H 2118674 472 879 V151I(.0085) 1209 Q148H 127663 147 410 1210 Y143R 41637 922 2 1212 Q148H 373713 321 207 1214 Y143C 14830 782 863 L74M(.0508) 1215 E92Q 50023 1237 595 1217 Q148R 84534 239 869 1221 N155H 25681 974 251 1241 Q148H 47143 585 483 G140S(.0399), 1243 Q148H 171547 357 2 G140G/S Q148H(.0406) 1265 N155H 7743 428 614 b b 1271 N155H 1309 468 224 NR 1272 Q148H 1194036 153 461 T66A(.0085), T97A(.9899), RAL FC = V151I(.0286), 1273 2.86 50738 717 2 T97A G163R(.0754) 1274 N155H 633135 385 905 L74M(.9459), RAL FC = T97A(.9966), 1401 1.62 81587 918 2 L74M, T97A V151I(.0133) G140S(.008), V151I(.9967), V151I, N155H(.0062), 1402 N155H 34035 1232 211 G163R G163R(.9875) 1403 Q148R 289238 322 623 1481 N155H 38581 690 469 G193E(.0104) L74M(.0287)/Q(.7574), RAL FC = T97A(.9912), 1611 4.12 804 1460 1 T97A E138A(.0058) 1612 Q148H 3045 647 1052 1861 Q148H 2724 1067 455 RAL FC = L74M(.1527), 1902 66 26658 1399 133 L74L/M V151I(.1639)

102 CONFIDENTIAL Module 2.7.2.4 Special Studies

Subject Historic IN Baseline Duration Time to Baseline IN Baseline Minority Comments ID resistance HIV-1 of prior IP since Genotype Variants detecteda provided RNA INI INI and (proportion) treatment stopped (days) (days) RAL FC = 1922 38 12149 192 433 1961 N155H 7789 162 835 E157K(.0063)/Q(.0064) 1962 N155H 121371 396 1636 a. 0.5% detection level, b. All amplicons did not provide sequence but results were obtained from amplicon containing IN primary resistance mutations. Data Source: ING112574 Week 24 CSR: NON-ICH Listing 13, NON-ICH Listing 45 and NON –ICH Listing 47

Discussion

In a minor variant analysis conducted on 52 Baseline samples of study ING112574 with only historic evidence of IN resistance for study enrollment, only 9.6% of the samples tested had evidence of IN primary resistance mutations as minor variants in the viral population. Ultra deep pyrosequencing of integrase with a detection level of 0.5% was used for this evaluation [Mukherjee, 2011; Codoner, 2010]. All minor variants of IN primary resistance mutations detected were at <11% of the total viral population for each tested viral sample. This detection level would preclude their identification on a population-based genotyping assay as was used at Baseline to determine IN resistance in these subjects.

In this study the average number of days off RAL treatment before minor variant testing was 504 days and in only 2/40 subjects off RAL treatment for >6 months were minor variants of IN primary resistance mutations detected. Prior studies have shown that virus resistant to RAL can appear to revert to wild type by the outgrowth of more fit wildtype viral variants or within weeks after RAL treatment interruption [Canducci, 2011]. In another study it was shown that interruptions or incomplete adherence could impact detection of minor variant to a 1% detection level [Codoner, 2011]. Therefore given the number of samples tested in this study off RAL treatment for longer periods of time, the low proportion of minor variant detection of IN primary resistance is an expected finding.

Reduced INI susceptibility (elevated RAL FC) was provided as historic evidence of IN resistance for 13 (25%) samples tested and therefore no IN primary resistance mutations were provided to confirm with minor variant evaluation. Study ING112574 was conducted in both the US and EU, and the monitoring of INI resistance in the US is typically performed with a phenotypic assay to measure RAL susceptibility. In this study, 10/13 samples did have minor variants of one or more IN secondary mutations present at Baseline, suggesting reduced RAL susceptibility could be the result of a virus with only IN secondary mutations present.

In this exploratory analysis only 5 subjects had IN primary resistance minor variants detected at >0.5%. The low proportion of viral samples with detectable IN primary resistance on pyrosequencing, below the level of population genotyping detection is likely due to the increased time off prior RAL treatment at the time of testing.

103 CONFIDENTIAL Module 2.7.2.4 Special Studies

Conclusions

4.2.1.3.3. Antiviral Activity of DTG in ING112574 by Baseline Resistance

Analyses of antiviral activity of DTG observed in Study ING112574 according to genotypic and/or phenotypic resistance (m5.3.5.4, RM2008/00752/01) were conducted as per the requirements set out FDA and EMA guidance (FDA, 2007; EMA, 2008)

Antiviral activity (e.g. change from Baseline in HIV-1 RNA log10 c/mL) at Day 8 was used for quantifying the association of response in relation to Baseline genotypic/ phenotypic data.

The change from Baseline in HIV-1 RNA at Day 8 was also categorized in line with the categories specified in Annex B, i.e. ‘activity not affected’, ‘activity decreased’, and ‘resistance’. The summaries of the response category by the derived phenotypic/genotypic cut-offs/groups were produced.

 Full response (i.e. activity not affected): reduction >1.0 log10 c/mL or HIV-1 RNA <50 c/mL at Day 8

 Intermediate (i.e. activity decreased): reduction 0.5 – 1.0 log10 c/mL or HIV-1 RNA <400 c/mL at Day 8

 No response (i.e. resistance): reduction <0.5 log10 c/mL at Day 8

The Week 24 response summary by Baseline resistance (i.e. genotypic/phenotypic groupings based on the derived cut-offs/groups from Day 8 analyses) was also produced. The antiviral activity (HIV-1 RNA viral load at Week 24) was defined as:

 Response: <50 c/mL

 No response: ≥50 c/mL based on FDA ‘Snapshot’ (missing, switch, discontinuation=failure) algorithm.

Study population and baseline characteristics

The ITT-E Population consisted of 183 subjects who received DTG 50mg twice daily in ING112574. Of these, 177 (98%) were included in the Day 8 Virologic Outcome (VO) Population. Of a total of 114 subjects who had completed the Week 24 visit or discontinued IP as of the data cut-off for this analysis, 101 met virologic outcome population criteria for the Week 24 timepoint.

The ITT-E population of ING112574 showed diverse IN resistance patterns, and 31% of subjects had virus with mutations at position Q148 at Baseline (m5.3.5.1 ING112574 Week 24 Clinical Study Report Source Data: Table 12.7). Subjects had moderate to high

104 CONFIDENTIAL Module 2.7.2.4 Special Studies

DTG FC in virus harboring Q148 mutations with additional primary or secondary mutations present. Subjects with virus harbouring 143 and 155 mutations had lower DTG FC. The highest DTG FC was seen with Q148 with two or more secondary mutations. Thirty-three percent of subjects harboured virus with historic IN resistance only (Table 77, Table 78).

Table 77 Genotypic and phenotypic resistance at Baseline, ITT-E population

DTG 50mg BID (N=183) Mutation category Q148+≥2 21 (11%) Q148+1 32 (17%) N155 33 (18%) Y143 28 (15%) T66 1 (<1%) >=2 Primary 8 (4%) Primary not detected 60 (33%) Median FC (range) DTG 1.29 (0.45-37) RAL 47.5 (0.49->127) Data Source: m5.3.5.4 ING112574 Annex B Clinical Virology Report Table 12.9 Table 12.42, Figure 12.1

Table 78 Baseline DTG FC by Baseline pre-defined IN mutation category, ITT- E population

DTG 50mg BID (N=183)a Q148+≥2 Q148+1 N155 Y143 ≥2 Primary Primary not detected n 21 31 30 28 7 59

Median 10.00 4.60 1.49 1.10 4.57 0.89

Q1 4.47 3.39 1.29 0.91 1.68 0.80 Q3 13.00 6.27 1.76 1.18 20.00 1.04 Min. 2.56 0.47 0.82 0.78 1.46 0.45 Max. 37.00 12.00 3.89 2.01 27.00 3.97 a. Six subjects had missing DTG FC at Baseline Data Source: m5.3.5.4 ING112574 Annex B Clinical Virology Report Table 12.66

Limited DTG cross resistance with RAL was noted at baseline. While only 15 (8%) subjects enrolled had virus with DTG FC >10, 112 (61%) subjects had baseline viral phenotypes showing RAL FC at >10.

105 CONFIDENTIAL Module 2.7.2.4 Special Studies

Antiviral activity by baseline phenotypic resistance based on short term functional monotherapy

Phenotypic cut-offs

In the Day 8 VO population (N=177, which consisted of all subjects in the ITT-E population excluding subjects who received incorrect IP, had IP interruption, received a prohibited medication, or discontinued IP prior to the analysis timepoint for a reason other than lack of efficacy) the median change from baseline in HIV-1 RNA was - 1.4 log10 c/mL. When the Day 8 response data was categorized using the response categories defined above, 82% of subjects achieved a full response and 93% achieved an intermediate or full response.

In the Day 8 VO Population, 3% (6/177) subjects who had missing DTG FC at Baseline were not included in this analysis. Figure 1 plots Baseline DTG FC against Day 8 virologic response category for the 171 subjects with DTG FC available at Baseline. On average, the 12 subjects with no response at Day 8 had the highest DTG FC. Considerable overlap in DTG FC was noted between subjects with intermediate and full responses, and several subjects with full responses had FC values that were within the FC IQR for subjects with no response.

Figure 1 Box Plot of Baseline DTG FC by Day 8 Response Category (N=177)

141

Note: diamond indicates mean of DTG FC; Triangle indicates outliers of 95% CI Data Source: ING112574 Annex B Clinical Virology Report Figure 12.103

Linear regression model

As reported in the ING112574 CSR a multivariate analysis was conducted to assess the impact of Day 1 covariates (e.g. demographics, HIV RNA, resistance to DTG, overall susceptibility score of background ART) and PK on antiviral. The results (impact) of

106 CONFIDENTIAL Module 2.7.2.4 Special Studies

those factors that remained in the best fit model are summarized in Table 79 for the Day 8 Virologic Outcome population.

Baseline IN resistance (represented by DTG FC in susceptibility) was strongly associated with the Day 8 response. For every doubling of the DTG FC a smaller reduction in viral load was observed. In addition to DTG FC, Baseline HIV-1 RNA was also significantly associated with Day 8 response. Although the PSS score of the failing regimen remained in this final model, increasing the PSS score was not associated with improved response.

Table 79 Multivariate Analysis of Day 8 Response, Day 8 VO Population

n Baseline Factors Effect of Estimated SE 95% CI for P Value Effect estimated effect 138 PSSf of Day 1 – 8 0 (Ref) ART 1 -0.07 0.095 (-0.26, 0.11) 0.4404 2 0.37 0.199 (-0.02, 0.77) 0.0626 >2 0.52 0.243 (0.04, 1.00) 0.0355 DTG exposure: Day 8 One unit -0.04 0.023 (-0.09, 0.00) 0.0607 C0 (g/mL) increase Baseline DTG FC 2-fold 0.18 0.032 (0.12, 0.24) <0.0001 increase Baseline HIV-1 RNA 10-fold -0.12 0.050 (-0.22, -0.02) 0.0175 (c/mL) increase Ref = reference Note: Baseline characteristics (i.e. viral load, CD4+ cell count, IN resistance mutation category, DTG FC for RAL and DTG, No. of IN pre-specified resistance mutations, PSS/GSS/OSS to Day 1 ARTs, Day 8 PK C0 and PIQ, status of RAL/EVG treatment, duration of prior INI, and taking prohibited medication) were explored in this multivariate linear regression analysis, but only factors that remained in the final main effects model are presented here. Data Source: ING112574 Annex B Clinical Virology Report Table 7.8

Non-linear regression model

The predicted change from Baseline in HIV-1 RNA at Day 8 for each subject with 95% confidence intervals (CI), from a non-linear regression analysis, against baseline DTG FC was plotted in Figure 2. This non-linear analysis adjusted for other potential clinically appropriate confounding factors that were identified from the linear regression model (i.e. Baseline viral load and Day 8 C0). Sensitivity analyses were also performed by excluding 18 subjects with PSS of the failing regimen ≥2, or by removing Day 8 C0 from the model due to its small impact on the response.

DTG FC cut points and their 95% CIs that correspond to an HIV-1 RNA reduction of 0.5 and l.0 log10 c/mL at Day 8 are summarized in Table 80. From the non-linear regression model, the DTG FC cut-off for a no response was 25.99 and the DTG FC cut-off for a full response was <9.45.

Due to the small numbers of subjects in this population with no response (n=12), the upper limit of 95% CI corresponding to ‘no response’ (i.e. <0.5 log10 c/mL viral load

107 CONFIDENTIAL Module 2.7.2.4 Special Studies

reduction, DTG FC cut-off: 25.99) could not be obtained (Table 80). The cut-off for full response was also subject to a large variation with 95% CIs ranging from 5.98 to 15.88.

Figure 2 Plot of Change from Baseline in HIV-1 RNA log10 c/mL by DTG FC, Day 8 VO Population*

*Based on a non-linear regression model adjusted for Baseline viral load and DTG exposure (Day 8 C0). Data Source: ING112574 Annex B Clinical Virology Report Figure 12.101

Table 80 Estimated Baseline DTG FC Cut-offs for Predicting Change from Baseline in Plasma HIV1-RNA at Day 8 (LOCFDB), Day 8 VO Population*

n Change from Baseline in HIV-1 RNA at Day Estimated DTG FC (95% CI) 8 (log10 c/mL) 138 -0.5 25.99 (15.92, - ) -1 9.45 (5.98, 15.88) Based on a non-linear regression model adjusted for Baseline viral load and DTG exposure (Day 8 C0). Data Source: ING112574 Annex B Clinical Virology Report Table 12.102

Since some subjects had no Day 8 C0 assessment, only 78% (138/177) of subjects were included in this non-linear regression analysis (Table 80). To ensure the robustness of results, a sensitivity analysis was performed by excluding the covariate of Day 8 C0 from this modeling (based on 171 subjects with non-missing Baseline DTG FC and baseline viral load). The estimated DTG cut-offs were consistent with the findings from the

108 CONFIDENTIAL Module 2.7.2.4 Special Studies

original analysis. These similar findings were also observed from the sensitivity analysis by excluding subjects with PSS of the failing regimen ≥2.

Day 8 C0 was not included in the genotypic modeling analysis described in the remaining sections, due to a large proportion of subjects with missing Day 8 C0 and no clinically significant impact of DTG exposure on antiviral activity.

Agreement between the derived phenotypic cut-offs and observed response at Day 8 and Week 24

Table 81 summarizes the agreement between the derived phenotypic group and observed response at Day 8. For subjects with DTG FC <9.45 at Baseline (who were predicted to have a full response), 87% (136/156, PPV) achieved a full response. For subjects with DTG FC ≥9.45 (who were predicted to have either an intermediate or no response), 67% (10/15, NPV) had a ‘less than full response’, which means the cut-off of 9.45 misclassifies 33% of subjects with ‘full response’ as ‘less than full response’. For subjects with DTG FC <25.99 at Baseline, 95% (159/168, PPV) achieved full/intermediate responses. For subjects with DTG FC ≥25.99, 100% (3/3, NPV) had no response as predicted.

Table 81 Summary of Phenotypic Cut-offs and Virologic Response at Day 8, Day 8 VO Population

Observed Response Full response Intermediate No response response Predicted Full response (<9.45) 136 (77) 16 (9) 4 (2) Response, Intermediate (9.45 - <25.99) 5 (3) 2 (1) 5 (3) n (%) No response (≥25.99) 0 0 3 (2) Unknown DTG FC 5 (3) 1 (<1) 0 Total 146 (82%) 19 (11) 12 (7) Data Source: ING112574 Annex B Clinical Virology Report Table 12.103

Although both negative and positive predictive values for the DTG cut-off of 25.99 were above 70%, the predicted values were derived from a population with DTG FC ≥25.99 in 3 subjects only. Hence, the PPVs and NPVs pertaining to these cut-offs are subject to large uncertainty.

For the DTG cut-off of response (full or intermediate) determined as 25.99, the PPV was 159/168 (95%) and the NPV was 3/3 (100%) which suggests that any DTG FC below 25.99 FC could be predicted to achieve at least a 0.5 log10 decline in HIV-1 RNA. As noted, few subjects enrolled had high DTG FC, and the DTG FC cut-off of 25.99 was confirmed in this analysis with only three baseline samples. While this phenotypic cut- off did achieve a moderate prediction level of 70%, caution should be used in interpreting these results, given the small number of subjects with ‘no response’ with elevated DTG FC.

109 CONFIDENTIAL Module 2.7.2.4 Special Studies

For the DTG FC cut-off for full response of 9.45, the PPV was 87% (136/156) and the NPV was 67% (10/15). The less than 70% NPV indicates that more than 30% subjects with a DTG FC> 9.45 and achieving full response would be misclassified to ‘less than full response’ based on this cut-off. Therefore the DTG cut-off of 9.45 is not precise in predicting antiviral response.

Analysis of virologic response (Day 8/Week 24) by pre-specified phenotypic group

The data failed to provide a precise phenotypic cut-off for predicting antiviral activity. Therefore, antiviral response at both Day 8 and Week 24 were analyzed by pre-specified clinical phenotypic groupings (Table 82).

Table 82 Virologic Response by pre-specified DTG fold change group at Baseline, VO populations

Day 8 Responsea WK 24 Response n (%) n/N (%) (N=177) (N=101) DTG FC Full response Intermediate No response HIV-1 RNA <50 c/mL response (Snapshot) Missing 5 (83) 1 (17) 0 4/4 (100) 0 to 2.5 109 (92) 10 (8) 0 55/71 (77) >2.5 to 4 11 (92) 1 (8) 0 2/6 (33) >4 to 8 14 (64) 5 (23) 3 (14) 5/11 (45) >8 to 10 3 (75) 0 1 (25) 1/4 (25) >10 to 15 2 (29) 2 (29) 3 (43) 0/2 >15 to 20 1 (33) 0 2 (67) 0/2 >20 to 25 1 (100) 0 0 0 >25 0 0 3 (100) 0/1 a. Full response: HIV-1 RNA reduction from Baseline >1.0 log10 c/mL or HIV-1 RNA <50 c/mL at Day 8; Intermediate: HIV-1 RNA reduction from Baseline 0.5 - 1.0 log10 c/mL or HIV-1 RNA <400 c/mL at Day 8; No response: HIV-1 RNA reduction from Baseline reduction < 0.5 log10 c/mL at Day 8 Data Source: ING112574 Annex B Clinical Virology Report Table 12.111 and Table 12.18

The proportion of subjects with plasma HIV-1 RNA <50 c/mL at Week 24 by the snapshot algorithm are presented in Table 83 by susceptibility of OBR (i.e. OSS) and phenotypic resistance cut-offs derived from the Day 8 response analysis for the Week 24 VO Population (N=101). The DTG FC cut-off of 9.45 correctly predicted a full response at Week 24 in 69% of subjects with DTG FC<9.45. However, only six subjects had a DTG FC ≥9.45 available for analysis at Week 24.

DTG FC cut-off could not be applied to 4 subjects with full response at Week 24 due to missing DTG FC at Baseline.

Data presented in Table 83 also show that the response at Week 24 did not increase with increasing OSS, which is consistent with findings from the multivariate analysis reported in the m5.3.5.1, ING112574 Week 24 Clinical Study Report.

110 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 83 Summary of Virologic Response by Phenotypic Cut-offs and OBR OSS at Week 24, Week 24 VO Population

HIV-1 RNA <50 c/mL at Week 24 (Snapshot) Predicted response based on OSS = 0 OSS = 1 OSS ≥2 Overall DTG FC cut-offs Full response (<9.45), n (%) 3/4 (75) 26/36 (72) 34/51 (67) 63/91 (69) Intermediate (9.45 - <25.99), n (%) 0 0/5 (0) 0 0/5 (0) No response (≥25.99), n (%) 0 0/1 (0) 0 0/1 (0) Unknown DTG FC, n (%) 2/2 (100) 1/1 (100) 1/1 (100) 4/4 (100) Data Source: ING112574 Annex B Clinical Virology Report Table 12.108

A similar analysis for HIV-1 RNA <400 c/mL at Week 24 is presented in Table 84. The DTG FC cut-off of 9.45 correctly predicts a response (i.e. <400c/mL) at Week 24 in 75% of subjects with DTG FC <9.45. One of the 6 subjects (17%) with DTG FC ≥9.45 achieved HIV-1 RNA <400 c/mL.

Table 84 Summary of Virologic Response by Phenotypic Cut-off and OBR OSS at Week 24, Week 24 VO Population

HIV-1 RNA <400 c/mL at Week 24 (Snapshot) Predicted response based on DTG FC OSS = 0 OSS = 1 OSS ≥2 Overall cut-offs Full response (<9.45), n (%) 3/4 (75) 27/36 (75) 38/51 (75) 68/91 (75) Intermediate (9.45 - <25.99), n (%) 0 1/5 (20) 0 1/5 (20) No response (≥25.99), n (%) 0 0/1 (0) 0 0/1 (0) Unknown DTG FC, n (%) 2/2 (100) 1/1 (100) 1/1 (100) 4/4 (100) Data Source: ING112574 Annex B Clinical Virology Report Table 12.115

Antiviral activity by baseline genotypic resistance based on the short term functional monotherapy

As outlined in the analysis, if at least one of the above cut-offs has both a PPV >70% and a NPV >70%, it would provide the rationale for further analysis of predictors of response.

Genotypic resistance was closely correlated with phenotypic resistance at Baseline. Also because both negative and positive predictive values for Day 8 response by the DTG cut- off (25.99) were above 70% (with the caveat of DTG FC ≥25.99 observed in 3 subjects only), virologic response by baseline genotypic resistance was performed as planned.

Prevalence

At Baseline in this population, 31% (57/183) of subjects had virus with Q148H, Q148K, or Q148R as a full mutation or a mixture of mutations (Table 85). In the 57 viruses with

111 CONFIDENTIAL Module 2.7.2.4 Special Studies

Q148 mutations, additional IN secondary mutations were detected at 11 different codons (Table 86).

Table 85 Prevalence of IN Resistance Mutation at Baseline, ITT-E population

IN Resistance Mutation DTG 50mg BID (N=183) Any IN Resistance Mutation 136 (74%) E92Qa 2 (1%) T66A/I/Ka 4 (2%) L68I/V 4 (2%) G193E 6 (3%) S147G 5 (3%) Q95K 7 (4%) E157Q 15 (8%) G163K/R 18 (10%) E138A/K/T 24 (13%) V151I 27 (15%) T97A 32 (17%) Y143C/H/Ra 32 (17%) L74I/M 35 (19%) N155H* 36 (20%) G140A/C/S 54 (30%) Q148H/K/R* 57 (31%) a. Primary IN resistance mutation. Data Source: m5.3.5.4 ING112574 Annex B Clinical Virology Report Table 12.7

Table 86 Prevalence of IN Resistance Mutation at Baseline, ITT-E Population with Q148 Mutation at Baseline

IN Resistance Mutation at Baseline DTG 50mg BID (N=57) T97A 1 (2%) T66A 2 (4%) Y143H/R 2 (4%) E157Q 2 (4%) G163R 2 (4%) V151I 3 (5%) S147G 4 (7%) G193E 4 (7%) L74I/M 7 (12%) E138A/K/T 20 (35%) G140A/C/S 53 (93%) Q148 57 (100%) Data Source: ING112574 Annex B Clinical Virology Report Table 12.67

112 CONFIDENTIAL Module 2.7.2.4 Special Studies

Correlation between mutations

The baseline mutations with a p value <0.01 and Phi statistics >0.6 from the pair-wise correlation analysis are summarized in Table 87. G140 mutations were strongly correlated with mutations at Q148 with Phi statistics of 0.93; 51 subjects harboured virus with both G140A/C/S and Q148H/K/R and very few subjects had virus with only one of the two mutations.

If two highly correlated parameters were entered into the same regression model, the estimates of these parameters from the model may not be valid due to colinearlity. Hence, the pair was not concurrently entered into the same regression model in the analyses that were described in the remaining sections. Only Q148 was entered in the model in conjunction with other mutations.

Table 87 Summary of Pair-wise Correlation Analysis between Pre-Specified IN mutations (Day 8 Virologic Outcome pop N=177) (DTG 50mg BID)

Mutation pair N with one N for both N for both not Phi P value mutation detected detected detected Statistics N155H vs V151I 13 (7%) : 6 (3%) 20 (11%) 138 (78%) 0.62 <0.0001 N155H vs V151/IL 13 (7%) : 6 (3%) 20 (11%) 138 (78%) 0.62 <0.0001 T97A vs Y143C/H/R 9 (5%) : 10 (6%) 21 (12%) 137 (77%) 0.62 <0.0001 S147G vs T66A 3 (2%) : 0 (0%) 2 (1%) 172 (97%) 0.63 0.00064 G140A vs Q148R 0 (0%) : 5 (3%) 4 (2%) 168 (95%) 0.66 <0.0001 G140S vs Q148H/K/R 1 (1%) : 8 (5%) 47 (27%) 121 (68%) 0.88 <0.0001 G140A/C/S vs Q148H 6 (3%) : 0 (0%) 46 (26%) 125 (71%) 0.92 <0.0001 G140A/C/S vs 1 (1%) : 4 (2%) 51 (29%) 121 (68%) 0.93 <0.0001 Q148H/K/R G140S vs Q148H 2 (1%) : 0 (0%) 46 (26%) 129 (73%) 0.97 <0.0001 Note: only Phi statistics>0.6 and P<0.01 are listed Data Source: ING112574 Annex B Clinical Virology Report Table 12.104

113 CONFIDENTIAL Module 2.7.2.4 Special Studies

Regression analyses

Regression analyses were used to determine specific mutations associated with Day 8 responses in a stepwise fashion. First mutations with a moderate association (p<0.3) were identified, Second, the identified mutations from step 1 were entered into a boostrap re-sampling analysis to quantify mutations significantly predicting Day 8 responses. Mutations identified in this analysis were E138A/K/T, E92Q, L68I, L74I, Q148H/K/R. Third, these mutations and their 2-way interaction terms were entered into a series of linear regression models with all possible parameter combinations. The results (impact) of these mutations and their interaction terms that remained in the best fit of model with the smallest AIC were displayed. Based on the results from this third step and the mutation prevalence analyses, IN mutation groups at Baseline were derived to better predict virologic response.

Derived IN resistance mutation group

Three IN mutation groups at Baseline were derived based on the results from the multivariate analysis:

 No Q148 mutation (143, 155, 66, 92, or historical resistance only),

 Q148+ 1 (Q148H/K/R with one mutation [G140A/C/S, L74I, E138A/K/T]), and

 Q148 +2 (Q148H/K/R with two or three mutations (G140A/C/S, L74I, E138A/K/T).

Analysis of virologic response (Day 8/Week 24) by derived genotypic group

The analysis of Day 8 antiviral response by the derived IN mutation groups revealed that a full response (>1 log10 c/ml decrease in HIV-1 RNA or <50c/mL) was seen in 92% of subjects harbouring virus with no Q148 mutations. In virus with Q148 mutations, decreased proportions of subjects with full response were seen with each additional IN secondary resistance mutation (i.e. L74I, E138_AKT) (Table 88). A similar pattern of response by the derived IN mutation groups was seen at Week 24, which was independent of the activity of the background regimen as determined by the overall susceptibility score (OSS) (Table 89 and Table 90).

Table 88 Day 8 Virologic Response by Derived Mutational Group from the Part II Analysis, Day 8 VO Population

b DTG 50mg BID Change from Baseline in VL (log10 c/mL) Full Response Derived Group N Mean SD Median Min Max n (%) No Q148 122 -1.59 0.509 -1.65 -3.4 0.0 112 (92) Q148 + 1a 35 -1.18 0.520 -1.10 -2.6 -0.1 25 (71) Q148 + 2a 20 -0.92 0.810 -0.735 -2.3 0.4 9 (45) a. L74I, Q138A/K/T , G140A/C/S b. Full response: reduction from baseline in HIV-1 RNA>1 log10 c/mL or HIV-1 RNA <50 c/mL at Day 8 Data Source: ING112574 Annex B Clinical Virology Report Table 12.106, Table 12.110

114 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 89 Week 24 Virologic Response (HIV-1 RNA <50 c/mL) by Derived Mutational Group and OSS of OBR, Week 24 VO Population

HIV-1 RNA <50 c/mL at Week 24 (Snapshot) Derived IN Mutation Group OSS=0 OSS=1 OSS=2 OSS>2 Total No Q148a, n (%) 2/2 (100) 24/29 (83) 21/28 (75) 10/13 (77) 57 (79) Q148 + 1b, n (%) 2/2 (100) 3/7 (43) 4/11 (36) 0 9 (45) Q148 + 2b, n (%) 1/2 (50) 0/7 (0) 0 0 1 (11) a. 143, 155, 66, 92, historical resistant evidence only. b. G140A/C/S, E138A/K/T, L74I Data Source: ING112574 Annex B Clinical Virology Report Table 12.107

Table 90 Week 24 Virologic Response (HIV-1 RNA <400 c/mL), by Derived Mutational Group and OSS of OBR, Week 24 VO Population

HIV-1 RNA <400 c/mL at Week 24 (Snapshot) Derived IN Mutation Group OSS=0 OSS=1 OSS2 Total No Q148a, n (%) 2/2 (100) 24/29 (83) 35/41 (85) 61 (85) Q148 + 1b, n (%) 2/2 (100) 4/7 (57) 4/11 (36) 10 (50) Q148 +2b, n (%) 1/2 (50) 1/7 (14) 0 2 (22) a. 143, 155, 66, 92, historical resistant evidence only. b. G140A/C/S, E138A/K/T, L74I Data Source: m5.3.5.4 ING112574 Annex B Clinical Virology Report Table 12.114

Summary of analysis for phenotypic and genotypic correlates to antiviral response

CHMP guidance for new drug application in an existing class requires an attempted summary of antiviral activity for a new drug by phenotypic cut points and genotypic mutation scoring. This summary cannot be provided for DTG for the following reasons. Upper and lower phenotypic clinical cut-offs were estimated for DTG, but the confidence intervals around these values were very wide suggesting large uncertainty with the cut- offs (Table 84). No genotypic scoring could be derived from the dataset for this patient population, however 3 derived IN mutation groups were identified and short term and Week 24 responses are provided by these groups (Table 88 and Table 89). Study specific factors influencing this conclusion were a small study size, few subjects with high DTG FC and excellent short term antiviral response rates.

Ad-hoc analyses

As per the EMA guideline, data from the functional monotherapy phase were used to derive phenotypic cut-off points. The use of the functional monotherapy phase data allows assessment of the intrinsic activity of this investigational product and minimizes confounding factors. In study ING112574 the functional monotherapy phase was short (7 days), However, there were several limitations to using longer term on treatment study data to determine the phenotypic cut-off points for DTG in this clinical study.

115 CONFIDENTIAL Module 2.7.2.4 Special Studies

Given that the activity of the background regimen was optimized at Day 8, investigating the impact of only DTG on antiviral response after this timepoint would be complicated by the need of controlling for the activity of the background regimen co-administered with DTG. This is further complicated when a ‘precise’ measure of the activity of the background regimen is difficult to obtain in such a highly treatment experienced population with potential archived resistant virus.

In a longer term investigation of the activity of DTG, drug adherence could also impact the accuracy of the derived phenotypic cut points. Incomplete compliance over time would provide an inaccurate determination of drug activity and could potentially result in lower phenotypic cut points.

Understanding these limitations and their potential impact on the derivation of a phenotypic cut point, an analysis was conducted using antiviral response data at Week 24 and DTG FC. This investigation was not part of the planned analysis and does not meet the EMA requirements for phenotypic cut point derivation and as such should be considered exploratory.

The number and proportion of subjects achieving full response (i.e. <50 c/mL, Snapshot) at Week 24 for each pre-specified DTG FC value at Baseline are summarized in Table 91. For example, 74% (57/77) of subjects with DTG FC ≤4 at baseline achieved full response at Week 24 and 30% ( 6/20) of subjects with DTG FC >4 also achieved full response at Week 24.

The number of subjects with DTG FC >10 is small (n=9).

Table 91 HIV-1 RNA <50 copies/mL (Snapshot) at Week 24 by Pre-specified DTG FC Value at Baseline (N=101)

Baseline DTG FC Pre- Less or Equal to Pre-specified Value Greater than Pre-specified Value specified value n (%) n (%) 2.5 55/71 (77) 8/26 (31) 4 57/77 (74) 6/20 (30) 8 62/88 (70) 1/9 (11) 10 63/92 (68) 0/5 15 63/94 (67) 0/3 20 63/96 (66) 0/1 25 63/97 (65) 0/0 Note: Only 97 subjects with DTG FC available at Baseline were included in this analysis. Data Source: ING112574 Annex B Clinical Virology Report Table 7.32

A receiver operating characteristic (ROC) analysis was produced in attempt to identify a DTG cut-off that would differentiate the Week 24 response (Figure 3). The X axis indicates ‘1 minus specificity’ (i.e. specificity: the proportion of responders at Week 24 with DTG FC ≤cut-off ). The Y axis indicates sensitivity (i.e. proportion of non- responders at Week 24 with DTG FC >cut-off). The perfect predictor would yield a point in the upper left corner or coordinate (0, 1) of the ROC space, representing 100%

116 CONFIDENTIAL Module 2.7.2.4 Special Studies

sensitivity (no false negatives) and 100% specificity (no false positives). A completely random guess would give a point along a diagonal line (i.e. a line of no-discrimination) from the left bottom to the top right corner (the dot reference line in Figure 3). Figure 3 shows that the observed ROC curves for DTG FC is not far away from the line of no- discrimination, suggesting that the prediction effect of DTG FC on Week 24 response may be confounded by other factors (e.g. OBR, non-compliance). The ‘best’ cut-off from this ROC analysis is DTG FC=3.39 with a sensitivity of 53% and specificity of 90%. The low sensitivity indicates that only 53% of non-responders had DTG FC >3.39 at Baseline. Hence, the ROC cutoff analysis based on Week 24 response data is not helpful and inappropriate for predicting virologic response.

Figure 3 ROC Analysis of Week 24 Response (<50c/mL, Snapshot) by Baseline DTG FC (N=101)

Data Source: ING112574 Annex B Clinical Virology Report Figure 12.104 and Table 12.66

Results from this exploratory analysis illustrate the problematic interpretation of this analysis (Table 92). The DTG phenotypic cut-off of 3.39 provided a PPV and a NPV of >70% in predicting Week 24 response. However, when this phenotypic cut-off was applied to the Day 8 antiviral response, a better endpoint for quantifying the independent contribution of DTG, the NPV was only 41%, indicating that almost 60% of subjects with DTG FC ≥3.39 would be misclassified as having a ‘less than full response’ (≤1 log10 c/mL reduction in viral load) by this cut-off rather than their actual observed ‘full response’ (>1 log reduction of viral load). As this cut-off could not predict antiviral activity of DTG at Day 8, this analysis is invalid and should therefore not be used in this situation to derive DTG FC cut-offs.

117 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 92 Response Rate based on DTG FC Cut-off of 3.39

Timepoint DTG FC at Baseline Observed PPV NPV Response rate WK24 (<50c/mL) <3.39 56/72(78%) 78% ≥3.39 7/25 (28%) 72% Day 8 (HIV-1 RNA <3.39 112/122 (92%) 92% reduction >1.0 log10 c/mL or <50 c/mL ) ≥3.39 29/49 (59%) 41% Data Source: ING112574 Annex B Clinical Virology Report Table 12.113 and Table 12.109

Discussion:

According to the FDA and EMA Guidance for clinical development of medicinal products, antiviral activity of a new agent should be provided by Baseline phenotypic and genotypic resistance. In this report, phenotypic resistance was defined as the DTG FC cut-off and genotypic resistance was defined as the mutation or mutational group that leads to a reduced response. Since DTG phenotypic data are highly correlated to genotypic data, an assessment of DTG cut-off was conducted first. If this analysis provided a DTG FC cut-off with a modest PPV and NPV of >70%, an investigation of genotype would be performed.

Upper and lower phenotypic cut-offs were estimated from a non-linear regression model based on the antiviral response data at Day 8. However, the confidence intervals for both estimated cut-offs were very wide or not definable, suggesting large uncertainties with the two cut-offs. Not surprisingly, the prediction of long term response at Week 24 with these cut-offs was not accurate. The derived genotypic grouping appears to be more effective in predicting both short and long-term response. Results from this analysis complement those from the multivariate analysis presented in the m5.3.5.1,ING112574 Week 24 Clinical Study Report, which showed that baseline resistance (as DTG FC) was strongly associated with the Day 8 response in that increasing DTG FC led to smaller reductions in HIV-1 RNA. The low prediction rate of derived phenotypic cut-offs seen in this study could potentially be due to the study population responding well to DTG BID. In fact, 82% of subjects had a full response to DTG (>1 log10 c/mL decline from baseline in plasma HIV-1 RNA) at Day 8. Additional reasons for the low predictive value of the derived DTG FC cut-offs could be the small number of subjects with DTG FC greater than the derived cut-off for full response (8%, 15/177) in this INI-resistant population. Previous studies have shown that adequate sample size and sufficient numbers of subjects with elevated FC are required to ensure the accuracy of these determinations [de Meyer , 2008; Schapiro, 2010; de Luca , 2011].

Three IN mutation groups were derived from the analysis: ‘No Q148 mutation’ (Y143, N155H, T66, and E92Q mutations or historical evidence of INI resistance), ‘Q148+1’ (Q148H/K/R with one mutation [G140ACS, L74I, E138_AKT]), and ‘Q148+2’ (Q148H/K/R with two or three mutations [G140A/C/S, L74I, E138A/K/T]). At Day 8,

118 CONFIDENTIAL Module 2.7.2.4 Special Studies

the majority (92%) of subjects harbouring virus with “No Q148” had a >1 log10 c/mL decline in HIV-1RNA, while 71% and 48% response rates were seen in subjects from the IN mutation groups Q148+1 and Q148+2, respectively. In this patient population, the Q148+2 virus was detected in only 11% of subjects at Baseline. This proportion is similar to that observed in larger INI resistant populations (m5.3.5.2, 2012N146158_00).

Results from this analysis confirm earlier in vitro and in vivo investigations of DTG, which showed that each additional IN secondary mutation in a Q148 mutant virus further reduced antiviral responses are expected [Kobayashi, 2011; Vavro, 2012]. One explanation for the better observed predictions with IN genotypic correlates as compared to DTG FC involves the broad range of DTG FC seen with Q148 mutant virus. As noted in earlier clinical investigation, DTG FC was highly correlated to IN resistance pathways in that moderate to high DTG FC was seen with the Q148 mutant virus and. the highest DTG FC was detected in virus with Q148+2 additional IN resistance mutations. In this study, a broad diversity in DTG FC was seen with Q148+2 virus. This broad diversity in DTG FC may be due to the presence of secondary mutations in disparate number and combinations, or due to wild-type virus masking mutant virus resistance when present as a positional mixture (e.g. as Q148Q/H G140G/S) [Underwood, 2009].

The three derived IN mutation groups also provided good prediction for Week 24 antiviral responses. As was seen with the Day 8 analysis, the vast majority of subjects with virus in the “No Q148” group achieved <400 c/mL at Week 24 (85%) and lower response rates were seen with Q148+1 and Q148 +2, 50% and 22 % respectively. Given the heavily treatment-experienced population that was enrolled in ING112574, the 22% of subjects with Q148+2 achieving HIV-1 RNA of <400 c/mL at Week 24 is an encouraging result, which may potentially be improved upon with the co-administration of a background regimen with robust antiviral activity (in this study a fully active boosted PI as part of Day 8 OBR was used in only 23% of subjects). In comparison with other studies in a similar patient population [Clotet 2007], the findings from this analysis suggest that a regimen of DTG BID given with an OBR with PSS1 will provide benefit to the majority of subjects and that the derived IN mutation groups can further aid prescribers who would use DTG in INI-resistant patients.

An exploratory analysis to produce DTG FC cut-offs using Week 24 viral responses was attempted and produced a DTG FC cut-off of 3.39 for full response (HIV-1 RNA <50 c/mL). However, when this cut-off was applied to Day 8 responses it did not accurately predict viral response. Possible limitations to this exploratory analysis included additional antiviral effect of the background regimen at Week 24 and poor adherence over longer term evaluation [Brun-Vézinet , 2004]. The background regimen was optimized after 7 days of functional monotherapy, thereby limiting the opportunity to evaluate the precise effect of DTG alone longer-term. This exploratory analysis was conducted outside of the CHMP-recommended short-term treatment duration.

In conclusion, the analysis to determine phenotypic and genotypic correlates to viral responses provided IN genotypic mutational groups but no DTG FC cut-off that effectively predicted antiviral response. Therefore, Annex B requirements were met by providing Week 24 responses by OSS of the OBR and the derived IN genotypic mutational groups or pre-specified DTG FC categories. Our analyses suggest that the

119 CONFIDENTIAL Module 2.7.2.4 Special Studies

derived IN genotypic group best describes the likelihood of response according to baseline resistance profile.

Periodic surveys of emerging IN mutation patterns may be necessary to sustain the accuracy of the derived genotypic groups to predict DTG antiviral response, particularly following more widespread use of the drug.

 Conclusions

 Increasing Baseline DTG FC was significantly associated with decreasing antiviral activity. However, no precise phenotypic FC cut-off could be defined to effectively predict antiviral activity at both Day 8 and Week 24.

 Three baseline genotypic resistance groups were identified based on their differential impact on DTG antiviral response. These three distinct IN genotypic groups are:

o No Q148: includes Y143, N155H, T66, E92 mutations, or historical evidence of resistance;

o Q148+1: Q148H/K/R with one mutation of G140A/C/S, L74I, E138A/K/T]; and

o Q148+2: Q148H/K/R with two or more mutations of G140A/C/S, L74I, E138A/K/T.

 The best antiviral responses (at both Day 8 and Week 24) were seen in the ‘No Q148’ group. In subjects harbouring virus of Q148, a decreased response was observed with increasing numbers of mutations of G140A/C/S, L74I, E138A/K/T.

 The derived genotypic groups provide a robust and predictive genotypic guidance for response in this INI-resistant patient population.

4.2.2. Phase IIb Clinical Studies

Two Phase IIb studies were conducted for dose selection in INI-naive and INI-resistant patients, ING112276 (treatment-naive) and ING112961 (treatment-experienced, integrase-resistant). There were no INI resistance mutations nor changes in DTG susceptibility at the time of virologic failure for any of the three subjects receiving DTG in ING112276. DTG trough concentration for a single 50 mg dose in integrase inhibitor naïve subjects was 1.20 g/mL, 19 times higher than the estimated PA-IC90.

Due to the large diversity of IN genotypic profiles at baseline in ING112961 and upon virologic failure, and the limited number of subjects’ data, it is difficult to make any conclusions about INI resistance mutations selected by DTG and potential relationship with treatment outcome. The data in this Phase 2b study support the continued and definitive evaluation of 50mg BID DTG in Phase III in subjects with evidence of INI resistance at current or prior virologic failure with RAL or EVG containing regimen.

120 CONFIDENTIAL Module 2.7.2.4 Special Studies

4.2.2.1. ING112276

Location of Report: 5.3.5.1

Study Design: Study ING112276 is a Phase IIb, randomized, multicentre, parallel group, dose-ranging study conducted in HIV-1 infected ART-naïve adults. The trial was partially blinded, i.e. subjects and their investigators were blinded to the dose of DTG. Subjects received DTG, at one of three doses, or EFV once daily, both co-administered with either abacavir sulfate (abacavir, ABC) and lamivudine (3TC), (abacavir/lamivudine, ABC/3TC), or tenofovir/emtricitabine (TDF/FTC) fixed dose combinations (FDC) as background therapy. The current analysis was conducted after the last subject completed Week 96. At the Week 96 visit, subjects randomized to EFV were discontinued from the study, while subjects randomized to receive DTG were given the opportunity to remain on the study while receiving DTG 50 mg during an open-label phase of the study.

Virologic failure was defined as a less than 1.0 log10 c/mL decrease in plasma HIV-1 RNA by week 4 unless the measure was lower than 400 c/mL, failure to suppress plasma HIV-1 RNA to less than 400 c/mL on or after week 24, rebound to 400 c/mL or more after suppression to less than 400 c/mL, or rebound to greater than 0.5 log10 above nadir if 400 c/mL or greater. Participants with confirmed virologic failure (two consecutive samples 1-4 weeks apart) were assessed for study discontinuation and had samples analyzed for genotypic and phenotypic resistance.

Results: Four subjects, including one subject who received EFV, had PDVF by week 48. No additional subjects had PDVF through week 96.

Subject 77, who received TDF/FTC and 10 mg of DTG, had a 2.84 log10 c/mL decline in RNA at Week 2, but rebounded at Week 4. The only RT resistance mutation observed on treatment was M184M/V. No INI-associated substitutions or changes in susceptibility to either DTG or RAL were demonstrated. This subject was withdrawn at the time of conformation.

Subject 102 received TDF/FTC and EFV, and had less than a 1 log10 c/mL decrease in HIV-1 RNA by Week 4. On treatment GT and PT showed no changes in RT, and the subject continued on study with subsequent suppression at Week 20.

Subject 99 met the definition of protocol-defined virologic failure at Week 24. The subject received ABC/3TC and DTG 25 mg and had a plasma HIV-1 RNA value of 404 c/mL at the Week 24 visit. The confirmatory plasma HIV-1 RNA value was 483 c/mL. There is documented noncompliance with study medication for this subject. At Baseline, this subject had no primary mutations in HIV reverse transcriptase or protease (RT/PRO) and no phenotypic resistance to NRTIs, NNRTIs or protease inhibitors (PIs).

121 CONFIDENTIAL Module 2.7.2.4 Special Studies

Genotypic data (RT/PRO) could not be generated at virologic failure (Week 24), likely due to the low level of plasma HIV-1 RNA. There were no primary INI resistance mutations detected at either Day 1 or Week 24. This subject was withdrawn at the time of conformation.

Subject 808 who received ABC/3TC and 10 mg DTG, rebounded to >400 c/mL at Week 40. The subject was non-compliant with study medications at the time of virologic failure. Virologic failure was confirmed two week later prior to the subject becoming compliant with study medications. The subject began taking study medications and HIV-1 RNA was <400 c/mL three weeks after the confirmatory sample. No RT or INI mutations or changes in PT were detected at the time of virologic failure (Week 40). The subject continued in the study with continued response to therapy up to Week 108 at which time the subject withdrew..

There were no integrase inhibitor resistance mutations nor changes in DTG susceptibility at the time of virologic failure for any of the three subjects receiving DTG.

Dolutegravir trough concentration for a single 50 mg dose in integrase inhibitor naïve subjects was 1.20 g/mL, 19 times higher than the estimated PA-IC90.

Discussion

A low rate of confirmed protocol-defined virological failure was observed with no treatment emergent mutations in the integrase gene detected in the three subjects receiving DTG who developed virologic failure. The rate of viral decay was much faster in the DTG treatments arms than the EFV arm, similar to what has been observed for Raltegravir, indicating a unique mechanism of the antiviral activity of integrase inhibitors. A post hoc analyses using an assay with a lower limit of detection of <2 c/mL at Weeks 16, 24, 48 and 96 confirmed the faster rate of decay of subjects in the 50 mg dose arm than the EFV control

Conclusions

No subject in the 50 mg DTG group met protocol defined virologic failure through 96 weeks. No integrase mutation swere identified in this study.

Dolutegravir trough concentration for a single 50 mg dose in integrase inhibitor naïve subjects was 1.20 mcg/mL, 19 times higher than the estimated PA-IC90.

4.2.2.2. ING112961

Study Title: A Phase IIb pilot study to assess the antiviral activity of dolutegravir containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance (Cohort I Week 96, Cohort II Week 48)

Location of Report: 5.3.5.2

122 CONFIDENTIAL Module 2.7.2.4 Special Studies

Study Design: Study ING112961 (VIKING) was a Phase IIb, multicenter, open-label, single arm pilot study to assess the antiviral activity of dolutegravir (DTG) containing regimen in human immunodeficiency virus type 1 (HIV-1) infected ART-experienced adults with raltegravir (RAL) resistance. The study was originally designed to include approximately 30 ART-experienced subjects with either current or past virologic failure to RAL and harbouring RAL associated, primary IN resistance mutations. As pre- specified in the protocol, as some subjects with higher level of DTG resistance had an inadequate response to DTG 50 mg once daily, an additional cohort exploring a higher dose of DTG (50 mg BID) was initiated. In Cohorts I and II, subjects with current RAL virologic failure substituted RAL with DTG 50 mg once daily (Cohort I) or twice daily (Cohort II) or subjects with historical RAL virologic failure added DTG 50 mg once daily (Cohort I) or twice daily (Cohort II). On Day 11 all subjects continued DTG and optimized their background therapy, where feasible, but were required to have at least 1 fully active background drug (PSS1) in Cohort II. Antiviral activity, safety and tolerability of DTG were evaluated at Day 11 and over time.

Methods for Virologic Analysis: Baseline IN genotypic resistance data were used to produce 6 categories for analysis based on mutational pathway: (1) Q148 + 1 (associated mutation at one of codons 74, 138, or 140, but not codons 155 or 143); (2) Q148 + 2 (associated mutations at 2 of codons 74, 138, or 140, but not 155 or 143); (3) mixture (mutations at codons 148,155 or 143); (4) N155 (mutations at codon 155 but not at 148 or 143); (5) Y143 (mutations at codon 143 but not at 148 or 155); and (6) other (no mutations at codons 148, 155, or 143). A comparison of on-treatment to Day 1 genotypic and phenotypic data was made for all subjects with data available at Day 11 (samples with plasma HIV-1 RNA ≥150c/mL) and for subjects meeting the criteria for PDVF.

Protocol-defined virologic failure was defined as the following: at Day 11, <0.7 log10 c/mL decrease in plasma HIV 1 RNA unless absolute value was <400 c/mL; at or after Week 8, <1.0 log10 c/mL decrease unless absolute value was <400 c/mL, or 1.0 log10 c/mL increase in plasma HIV-1 RNA from the nadir value; or for visits at or after Week 16, plasma HIV-1 400 c/mL. Virologic failure at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8.

Results:

The Baseline Populations for viral genotyping/phenotyping analyses for Cohort I (N=27) and Cohort II (N=24) included all subjects in the Intent-to-Treat (Exposed) population (ITT-E). All on-treatment genotypic and phenotypic data were compared with Baseline data (Day 1).

The On-treatment Resistance Populations for Cohort I (N=16) and Cohort II (N=5) consisted of ITT-E subjects who met the criteria for protocol-defined virologic failure (PDVF). These subjects were tested at the first timepoint of the PDFV criterion rather than at the confirmatory test (if applicable) and the resulting viral genotypic and/or phenotypic data were compared to the Baseline (Day 1) data. Additionally, an ad hoc analysis of INI genotype and phenotype was conducted at Day 11 for any subject with plasma HIV-1 RNA 150 c/mL.

123 CONFIDENTIAL Module 2.7.2.4 Special Studies

Baseline (Day 1) Viral Genotyping/Phenotyping Analyses

Prior RAL duration by In Mutational Group

In Cohort I, 18/27 subjects entered the study with Screening RAL signature mutations consistent with the protocol-led Group Q148, Y143 or N155 and 9/27 subjects entered with RAL associated mutations consistent with Group Q148+>1. For the 24 subjects enrolled in Cohort II, 13/24 subjects entered with Screening RAL signature mutations consistent with Group Q148, Y143 or N155 and 11/24 subjects entered with RAL associated mutations consistent with Group Q148+>1.

Prevalence of IN Substitutions at Day 1 by IN Mutational Group.

Table 93 and Table 94 give the summary of INI resistance-associated substitutions as well as several additional IN substitutions observed in greater than 50% of the viral genotypes examined.

Cohort I

The Y143 group (N=12) was the largest mutational group and showed the most viral diversity with 10/12 viral populations also harbouring: L74L/M, M or I; T97T/A or A and less frequently substitutions at the 138 or 163 positions.

124 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 93 Cohort I: Summary of the Prevalence of IN substitutions by INI Mutational Groupa

IN Codonb Q148 + 2 Q148 Mixture Y143 N155 Other Total N=3 +1 N=2 N=12 N=4 N=2 N=27 N=4 V72I 3 4 2 12 4 2 27 L74I,M 2 - - 10 1 - 13 E92Q - - - - - 1 1 T97A - - - 10 2 - 12 L101I,T 2 3 2 7 2 1 17 V113I,L 3 4 2 11 3 2 25 S119P,R,G,T 1 3 1 10 2 1 18 T124N,S,A,D 3 2 1 7 4 2 19 E138K,T,A,D,Q,P 1 - 1 4 1 - 7 G140S 3 4 2 - - - 9 Y143H,R,C 2 12 - - 14 Q148H,R 3 4 2 - - - 9 V151I - - - - 3 - 3 N155H - - - - 4 - 4 G163R 1 - - 3 1 - 5 G193D - - - 1 - - 1 V201I 1 3 1 6 3 1 15 V234L,I 2 4 2 11 4 1 24 a. Pre-defined IN mutations are highlighted in grey rows b. Note that some mutations detected were mixtures of amino acids. Data Source: m5.3.5.1 ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.4 and Table 12.11

Each subject with viral isolates harbouring the Q148H/R mutation (n=9), also had RAL associated mutation G140S, and IN substitutions at position 113 and 72. The Q148K mutation was not observed. For those in the Q148+2 mutational group (N=3), all 3 had G140S, two viruses harboured L74I and one had E138K/T. For the viral isolates in the Q148+1 mutational group (N=4), all 4 had G140S only. The Mixture group (N=2) could include viruses with Q148H/K/R and N155H or Y143C/H/R. In this study only mixtures of Q148H and Y143H were detected.

For the 4 subjects with virus from the N155H group, 3/4 viral populations additionally had the V151I or V/I, 2/4 had T97A and one had L74 L/M/I.

125 CONFIDENTIAL Module 2.7.2.4 Special Studies

Cohort II

In Cohort II, each subject with viral isolates harbouring the Q148H mutation (n=11), also had RAL associated mutation G140S. Like Cohort I, the Mixture group (n=1) had only mixtures of Q148H and Y143H detected. In Cohort II, viral diversity was detected in both the N155H (n=6) and the Y143 groups (n=6).

Table 94 Cohort II: Summary of the Prevalence of IN substitutions by INI Mutational Groupa

IN Codona Q148 + 2 Q148 Mixture Y143 N155 Other Total N=2 +1 N=1 N=6 N=6 N=1 N=24 N=8 V72I, V/I 2 8 1 4 5 1 21 L74I,L/M/I,L/M,I,M - - - 4 1 - 5 E92Q - - - 1 - 1 T97A,T/A - - - 4 2 - 6 V113I,L,V/I 2 7 1 6 5 1 22 T124N,S,A,N/D,T/A 5 - 3 4 - 12 E138A,D, 2 - - 1 - - 3 K/T/Q/P,E/K, G140S 2 8 1 - - - 11 Y143H,R,C 1 6 - - 7 Q148H,Q/H 2 8 1 - - - 11 V151I, V/I - - - - 2 - 2 N155H - - - - 6 - 6 G163R, G/R - - - - 1 - 1 G193D, R, E - 1 - 1 - - 2 V201I, V/I 2 4 1 3 5 - 15 V234L,V/L,I, H,N 2 8 1 6 5 1 23 a. Pre-defined IN mutations are highlighted in grey rows Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.4

Phenotypic susceptibilities to RAL and DTG at Day 1

Results from Table 95 demonstrate that Cohorts I and II had similar median FC for DTG (Cohort I: 1.46 and Cohort II: 2.72), and RAL (Cohort I: 161.35 and Cohort II: 128.01).

126 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 95 Summary of Day 1 Susceptibility for DTG and RAL in Cohorts I and II

Drug Fold Change compared to Cohort I Cohort II wildtype virus 50 mg once daily 50 mg twice daily N=27 N=24 n (%) n (%) DTG <1 5 (19) 2 (8) 1-<2 11 (41) 7 (29) 2-<4 2 (7) 5 (21) 4-<8 4(15) 8 (33) 8 5 (19) 2 (8) DTG - 1.46 2.72 Median (0.55-35) (0.87-9.48) (range) Raltegravir <1 1 (4) 1 (4) 1-<2 - 1 (4) 2-<4 - - 4-<8 1 (4) - 8 to Max of assay limit 7 (26) 9 (38) Max of assay limit 18 (67) 13 (54) Raltegravir - 161.35 128.01 Median (0.57-165.54) (0.78-182.79) (range) Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.26

Results from Table 96 demonstrate that viruses with RAL signature changes, Y143 and N155 have relatively low fold changes in susceptibility to DTG. However for viruses in both Cohorts harbouring multiple mutations with Q148 (Q148+2, Q148+1, and Mixture groups), all but one subject’s virus have DTG FC >3 suggesting that as the number of RAL associated secondary mutations increased so did DTG FC for these viruses.

127 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 96 Summary of Median Fold Change for DTG by IN Mutational Group

INI Cohort I Cohort II Mutational 50 mg once daily 50 mg twice daily Group (N=27) (N=24) n Median FC (range) n Median FC (range) All 27 1.46 24 2.72 (0.55-35) (0.87-9.48) Q148 +2 3 21 2 4 (14-35) (2.1-6.0) Q148 +1 4 5.5 8 5.5 (3.3-25) (4.1-8.2) Mixturea 2 7.8 1 9.48 (6.5-9.1) Y143 12 1.1 6 1.2 (0.6-1.4) (0.92-1.8) N155 4 1.8 6 2.3 (1.5-5.1) (1.3-4.0) Otherb 2 1.2 1 0.9 (0.9-1.5) a. Subjects with virus containing more than one Y143, Q148 or N155 mutation at Day 1. For Cohort I –Subject 1680: Q148H, Y143H, and G140S; Subject 1703: Q148H, Y143H, G140S, and E138A and for Cohort II – Subject 2432: Q148H, Y143Y/H, and G140S b. Subjects with virus having no mutations at codons 143, 148, or 155 at Day 1. Cohort I - Subject 1662 and 1811 and Cohort II – Subject 2320 Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.39

On Treatment Viral Genotyping / Phenotyping

Paired Analysis of Day 1 and Day 11 Integrase Genotypic and Phenotypic Results

Of the 27 subjects in Cohort I and the 24 subjects in Cohort II, 18 and 15 subjects respectively, had samples at Day 11 with HIV-1 RNA 150 c/mL allowing assessment of further IN genotypic evolution or reduction in DTG susceptibility during the functional monotherapy phase of the study. Table 97 and Table 98 provide data summaries in Cohorts I and II, respectively.

IN genotypic and/or phenotypic changes resulting in further IN genotypic evolution or further reduced susceptibility to DTG were noted in 3 (1630, 1680 and 1633) of the 18 subjects with paired Day 1 and Day 11 data from Cohort I. Two (subjects 1630 and1680) of these 3 subjects, each with <0.7 log10 c/mL decline at Day 11 (virologic failure), had apparent changes in DTG FC although values for subject 1630 were within 1 standard deviation of each other, possibly reflecting assay variance.

128 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 97 Cohort I: Summary of 18 Subjects with Paired Day 1 and Day 11 IN Genotype and Phenotype

HIV-1 RAL-associated Resistance DTG FCa INI RNA Mutationa Subject Mutational Change Day 1 Day 11 Day 1 Day 11 Group from Day 1 L74M, T97A, L74M, T97A, 1111 Y143 -0.73 T124A, Y143C T124A, Y143C 1.42 1.01 T97A, T124A, T97A, T124A, 1151 N155 -1.23 V151I, N155H V151I, N155H 5.09 3.59 T124T/Ac, 1610 N155 -1.92 V151I, N155H V151V/I, N155H 1.54 1.42 L74I, T97A, L74I, T97A, 1612 Y143 -1.71 T124A, Y143R T124A, Y143R 1.21 1.21 L74M, T97A, L74M, T97A, 1621 Y143 -2.54 E138A, Y143R E138A, Y143R 0.77 0.92 L74I T97T/A, L74I, T97A E138E/K, E138E/T/K/A, 1623 Y143 -1.76 Y143R Y143R 1.22 1.35 T124A, E138K/T,G140 T124A, E138K, b 1624 Q148+2 -0.13 S, Q148H G140S, Q148H 14 15 L74I, G140S, L74I, G140S, b 1625 Q148+2 -0.43 Q148R, G163R Q148R, G163R 35 28 L74L/M, T97A, L74L/M, T97A, 1626 Y143 -2.29 Y143R Y143R 0.82 1.1 L74I, T124A, L74I, T124A, b 1630 Q148+2 -0.63 G140S, Q148H G140S, Q148H 21 40 L74M, T97A, L74L/M, T97A Y143R, E138E/K, G163G/R Y143Y/R/H/C, 1633 Y143 -1.61 G163G/R 1.03 1.09 L74M, T97A, L74M, T97A, 1640 Y143 -2.10 Y143R Y143R 0.91 0.81 L74I/M, T124A, T124A, G140S, E138E/A, b 1680 Mixture -0.32 Y143H, Q148H G140S, Q148H 6.49 38 b 1681 Q148+1 -0.16 G140S, Q148H G140S, Q148H 25 22 L74L/M, T124A, Y143R 1700 Y143 -1.08 T124A, Y143R 1 1.14 E138A, G140S, E138A, G140S, b 1703 Mixture -0.27 Y143H, Q148H Y143H, Q148H 9.12 11 T97A, T124T/A, Y143R, 1807 Y143 -2.17 G163G/R, T97A, Y143R 1.21 1.24 1811 Other -1.91 none none 0.87 0.84 a. Differences in IN genotype or phenotype between Day 1 and Day 11 are bolded. b. Subjects who did not meet the primary endpoint (<0.7 log10 c/mL or <400 c/ml) by Day 11 and the associated HIV-1 RNA change from Day 1 are noted by Italics c. A polymorphic site in IN with no known impact on DTG susceptibility Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.43

129 CONFIDENTIAL Module 2.7.2.4 Special Studies

For Cohort II, the single subject (2340) who met the virologic failure definition at Day 11, showed no evidence of IN genotypic or phenotypic change in his virus. IN genotypic and phenotypic differences were noted in only 3 (2202,2310 and 2430) of the 15 subjects with paired Day 1 and Day 11 viral isolate data and all were mixtures of INI mutations that were not seen at Day 1 and detected in virus with Q148H +>1 additional INI resistance associated mutations at Day 1. Genotypic changes in integrase resulted in changes in DTG FC in 2/2 subjects (2202 and 2430) with Day 11 phenotypic data. In both subjects a mixture at T97T/A was noted. One additional subject (2310) had virus with a mixture of N155N/H at Day 11 with no corresponding IN phenotypic result for comparison.

130 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 98 Cohort II: Summary of 15 Subjects with Paired Day 1 and Day 11 IN Genotype and Phenotype

RAL-associated Resistance INI HIV-1 RNA DTG FCa Mutationa Subject Mutational Change from Day 1 Day 11 Day Day Group Day 1 1 11 T124Ac, G140S, T124A, G140S, 2110 Q148+1 -0.79 8.23 8.94 Q148H Q148H T124A, G140S, T124A, G140S, 2115 Q148+1 -1.43 4.84 5.08 Q148H Q148H 2200 Y143 -1.95 L74M,T97A, Y143C L74M,T97A, Y143C 1.77 1.74 E138E/K, G140G/S, T97T/A, E138E/K, 2202 Q148+2 -1.79 2.10 11 Q148Q/H G140S, Q148H G140S, Q148H, 2310 Q148+1 -1.57 G140S, Q148H 6.23 NR N155N/H 2320 Other -2.92 None None 0.87 0.90 T97A, T124A,V151I, T97A, T124A,V151I, 2340b N155H -0.46 3.94 4.25 N155H N155H 2400 Q148+1 -1.99 G140S, Q148H G140S, Q148H 4.48 4.65 L74L/M, T97T/A, L74L/M, T97T/A, 2415 Y143 -2.08 1.01 1.26 T124A, Y143Y/C, T124A, Y143Y/C, E138A, G140S, T97T/A, E138T/A, 2430 Q148+2 -0.9 6.04 21 Q148H G140S, Q148H T124T/Ac, Y143C, 2431 Y143 -2.06 Y143C, G193/E 1.63 1.77 G193E Mixture G140S, G140S, Y143Y/H, 2432 -1.35 9.48 4.94 (Q148+Y143) Y143Y/H/R/C, Q148H Q148H 2440 Y143 -2.07 T97A,Y143C T97A,Y143C 1.35 1.56 L74L/M, T97T/A, L74M, T97A, 2442 Y143 -2.06 0.92 1.11 T124A, Y143Y/R/H/C T124A, Y143R -1.97 T124A, G140S, 2462 Q148+1 NR 4.11 NR Q148H T124A, G140S, T124A, G140S, 2110 Q148+1 -0.79 8.23 8.94 Q148H Q148H T124A, G140S, T124A, G140S, 2115 Q148+1 -1.43 4.84 5.08 Q148H Q148H 2200 Y143 -1.95 L74M,T97A, Y143C L74M,T97A, Y143C 1.77 1.74 a. Differences in IN genotype or phenotype between Day 1 and Day 11 are bolded. b. Subjects who did not meet the primary endpoint (<0.7 log10c/mL or <400 c/ml) by Day 11 and the associated HIV- 1 RNA change from Day 1 are noted by Italics. c. A polymorphic site in IN with no known impact on DTG susceptibility. Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.43

IN Genotypic and Phenotypic Analyses of Virus at Protocol-Defined Virologic Failure

131 CONFIDENTIAL Module 2.7.2.4 Special Studies

single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8.

For Cohort I, during the 96 weeks of DTG treatment (with OBR from Day 11 onward), 16/27 (59%) subjects met the PDVF criteria, with 13 identified by Week 48 . In Cohort II there was no new subject experiencing virologic failure post Week 24. Seven of the 24 subjects in this cohort had completed Week 60 by the data cut-off. Table 99 summarises protocol-defined virologic failure for both cohorts.

Table 99 Summary (cumulative) of Protocol-Defined Virologic Failures by Visit (ITT-E)

Week Cohort I Cohort II 50 mg once daily 50 mg twice daily (N=27) (N=24) n (%) n (%) Day 11 6 (22) 1(4) Week 8 7 (26) 3 (13) Week 12 9 (33) 3 (13) Week 16 10 (37) 5 (21) Week 20 10 (37) 5 (21) Week 24 12 (44) 5 (21) Week 32 12 (44) 5 (21) Week 40 12 (44) 5 (21) Week 48 13 (48) 5 (21) Week 60 13 (48) NA Week 72 14 (52) NA Week 84 15 (56) NA Week 96 16 (59) NA NA=not applicable Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 7.20

In Table 100 and Table 101 below IN genotypic and phenotypic data are summarised for the subjects in Cohorts I and II experiencing virologic failure, noting subjects regarded as PDVFs through Weeks 48 (Cohort I) and 24 (Cohort II) have been discussed previously [m5.3.5.2, 2011N116146].

Through Week 96, 8/16 subjects identified as PDVFs in Cohort I harboured virus at the failure timepoint with IN genotypic and/or phenotypic treatment emergent changes. These 8 subjects were 1680, 1811, 1623, 1621, 1640, 1141, 1151 and 1171 (subject 1630 is not included, because the DTG FC increase was <2 fold). Three additional subject in Cohort I have met the PDFV criteria since the cut-off for the previous report (subjects1141, 1151, 1171):

Subject 1141 with virologic failure at Week 72 harboured virus with L74L/M/I, T124A, V151V/I, N155H, G163G/R at Day 1 but had further evolution to L74M, T124A, G140S,

132 CONFIDENTIAL Module 2.7.2.4 Special Studies

Q148H N155H and the DTG FC for this subject was 2.14 and 109 respectively for Day 1 and Week72.

Subject 1171 who experienced virologic failue at Week 96 had virus at Day 1 with Q148H + 1 but added T97A and E138E/K at the virologic failure timepoint while the DTG FC increased from 5.9 at Day 1 to 68.5 at Week 96.

Subject 1151, who met the PDVF criteria at Week 84, was one of three subjects (1151, 1630, 1623) whose virus exhibited an increased DTG FC without corresponding change in IN genotype.

133 CONFIDENTIAL Module 2.7.2.4 Special Studies

Table 100 Cohort I: Summary of IN Genotype and Phenotype for Subjects with Virologic Failure

RAL-associated Resistance DTG FCb INI Virological Mutationb Subject Mutational PSSa Failure Visit Day 1 VF Day VF Group 1 1680 Mixture Day 11 1 T124Ac, G140S L74I/M, T124A, Y143H, Q148H E138E/A, G140S, Q148H 6.49 38 1630 Q148+2 Day 11 0 L74I, T124A, L74I, T124A, G140S, Q148H G140S, Q148H 21 40 1624 Q148+2 Day 11 0 T124A, E138K/T, T124A, E138K, G140S, Q148H G140S, Q148H 14 15 1625 Q148+2 Day 11 0 L74I, G140S, L74I, G140S, Q148R,G163R Q148R, G163R 35 28 1681 Q148+1 Day 11 0 G140S, Q148H G140S, Q148H 25 22 1703 Mixture Day 11 0 E138A, G140S, E138A, G140S, Y143H, Q148H Y143H, Q148H 9.12 11 1811d Other Week 8 0 None L74L/M/I, T97A, 0.87 68 G140S, Q148H 1610 N155 Week 12 1 T124T/A, V151V/I, N155H 1.54 1.50 V151I, N155H 1623 Y143 Week 12 0 L74I, T97T/A, L74I, T97A, 1.22 16 E138E/K, 143R E138K, Y143R 1700 Y143 Week 16 0 L74L/M, T124A,Y143R 1.00 1.66 T124A, Y143R 1621 Y143 Week 24 0 L74M, T97A, L74M, T97A, 0.77 6.58 E138A ,Y143R, E138A ,Y143R, N155H 1640 Y143 Week 24 0 L74M, T97A, L74M, T97A, 0.91 8.44 Y143R Y143R, N155H 1611 Y143 Week 48 0 L74M, T97A, NR 1.42 NR T124A, Y143C 1141 N155 Week 72 >2 L74L/M/I, T124A, L74M, T124A, 2.14 109 V151V/I, N155H, G140S, Q148H G163G/R N155H 1151 N155 Week 84 2 T97A, T124A, T97A, T124A, 5.09 18 V151I, N155H N155H 1171 Q148 + 1 Week 96 1 G140S, Q148H T97A, E138E/K, 5.89 64.52 G140S, Q148H NR = No result a. PSS for subjects at the time of virologic failure. b. Differences in IN genotype or phenotype between Day 1 and On Treatment are bolded. c. A polymorphic site in IN with no known impact on DTG susceptibility. d. At the screen visit mixtures of G140G/S and Q148Q/H were detected. Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.42

. For subject 1151 the 3.5 fold reduction in DTG susceptibility was detected with a loss of theV151I mutation in integrase, however there is no viral resistance data to suggest that a loss of V151I from a virus harbouring N155H and T97A would result in this DTG FC.

134 CONFIDENTIAL Module 2.7.2.4 Special Studies

For the 16/27 subjects meeting the protocol definition for virologic failure in Cohort I per the current data cut-off, 11 subjects had a PSS of 0 for their background regimen administered at time of failure.

In Cohort II, 5/24 subjects met the definition for virologic failure through Week 48, all of whom have been discussed previously [m5.3.5.2, 2011N116146_00]. Inclusion into Cohort II mandated one fully active drug in the OBR from Day 11 onward and as such no subject with virologic failure in Cohort II had PSS=0.

Three of the 5 PDVFs in Cohort II had treatment emergent resistance-associated IN mutations and reduced DTG susceptibility at the time point of failure. All 3 subjects (2310, 2430 and 2462) at Day 1 harboured virus with Q148 +1 additional IN resistance associated mutations and virus all 3 subjects had further evolution in integrase resulting in a virus with Q148H + >3 additional INI associated resistance mutations Furthermore in each case there was an increase in DTG FC detected.

Table 101 Cohort II: Summary of IN Genotype and Phenotype for Subjects with Virologic Failure

RAL-associated Resistance DTG FCb INI Virologic Mutationb Subject Mutational Failure PSSa Day 1 VF Day VF Group Visit 1 G140S, T97T/A,E138E/K,G140S, 2310 Q148+1 Week 16 2 6.23 93 Q148H Q148H, N155H T97A, T97A, T124A,V151I, 2340 N155H Day 11 1 T124A,V151I, 3.94 4.25 N155H N155H L74L/M, T97T/A, 2415 Y143 Week 16 1 T97T/A, T124A, Y143Y/C, 1.01 1.21 T124A, Y143Y/C, E138A, E92E/Q, T97T/A, 2430 Q148+2 Week 8 1 G140S, T124T/Ad, E138Tc, 6.04 42.32 Q148H G140S, Q148H T124A, E92E/Vc, T124A, E138E/K, 2462 Q148+1 Week 8 4 G140S, 4.11 63 G140S, Q148H, N155H Q148H a. PSS for subjects at the time of virologicafailure. b. Differences in IN genotype or phenotype between Day 1 and Day 11 are bolded. c. Specific amino acids seen at these positions not identified in list of amino acids associated with INI resistance. d. A polymorphic site in IN with no known impact on DTG susceptibility Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.42.

For subjects meeting protocol-defined virologic failure in both Cohort I and II, there was minimal further evolution in RT and PR.

In viral genotypic an phenotypic data for the last timepoint on study for selected subjects

To further monitor the development of resistance to DTG, both the genotypic and phenotypic susceptibility to DTG were determined at the last timepoint on study meeting

135 CONFIDENTIAL Module 2.7.2.4 Special Studies

one or more of the following criteria; unconfirmed suspected protocol-defined virologic failure (Subjects1626 and 2410), HIV-1 RNA 400 c/mL (Subject1111), or >12 weeks from previous virologic failure testing (Subjects 1623, 1703 and 1640). Five subjects in Cohort I and one subject in Cohort II met these criteria for testing. Table 102 below provides a summary of these results.

Table 102 Summary of Additional IN Genotypic and Phenotypic Results Collected On-Treatment in Cohort I

IN IN Genotypeb DTG FCb Study Visit HIV-1 RNA at Subject Mutational Day 1 Final Day 1 Final Tested testing Group 1111 Y143 Week 4 7254 L74M, T97A, L74M, T97A, 1.42 1.38 Y143C Y143C 1623a Y143 Week 24 60163 L74I , T97T/A, L74I , T97A, E138E/K, Y143R, E138K 1.22 5.83 Y143R 1626 Y143 Withdrawal 126389 L74L/M T97A, L74L/M, T97A, 0.82 1.03 (Week 8) Y143R Y143R 1703a Mixture Withdrawal 36681 E138A, E138A, (Week 16) G140S, G140S, 9.12 146.2 Y143H, Y143H, Q148H Q148H, T97A 1640a Y143 Week 48 37546 L74M, T97A, L74M, T97A, Y143R E138E/K/T/A, 0.91 90 G140S, Y143R, Q148H 2410 Y143 Week 40 4177 L74L/M, E138E/K, 1.1 1.07 Y143R V151V/I a. Subjects with protocol-defined virologic failure who had >12 weeks of DTG treatment post the virologic failure timepoint. b. Differences in IN genotype or phenotype between Day 1 and On Treatment are bolded. Data Source: ING112961 Cohort I Week 96/ Cohort II Week 48 CSR Table 12.44

Discussion

Treatment-emergent integrase genotypic resistance and/or DTG reduced susceptibility was observed in viral isolates at the timepoint of protocol-defined virologic failure for 8/16 subjects identified as PDVFs in Cohort I and 3/5 subjects in Cohort II. For 3/8 subjects in Cohort I and all 3 subjects in Cohort II this further evolution was observed in viral isolates with Q148 + 1 additional IN resistance associated mutations at Screen or Baseline. This observation was consistent with the earlier finding from IN genotypic and phenotypic data in vitro, suggesting that mutations at position Q148 (Q148H/K/R) with multiple additional INI resistance associated mutations can reduce DTG susceptibility [Kobayashi, 2011]. The data from both cohorts showed that virus harbouring Q148H +G140S with additional INI resistance associated mutations was more likely to have a higher DTG FC.

Due to the large diversity of IN genotypic profiles at baseline and upon virologic failure, and the limited number of subjects’ data, it is difficult at this time to make any

136 CONFIDENTIAL Module 2.7.2.4 Special Studies conclusions about integrase resistance mutations selected by DTG and potential relationship with treatment outcome. Future studies in INI-naive and INI-experienced subjects may provide further clarity around the resistance profile of DTG. The efficacy data, however, show that DTG 50 mg BID effectively inhibited and suppressed over the longer term the majority of viruses with RAL resistance.

These data and the safety data determined in this Phase 2b study support the continued and definitive evaluation of 50mg BID DTG in Phase III in subjects with evidence of INI resistance at current or prior virologic failure with RAL or ELV containing regimen.

Conclusions:

Of the 21 subjects with protocol defined virologic failure through Week 96 (n=16, Cohort I) or Week 48 (n=5, Cohort II), 11 subjects (n=8 Cohort I and n=3 Cohort II), harboured virus exhibiting treatment emergent resistance with further IN genotypic and/or phenotypic evolution.

Ten of the 11 virus isolates had 4 INI resistance-associated mutations at the virologic failure timepoint but the limited data set preclude conclusions on mutations selected under DTG pressure and relationship with treatment outcome.

4.2.3. Conclusions

Nonclinical Virology

 Dolutegravir (DTG) inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for the HIV replication cycle.

 DTG has low nM activity against wild type HIV-1 and HIV-2 in a variety of cells lines, regardless of subtype. Human serum causes approximately 75-fold increase in DTG IC50. DTG is additive or synergistic when assayed in combination with other antiretroviral agents.

 When HIV-1 Strain IIIB was passaged in the presence of DTG for 112 days, viruses with a 4.1-fold maximum increase in IC50 and S153Y or S153F substitutions in integrase were observed. Passage of the wild type HIV-1 NL432 in the presence of 6.4 nM DTG selected for E92Q (FR=3.1) and G193E (FC=3.2) substitutions in the IN region on Day 56. Passage of HIV-1 NL432 with Q148H, Q148K, or Q148R RAL resistant mutations resulted in selection of additional mutations and an increase in DTG FC. Passage of HIV-1 subtypes B, and A/G in TZM-bl cells selected for integrase mutation R263K.

 Comparative susceptibilities to DTG and raltegravir (RAL) were obtained from 60 RAL resistant site directed HIV-1 mutants and 6 site directed HIV-2 mutants. DTG retained activity against a vast majority of these mutants. Additionally,

137 CONFIDENTIAL Module 2.7.2.4 Special Studies

susceptibilities to DTG and RAL were determined for over 700 RAL resistant clinical isolates, with DTG retaining activity (<10 FC) against >90% of them.

 The dissociation of DTG, RAL, and EVG from wild type and mutant IN proteins complexed with DNA was investigated to obtain a better understanding of INI resistance and dissociation kinetics. DTG demonstrated slower dissociation from all IN-DNA complexes tested, including those with single, double, and up to four residue clinically relevant IN substitutions.

 There has been a decrease in the number of Q148 isolate samples from the 2008 – to – , including those which had Q148 plus additional primary mutations present at Y143 and N155.

 The proportions of samples harboring key RAL associated secondary resistance mutations (L74I, E138A/K/T, and G140A/C/S) associated with reduced response within the Q148 + ≥2 category were evaluated. Overall isolates with ≥two of the derived key mutations were present in ~53.9% of the isolates with Q148 + ≥2.

 Clonal analyses on paired Day 1 and PDVF virus provided information that the INI-associated resistance mutation that emerged at PDVF were added to pre- existing Day 1 INI associated resistance mutation profiles and that this accumulation of INI-associated resistance mutations results in the reduction of DTG susceptibility.

 Analysis of site directed mutants at IN sites 101 and 124 as either single or double mutants demonstrated no effect on DTG susceptibility

Clinical Virology

 DTG 50 mg once daily has a higher barrier to resistance in INI-naïve patients, as demonstrated in the treatment-experienced (INI-naïve) population where significantly fewer virologic failures and significantly fewer subjects with INI resistance (in addition to less treatment-emergent resistance to the background regimens) were observed when compared with RAL.

 Data from two studies including over 1600 treatment-naïve patients are also supportive of DTG’s higher barrier to resistance, given that no subjects on the DTG regimen developed resistance to either the INI or the background NRTIs, whereas resistance to both the third agent and the background NRTIs was observed in both the RAL and EFV-based comparator arms.

 A unique IN substitution was observed (R263K or R263R/K mixture) in two subjects with protocol-defined virologic failure in ING111762 on DTG; these conferred no to a low fold change in susceptibility to DTG and to RAL.  Low DTG FC was observed in subjects harbouring 143/155/66 or historic evidence of IN resistance while moderate to high DTG FC was observed with virus harbouring Q148 plus additional RAL secondary mutations in ING112574. Highest DTG FC was observed in virus harbouring Q148+2 additional IN

138 CONFIDENTIAL Module 2.7.2.4 Special Studies

mutations however this subgroup was represented in only 11% of the enrolled population.  Good short term and long term responses were seen in subjects with 143/155/66 mutations or historic evidence of IN resistance which make up the majority of RAL resistant virus; lower response rates were observed in virus harbouring Q148/G140 dual mutations in ING112574. Protocol-defined virologic failure (PDVF) was observed in 19% of subjects the majority of whom harboured Q148 pathway virus at Baseline.  Limited viral evolution was detected at PDVF in ING112574 consisting of previously identified, INI secondary mutations which lead to an increase in DTG FC; the majority of these were identified in virus harbouring Q148 mutations.

 For the 52 Baseline samples from ING112574 which were tested for minor variants in integrase to confirm the provided historic IN resistance, only 5/52 (9.6%) samples tested had minor variants of IN primary resistance associated mutations (at a 0.5% detection threshold)

 Increasing Baseline DTG FC was significantly associated with decreasing antiviral activity in ING112574. However, no precise phenotypic FC cut-off could be defined to effectively predict antiviral activity at both Day 8 and Week 24.

 The best antiviral responses (at both Day 8 and Week 24) in ING112574 were seen in the ‘No Q148’ group. In subjects harbouring virus of Q148, a decreased response was observed with increasing numbers of mutations of G140A/C/S, L74I, E138A/K/T.

4.3. References

Akaike, H. Information measures and model selection. Bulletin of the International Statistical Institute 1983; 50:277-290.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultr-deep 454 pyrosequencing. The Journal of Infectious Diseases 2012; 205:557–567.

Blanco J, Varghese V, Rhee S, Gtell J, and Shafer R. HIV-1 integrase inhibitor resistance and its clinical implications. Journal of Infectious Diseases. 2011, 203: 1204- 1214.

Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M: Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. Journal of Medical Virology 2011, 83:751-759.

Brun-Vézinet F, Costagliola D, Ait Khaled M, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004; 9:465-478.

139 CONFIDENTIAL Module 2.7.2.4 Special Studies

Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clinical Microbiology and Infection, 2011; 17: 928–934.

Clotet B, Bellos N, Molina J-M, Cooper D, Goffard J-C, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. The Lancet, 2007; 369: 1169–78.

Clotet B, Katlama C, Lalezari J, et al. HIV integrase resistance profiles and S/GSK1349572 Baseline phenotypic susceptibility for individuals experiencing virologicalfailure on raltegravir and enrolling in the VIKING phase IIb pilot study (ING112961). HIV and Hepatitis Drug Resistance Workshop. June 8-12, 2010. Dubrovnik, Croatia. Abstract 50.

Codoner F, Pou C, Thielen A, Garcia F, Delgado R, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS ONE, 2011; 6(5): e19461. doi:10.1371/journal.pone.0019461

Codoner F, Pou C, Thielen A, Garcia F, Delgado R, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Research. 2010; 88: 281-286.

Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New England Journal of Medicine. 2008; 359: 355-365.

Dalmau J, Codoner F, Erkizia I, Pino M Pou C. In–Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection. PLoS ONE, 2012; 7(2): e32714. doi:10.1371/journal.pone.0032714

De Houwer S, Demeulemeester J, Thys W, Taltynov O,Christ F, Debyser Z. Identification of residues in the C-terminal domain of HIV-1 integrase that mediate binding to TRN-SR2. JBC Papers in Press. Published on August 7, 2012 as Manuscript M112.387944 de Luca A, Di Giambenedetto S, Maserati R, et al. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. Antivir Ther 2011; 16:489-497. de Meyer S, Vangeneugden, T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retrovir 2008; 24:379-388.

EMA. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of HIV infection. London, 20 November 2008.

140 CONFIDENTIAL Module 2.7.2.4 Special Studies

FDA. Guidance for Industry. Role of HIV Resistance Testing in Antiretroviral Drug Development. October 2007. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrobial Agents and Chemotherapy. 2012; [Epub ahead of print].

Hatano H, Lampiris H, Fransen S et al. Evolution of Integrase resistance during failure of Integrase Inhibitor based anti-retroviral therapy. JAIDS. 2010; 54 (4): 389-392.

HIVdb (Integrated Genotypic Resistance Interpretation Systems) by Stanford: http://hivdb.stanford.edu/.

Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). [Abstract 627.] 14th Conference on Retroviruses and Opportunistic Infections (CROI). February 25-28, 2007; Los Angeles, CA.

Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Ch. 2011;55:813–821.

Lennox J, DeJesus E, Berger D, et al. for the STARTMRK Investigators. Raltegravir- versus efavirenz regimens in treatment-naïve HIV-1-Infected patients: 96-week efficacy, durability, subgroup, safety,and metabolic analyses. J Acquir Immune Defic Syndr.2010;55(1):39-48.

Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, and Markowitz M. Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors. Antimicrob Agents and Chemother. 2009:53(10): 4275–4282.

Malet I, Delelis O, Valantin M, Montes B, Coulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet J, Katlama C, Calvez V, and Marcelin A. Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrob Agents and Chemother. 2008:52(4): 1351–1358.

Margot N, Rhee M, Szwarcberg J, Miller M. Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183- 0145. XIX International AIDS Conference. July 22-27, 2012. Washington DC, USA. #TUPE050.

Min s, Sloan L, DeJesus e, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1- infected adults AIDS.2011:25:1737-1745

Molina J-M, LaMarca A, Andrade-Villanueva J, Clotet B, Clumeck N, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-

141 CONFIDENTIAL Module 2.7.2.4 Special Studies

blind, phase 3, non-inferiority study. The Lancet Infectious Diseases, 2012; 12(1):27-35. Published online October 19, 2011, DOI:10.1016/S1473-3099(11)70249-3

Mukherjee R, Jensen S, Male F, Bittinger K, Hodinka R, Miller M, Bushman F. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS. 2011; 25:1951-1959.

Oliveira et al. Novel Mutational Changes Involved in Delayed Development of Dolutegravir Resistance in HIV-1 B and non-B Subtypes. Abstract M-166. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, WA.

Paredes R, Lalama C, Ribaudo H, Schackman B, Shikuma C, Meyer W, et al. Presence of minor populations of Y181C mutants detected by allele-specific PCR and risk of efavirenz failure in treatment-naïve patients: results of an ACTG 5095 case-cohort study. 17th Annual Conference on Retroviruses and Opportunistic Infections. February 16-19, 2010. San Francisco, CA. #83.

Quashie P, Thibault M, Han Y-S, Oliveira M, Singhroy D, Fujiwara T, Underwood M, and Wainberg M. Characterization of the R263K Mutation in HIV-1 Integrase that Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor dolutegravir. J Virol. 2012:86(5):2696-2705.

Schapiro JM, Scherer J, Boucher CA, et al. Improving the prediction of the virological response of tipranavir: the development and validation of a tipranavir-weighted mutation score. Antiviral Therapy 2010; 15:1001-1019

Sax P, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D. Co-formulated elvitegravir, cobicicstat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtrecitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-2448.

Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 2009; 199:84–88.

Vavro C, Underwood M, Madsen H, et al. Polymorphisms at position 101 and 124 in the HIV-1 integrase (IN) gene: Lack of effects on in vitro susceptibility to S/GSK1349572. 2010 ICAAC.Abstract H-935

Vavro C, Dudas K, Hasan S, et al. Dolutegravir treatment of HIV subjects with raltegravir resistance: integrase resistance evolution in Cohort II of the VIKING study. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 5-9 June, 2012, Sitges, Spain.

142 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Summary of Amino Acid Conservation for 2997 Integrase Sequencesa prior to 2005

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 1 F1 F 2957 2964 99.76 1 F1 S 5 2964 0.17 1 F1 F/L 1 2964 0.03 1 F1 V 1 2964 0.03 2 L2 L 2961 2964 99.90 2 L2 W/L 1 2964 0.03 2 L2 F 1 2964 0.03 2 L2 I 1 2964 0.03 3 D3 D 2858 2971 96.20 3 D3 E 107 2971 3.60 3 D3 N 4 2971 0.13 3 D3 G 2 2971 0.07 4 G4 G 2959 2970 99.63 4 G4 E 4 2970 0.13 4 G4 R 3 2970 0.10 4 G4 S 2 2970 0.07 4 G4 K 1 2970 0.03 4 G4 G/E 1 2970 0.03 5 I5 I 2978 2988 99.67 5 I5 V 5 2988 0.17 5 I5 L 2 2988 0.07 5 I5 M 1 2988 0.03 5 I5 T 1 2988 0.03 5 I5 K 1 2988 0.03 6 D6 D 2856 2989 95.55 6 D6 E 82 2989 2.74 6 D6 S 21 2989 0.70 6 D6 N 20 2989 0.67 6 D6 T 4 2989 0.13 6 D6 D/E 3 2989 0.10 6 D6 G 2 2989 0.07 6 D6 S/T 1 2989 0.03 7 K7 K 2798 2988 93.64 7 K7 Q 102 2988 3.41 7 K7 R 54 2988 1.81 7 K7 E 16 2988 0.54 7 K7 R/K 10 2988 0.33 7 K7 T 2 2988 0.07 7 K7 I 2 2988 0.07 7 K7 D/E 1 2988 0.03 7 K7 I/K 1 2988 0.03 7 K7 M/K 1 2988 0.03

Page 1 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 7 K7 M 1 2988 0.03 8 A8 A 2988 2991 99.90 8 A8 V 2 2991 0.07 8 A8 A/P 1 2991 0.03 9 Q9 Q 2988 2993 99.83 9 Q9 H 2 2993 0.07 9 Q9 Q/P 1 2993 0.03 9 Q9 R 1 2993 0.03 9 Q9 L 1 2993 0.03 10 D10 E 2761 2983 92.56 10 D10 D 176 2983 5.90 10 D10 A 28 2983 0.94 10 D10 D/E 6 2983 0.20 10 D10 G 6 2983 0.20 10 D10 V 3 2983 0.10 10 D10 K 2 2983 0.07 10 D10 A/E 1 2983 0.03 11 E11 E 2236 2993 74.71 11 E11 D 716 2993 23.92 11 E11 D/E 24 2993 0.80 11 E11 A 7 2993 0.23 11 E11 G 4 2993 0.13 11 E11 K 2 2993 0.07 11 E11 Q 2 2993 0070.07 11 E11 G/E 1 2993 0.03 11 E11 V 1 2993 0.03 12 H12 H 2991 2993 99.93 12 H12 S 1 2993 0.03 12 H12 R 1 2993 0.03 13 E13 E 2911 2994 97.23 13 E13 D 62 2994 2.07 13 E13 G/E 4 2994 0.13 13 E13 G 4 2994 0.13 13 E13 A 3 2994 0.10 13 E13 D/E 3 2994 0.10 13 E13 K 3 2994 0.10 13 E13 V 2 2994 0.07 13 E13 Q 1 2994 0.03 13 E13 K/E 1 2994 0.03 14 K14 K 1925 2993 64.32 14 K14 R 1040 2993 34.75 14 K14 R/K 25 2993 0.84 14 K14 S 1 2993 0.03 14 K14 T 1 2993 0.03

Page 2 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 14 K14 E 1 2993 0.03 15 Y15 Y 2985 2994 99.70 15 Y15 C 3 2994 0.10 15 Y15 F 2 2994 0.07 15 Y15 H 2 2994 0.07 15 Y15 */Y 1 2994 0.03 15 Y15 * 1 2994 0.03 16 H16 H 2984 2993 99.70 16 H16 R 5 2993 0.17 16 H16 P 1 2993 0.03 16 H16 Y 1 2993 0.03 16 H16 H/P 1 2993 0.03 16 H16 H/L 1 2993 0.03 17 S17 S 2459 2994 82.13 17 S17 N 445 2994 14.86 17 S17 C 37 2994 1.24 17 S17 T 26 2994 0.87 17 S17 S/N 9 2994 0.30 17 S17 R 6 2994 0.20 17 S17 G 4 2994 0.13 17 S17 S/T 2 2994 0.07 17 S17 H/N 1 2994 0.03 17 S17 N/K 1 2994 0.03 17 S17 S/C 1 2994 0030.03 17 S17 I 1 2994 0.03 17 S17 S/R 1 2994 0.03 17 S17 S/T/I 1 2994 0.03 18 N18 N 2986 2996 99.67 18 N18 S 3 2996 0.10 18 N18 H/N 2 2996 0.07 18 N18 S/N 1 2996 0.03 18 N18 K 1 2996 0.03 18 N18 Y 1 2996 0.03 18 N18 H 1 2996 0.03 18 N18 D 1 2996 0.03 19 W19 W 2987 2997 99.67 19 W19 * 6 2997 0.20 19 W19 K 1 2997 0.03 19 W19 W/* 1 2997 0.03 19 W19 R 1 2997 0.03 19 W19 G 1 2997 0.03 20 R20 R 2824 2997 94.23 20 R20 K 159 2997 5.31 20 R20 R/K 9 2997 0.30

Page 3 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 20 R20 T 2 2997 0.07 20 R20 R/G 2 2997 0.07 20 R20 G 1 2997 0.03 21 A21 A 2657 2996 88.68 21 A21 T 315 2996 10.51 21 A21 S 18 2996 0.60 21 A21 A/T 4 2996 0.13 21 A21 Q 1 2996 0.03 21 A21 S/A 1 2996 0.03 22 M22 M 2894 2997 96.56 22 M22 L 77 2997 2.57 22 M22 I 20 2997 0.67 22 M22 R 2 2997 0.07 22 M22 K 1 2997 0.03 22 M22 M/R 1 2997 0.03 22 M22 V 1 2997 0.03 22 M22 M/I 1 2997 0.03 23 A23 A 2882 2997 96.16 23 A23 V 99 2997 3.30 23 A23 A/V 10 2997 0.33 23 A23 T 4 2997 0.13 23 A23 A/G 1 2997 0.03 23 A23 D 1 2997 0.03 24 S24 S 2669 2997 89. 06 24 S24 N 184 2997 6.14 24 S24 G 81 2997 2.70 24 S24 H 13 2997 0.43 24 S24 A 11 2997 0.37 24 S24 D 11 2997 0.37 24 S24 S/G 9 2997 0.30 24 S24 S/N 6 2997 0.20 24 S24 S/R 4 2997 0.13 24 S24 T 2 2997 0.07 24 S24 K 2 2997 0.07 24 S24 Q 2 2997 0.07 24 S24 C 2 2997 0.07 24 S24 I 1 2997 0.03 25 D25 D 2437 2996 81.34 25 D25 E 547 2996 18.26 25 D25 D/E 3 2996 0.10 25 D25 N 3 2996 0.10 25 D25 A 2 2996 0.07 25 D25 D/G 1 2996 0.03 25 D25 K 1 2996 0.03

Page 4 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 25 D25 D/N 1 2996 0.03 25 D25 G 1 2996 0.03 26 F26 F 2991 2997 99.80 26 F26 Y 5 2997 0.17 26 F26 F/Y 1 2997 0.03 27 N27 N 2899 2997 96.73 27 N27 G 77 2997 2.57 27 N27 S 7 2997 0.23 27 N27 H 5 2997 0.17 27 N27 D 4 2997 0.13 27 N27 S/N 2 2997 0.07 27 N27 T 1 2997 0.03 27 N27 D/N 1 2997 0.03 27 N27 I 1 2997 0.03 28 L28 L 2891 2997 96.46 28 L28 I 99 2997 3.30 28 L28 P 4 2997 0.13 28 L28 M 2 2997 0.07 28 L28 M/I/L 1 2997 0.03 29 P29 P 2996 2997 99.97 29 P29 S 1 2997 0.03 30 P30 P 2962 2996 98.87 30 P30 S 16 2996 0.53 30 P30 A 11 2996 0370.37 30 P30 H 4 2996 0.13 30 P30 P/L 2 2996 0.07 30 P30 L 1 2996 0.03 31 V31 I 1528 2995 51.02 31 V31 V 1439 2995 48.05 31 V31 I/V 24 2995 0.80 31 V31 M 2 2995 0.07 31 V31 */L/E/V 1 2995 0.03 31 V31 I/R 1 2995 0.03 32 V32 V 2830 2996 94.46 32 V32 I 148 2996 4.94 32 V32 L 13 2996 0.43 32 V32 I/V 5 2996 0.17 33 A33 A 2993 2996 99.90 33 A33 P 3 2996 0.10 34 K34 K 2927 2996 97.70 34 K34 R 64 2996 2.14 34 K34 R/K 3 2996 0.10 34 K34 T 1 2996 0.03 34 K34 E 1 2996 0.03

Page 5 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 35 E35 E 2982 2995 99.57 35 E35 K 5 2995 0.17 35 E35 Q 4 2995 0.13 35 E35 G 3 2995 0.10 35 E35 D 1 2995 0.03 36 I36 I 2990 2997 99.77 36 I36 V 4 2997 0.13 36 I36 M 1 2997 0.03 36 I36 R 1 2997 0.03 36 I36 L 1 2997 0.03 37 V37 V 2876 2997 95.96 37 V37 I 115 2997 3.84 37 V37 I/V 3 2997 0.10 37 V37 L 3 2997 0.10 38 A38 A 2989 2997 99.73 38 A38 T 3 2997 0.10 38 A38 S 2 2997 0.07 38 A38 P 2 2997 0.07 38 A38 R 1 2997 0.03 39 S39 S 2625 2997 87.59 39 S39 C 181 2997 6.04 39 S39 N 167 2997 5.57 39 S39 S/C 6 2997 0.20 39 S39 G 6 2997 0200.20 39 S39 R 5 2997 0.17 39 S39 S/N 3 2997 0.10 39 S39 S/G 1 2997 0.03 39 S39 T 1 2997 0.03 39 S39 S/T 1 2997 0.03 39 S39 S/A/T/R/G 1 2997 0.03 40 C40 C 2991 2996 99.83 40 C40 R 3 2996 0.10 40 C40 Y 1 2996 0.03 40 C40 G 1 2996 0.03 41 D41 D 2825 2996 94.29 41 D41 N 88 2996 2.94 41 D41 P 71 2996 2.37 41 D41 G 4 2996 0.13 41 D41 S 2 2996 0.07 41 D41 A 2 2996 0.07 41 D41 H 2 2996 0.07 41 D41 E 1 2996 0.03 41 D41 D/N 1 2996 0.03 42 K42 K 2932 2996 97.86

Page 6 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 42 K42 Q 46 2996 1.54 42 K42 R 9 2996 0.30 42 K42 R/K 4 2996 0.13 42 K42 G 2 2996 0.07 42 K42 I/K 1 2996 0.03 42 K42 E 1 2996 0.03 42 K42 I 1 2996 0.03 43 C43 C 2991 2997 99.80 43 C43 R 3 2997 0.10 43 C43 F 1 2997 0.03 43 C43 I 1 2997 0.03 43 C43 G 1 2997 0.03 44 Q44 Q 2919 2996 97.43 44 Q44 H 72 2996 2.40 44 Q44 L 3 2996 0.10 44 Q44 P 1 2996 0.03 44 Q44 R 1 2996 0.03 45 L45 L 2742 2996 91.52 45 L45 I 108 2996 3.60 45 L45 Q 74 2996 2.47 45 L45 V 46 2996 1.54 45 L45 T 8 2996 0.27 45 L45 S 7 2996 0.23 45 L45 I/L 3 2996 0100.10 45 L45 L/V 3 2996 0.10 45 L45 M 2 2996 0.07 45 L45 P 1 2996 0.03 45 L45 T/I 1 2996 0.03 45 L45 E 1 2996 0.03 46 K46 K 2972 2995 99.23 46 K46 R 17 2995 0.57 46 K46 N 2 2995 0.07 46 K46 Q 2 2995 0.07 46 K46 Q/K 1 2995 0.03 46 K46 R/K 1 2995 0.03 47 G47 G 2986 2994 99.73 47 G47 R 4 2994 0.13 47 G47 E 3 2994 0.10 47 G47 R/G 1 2994 0.03 48 E48 E 2956 2995 98.70 48 E48 Q 24 2995 0.80 48 E48 K 11 2995 0.37 48 E48 G 2 2995 0.07 48 E48 V 1 2995 0.03

Page 7 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 48 E48 K/E 1 2995 0.03 49 A49 A 2980 2996 99.47 49 A49 P 12 2996 0.40 49 A49 T 4 2996 0.13 50 M50 M 2084 2993 69.63 50 M50 I 703 2993 23.49 50 M50 T 87 2993 2.91 50 M50 L 83 2993 2.77 50 M50 V 14 2993 0.47 50 M50 M/I 11 2993 0.37 50 M50 R 5 2993 0.17 50 M50 T/I 2 2993 0.07 50 M50 K 1 2993 0.03 50 M50 M/T 1 2993 0.03 50 M50 I/R 1 2993 0.03 50 M50 R/K 1 2993 0.03 51 H51 H 2988 2997 99.70 51 H51 Q 3 2997 0.10 51 H51 S 2 2997 0.07 51 H51 Y 2 2997 0.07 51 H51 P 1 2997 0.03 51 H51 R 1 2997 0.03 52 G52 G 2990 2996 99.80 52 G52 R 4 2996 0130.13 52 G52 S/G 1 2996 0.03 52 G52 G/E 1 2996 0.03 53 Q53 Q 2985 2996 99.63 53 Q53 R 5 2996 0.17 53 Q53 H 3 2996 0.10 53 Q53 K 1 2996 0.03 53 Q53 * 1 2996 0.03 53 Q53 L 1 2996 0.03 54 V54 V 2981 2997 99.47 54 V54 I 12 2997 0.40 54 V54 A 2 2997 0.07 54 V54 I/V 1 2997 0.03 54 V54 E/V 1 2997 0.03 55 D55 D 2974 2997 99.23 55 D55 N 13 2997 0.43 55 D55 G 5 2997 0.17 55 D55 A 2 2997 0.07 55 D55 Y 1 2997 0.03 55 D55 H 1 2997 0.03 55 D55 D/N 1 2997 0.03

Page 8 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 56 C56 C 2966 2996 99.00 56 C56 Y 17 2996 0.57 56 C56 S 8 2996 0.27 56 C56 R 4 2996 0.13 56 C56 F 1 2996 0.03 57 S57 S 2865 2995 95.66 57 S57 G 110 2995 3.67 57 S57 N 9 2995 0.30 57 S57 S/G 6 2995 0.20 57 S57 R 2 2995 0.07 57 S57 D 1 2995 0.03 57 S57 C 1 2995 0.03 57 S57 I 1 2995 0.03 58 P58 P 2992 2997 99.83 58 P58 T 4 2997 0.13 58 P58 P/L 1 2997 0.03 59 G59 G 2913 2995 97.26 59 G59 E 75 2995 2.50 59 G59 R 3 2995 0.10 59 G59 A 2 2995 0.07 59 G59 G/E 1 2995 0.03 59 G59 K/E 1 2995 0.03 60 I60 I 2841 2997 94.79 60 I60 V 89 2997 2972.97 60 I60 M 57 2997 1.90 60 I60 L 4 2997 0.13 60 I60 T 2 2997 0.07 60 I60 M/I/V 1 2997 0.03 60 I60 K 1 2997 0.03 60 I60 I/V 1 2997 0.03 60 I60 M/I 1 2997 0.03 61 W61 W 2995 2997 99.93 61 W61 * 1 2997 0.03 61 W61 R 1 2997 0.03 62 Q62 Q 2991 2997 99.80 62 Q62 H/Q 2 2997 0.07 62 Q62 K 1 2997 0.03 62 Q62 * 1 2997 0.03 62 Q62 R 1 2997 0.03 62 Q62 L 1 2997 0.03 63 L63 L 2882 2996 96.19 63 L63 I 58 2996 1.94 63 L63 M 43 2996 1.44 63 L63 V 10 2996 0.33

Page 9 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 63 L63 S/L 1 2996 0.03 63 L63 I/L 1 2996 0.03 63 L63 I/V 1 2996 0.03 64 D64 D 2986 2996 99.67 64 D64 N 4 2996 0.13 64 D64 G 3 2996 0.10 64 D64 D/Y 1 2996 0.03 64 D64 E 1 2996 0.03 64 D64 H 1 2996 0.03 65 C65 C 2994 2996 99.93 65 C65 R 1 2996 0.03 65 C65 G 1 2996 0.03 66 T66 T 2984 2996 99.60 66 T66 A 8 2996 0.27 66 T66 P 2 2996 0.07 66 T66 S 1 2996 0.03 66 T66 T/P 1 2996 0.03 67 H67 H 2993 2994 99.97 67 H67 L 1 2994 0.03 68 L68 L 2949 2993 98.53 68 L68 V 20 2993 0.67 68 L68 T 9 2993 0.30 68 L68 I 7 2993 0.23 68 L68 A 5 2993 0170.17 68 L68 I/L 1 2993 0.03 68 L68 A/T 1 2993 0.03 68 L68 M 1 2993 0.03 69 E69 E 2990 2994 99.87 69 E69 K 1 2994 0.03 69 E69 G/E 1 2994 0.03 69 E69 D 1 2994 0.03 69 E69 G 1 2994 0.03 70 G70 G 2977 2993 99.47 70 G70 E 11 2993 0.37 70 G70 R 3 2993 0.10 70 G70 N 1 2993 0.03 70 G70 D 1 2993 0.03 71 K71 K 2971 2995 99.20 71 K71 Q 11 2995 0.37 71 K71 R 7 2995 0.23 71 K71 N 3 2995 0.10 71 K71 E 2 2995 0.07 71 K71 Q/K 1 2995 0.03 72 V72 I 1524 2994 50.90

Page 10 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 72 V72 V 1420 2994 47.43 72 V72 I/V 25 2994 0.84 72 V72 T 22 2994 0.73 72 V72 S 1 2994 0.03 72 V72 T/I 1 2994 0.03 72 V72 G 1 2994 0.03 73 I73 I 2986 2995 99.70 73 I73 V 6 2995 0.20 73 I73 T 1 2995 0.03 73 I73 I/L 1 2995 0.03 73 I73 L 1 2995 0.03 74 L74 L 2584 2994 86.31 74 L74 I 311 2994 10.39 74 L74 M 77 2994 2.57 74 L74 M/I 7 2994 0.23 74 L74 V 5 2994 0.17 74 L74 P 3 2994 0.10 74 L74 M/L 2 2994 0.07 74 L74 I/L 2 2994 0.07 74 L74 M/I/L 2 2994 0.07 74 L74 L/V 1 2994 0.03 75 V75 V 2992 2997 99.83 75 V75 A 3 2997 0.10 75 V75 A/V 1 2997 0030.03 75 V75 I 1 2997 0.03 76 A76 A 2991 2996 99.83 76 A76 T 2 2996 0.07 76 A76 A/P 1 2996 0.03 76 A76 P 1 2996 0.03 76 A76 V 1 2996 0.03 77 V77 V 2977 2996 99.37 77 V77 A 11 2996 0.37 77 V77 I 5 2996 0.17 77 V77 A/V 1 2996 0.03 77 V77 I/V 1 2996 0.03 77 V77 G 1 2996 0.03 78 H78 H 2988 2997 99.70 78 H78 R 8 2997 0.27 78 H78 H/N 1 2997 0.03 79 V79 V 2983 2997 99.53 79 V79 A 6 2997 0.20 79 V79 I 4 2997 0.13 79 V79 L 3 2997 0.10 79 V79 E/V 1 2997 0.03

Page 11 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 80 A80 A 2991 2997 99.80 80 A80 S 3 2997 0.10 80 A80 T 2 2997 0.07 80 A80 P 1 2997 0.03 81 S81 S 2988 2997 99.70 81 S81 G 6 2997 0.20 81 S81 T 1 2997 0.03 81 S81 N 1 2997 0.03 81 S81 R 1 2997 0.03 82 G82 G 2984 2991 99.77 82 G82 S 2 2991 0.07 82 G82 R 2 2991 0.07 82 G82 G/E 1 2991 0.03 82 G82 E 1 2991 0.03 82 G82 D 1 2991 0.03 83 Y83 Y 2922 2994 97.60 83 Y83 F 71 2994 2.37 83 Y83 F/Y 1 2994 0.03 84 I84 I 2688 2997 89.69 84 I84 M 171 2997 5.71 84 I84 L 101 2997 3.37 84 I84 V 30 2997 1.00 84 I84 M/I 6 2997 0.20 84 I84 M/L 1 2997 0030.03 85 E85 E 2993 2997 99.87 85 E85 Q/E 1 2997 0.03 85 E85 K 1 2997 0.03 85 E85 Q 1 2997 0.03 85 E85 D 1 2997 0.03 86 A86 A 2994 2997 99.90 86 A86 T 2 2997 0.07 86 A86 P 1 2997 0.03 87 E87 E 2994 2997 99.90 87 E87 A 1 2997 0.03 87 E87 K 1 2997 0.03 87 E87 K/E 1 2997 0.03 88 V88 V 2979 2995 99.47 88 V88 I 15 2995 0.50 88 V88 L 1 2995 0.03 89 I89 I 2985 2997 99.60 89 I89 T 4 2997 0.13 89 I89 V 4 2997 0.13 89 I89 L 2 2997 0.07 89 I89 F/I 1 2997 0.03

Page 12 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 89 I89 I/V 1 2997 0.03 90 P90 P 2955 2997 98.60 90 P90 S 26 2997 0.87 90 P90 T 8 2997 0.27 90 P90 A 7 2997 0.23 90 P90 Q 1 2997 0.03 91 A91 A 2909 2997 97.06 91 A91 T 39 2997 1.30 91 A91 E 21 2997 0.70 91 A91 G 18 2997 0.60 91 A91 S 6 2997 0.20 91 A91 V 2 2997 0.07 91 A91 P 1 2997 0.03 91 A91 A/T 1 2997 0.03 92 E92 E 2989 2997 99.73 92 E92 K 3 2997 0.10 92 E92 D 2 2997 0.07 92 E92 G 2 2997 0.07 92 E92 A 1 2997 0.03 93 T93 T 2980 2997 99.43 93 T93 S 7 2997 0.23 93 T93 A 3 2997 0.10 93 T93 I 3 2997 0.10 93 T93 N 2 2997 0070.07 93 T93 K 1 2997 0.03 93 T93 T/P 1 2997 0.03 94 G94 G 2992 2997 99.83 94 G94 R 4 2997 0.13 94 G94 A 1 2997 0.03 95 Q95 Q 2954 2997 98.57 95 Q95 S 11 2997 0.37 95 Q95 H 8 2997 0.27 95 Q95 P 7 2997 0.23 95 Q95 R 6 2997 0.20 95 Q95 Q/P 3 2997 0.10 95 Q95 K 3 2997 0.10 95 Q95 H/Q 2 2997 0.07 95 Q95 N 1 2997 0.03 95 Q95 * 1 2997 0.03 95 Q95 S/H/Q/N/R/K 1 2997 0.03 96 E96 E 2906 2997 96.96 96 E96 D 79 2997 2.64 96 E96 G 6 2997 0.20 96 E96 D/E 4 2997 0.13

Page 13 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 96 E96 A 1 2997 0.03 96 E96 G/E 1 2997 0.03 97 T97 T 2902 2997 96.83 97 T97 A 84 2997 2.80 97 T97 A/T 6 2997 0.20 97 T97 S 2 2997 0.07 97 T97 P 2 2997 0.07 97 T97 I 1 2997 0.03 98 A98 A 2987 2997 99.67 98 A98 G 6 2997 0.20 98 A98 T 1 2997 0.03 98 A98 V 1 2997 0.03 98 A98 R/G 1 2997 0.03 98 A98 S/A 1 2997 0.03 99 Y99 Y 2948 2997 98.37 99 Y99 F 36 2997 1.20 99 Y99 H 7 2997 0.23 99 Y99 L 2 2997 0.07 99 Y99 H/Y 1 2997 0.03 99 Y99 F/Y 1 2997 0.03 99 Y99 * 1 2997 0.03 99 Y99 D 1 2997 0.03 100 F100 F 2540 2997 84.75 100 F100 Y 444 2997 14. 81 100 F100 S 3 2997 0.10 100 F100 C 3 2997 0.10 100 F100 F/Y 2 2997 0.07 100 F100 L 2 2997 0.07 100 F100 W 1 2997 0.03 100 F100 F/C 1 2997 0.03 100 F100 F/L 1 2997 0.03 101 L101 I 1778 2997 59.33 101 L101 L 1166 2997 38.91 101 L101 V 23 2997 0.77 101 L101 I/L 17 2997 0.57 101 L101 I/V 3 2997 0.10 101 L101 M 2 2997 0.07 101 L101 F 1 2997 0.03 101 L101 T 1 2997 0.03 101 L101 F/I 1 2997 0.03 101 L101 M/I/L 1 2997 0.03 101 L101 P/L 1 2997 0.03 101 L101 L/V 1 2997 0.03 101 L101 F/I/L 1 2997 0.03

Page 14 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 101 L101 M/I 1 2997 0.03 102 L102 L 2992 2996 99.87 102 L102 P 2 2996 0.07 102 L102 F 1 2996 0.03 102 L102 S 1 2996 0.03 103 K103 K 2975 2997 99.27 103 K103 R 16 2997 0.53 103 K103 T 2 2997 0.07 103 K103 N 1 2997 0.03 103 K103 P 1 2997 0.03 103 K103 R/K 1 2997 0.03 103 K103 I/K/*/L 1 2997 0.03 104 L104 L 2996 2996 100.00 105 A105 A 2995 2997 99.93 105 A105 S 1 2997 0.03 105 A105 V 1 2997 0.03 106 G106 G 2860 2997 95.43 106 G106 A 128 2997 4.27 106 G106 E 2 2997 0.07 106 G106 A/G 2 2997 0.07 106 G106 R 2 2997 0.07 106 G106 S/A 2 2997 0.07 106 G106 S 1 2997 0.03 107 R107 R 2991 2997 99. 80 107 R107 G 4 2997 0.13 107 R107 S 2 2997 0.07 108 W108 W 2995 2996 99.97 108 W108 * 1 2996 0.03 109 P109 P 2995 2997 99.93 109 P109 S 1 2997 0.03 109 P109 R/P 1 2997 0.03 110 V110 V 2978 2995 99.43 110 V110 I 14 2995 0.47 110 V110 A 1 2995 0.03 110 V110 G 1 2995 0.03 110 V110 E/V 1 2995 0.03 111 K111 K 2814 2992 94.05 111 K111 R 77 2992 2.57 111 K111 T 53 2992 1.77 111 K111 Q 23 2992 0.77 111 K111 N 10 2992 0.33 111 K111 R/K 8 2992 0.27 111 K111 A 2 2992 0.07 111 K111 A/T 2 2992 0.07

Page 15 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 111 K111 S 1 2992 0.03 111 K111 A/T/K/E 1 2992 0.03 111 K111 N/K/*/Y 1 2992 0.03 112 T112 V 1712 2995 57.16 112 T112 T 921 2995 30.75 112 T112 I 251 2995 8.38 112 T112 A 58 2995 1.94 112 T112 M 19 2995 0.63 112 T112 I/V 10 2995 0.33 112 T112 R 8 2995 0.27 112 T112 T/I 6 2995 0.20 112 T112 A/T 3 2995 0.10 112 T112 A/V 1 2995 0.03 112 T112 K 1 2995 0.03 112 T112 T/P 1 2995 0.03 112 T112 M/I 1 2995 0.03 112 T112 P 1 2995 0.03 112 T112 I/L 1 2995 0.03 112 T112 M/T/I 1 2995 0.03 113 I113 I 2569 2996 85.75 113 I113 V 381 2996 12.72 113 I113 L 29 2996 0.97 113 I113 I/V 11 2996 0.37 113 I113 M 3 2996 0100.10 113 I113 E 1 2996 0.03 113 I113 T/I 1 2996 0.03 113 I113 I/L 1 2996 0.03 114 H114 H 2993 2996 99.90 114 H114 N 1 2996 0.03 114 H114 Q 1 2996 0.03 114 H114 R 1 2996 0.03 115 T115 T 2989 2997 99.73 115 T115 A 3 2997 0.10 115 T115 S 2 2997 0.07 115 T115 T/P 1 2997 0.03 115 T115 P 1 2997 0.03 115 T115 R 1 2997 0.03 116 D116 D 2992 2997 99.83 116 D116 G 4 2997 0.13 116 D116 V 1 2997 0.03 117 N117 N 2989 2997 99.73 117 N117 S 3 2997 0.10 117 N117 D 2 2997 0.07 117 N117 Y 1 2997 0.03

Page 16 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 117 N117 N/K 1 2997 0.03 117 N117 H 1 2997 0.03 118 G118 G 2995 2997 99.93 118 G118 S 1 2997 0.03 118 G118 R 1 2997 0.03 119 S119 S 2324 2997 77.54 119 S119 P 351 2997 11.71 119 S119 T 140 2997 4.67 119 S119 G 89 2997 2.97 119 S119 R 73 2997 2.44 119 S119 A 6 2997 0.20 119 S119 S/G 4 2997 0.13 119 S119 S/T 3 2997 0.10 119 S119 T/P 2 2997 0.07 119 S119 S/R 2 2997 0.07 119 S119 S/A/T/G 1 2997 0.03 119 S119 S/N/R/K 1 2997 0.03 119 S119 I 1 2997 0.03 120 N120 N 2997 2997 100.00 121 F121 F 2992 2997 99.83 121 F121 S 2 2997 0.07 121 F121 L 2 2997 0.07 121 F121 F/S 1 2997 0.03 122 T122 T 2757 2996 92. 02 122 T122 I 216 2996 7.21 122 T122 T/I 10 2996 0.33 122 T122 S 6 2996 0.20 122 T122 V 4 2996 0.13 122 T122 A 2 2996 0.07 122 T122 T/P 1 2996 0.03 123 G123 S 2966 2996 99.00 123 G123 G 17 2996 0.57 123 G123 C 7 2996 0.23 123 G123 I 2 2996 0.07 123 G123 N 1 2996 0.03 123 G123 S/R 1 2996 0.03 123 G123 S/G 1 2996 0.03 123 G123 S/T 1 2996 0.03 124 A124 A 1799 2995 60.07 124 A124 T 759 2995 25.34 124 A124 N 278 2995 9.28 124 A124 S 86 2995 2.87 124 A124 G 42 2995 1.40 124 A124 A/T 11 2995 0.37

Page 17 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 124 A124 Q 6 2995 0.20 124 A124 D/N 2 2995 0.07 124 A124 S/G 2 2995 0.07 124 A124 S/N 2 2995 0.07 124 A124 A/V 1 2995 0.03 124 A124 E 1 2995 0.03 124 A124 T/N 1 2995 0.03 124 A124 V 1 2995 0.03 124 A124 S/A 1 2995 0.03 124 A124 P 1 2995 0.03 124 A124 A/G 1 2995 0.03 124 A124 D 1 2995 0.03 125 T125 A 1976 2996 65.95 125 T125 T 857 2996 28.60 125 T125 V 112 2996 3.74 125 T125 S 19 2996 0.63 125 T125 A/T 9 2996 0.30 125 T125 P 8 2996 0.27 125 T125 A/V 5 2996 0.17 125 T125 I 4 2996 0.13 125 T125 K 1 2996 0.03 125 T125 M/V 1 2996 0.03 125 T125 Q 1 2996 0.03 125 T125 M 1 2996 0030.03 125 T125 T/P 1 2996 0.03 125 T125 M/T 1 2996 0.03 126 V126 V 2812 2994 93.92 126 V126 M 104 2994 3.47 126 V126 F 60 2994 2.00 126 V126 L 11 2994 0.37 126 V126 A 6 2994 0.20 126 V126 C 1 2994 0.03 127 R127 K 2951 2996 98.50 127 R127 R 40 2996 1.34 127 R127 R/K 2 2996 0.07 127 R127 E 1 2996 0.03 127 R127 M 1 2996 0.03 127 R127 M/K 1 2996 0.03 128 A128 A 2973 2995 99.27 128 A128 T 22 2995 0.73 129 A129 A 2989 2997 99.73 129 A129 S 3 2997 0.10 129 A129 T 3 2997 0.10 129 A129 V 2 2997 0.07

Page 18 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 130 C130 C 2995 2997 99.93 130 C130 F/C 1 2997 0.03 130 C130 W 1 2997 0.03 131 W131 W 2993 2997 99.87 131 W131 W/* 2 2997 0.07 131 W131 R 1 2997 0.03 131 W131 G 1 2997 0.03 132 W132 W 2991 2997 99.80 132 W132 * 4 2997 0.13 132 W132 W/G 1 2997 0.03 132 W132 C 1 2997 0.03 133 A133 A 2939 2997 98.06 133 A133 T 55 2997 1.84 133 A133 S 2 2997 0.07 133 A133 V 1 2997 0.03 134 G134 G 1932 2996 64.49 134 G134 N 866 2996 28.91 134 G134 D 137 2996 4.57 134 G134 S 41 2996 1.37 134 G134 E 6 2996 0.20 134 G134 D/N 5 2996 0.17 134 G134 S/D/N/G 3 2996 0.10 134 G134 S/N 3 2996 0.10 134 G134 R 2 2996 0070.07 134 G134 K 1 2996 0.03 135 I135 I 2291 2997 76.44 135 I135 V 690 2997 23.02 135 I135 I/V 12 2997 0.40 135 I135 T 2 2997 0.07 135 I135 A/V 1 2997 0.03 135 I135 L 1 2997 0.03 136 K136 K 1212 2995 40.47 136 K136 Q 1049 2995 35.03 136 K136 T 585 2995 19.53 136 K136 R 102 2995 3.41 136 K136 H 14 2995 0.47 136 K136 N 13 2995 0.43 136 K136 Q/K 2 2995 0.07 136 K136 L 2 2995 0.07 136 K136 K/* 2 2995 0.07 136 K136 I 2 2995 0.07 136 K136 Q/R/K 1 2995 0.03 136 K136 * 1 2995 0.03 136 K136 H/Q 1 2995 0.03

Page 19 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 136 K136 E 1 2995 0.03 136 K136 Y 1 2995 0.03 136 K136 A/T 1 2995 0.03 136 K136 T/K 1 2995 0.03 136 K136 T/P 1 2995 0.03 136 K136 Q/T/P/K 1 2995 0.03 136 K136 A 1 2995 0.03 136 K136 N/K 1 2995 0.03 136 K136 Q/R 1 2995 0.03 137 Q137 Q 2916 2997 97.30 137 Q137 H 75 2997 2.50 137 Q137 R 4 2997 0.13 137 Q137 S 1 2997 0.03 137 Q137 * 1 2997 0.03 138 E138 E 2974 2997 99.23 138 E138 D 14 2997 0.47 138 E138 D/E 3 2997 0.10 138 E138 K 2 2997 0.07 138 E138 A 2 2997 0.07 138 E138 G/E 1 2997 0.03 138 E138 G 1 2997 0.03 139 F139 F 2978 2997 99.37 139 F139 Y 12 2997 0.40 139 F139 S 3 2997 0100.10 139 F139 L 3 2997 0.10 139 F139 C 1 2997 0.03 140 G140 G 2985 2997 99.60 140 G140 E 4 2997 0.13 140 G140 S 2 2997 0.07 140 G140 R 2 2997 0.07 140 G140 A 1 2997 0.03 140 G140 W 1 2997 0.03 140 G140 G/E 1 2997 0.03 140 G140 R/G 1 2997 0.03 141 I141 I 2966 2996 99.00 141 I141 V 14 2996 0.47 141 I141 T 9 2996 0.30 141 I141 S 3 2996 0.10 141 I141 I/V 3 2996 0.10 141 I141 D 1 2996 0.03 142 P142 P 2993 2996 99.90 142 P142 S 2 2996 0.07 142 P142 A 1 2996 0.03 143 Y143 Y 2990 2997 99.77

Page 20 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 143 Y143 H 6 2997 0.20 143 Y143 S/Y 1 2997 0.03 144 N144 N 2986 2996 99.67 144 N144 S 7 2996 0.23 144 N144 N/Y 1 2996 0.03 144 N144 H/Y 1 2996 0.03 144 N144 D 1 2996 0.03 145 P145 P 2994 2997 99.90 145 P145 S 1 2997 0.03 145 P145 T 1 2997 0.03 145 P145 L 1 2997 0.03 146 Q146 Q 2995 2997 99.93 146 Q146 H/Q 1 2997 0.03 146 Q146 P 1 2997 0.03 147 S147 S 2993 2997 99.87 147 S147 G 4 2997 0.13 148 Q148 Q 2995 2997 99.93 148 Q148 P 1 2997 0.03 148 Q148 H 1 2997 0.03 149 G149 G 2992 2996 99.87 149 G149 G/E 2 2996 0.07 149 G149 E 1 2996 0.03 149 G149 R 1 2996 0.03 150 V150 V 2984 2997 99. 57 150 V150 A 10 2997 0.33 150 V150 I 2 2997 0.07 150 V150 I/V 1 2997 0.03 151 V151 V 2914 2996 97.26 151 V151 I 74 2996 2.47 151 V151 I/V 4 2996 0.13 151 V151 L 2 2996 0.07 151 V151 M 1 2996 0.03 151 V151 L/V 1 2996 0.03 152 E152 E 2969 2996 99.10 152 E152 K 14 2996 0.47 152 E152 Q 3 2996 0.10 152 E152 V 2 2996 0.07 152 E152 K/E 2 2996 0.07 152 E152 D 2 2996 0.07 152 E152 G 2 2996 0.07 152 E152 A 1 2996 0.03 152 E152 G/E 1 2996 0.03 153 S153 S 2908 2995 97.10 153 S153 A 83 2995 2.77

Page 21 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 153 S153 P 2 2995 0.07 153 S153 T 1 2995 0.03 153 S153 Y 1 2995 0.03 154 M154 M 2890 2995 96.49 154 M154 I 86 2995 2.87 154 M154 L 11 2995 0.37 154 M154 T 4 2995 0.13 154 M154 V 2 2995 0.07 154 M154 M/I 2 2995 0.07 155 N155 N 2991 2996 99.83 155 N155 H 2 2996 0.07 155 N155 S 1 2996 0.03 155 N155 T 1 2996 0.03 155 N155 K 1 2996 0.03 156 K156 K 2902 2996 96.86 156 K156 N 82 2996 2.74 156 K156 R 9 2996 0.30 156 K156 T 1 2996 0.03 156 K156 H 1 2996 0.03 156 K156 I 1 2996 0.03 157 E157 E 2908 2996 97.06 157 E157 Q 60 2996 2.00 157 E157 K 12 2996 0.40 157 E157 D 5 2996 0170.17 157 E157 N 4 2996 0.13 157 E157 K/E 2 2996 0.07 157 E157 Q/E 1 2996 0.03 157 E157 H/Q 1 2996 0.03 157 E157 A 1 2996 0.03 157 E157 G/E 1 2996 0.03 157 E157 G 1 2996 0.03 158 L158 L 2995 2996 99.97 158 L158 V 1 2996 0.03 159 K159 K 2987 2997 99.67 159 K159 R 6 2997 0.20 159 K159 E 2 2997 0.07 159 K159 Q 2 2997 0.07 160 K160 K 2845 2994 95.02 160 K160 S 70 2994 2.34 160 K160 Q 33 2994 1.10 160 K160 R 24 2994 0.80 160 K160 T 10 2994 0.33 160 K160 N 6 2994 0.20 160 K160 E 3 2994 0.10

Page 22 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 160 K160 N/K 2 2994 0.07 160 K160 R/K 1 2994 0.03 161 I161 I 2978 2996 99.40 161 I161 V 7 2996 0.23 161 I161 T 5 2996 0.17 161 I161 L 5 2996 0.17 161 I161 S 1 2996 0.03 162 I162 I 2981 2996 99.50 162 I162 V 12 2996 0.40 162 I162 T 1 2996 0.03 162 I162 Q 1 2996 0.03 162 I162 M 1 2996 0.03 163 G163 G 2743 2996 91.56 163 G163 E 88 2996 2.94 163 G163 Q 68 2996 2.27 163 G163 K 19 2996 0.63 163 G163 R 15 2996 0.50 163 G163 T 14 2996 0.47 163 G163 V 14 2996 0.47 163 G163 A 12 2996 0.40 163 G163 S 9 2996 0.30 163 G163 N 5 2996 0.17 163 G163 Q/E 1 2996 0.03 163 G163 A/T 1 2996 0030.03 163 G163 M 1 2996 0.03 163 G163 G/E 1 2996 0.03 163 G163 H 1 2996 0.03 163 G163 A/G 1 2996 0.03 163 G163 I 1 2996 0.03 163 G163 R/G 1 2996 0.03 163 G163 Q/R 1 2996 0.03 164 Q164 Q 2995 2997 99.93 164 Q164 K 1 2997 0.03 164 Q164 R 1 2997 0.03 165 V165 V 2839 2996 94.76 165 V165 I 152 2996 5.07 165 V165 I/V 4 2996 0.13 165 V165 A 1 2996 0.03 166 R166 R 2981 2997 99.47 166 R166 K 8 2997 0.27 166 R166 G 6 2997 0.20 166 R166 S 1 2997 0.03 166 R166 T 1 2997 0.03 167 D167 D 2446 2997 81.61

Page 23 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 167 D167 E 541 2997 18.05 167 D167 D/E 6 2997 0.20 167 D167 G 3 2997 0.10 167 D167 N 1 2997 0.03 168 Q168 Q 2993 2997 99.87 168 Q168 L 1 2997 0.03 168 Q168 P 1 2997 0.03 168 Q168 H 1 2997 0.03 168 Q168 R 1 2997 0.03 169 A169 A 2986 2996 99.67 169 A169 T 5 2996 0.17 169 A169 A/G 2 2996 0.07 169 A169 V 1 2996 0.03 169 A169 S/A 1 2996 0.03 169 A169 D 1 2996 0.03 170 E170 E 2989 2997 99.73 170 E170 G 5 2997 0.17 170 E170 D/E 1 2997 0.03 170 E170 Q/E 1 2997 0.03 170 E170 A 1 2997 0.03 171 H171 H 2964 2997 98.90 171 H171 Q 11 2997 0.37 171 H171 Y 9 2997 0.30 171 H171 L 6 2997 0200.20 171 H171 R 5 2997 0.17 171 H171 H/Q 1 2997 0.03 171 H171 H/Y 1 2997 0.03 172 L172 L 2982 2996 99.53 172 L172 F 4 2996 0.13 172 L172 P 4 2996 0.13 172 L172 F/L 2 2996 0.07 172 L172 H 2 2996 0.07 172 L172 I/L 1 2996 0.03 172 L172 I 1 2996 0.03 173 K173 K 2865 2996 95.63 173 K173 R 123 2996 4.11 173 K173 R/K 3 2996 0.10 173 K173 E 2 2996 0.07 173 K173 T 1 2996 0.03 173 K173 * 1 2996 0.03 173 K173 M 1 2996 0.03 174 T174 T 2989 2996 99.77 174 T174 A 4 2996 0.13 174 T174 T/R 1 2996 0.03

Page 24 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 174 T174 A/T 1 2996 0.03 174 T174 R 1 2996 0.03 175 A175 A 2995 2997 99.93 175 A175 T 1 2997 0.03 175 A175 V 1 2997 0.03 176 V176 V 2986 2997 99.63 176 V176 L 5 2997 0.17 176 V176 F 1 2997 0.03 176 V176 A/V 1 2997 0.03 176 V176 I/V 1 2997 0.03 176 V176 A 1 2997 0.03 176 V176 I 1 2997 0.03 176 V176 G 1 2997 0.03 177 Q177 Q 2978 2995 99.43 177 Q177 L 13 2995 0.43 177 Q177 H 2 2995 0.07 177 Q177 Q/L 1 2995 0.03 177 Q177 P 1 2995 0.03 178 M178 M 2991 2996 99.83 178 M178 V 3 2996 0.10 178 M178 T 1 2996 0.03 178 M178 M/R 1 2996 0.03 179 A179 A 2993 2996 99.90 179 A179 S 1 2996 0030.03 179 A179 T 1 2996 0.03 179 A179 V 1 2996 0.03 180 V180 V 2989 2995 99.80 180 V180 A 4 2995 0.13 180 V180 I 2 2995 0.07 181 F181 F 2925 2996 97.63 181 F181 L 54 2996 1.80 181 F181 Y 11 2996 0.37 181 F181 F/L 4 2996 0.13 181 F181 S 1 2996 0.03 181 F181 H 1 2996 0.03 182 I182 I 2913 2996 97.23 182 I182 V 79 2996 2.64 182 I182 I/V 2 2996 0.07 182 I182 F 1 2996 0.03 182 I182 T 1 2996 0.03 183 H183 H 2988 2995 99.77 183 H183 R 3 2995 0.10 183 H183 Y 2 2995 0.07 183 H183 H/R 1 2995 0.03

Page 25 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 183 H183 P 1 2995 0.03 184 N184 N 2992 2996 99.87 184 N184 D 2 2996 0.07 184 N184 H/N 1 2996 0.03 184 N184 I 1 2996 0.03 185 F185 F 2979 2997 99.40 185 F185 Y 16 2997 0.53 185 F185 S 1 2997 0.03 185 F185 F/Y 1 2997 0.03 186 K186 K 2989 2997 99.73 186 K186 R 3 2997 0.10 186 K186 R/K 2 2997 0.07 186 K186 T 1 2997 0.03 186 K186 * 1 2997 0.03 186 K186 I 1 2997 0.03 187 R187 R 2973 2997 99.20 187 R187 K 17 2997 0.57 187 R187 G 4 2997 0.13 187 R187 R/K 2 2997 0.07 187 R187 T 1 2997 0.03 188 K188 K 2853 2992 95.35 188 K188 R 125 2992 4.18 188 K188 R/K 10 2992 0.33 188 K188 E 2 2992 0070.07 188 K188 I/K 1 2992 0.03 188 K188 N 1 2992 0.03 189 G189 G 2986 2997 99.63 189 G189 R 9 2997 0.30 189 G189 E 1 2997 0.03 189 G189 R/G 1 2997 0.03 190 G190 G 2993 2997 99.87 190 G190 R 3 2997 0.10 190 G190 E 1 2997 0.03 191 I191 I 2987 2997 99.67 191 I191 L 5 2997 0.17 191 I191 V 3 2997 0.10 191 I191 I/V 1 2997 0.03 191 I191 R 1 2997 0.03 192 G192 G 2990 2994 99.87 192 G192 E 2 2994 0.07 192 G192 V 1 2994 0.03 192 G192 A 1 2994 0.03 193 G193 G 2871 2993 95.92 193 G193 E 70 2993 2.34

Page 26 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 193 G193 D 28 2993 0.94 193 G193 R 17 2993 0.57 193 G193 G/E 4 2993 0.13 193 G193 R/G 3 2993 0.10 193_1 _193_1 N 1 1 100.00 194 Y194 Y 2976 2997 99.30 194 Y194 C 13 2997 0.43 194 Y194 T 2 2997 0.07 194 Y194 C/Y 2 2997 0.07 194 Y194 H 2 2997 0.07 194 Y194 S 1 2997 0.03 194 Y194 */Y 1 2997 0.03 195 S195 S 2877 2997 96.00 195 S195 T 97 2997 3.24 195 S195 C 20 2997 0.67 195 S195 G 2 2997 0.07 195 S195 S/N 1 2997 0.03 196 A196 A 2985 2997 99.60 196 A196 P 7 2997 0.23 196 A196 V 3 2997 0.10 196 A196 S 1 2997 0.03 196 A196 T 1 2997 0.03 197 G197 G 2993 2996 99.90 197 G197 R 3 2996 0100.10 198 E198 E 2988 2997 99.70 198 E198 D 5 2997 0.17 198 E198 G 3 2997 0.10 198 E198 K 1 2997 0.03 199 R199 R 2987 2994 99.77 199 R199 G 5 2994 0.17 199 R199 K 1 2994 0.03 199 R199 R/K 1 2994 0.03 200 I200 I 2927 2994 97.76 200 I200 L 36 2994 1.20 200 I200 M 24 2994 0.80 200 I200 V 4 2994 0.13 200 I200 T 2 2994 0.07 200 I200 D 1 2994 0.03 201 V201 I 2288 2994 76.42 201 V201 V 687 2994 22.95 201 V201 I/V 9 2994 0.30 201 V201 L 7 2994 0.23 201 V201 M 2 2994 0.07 201 V201 T 1 2994 0.03

Page 27 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 202 D202 D 2987 2992 99.83 202 D202 H 2 2992 0.07 202 D202 D/Y 1 2992 0.03 202 D202 Y 1 2992 0.03 202 D202 G 1 2992 0.03 203 I203 I 2901 2995 96.86 203 I203 M 87 2995 2.90 203 I203 M/I 3 2995 0.10 203 I203 L 3 2995 0.10 203 I203 T/I 1 2995 0.03 204 I204 I 2906 2997 96.96 204 I204 L 78 2997 2.60 204 I204 V 7 2997 0.23 204 I204 I/V 4 2997 0.13 204 I204 M 1 2997 0.03 204 I204 R 1 2997 0.03 205 A205 A 2910 2997 97.10 205 A205 S 80 2997 2.67 205 A205 T 3 2997 0.10 205 A205 P 2 2997 0.07 205 A205 V 1 2997 0.03 205 A205 A/T 1 2997 0.03 206 T206 T 2132 2996 71.16 206 T206 S 849 2996 28. 34 206 T206 A 6 2996 0.20 206 T206 S/T 6 2996 0.20 206 T206 P 2 2996 0.07 206 T206 T/P 1 2996 0.03 207 D207 D 2870 2997 95.76 207 D207 Q 57 2997 1.90 207 D207 E 36 2997 1.20 207 D207 H 15 2997 0.50 207 D207 D/E 8 2997 0.27 207 D207 G 5 2997 0.17 207 D207 N 4 2997 0.13 207 D207 D/G 1 2997 0.03 207 D207 V 1 2997 0.03 208 I208 I 2832 2997 94.49 208 I208 L 115 2997 3.84 208 I208 M 37 2997 1.23 208 I208 M/I 6 2997 0.20 208 I208 I/L 6 2997 0.20 208 I208 M/I/L 1 2997 0.03 209 Q209 Q 2987 2996 99.70

Page 28 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 209 Q209 P 4 2996 0.13 209 Q209 R 3 2996 0.10 209 Q209 H 1 2996 0.03 209 Q209 Q/R 1 2996 0.03 210 T210 T 2975 2996 99.30 210 T210 I 7 2996 0.23 210 T210 T/I 4 2996 0.13 210 T210 S 3 2996 0.10 210 T210 A 3 2996 0.10 210 T210 V 1 2996 0.03 210 T210 A/T 1 2996 0.03 210 T210 T/P 1 2996 0.03 210 T210 S/T 1 2996 0.03 211 K211 K 2553 2994 85.27 211 K211 R 283 2994 9.45 211 K211 T 114 2994 3.81 211 K211 Q 23 2994 0.77 211 K211 R/K 13 2994 0.43 211 K211 N 4 2994 0.13 211 K211 E 2 2994 0.07 211 K211 Q/P 1 2994 0.03 211 K211 Q/K/* 1 2994 0.03 212 E212 E 2941 2994 98.23 212 E212 A 22 2994 0730.73 212 E212 Q 13 2994 0.43 212 E212 K 7 2994 0.23 212 E212 A/V 3 2994 0.10 212 E212 V 3 2994 0.10 212 E212 D/E 1 2994 0.03 212 E212 N 1 2994 0.03 212 E212 A/Q/P/E 1 2994 0.03 212 E212 I 1 2994 0.03 212 E212 G 1 2994 0.03 213 L213 L 2986 2993 99.77 213 L213 F 3 2993 0.10 213 L213 S 2 2993 0.07 213 L213 S/L 1 2993 0.03 213 L213 P/L 1 2993 0.03 214 Q214 Q 2986 2995 99.70 214 Q214 E 2 2995 0.07 214 Q214 P 2 2995 0.07 214 Q214 H 2 2995 0.07 214 Q214 H/Q 1 2995 0.03 214 Q214 R 1 2995 0.03

Page 29 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 214 Q214 Q/R 1 2995 0.03 215 K215 K 2864 2995 95.63 215 K215 N 95 2995 3.17 215 K215 R 20 2995 0.67 215 K215 T 8 2995 0.27 215 K215 Q 3 2995 0.10 215 K215 N/K 2 2995 0.07 215 K215 R/K 1 2995 0.03 215 K215 L 1 2995 0.03 215 K215 K/* 1 2995 0.03 216 Q216 Q 2895 2996 96.63 216 Q216 H 62 2996 2.07 216 Q216 R 18 2996 0.60 216 Q216 N 13 2996 0.43 216 Q216 H/Q 3 2996 0.10 216 Q216 P 2 2996 0.07 216 Q216 Q/P 1 2996 0.03 216 Q216 K 1 2996 0.03 216 Q216 Q/R 1 2996 0.03 217 I217 I 2976 2995 99.37 217 I217 V 15 2995 0.50 217 I217 M 2 2995 0.07 217 I217 F 1 2995 0.03 217 I217 F/I 1 2995 0030.03 218 T218 T 1918 2996 64.02 218 T218 I 834 2996 27.84 218 T218 L 107 2996 3.57 218 T218 S 75 2996 2.50 218 T218 T/I 23 2996 0.77 218 T218 F 18 2996 0.60 218 T218 M 14 2996 0.47 218 T218 S/T 2 2996 0.07 218 T218 N 1 2996 0.03 218 T218 M/I 1 2996 0.03 218 T218 A 1 2996 0.03 218 T218 M/T 1 2996 0.03 218 T218 R 1 2996 0.03 219 K219 K 2870 2995 95.83 219 K219 N 54 2995 1.80 219 K219 Q 52 2995 1.74 219 K219 R 8 2995 0.27 219 K219 Q/K 4 2995 0.13 219 K219 E 3 2995 0.10 219 K219 R/K 2 2995 0.07

Page 30 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 219 K219 N/K 1 2995 0.03 219 K219 I 1 2995 0.03 220 I220 I 2897 2994 96.76 220 I220 V 41 2994 1.37 220 I220 L 36 2994 1.20 220 I220 M 9 2994 0.30 220 I220 I/V 5 2994 0.17 220 I220 F 2 2994 0.07 220 I220 F/I 2 2994 0.07 220 I220 I/L 1 2994 0.03 220 I220 D 1 2994 0.03 221 Q221 Q 2926 2997 97.63 221 Q221 R 16 2997 0.53 221 Q221 S 12 2997 0.40 221 Q221 H 11 2997 0.37 221 Q221 T 8 2997 0.27 221 Q221 P 5 2997 0.17 221 Q221 K 4 2997 0.13 221 Q221 Q/R/K 2 2997 0.07 221 Q221 N 2 2997 0.07 221 Q221 Q/K 2 2997 0.07 221 Q221 H/Q 2 2997 0.07 221 Q221 E 2 2997 0.07 221 Q221 Q/P 1 2997 0030.03 221 Q221 * 1 2997 0.03 221 Q221 Q/R/* 1 2997 0.03 221 Q221 Q/R 1 2997 0.03 221 Q221 G 1 2997 0.03 222 N222 N 2842 2995 94.89 222 N222 K 120 2995 4.01 222 N222 H 14 2995 0.47 222 N222 H/N 5 2995 0.17 222 N222 T 3 2995 0.10 222 N222 N/K 3 2995 0.10 222 N222 S 2 2995 0.07 222 N222 T/N 2 2995 0.07 222 N222 D 2 2995 0.07 222 N222 I 2 2995 0.07 223 F223 F 2990 2995 99.83 223 F223 C 2 2995 0.07 223 F223 Y 1 2995 0.03 223 F223 F/S 1 2995 0.03 223 F223 L 1 2995 0.03 224 R224 R 2956 2995 98.70

Page 31 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 224 R224 Q 34 2995 1.14 224 R224 W 3 2995 0.10 224 R224 W/R 1 2995 0.03 224 R224 Q/R 1 2995 0.03 225 V225 V 2991 2995 99.87 225 V225 A 3 2995 0.10 225 V225 C 1 2995 0.03 226 Y226 Y 2990 2995 99.83 226 Y226 F 2 2995 0.07 226 Y226 C 2 2995 0.07 226 Y226 * 1 2995 0.03 227 Y227 Y 2834 2995 94.62 227 Y227 F 154 2995 5.14 227 Y227 F/Y 4 2995 0.13 227 Y227 S 1 2995 0.03 227 Y227 C/Y 1 2995 0.03 227 Y227 H 1 2995 0.03 228 R228 R 2990 2995 99.83 228 R228 G 4 2995 0.13 228 R228 K 1 2995 0.03 229 D229 D 2990 2997 99.77 229 D229 E 5 2997 0.17 229 D229 D/N 1 2997 0.03 229 D229 G 1 2997 0030.03 230 S230 S 2894 2997 96.56 230 S230 N 98 2997 3.27 230 S230 S/N 3 2997 0.10 230 S230 R 1 2997 0.03 230 S230 G 1 2997 0.03 231 R231 R 2974 2997 99.23 231 R231 K 16 2997 0.53 231 R231 G 4 2997 0.13 231 R231 S 1 2997 0.03 231 R231 T/R 1 2997 0.03 231 R231 I 1 2997 0.03 232 N232 D 2920 2996 97.46 232 N232 E 38 2996 1.27 232 N232 N 31 2996 1.03 232 N232 G 5 2996 0.17 232 N232 D/E 2 2996 0.07 233 P233 P 2986 2997 99.63 233 P233 S 9 2997 0.30 233 P233 P/L 1 2997 0.03 233 P233 R/P 1 2997 0.03

Page 32 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 234 L234 I 1896 2996 63.28 234 L234 L 889 2996 29.67 234 L234 V 181 2996 6.04 234 L234 S 13 2996 0.43 234 L234 F 5 2996 0.17 234 L234 T 4 2996 0.13 234 L234 H 3 2996 0.10 234 L234 I/V 2 2996 0.07 234 L234 M 1 2996 0.03 234 L234 P 1 2996 0.03 234 L234 R 1 2996 0.03 235 W235 W 2993 2997 99.87 235 W235 R 2 2997 0.07 235 W235 W/G 1 2997 0.03 235 W235 W/* 1 2997 0.03 236 K236 K 2995 2997 99.93 236 K236 R 2 2997 0.07 237 G237 G 2995 2997 99.93 237 G237 R 2 2997 0.07 238 P238 P 2992 2996 99.87 238 P238 L 2 2996 0.07 238 P238 S 1 2996 0.03 238 P238 H 1 2996 0.03 239 A239 A 2995 2996 99. 97 239 A239 T 1 2996 0.03 240 K240 K 2903 2994 96.96 240 K240 Q 70 2994 2.34 240 K240 R 14 2994 0.47 240 K240 E 6 2994 0.20 240 K240 I 1 2994 0.03 241 L241 L 2993 2996 99.90 241 L241 V 1 2996 0.03 241 L241 Q 1 2996 0.03 241 L241 P 1 2996 0.03 242 L242 L 2992 2996 99.87 242 L242 I 2 2996 0.07 242 L242 F 1 2996 0.03 242 L242 P 1 2996 0.03 243 W243 W 2988 2994 99.80 243 W243 R 2 2994 0.07 243 W243 * 1 2994 0.03 243 W243 W/* 1 2994 0.03 243 W243 W/L 1 2994 0.03 243 W243 G 1 2994 0.03

Page 33 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 244 K244 K 2993 2996 99.90 244 K244 E 2 2996 0.07 244 K244 R 1 2996 0.03 245 G245 G 2993 2996 99.90 245 G245 S 3 2996 0.10 246 E246 E 2989 2997 99.73 246 E246 G 3 2997 0.10 246 E246 D/E 1 2997 0.03 246 E246 Y 1 2997 0.03 246 E246 Q 1 2997 0.03 246 E246 A 1 2997 0.03 246 E246 D 1 2997 0.03 247 G247 G 2995 2997 99.93 247 G247 R 2 2997 0.07 248 A248 A 2991 2997 99.80 248 A248 V 5 2997 0.17 248 A248 T 1 2997 0.03 248_1 _248_1 V 1 1 100.00 249 V249 V 2989 2997 99.73 249 V249 I/V 2 2997 0.07 249 V249 I 2 2997 0.07 249 V249 E 1 2997 0.03 249 V249 L 1 2997 0.03 249 V249 A 1 2997 0030.03 249 V249 G 1 2997 0.03 250 V250 V 2980 2996 99.47 250 V250 I 7 2996 0.23 250 V250 L 5 2996 0.17 250 V250 Y 1 2996 0.03 250 V250 E 1 2996 0.03 250 V250 A 1 2996 0.03 250 V250 P 1 2996 0.03 251 I251 I 2922 2997 97.50 251 I251 L 65 2997 2.17 251 I251 I/L 5 2997 0.17 251 I251 V 4 2997 0.13 251 I251 T 1 2997 0.03 252 Q252 Q 2985 2997 99.60 252 Q252 E 5 2997 0.17 252 Q252 K 4 2997 0.13 252 Q252 R 2 2997 0.07 252 Q252 T/K 1 2997 0.03 253 D253 D 2943 2997 98.20 253 D253 E 42 2997 1.40

Page 34 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 253 D253 H 5 2997 0.17 253 D253 D/E 2 2997 0.07 253 D253 Y 2 2997 0.07 253 D253 D/N 1 2997 0.03 253 D253 H/Y 1 2997 0.03 253 D253 G 1 2997 0.03 254 N254 N 2841 2992 94.95 254 N254 K 109 2992 3.64 254 N254 S 12 2992 0.40 254 N254 Q 12 2992 0.40 254 N254 H 4 2992 0.13 254 N254 D 3 2992 0.10 254 N254 T 2 2992 0.07 254 N254 N/I 2 2992 0.07 254 N254 N/K 2 2992 0.07 254 N254 G 2 2992 0.07 254 N254 N/Y 1 2992 0.03 254 N254 D/N 1 2992 0.03 254 N254 S/N 1 2992 0.03 255 S255 S 2620 2992 87.57 255 S255 N 213 2992 7.12 255 S255 G 131 2992 4.38 255 S255 T 9 2992 0.30 255 S255 K 8 2992 0270.27 255 S255 D 3 2992 0.10 255 S255 R 3 2992 0.10 255 S255 D/N 1 2992 0.03 255 S255 C 1 2992 0.03 255 S255 S/G 1 2992 0.03 255 S255 N/I 1 2992 0.03 255 S255 S/N 1 2992 0.03 255_1 _255_1 G 1 1 100.00 256 D256 D 2354 2991 78.70 256 D256 E 614 2991 20.53 256 D256 G 13 2991 0.43 256 D256 D/E 3 2991 0.10 256 D256 A 3 2991 0.10 256 D256 Y 1 2991 0.03 256 D256 V 1 2991 0.03 256 D256 D/N 1 2991 0.03 256 D256 K/E 1 2991 0.03 257 I257 I 2987 2996 99.70 257 I257 V 5 2996 0.17 257 I257 T 2 2996 0.07

Page 35 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 257 I257 M 1 2996 0.03 257 I257 L 1 2996 0.03 258 K258 K 2989 2996 99.77 258 K258 E 2 2996 0.07 258 K258 R 2 2996 0.07 258 K258 N 1 2996 0.03 258 K258 Q 1 2996 0.03 258 K258 N/K 1 2996 0.03 259 V259 V 2978 2997 99.37 259 V259 I 12 2997 0.40 259 V259 I/V 4 2997 0.13 259 V259 L 1 2997 0.03 259 V259 A 1 2997 0.03 259 V259 L/V 1 2997 0.03 260 V260 V 2962 2996 98.87 260 V260 I 30 2996 1.00 260 V260 A 2 2996 0.07 260 V260 I/V 1 2996 0.03 260 V260 L 1 2996 0.03 261 P261 P 2996 2997 99.97 261 P261 L 1 2997 0.03 262 R262 R 2994 2997 99.90 262 R262 R/K 1 2997 0.03 262 R262 P 1 2997 0030.03 262 R262 R/G 1 2997 0.03 263 R263 R 2990 2997 99.77 263 R263 K 3 2997 0.10 263 R263 S 2 2997 0.07 263 R263 T 1 2997 0.03 263 R263 R/K 1 2997 0.03 264 K264 K 2986 2997 99.63 264 K264 R 7 2997 0.23 264 K264 E 3 2997 0.10 264 K264 R/K 1 2997 0.03 265 A265 A 2179 2995 72.75 265 A265 V 787 2995 26.28 265 A265 A/V 22 2995 0.73 265 A265 T 4 2995 0.13 265 A265 E 1 2995 0.03 265 A265 A/T 1 2995 0.03 265 A265 I 1 2995 0.03 266 K266 K 2989 2994 99.83 266 K266 Q 2 2994 0.07 266 K266 Q/K 1 2994 0.03

Page 36 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 266 K266 T/K 1 2994 0.03 266 K266 R 1 2994 0.03 267 I267 I 2988 2995 99.77 267 I267 V 3 2995 0.10 267 I267 T 2 2995 0.07 267 I267 I/V 2 2995 0.07 268 I268 I 2926 2993 97.76 268 I268 L 52 2993 1.74 268 I268 V 8 2993 0.27 268 I268 I/L 5 2993 0.17 268 I268 T 1 2993 0.03 268 I268 P 1 2993 0.03 269 R269 R 2309 2991 77.20 269 R269 K 665 2991 22.23 269 R269 R/K 15 2991 0.50 269 R269 T 1 2991 0.03 269 R269 G 1 2991 0.03 270 D270 D 2884 2988 96.52 270 D270 H 54 2988 1.81 270 D270 N 24 2988 0.80 270 D270 E 15 2988 0.50 270 D270 G 6 2988 0.20 270 D270 C 2 2988 0.07 270 D270 D/E 1 2988 0030.03 270 D270 D/N 1 2988 0.03 270 D270 H/D 1 2988 0.03 271 Y271 Y 2960 2967 99.76 271 Y271 H 5 2967 0.17 271 Y271 C 1 2967 0.03 271 Y271 F/Y 1 2967 0.03 272 G272 G 2969 2970 99.97 272 G272 G/E 1 2970 0.03 273 K273 K 2954 2970 99.46 273 K273 Q 7 2970 0.24 273 K273 N 2 2970 0.07 273 K273 E 2 2970 0.07 273 K273 R 2 2970 0.07 273 K273 T 1 2970 0.03 273 K273 Q/K 1 2970 0.03 273 K273 I 1 2970 0.03 274 Q274 Q 2967 2969 99.93 274 Q274 P 1 2969 0.03 274 Q274 R 1 2969 0.03 275 M275 M 2927 2967 98.65

Page 37 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 275 M275 V 37 2967 1.25 275 M275 T 2 2967 0.07 275 M275 M/V 1 2967 0.03 276 A276 A 2961 2963 99.93 276 A276 T 1 2963 0.03 276 A276 G 1 2963 0.03 277 G277 G 2957 2961 99.86 277 G277 S 3 2961 0.10 277 G277 V 1 2961 0.03 278 D278 D 2196 2958 74.24 278 D278 A 640 2958 21.64 278 D278 T 47 2958 1.59 278 D278 N 38 2958 1.28 278 D278 G 16 2958 0.54 278 D278 E 6 2958 0.20 278 D278 S 4 2958 0.14 278 D278 P 3 2958 0.10 278 D278 D/N 2 2958 0.07 278 D278 D/G 1 2958 0.03 278 D278 V 1 2958 0.03 278 D278 T/N 1 2958 0.03 278 D278 A/T 1 2958 0.03 278 D278 H 1 2958 0.03 278 D278 I 1 2958 0030.03 279 D279 D 2903 2951 98.37 279 D279 G 34 2951 1.15 279 D279 N 5 2951 0.17 279 D279 A 4 2951 0.14 279 D279 A/D 1 2951 0.03 279 D279 D/G 1 2951 0.03 279 D279 E 1 2951 0.03 279 D279 V 1 2951 0.03 279 D279 H 1 2951 0.03 280 C280 C 2882 2950 97.69 280 C280 S 62 2950 2.10 280 C280 N 1 2950 0.03 280 C280 C/Y 1 2950 0.03 280 C280 W 1 2950 0.03 280 C280 C/R 1 2950 0.03 280 C280 C/G 1 2950 0.03 280 C280 G 1 2950 0.03 281 V281 V 2808 2947 95.28 281 V281 M 132 2947 4.48 281 V281 M/V 3 2947 0.10

Page 38 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 281 V281 A 2 2947 0.07 281 V281 E 1 2947 0.03 281 V281 M/L 1 2947 0.03 282 A282 A 2941 2945 99.86 282 A282 S 2 2945 0.07 282 A282 V 1 2945 0.03 282 A282 G 1 2945 0.03 283 S283 G 1653 2938 56.26 283 S283 S 1253 2938 42.65 283 S283 D 14 2938 0.48 283 S283 S/G 9 2938 0.31 283 S283 N 6 2938 0.20 283 S283 D/G 1 2938 0.03 283 S283 C 1 2938 0.03 283 S283 S/R 1 2938 0.03 284 R284 R 2754 2939 93.71 284 R284 G 164 2939 5.58 284 R284 R/G 9 2939 0.31 284 R284 K 6 2939 0.20 284 R284 T 5 2939 0.17 284 R284 I 1 2939 0.03 285 Q285 Q 2919 2937 99.39 285 Q285 R 8 2937 0.27 285 Q285 P 4 2937 0140.14 285 Q285 Q/P 2 2937 0.07 285 Q285 Q/R 2 2937 0.07 285 Q285 E 1 2937 0.03 285 Q285 H 1 2937 0.03 286 D286 D 2706 2877 94.06 286 D286 N 98 2877 3.41 286 D286 T 19 2877 0.66 286 D286 E 18 2877 0.63 286 D286 A 18 2877 0.63 286 D286 D/N 5 2877 0.17 286 D286 G 5 2877 0.17 286 D286 V 3 2877 0.10 286 D286 S 2 2877 0.07 286 D286 A/T 2 2877 0.07 286 D286 A/G 1 2877 0.03 287 E287 E 2849 2875 99.10 287 E287 K 6 2875 0.21 287 E287 G 5 2875 0.17 287 E287 Q 4 2875 0.14 287 E287 A 4 2875 0.14

Page 39 of 40 m2.7.2.4 Integrase Amino Acid Frequency Table CONFIDENTIAL

Position in b c d Integrase Reference Variant Variant Count Total Count Percentage 287 E287 D 3 2875 0.10 287 E287 A/E 1 2875 0.03 287 E287 T 1 2875 0.03 287 E287 * 1 2875 0.03 287 E287 K/E 1 2875 0.03 288 D288 D 2650 2867 92.43 288 D288 N 182 2867 6.35 288 D288 S 22 2867 0.77 288 D288 G 9 2867 0.31 288 D288 D/N 2 2867 0.07 288 D288 D/G 1 2867 0.03 288 D288 I 1 2867 0.03 a Los Alamos National Laboratory. 2010. HIV Sequence Database. www.hiv.lanl.gov Accessed November 1, 2011 Stanford Resistance Database. http://hivdb.stanford.edu/ b HIV HXB2 Genbank # K03455 c Mixtures counted as unique variants. Variant * = stop codon. Insertions are annotated as ref position underscore 1. Occur at 193_1 , 248_1, 255_1 d Total Count: The count of sequences at reference position. Sequences containing incomplete or missing codon sequence are not considered in count.

Page 40 of 40 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Module 2.7.3

Summary of Clinical Efficacy

1 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

TABLE OF CONTENTS

PAGE

ABBREVIATIONS ...... 5

1. BACKGROUND AND OVERVIEW OF CLINICAL EFFICACY...... 8 1.1. HIV Infection...... 8 1.2. Current Therapies and its Unmet Clinical Need ...... 8 1.3. Summary of Dolutegravir Efficacy...... 10 1.4. Overview of the Dolutegravir Clinical Development Program ...... 10 1.4.1. Overall Clinical Strategy and Objectives ...... 11 1.4.2. Dolutegravir Clinical Development Program...... 12 1.4.3. Organization of Data Presentations in the Summary of Clinical Efficacy...... 16 1.5. Patient Population...... 17 1.6. Rationale for Dose Selection in Clinical Development...... 18 1.6.1. ART-Naive/-Experienced (INI-Naive) ...... 18 1.6.2. ART-Experienced (INI-Resistant)...... 19 1.7. Design of Efficacy Studies ...... 20 1.7.1. Pivotal Efficacy Studies...... 20 1.7.1.1. Study ING113086...... 20 1.7.1.2. Study ING114467...... 21 1.7.1.3. Study ING111762...... 22 1.7.1.4. Study ING112574...... 24 1.7.2. Supportive Efficacy Studies ...... 25 1.7.2.1. Study ING111521 (PoC)...... 26 1.7.2.2. Study ING112276...... 26 1.7.2.3. Study ING112961...... 27 1.8. Efficacy Endpoints ...... 28 1.8.1. Primary Efficacy Endpoints ...... 29 1.8.2. Secondary Efficacy Endpoints ...... 30 1.9. Statistical Considerations...... 31 1.9.1. Sample Size and Randomization ...... 31 1.9.1.1. Pivotal Efficacy Studies ...... 31 1.9.1.1.1. Study ING113086...... 31 1.9.1.1.2. Study ING114467...... 32 1.9.1.1.3. Study ING111762...... 32 1.9.1.1.4. Study ING112574...... 33 1.9.1.2. Supportive Efficacy Studies ...... 33 1.9.1.2.1. Study ING111521...... 33 1.9.1.2.2. Study ING112276...... 33 1.9.1.2.3. Study ING112961...... 33 1.9.2. Analysis Populations...... 34 1.9.3. Statistical Methods...... 36 1.9.4. Missing Data...... 39 1.9.4.1. Missing, Switch or Discontinuation = Failure (Snapshot)...... 39 1.9.4.2. Last Observation Carried Forward Discontinuation = Baseline (LOCFDB)...... 39 1.9.4.3. Time to Loss of Virologic Response (TLOVR) ...... 39 1.9.5. Subgroup Analysis...... 39

2 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.9.6. Sensitivity Analyses ...... 42 1.9.7. Antiviral Activity of DTG by Baseline Resistance in an INI- resistant population in ING112574...... 43

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES...... 43 2.1. Pivotal Efficacy Studies...... 44 2.1.1. Study ING113086 ...... 44 2.1.2. Study ING114467 ...... 45 2.1.3. Study ING111762 ...... 45 2.1.4. Study ING112574 ...... 46 2.2. Supportive Efficacy Studies ...... 47 2.2.1. Study ING111521 ...... 47 2.2.2. Study ING112276 ...... 49 2.2.3. Study ING112961 ...... 51

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES ...... 53 3.1. Study Populations...... 54 3.1.1. ART-Naïve subjects...... 54 3.1.2. ART-Experienced, INI-Naïve Subjects ...... 59 3.1.3. ART-Experienced, INI-Resistant Subjects...... 65 3.2. Comparison of Efficacy Results of all Studies ...... 70 3.2.1. ART-Naïve subjects...... 70 3.2.1.1. Primary Efficacy Results...... 70 3.2.1.2. Secondary Efficacy Results ...... 72 3.2.2. ART-Experienced, INI-Naïve Subjects ...... 77 3.2.2.1. Principal Efficacy Results ...... 77 3.2.2.2. Secondary Efficacy Results ...... 79 3.2.3. Treatment Emergent Resistance in INI-Naïve Subjects (ART-Naïve and ART-Experienced Subjects) ...... 81 3.2.4. Studies in ART-Experienced, INI-Resistant Subjects ...... 83 3.2.4.1. Primary Efficacy Results...... 83 3.2.4.2. Secondary Efficacy Results ...... 86 3.2.4.3. Treatment Emergent Resistance ...... 88 3.3. Comparison of Results in Sub-Populations...... 90 3.3.1. ART-Naïve Subjects ...... 90 3.3.1.1. Primary Efficacy by Age, Gender and Race...... 90 3.3.1.2. Primary Efficacy by Stratification Factors (Baseline HIV-1 RNA/CD4+ cell count, Background NNRTI) ...... 91 3.3.2. ART-Experienced, INI-Naïve Subjects ...... 94 3.3.2.1. Principal Efficacy by Age, Gender and Race ...... 94 3.3.2.2. Plasma HIV-1 RNA <50 c/mL at Week 24 by Strata Related to Randomization...... 95 3.3.2.3. Plasma HIV-1 RNA <50 c/mL at Week 24 by Selected Baseline Background Regimen and Resistance Subgroups ...... 96 3.3.3. Studies in ART-Experienced, INI-resistant Subjects ...... 97 3.3.3.1. Functional Monotherapy Phase ...... 97 3.3.3.2. Optimized Phase ...... 100 3.3.3.3. Antiviral Activity of DTG by Baseline Resistance in INI-resistant Subjects in ING112574...... 103

3 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

3.3.4. Virologic Response Rates in Historical Studies...... 104

4. ANALYSIS OF CLINICAL INFORMATION RELEVANT TO DOSING RECOMMENDATIONS ...... 106 4.1. Dose Selection for ART-Naïve Adult Subjects ...... 106 4.1.1. Phase IIb Study ING112276 ...... 106 4.1.2. Pivotal Phase III ART-Naive Studies...... 106 4.1.3. ART-Naïve Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis...... 107 4.1.3.1. Supportive Study ING111521 ...... 108 4.2. Dose Selection for ART-Experienced, INI-Naive Adult Subjects ...... 108 4.2.1. Principle of Dose Selection ...... 108 4.2.1.1. Impact of Background Therapy and Predicted Durability of DTG on Selected Dose ...... 108 4.2.2. Pivotal Phase III Study ING111762 (ART-Experienced, INI-Naive) ...... 109 4.2.2.1. Comparison to Historical Studies...... 109 4.2.2.2. ING111762 Pharmacokinetics and Pharmacokinetics/ Pharmacodynamics ...... 110 4.3. Dose Selection for ART-Experienced, INI-Resistant Adult Subjects...... 111 4.3.1. Pivotal Phase III Study ING112574...... 111 4.3.1.1. Correlation between Baseline Factors and Efficacy...... 111 4.3.1.2. Comparison to Historical Studies...... 112 4.3.1.3. Pharmacokinetics ...... 112 4.3.2. Supportive Phase II Study ING112961 ...... 113 4.4. Dose Selection for Adolescent Subjects ...... 114

5. PERSISTENCE OF EFFICACY AND/OR TOLERANCE EFFECTS ...... 114 5.1. Treatment-Naïve Subjects ...... 114 5.2. Treatment-Experienced, INI-Naïve Subjects ...... 116 5.3. Treatment-Experienced, INI-Resistant Subjects...... 116

6. EFFICACY SUMMARY ...... 117 6.1. Efficacy Conclusions...... 118

7. REFERENCES...... 119

8. APPENDIX...... 123

4 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

ABBREVIATIONS

3TC lamivudine ABC abacavir AE Adverse event AIDS Acquired immunodeficiency syndrome ALT Alanine aminotransferase AST Aspartate aminotransferase ART Antiretroviral therapy ARV Antiretroviral AUC Area under the curve BID Twice daily BL Baseline C0 Pre-dose concentration C0_avg Average of concentrations at time 0 C Concentration at the end of the dosing period c/mL copies per milliliter Cavg Average of concentrations CDC Centers for Disease Control and Prevention CFB Change from Baseline CHMP Committee for Medical Products for Human Use CI Confidence Interval CMH Cochran-Mantel-Haenszel COBI cobicistat CPSR Clinical Pharmacology Study Report CSR Clinical Study Report CYP Cytochrome P450 DHHS Department of Health and Human Services DRV darunavir DTG dolutegravir, S/GSK1349572 EACS European AIDS Clinical Society EFV efavirenz EMA European Medicines Agency Emax Maximum effect EPAR European Public Assessment Report ETR etravirine EVG elvitegravir FC Fold change FDA (US) Food and Drug Administration FDC Fixed dose combination FPV fosamprenavir FTC emtricitabine GCP Good Clinical Practice GSK GlaxoSmithKline GSS Genotypic susceptibility score HBsAG Hepatitis B Surface Antigen HBV Hepatitis B Virus HCV Hepatitis C Virus

5 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

HIV Human Immunodeficiency Virus HIV-1 Human Immunodeficiency Virus Type 1 HIV-2 Human Immunodeficiency Virus Type 2 IAS International AIDS Society IC50 Half-maximal inhibitory concentration ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use IN Integrase IND Investigational New Drug INI Integrase inhibitor IP Investigational product IQR Interquartile range ITT-E Intent-to-Treat Exposed LOCFDB Last observation carried forward (discontinuation equals Baseline) MAA Marketing Authorization Application mg Milligram mITT-E Modified Intent-to-Treat Exposed mm3 Cubic millimeter MDF Missing or Discontinuation = Failure MSDF Missing, Switch or Discontinuation = Failure NDA New Drug Application NDS New Drug Submission ng Nanogram NI Non-inferiority NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBR Optimized background regimen OSS Overall susceptibility score PDVF Protocol defined virologic failure PI Protease inhibitor PIQ Phenotypic inhibitory quotient PIQ_C0 Phenotypic inhibitory quotient for predose concentration PIQ_Cavg Phenotypic inhibitory quotient for average concentration PK Pharmacokinetic PK/PD Pharmacokinetic/pharmacodynamic PML Progressive multifocal leucoencephalopathy PP Per-protocol PSS Phenotypic susceptibility score RAL raltegravir RAM Resistance associated mutation RAP Reporting and analysis plan RNA Ribonucleic acid RTV ritonavir SPC Summary of Product Characteristics TLOVR Time to Loss of Virologic Response TDF tenofovir disoproxil fumarate

6 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

TPV tipranavir UNAIDS Joint United Nations Programme on HIV/AIDS US United States VL Viral load VO Virological outcome by Baseline genotype or phenotype WMA World Medical Association WT Wild type

Trademark Information

Trademarks of ViiV Healthcare Trademarks not owned by ViiV Healthcare COMBIVIR Atripla EPZICOM Truvada

7 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1. BACKGROUND AND OVERVIEW OF CLINICAL EFFICACY

1.1. HIV Infection

An estimated 34.2 million adults and children worldwide, were living with Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) in 2011 [UNAIDS, 2012a].

In 2011, the global adult (15 to 49 years) HIV prevalence rate was 0.8% [UNAIDS, 2012b]. During that year, 2.5 million people were newly infected with HIV, and there were 1.7 million deaths due to HIV/AIDS. Of newly infected people, an estimated 1.2 million were women and girls, and 330,000 were children. As well, 3.4 million children younger than 15 years were living with HIV in 2011 [UNAIDS, 2012a]. In 2009, an estimated 370,000 children contracted HIV during the perinatal and breastfeeding period. Overall, the epidemic appears to have stabilized in most regions, although prevalence continues to increase in Eastern Europe and Central Asia and in other parts of Asia due to a high rate of new HIV infections [UNAIDS, 2010]. In 2011, Sub-Saharan Africa remained the most heavily affected region, accounting for 68% (1.7 million) of all new HIV infections among adults and children [UNAIDS, 2012b].

1.2. Current Therapies and its Unmet Clinical Need

Combination antiviral therapy with HIV type-1 (HIV-1) protease and reverse transcriptase inhibitors has significantly reduced AIDS-related morbidity and mortality. However, emerging multi-class drug-resistant HIV strains and long-term toxicities warrant development of new classes of antiretroviral therapies. Integrase inhibitors (INIs) are a newer class of antiretroviral drugs designed to block the action of the integrase (IN) viral enzyme, which catalyzes two key steps in the HIV life cycle and is responsible for insertion of the viral genome into the deoxyribonucleic acid (DNA) of the host cell. Since genome integration is a vital step in retroviral replication, it is an attractive target for HIV therapy.

Dolutegravir (DTG, GSK1349572) is an INI owned by ViiV Healthcare, which is working with GlaxoSmithKline to develop the asset.

Raltegravir, the first marketed INI, and elvitegravir (EVG), which recently gained United States (US) Food and Drug Administration (FDA) approval (in August 2012 in a combination product), have demonstrated good antiviral activity in clinical trials, confirming the INI class as a new option for constructing effective HIV-1 treatment regimens. In the STARTMRK study, raltegravir (RAL) demonstrated excellent antiviral activity as first-line treatment and was shown to be non-inferior to an efavirenz (EFV)- containing standard of care regimen [Lennox, 2010]. In this trial, a similar proportion of subjects randomized to RAL versus EFV (both in combination with tenofovir disoproxil fumarate/emtricitabine [TDF/FTC]) achieved undetectable HIV-1 ribonucleic acid (RNA) (<50 copies/milliliter [c/mL]) at Week 48 (86% vs. 82%) and Week 96 (81% vs. 79%). Additionally, the time to achieve viral suppression was shorter for subjects on RAL than on EFV (log rank test P<0.001).

8 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Similarly, in the GS-US-236-0102 study, EVG co-formulated with the cytochrome P450 (CYP) 3A4 inhibitor cobicistat (COBI), TDF, and FTC (now approved in the US as Stribild), was shown to be non-inferior to the co-formulated standard of care regimen EFV/TDF/FTC as a first-line treatment, with 87.6% versus 84.1% of patients, respectively, achieving <50 c/mL HIV RNA at Week 48 [Sax, 2012].

Integrase inhibitors have also shown potent antiviral activity in treatment-experienced patient populations. In the BENCHMRK study, patients with three-class antiretroviral resistance (naïve to INIs) received RAL or placebo plus optimized background therapy; 62% of RAL subjects (versus 33% of placebo subjects) had HIV RNA <50 c/mL at Week 48 [Steigbigel, 2008]. In Study 145, a study in treatment-experienced subjects with at least two-class resistance, but naïve to INIs, EVG once daily was non-inferior to RAL twice daily (BID), each administered with a background regimen that included a ritonavir-boosted protease inhibitor and a second antiretroviral agent. At Week 48 of Study 145, 59% of the EVG group versus 58% of the RAL group achieved virologic response (<50 c/mL) [Molina, 2012].

In addition to providing good virologic suppression in treatment-naïve and treatment- experienced patients, the INIs have been well-tolerated in clinical trials. In STARTMRK, there were fewer drug-related adverse events (AEs) reported for the RAL group compared with the EFV group, and fewer subjects randomized to RAL discontinued from the study due to adverse events. In GS-US-236-0102, adverse events were similar between the EVG and EFV groups, with the exception of nausea (significantly higher in the EVG group), and dizziness, abnormal dreams, and rash (significantly higher in the EFV group); similar numbers of subjects in the two groups discontinued treatment because of adverse events (4% versus 5%).

While these trials highlight the potent antiviral efficacy and promise of better long-term tolerability with INI-based therapy, clinical resistance to both RAL and EVG has been reported from Phase II studies in treatment-experienced subjects [Hazuda, 2007; McColl, 2007], and also from Phase III studies in both treatment-experienced [Cooper, 2008; Molina, 2012] and treatment-naïve subjects [Lennox, 2010; Sax, 2012; DeJesus, 2012]. In Study 145, comparing EVG- versus RAL-based therapy in treatment-experienced subjects, among subjects who failed therapy, 16/60 (27%) and 15/72 (21%) of patients who had integrase genotype data available at the time of virologic failure developed INI resistance mutations. In addition, phenotypic cross-resistance to both drugs was typical, preventing sequencing from one drug to the other [Molina, 2012]. Therefore, the development of new INIs with different resistance profiles is desirable, and in the case of many treatment-experienced patients with clinical resistance to RAL and EVG, is essential for providing HIV-infected individuals an option for constructing an effective antiretroviral regimen.

Along with a low barrier to resistance for RAL and EVG, there are other disadvantages for these two INIs compared to DTG. RAL requires twice daily (BID) dosing and is currently not available in a fixed dose combination regimen. EVG requires co- administration with a pharmacokinetic booster, such as ritonavir or cobicistat [German, 2010], and therefore, has the potential for clinically-significant drug-drug interactions with drugs that depend on CYP3A4 for clearance. Additionally, EVG-containing

9 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

regimens had higher rates of gastrointestinal (GI) AEs than a RAL-containing regimen and Atripla in treatment-experienced and treatment-naïve patients, respectively [Molina, 2012; Sax, 2012]; Stribild is also not recommended for patients with creatinine clearance under 70 mL/min.

Finally, both ritonavir and cobicistat (one of which is required in conjunction with EVG; cobicistat is a component of the fixed dose combination tablet that contains EVG/cobicistat/TDF/FTC) boost TDF concentrations, which may increase TDF proximal tubular toxicity [FDA, 2012].

Dolutegravir is a potent, low nanomolar inhibitor of HIV integrase, which demonstrates the excellent antiviral activity and tolerability demonstrated for the INI class, and also offers once-daily dosing without the requirement for pharmacokinetics boosters. Based on in vitro and clinical data, DTG has the potential for a higher barrier to resistance. Finally, most HIV isolates with resistance to RAL and EVG remain susceptible to DTG, making DTG an important option for many treatment-experienced patients with multi- class drug resistance. 1.3. Summary of Dolutegravir Efficacy

Data presented in this Summary of Clinical Efficacy (m2.7.3) will demonstrate that:

 DTG 50 milligrams (mg) once daily is effective for the treatment of HIV-infection in combination with other antiretroviral therapy (ART) in treatment-naïve adults;  DTG 50 mg once daily is effective for the treatment of HIV-infection in combination with other antiretroviral therapy in INI-naïve, treatment-experienced adults;  DTG 50 mg twice daily is effective for the treatment HIV-infection in combination with other antiretroviral therapy in INI-resistant (current and historical) treatment- experienced adults (and more effective than DTG 50 mg once daily in this population);  DTG-based regimens had a higher barrier to resistance in INI-naïve patients, as demonstrated in ING111762 where significantly fewer virologic failures with INI resistance were observed when compared with RAL. Data from ING113086 and ING114467 were also supportive, as no subjects on the DTG regimen developed resistance to either the INI or the background NRTIs, whereas resistance to both the third agent and the background NRTIs was observed in both the RAL and EFV- based comparator arms;  DTG-containing regimens across all patient populations evaluated resulted in increases in CD4+ cell counts;  DTG was efficacious across a broad range of Clades and against both HIV-1 and HIV type 2 (HIV-2) (m2.7.2.4). 1.4. Overview of the Dolutegravir Clinical Development Program

The clinical program investigating DTG involves: 31 Phase I studies (1 remains ongoing), 4 Phase IIa/b studies (1 completed Phase IIa study, 3 ongoing), and 7 ongoing Phase III/IIIb studies. In addition, there is an active compassionate use program designed

10 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

for patients who are unable to participate in Phase III studies, who have documented RAL or EVG resistance, limited treatment options and who require DTG to construct a viable antiretroviral (ARV) regimen for therapy. A description of all clinical efficacy and safety studies in the DTG clinical program is provided in Appendix Table 1.

Descriptions of all the clinical studies in subjects with HIV that support the Summary of Efficacy data are presented in Table 1. This New Drug Application (NDA)/Marketing Authorization Application (MAA)/New Drug Submission (NDS) for the DTG submission includes long-term clinical safety data for approximately 1400 subjects receiving DTG for 24 weeks or longer.

The clinical development program for DTG has been conducted in accordance with available regulatory guidance on the clinical investigation of medicinal products in the treatment of HIV-1 infection [EMA, 2009; FDA, 2002] and has further benefited from advice received from Regulators in both the United States and Europe, where feedback on study design features was obtained on the primary efficacy studies.

1.4.1. Overall Clinical Strategy and Objectives

The Sponsor’s strategy for the development of DTG is to file for a NDA/MAA/NDS by demonstrating improvements over the first marketed INI RAL, and the preferred fixed dose combination single tablet regimen Atripla (EFV/TDF/FTC). The clinical program for DTG was also designed in order to demonstrate its activity against HIV that is resistant to either RAL or EVG.

The clinical development program has been designed to achieve a broad indication for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and children over 12 years of age.

To support this proposed indication, the submission includes a Clinical Pharmacology package describing the pharmacokinetics and the pharmacokinetic/pharmacodynamic (PK/PD) relationship of DTG across a broad range of studies in both healthy volunteers and HIV-infected subjects. This package is described in detail in module 2.7.2.

Early Phase I and IIa studies were designed to obtain initial pharmacokinetic, safety and tolerability information, and define the dose regimen to be utilized in the dose ranging and pivotal efficacy studies in patients with HIV. Phase I studies utilized either an oral tablet or oral suspension formulation and the Phase II and Phase III studies utilized an oral tablet formulation.

The Phase II package (Studies ING111521, ING112276 and ING112961) includes initial efficacy data as well as enabling dose-ranging data and longer-term efficacy and safety data in antiretroviral therapy-naive, -experienced and integrase inhibitor-resistant subjects. In these supportive efficacy studies, patients were treated with doses of dolutegravir from 2 mg daily up to 100 mg daily, administered via once daily or BID dosing.

The Phase III Studies ING113086, ING111762, ING114467, and ING112574 assessed DTG across a broad range of treatment experience in HIV-infected patients and support

11 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

an unrestricted indication for the treatment of HIV-infected patients. All pivotal efficacy studies with more than one arm were international, multi-center, randomized, double- blind studies and each have the characteristics of “adequate and well-controlled clinical trials” as described in Title 21 of the US Code of Federal Regulations, Section 314.126 and ICH Topic E8, General Considerations for Clinical Trials. Study ING112574 is a single arm study, reflecting ethical difficulties in randomizing subjects with multi-drug resistance and INI resistance to a control arm.

ING112578 (P1093) is a Phase I/II, multi-centre, open-label study assessing the PK, safety, tolerability and antiviral activity of DTG in HIV-1 infected infants, children and adolescents (6 weeks to <18 years). Cohort I, ages 12 to <18 years, is fully enrolled and Cohort II, ages 6 to <12 years, is currently enrolling. The protocol is in the process of being amended to lower the inclusion age to 4 weeks. The final amended protocol will not be available before the submission.

1.4.2. Dolutegravir Clinical Development Program

The pivotal efficacy populations included 2553 subjects from:

 1655 ART-naïve subjects from ING113086 (n=822) and ING114467 (n=833) with data at least to 48 weeks,  715 ART-experienced, INI-naïve subjects from ING111762 with data at least to 24 weeks,  183 ART-experienced, INI-resistant subjects from ING112574 with data at least to day 8 and 114/183 subjects with data at least to 24 weeks. Studies ING113086, ING111762, ING114467, and ING112574 are ongoing and will continue pending the outcome of regulatory evaluation of the marketing applications.

Longer term efficacy data are available from Studies ING112276 (150 ART-naïve subjects with data up to 96 weeks) and ING112961 (183 ART-experienced, INI-resistant subjects with Cohort I 96 weeks, Cohort II 48 weeks).

Furthermore, clinical pharmacology provided PK data to support the Phase III efficacy studies.

The following is a list of other ongoing studies that will not contribute to this summary of efficacy with a rationale for their exclusion:

 ING112578 (P1093): efficacy was a secondary endpoint;  ING116070 (CSF study) was conducted in a limited number of subjects and will include a limited dataset (i.e. Week 2) for this submission;  ING114915 (FLAMINGO) and ING116529 (VIKING-4): at the time of data cut off for this ISE, studies ING114915 and ING116529 will not have reached a planned interim or primary endpoint analysis.  ING114916 (Expanded Access Program) and ING115502 (Named Patient Program) are only collecting safety data.

12 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 1 Summary of Studies Supporting Clinical Efficacy of Dolutegravir in the Treatment of HIV-1 Infection

Study Number of Number Phase Study Design Primary Objectives Durationa Regimens Patientsb Pivotal Efficacy Studies ING113086 III Multicenter randomized, To assess safety and efficacy 48 weeks DTG 50 mg once daily; oral tablet or DTG: (SPRING-2) double blind, double- of DTG 50 mg once daily RAL 400 mg once daily; oral tablet 413 Randomized dummy, active-controlled, compared to RAL 400 mg BID + abacavir (ABC)/lamivudine (3TC) 600 mg/ 364 Ongoing parallel group, fully- both administered with fixed- 300 mg once daily; oral tablet 0 Completed powered non-inferiority dose dual NRTI therapy or study + TDF/ FTC 300 mg/ 200 mg once daily; oral RAL: tablet 414 Randomized 355 Ongoing 0 Completed ING114467 III Randomized, double- To assess safety and efficacy 48 weeks DTG 50 mg once daily; oral tablet + DTG + ABC/3TC: (SINGLE) blind, double-dummy, of DTG plus ABC/3TC fixed- ABC/3TC 600/300 mg once daily; oral tablet 422 Randomized active-controlled, dose combination therapy 363 Ongoing multicenter, parallel group, administered once daily EFV/TDF/FTC 600/200/300 mg once daily; 0 Completed fully-powered non- compared to Atripla oral tablet inferiority study EFV/TDF/FTC: 422 Randomized 363 Ongoing 0 Completed ING111762 III Multicenter randomized, To evaluate safety and 24 weeks DTG 50 mg once daily; oral tablet DTG (SAILING) double-blind, active- efficacy of DTG 50 mg once RAL 400 mg BID; oral tablet 354 Randomized controlled, parallel group, daily vs. RAL 400 mg BID, 305 Ongoing non-inferiority study both administered with an + Investigator-selected background regimen 1 Completedc investigator-selected background regimen RAL 361 Randomized 189 Ongoing 111 Completed

13 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Number of Number Phase Study Design Primary Objectives Durationa Regimens Patientsb ING112574 III Multicenter, open-label, To assess the antiviral activity 24 weeks DTG 50 mg BID; oral tablet DTG (VIKING-3) single arm of DTG administered with 183 Enrolled failing background therapy to 155 Ongoing Day 8 and thereafter with 0 Completed optimized background ART

Supportive Efficacy Studies ING111521 IIa Dose-ranging, 10-day, To assess the safety, 10 days DTG 2, 10, 50 mg once daily for 10 days; 35 (including 7 repeat dose, placebo- tolerability and efficacy of oral tablet; fasted placebo) controlled monotherapy repeat dose DTG Randomized study 35 Completed

14 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Number of Number Phase Study Design Primary Objectives Durationa Regimens Patientsb ING112276 IIb Randomized, multicenter, To select a once daily oral 96 weeks DTG 10 mg once daily; oral tablet DTG 10 mg (SPRING-1) parallel group, dose- dose of DTG administered DTG 25 mg once daily; oral tablet 53 Randomized ranging with either ABC/3TC or DTG 50 mg once daily; oral tablet 47 Ongoingd TDF/FTC and to evaluate EFV 600 mg once daily; oral tablet antiviral activity, safety and DTG 25 mg PK over time + ABC/3TC 600 mg/ 300 mg once daily; oral 51 Randomized tablet 45 Ongoingd

or DTG 50 mg 51 Randomized + TDF/ FTC 300 mg/ 200 mg once daily; oral 46 Ongoing tablet [At the Week 96 visit, all DTG subjects were EFV switched to the selected dose of 50 mg once 50 Randomized daily] 41 Completed ING112961 IIb Multicenter, open-label, To assess the antiviral activity Cohort I 96 DTG 50 mg once daily; oral tablet DTG 50 mg once (VIKING) single arm, sequential of DTG containing regimen weeks DTG 50 mg BID; oral tablet daily cohort, pilot study Cohort II 48 27 Enrolled weeks 13 Ongoing 0 Completed

DTG 50 mg BID 24 Enrolled 19 Ongoing 0 Completed a. Weeks for evaluation of efficacy reported in this ISE b. Number of subjects “Ongoing” as of data cut off in respective Clinical Study Reports c. One subject who completed the DTG decided they did not want to participate in the open label phase. d. DTG 10 mg and 25 mg subjects are currently ongoing on DTG 50 mg.

15 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Estimated timings for the completion of study reports following submission are presented in Table 2.

Table 2 Data Availability for Ongoing Studies

Study Data Available at Initial Estimated Completion Length of Study Identifier Submission of Study Report 48 weeks, with up to 3- 10 subjects (Stage 1) from / Week 24 Analysis ING112578 year follow-up Cohort 1 through 24 weeks (Cohort 1, Stages 1 & 2) 96 weeks (primary ING116070 All subjects through 2 weeks / Week 16 Analysis endpoint at Week 16) ING113086 96 weeks All subjects through 48 weeks / Week 96 Analysis All subjects through Day 8, / Week 24 (all)/ ING112574 24 and 48 weeks 114/183 subjects through 24 Week 48 (first 114 subjects) Analysis weeks 7 days double-blind ING116529 phase and 48 weeks No efficacy data / Day 8 Analysis open-label phase. ING111762 48 weeks All subjects through 24 weeks / Week 48 Analysis ING114915 96 weeks No efficacy data / Week 48 Analysis ING114467 96 weeks All subjects through 48 weeks / Week 96 Analysis

1.4.3. Organization of Data Presentations in the Summary of Clinical Efficacy

In this summary there are references to four types of presentations for tables and figures:

 in-text tables and figures;  appendix tables;  statistical source tables and figures from individual clinical study reports (CSR). The original electronic format, location and reference format for these various presentations are summarized in Table 3.

Table 3 Table and Figure Types and Descriptions

Table/Figure Tool Used to Location How Referenced Type Generate Table In-text WORD In body of summary document Consecutive integers (e.g., Table 1, Table 2, Figure 1, Figure 2 ) Appendix WORD Precedes SAS Tables, Figures Consecutive integers & Listings in appendix of (e.g., Appendix Table 1, Appendix summary document Table 2…) Statistical Source WORD Individual CSRs in m5 Clinical Study Report number followed Tables by statistical source tables (e.g., CSR ING113086, Table 6.1).

In this summary, the efficacy data from pivotal and supportive studies were not integrated due to significant variations in study designs and comparator arms (Section 1.7);

16 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

therefore, efficacy data are presented in a side-by-side format for comparative purposes (Section 3). Studies are organized as follows:

 ART-Naive Population (ING113086, ING114467): The data from these two Phase III studies provide supportive evidence of the efficacy of DTG for the primary and secondary endpoints in an ART-naive population. These studies use two different comparators, RAL and Atripla, respectively; therefore, the data from these studies were not integrated.  ART-Experienced, INI-Naive Population (ING111762): Study ING112762 provides supportive evidence of the efficacy of DTG in an ART- experienced population.  ART-Experienced, INI-Resistant Population (ING112574, ING112961). Similarities in study design for the Phase III study ING112574 and the Phase IIb study ING112961 Cohort II (DTG 50 mg BID) facilitated the presentation of data side by side. The data from these two studies provide supportive evidence of the efficacy of DTG for the primary and secondary endpoints in an INI-resistant population. Data from Cohort I DTG 50 mg once daily are not presented side by side with data from DTG 50 mg BID, as the 50 mg once daily dose was not selected for Phase III assessment in this patient population.

The data from these studies provide supportive evidence of the efficacy of DTG for the primary endpoints in ART-naive, ART-experienced (INI-naive) and ART-experienced (INI-resistant) populations. The data also provide supportive evidence of the efficacy of DTG on secondary endpoints that were observed in the individual studies (Section 2) and for specific subgroups. Side-by-side presentation of ART-naive, ART-experienced (INI- naive) and ART-experienced (INI-resistant) studies can be found in Section 3.

1.5. Patient Population

The studies in adults supporting this submission recruited HIV-1 infected subjects 18 years who were able to provide written informed consent. Women of child-bearing potential were eligible for enrolment if using a reliable method of contraception. Subjects were excluded on the basis of medical history (e.g. active Centers for Disease Control and Prevention [CDC] Category C disease with certain exceptions, moderate to severe hepatic impairment, gastrointestinal bleeding, allergy to study drugs, history of malignancies), concomitant or recent medical therapy (e.g. HIV-1 vaccines, treatments with activity against HIV-1 that are not licensed for that purpose, radiation therapy, immunomodulators, cytotoxic chemotherapeutic agents or recent use of experimental drugs) or screening laboratory values (e.g. any verified Grade 4 lab abnormalities, or liver chemistries above specified thresholds). The specific criteria during each phase of development reflected the data on dolutegravir that were available at that time and are therefore slightly different for (e.g.) the Phase IIb studies compared to the Phase III studies. Notwithstanding the minimum inclusion and exclusion criteria defined in each protocol, investigators were also required to follow any existing country specific guidelines when making decisions about subjects who are eligible for study participation.

17 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 4 Study Population for Pivotal and Supportive Efficacy Studies

Study Number Phase Population Specific Eligibility Criteria Pivotal Efficacy Studies ING113086 III ART-naive Screening viral load (VL) >1000 c/mL, <10 days prior ART, No evidence of resistance at screening ING114467 III ART-naive Screening VL >1000 c/mL, HLA-B*5701 negative, <10 days prior ART, No evidence of resistance at screening ING111762 III ART-experienced, 2 Screening VL>400 c/mL or 1 Screening VL INI-naive >1000 c/mL, at least 2-class resistance, Potential for 1 fully active agent in BR (limit of 2 background ARVs) No INI experience ING112574 III ART-experienced, Screening VL >500 c/mL, Documented virologic INI-resistant failure on RAL or EVG, Documented resistance to RAL or EVG, at least 2-class resistance (excluding INIs), Potential for 1 fully active agent in optimized background regiment (OBR) Supportive Efficacy Studies ING111521 IIa ART-naive/-experienced Screening VL >5000 c/mL, CD4+ cell count >100 cells/mm3, No use of ART within 12 weeks ING112276 IIb ART-naive Screening VL >1000 c/mL, Screening CD4+ >200 cells/mm3, <10 days prior ART, No evidence of resistance at screening ING112961 IIb ART-experienced, Screening VL >1000 c/mL, RAL resistance at INI-resistant Screening, at least 2-class resistance (excluding INIs), Potential for 1 fully active agent in OBR (BID Cohort II only)

1.6. Rationale for Dose Selection in Clinical Development

1.6.1. ART-Naive/-Experienced (INI-Naive)

The 50 mg once daily dose for DTG in ART-naïve/-experienced (INI-naïve) subjects was selected based on the following:

 Results from ING111521, 10-day monotherapy study in treatment-naive or treatment- experienced and INI-naive subjects demonstrating that once daily dosing of DTG achieved viral load declines for 2 mg, 10 mg and 50 mg of 1.54, 2.04, and 2.48 log10 c/mL, respectively. The 50 mg once daily dose achieved an inhibitory quotient (observed DTG concentration at the end of the dosing interval [C]/fold above protein adjusted 90% inhibitory concentration [PA-IC90]) of 19, demonstrating considerable coverage above the in vitro protein adjusted target concentration of 0.064 ng/ml.

 A PK/PD analysis from ING111521 evaluated the relationship between C and change in HIV RNA from Baseline. The data were fit to a maximum effect model and demonstrated that the 50 mg dose was on the plateau of the concentration-response curve after monotherapy.

18 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

 ING112276, a Phase IIb dose-ranging study in treatment-naive subjects that evaluated DTG at doses of 10 mg, 25 mg and 50 mg once daily with 2 NRTIs compared to EFV plus 2 NRTIs. DTG was well tolerated across all doses studied. A good safety and tolerability profile with a low discontinuation rate due to AEs was observed in all three arms with no significant dose-dependent trends in safety parameters. All three doses showed similar robust antiviral responses and no apparent dose-response relationship was observed, suggesting DTG doses from 10 mg to 50 mg once daily in combination with 2 NRTIs achieved maximum virologic suppression. Therefore, the maximal tolerated and highest dose, DTG 50 mg once daily, was selected as the dose for the Phase III studies in INI-naive population. Selection of 50 mg once daily dose was also to accommodate decreases in DTG in light of drug interactions, poor absorption, imperfect adherence, or other causes.

 The metabolic inducers darunavir/ritonavir (DRV/RTV), etravirine (ETR)/DRV/RTV, EFV, fosamprenavir (FPV)/RTV, and tipranavir (TPV)/RTV decreased DTG exposure to various degrees; however DTG exposures in the face of these interactions are still comparable to or higher than those demonstrated with 10 mg once daily dosing in ING112276. In summary, a dose of 50 mg once daily demonstrated safety and efficacy while providing a significant coverage in plasma exposure to account for reductions due to drug interactions or other events that could decrease concentrations. This dose was selected for Phase III studies in ART-naive/-experienced, INI-naive adult subjects.

1.6.2. ART-Experienced (INI-Resistant)

The 50 mg BID dose selection for DTG in ART-experienced, INI-resistant subjects was based on the following:

 ING112961 Cohort I evaluated 50 mg once daily in subjects with resistance to raltegravir, but a sub-optimal anti-viral response observed in some subjects harboring virus with higher fold change (FC) to DTG prompted the evaluation of an increased dose of DTG in a second cohort of subjects.

 PK/PD modeling predicted that increasing the DTG dosage from 50 mg once daily to 100 mg total daily dose in populations of raltegravir-resistant subjects would yield substantive improvements in treatment response.

 A dose of 100 mg once daily was initially considered for evaluation, however data from healthy subjects in ING114005 demonstrated that plasma DTG exposures increase less-than-dose-proportionally from 50 mg to 100 mg. In addition, one-third of subjects did not have an appreciable increase in C between 50 mg and 100 mg doses. These data demonstrated that a 50 mg twice daily dose would provide more consistent exposures than a dose of 100 mg once daily.

 ING112961 Cohort II evaluated DTG 50 mg twice daily in a similar population of subjects as Cohort I, but with more limited high-level resistance to DTG. Comparison of the primary endpoint (proportion of subjects with Day 11 plasma HIV-1 RNA <400 c/mL or at least 0.7 log10 c/mL below their Baseline values)

19 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

between Cohort I and Cohort II suggested a higher response rate may be achieved with 50 mg twice daily of DTG.

 Analyses of data through Week 24 for Cohort II (and Week 72 for Cohort I) confirmed the continued benefit of the 50 mg DTG twice daily regimen without clinically significant differences in tolerability compared to the 50 mg once daily regimen.

In summary, the short term antiviral response rates, pharmacokinetics, and data through Week 24 of Cohort II (and Week 72 in Cohort I) of ING112961 suggested additional benefit would be realized with DTG 50 mg twice daily compared to the DTG 50 mg once daily dose in this population harboring INI-resistant virus. Therefore the DTG 50 mg twice daily dose was selected for Phase III evaluation in this population.

1.7. Design of Efficacy Studies

All efficacy studies were multicenter, international studies conducted in accordance with the Declaration of Helsinki and amendments [WMA, 2008]. All studies followed local laws and local guidelines including guidelines on Good Clinical Practice (GCP) for Trials on Medicinal Products in the European Community [GCP, 1996]. In addition, studies were all conducted under Investigational New Drug (IND) Application 75,382 and in accordance with FDA legal requirements.

1.7.1. Pivotal Efficacy Studies

1.7.1.1. Study ING113086

ING113086 is designed as a Phase III, randomized, double blind study to compare the safety and efficacy of 50 mg DTG once daily to 400 mg RAL BID, both administered with fixed-dose dual NRTI therapy over 96 weeks in HIV-1 infected, ART- naïve adults. The primary objective was to demonstrate the antiviral activity of DTG 50 mg administered once daily compared to RAL 400 mg BID over 48 weeks using the Missing, Switch or Discontinuation = Failure (MSDF), or FDA “Snapshot” algorithm. Secondary objectives included antiviral and immunological responses over time (including through Week 96); incidence, severity and changes over time in laboratory and clinical safety parameters, assessment of population-based PK and PK/PD relationship and changes in virologic genotype and phenotype.

A total of 827 subjects were randomized (1:1) and treated with either 50 mg DTG once daily, or RAL 400 mg twice daily. Subjects also received a dual NRTI backbone (TDF/FTC or ABC/3TC) chosen by the investigator. Subjects were stratified on Baseline HIV-1 RNA (100,000 c/mL or >100,000 c/mL) and choice of NRTI. To be considered eligible for this study, potential subjects must have received no more than 10 days of prior antiretroviral therapy, have no evidence of viral resistance and have screening laboratory values within protocol-defined ranges.

Subjects will be followed until the Week 96 visit at which time subjects originally randomized to RAL will discontinue from the study. Subjects originally randomized to DTG will be given the opportunity to continue to receive DTG and be followed in the

20 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

study until DTG is locally approved and commercially available, they no longer derive clinical benefit, they meet a protocol-defined reason for discontinuation, or until development of DTG is terminated.

Figure 1 ING113086 Study Design

1.7.1.2. Study ING114467

ING114467 is a Phase III randomized, stratified, double-blind, double-dummy, active- controlled, multicenter, parallel group, fully-powered non-inferiority study. The study was conducted in approximately 800 HIV-1 infected ART-naïve subjects. Subjects were randomized 1:1 to receive DTG 50 mg plus ABC/3TC fixed dose combination (FDC) therapy once daily (approximately 400 subjects) or Atripla once daily (approximately 400 subjects). Subjects were stratified by screening HIV-1 RNA and CD4+ cell count. The primary analysis took place after the last subject completed 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study. Due to the use of fixed dose formulations in both treatment arms, no dose reductions, modifications in dosage, or changes in the frequency of dosing were allowed in this study.

The primary objective of this study is to demonstrate the antiviral activity of DTG plus ABC/3TC FDC once daily therapy compared to Atripla over 48 weeks in HIV-1 infected ART-naïve subjects.

Secondary objectives include antiviral and immunological responses over time; incidence, severity and changes over time in laboratory and clinical safety parameters, and changes in virologic genotype and phenotype.

Subjects randomized to receive DTG plus ABC/3TC FDC once daily therapy and who successfully completed 96 weeks of treatment were given the opportunity to continue to receive these agents until either DTG is locally approved and commercially available, they no longer derive clinical benefit, they meet a protocol-defined reason for discontinuation, or until development of DTG is terminated. Subjects randomized to the Atripla arm will receive Atripla through their Week 96 visit, after which they will be discontinued from the study and will need to make alternative arrangements to access antiretroviral medication. The study has since been modified to continue the randomized

21 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

comparative phase to Week 144 (open label from Week 96 to 144) in order to further characterize the long-term safety of the DTG + ABC/3TC regimen (Figure 2).

The use of Atripla from the outset of treatment was not consistent with the European labeling at the time of study initiation; however this regimen is approved for initial use in treatment-naïve patients in other markets (e.g. US). An initial ART regimen comprising co-formulated EFV, FTC, and TDF has been established as a preferred regimen in treatment guidelines for therapy-naïve, HIV infected subjects [EACS, 2012; DHHS, 2012].

The efficacy of Atripla was established in a large 96 week clinical study (GS-934) in which EFV and the FDC of TDF/FTC were utilized and shown to be effective. The safety and resistance/cross resistance profiles of individual components have been well characterized in the regulatory submissions for each agent. Of particular note, the components of Atripla were also utilized as the comparator arm in the STARTMRK trial, which served as a RAL pivotal study for treatment-naive patients, and the Atripla FDC was used as comparator in one of the pivotal registrational studies for the recently approved Stribild (EVG/cobicistat/TDF/FTC) fixed dose combination [Sax, 2012].

As ING114467 is intended to support the global regulatory filing for the second integrase-containing three-drug FDC tablet, consisting of DTG/ABC/3TC, the use of Atripla in this study as a comparator is viewed as necessary by the Sponsor. As outlined below, the results from ING114467 provide further clinical data that address the clinical relevance of the conditions under which tenofovir is dosed from study initiation. In particular, the low rate of protocol defined virologic failure in ING114467 (4% on TDF/FTC/EFV and 4% on DTG + ABC/3TC) suggests that both combinations are efficacious.

Figure 2 ING114467 Study Design

GSK1349572 Plus ABC/3TC Screening Period Double-Blind Phase Open-Label Phase Continuation Phase

GSK1349572 + ABC/3TC + GSK1349572 + GSK1349572 + ABC/3TC HIV ART-Naïve subjects Atriplaplacebo (n=~400) ABC/3TC open label open label HLA-B*5701 negative HIV-1 RNA ≥ 1,000 c/mL 1:1 Randomization GSK1349572 placebo + ABC/3TC Atripla placebo + Atripla (n=~400) Open Label

Screening Visit Randomization Week 48 Week 96 Week 144 ~ Day -21 Day 1 Analysis Analysis Analysis

1.7.1.3. Study ING111762

ING111762 is designed as a Phase III randomized, double-blind, double dummy study to compare the safety and efficacy of the selected dose of DTG once daily to RAL 400 mg BID, both administered with an investigator-selected background regimen over 48

22 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Weeks. Subjects enrolled in the study were HIV-1 infected, INI-naïve, ART-experienced adults. The primary objective of the study is to assess the non-inferiority (NI margin=12%) of DTG to RAL using the proportion of subjects with HIV-1 RNA <50 c/mL (Snapshot [MSD=F]) through Week 48 as the primary endpoint. Secondary objectives include antiviral and immunological response over time; incidence, severity and changes over time in laboratory and clinical safety parameters, assessment of population based PK and PK/PD parameters and changes in virologic genotype and phenotype.

The primary analysis will take place after the last subject completes 48 weeks on therapy. An additional data cut and analysis was conducted after the last subject completed 24 weeks on therapy. Data from this Week 24 pre-specified interim analysis is included with this initial registration package.

Approximately 688 subjects were randomized 1:1 to receive either DTG 50 mg once daily or RAL 400 mg BID each added to an investigator selected background regimen consisting of one fully active single agent plus no more than one second single agent which may or may not be active. Recruitment of subjects with highly potent regimens containing DRV/RTV was capped in order to ensure that the contribution of DTG to successful suppression could be satisfactorily demonstrated in a patient population similar to BENCHMRK-1 and 2 [Steigbigel, 2008].

Therefore, in line with the guidelines and the most recent approach of conducting clinical trials in moderately treatment-experienced subjects, this study was designed to evaluate DTG vs. the only approved in-class comparator, RAL, in subjects able to construct a background regimen consisting of at least one fully active agent and no more than one single second agent which may or may not be active, and used the primary endpoint of proportion of subjects with plasma HIV-1 RNA <50 c/mL (Snapshot [MSDF]).

In order to achieve balance across the two treatment groups of the study, randomization was stratified by:

 Screening plasma HIV-1 RNA: 50,000 c/mL versus >50,000 c/mL;  DRV/RTV use without primary PI resistance (as defined by presence of primary mutations based on current International AIDS Society [IAS, 2009] guidelines): subjects who use DRV/RTV in their background regimen and whose Screening genotype shows no primary PI mutations versus subjects who either do not use DRV/RTV or whose Screening genotype shows primary PI mutations. The total number of subjects in the first category was restricted to 170.  Number of fully active drugs in investigator selected background regimen (study background regimen): 2 versus <2. Subjects will be followed until the Week 48 visit at which time subjects originally randomized to RAL will discontinue from the study. Subjects originally randomized to DTG will be given the opportunity to continue to receive DTG and be followed in the study until DTG is locally approved and commercially available, they no longer derive clinical benefit, they meet a protocol-defined reason for discontinuation, or until development of DTG is terminated.

23 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Figure 3 ING111762 Study Design

GSK1349572 + Raltegravir PCB + GSK1349572 (open-label) background regimen b + background regimen HIV-1 treatment experienced, INI- naive Subjects • HIV-1 RNA >400 copies/mLa • Resistance to 2 different ART classes Raltegravir + GSK1349572 PCB + background regimen b

Screening Visit Randomization Analysis Analysis ~Day -35 Day 1 Week 24c Week 48c

Screening Period Randomized Phase Non-Randomized Phase

a. At Screening and a second consecutive test >400 c/mL within four months prior to Screening (unless the Screening HIV-1 RNA >1000 c/mL where no additional plasma HIV-1 RNA assessment is needed). (If an additional HIV-1 RNA within four months prior to Screening was not available, a second HIV-1 RNA must have been performed during the Screening period [after the first result is available] to serve as a confirmatory sample.) b. Subjects randomized to the RAL arm will discontinue study after Week 48, but subjects randomized to DTG will continue into Open-Label Phase. If a subject successfully completes Week 48 and RAL is not approved and commercially available within the country, GSK will continue to supply RAL in the Open-Label Phase until it is commercially available. c. An interim analysis of Week 48 data was planned once 60% of subjects completed that assessment, using group-sequential statistical rules. However, with protocol amendment 6, a decision was made that this group- sequential interim analysis would not be conducted.

1.7.1.4. Study ING112574

Study ING112574 is a multicenter, single arm, open-label study to assess the antiviral activity and safety of a DTG containing regimen in HIV-1 infected, ART-experienced adults who had experienced virological failure on an INI containing regimen with historical or current evidence of genotypic and/or phenotypic resistance to RAL or EVG. Initially, a minimum of 100 subjects were enrolled to receive DTG 50 mg BID with the current failing regimen for 7 days but with optimized background regimen (OBR) from Day 8. Subjects must also have had documented genotypic and/or phenotypic resistance to at least one compound in two or more of the other approved classes of ART but must also have been able to include at least one fully active drug in the OBR to be commenced at Day 8. The first data cut took place after the 100th subject enrolled completed the Week 24 assessment visit and as agreed with regulatory agencies, this will be used to support initial regulatory filings.

All subjects who successfully completed 24 weeks of treatment will continue to have access to DTG until it is locally approved and commercially available, they no longer derive clinical benefit, they meet a protocol-defined reason for discontinuation or until the development of DTG is terminated.

Once the initial 100 subjects were enrolled, enrolment to the study continued until a further 50 to 100 subjects were recruited to a total study enrolment of 150 to 200

24 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

subjects. Subsequent analyses, which will be provided to regulatory agencies post the initial submission, will include longer term data (Week 48) from the initial cohort of approximately 100 subjects enrolled in addition to data through at least 24 weeks from the 50 to 100 subjects subsequently enrolled.

The primary objective of ING112574 was to assess the efficacy and safety of DTG 50 mg twice daily when administered to subjects exhibiting INI resistance with an OBR for at least 24 weeks. An additional objective was to try to define the population of subjects with INI-resistant virus that may be successfully treated with a DTG containing regimen.

Secondary objectives include assessments of safety, tolerability, the antiviral effects on selected virologic and immunologic markers of HIV infection, Baseline resistance patterns, the impact of different Baseline DTG resistance profiles and activity of background antiretroviral regimen (phenotypic susceptibility score [PSS]/ genotypic susceptibility score [GSS]/ overall susceptibility score [OSS]) on treatment response, the pharmacokinetics of DTG and exploration of exposure-response relationships. Further development on study or evolution of viral resistance was also assessed.

The impact of Baseline factors/covariates on both the Day 8 and Week 24 response were explored including assessment of response by Baseline resistance profiles, facilitating the inclusion of guidance about the population most likely to respond to DTG-based therapy for inclusion in the proposed label.

Figure 4 ING112574 Study Design

HIV-1 Integrase Inhibitor – experienced Subjects

• HIV-1 RNA > 500 copies/ mL • DTG Naive •Screening or documented resistance to Functional raltegravir and/or elvitegravir Monotherapy Phase Optimised Phase • Screening or documented resistance to 2 ART classes other than Integrase Inhibitors DTG 50mg BID and DTG 50mg BID •Subjects with only historical RAL or ELV continue remaining + resistance capped at approximately 50%. components of failing Optimised Background Regimen with Regimen OSS 1

Screening Period up to a maximum of 42 Days Week 24 Screening Visit Day 1 Day 8 ~ Day -35 Analysis

1.7.2. Supportive Efficacy Studies

A total of three studies are considered supporting efficacy studies. A full description of these studies can be found in the corresponding clinical study reports.

These studies are briefly described in the following sections and details are listed in Table 1.

25 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.7.2.1. Study ING111521 (PoC)

ING111521 was a Phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability, and PK of DTG monotherapy versus placebo over 10 days in ART-naïve and experienced (integrase inhibitor-naïve) HIV-1 infected adults who were not currently receiving antiretroviral therapy. This study consisted of a Screening visit, a 10 day treatment period, and follow-up evaluations for 11 days following last dose.

Subjects were assigned to DTG or placebo in accordance with the randomization schedule. A description of each dose is provided below:

1. Treatment A: DTG 2 mg every 24 hours (q24h, n=8) or Placebo q24 h (n=2) 2. Treatment B: DTG 10 mg q24 h (n=8) or Placebo q24 h (n=2) 3. Treatment C: DTG 50 mg q24 h (n=8) or Placebo q24 h (n=2) Each active treatment (8 subjects) with matching placebo (2 subjects) was dosed in the same frequency and with matching number of tablets to achieve the double-blind.

The primary objective of this study was to evaluate antiviral activity of DTG vs. placebo in HIV-1 infected patients during 10 days of monotherapy.

Secondary objectives include PK of DTG, safety and tolerability when administered as monotherapy over 10 days, and the relationship between DTG exposure and change in plasma HIV-1 RNA.

1.7.2.2. Study ING112276

ING112276 was designed to select the optimal once daily dose of DTG for Phase III studies in integrase-naive subjects and to provide an early assessment of antiviral activity and durability of DTG as a component of ART. EFV-based ART served as the control arm. All subjects also received investigator-selected dual NRTI combination i.e., once daily ABC/3TC or TDF/FTC fixed dose combination (FDC) tablets. This study was conducted in HIV-1 infected ART-naïve adult subjects with 10 days of previous antiretroviral therapy, HIV-1 RNA 1000 c/mL, CD4+ cells 200 cells/mm3 and no primary resistance mutations at Screening.

The primary objective of the ING112276 trial was to select a DTG once daily dose for further evaluation in Phase III based on a comparison of the Week 16 antiviral activity and tolerability of a range of oral doses of DTG in HIV-1 infected therapy-naïve adult subjects. Secondary objectives included assessment of various DTG doses on selected virological and immunological markers of HIV infection over time, assessment of the safety and tolerability of DTG, characterization of the PK parameters and the PK/PD relationship of DTG and assessment of the development of viral resistance to DTG and other on-study ART in subjects experiencing virological failure.

Eligible subjects were randomized 1:1:1:1 to one of three doses of DTG (10 mg, 25 mg or 50 mg once daily) or to the EFV control in accordance with the randomization schedule. A description of each dose is provided below:

26 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1. DTG 10 mg once daily +dual NRTI once daily 2. DTG 25 mg once daily +dual NRTI once daily 3. DTG 50 mg once daily +dual NRTI once daily 4. EFV 600 mg once daily +dual NRTI once daily

Figure 5 ING112276 Study Design

1.7.2.3. Study ING112961

Study ING112961 (VIKING) is a Phase IIb, multicenter, open-label, single arm pilot study to assess the antiviral activity of DTG containing regimen in HIV-1 infected, ART- experienced adults with RAL resistance. The study was originally designed to include approximately 30 ART-experienced subjects with either current or past virologic failure to RAL. As specified in the protocol, as some subjects with higher level of DTG resistant had an inadequate response to DTG 50 mg once daily, an additional cohort exploring a higher dose of DTG (50 mg BID) was initiated.

All subjects were required to harbor viral isolates with RAL resistance mutations at Screening. Subjects were also required to have documented genotypic and/or phenotypic resistance to at least one compound from each of three or more of the approved classes of ART including integrase inhibitors.

The screening genotype was used to assign subjects to one of two genotypic groups: Genotypic Group A comprised those with virus exhibiting the mutation Q148H/K/R plus one or more Q148 associated secondary resistance mutations, whilst genotypic Group B comprised those with virus exhibiting alternative genotypes conferring RAL resistance (N155H and Y143H pathways with or without secondary mutations or Q148H/K/R single mutants without secondary mutations). The groups were capped at approximately 15

27 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

subjects per group (Cohort I) and 10 subjects per group (Cohort II) to ensure enrolment of subjects harboring virus with a broad range of sensitivity to DTG.

Subjects with current RAL virologic failure substituted RAL with DTG 50 mg once daily (Cohort I) or 50 mg BID (Cohort II) and continue the remaining components of their failing regimen through Day 10. Subjects with historical RAL virologic failure were required to add DTG 50 mg once daily (Cohort I) or BID (Cohort II) to their failing regimen through Day 10. On Day 11 all subjects continued DTG and for Cohort I optimized, where feasible, their background therapy. With Cohort II, all subjects were required to have a PSS1 for their optimized background therapy.

Antiviral activity, safety and tolerability of DTG were evaluated at Day 11 and over time through at least Week 24.

The primary objective of Study ING112961 was to assess the short term anti-viral activity of DTG plus failing background regimen. Secondary objectives include the impact of Baseline resistance to DTG on treatment response, the relationship between PK measures and response (antiviral activity and safety) and PK/PD assessment. Antiviral activity and safety over the longer term (when DTG is administered with the OBR) was also to be determined and variables correlated with response explored. Further development on study or evolution of viral resistance was also to be assessed.

Figure 6 ING112961 Study Design

1.8. Efficacy Endpoints

The primary endpoint for pivotal studies ING113086, ING114467, ING111762, and ING112574 (Week 24 endpoint) was analyzed using a Missing, Switch or Discontinuation = Failure (MSDF) algorithm as codified by the FDA’s “snapshot” algorithm.

28 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

This algorithm treats all subjects without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of Investigational Product [IP] prior to the visit window) as non-responders, as well as subjects who switch their concomitant ART prior to the visit of interest as follows:

 Background ART substitutions not permitted per protocol;  Background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first On-treatment visit where HIV-1 RNA is assessed. Since changes in ART were not permitted in the ING114467 protocol, all such subjects who changed ART were considered non-responders. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the subject is On-treatment within the visit of interest analysis window. It was intended to be primarily a virologic assessment of the endpoint, and as such followed a “virology first” hierarchy.

When no HIV-1 RNA data was available within a window, a subject cannot be a Virologic Success. Depending on the reason for lack of data, the subject was classified as a Virologic Failure or reported as ‘No Virologic Data at Week X’; in the latter case, the algorithm further classifies the nature of the missing data. Typically, a subject withdrawn (i) due to AE or, (ii) for another reason yet was suppressed at the time, was counted as ‘No Virologic Data at Week X’. Should a subject withdraw for reasons other than AE and was not suppressed at the time, they were a Virologic Failure.

1.8.1. Primary Efficacy Endpoints

The primary endpoints for pivotal and supportive studies are listed in Table 5. More detail pertaining to non-efficacy primary endpoints can be found within the individual study Reporting and Analysis Plans (RAPs).

Table 5 Primary Efficacy Endpoints in Pivotal and Supportive Studies

Pivotal Studies ING113086 ING114467 ING111762 ING112574 Proportion of subjects with HIV-1 RNA <50 c/mL through X X X Week 48 (Snapshot)a Mean change from Baseline in plasma HIV-1 RNA X (log10 c/mL) at Day 8 (LOCFDB) (for hypothesis testing)b Proportion of subjects with plasma HIV-1 RNA <50 c/mL at X Week 24 (Snapshot)a

Supportive Studies ING112961 ING112276 ING111521 Proportion of subjects with Day 11 plasma HIV-1 RNA <400 c/mL or at X least 0.7 log10 c/mL below Baseline Proportion of subjects with HIV-1 RNA <50 c/mL through Week 16 (Time to X Loss of Virologic Response [TLOVR]) c Change from Baseline in plasma HIV-1 RNA to Day 11 X DTG PK parameters following dose administration on Day 1 X a. Analyzed using the Snapshot (MSDF) algorithm. b. Analyzed using a last observation carried forward (discontinuation equals Baseline) (LOCFDB) dataset. c. Analyzed using time to loss of virologic response (TLOVR) algorithm.

29 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.8.2. Secondary Efficacy Endpoints

Table 6 Secondary Efficacy Endpoints in Pivotal and Supportive Studies

Pivotal Studies ING113086 ING114467 ING111762 ING112574 Proportion of subjects with plasma HIV-1 RNA <50 c/mL Xb at Week 24 (Snapshot)b Proportion of subjects with detectable geno/pheno INI X X X resistance by Weeks 24/48/96 Week 48/96 Week 24/48a Week 24 Proportion of subjects with plasma HIV-1 RNA <50 c/mL X X at Week 96 (Snapshot [MSDF]) Proportion of subjects with plasma HIV-1 RNA X X <400 c/mL at Weeks 48/96 (Snapshot [MSDF]) Week 48/96 Week 24/48 Proportion of subjects with plasma HIV-1 RNA <50 c/mL X X and <400 c/mL over time (Snapshot [MSDF]) Absolute values and change from Baseline in plasma X X X HIV-1 RNA over time Absolute values and change from Baseline in CD4+ and X X X X CD8+ cell counts over time Change from Baseline in CD4+ cells at Week 48 Xa Incidence of disease progression (HIV-associated X X X X conditions, AIDS and death) Time to viral suppression (<50 c/mL) Xa Proportion of subjects with HIV-1 RNA ≥1000 c/mL at or X after Week 16 and before Week 24, or ≥200 c/mL at Week 24 Symptom distress module: change in overall symptom Xa bother count from Baseline to Week 4 Supportive Studies ING112961 ING112276 ING111521 Mean change from Baseline (Day 1) in plasma HIV-1 RNA on Day 11 X and over time Proportion of subjects with plasma HIV-1 RNA <50 c/mL and <400 c/mL X over time (TLOVR) Proportion of protocol defined virologic failures over time X Estimation of TLOVR based on plasma HIV-1 RNA <400 c/mL and X <50 c/mL using Kaplan-Meier methods Change from Baseline in CD4+ cell counts over time X Incidence of HIV-1 associated conditions and disease progression X Change in HIV-1 RNA from Baseline over time by Baseline integrase inhibitor resistance mutation, Baseline FC in half-maximal inhibitory X concentration (IC50) to DTG and DTG PK parameters HIV-1 RNA decay rate over the initial 2 weeks of treatment X Proportion of subjects with plasma HIV-1 RNA <400 and <50 c/mL X using the TLOVR algorithm Absolute values and Change from Baseline in plasma HIV-1 RNA X Incidence of disease progression (HIV-associated conditions, AIDS, X death) Absolute values and changes from Baseline in CD4+ and CD8+ cell X counts Incidence of treatment emergent genotypic and phenotypic resistance to X X DTG and other on-study ART Change from Baseline in plasma HIV-1 RNA to nadir (maximum X change) Plasma HIV-1 RNA rate of decline (slope) over 10 days X Proportion of subjects with HIV-1 RNA<400 c/mL X Proportion of subject with HIV-1 RNA <50 c/mL X

30 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Supportive Studies ING112961 ING112276 ING111521 Change in plasma HIV-1 RNA levels during follow-up period (Days 11- X 21) Change from Baseline in CD4+ cell count to Day 11 X Emergence of drug resistance mutations, if appropriate X DTG PK parameters at Day 10 X a. Overall type I error rate was controlled for these key secondary analysis comparisons. b. Principal secondary endpoint for Week 24 interim analysis 1.9. Statistical Considerations

Due to differences in study designs and comparator arms, data from the studies were not combined and therefore are presented in a side-by-side format for comparative purposes. Complete details of the statistical analysis methods for the individual studies are found in the RAPs for the studies. The statistical methods described in this section are for the analyses that are included in this module.

1.9.1. Sample Size and Randomization

1.9.1.1. Pivotal Efficacy Studies

For Studies ING113086 and ING114467, the endpoint for the primary comparison is response rate, i.e., the proportion of subjects with plasma HIV-1 RNA below 50 c/mL at Week 48. The response rates of dual-NRTI therapy and dual-NRTI + third agent therapy in recent studies is presented in m5.3.5.1 ING113086 CSR Section 4.11.1. Though time points are different among the studies, the differences of response rates between dual- NRTI therapy and dual-NRTI + third agent are similar. These response rates range from 34% to 49% and all of the lower bounds of 95% confidence interval are no less than 0%, which shows that the additional effect of third agent therapy in each study is statistically significant. Moreover, the pooled difference (the 95% confidence interval) of these response rates is 39% (33%, 45%). A non-inferiority margin of 10% is small enough compared to the additional effect of third agent therapy, because the non-inferiority margin is much less than the half of the lower bound of 95% confidence interval for the pooled difference.

Also the non-inferiority margin of 10% is at the low end of the margins described in a review of non-inferiority trials in HIV conducted between 2000 and 2007, where the margins vary between 10% and 15% [Hill, 2008]. This suggests further that a non-inferiority margin of 10% is reasonable.

1.9.1.1.1. Study ING113086

Assuming a 75% response rate in the RAL arm, the study required 394 evaluable subjects per arm to have 90% power with a 10% non-inferiority margin and a one-sided 2.5% significance level.

The RAL response rate assumed prior to the conduct of this study combined the failure rate for drug reasons from RAL studies, with the failure rate for non-drug reasons from GSK studies. The failure rate in any study is a combination of the performance of the drug and discontinuations for reasons less likely to be related to the performance of the drug (lost to follow up, withdrawal of consent, etc.).

31 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Data on RAL from studies in treatment-naïve HIV-1 infected subjects showed response rates of approximately 86% at Week 48 and 81% to 83% at Week 96. The rate of discontinuations for non-drug reasons historically has been higher for GSK studies than for the studies of RAL (GSK Data on File). This gave response rates of approximately 80% at Week 48 and 75% at Week 96. Using the lower of the two response rates for the power calculation yielded 90% power at each time point.

1.9.1.1.2. Study ING114467

Assuming a 75% response rate in the TDF/FTC/EFV arm, the study required 394 evaluable subjects per arm to have 90% power with a 10% non-inferiority margin and a one-sided 2.5% significance level.

The power of this study is based on a response rate of 75% which is in the mid-range of response rates observed in EFV arms in recent large clinical studies ranges from 71% to 82%.

1.9.1.1.3. Study ING111762

Assuming a 65% response rate in the RAL arm, the study required 333 subjects per arm to have 90% power with a 12% non-inferiority margin and a one-sided 2.5% significance level.

Data on RAL from studies in treatment-experienced, INI-naïve HIV-1 infected subjects with either one or two active background antiretroviral agents have shown response rates of approximately 66% at Week 48 [Cooper, 2008]. The appropriate control response rate to assume for this study combines the failure rate for drug reasons from the RAL studies with the failure rate for non-drug reasons from GSK studies. This gives an estimated response rate between 60 and 65% at Week 48, (25-30% drug-related failure rate plus 5- 10% failure for non-drug reasons).

The 12% NI margin was chosen based on prior studies with consistent evidence of sensitivity to drug effects, with consideration for the difficulty in recruiting a treatment-experienced yet RAL naïve population.

Specifically, the non-inferiority margin was chosen based on the observed benefit of raltegravir vs. placebo in INI-naïve patients in the BENCHMRK studies within the population of subjects with Phenotypic Susceptibility Score (PSS)=1-2.

The treatment difference in HIV-1 RNA <50 c/mL at Week 48 of raltegravir versus placebo in the BENCHMRK studies was almost exactly the same in PSS=1 and PSS=2 populations (PSS=1: 32%, 95% CI 18% to 45%; and PSS=2: 33%, 95% CI 18% to 47%); benefit for pooled PSS 1-2 population 32%, CI 22% to 42%. These confidence intervals and observed treatment differences were far enough from zero to justify a NI margin of 12% in subjects with PSS=1, PSS=2 or PSS 1-2 [Cooper, 2008].

The non-inferiority design used is in alignment with applicable HIV-specific guidelines [EMA, 2009] and statistical guidelines [ICH, 2001]. The active control has reproducible and well-defined clinical activity shown in the placebo-controlled BENCHMRK studies

32 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

[Steigbigel, 2008] and the non-inferiority margin has been chosen based on statistical considerations and clinical judgment in line with applicable guidelines [EMA, 2009].

1.9.1.1.4. Study ING112574

Assuming a standard deviation of 0.5 log10 c/mL for the change from Baseline in plasma HIV-1 RNA at Day 8, this study required fewer than twenty subjects to be powered at 90% on the primary hypothesis test. However, the minimal sample size was expanded to 150 to 200 subjects to allow a comprehensive assessment of the safety, antiviral activity and PK of DTG in this study, acknowledging constraints on the availability of the study patient population.

1.9.1.2. Supportive Efficacy Studies

1.9.1.2.1. Study ING111521

The sample size for this study was based primarily on feasibility to provide adequate precision for the estimations.

After successfully completing screening evaluations, approximately 30 eligible HIV-1 infected subjects were randomized to one of three active treatments or placebo, 8 subjects in each active dose and 6 in placebo.

1.9.1.2.2. Study ING112276

The endpoint for the primary efficacy comparison was the proportion of subjects with plasma HIV-1 RNA below 50 c/mL at Week 16. The sample size (50 subjects per arm) was chosen to ensure a high probability (more than 95%) that a dosage regimen with truly poor response (i.e., at least 10% worse than on another dose) was not selected for further study on the basis of the analysis of the primary endpoint.

1.9.1.2.3. Study ING112961

There was no formal calculation of power or sample size for this pilot study.

33 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.9.2. Analysis Populations

Table 7 Analysis Populations Discussed in ISE

Population Name Population Definition Pivotal Efficacy Supportive Studies Efficacy Studies All Subjects The All Subjects Screened population will consist ING113086, ING112961, Screened of all subjects screened for inclusion in the study. ING114467, ING112276 Population ING111762, ING112574 Intent-to-Treat The Intent-to-Treat Exposed population will consist ING113086, ING112961, Exposed (ITT-E) of all randomized subjects who receive at least one ING114467, ING112276, Population dose of investigational product. For studies ING112574:(single ING111521 ING112961, ING111521, subjects had to have at arm) least one post-Baseline measure of plasma HIV-1 RNA. The ITT-E population will be the primary population used for efficacy analyses. In randomized studies, subjects will be analyzed according to their randomized treatment, regardless of the treatment they actually received. Note for ING111762 the modified ITT-E Population is described below (Modified Intent-to-Treat Exposed (mITT-E) Population). Per-Protocol (PP) Per-Protocol population will consist of subjects in ING113086, ING112961, Population the ITT-E Population (mITT-e for ING111762) with ING114467, ING112276, the exception of those with a protocol deviation ING111762, ING111521 before a specified analysis time point. PP ING112574 Population will be used for a supporting analysis of the primary endpoint analysis only. On-treatment The On-treatment Genotypic and Phenotypic ING113086 ING112276 Genotypic and Resistance populations will consist of all subjects ING114467 Phenotypic in the ITT-E population with available On-treatment Resistance genotypic and phenotypic resistance data, Populations respectively, excluding subjects who are not protocol-defined virologic failures. These populations will be used for analysis of On- treatment and treatment-emergent genotype and phenotype.

The following analysis populations are specific to ING111762:

Modified Intent-to-Treat Exposed (mITT-E) Population

The Modified Intent-to-Treat Exposed population consists of all randomized subjects who receive at least one dose of investigational product, and who were not at one study site (Site 083523, Investigator ID=096536) in Russia (enrolled 4 subjects in ING111762) that was closed early after the sponsor became aware of GCP noncompliance issues in another ViiV Healthcare-sponsored study. Further details will be provided in the clinical study report.

34 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Week 24 Protocol Defined Virologic Failure (PDVF) Genotypic and Phenotypic Populations

The Week 24 PDVF Genotypic and Phenotypic populations consists of all subjects in the mITT-E population with protocol defined virologic failure occurring by Week 24 and available On-treatment genotypic and phenotypic resistance data, respectively, at time of protocol defined virologic failure. These populations were used for selected analysis of genotype/phenotype data for the Week 24 clinical study report.

The following analysis populations are specific to ING112574:

Week 24 ITT-E Population

The Week 24 ITT-E population will consist of the initial 100 (approximate) subjects recruited in the ITT-E population who have completed the analysis timepoint (e.g. Week 24) at the data cut of the Week 24/48 interim analysis or withdrawn. The exact number of subjects included in this population will depend on the timing of the interim analysis.

For the Week 24 interim analysis, this population is the main population for assessing efficacy.

Day 8/Week 24 Per-Protocol (PP) Populations

Day 8/Week 24 Per-Protocol populations will consist of subjects in the ITT-E /Week 24 ITT-E Population with the exception of those with a protocol deviation, before a specified analysis timepoint, which may directly or indirectly impact the efficacy endpoint of HIV-1 RNA. Week 24 PP Population was used for a supporting analysis of the primary endpoint analysis at Week 24. Day 8 PP population was used for a supporting analysis of the primary efficacy endpoint analysis at Day 8.

Virologic Outcome By Baseline Genotype or Phenotype (VO) Population

Virologic Outcome by Baseline Genotype or Phenotype Population at a time-point of interest (e.g. Day 8, Week 24) included all subjects in the ITT-E /Week 24 ITT-E Population, excluding

 Subjects who received incorrect IP, had IP interruption, or received prohibited medication prior to a time-point of interest.(i.e. consistent with the criteria for defining Per-protocol population),  Subjects who discontinued IP (before confirmed protocol defined virologic failure) at any time up to a time-point of interest (e.g. Day 8, Week 24) for reasons other than lack of efficacy. VO Populations were used for analyzing the association between the virologic response (Day 8 and Week 24) and Baseline characteristics (e.g. Baseline resistance).

35 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.9.3. Statistical Methods

An overview of the statistical methods used to analyze efficacy variables in the individual pivotal and supporting studies is shown in Table 8. A more detailed review of statistical methodology can be found in the RAP for each study.

36 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 8 Overview of Statistical Methods Used to Analyze Efficacy Variables

Study Comparisons Statistical Tests Phase(s) Primary Methods of Analysis of Interest of Endpoints interest Pivotal Efficacy Studies ING113086 Non-inferiority The lower end of a two-sided Week 48 Section Adjusted estimates of the difference in the proportion of responders between each of the DTG 95% confidence interval for 1.8.1 treatment group will be presented along with two-sided 95% CIs based on a stratified treatment Arm the difference between the analysis using Cochran-Mantel-Haenszel (CMH) weights. vs. the RAL two groups in response rates treatment Arm lies above -10%. Four strata (subgroups) will be formed according to the combinations of levels of the following categorical variables: Baseline plasma HIV-1 RNA (≤ vs. >100,000 c/mL) and background dual NRTI therapy (ABC/3TC vs. TDF/FTC). ING114467 Non-inferiority The lower end of a two-sided Week 48 Section Adjusted estimates of the difference in the proportion of responders between each of the DTG 95% confidence interval for 1.8.1 treatment group will be presented along with two-sided 95% CIs based on a stratified plus ABC/3TC the difference between the analysis using Cochran-Mantel-Haenszel (CMH) weights. treatment Arm two groups in response rates vs. the Atripla lies above -10%. For the statistical analysis, four strata (subgroups) will be formed according to the treatment Arm combinations of levels of the following categorical variables: Baseline plasma HIV-1 RNA ( vs. >100,000 c/mL) and Baseline CD4+ cell count ( vs. >200 cells/mm3). ING111762 Non-inferiority The lower end of a two-sided Week 24 Section Adjusted estimates of the difference in the proportion of responders between each of the DTG 95% confidence interval for for ISE 1.8.1 treatment group will be presented along with two-sided 95% CIs based on a stratified treatment Arm the difference between the (Note analysis using Cochran-Mantel-Haenszel (CMH) weights. vs. the RAL two groups in response rates Week 48 treatment Arm at Week 24 (and Week 48 for is the For the statistical analysis, eight strata (subgroups) will be formed according to the primary analysis) lies above - primary combinations of levels of the following categorical variables: 12%. endpoint) •Baseline plasma HIV-1 RNA ( vs. >50,000 c/mL); • DRV/RTV use in background ART regimen without primary PI mutations at Baseline: (yes vs. either no DRV/RTV use or presence of primary PI mutations at Baseline); • Baseline PSSf (<2 vs. 2) to background regimen. ING112574 As this is a The hypothesis of no change Day 8 Section The p value and the Day 8 mean change from Baseline with 95% confidence interval single arm from Baseline will be tested at Week 24 1.8.1 will be displayed. study there the two-sided five per cent will be no significance level using a The proportion of subjects with viral load <50 c/mL at week 24 by Snapshot (MSDF) treatment single sample t- test (Day 8). algorithm will be reported comparisons

37 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Comparisons Statistical Tests Phase(s) Primary Methods of Analysis of Interest of Endpoints interest Supportive Efficacy Studies ING111521 DTG 2, 10, No hypothesis testing will be Day 11 Section Change from Baseline to will be calculated for each subject and summarized for 50 mg once performed. 1.8.1 each treatment. daily for 10 days vs. placebo ING112276 DTG 10, 25, No hypothesis testing will be Week 16 Section A dose of DTG on which four more patients are failures than on the next highest 50 mg vs. performed. Dose selection 1.8.1 dose will not be considered for further study unless safety or tolerability concerns EFV will be based primarily on pre- rule out the higher dose. treatment arm specified go/no go thresholds for antiviral activity and tolerability endpoints in conjunction with immunologic, safety, and PK data secondary endpoint. ING112961 Sequential No hypothesis testing was Day 11 Section The proportion of subjects achieving ≤0.7 log10c/mL reduction of viral load or Cohort study planned, however the mean 1.8.1 <400 c/mL at Day 11 (i.e. primary endpoint) will be presented for Cohort II. change from Baseline in plasma HIV-1 RNA was compared between the two cohorts to provide further information for the Phase III dose selection.

38 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

1.9.4. Missing Data

1.9.4.1. Missing, Switch or Discontinuation = Failure (Snapshot)

Subjects’ responses (e.g., <50 c/mL) were calculated according to a Missing, Switch or Discontinuation = Failure (MSDF) algorithm – as codified by the FDA’s “snapshot” algorithm (ING113086, ING114467, ING111762 and ING112574).

Full details of the MSDF algorithm are in Section 1.8.

1.9.4.2. Last Observation Carried Forward Discontinuation = Baseline (LOCFDB)

The algorithm for the LOCFDB imputation, specific to ING112961 and ING112574, was described as follows: If an assessment is missing at an on-treatment visit, then the last non-missing on-treatment result from a prior visit was carried forward and analyzed. However, if subjects have missing values due to premature withdrawal, these missing values were set to their Baseline values.

1.9.4.3. Time to Loss of Virologic Response (TLOVR)

In each assessment window, a subject was defined as a responder if their treatment had not yet failed according to the TLOVR algorithm (ING112276 Week 96 CSR Section 4.8 and ING112961 Cohort I Week 96/Cohort II Week 48 CSR Section 4.6). That is, a responder had confirmed plasma HIV-1 RNA response at a certain threshold (e.g., <50 c/mL), but none of the events that define TLOVR treatment failure before the end of the window of interest. A non-responder was defined as a subject whose treatment has failed according to the TLOVR algorithm.

A subject was a failure in the time window of interest if they reached any of the events described in the algorithm in that or any previous window. A subject will only have a missing visit imputed as a treatment failure if they met the TLOVR definition of treatment failure in the subsequent visit.

1.9.5. Subgroup Analysis

Subgroups summarized within this report are listed below. Refer to individual study RAPs for a full listing of subgroups.

39 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 9 Subgroups in Efficacy Studies

Subgroup Levels Studies Baseline plasma HIV-1 RNA ≤100,000 c/mL ING113086 >100,000 c/mL ING114467 ING112276 <1000 c /mL ING112574 1000 to <10,000 10,000 to <50,000 50,000 to <100,000 100,000 to 500,000 >500,000 ≤50, 000 c/mL ING111762 >50,000 c/mL Background dual NRTI at Day 1 (for ING113086) and Week 16 or ABC/3TC ING113086 discontinuation (ING112276) TDF/FTC ING112276

Baseline CD4+ cell count <200 cells/mm3 ING114467 ≥200 cells/mm3 <50 ING113086 50 to <200 ING114467 200 to <350 ING111762 350 to <500 ING112276 ≥500 cells/mm3 ING112574 Cutoff using study ING111762 median Baseline Centers for Disease Control and Prevention (CDC) CDC Category A ING113086 category CDC Category B ING114467 CDC Category C ING111762 ING112276 ING112574 Race white ING113086 non-white ING114467 ING111762 ING112574 Gender female ING113086 male ING114467 ING111762 ING112574 Age <50 years ING114467 50 years ING113086 ING111762 <36 years ING114467 36 years ING113086 <65 years ING112574 65 years

40 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 10 Subgroups in ING111762

Susceptibility scores: a. PSSf: Baseline PSSf to background regimen: <2, 2; 1 vs. 2; Maximum Baseline potential PSSf : 2 vs. >2; b. PSSp: Baseline PSSp to background regimen: <2, 2; 1 vs. >1; c. GSS: Baseline GSS to background regimen: <2, 2; <2 vs. 2 Baseline resistance: three class resistance vs. two class resistance; Subjects receiving recently approved ART in background regimen (i.e. darunavir, etravirine, enfuvirtide or maraviroc): (yes/no); Use of DRV/RTV in background regimen: (yes/no); Use of T20 in background regimen: (yes/no); Use of etravirine in background regimen: (yes/no) Number of fully active PIs in background regimen (based on phenotypic susceptibility): (yes/no) Screening plasma HIV-1 RNA 1,000 c/mL Subjects utilizing historical drug class resistance to establish eligibility: (yes/no) DRV/RTV use without primary PI mutations at Baseline: (yes vs. either no DRV/RTV use or presence of primary PI mutations); Taking prohibited medications potentially reducing DTG concentration (yes/no); Clades (Clade B, Clade C, Other) Adherence rate based on pill counts (with imputation): <70%, 70 to <80%, 80 to <90%, 90 to <95%, 95%

Table 11 Subgroups in ING112574

RAL/EVG treatment status: Discontinued prior to Screening; On-going at Screening Duration of prior INI use: Missing, 6 months, >6 months to 24 months, >24 months FC in IC50 to RAL: 0 to 1.5, >1.5 to 4, >4 to 8, >8 to 10, >10 to 20, >20 to Max, >Max, Missing FC in IC50 to DTG: 0 to 2.5, >2.5 to 4, >4 to 8, >8 to 10, >10 to 15, >15 to 20, >20 to 25, >25, Missing Evidence at Baseline of Primary genotypic IN resistance: Detected, Not detected Number of pre-specified (primary or secondary) IN mutations: 0, 1, 2, 3, 4, 5 Baseline IN mutation categories: Q148+2 secondary mutations, Q148+1 secondary mutation, N155, Y143, T66, 2 primary mutations, Primary not detected PSS of failing background regimen: 0, 1, 2, >2 OSS of failing background therapy: 0, 1, 2, >2 Baseline PSSf to OBR at Day 8: 0, 1, 2, >2 Baseline OSS to OBR at Day 8: 0, 1, 2, >2 Baseline GSS to OBR at Day 8: >0 to 1, >1 to 2, >2 Taking prohibited medications potentially reducing DTG concentration: Yes, No

41 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

In the analyses of the antiviral activity at Day 8 and Week 24, the association between virologic responses and the factors described below were explored.

Table 12 Covariates Explored in Statistical Regression Modeling in ING112574

Day 8 Week 24 Age b X Gender X Race X Country X Duration of prior INIb X Status of RAL/EVG Treatment X X HIV risk factor X Baseline viral load b X X Baseline CD4+ cell countb X X Baseline IN resistant mutation category X X Number of IN pre-specified resistance mutation at Baselineb X X Baseline FC in IC50 relative to wild type (WT) virus for RALb X X Baseline FC in IC50 relative to WT virus for DTGb X X Evidence of genotypic IN resistance at Baseline X X Baseline phenotypic and overall sensitivity score (full sensitivity only – PSS and OSS) to Day 1 X background ART regimen Baseline PSS, GSS, and OSS to OBR used at Day 8 X Taking prohibited medications potentially reducing DTG concentration X X DTG PK Exposure (i.e. pre-dose concentration [C0] and phenotypic inhibitory quotient for X predose concentration [PIQ_C0] at Day 8)a,b DTG PK Exposure (average of concentrations at time 0 [C0_avg] and phenotypic inhibitory X quotient for average concentration [PIQ_Cavg])a,b a. Only C0 and PIQ_C0 will be included as a covariate for the multivariate analyses of the association between factors and virologic response in this document. The multivariate PK/PD analyses using PK parameters estimated based on population PK analysis will be described in a separate Population PK and PK/PD reporting and analysis plan. b. The continuous data of these factors rather than subgroups will be included in the multivariate analysis

1.9.6. Sensitivity Analyses

To assess the impact of major protocol deviations, the primary analyses described above were performed using the Per-protocol population and the results were compared for consistency with the results from the ITT-E (or mITT-E) population in ING113086, ING114467, ING111762, ING112574, and ING112961. Refer to individual study RAPs for a full listing of sensitivity analyses.

Phase II studies were designed and implemented according to the TLOVR algorithm, which was the accepted regulatory analysis at the time. Prior to the start of the Phase III program, FDA’s Division of Antiviral Products adopted the Snapshot (MSDF) algorithm; subsequently, this analysis method was employed in Phase III. The Missing or Discontinuation=Failure (MDF) analysis was an additional pre-planned analysis performed for the Phase II studies, which closely approximates the Snapshot analysis. A key difference is the lack of penalty for switching of background regimen in the MDF analysis, therefore, a brief summary of background regimen switches in the Phase II

42 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

studies is presented along with the MDF analysis. The MDF analysis is shown in this ISE to allow for a comparison with Snapshot response rates in the Phase III studies.

1.9.7. Antiviral Activity of DTG by Baseline Resistance in an INI- resistant population in ING112574

The Committee for Medical Products for Human Use (CHMP) Guideline on the clinical development of medicinal products for the treatment of HIV infection provides a template in Annex B for how to present information on efficacy by Baseline resistance for inclusion in Section 5.1 of the Summary of Product Characteristics (SPC) and the European Public Assessment Report (EPAR) [EMA, 2009].

Pre-specified IN resistance associated mutations that are listed in Table 13 were included in the analysis of response by Baseline DTG resistance to determine the genotypic correlates to virologic response.

Table 13 Pre-specified IN-resistance Associated Mutations

H51Y, T66A, T66I, T66K, L68V, L68I, L74I, L74M, L74R, E92Q, E92V, Q95K, T97A, G118R, E138A, E138K, E138T, G140A, G140C, G140S, Y143C, Y143H, Y143R, P145S, S147G, Q148H, Q148K, Q148R, V151I, V151L, S153F, S153Y, N155H, E157Q, G163R, G163K, G193E, R263K Note: IN substitutions listed above were defined from http://hivdb.stanford.edu/ with a score of >45. All other mutations were detected during INI clinical investigation or during in vitro studies with DTG. The mutations bolded are referred to ‘primary’ mutations, and those unbolded are referred to ‘secondary’ mutations for this analysis.

The association between change from Baseline in plasma HIV-1 RNA (log10 c/mL) at Day 8 and Baseline IN resistance associated mutations was explored through linear regression analysis by adjusting for other potential confounding factors (i.e. susceptibility to failing regimen and Baseline viral load). The Baseline IN resistance associated mutations that significantly affect the Day 8 response were identified. Baseline IN resistance mutations were categorized based on results from this analysis in predicting Day 8 virologic response.

The virologic response at both Day 8 and Week 24 were summarized by the Baseline IN resistance mutation groups derived from the Day 8 analysis, as per the requirement of table template from Annex B Section 5.1 [EMA, 2009].

2. SUMMARY OF RESULTS OF INDIVIDUAL STUDIES

This section provides summaries of key results from pivotal and supportive studies in INI-naïve and INI-resistant populations:

 Pivotal Efficacy Phase III studies include:  ING113086 (ART-naive),  ING114467 (ART-naive),  ING111762 (ART-experienced, INI-naive),  ING112574 (INI-resistant).

43 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

 Supportive Efficacy Phase II studies include:  ING111521 (ART-naive or experienced, but INI-naive).  ING112276 (ART-naive),  ING112961 (INI-resistant), A complete listing of all studies included in this marketing application is included in Appendix Table 1.

2.1. Pivotal Efficacy Studies

The Phase III Studies ING113086, ING114467, ING111762, and ING112574 assessed DTG across a broad range of treatment experience in HIV-infected patients and support the indication for the treatment of HIV-infected patients.

2.1.1. Study ING113086

Refer to ING113086 CSR for a full presentation and discussion of Week 48 results (m5.3.5.1 ING113086 Week 48 CSR).

In this multicenter, double-dummy-blinded, Phase III, non-inferiority study, HIV-1 infected ART-naive adults with HIV-1 RNA 1000 c/mL and no evidence of viral resistance were randomized 1:1 to receive DTG 50 mg once daily or RAL 400 mg BID, in addition to investigator-selected backbone NRTIs of either TDF/FTC or ABC/3TC. Subjects were stratified by screening HIV-1 RNA ( and >100,000 c/mL) and backbone NRTI selection. The primary endpoint was proportion of subjects with HIV-1 RNA <50 c/mL through Week 48 (FDA “snapshot” algorithm).

Eight hundred twenty-seven subjects were randomized (DTG n=413, RAL n=414). At Baseline the median age was 36 years, 14% were female, 15% non-white, 28% had HIV-1 RNA >100,000 c/mL, and 41% used ABC/3TC as their background dual NRTI. Proportion of subjects achieving the primary endpoint was 88% for DTG and 85% for RAL; difference (2.5%; 95% CI: -2.2% to 7.1%) met 10% non-inferiority criteria. For subjects with HIV-1 RNA >100,000 c/mL, response rate was 82% for DTG vs 75% for RAL. Secondary analyses supported non-inferiority: HIV-1 RNA < 50 c/mL per- protocol (DTG 90% vs RAL 88%), treatment-related discontinuation=failure (93% vs 92%) and virologic non-response (5% vs 8%). Median CD4+ cell count increases were similar (230 cells/mm3 each). At virologic failure, there was no genotypic integrase or NRTI resistance in the DTG group vs 1 subject and 4 subjects, respectively, in the RAL group.

At Week 48, once-daily DTG was non-inferior to twice daily RAL in treatment-naïve HIV-1 infected subjects, with no evidence of emergent resistance to DTG in virologic failure. DTG has shown rapid and durable antiviral responses and could be an option for first-line HIV treatment.

44 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

2.1.2. Study ING114467

Refer to ING114467 CSR for a full presentation and discussion of Week 48 results (m5.3.5.1 ING114467 Week 48 CSR).

ING114467 is a double-blind, double-dummy, non-inferiority Phase III study in therapy- naïve adults with HIV-1 RNA ≥1000 c/mL, randomized subjects to DTG 50 mg + ABC/3TC once daily or EFV/TDF/FTC once daily.

Eight hundred thirty-three subjects enrolled in the study (DTG + ABC/3TC n=414, Atripla n=419); 16% were females and 32% were non-white. At Week 48, 88% of DTG + ABC/3TC and 81% of EFV/TDF/FTC subjects had HIV-1 RNA <50 c/mL confirming non-inferiority (Table 14). Using pre-specified testing procedures, statistical superiority was concluded (p=0.003). The statistically significant difference in response rates noted in ING114467 was primarily due to lower discontinuations due to AEs on the DTG regimen. Both time to virologic suppression and change from Baseline in CD4+ favored the DTG arm and were significant. Protocol defined virological failure was 4% in each arm. No INI or NRTI resistance was observed in the DTG arm vs. 1 NRTI resistance associated mutation (RAM) and 4 NNRTI RAMs on EFV/TDF/FTC. DTG + ABC/3TC was highly effective and better tolerated through 48 weeks than EFV/TDF/FTC single- tablet regimen. DTG has shown rapid and durable antiviral responses.

Table 14 ING114467 Week 48 Study Data

DTG 50 mg +ABC/3TC EFV/TDF/FTC Difference once daily once daily [95% CI] (N=414) (N=419) (P value) Proportion <50 c/mL (Snapshot [MSDF]) 364 / 414 (88%) 338 / 419 (81%) 7.4% [2.5, 12.3] P=0.003 Proportion <50 c/mL (Per protocol) 362 / 403 (90%) 335 / 412 (81%) 8.7% [3.9, 13.4] Median time to <50 c/mL and hazard ratio 28 days 84 days 2.3 [2.0; 2.7] P<0.0001 Change from Baseline in CD4+ cells/mm3 267 208 59 [33, 84] P<0.001 Data Source: ING114467 Week 48 CSR Table 7.1, Table 7.2, Table 7.11, Table 7.14

2.1.3. Study ING111762

Refer to ING111762 CSR for a full presentation and discussion of Week 24 results (m5.3.5.1 ING111762 CSR).

ING111762 is a double-dummy-blinded, Phase III, non-inferiority study, in HIV-1 infected ART-experienced, integrase inhibitor naive adults with 2 consecutive HIV-1 RNA values >400 c/mL (or 1 value >1000 c/mL). Subjects were required to have at least 2 class resistance, and have one fully active agent available to construct the background therapy (no more than 2 ARTs total). Subjects were randomized 1:1 to receive DTG

45 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

50 mg once daily or RAL 400 mg BID, in addition to this investigator-selected resistance test guided background regimen. Subjects were stratified by screening HIV-1 RNA (50,000 or >50,000 c/mL), investigator specified number of fully active agents in the background regimen (2, <2), and DRV use (No DRV/RTV use or DRV/RTV with primary PI mutations vs. DRV/RTV use without primary PI mutations). The primary endpoint is the proportion of subjects with HIV-1 RNA <50 c/mL through Week 48 (Snapshot [MSDF]). The proportion of subjects with HIV-1 RNA <50 c/mL is a secondary study endpoint and is the principal analysis for the Week 24 study report.

Seven hundred and nineteen subjects were randomized (DTG n=357, RAL n=362) into the study and received at least one dose of investigational product. Four additional subjects were excluded from the ITT analyses for GCP issues at one site in Russia. Therefore, the modified ITT population for the primary efficacy analysis included 715 subjects. At Baseline the median age was 43 years, 32% were female, 42% were African American/African Heritage, and 49% of subjects had at least 3 class resistance.

Virologic suppression (HIV-1 RNA <50 c/mL) in the DTG arm (79%) was statistically superior to the RAL arm (70%), based on the Week 24 prespecified analysis of outcomes of the FDA Snapshot (MSDF) algorithm with the mITT-E Population (adjusted treatment difference and 95% CI 9.7 [3.4, 15.9], p=0.003). This finding demonstrates a statistically significant difference in favor of DTG and was supported by additional analyses including: Per-Protocol (DTG: 81%, RAL: 72%), and treatment-related discontinuation=failure (DTG: 86%, RAL: 78%).

Median CD4+ cell count increases were similar (DTG: 99.0 cells/mm3; RAL: 93.0 cells/mm3) (ING111762 Week 24, Section 6.2.2). There were fewer virologic nonresponders using the Snapshot (MSDF) algorithm through Week 24 in the DTG group compared to the RAL group (DTG: 15%; RAL: 24%). This result was driven by data within the window for HIV-1 RNA not being <50 c/mL (DTG: 11%; RAL: 18%). At virologic failure, there was also a statistically significant difference in favor of DTG for the proportion of subjects harboring virus with evidence of INI Resistance by Week 24 (DTG 2/354 [0.6%]; RAL 10/361 [2.8%]; p=0.016).

2.1.4. Study ING112574

Refer to ING112574 CSR for a full presentation and discussion of Week 24 results (m5.3.5.2 ING112574 Week 24 CSR).

ING1122574 examined the efficacy of DTG 50 mg BID in patients with resistance to multiple ARV classes, including INIs.

RAL and/or EVG-resistant (current or historical) adult subjects with screening plasma HIV-1 RNA 500 c/mL and resistance to 2 other ART classes received open-label DTG 50 mg BID while continuing their failing regimen (without RAL/EVG). At Day 8 the background regimen was optimized and DTG continued. Activity of the OBR was determined by Monogram Net Assessment. Primary endpoints were antiviral efficacy at Day 8 and Week 24.

46 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

One hundred eighty-three subjects enrolled, 124 with INI-resistance at Screening and 59 with historical resistance (but no resistance at Screening). The population enrolled was advanced: at Baseline median CD4+ was 140 cells/mm3, median prior ART was 13 years, 56% were CDC Class C, 79% had 2 NRTI, 75% 1 NNRTI, and 70% 2 PI resistance- associated mutations, and 62% had non-R5 HIV detected (Data Source: ING112574 Week 24 CSR, Section 5, Table 12.11 and Table 12.45).

Of the 114 subjects who had the opportunity to complete 24 weeks on study before data cutoff, 72 (63%) had <50 c/mL RNA at Week 24 (Snapshot [MSDF]). Mean HIV-1 RNA declined by 1.4 log10 c/mL (95% CI: 1.3, 1.5; p<0.001) at Day 8; response differed by genotype pathway (Table 15).

Table 15 Response by Primary INI Mutations at Baseline

Primary INI mutations at n Mean HIV RNA (log10) Change % >1 log10 HIV RNA decline or Baseline (BL) from BL (SD) at Day 8 <50 c/mL at Day 8 TOTAL 182 -1.4 (0.61) 82% T66 1 -1.9 100% Y143 28 -1.7 (0.42) 96% N155 33 -1.4 (0.51) 82% Q148 + 1 secondary mutationa 32 -1.1 (0.51) 69% Q148 + 2 secondary mutationsa 20 -1.0 (0.81) 48% 2 primary mutations 8 -1.4 (0.76) 75% No primary mutations 60 -1.6 (0.55) 95% Data Source: ING112574 Week 24 CSR Table 7.6, Table 7.42 and Table 12.112 a. Key secondary mutations comprised G140A/C/S, L74I, E138A/K/T

In subjects with Q148 pathway mutations, virologic response decreased with increasing number of secondary mutations. Assessing all subjects who had the opportunity to reach Week 24 before the data cut-off, 63% of this Week 24 ITT-E population (N=114) achieved viral suppression to <50 c/mL based on the Snapshot (MSDF) algorithm (Data Source: ING112574 Week 24 CSR Table 7.21). Background overall susceptibility score (OSS) was not associated with Week 24 response: percentage of subjects <50 c/mL were 83%, 63%, 59% and 69% for OSS 0, 1, 2 and >2, respectively (ING112574 Week 24 CSR, Table 7.31).

A majority of the highly treatment-experienced subjects in ING112574 achieved suppression with DTG-based therapy. Responses were associated with Baseline IN genotype but not OSS, highlighting the importance and independence of DTG antiviral activity.

2.2. Supportive Efficacy Studies

2.2.1. Study ING111521

Refer to ING111521 Clinical Pharmacology Study Report (CPSR) for a full presentation and discussion of results (m5.3.4.2 ING111521 CPSR).

47 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

The objective of this study was to evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/ pharmacodynamics of DTG, a next-generation HIV integrase inhibitor (INI), as short-term monotherapy.

Study ING111521 was a Phase IIa, randomized, double-blind, dose-ranging study.

In this study, INI-naive, HIV-1-infected adults currently off antiretroviral therapy were randomized to receive DTG (2, 10, or 50 mg) or placebo once daily for 10 days in an eight active and two placebo randomization scheme per DTG dose. Placebo patients were pooled for the purpose of analysis.

Thirty-five patients (n=9 for DTG 2 mg, n=9 for DTG 10 mg, n=10 for DTG 50 mg, and n=7 for placebo) were enrolled. Baseline characteristics were similar across dose groups. Significant reductions in plasma HIV-1 RNA from Baseline to Day 11 were observed for all DTG dose groups compared with placebo (p <0.001), with a mean decrease of 1.51 to 2.46 log10 c/mL. In addition, a well characterized dose-response relationship was observed for viral load decrease. Most patients (7/10, 70%) receiving DTG 50 mg achieved plasma HIV-1 RNA less than 50 c/mL.

The pharmacokinetic variability was low (coefficient of variation, range 25 to 50%). Plasma HIV-1 RNA reduction was best predicted by Cτ using an Emax model (Figure 7).

Based on this model, EC90 was estimated at 0.32 g/mL. The range of C values for subjects receiving 50 mg once daily was 0.60 to 1.17 g/mL which were on the plateau of the concentration-response curve. These data indicate the 50 mg dose achieves plasma concentrations in excess of those required for maximal antiviral activity.

48 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Figure 7 Relationship between Reduction in Log10 Plasma HIV-1 RNA from Baseline to Day 11 and Day 10 Ctau (Model 1), Best Model in ING111521

3.0

2.5

2.0

1.5

1.0

0.5 Emax = 2.60 log10 EC50 = 35.68 ng/mL

0.0 Plasma HIV-1 Copies/mL) Plasma (log10 from to RNA Day 11 Baseline Change 0 200 400 600 800 1000 1200

Ctau on Day 10 (ng/mL)

Data Source: ING111521 CPSR (in text Figure 1)

2.2.2. Study ING112276

Refer to ING112276 CSR for a full presentation and discussion of Week 96 results (m5.3.5.1 ING112276 Week 96 CSR).

SPRING-1 is a four-arm dose-ranging study designed to select a Phase III dose; all arms were continued through 96 weeks to assess durability of response and safety profiles across DTG doses.

In this multicenter, partially-blinded, Phase IIb, dose-ranging study, therapy-naive HIV- infected adults were randomized 1:1:1:1 to receive DTG 10, 25, or 50 mg once daily or EFV 600 mg once daily with TDF/FTC or ABC/3TC and stratification based on screening HIV-1 RNA (viral load) and NRTI selection. The primary endpoint for this study was proportion of subjects with plasma HIV-1 RNA <50 c/mL at Week 16, with a planned analysis at Week 96.

Two hundred and five subjects received study drug: 14% female, 20% non-white, 21% with Baseline HIV-1 RNA >100,000 c/mL, and 33% receiving ABC/3TC as background dual NRTI. At Week 96 the proportion of subjects with plasma HIV-1 RNA <50 c/mL (TLOVR) was 88% for the DTG 50 mg dose vs. 72% for EFV; responses in the DTG 10 mg and 25 mg arms were 79% and 78%, respectively. There were no cases of protocol defined virologic failure (PDVF, confirmed viral load >400 c/mL) on the DTG

49 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

50 mg arm through 96 weeks; no new cases of PDVF occurred on any arm between Week 48 and 96. The difference in response by TLOVR analysis for the DTG 50 mg arm compared with the DTG 10 mg and 25 mg arms was driven by the subjects experiencing a transient, low-level virologic rebound. As detailed in Table 16, for the majority of cases of virologic non-response, the viral load during rebound typically remained <400 c/mL, PDVF criteria were not met, and there was re-suppression to <50 c/mL after the transient, detectable viremia. Thus, even at the 10 mg DTG dose, a majority of subjects achieved and maintained an undetectable viral load, suggesting that no dose adjustment would be required to achieve long-term virologic control when DTG is used with medications that lower the overall DTG exposure.

To approximate the response rate expected with Snapshot (MSDF), virologic response rates using the MDF (Missing and Discontinuation = Failure) analysis (Table 16) and details on treatment switches are presented below.

Table 16 Proportion of Subjects with Plasma HIV-1 RNA <50 c/mL by Visit (MDF analysis)

Visit DTG EFV 10 mg 25 mg 50 mg 600 mg (N=53) (N=51) (N=51) (N=50) n (%) n (%) n (%) n (%) Baseline 0/53 0/51 0/51 0/50 Week 1 6/53 (11) 4/51 (8) 4/51 (8) 3/50 (6) Week 2 22/53 (42) 19/51 (37) 12/51 (24) 6/50 (12) Week 4 38/53 (72) 35/51 (69) 31/51 (61) 10/50 (20) Week 8 46/53 (87) 46/51 (90) 44/51 (86) 18/50 (36) Week 12 50/53 (94) 46/51 (90) 45/51 (88) 27/50 (54) Week 16 51/53 (96) 47/51 (92) 45/51 (88) 32/50 (64) Week 20 49/53 (92) 46/51 (90) 45/51 (88) 38/50 (76) Week 24 50/53 (94) 46/51 (90) 47/51 (92) 40/50 (80) Week 48 47/53 (89) 46/51 (90) 43/51 (84) 41/50 (82) Week 60 47/53 (89) 48/51 (94) 47/51 (92) 44/50 (88) Week 72 51/53 (96) 45/51 (88) 47/51 (92) 41/50 (82) Week 84 49/53 (92) 46/51 (90) 46/51 (90) 41/50 (82) Week 96 46/53 (87) 41/51 (80) 44/51 (86) 39/50 (78) Data Source: ING112276 Week 96 CSR Table 7.4

Four subjects (3 DTG, 1 EFV) had an on-therapy switch of NRTI during the study.

 Subject 92 (randomized to receive DTG 10 mg) received ABC/3TC beginning 17 SEP , switching to Truvada 7 SEP b*. The HIV-1 RNA at the time of the switch was <50 c/mL. This subject is a responder in the MDF analysis at Week 96.  Subject 611 (randomized to receive DTG 25 mg) received Truvada beginning 02 SEP , switching to ABC/3TC 24 SEP a*. The Baseline HIV-1 RNA was 154976 c/mL, and at the time of the switch was 382 c/mL. This subject is a non- responder in the MDF analysis at Week 96. a*: The year b*: Following year * 新薬承認情報提供時に置き換え 50 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

 Subject 60 (randomized to receive DTG 25 mg) received ABC/3TC beginning 03 NOV . On 17 FEB b*, Truvada was dispensed to the subject in error. Once the error was discovered, the subject was switched back to ABC/3TC on 21 MAR b*. The HIV-1 RNA at the time of both switches was <50 c/mL. This subject is a responder in the MDF analysis at Week 96.  Subject 821 (randomized to receive EFV) received ABC/3TV beginning 06 OCT . The subject developed symptoms on 21 OCT a* which the investigator thought were associated with a possible hypersensitivity reaction to abacavir so both EFV and ABC/3TC were stopped. The subject was switched to COMBIVIR™ on 27 OCT a* and EFV was also resumed at that time. The symptoms returned, and the investigator diagnosed an allergy to EFV, so the subject was withdrawn. The Baseline HIV-1 RNA was 26584 c/mL, and at the time of the switch was 209 c/mL. This subject is a non-responder in the MDF analysis at all timepoints through Week 96. Three other subjects (Subjects 46, 101 and 927) were placed on short-term commercial supplies of EFV and/or ABC/3TC/Truvada due to shipping delays of study supplied IP and NRTIs. These subjects appear on the listing of subjects with changes in antiretroviral therapy to record the temporary change in medication source, but their actual NRTI treatment was not switched during the study.

No genotypic or phenotypic evidence of INI or NNRTI resistance was observed through Week 96 in any of the treatment arms; no NRTI mutations were observed through 96 weeks at the selected DTG 50 mg dose. The median change from Baseline in CD4+ cells in the combined DTG arms trended higher for DTG (combined) (+338.5 cells/mm3) versus EFV (+301 cells/mm3) (p=0.155).

Once daily, unboosted DTG demonstrated durable antiviral activity for all dosing arms with 88% responders through 96 weeks at the selected 50 mg once daily dose.

2.2.3. Study ING112961

Refer to ING112961 CSR for a full presentation and discussion of Cohort I Week 96/Cohort II Week 48 results (m5.3.5.2 ING112961 Cohort I Week 96/Cohort II Week 48 CSR).

Study ING112961 aimed to assess the antiviral activity through Week 48 of DTG given to HIV-infected subjects with RAL resistance.

Two sequential cohorts of HIV+ adults with genotypic resistance to RAL and to ≥2 other ARV classes at Baseline received DTG 50 mg once daily (Cohort I) or twice daily (Cohort II). All continued failing background therapy through to Day 11 which was then to be optimized. The inclusion of at least one fully active drug in the OBR was required for Cohort II.

The Baseline characteristics of the 51 subjects enrolled and antiviral responses at Day 11 and Week 48 are provided below.

a*: The year b*: Following year * 新薬承認情報提供時に置き換え 51 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 17 Key Baseline Characteristics

Baseline Characteristics ING112961 Cohort I (n=27) Cohort II (n=24) DTG 50 mg once daily + BR DTG 50 mg BID + BR Median CD4+cells/mm3 (range) 114 (19,729) 202 (19, 528) Median HIV-1 RNA log10c/mL (range) 4.48 (2.64, 6.06) 4.26 (3.32, 5.84) Q148 + ≥1 9 (33%) 11 (46%) N155 or Y143 or other 18 (67%) 13 (54%) Median RAL FC (range) 161 (0.57, 165) 128 (0.78, 183) Median DTG FC (range) 1.5 (0.6, 35) 2.7 (0.9, 9.5) Median years prior ARV (range) 14 (4, 21) 15 (3, 22) PSS of OBR =0/1/≥2 12/7/8 1/9/14 Data Source: ING112961 Cohort I Week 96/Cohort II Week 48 CSR Table 6.21, Table 6.23, Table 6.30, Table 12.25, Table 12.26 and Table 12.48

Table 18 Antiviral Response to DTG

ING112961 Cohort I (n=27) Cohort II (n=24) DTG 50 mg once daily + BR DTG 50 mg BID + BR Mean Plasma HIV-1 RNA log10c/mL -1.45 (S.D=0.77) -1.76 (S.D=0.54) reduction at Day 11a <50 c/mL (TLOVR) at Week 48 9/27 (33%) 17/24 (71%) <400 c/mL (TLOVR) at Week 48 13/27 (48%) 18/24 (75%) Data Source: ING112961 Cohort I Week 96/Cohort II Week 48 CSR Table 7.31, Table 7.11, and Table 7.14 a. p=0.017 for treatment difference was derived using multivariate linear regression model (F-test) by adjusting for Baseline viral load, DTG FC, IN genotypic pathway, PSS of failing background regimen.

To approximate the response rate expected with Snapshot (MSDF), virologic response rates using the MDF (Missing and Discontinuation = Failure) analysis (Table 19) and details on treatment switches are presented below.

52 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 19 Proportion of Subjects with Plasma HIV-1 RNA <50 c/mL by Visit (MDF Analysis)

Visit ING112961 Cohort I (n=27) Cohort II (n=24) DTG 50 mg once daily + BR DTG 50 mg BID + BR n (%) n (%) Baseline 0 0 Day 6-8 1 (4) 1 (4) Day 11 3 (11) 4 (17) Day 21 5 (19) 6 (25) Week 4 10 (37) 12 (50) Week 8 10 (37) 15 (63) Week 12 12 (44) 16 (67) Week 16 12 (44) 18 (75) Week 20 9 (33) 18 (75) Week 24 12 (44) 17 (71) Week 32 10 (37) 20 (83) Week 40 10 (37) 16 (67) Week 48 9 (33) 16 (67) Week 60 9 (33) Week 72 9 (33) Week 84 8 (30) Week 96 7 (26) Data Source: ING112961 Cohort I Week 96/Cohort II Week 48 CSR Table 7.26

Two subjects had an on-therapy switch of ART prior to Week 48.

Subject 1811 from Cohort I (DTG 50 mg once daily) on ABC and TDF switched to Truvada and DRV/RTV on Day 24. This subject never achieved plasma HIV-1 RNA suppression to <50 c/mL prior to withdrawal for PDVF and is therefore an non-responder in the MDF and snapshot analyses.

Subjects 2415 from Cohort II (DTG 50 mg BID) added MVC on Day 65. This subject achieved a plasma HIV-1 RNA <400 c/mL at Week 48 and has continued on study, but never achieved plasma HIV-1 RNA suppression to <50 c/mL and is therefore an non- responder in the MDF and snapshot analyses.

DTG exerted potent antiviral activity in highly treatment-experienced, RAL-resistant subjects. An improved Week 48 response rate was observed in Cohort II. The Cohort II efficacy and safety supported the higher potency of DTG 50 mg BID in this highly treatment experienced, INI resistant patient population.

3. COMPARISON AND ANALYSES OF RESULTS ACROSS STUDIES

Data from these studies provide evidence of the efficacy of DTG for the treatment of HIV infection in ART-naive, ART-experienced and INI-resistant adult populations. In this section, efficacy data are not integrated due to significant variations in study designs,

53 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy patient populations, background therapy, and comparator arms (Section 1.7); therefore, efficacy data are presented in a side-by-side format for comparative purposes.

Data summarized include study population, primary and secondary efficacy endpoints, and efficacy data for specific subgroups.

Studies in INI-naive subjects:

 ART-naive: ING113086 (DTG 50 mg once daily), and ING114467 (DTG 50 mg+ABC/3TC),  ART-experienced: ING111762 (DTG 50 mg once daily + BR). Studies in INI-resistant subjects:  ING112961 Cohort II DTG 50 mg BID and ING112574 (DTG 50 mg BID). 3.1. Study Populations

3.1.1. ART-Naïve subjects

In ING113086 and ING114467, the percentages of subjects from the DTG treatment arms who prematurely withdrew for any reason were 11% and 12%, respectively. Specifically, with respect to DTG treatment arms, withdrawals due to an adverse event, lack of efficacy and protocol deviation were not common (4% of subjects for each reason) (Table 20).

54 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 20 Subject Accountability

Population ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily All subjects screened, N 413 414 422 422 Randomized, N 413 414 422 422 Completion Status, n (%) Completed 0 0 0 0 Withdrawal 47 (11) 56 (14) 51 (12) 84 (20) Ongoing 364 (89) 355 (86) 363 (88) 335 (80) Premature Withdrawal, n (%) 47 (11) 56 (14) 51 (12) 84 (20) Adverse Event 8 (2) 6 (1) 10 (2) 42 (10) Lack of Efficacy 16 (4) 24 (6) 14 (3) 13 (3) Protocol Deviation 13 (3) 11 (3) 7 (2) 7 (2) Lost to Follow-Up 4 (<1) 7 (2) 14 (3) 9 (2) Subject Reached Protocol-defined 2 (<1) 1 (<1) 0 0 stopping criteria Withdrew consenta 4 (<1) 7 (2) 5 (1) 11 (3) Subject relocated 2 (<1) 1 (<1) 2 (<1) 2 (<1) Burden of/lack of access to travel 1 (<1) 0 0 0 Data Source: ING113086 Week 48 CSR Table 6.1 and Table 6.3; ING114467 Week 48 CSR Table 6.1 and Table 6.4. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group. a. Sub-reasons provided where known

Overall, the percentage of protocol deviations was 6% (Table 21). The number of protocol deviations was deemed not to have significantly interfered with the interpretation of the results. See individual CSRs for additional details on protocol deviations (ING113086 Week 48 CSR, Section 5.2, and ING114467 Week 48 CSR, Section 5.2).

55 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 21 Summary of Protocol Deviations Leading to Exclusion from the PP Population

Protocol Deviation ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=419 N=411 N=411 N=414 Any deviation, n (%) 24 (6) 24 (6) 11 (3) 7 (2) Reasons, n (%) Inclusion/exclusion criteria 5 (1) 2 (<1) 1 (<1) 1 (<1) Subject took/received incorrect IP 1 (<1) 1 (<1) 1 (<1) 0 >10% of total treatment time Use of prohibited medication 9 (2)b 10 (2)b 2 (<1)c 3 (<1)c Permanent discontinuation of IP due 12 (3) 10 (2) 6 (1) 4 (<1) to protocol deviation IP Interruption for >10% of total 0 0 2 (<1) 1 (<1) treatment time Data Source: ING113086 Week 48 CSR Table 6.7 and Table 6.8; ING114467 Week 48 CSR Table 6.9. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group. Some subjects may have multiple deviations leading to exclusion from the PP population; deviations may appear in more than one category. a. ING113086: Prohibited medications included prednisone, metformin, imiquimod, betamethasone, cortisone, methylprednisolone, bleomycin, cyclophosphamide, docetaxel, epirubicin, and fluorouracil. b. ING114467: Prohibited medications included prednisone, methylprednisolone, methotrexate and infliximab.

The number of subjects analyzed was consistent across the treatment groups within each study (Table 22). See Section 1.9.2 for definitions of analysis populations.

Table 22 Analysis Populations

Population ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily All randomized subjects 413 414 422 422 Intent-to-Treat (Exposed) 411 411 414 419 Per Protocol 387 387 403 412 On-treatment Genotype Resistance 14 24 11 9 On-treatment Phenotype Resistance 13 24 11 9 Data Source: ING113086 Week 48 CSR Table 6.1 and Table 9.1; ING114467 Week 48 CSR Table 6.1. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group.

56 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Overall, enrolment into each trial reflects the demographic characteristic of the general population with HIV(Table 23). There were no meaningful differences among treatment groups with respect to gender or age; median age was 35 years. The majority of subjects in both studies were male and White/Caucasian. Study ING114467 included a greater percentage of Black and Other race subjects than Study ING113086.

Table 23 Summary of Demographic Characteristics (ITT-E population)

Demographic Characteristic ING113086 ING114467 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=419 N=411 N=411 N=414 Age (years) Median (Range) 37 35 36 35 (18, 68) (18, 75) (18, 68) (18, 85) Sex, n (%) Male 348 (85) 355 (86) 347 (84) 356 (85) Ethnicity, n (%) Hispanic/Latino 43 (10) 52 (13) 56 (14) 56 (13) Race, n (%) African American/ African Heritage 49 (12) 39 (9) 98 (24) 99 (24) American Indian or Alaska Native 7 (2) 9 (2) 13 (3) 17 (4) Asian - 6 (1) 10 (2) 9 (2) 9 (2) Central/ South Asian Heritage 2 (<1) 0 2 (<1) 3 (<1) Japanese/ East Asian/ Southeast Asian 4 (<1) 10 (2) 7 (2) 6 (1) Native Hawaiian or other Pacific Islander 2 (<1) 0 0 0 White – White/Caucasian/ European Heritage 346 (84) 352 (86) 284 (69) 285 (68) Other 1 (<1) 1 (<1) 10 (2) 6 (1) Data Source: ING113086 Week 48 CSR Table 6.9 and Table 6.10; ING114467 Week 48 CSR Table 6.10 and Table 6.11. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group.

Other Baseline characteristics were well distributed across the studies and treatment arms (Table 24). Median Baseline HIV-1 RNA ranged from 4.52 to 4.70 log10 c/mL, and median Baseline CD4+ cell count ranged from 332 to 362 cells/mm3. Overall, most subjects had negative test results at screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection (87% to 93%), and were in CDC Class A (83% to 87%).

57 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 24 Summary of Baseline Characteristics (ITT-E population)

Baseline Characteristic ING113086 ING114467 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 Baseline HIV-1 RNA (log10 c/mL) Median (range) 4.52 4.58 4.67 4.70 (1.59, 6.61) (2.67,6.70) (3.06, 6.46) (2.48, 6.35) Baseline HIV-1 RNA (c/mL), n (%) 100,000 297 (72) 295 (72) 280 (68) 288 (69) >100,000 114 (28) 116 (28) 134 (32) 131 (31) Baseline CD4+ cell counts cells/mm3 Median CD4+ (range) 359.0 362.0 331.5 339.0 (19, 1119) (19, 1033) (19, 1022) (19, 1320) Baseline CD4+ (cells/mm3), n (%) <50 8 (2) 6 (1) 13 (3) 14 (3) 50 to <200 47 (11) 44 (11) 44 (11) 48 (11) 200 to <350 144 (35) 139 (34) 163 (39) 159 (38) 350 to <500 126 (31) 136 (33) 131 (32) 128 (31)  500 86 (21) 86 (21) 63 (15) 70 (17) <300 - - - - 300 - - - - Hepatitis B & C test results, n (%)a B only 7 (2) 8 (2) 1 (<1) 1 (<1) C only 41 (10) 35 (9) 27 (7) 29 (7) B and C 1 (<1) 0 0 0 Neither 359 (87) 363 (89) 385 (93) 385 (92) Missing 3 (<1) 4 (<1) 1 (<1) 4 (<1) CDC Category, n (%) A: Asymptomatic or 359 (87) 347 (84) 343 (83) 350 (84) lymphadenopathy or acute HIV B: Symptomatic, not AIDS 43 (10) 55 (13) 53 (13) 52 (12) C: AIDS 9 (2) 9 (2) 18 (4) 17 (4) NRTI backbone TDF/FTC 242 (59) 247 (60) - 419 ABC/3TC 169 (41) 164 (40) 414 - Data Source: ING113086 Week 48 CSR Table 6.12, Table 6.13, Table 6.20, Table 6.21, and Table 6.26; ING114467 Week 48 CSR Table 6.13, Table 6.14, Table 6.21, and Table 6.22. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group. a. ING113086: Denominator reflects subjects with result for Hepatitis B or Hepatitis C (RAL N=410).

58 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

3.1.2. ART-Experienced, INI-Naïve Subjects

In ING111762, the percentage of subjects from the DTG treatment arm who prematurely withdrew for any reason was 14%. Specifically, withdrawal due to an adverse event, lack of efficacy and protocol deviation was not common (4% of subjects for each reason in the DTG Arm) (Table 25).

Due to the challenge of finding this patient population, enrollment occurred over a 15 month period (November 2010 – January 2012). Therefore, by the time of this Week 24 analysis, a total of 111 subjects (31%) in the RAL group had completed the Week 48 visit and were discontinued from the study as planned. Additionally 137 subjects (42%) in the DTG arm had completed the Week 48 visit and continued in the Open Label Phase of the study (ING111762 Week 24 CSR Table 6.5).

Table 25 Subject Accountability (mITT-E Population)

Population ING111762 DTG 50 mg RAL 400 mg Total once daily +BR BID +BR n (%) n (%) n (%) Completion Status Completed, n (%)a 1 (<1) 111 (31) 112 (16) Ongoing at time of analysis, n (%)b 305 (86) 189 (52) 494 (69) Withdrawal, n (%) 48 (14) 61 (17) 109 (15) Primary Reason for Withdrawal Adverse Event 3 (<1) 12 (3) 15 (2) Lack of Efficacy (Virologic Failure) 15 (4) 26 (7) 41 (6) Protocol Deviationc 10 (3) 6 (2) 16 (2) Prohibited medication use 2 (<1) 2 (<1) 4 (<1) Non-compliance with IP treatment 3 (<1) 1 (<1) 4 (<1) Prohibited ART 5 (1) 1 (<1) 6 (<1) Non-compliance with protocol procedures 0 1 (<1) 1 (<1) Subject met the GSK defined Liver Chemistry 5 (1) 1 (<1) 6 (<1) Stopping Criteriad Lost to Follow-Upc 5 (1) 10 (3) 15 (2) Subject was incarcerated 0 1 (<1) 1 (<1) Investigator discretion 1 (<1) 2 (<1) 3 (<1) Withdrew Consentc 9 (3) 4 (1) 13 (2) Subject relocated 1 (<1) 2 (<1) 3 (<1) Burden of time / travel 1 (<1) 1 (<1) 2 (<1) Data Source: ING111762 Week 24 CSR Table 6.3 a. Based on subjects completing study: defined as 1) completing the Randomized Phase and not enrolling in the Open-label Phase or 2) completing the Randomized Phase, continuing into and completing the Open-label Phase b. Includes subjects still in the Randomized Phase or participating in the Open-label Phase c. Sub-reasons provided where known. d. Subjects who were withdrawn from the study due to meeting GSK-defined liver chemistry stopping criteria are discussed in ING111762 Week 24 Section 8.7.2.

A total of 53 (7%) subjects had protocol deviations leading to exclusion from the per protocol analyses (DTG: 31; RAL: 22) (Table 26). The number of protocol deviations was deemed not to have significantly interfered with the interpretation of the results. See

59 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

CSR for additional details on protocol deviations (ING111762 Week 24 CSR, Section 5.2).

Table 26 Summary of Protocol Deviations (mITT-E Population) Leading to Exclusion from the Per Protocol Population Protocol Deviationsa ING111762 DTG 50 mg RAL 400 mg Total once daily +BR BID + BR N=354 N=361 N=715 n (%) n (%) n (%) Any deviation 31 (9) 22 (6) 53 (7) Other incorrect ART regimensb 15 (4) 4 (1) 19 (3) Permanent discontinuation of IP due to protocol deviationc 10 (3) 6 (2) 16 (2) Inclusion/Exclusion Criteria 6 (2) 3 (<1) 9 (1) Use of prohibited non-ART medication potentially impacting 1 (<1) 5(1) 6 (<1) IP exposure Non-permitted change of ARTd 1 (<1) 4 (1) 5 (<1) IP interruption for >10% of total treatment time 2 (<1) 2 (<1) 4 (<1) Use of prohibited ART combinations potentially impacting IP 1 (<1) 2 (<1) 3 (<1) exposure Data Source: ING111762 Week 24 CSR Table 6.9 a. Some subjects may have multiple deviations leading to exclusion from the PP population; deviations may appear in more than one category. b. Includes subjects with Screening PSSf to BR of 0 (DTG: 8, RAL: 2) (or results unable to be obtained) and subjects receiving more than 2 ART in their BR (DTG: 7, RAL: 2). c. Primarily for non-compliance with IP or use of prohibited ART d. Includes but is not limited to switches to correct the number of BR components and switches to correct improperly administered etravirine (incorrectly administered in the absence of a boosted PI)

The number of subjects analyzed was consistent across the treatment groups with the exception of the PDVF populations where there were higher percentages of subjects in the RAL treatment group contributing to these populations (Table 27). See Section 1.9.2 for definitions of analysis populations.

Table 27 Populations Analyzed Populations ING111762 DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N (%) N (%) All Subjects Screeneda 360 (50) 364 (50) 1441 Randomized 360 (50) 364 (50) 724 Intent-to-Treat Exposed 357 (50) 362 (50) 719 Modified Intent-to-Treat Exposedb 354 (50) 361 (50) 715 Per-Protocol at Week 24 323 (49) 339 (51) 662 Week 24 PDVF Genotypic 11 (26) 31 (74) 42 Week 24 PDVF Phenotypic 11 (27) 30 (73) 41 Data Source: ING111762 Week 24 CSR Table 6.1 a. 717 (50%) subjects were screened and not randomized b. Four subjects (DTG: 3; RAL: 1) from one site in Russia (Site 083523, Investigator 096536) were removed from the ITT-E Population following site closure due to GCP non-compliance on another ViiV sponsored study.

60 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

The study population was very diverse in both race and gender, with 42% African American / African heritage and 32% female subjects. Of the 230 women entered in the study, 138 (60%) were enrolled in countries outside of North America and Europe (Data Source: ING111762 Week 24 CSR Table 6.23). The majority of non-white subjects were enrolled in North America (44%) and non-European countries (52%). The median age of the mITT-E population was 43.0 years (Table 28). Twelve (2%) subjects (DTG: 6; RAL: 6) were 65 years of age (Data Source: ING111762 Week 24 CSR Table 7.8).

Table 28 Summary of Demographic Characteristics (mITT-E population)

Demographic Characteristic ING111762 DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 Age In Years, median (range) 42.0 (21-69) 43.0 (18-73) 43.0 (18-73) Sex, n (%) Male 247 (70) 238 (66) 485 (68) Female 107 (30) 123 (34) 230 (32) Ethnicity, n (%) Hispanic/Latino 135 (38) 119 (33) 254 (36) Not Hispanic/Latino 219 (62) 242(67) 461(64) Race, n (%) African American/African Heritage 143 (41) 160 (44) 303 (42) American Indian or Alaska Native 10 (3) 17 (5) 27 (4) Asian 9 (3) 6 (2) 15 (2) Central/South Asian Heritage 2 (<1) 2 (<1) 4 (<1) Japanese/East Asian Heritage/Southeast Asian 7 (2) 4 (1) 11 (2) Heritage Native Hawaiian or other Pacific Islander 1 (<1) 0 1 (<1) White – White/Caucasian/European Heritage 175 (50) 172(48) 347(49) Other/Mixed Race 12 (3) 2 (<1) 14 (2) Data Source: ING111762 Week 24 Table 6.10, Table 6.11 and Table 6.12

Baseline characteristics were well balanced across the treatment groups (Table 29). Study subjects had relatively advanced HIV-1 disease with a median Baseline CD4+ cell count of 200 cells/mm3 and almost half of the study population having CDC Category C Classification at entry. Subjects predominantly had HIV-1 subtype B (68%) and C (14%). In other subjects, a variety of subtypes were seen in small numbers, including A1, AB, AE, AG, BF, CD, complex, F, F1, and G (Data Source: ING111762 Week 24 CSR, Section 5.4).

61 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 29 Summary of Baseline Characteristics (mITT-E population)

Baseline Characteristic ING111762 DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 Baseline HIV-1 RNA (log10 c/mL) Median plasma HIV-1 RNA (range) 4.17 (1.59, 6.79) 4.21 (1.59, 6.54) 4.18 (1.59, 6.79) HIV-1 RNA c/mL, n (%) <1,000 45 (13) 50 (14) 95 (13) 1,000 to <10,000 111 (31) 103 (29) 214 (30) 10,000 to <50,000 93 (26) 101 (28) 194 (27) 50,000 to 100,000 38 (11) 34 (9) 72 (10) >100,000 67 (19) 73 (20) 140 (20) Baseline CD4+ (cells/mm3) Median CD4+ (range) 204.5 (19.0, 1017.0) 193.0 (19.0, 1219.0) 200.0 (19.0, 1219.0) CD4+ (cells/mm3), n (%) <50 62 (18) 59 (16) 121 (17) 50 to <200 111 (31) 125 (35) 236 (33) 200 to <350 82 (23) 79 (22) 161 (23) 350 to <500 56 (16) 59 (16) 115 (16) 500 43 (12) 39 (11) 82 (11) Hepatitis B & C test results, n (%) B only 17 (5) 16 (4) 33 (5) C only 31 (9) 48 (13) 79 (11) B and C 1 (<1) 1 (<1) 2 (<1) Neither 288 (81) 271 (75) 559 (78) Missing 17 (5) 25 (7) 42 (6) CDC Category, n (%) A: Asymptomatic or lymphadenopathy or 111 (31) 114 (32) 225 (31) acute HIV B: Symptomatic, not AIDS 70 (20) 89 (25) 159 (22) C: AIDS 173 (49) 158 (44) 331 (46) HIV-1 Cladea, n (%) B 241 (68) 245 (68) 486 (68) C 55 (16) 48 (13) 103 (14) Other 57 (16) 68 (19) 125 (17) Data Source: ING111762 Week 24 CSR Table 6.13, Table 6.14, Table 6.21, Table 6.22, and Table 6.52 a. Clades are at PR/RT mutation region, and there were no assessments of clades at IN mutation region at Baseline.

Prior ART

Of the 715 subjects in the mITT-E Population, 714 subjects had received any ART prior to entering the study (Table 30). One ART-naive subject was randomized based on transmitted resistance and thus had no prior ART listed. This subject enrolled in the study prior to protocol amendment 1, where inclusion criteria were updated to clarify that only ART-experienced subjects could enter the study.

Overall, subjects enrolled in this study had prior treatment with a broad range of ART (Table 30). In line with this high use of various ART, 47% of subjects had previously been exposed to drugs in three or more ART classes (ING111762 Week 24 CSR Table 6.32).

62 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

See ING111762 Week 24 CSR Section 5.6.1 for detail.

Table 30 Summary of Prior ART (mITT-E Population)

DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 Median Duration in Weeks, (range) n= 354 n=360 n=714 Any ART in All Subjects 345.2 (17.3, 1657.6) 309.6 (15.9, 1396.1) 331.6 (15.9, 1657.6) Any ART Subjects with 2-Class n=185 n=179 n=364 Resistance at BL 283.4 (23.0, 1657.6) 262.1 (17.7, 1256.4) 276.6 (17.7, 1657.6) Any ART Subjects with 3-Class or n=169 n=181 n=350 More resistance at BL 432.3 (17.3, 1416.1) 358.7 (15.9, 1396.1) 387.7 (15.9, 1416.1) Number of Prior ART taken, No. (%) Subjects No. of Any ART taken Any ARTI 354 (100) 360 (>99) 714 (>99) 1 0 1 (<1) 1 (<1) 2 7 (2) 7 (2) 14 (2) 3 116 (33) 103 (29) 219 (31) 4 43 (12) 49 (14) 92 (13) 5 37 (10) 44 (12) 81 (11) 6 151 (43) 156 (43) 307 (43) No. of NRTIs taken Any NRTI 354 (100) 360 (>99) 714 (>99) 1 11 (3) 12 (3) 23 (3) 2 138 (39) 134 (37) 272 (38) 3 56 (16) 53 (15) 109 (15) 4 149 (42) 161 (45) 310 (43) No. of NNRTIs taken Any NNRTI 295 (83) 309 (86) 604 (84) 1 238 (67) 245 (68) 483 (68) 2 57 (16) 64 (18) 121 (17) No. of PIs taken Any PI 204 (58) 222 (61) 426 (60) 1 82 (23) 94 (26) 176 (25) 2 56 (16) 56 (16) 112 (16) 3 32 (9) 26 (7) 58 (8) 4 34 (10) 46 (13) 80 (11) No. of Fusion Inhibitors taken Any Fusion inhibitor 17 (5) 12 (3) 29 (4) 1 17 (5) 12 (3) 29 (4) No. of CCR5 antagonist taken Any CCR5 antagonist 4 (1) 10 (3) 14 (2) 1 4 (1) 10 (3) 14 (2) No. of Other ART taken Any Other ART 4 (1) 5 (1) 9 (1) 1 4 (1) 4 (1) 8 (1) 2 0 1 (<1) 1 (<1) No. of INIs taken Any INI 0 1 (<1) 1 (<1) 1 0 1 (<1) 1 (<1) Data Source: ING111762 Week 24 CSR Table 6.28, Table 6.29, Table 6.30 and Table 6.31

63 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Baseline Genotypic and Phenotypic Resistance

Baseline resistance testing indicated that overall, similar proportions of subjects had 2- class resistance (364/715; 51%) versus 3-class resistance or more (351/715; 49%) (Table 31).

Table 31 Summary of Baseline Resistance: Number of Drug Classes to which Subjects are Resistant (mITT-E Population)

ING111762 Baseline Resistance DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 n (%) n (%) n (%) 2 Class Resistance 185 (52) 179 (50) 364 (51) 3 Class Resistance 125 (35) 149 (41) 274 (38) 4 Class Resistance 40 (11) 30 (8) 70 (10) 5 Class Resistance 4 (1) 3 (<1) 7 (<1) Data Source: ING111762 Week 24 CSR Table 6.33

Background Regimen

Background regimens received during the treatment phase of the study were diverse with over 60 different individual regimens being prescribed (Table 32). Eight-five percent (n=605) of subjects were on a boosted PI regimen (Data Source: ING111762 Week 24 CSR Table 6.35). Darunavir/ritonavir (DRV/RTV) was the most commonly administered ART in Europe and North America (74% and 60% respectively), but was only administered to 16% of subjects in the Rest of World region including no use in the Russian Federation or South Africa (Data Source: ING111762 Week 24 CSR Table 6.36), likely reflecting lower levels of access to more recently approved ART in these countries.

Table 32 Summary of Background Antiretroviral Regimen (>=5% in any treatment arm) – mITT-E Population

Background Regimen DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 n (%) n (%) n (%) darunavir/ritonavir, tenofovir 62 (18) 73 (20) 135 (19) lopinavir/ritonavir. tenofovir 40 (11) 40 (11) 80 (11) darunavir/ritonavir, etravirine 33 (9) 40 (11) 73 (10) lopinavir/ritonavir 36 (10) 35 (10) 71 (10) atazanavir/ritonavir, tenofovir 36 (10) 33 (9) 69 (10) darunavir/ritonavir, maraviroc 23 (6) 19 (5) 42 (6) Data Source: ING111762 Week 24 CSR Table 6.35

The study design presented a risk that recruitment of many subjects with resistance to only two classes of ART (most likely to NRTIs and NNRTIs but not PIs) may have highly potent background therapy available to them (i.e. DRV/RTV) such that the

64 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy contribution to virologic success by DTG would be difficult to assess. When enrolment was complete, similar numbers of subjects received DRV/RTV in both the presence and the absence of primary PI mutations and the cap of 170 for DRV/RTV in the absence of primary PI mutations was not reached (Table 33).

Table 33 Summary of Darunavir Use in Background ART Regimen

DRV/RTV Use DTG 50 mg RAL 400 mg Total once daily + BR BID + BR N=354 N=361 N=715 n (%) n (%) n (%) No 214 (60) 209 (58) 423 (59) Yes, with Primary PI Mutations 69 (19) 74 (20) 143 (20) Yes, without Primary PI Mutations 71 (20) 78 (22) 149 (21) Data Source: ING111762 Week 24 CSR Table 6.38 3.1.3. ART-Experienced, INI-Resistant Subjects

In the studies with INI-resistant subjects, ING112961 and ING112574, the percentages of subjects from the DTG treatment arms who prematurely withdrew for any reason ranged from 15% to 21%. The primary reason for withdrawal across both studies was lack of efficacy (8% to 10%) with few subjects withdrawing for AE (2% to 8%) (Table 34).

Table 34 Summary of Subject Disposition in ART-Experienced, INI-Resistant Studies ING112961 ING112574 Week 48 Cohort II ITT-E Week 24 ITT-E DTG 50 mg DTG 50 mg DTG 50 mg BID + BR BID + BR BID + BR N=24 N=183 N=114 All subjects screened, N 30 323 Completion Status, n (%) Completed 0 0 0 Withdrawal 5 (21) 28 (15) 24 (21) Ongoing 19 (79) 155 (85) 90 (79) Primary reason for Withdrawal, n (%) Adverse Event 2 (8) 4 (2) 4 (4) Lack of Efficacy 2 (8) 19 (10) 15 (13) Insufficient viral load response 2 (8) 0 0 Disease progressed/progression 0 1 (<1) 0 Insufficient CD4+ cell response 0 1 (<1) 1 (<1) Virological failure 0 18 (10) 15 (13) Protocol deviation 1 (4) 2 (1) 2 (2) Non-compliance with IP treatment 1 (4) 2 (1) 2 (2) Subject reached protocol-defined stopping criteria 0 1 (<1) 1 (<1) Subject met the GSK defined Liver Chemistry 0 1 (<1) 1 (<1) Stopping Criteria Lost to follow-up 0 2 (1) 2 (2) Data Source: ING112961 Cohort II Week 48 CSR Table 6.5; ING112574 Week 24 CSR Table 6.3 and Table 6.4. Note: Subjects could have more than one Sub-reason or no sub-reason indicated for withdrawal. No subject withdrew for fatal AE, one subject died of progressive multifocal leucoencephalopathy (PML) post-study discontinuation.

65 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

See Section 1.9.2 for definitions of analysis populations.

Table 35 Summary of Study Populations in ART-Experienced, INI-Resistant Studies

ING112961 ING112574 Study Population Week 48 Cohort II Study Population ITT-E DTG 50 mg DTG 50 mg BID + BR BID + BR All Subjects Screened 54 All Subjects Screened 323 Intent-to-Treat Exposed 24 Intent-to-Treat Exposed (ITT-E) 183 Day 11 Genotype 15 Week 24 ITT-Ec 114 On-treatment Genotype for PDVFa 5 Day 8 Per Protocol 173 Day 11 INI Phenotype 15 Week 24 Per Protocolc 101 On-treatment Phenotype for PDVFa 5 PDVF Genotypic/Phenotypicd 31 Day 8 Genotypice 112 Day 8 Phenotypice 111 Virological outcome by Baseline 177 genotype/phenotype at Day 8 Virological outcome by Baseline 101 genotype/phenotype at Week 24c Data Source: ING112961 Cohort II Week 48 CSR Table 6.1; ING112574 Week 24 CSR Table 6.1. a. ING112961 PDVF = protocol-defined virological failure b. ING112961 Subjects with PK data at any one of the timepoints (i.e. Day 11, Week 4, and Week 24). c. Subjects who could have completed Week 24 at the data cut-off. d. Protocol-defined virological failure subjects with available resistance test result (31 of 35 PDVF subjects). e. Subjects with available IN genotypic/phenotypic data: all subjects with Day 8 Plasma HIV-1 RNA 150 c/mL provided samples for resistance analysis.

Overall, in Studies ING112961 and ING112574 there was a good representation of female (22% to 25%) and African American/African heritage (21% to 27%) subjects in the study population (Table 36). There was no meaningful difference between studies with respect to gender or age; median age was about 47 years.

66 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 36 Summary of Demographic Characteristics in ART-Experienced, INI- Resistant Studies

Demographic Characteristics ING112961 ING112574 Week 48 Cohort II ITT-E Week 24 ITT-E DTG 50 mg DTG 50 mg DTG 50 mg BID + BR BID + BR BID + BR N=24 N=183 N=114 Age (years) median (range) 47 (33,68) 48 (19, 67) 48 (19, 66) Sex, n (%) Male 18 (75) 141 (77) 89 (78) Ethnicity, n (%) Hispanic or Latino 5 (21) 20 (11) 11 (10) Race, n (%) African American / African Heritage 5 (21) 49 (27) 28 (25) American Indian or Alaska native & White 0 1 (<1) 0 Asian 0 1 (<1) 0 Central/South Asian heritage 0 1 (<1) 0 White 19 (79) 132 (72) 86 (75) White – Caucasian/ European Heritage 18 (75) 130 (71) 85 (75) White – Arabic/ North African Heritage 1 (4) 0 0 White & African American/African heritage 0 2 (1) 1 (<1) Data Source: ING112961 Cohort II Week 48 CSR Table 6.9 and Table 6.12; ING112574 Week 24 Table 6.9, Table 6.10, Table 6.12 and Table 6.13.

Subjects enrolled in Studies ING112961 and ING112574 had advanced HIV-1 disease (Table 37) and were highly antiretroviral treatment-experienced as shown by the long median duration of prior ART exposure and the high number of prior ARTs used, with extensive multi-class viral drug resistance at Baseline (Table 38; ING112961 Cohort II Week 48 CSR Section 5.7, ING112574 Week 24 CSR Section 5.6).

67 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 37 Summary of Baseline Characteristics in ART-experienced, INI- resistant Studies

Baseline Characteristics ING112961 ING112574 Week 24 Cohort II ITT-E Week 24 ITT-E DTG 50 mg DTG 50 mg DTG 50 mg BID + BR BID + BR BID + BR N=24 N=183 N=114 CDC Classification, n (%) A: Asymptomatic or lymphadenopathy or 10 (42) 44 (24) 21 (18) acute HIV B: Symptomatic, not AIDS 6 (25) 37 (20) 26 (23) C: AIDS 8 (33) 102 (56) 67 (59) Median plasma HIV-1 RNA (range) 4.26 (3.32, 5.84) 4.384 (1.59, 7.37) 4.443 (2.20, 7.37) Median CD4+ cell count (range) 202 (19, 528) 140.0 (19, 1100) 120.0 (19, 720) Hepatitis Status, n (%) Hepatitis B Surface Antigen (HBsAg) positive 2 (9) 10 (5) 5 (4) HCV antibody positive 6 (26) 26 (14) 18 (16) HBV or HCV status missing 2 (9) 0 0 HBsAg and HCV antibody positive 0 2 (1) 1 (<1) Data Source: ING112961 Cohort II Week 48 CSR Table 6.13, Table 6.14, Table 6.21, and Table 6.23; ING112574 Week 24 CSR Table 6.15, Table 6.16, Table 6.17, Table 6.18, Table 6.26, Table 6.27, Table 6.28, and Table 6.29.

Table 38 Number and Duration of Prior ART in ART-experienced, INI-resistant Studies

ING112961 ING112574 Week 24Cohort II ITT-E Week 24 ITT-E DTG 50 mg DTG 50 mg DTG 50 mg BID + BR BID + BR BID + BR N=24 N=183 N=114 Median Number of prior ART (range) 15 (6, 19) 14 (3, 23) 14 (3, 23) Median Duration (years) of prior ART (range) 15 (3, 22) 13 (4, 25) 13 (7, 25) Prior use of ART by class: n (%) 3 PIs 21 (88) 135 (74) 83 (73) 2 NNRTIs 12 (62) 108 (59) 71 (62) 3 NRTIs 24 (100) 164 (90) 103 (90) Prior ART used in later lines of therapy: n (%) ETR 11 (46) 103 (56) 70 (61) DRV/RTV 14 (58) 133 (76) 85 (78) enfuvirtide 13 (54) 88 (49) 59 (53) maraviroc 9 (38) 58 (32) 41 (36) Data Source: ING112961 Week Cohort II Week 48 CSR Table 6.28, and Table 6.30; ING112574 Week 24 CSR Table 6.34, Table 6.35, Table 6.37, and Table 6.38. Prior INI and Baseline IN Resistance

There was a good representation of all major integrase resistance pathways at Baseline (Table 39). Limited cross resistance between DTG and RAL was seen in the study population with a much lower median DTG FC compared to RAL.

68 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 39 Prior INI and Baseline IN Resistance in ART-experienced, INI- resistant Studies

Baseline Characteristics ING112961 ING112574 Week 24 Cohort II ITT-E Week 24 ITT-E DTG 50 mg DTG 50 mg BID DTG 50 mg BID BID + BR BID + BR BID + BR N=24 N=183 N=114 Raltegravir or EVG Treatment status, n (%) Ongoing at screening 20 (83) 101 (55) 58 (51) Discontinued prior to screening 4 (17) 82 (45) 56 (49) Median Duration (months) of prior RAL (range) 29.44 (10.3, 62.5) 29 (2, 132) 25 (2, 132) Median Duration (months) of prior EVG (range) 3.78 17 (11, 26) 17 (13, 26) (only one subject) Evidence of genotypic primary IN resistance at Baseline, n (%) Primary IN resistance detected 24 (100) 123 (67) 74 (65) Q148+1 8 (33) 32 (17) 20 (18) Q148+2 2 (8) 21 (11) 12 (11) N155 6 (25) 33 (18) 21 (18) Y143 6 (25) 28 (15) 15 (13) T66 - 1 (<1) 1 (<1) 2 Primary mutations 1 (4) 8 (4) 5 (4) Primary not detected 1 (4) 60 (33) 40 (35) Evidence of phenotypic IN resistance at Baseline DTG Median (range) 2.72 (0.87, 9.48) 1.29 (0.45, 37.00) 1.29 (0.47, 37.00) RAL Median (range) 128 (0.78, 183) 47.50 (0.49, 127.00) 40.50 (0.49, 127.00) Data Source: ING112961 Cohort II Week 48 CSR Table 6.30, Table 12.26 and Table 12.47; ING112574 Week 24 CSR Table 6.09, Table 6.10, Table 6.37, Table 6.38, Table 7.31, Table 12.9, Table 12.41, Table 12.42, Table 12.60, and Table 12.64. a. No EVG failures

In ING112574, in viruses with the Y143 and N155 mutational pathways, the median fold change to DTG and diversity in fold change to DTG was low in comparison to the higher median and diversity in DTG FC observed with viruses with the Q148 mutational pathway (Table 40). ING112574 enrolled sufficient range and diversity with respect to DTG FC and IN resistance patterns (respectively) allowing for an appropriate evaluation of DTG in the HIV-1 INI-resistant population.

69 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 40 Summary of Phenotypic Susceptibility to DTG and RAL at Baseline by IN Resistant Mutation Category

DTG FC Mutation Category Median IQR Range Q148+2, n=21 10.0 4.5 ,13.0 2.56, 37.0 Q148+1, n=31 4.6 3.4, 6.3 0.47, 12.0 N155, n=30 1.50 1.3 , 1.8 0.82, ,3.9 Y143, n=28 1.1 0.9, 1.2 0.78, 2.0 2 primary mutations, n=7 4.6 1.7, 20.0 1.46, 27.0 Primary Not Detected n=59 0.8 1.0, 1.0 0.45, 4.0 RAL FC Mutation Category Median IQR Range Q148+2 n=21 109.8 109.8, 109.8 11.0, 109.8 Q148+1, n=31 109.8 109.8, 109.8 1.0, 127.0 N155, n=30 31.0 16.0, 59.0 0.9, 109.8 Y143, n=28 109.8 109.8, 109.8 14.0, 109.8 2 primary mutations, n=7 109.8 35.0, 109.8 33.0, 109.8 Primary Not Detected, n=59 0.9 0.84, 1.2 0.49, 109.8 Data Source: ING112574 Week 24 CSR Table 12.66; IQR, Interquartile Range Note: Six subjects had missing DTG FC at Baseline

3.2. Comparison of Efficacy Results of all Studies

3.2.1. ART-Naïve subjects

3.2.1.1. Primary Efficacy Results

In treatment-naïve subjects, DTG administered once daily with two NRTIs demonstrated non-inferiority to RAL at Week 48 (ING113086) and co-administered with ABC/3TC demonstrated superiority compared to Atripla (ING114467) also at Week 48 (Table 41). Consistent response rates (i.e., HIV-1 RNA <50 c/mL; 88% for both studies) were observed across the two studies for the DTG treatment regimens. Per protocol and other sensitivity analyses in both studies supported the primary endpoint in each study.

70 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 41 Proportion of Subjects Responding based on Plasma HIV-1 RNA <50 c/mL by Visit in ART-Naïve Studies (ITT-E Population)

Visit ING113086 ING114467 Week 48/ Snapshot (MSDF) Week 48/ Snapshot (MSDF) DTG 50 mg RAL 400 mg DTG 50 mg + EFV/TDF/FTC once daily BID + 2 NRTI ABC/3TC once daily + 2 NRTI once daily N=411 N=411 N=414 N=419 n/N (%) n/N (%) n/N (%) n/N (%) Baseline 2 (<1) 0 0 0 Week 1 - - 106 (26) 24 (6) Week 2 - - 261 (63) 59 (14) Week 4 295 (72) 266 (65) 321 (78) 146 (35) Week 8 350 (85) 323 (79) 347 (84) 227 (54) Week 12 357 (87) 340 (83) 354 (86) 288 (69) Week 16 367 (89) 342 (83) - - Week 20 - - - - Week 24 384 (93) 369 (90) 379 (92) 350 (84) Week 32 373 (91) 363 (88) 368 (89) 343 (82) Week 40 362 (88) 349 (85) 358 (86) 333 (79) Week 48 361 (88)a 351 (85) 364 (88)b 338 (81) Data Source: ING113086 Week 48 CSR Table 7.18; ING114467 Week 48 CSR Table 7.26. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group. a. 2.5 (-2.2, 7.1) Adjusted Difference (95% CI) based on Cochran-Mantel Haenszel stratified analysis adjusting for the Baseline stratification factors: Baseline HIV-1 RNA and backbone dual NRTI [Data Source: ING113086 Table 7.1] b. 7.4 (2.5, 12.3) Adjusted Difference (95% CI) based on Cochran-Mantel Haenszel stratified analysis adjusting for the following Baseline stratification factors: Baseline plasma HIV-1 RNA ( vs >100,000 c/mL) and Baseline CD4+ cell count ( vs >200 cells/mm3). Test for superiority: p = 0.003. [Data Source: ING114467 Table 7.1].

The statistically significant difference in response rates noted in ING114467 was primarily due to lower discontinuations due to AEs on the DTG regimen. Additionally, in both ING113086 and ING114467, there were numerically fewer virologic non- responders in the DTG treatment arms compared to RAL and Atripla, respectively (Table 42).

71 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 42 Summary of Study Outcomes <50 c/mL at Week 48 in ART-Naives – Snapshot (MSDF) Analysis (ITT-E Population)

ING113086 ING114467 DTG 50 mg RAL 400 mg DTG 50 mg + EFV/TDF/FTC once daily BID ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 HIV-1 RNA <50 c/mL, n (%) 361 (88) a 351 (85) 364 (88)b 338 (81) Virologic failurec 20 (5) 31 (8) 21 (5) 26 (6) Data in window not <50 c/mL 8 (2) 5 (1) 6 (1) 5 (1) Discontinued for lack of efficacy 5 (1) 13 (3) 7 (2) 9 (2) Discontinued for other reason 2 (<1) 11 (3) 8 (2) 12 (3) while not <50 c/mL Change in ART 5 (1) 2 (<1) - - No virologic data at Week 48 30 (7) 29 (7) 29 (7) 55 (13) window Reasons Discontinued study/study drug due 9 (2) 6 (1) 9 (2) 40 (10) to adverse event or deathd Discontinued study/study drug for 21 (5) 23 (6) 20 (5) 14 (3) other reasonse Missing data during window but on 0 0 0 1 (<1) study Data Source: ING113086 Week 48 CSR Table 7.4; ING114467 Week 48 CSR Table 7.3. a. 2.5 (-2.2, 7.1) Adjusted Difference (95% CI) based on Cochran-Mantel Haenszel stratified analysis adjusting for the Baseline stratification factors: Baseline HIV-1 RNA and backbone dual NRTI [Data Source: ING113086 Table 7.1] b. 7.4 (2.5, 12.3) Adjusted Difference (95% CI) based on Cochran-Mantel Haenszel stratified analysis adjusting for the following Baseline stratification factors: Baseline plasma HIV-1 RNA ( vs >100,000 c/mL) and Baseline CD4+ cell count ( vs >200 cells/mm3). Test for superiority: p = 0.003. [Data Source: ING114467 Table 7.1] c. Includes subjects who changed BR to new class or changed BR not permitted per protocol or due to lack of efficacy prior to Week 48 (for ING113086 only), subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are 50 c/mL in the 48 week window. d. Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 window if this resulted in no virologic data on treatment during the Week 48 window. e. Other includes: withdrew consent, loss to follow-up, moved, etc. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group

Sustained virological response was demonstrated in ING112276, in which 88% of patients receiving DTG 50 mg (n=51) once daily had HIV-1 RNA <50 c/mL, compared to 72% of patients in the EFV group (n=50) at 96 weeks. No INI-resistant mutations or treatment emergent resistance in NRTI background therapy were isolated with DTG 50 mg once daily through 96 weeks.

3.2.1.2. Secondary Efficacy Results

Time to Viral Suppression (<50 c/mL) in ART-Naïve Studies

In ING113086, subjects achieved rapid viral suppression with DTG (comparable to RAL) and once suppressed, remain suppressed through to Week 48 in treatment-naive

72 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy population (Figure 8, and Figure 9). In ING114467, subjects on DTG + ABC/3TC reached viral suppression significantly earlier than Atripla (median time to suppression 28 days with DTG versus 84 days on Atripla; p<0.0001 Hazard ratio: 2.32 [2.00, 2.68]). This analysis was pre-specified and adjusted for multiplicity.

Figure 8 ING113086 Week 48, Proportion (95% CI) of Subjects with Plasma HIV-1 RNA <50 c/mL (Snapshot [MSDF]) by Visit

Data Source: ING113086 Week 48 CSR Figure 7.1

73 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Figure 9 ING114467 Week 48, Kaplan-Meier Plot of Time to Viral Suppression (Viral Load <50 c/mL)

Data Source: ING114467 Week 48 CSR Figure 7.5

CD4+ cell Counts over Time in ART-Naïve Studies

Immunologic activity over time was compared using summaries of CD4+ values and changes from Baseline at each visit. The rapid and significant viral load reductions seen with DTG containing regimens are associated with substantial and sustained CD4+ cells increases over 4 to 48 weeks. The median change from Baseline to Week 48 in CD4+ cells in the DTG group was +224 to +230 cells/mm3 (Table 43).

These CD4+ cell count increases were comparable with RAL (ING113086) and greater than that seen with Atripla (ING114467) (Table 43).

74 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 43 Median (IQR)[Range] Change from Baseline in CD4+ Cell Counts (cells/mm3) by Visit in ART-Naïve Studies

Visit ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg + EFV/TDF/FTC once daily + BID + 2 NRTI ABC/3TC once daily 2 NRTI once daily N=411 N=411 N=414 N=419 Baseline 359.0 362.0 334.5 339.0 (276.0, 470.0) (267.0, 469.0) (248.0, 434.0) (243.0, 439.0) [19, 1119] [19, 1033] [19, 1027] [19, 1123] Week 4 87.0 88.0 107.0 72.0 (26.0, 149.0) (32.0, 163.0) (46.0, 176.0) (0.0, 139.0) [-633, 612] [-567, 710] [-327, 684] [-314, 830] Week 8 107.0 117.5 144.0 100 (48.0, 190.0) (46.0, 204.0) (72.0, 228.0) (21.0, 188.0) [-282, 932] [-348, 692] [-262, 892] [-274, 755] Week 16 147.0 154.0 179.5 140.0 (69.0, 222.0) (73.5, 248.0) (86.0, 279.0) (49.0, 226.0) [-481, 742] [-210, 990] [-474, 1078] [-169, 641] Week 24 183.0 182.0 194.5 133.0 (99.5, 295) (94.0, 296.0) (101.0, 294.0) (44.0, 233.0) [-437, 854] [-330, 896] [-396, 816] [-220, 932] Week 48 229.5 230.0 223.5 152.0 (128.0, 338.0) (139.0, 354.0) (103.0, 332.0)b (16.0, 280.0)b [-343, 927] [-148, 1046] [-430, 1180] [-518 748] Data Source: ING113086 Week 48 CSR Table 7.14; ING114467 Week 48 CSR Table 7.18 a. ING113086: Mean change: DTG 239 cells/mm3 (SD 171.81); RAL 258 cells/mm3 (SD 178.69). b. ING114467: Mean change: DTG + ABC/3TC 238 cell/mm3 (SD 199.6); EFV/TDF/FTC 172.0 (SD 169.22). Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla. N = Number of subjects in each treatment group.

In Study ING114467, using the Repeated Measures Mixed Model Analysis, DTG+ABC/3TC was statistically superior to Atripla with respect to change from Baseline in CD4+ cell count at Week 48 (Adjusted mean change from Baseline: DTG+ ABC/3TC 267 cells/mm3 and Atripla 208 cells/mm3, [33.4, 84.4] p <0.001). This analysis was pre-specified and adjusted for multiplicity.

75 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Figure 10 ING114467 Adjusted Mean (95% CI) Change from Baseline in CD4+ Cell Counts (cells/mm3) Over Time

Data Source: ING114467 Week 48 CSR Figure 7.7

Incidence of disease progression (HIV-associated conditions, AIDS and death) in ART-Naïve Studies

HIV-associated conditions in subjects treated with DTG compared to RAL and Atripla were assessed over time by summaries of the incidence of post-Baseline HIV conditions, and by the proportion of subjects with disease progression. Across treatment-naïve studies, there was a similar low incidence of HIV associated conditions (1 to 3% across all treatment-naive studies; Data Source: ING113086 Week 48 CSR, Section 6.3.4 and ING114467 Week 48 CSR, Section 6.3.5), and in the number of subjects with HIV disease progression (Table 44).

76 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 44 Summary of Post-Baseline HIV-1 Disease Progressions (ITT-E Population) in ART-Naïve Studies

Visit ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg + EFV/TDF/FTC once daily BID ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 n (%) n (%) n (%) n (%) Number of subjects progressing 4 (1) 4 (1) 5 (1) 6 (1) to Class C or Death Class A to Class C 2 (<1) 2 (<1) 4 (<1) 2 (<1) Class B to Class C 1 (<1) 1 (<1) 0 0 Class C to new Class C 0 0 1 (<1) 2 (<1) Class A, B, or C to Death 1 (<1) 1 (<1) 0 2 (<1) Data Source: ING113086 Week 48 CSR Table 7.17; ING114467 Week 48 CSR Table 7.25. Notes: EFV/TDF/FTC = EFV 600 mg, TDF 300 mg, FTC 200 mg in the form of Atripla.

3.2.2. ART-Experienced, INI-Naïve Subjects

3.2.2.1. Principal Efficacy Results

The definitive primary endpoint for ING111762 is Week 48. The results presented here are for Week 24, which is a secondary endpoint for the study. This Week 24 interim analysis was done to support regulatory submissions globally.

The virologic suppression (HIV-1 RNA <50 c/mL) in the DTG arm (79%) was statistically superior to the RAL arm (70%), based on the Week 24 prespecified analysis of outcomes of the FDA Snapshot (MSDF) algorithm with the mITT-E Population (adjusted treatment difference and 95% CI 9.7 [3.4, 15.9], p=0.003) (Table 45).

This result is supported by the Per-Protocol analysis where 81% and 72% of DTG and RAL subjects, respectively, achieved plasma HIV-1 RNA <50 c/mL at Week 24 (treatment difference and 95% CI 9.3 [3.0, 15.7], Data Source: ING111762 Week 24 CSR Table 7.2). An analysis using an alternate variance formula for the CI gave results matching those of the main Week 24 analysis (Data Source: ING111762 Week 24 CSR Table 7.3).

77 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 45 Proportion of Subjects with Plasma HIV-1 RNA <50 c/mL by Visit - Snapshot (MSDF) Analysis (mITT-E Population)

ING111762 DTG 50 mg RAL 400 mg once daily + BR BID + BR N=354 N=361 n/N (%) n/N (%) Baseline 2 / 354 (<1) 4 / 361 (1) Week 4 210 / 354 (59) 194 / 361 (54) Week 8 259 / 354 (73) 239 / 361 (66) Week 12 257 / 354 (73) 251 / 361 (70) Week 16 257 / 354 (73) 249 / 361 (69) Week 24a,b,c 281 / 354 (79) 252 / 361 (70) Data Source: ING111762 Week 24 CSR Table 7.23 and Table 7.1 a. Difference: Proportion on DTG - Proportion on RAL: 9.6 (3.2, 15.9) b. Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: baseline HIV-1 RNA, DRV/RTV use without primary PI mutations, and baseline PSSf: Difference 9.7 (3.4, 15.9). c. P-value 0.003

There were fewer virologic nonresponders using the Snapshot (MSDF) algorithm through Week 24 in the DTG group compared to the RAL group (DTG: 15%; RAL: 24%) (Table 46). This result was driven by data within the window for HIV-1 RNA not being <50 c/mL (DTG: 11%; RAL: 18%). Very few subjects in both groups were discontinued from the study due to lack of efficacy (DTG: <1%; RAL: 1).

Table 46 Study Outcomes (<50 c/mL) at Week 24 - Snapshot (MSDF) Analysis (mITT-E Population)

Outcome at Week 24 DTG 50 mg RAL 400 mg once daily + BR BID + BR N=354 N=361 n (%) n (%) Virologic Success 281 (79) 252 (70) Virologic Non-Responsea 53 (15) 86 (24) Data in window not below threshold 40 (11) 66 (18) Data in window not <50 c/mL 40 (11) 66 (18) Discontinued for lack of efficacy 2 (<1) 4 (1) Discontinued for other reason while not 7 (2) 6 (2) below threshold Change in ART 4 (1) 10 (3) No Virologic Data at Week 24 20 (6) 23 (6) Discontinued due to Adverse Event or Death 6 (2) 9 (2) Discontinued for Other Reasons 12 (3) 11 (3) Missing data during window but on study 2 (<1) 3 (<1) Data Source: ING111762 Week 24 CSR Table 7.4 a. Virologic failure

78 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

3.2.2.2. Secondary Efficacy Results

Time to Viral Suppression (<50 c/mL) in ART-Experienced, INI-Naïve Subjects

The proportion of subjects with plasma HIV-1 RNA <50 c/mL using Snapshot (MSDF) analysis for the mITT-E Population increased steeply in both treatment groups from Baseline to Week 4, then tended to plateau starting at Week 8 through Week 24 (Figure 11). Both treatment groups followed a similar pattern, but higher values were noted for DTG compared to RAL at all time points assessed.

Figure 11 Proportion (95% CI) of Subjects with Plasma HIV-1 RNA <50 c/mL by Visit – Snapshot (MSDF) Analysis (mITT-E Population)

Data Source: ING111762 Week 24 CSR Figure 7.1 Note: confidence intervals are derived using the normal approximation.

CD4+ cell Counts over Time in ART-Experienced, INI-Naïve Subjects

Immunologic activity over time was compared using summaries of CD4+ values (Data Source: ING111762 Week 24 CSR Table 7.18) and changes from Baseline at each visit (Table 47). Median CD4+ cell counts increased from Baseline to Week 24 in the DTG and RAL groups. The median changes in CD4+ cell count from Baseline were +99 cells/mm3 in the DTG group and +93 cells/mm3 in the RAL group at 24 weeks.

79 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 47 Median (IQR)[Range] Change from Baseline in CD4+ Cell Counts (cells/mm3) by Visit in an ART-Experience Study (mITT-E Population)

ING111762 DTG 50 mg once daily + BR RAL 400 mg BID + BR N=354 N=361 Baseline 204.5 193.0 (88.0, 368.0) (96.0, 365.0) [19, 1017] [19, 1219] Week 4 53.0 45.0 (0.0, 109.0) (5.0, 99.0) [-383, 718] [-382, 735] Week 8 60.5 59.0 (15.0 117.0) (12.0, 124.0) [-295, 665] [-209, 520] Week 12 74.0 75.0 (25.0, 135.0) (22.0, 141.0) [-250, 621] [-470, 533] Week 16 76.0 79.5 (20.0, 156.0) (28.0, 158.0) [-310, 578] [-374, 710] Week 24 99.0 93.0 (34.0, 184.0) (46.0, 166.0) [-422, 619] [-349, 682] Data Source: ING111762 Week 24 CSR Table 7.19

Incidence of Disease Progression (HIV-associated conditions, AIDS and death) in ART-Experienced, INI-Naïve Subjects

HIV-associated conditions in subjects treated with DTG compared to RAL were assessed over time by summaries of the incidence of post-Baseline HIV conditions, and by the proportion of subjects with disease progression. There was a similar low incidence of HIV associated conditions, excluding recurrences (DTG: 3%; RAL: 5%; Data Source: ING111762 Week 24 CSR, Section 6.4) and number of subjects with HIV disease progression to class C or death (2% in both treatment groups; Table 48).

80 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 48 Summary of Post-Baseline HIV-1 Disease Progressions (mITT-E Population)

DTG 50 mg RAL 400 mg once daily + BR BID + BR N=354 N=361 Category n (%) n (%) Progressed to CDC Class C or death, n (%) 8 (2) 8 (2) Class A to Class C 0 1 (13) Class B to Class C 0 2 (25) Class C to New Class C 8 (100) 3 (38) Class A, B, or C to Death 0 2 (25) Data Source: ING111762 Week 24 CSR Table 7.22 Note: Subjects may have had more than one HIV associated condition. Each condition was counted only once per subject, regardless of recurrence. Note: Excludes uncategorized condition of 'Anal Carcinoma, in situ' (n=1, RAL 400 mg BID). The condition was considered 'Class B' by GSK based on blinded medical review (categorization was not databased).

3.2.3. Treatment Emergent Resistance in INI-Naïve Subjects (ART-Naïve and ART-Experienced Subjects)

A low rate of confirmed virological failure with development of resistance mutations or decreased susceptibility to any drugs in the regimen was observed in the DTG treatment arms compared to EFV in ING114467 and RAL in ING113086 and ING111762.

Protocol defined virologic failure rates in ING113086 and ING114467 were low and consistent for the DTG-containing regimens (5% and 4%, respectively), despite stringent PDVF criteria (confirmed HIV-1 RNA 50 c/mL at or after Week 24).

In the ING111762 Week 24 analysis, treatment-experienced (INI-naive) subjects receiving DTG were less likely to have genotypic or phenotypic evidence of treatment- emergent resistance at PDVF (confirmed plasma HIV-1 RNA levels ≥400 c/mL on or after Week 24; full definition in ING111762 Week 24 CSR, Section 7.1). In a pre- specified analysis, there was a statistically significant difference in favor of DTG for the proportion of mITT-E subjects harboring virus with evidence of INI Resistance by Week 24 (DTG: 2/354 (0.6%); RAL: 10/361(2.8%); p=0.016).

Across the treatment-naive studies, no subjects on DTG treatment arms developed clinically relevant INI resistance mutations, but subjects on comparator agents (RAL, EFV) developed clinically relevant resistance mutations to these third agents. In ING111762, there were two subjects in the DTG arm with emergent integrase-defined substitutions. Both had experienced virologic rebound instead of non-response, had no defined integrase resistance substitutions at Baseline, and acquired a substitution at R263 in the integrase open reading frame. In each case the DTG fold change was <2, as was the maximum RAL fold change. Neither of these subjects with emergent substitutions at R263 had RAL-associated secondary mutations at Baseline.

Furthermore, no mutations were noted to background NRTI (ART-naive studies) with 50 mg DTG-based regimens in comparison to Atripla or RAL-based regimens in treatment-naïve subjects (Table 49). There were few examples of emergent resistance to

81 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy the background regimen at PDVF in the RAL arm (6/351) versus the DTG arm (3/354) in ART-experienced subjects (m2.7.2.4).

Table 49 Number of Protocol-Defined Virologic Failures (+/- Resistance to integrase, NNRTI, BR) in ART-Naïve and ART-experienced Subjects

ART-Naïve Adults ING113086 ING114467 Week 48 Week 48 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 Protocol-defined Virologic Failure, n (%) 20 (5) 28 (7) 18 (4) 17 (4) Genotype/phenotype Determinable, n (%) INI-r Mutations Present 0 1/18 (6)a 0c 0 NNRTI-r Mutations Present - - 0 4 (24)d NRTI-r Mutations Present 0 4/19 (21)b 0 1 (6)e ART-Experienced Adults ING111762 Week 24 DTG 50 mg RAL 400 mg once daily + BR BID + BR N=354 N=361 Protocol-defined Virologic Failure 14 (4) 34 (9) Genotype/phenotype Determinable INI Mutations Present 2/9 (22)f 9/27 (33) Data Source: ING113086 Week 48 CSR Table 7.22, Table 12.2, Table 12.4, and Listing 43; ING114467 Week 48 CSR Table 7.7, Table 12.2, Table 12.4, and Listing 47; ING111762 Week 24 CSR Table 12.2 and Table 7.10. R=resistance to integrase, NNRTI and BR a. T97T/A, E138E/D, V151V/I, N155H b. A62A/V (n=2), K65K/R, K70K/E, M184M/I, M184M/V, M184V c. IN Substitution (n=1) E157Q/P at Week 24. DTG FC = 1.13; RAL FC = 1.26 d. K101E, K101K/N, K103N, G190G/A (2) e. K65K/R f. DTG (n=2): R263R/K FC=1.12 and R263K FC=1.93.

Supporting the Phase III finding in treatment-naïve subjects, in ING112276, no subjects receiving the Phase III selected dose of DTG 50 mg once daily had a confirmed PDVF (400 c/mL) through Week 96, and no virologic resistance was observed in this treatment group. A low rate of confirmed PDVF was observed in the DTG 10 mg and 25 mg treatment groups and the EFV treatment group. No subjects demonstrated integrase or non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance at PDVF. The only demonstrated virologic resistance mutations were a M184V, consistent with 3TC/FTC resistance, in a subject receiving TDF/FTC and DTG 10 mg once daily (m2.7.2.4).

82 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

3.2.4. Studies in ART-Experienced, INI-Resistant Subjects

3.2.4.1. Primary Efficacy Results

The primary endpoint in ING112961 was the proportion of subjects with Day 11 plasma HIV-1 RNA <400 c/mL or reduced by at least 0.7 log10 c/mL compared to Baseline. Twenty-three of 24 (96%, CI: 79%, 100%) subjects in Cohort II receiving DTG 50 mg BID achieved the primary endpoint (Data Source: ING112961 Cohort II Week 48 CSR Table 7.1).

The primary efficacy endpoint in ING112574 included the change from Baseline in plasma HIV-1 RNA at Day 8 and an assessment of the proportion of subjects with <50 c/mL HIV-1 RNA at Week 24. Assessing all subjects who had the opportunity to reach Week 24 before the data cut-off, 63% of this Week 24 ITT-E population (N=114) achieved viral suppression to <50 c/mL based on the Snapshot (MSDF) algorithm (Data Source: ING112574 Week 24 CSR Table 7.21). A comparable proportion (66/101, 65%) was observed in this analysis for the Per Protocol population (Data Source: ING112574 Week 24 CSR Table 7.4). Additionally, a statistically significant mean reduction of 1.43 log10 c/mL HIV-1 RNA at Day 8 compared to Baseline was observed for the ITT-E population with an equivalent reduction observed for the Per Protocol population based on LOCDBF in sensitivity analyses (Table 50).

Table 50 ING112574: Mean Change from Baseline in Plasma HIV-1 RNA log10c/mL at Day 8

(LOCFDB, ITT-E) N Mean (SD) 95% CI p-value a Baseline 183 4.26 (0.93) Change from Baseline (CFB) 182 -1.43 (0.61) (-1.52,-1.34) <0.001 Day 8 (LOCFDB, Day 8 PP population) N Mean (SD) 95% CI p-value a Baseline 173 4.26 (0.93) Change from Baseline Day 8 173 -1.43 (0.60) (-1.52,-1.34) <0.001 Data Source: ING112574 Week 24 CSR Table 7.1 and Table 7.2 a. p-value is derived by testing the hypothesis of no change from Baseline at the two-sided 5% significance level using Student's t-test. Note: Proportion of CFB 0.5 log10 c/mL or <400 c/mL at Day 8: 169/183 (92%).

Change from Baseline in HIV-1 RNA

Across both studies with INI-resistant subjects, the mean change from Baseline in plasma HIV RNA was similar (~1.40 log10 c/mL reduction from Baseline) during the Functional Monotherapy Phase (Day 6 to 8 and Day 8 for ING112961 and ING112574, respectively). At Week 24 the mean change from Baseline ranged from -2.21 log10 c/mL in ING112574 to -2.50 log10 c/mL in ING112961.

83 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 51 Plasma HIV-1 RNA Mean (SD) Change from Baseline (log10 c/mL) by Visit in ART-Experienced, INI-resistant Subjects

Visit ING112961 ING112574 Cohort II Week 24 ITT-E DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=114 n Mean [SD] Plasma HIV-1 RNA n Mean [SD] Plasma HIV-1 RNA (log10 c/mL) (log10 c/mL) Baseline 24 4.38 [0.74] 114 4.34 [0.95] Day 8 24 -1.40 [0.43]a 113 -1.44 [0.60] Day 11 24 -1.76 [0.53] - - Week 4 24 -2.06 [0.78] 112 -2.12 [0.86] Week 12 24 -2.30 [0.93] 109 -2.13 [1.08] Week 24 22 -2.50 [0.81] 101 -2.21 [1.05] Week 48 20 -2.63 [0.78] 12 -2.11 [0.83] Data Source: ING112961 Cohort II Week 48 CSR Table 7.2; ING112574 Week 24 CSR Table 7.26. a. Day 6 to 8

Proportion of Subjects with HIV-1 RNA <50 and <400 c/mL Over Time

Assessing the longer-term effect of the DTG-containing regimen, the proportion of subjects responding based on plasma HIV RNA <50 c/mL at Week 24 was 63% for ING112574 and 79% ING112961 (Table 52). Differences in response rates at Week 24 in subjects in ING112961 Cohort II as compared to ING112574 were likely due to the less advanced treatment population and the more limited number of subjects with higher levels of resistance to DTG enrolled in ING112961 Cohort II (Table 37 and Table 39).

84 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 52 Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 and <400 c/mL by Visit in ART-Experienced, INI-Resistant Subjects (ITT-E Population)

Visit ING112961 ING112574 Week 48/TLOVR Week 24/Snapshot (MSDF) Cohort II Week 24 ITTE DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=114 n (%) n (%) <50 c/mL <400 c/mL <50 c/mL <400 c/mL Baseline 0 0 0 3 (3) Day 8 1 (4)a 8 (33)a 16 (14) 48 (42) Day 11 4 (17) 13 (54) - - Week 4 12 (50) 17 (71) 59 (52) 86 (75) Week 8 15 (63) 19 (79) 66 (58) 89 (78) Week 12 16 (67) 20 (83) 70 (61) 86 (75) Week 16 17 (71) 20 (83) 73 (64) 83 (73) Week 24 19 (79) 20 (83) 72 (63) 79 (69) Week 48 17 (71) 18 (75) - - Data Source: ING112961 Cohort II Week 48 CSR Table 7.11 and Table 7.14; ING112574 Week 24 CSR Table 7.21 and Table 7.22. Note: ING112961 and ING112574 are non-comparative studies a. Day 6 to 8

Study Outcomes in ART-Experienced, INI-Resistant Subjects

The proportion of subjects considered to be responders based on <50 c/mL was 17/24 (71%) in ING112961 Cohort II at Week 48 and 72/114 (63%) in ING112574 at Week 24. The study outcomes at Week 48 and Week 24 for the analyses of subjects with <50 c/mL by TLOVR and Snapshot (MSDF) are provided in Table 53 below for each study, respectively.

Between ING112961 and ING112574, there were fewer virologic non-responders in the ING112961 Cohort II by Week 48 compared to ING112574 at Week 24, respectively.

In ING112574 the study outcomes for the Week 24 ITT-E population (Table 53) indicated a lack of virological suppression to <50 c/mL as the primary sub-reason for virological failure. Six subjects had implemented a non-permitted change of background ART and two subjects had been withdrawn for reasons of protocol deviation and loss to follow up. Of the 5 subjects who had discontinued study drug due to AEs, one died from progressive multifocal leucoencephalopathy (PML) post study withdrawal.

85 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 53 Study Outcomes for Plasma HIV-1 RNA in INI-resistant Subjects (ITT-E)

ING112961 ING112574 Week 48/TLOVR Week 24/Snapshot (MSDF) Cohort II Week 24 ITT-E DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=114 n (%) n (%) <50 c/mL <50 c/mL <400 c/mL Responder 17 (71) 72 (63) 79 (69) Non-responder due to Virological failure: 5 (21) 37 (32) 29 (25) Virologic reasons for failure Discontinued for insufficient viral load response, 2 (8) never suppressed Never suppressed through Week 48 but ongoing 2 (8) with data at Week 48 or beyond Rebound 1 (4) Discontinued study drug or added new ART before 1 (4) achieving confirmed suppression: Discontinued due to Adverse event - Discontinued due to Death - Non-permitted change in ART 1 (4)a Discontinued study drug while suppressed 1 (4)b Virological failure (Non-response) 37 (32) 29 (25) Data in window not below threshold (<50 c/mL) 23 (20) 16 (14) Discontinued for lack of efficacy 6 (5) 5 (4) Discontinued for other reason while not below 2 (2) 2 (2) threshold Change in ART 6 (5) 6 (5) Non-Virologic reasons for failure No virological data at Week 24 5 (4) 6 (5) Discontinued study due to AE or death 5 (4)c 5 (4) Discontinued for Other Reasons 0 1 (<1) Data Source: ING112961 Cohort II Week 48 CSR Table 7.33 and Table 7.18; ING112574 Week 24 CSR Table 7.5 and Table 7.25. a. Subject 2415 started MVC Day 65 b. Subject 2463 died (suicide) while suppressed c. One subject, Subject 1203 with progressive multifocal leucoencephalopathy, died post study withdrawal.

3.2.4.2. Secondary Efficacy Results

CD4+ cell counts over time

There were similar increases in CD4+ cell counts over time across INI-resistant subjects in ING112961 and ING112574. The median change from Baseline to Week 24 in CD4+ cells ranged from +65 to +79 cells/mm3 across both studies (Table 54). At Week 48, the median change from Baseline in CD4+ cells was 100 cells/mm3 in ING112961.

86 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 54 Median [IQR] Change from Baseline in CD4+ Cell Count (cells/mm3) by Visit in ART-Experienced, INI-resistant Subjects (Observed)

Week ING112961 ING112574 Week 48 Cohort II Week 24 ITT-E DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=114 n Median [IQR] CD4+ Cell n Median [IQR] CD4+ Count (cells/mm3) Cell Count (cells/mm3) Baseline 24 202 [19, 384] 114 120 [20, 310) Day 11 24 14 [0, 69] - - Week 4 24 35 [8, 69] 110 31 [0, 90] Week 8 24 50 [-2, 106] 111 50 [0, 90] Week 12 24 57 [8,103] 106 60 [11, 110] Week 16 23 49 [-10, 134] 102 60 [30, 130] Week 24 22 79 [17, 147] 100 65 [30, 146] Week 48 20 106 [45, 245] - - Data Source: ING112961 Cohort II Week 48 CSR Table 7.22; ING112574 Week 24 CSR Table 7.11. IQR: interquartile range: between 25 and 75 percentile

Incidence of Disease Progression (HIV-associated conditions, AIDS and death)

Across the INI-resistant subjects in ING112961 and ING112574, there was a similar low incidence of HIV-associated condition (5% to 8% [Data Source: ING112961 Cohort II Week 48 CSR, Section 6.5: ING112574 Week 24 CSR,Section 6.5]) and the lack of disease progression to CDC category C or death in this salvage population aligned with the overall immune recovery (Table 55).

Table 55 Summary of Post-Baseline HIV-1 Disease Progressions in ART- Experienced, INI-resistant Subjects (ITT-E)

Disease Progression by CDC Class ING112961 ING112574 Week 48 Week 24 Cohort II ITT-E DTG 50 mg DTG 50 mg BID + BR BID + BR N=24 N=183 n (%) n (%) Number of subjects progressing to Class C or Death 1 (4) 8 (4)

From CDC Class A To CDC Class C 0 0 From CDC Class B To CDC Class C 0 2 (1) From CDC Class C To New CDC Class C 0 5 (3) From CDC Class A, B, or C To Death 1 (4) 1 (<1) Data Source: ING112961 Cohort II Week 48 CSR Table 7.25; ING112574 Week 24 CSR Table 7.20.

87 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

3.2.4.3. Treatment Emergent Resistance

Table 56 provides the summary of PDVF for Cohort II in ING112961, the ITT-E population in ING112574 to the point of data cut, and the Week 24 ITT-E population in ING112574. In ING112961 Cohort II, 5/24 subjects met the definition for virological failure through Week 48. In ING112574, 35/183 subjects met the PDVF to the point of data cut.

Table 56 Protocol Defined Virologic Failure for ART-Experienced, INI- Resistant Subjects

Cumulative Number of PDVF (%) ING112961 ING112574 Cohort II ITT-E Week 24 ITT-E Week 48 DTG 50 mg BID + BR DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=183 N=114 All PDVF 5 (21) 35 (19) 26 (23) Virologic non-response Not defined 18 (10) 13 (11) Rebound Not defined 17 (9) 13 (11) Data source: ING112574 Week 24 CSR Table 7.9 and Table 7.36; ING112961 Cohort II Week 48 CSR Table 7.20.

Table 57 summarizes the treatment-emergent IN genotypic results for the PDVF populations in ING112961 (Cohort II, Week 48) and ING112574 (ITT-E). Three of the 5 PDVFs in Cohort II had treatment emergent resistance-associated IN mutations and reduced DTG susceptibility at the time point of failure. All 3 subjects at Day 1 harbored virus with Q148 +≥1 additional IN resistance associated mutations and all 3 subjects had further evolution in integrase resulting in a virus with Q148H +≥3 additional INI associated resistance mutations. Furthermore in each case there was an increase in DTG FC detected.

In ING112574, of the 35 subjects with PDVF in the ITT-E population (N=183), 31 subjects had paired Baseline and time of virological failure samples. Of these, 15/31 had treatment-emergent mutations detected at virological failure (Table 57). The majority (70%) of viruses with genotypic resistance at PDVF included Q148 +2 mutations. In the majority of subjects (13/15; 87%) with treatment-emergent resistance leading to increases in DTG FC, the Q148 mutation was present at Baseline or identified historically (Table 58). The most prevalent treatment- emergent mutations detected were IN resistance- associated secondary mutations that were added to a viral genotype with IN primary mutations present. All treatment-emergent mutations detected were well characterized RAL and/or EVG resistance associated mutations. Of note, 4 subjects had virus with treatment emergent mutations at position 148. Three of these subjects entered the study with only historic evidence of IN resistance and for all 3, the historic IN resistance provided was Q148H. The fourth subject whose virus had a treatment emergent mixture of Q148Q/R/K at the time point of PDVF had the Q148R mutation at Day 1.

88 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 57 IN Genotypic Resistance Detected at Time of PDVF but not Detected at Baseline in ART-Experienced, INI-resistant Subjects

Codon Baseline Genotype ING112961 ING112574 Genotype at PDVF Cohort II ITT-E DTG 50 mg BID + BR DTG 50 mg BID + BR PDVF Genotypic Population PDVF Genotypic Population N=5 N=31 ANY 3 (60%) 15 (48%) 97 Any change 2 (40%) 6 (19%) T97T T97A 3 (10%) T97T/A 2 (40%) 3 (10%) 138 Any change 2 (40%) 5 (16%) E138E E138A 1 (3%) E138E/K 2 (40%) 2 (6%) E138K 2 (6%) 148 Any change 4 (13%) Q148Q Q148H 1 (3%) Q148Q/H 2 (6%) Q148R Q148Q/R/K 1 (3%) 92 Any change 2 (40%) 2 (6%) E92E/Q 1 (20%) 2 (6%) E92E/V 1 (20%) 140 Any change 2 (6%) G140G G140G/S 1 (3%) G140S 1 (3%) 155 N155N N155H 2 (6%) 157 E157E E157E/Q 1 (3%) 147 S147S S147G 1 (3%) 143 Y143Y Y143Y/H 1 (3%) Data Source: ING112574 Week 24 CSR Table 12.55; ING112961 Cohort II Week 48 CSR Table 12.42.

Table 58 Summary of Virus with Q148+ Additional IN Secondary Mutations at Baseline or PDVF

IN Mutation Category ING112574 ING112574 DTG 50 mg BID + BR DTG 50 mg BID + BR N=183 N=31 Baseline PDVF Q148+≥2 21 (11%) 16 (52%) 2 Primary mutations 8 (4%)a 7 (23%)b Data source: ING112574 Week 24 CSR Table 12.9 and Table 12.23 a. 4 subjects with Q148+≥ 2 with T66 or Y143 mutations b. 6 subjects with Q148+≥ 2 with N155, E92, Y143, or T66 mutations

Table 59 summarizes the treatment-emergent IN phenotypic results for the PDVF populations in ING112961 (Cohort II, Week 48) and ING112574 (Week 24 ITT-E) based

89 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

on the DTG FC ratio (DTG FC at PDVF/DTG FC at Baseline). Three of the 5 PDVFs in Cohort II had treatment emergent changes in DTG susceptibility with a DTG FC ratio of 4.

In ING112574, for subjects meeting PDVF while on study, only 12/31(39%) had increases in DTG FC of 2-fold of that detected at Baseline (Table 59). For all 12 subjects, there was additional IN resistance associated mutations detected with the increased DTG FC.

Table 59 Summary of Treatment Emergent Increases in DTG FC in ART- Experienced, INI-Resistant Subjects with PDVF (DTG FC Ratio)

Ratio of DTG FC at PDVF to DTG FC ING112961 ING112574 at Baseline DTG 50 mg BID + BR DTG 50 mg BID + BR PDVF phenotypic Pop PDVF phenotypic Pop N=5 N=31 n (%) n (%) N 5 31 <1 0 4 (13) 1-<2 2 (40) 15 (48) 2-<4 0 1 (3) 4-<8 1 (20) 4 (13) 8 2 (20) 7 (23) Data source: ING112961 Cohort II Week 48 CSR Table 12.42; ING112574 Week 24 CSR Table 12.53.

3.3. Comparison of Results in Sub-Populations

Results of various subgroup analyses support the findings of the primary analysis. To assess the generalizability of the primary analysis results, consistency of the treatment difference was explored within subgroups. Homogeneity of the treatment difference was formally tested within each strata related to randomization (in pre-specified analyses). Other subgroups were explored based on summaries of the treatment differences within the group to identify any potential interaction.

3.3.1. ART-Naïve Subjects

3.3.1.1. Primary Efficacy by Age, Gender and Race

A subgroup analysis in age categories above and below age 36 years, based upon an approximation of the mid-point for the age range in ING113086 and ING114467 was conducted for the primary efficacy endpoint. An analysis for subjects aged 65 years old was planned, however only 13 subjects in the two studies fell into this subgroup; therefore efficacy analyses for the 65 years age group was not conducted due to the limitation of the data. Analysis of subjects 50 years of age was performed as to provide sufficient numbers of subjects for relevant assessment in older HIV-1 infected subjects.

In the treatment-naïve studies ING113086 and ING114467, there was no clinically meaningful difference between the proportion of subjects aged <50 years or 50 years in

90 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

the DTG treatment groups who achieved HIV-1 RNA <50 c/mL by Week 48. In addition, the studies showed similar responses in the DTG treatment groups for the primary efficacy endpoint in other categories including gender and race (Table 60). In support of these conclusions, approximately 150 subjects or more were represented in each of these Baseline demographic variables across the two studies.

In ING113086 DTG performed as well as RAL across demographic subgroups including age (<36 years vs. 36), gender, and race (White vs. non-white). Furthermore, in ING114467 the treatment differences between DTG+ ABC/3TC and Atripla were maintained across these demographic subgroups.

Table 60 Primary Efficacy by Age, Gender, and Race in ING113086 and ING114467 at Week 48 (ITT-E, Snapshot [MSDF])

Subgroup of Interest ING113086 ING114467 DTG 50 mg RAL 400 mg DTG 50 mg EFV/TDF/FTC once daily BID + ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 n (%) n (%) n (%) n (%) Age <36 162 / 186 (87) 181/219 (83) 175/202 (87) 171/215 (80) 36 199 / 225 (88) 170 / 192 (89) 189/212 (89) 167/204 (82) Age <50 years 324/370 (88) 312/365 (85) 319/361 (88) 302/375 (81) 50 years 37/41 (90) 39/46 (85) 45/53 (85) 36/44 (82) Gender Females 53/63 (84) 46/56 (82) 57/67 (85) 47/63 (75) Males 308/348 (89) 305/355 (86) 307/347 (88) 291/356 (82) Race White 306/346 (88) 301/352 (86) 255/284 (90) 238 285 (84) Non-White 55/65 (85) 50/59 (85) 109/130 (84) 99/133 (74) Data Source: ING113086 Week 48 CSR Table 7.6 and ISE Table 1.1 ING114467 Week 48 CSR Table 7.8 and ISE Table 1.2

3.3.1.2. Primary Efficacy by Stratification Factors (Baseline HIV-1 RNA/CD4+ cell count, Background NNRTI)

Baseline HIV-1 RNA

Response rates were summarized for Baseline HIV-1 RNA ( and >100,000 c/mL). Across treatment-naive studies, the DTG response rate was comparable to or better than comparator for subjects whose Baseline HIV-1 RNA was >100,000 c/mL and for subjects whose Baseline HIV-RNA was <100,000 c/mL (Table 61). As seen in prior studies, responses in general were higher in subjects with HIV-1 RNA 100,000 c/mL (90% across studies) when compared to subjects whose Baseline HIV-1 RNA was >100,000 c/mL (82% to 83% across studies) (Table 61).

91 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Analyses according to Baseline HIV-1 RNA level support the conclusion that treatment effects are not heterogeneous across the predefined strata in ING113086 and ING114467, respectively.

Baseline CD4+ Cell Count

Across treatment-naive studies, a similar DTG response was observed across most Baseline CD4+ cell count categories (Table 61).

In ING113086, DTG showed a more favorable numerical treatment response compared to RAL among subjects with CD4+ cell count <350 cells/mm3 (DTG 86%, RAL 80%) (Table 61).

In addition, in ING114467, higher response rates were observed in the DTG + ABC/3TC treatment group across all Baseline CD4+ cell count subgroups, with the exception of the CD4+ cell count <50 cells/mm3 subgroup (69% for DTG + ABC/3TC and 86% for Atripla), though this finding should be interpreted in view of the very small sample size in this subgroup (Table 61).

In ING114467, CD4+ categories (<200, 200) were stratification variables. The treatment differences across the stratified levels of Baseline CD4+ supported non- inferiority of DTG+ABC/3TC vs. Atripla (ING114467 Week 48 CSR Section 6.2.2.2). In the >200 subgroup, the response rates were consistent with that of the overall study population (DTG +ABC/3TC 89%, Atripla 81%). In the <200 subgroup, the response rates were DTG +ABC/3TC 79% and Atripla 77%, with difference and 95% CI: 1.5% [-13.3%, 16.4%]. The numbers in the <200 subgroup were low (DTG +ABC/3TC n=57, Atripla n=62). However, the point estimate for the treatment difference was above 0, the CI of the treatment difference in that subgroup included the overall treatment difference point estimate, and the estimated difference overlapped the CD4+ >200 subgroup entirely (Data Source: ING114467 Week 48 CSR Table 7.10). These findings are further supported by heterogeneity of the treatment difference, which showed that treatment difference between the high and low Baseline CD4+ were not statistically significant.

Background NRTI

Treatment differences across NRTI backbones support non-inferiority of DTG vs. RAL. Response rates summarized by backbone NRTI were similar across the treatment groups in subjects receiving ABC/3TC, (DTG 86%, RAL 87%), and in subjects receiving TDF/FTC (DTG 89%, RAL 85%) (Table 61).

92 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 61 Summary of Proportion of Subjects Responding based on HIV-1 RNA <50 c/mL by Baseline HIV-1 RNA, CD4+ cell count, Background NNRTI in ART-naïve Subjects

Response <50 c/mL ING113086a,b ING114467 Week 48/ Snapshot (MSDF) Week 48/ Snapshot (MSDF) DTG 50 mg RAL 400 mg DTG 50 mg + EFV/TDF/FTC once daily BID ABC/3TC once daily + 2 NRTI + 2 NRTI once daily N=411 N=411 N=414 N=419 Baseline HIV-1 RNA (c/mL) ≤100,000 267/297 (90) 264/295 (89) 253/280 (90) 238/288 (83) >100,000 94/114 (82) 87/116 (75) 111/134 (83) 100/131 (76) Baseline CD4+ cell count (cells/mm3) <50 5/8 (62) 0/6 (0) 9/13 (69) 12/14 (86) 50 to <200 38/47 (81) 34/44 (77) 36/44 (82) 36/48 (75) 200 to <350 128/144 (89) 118/139 (85) 143/163 (88) 126/159 (79) 350 to <500 111/126 (88) 123/136 (90) 116/131 (89) 105/128 (82) 500 79/86 (92) 76/86 (88) 60/63 (95) 59/70 (84) Background NRTI ABC/3TC 145/169 (86) 142/164 (87) - TDF/FTC 216/242 (89) 209/247 (85) Data Source: ING113086 Week 48 CSR Table 7.5, Table 7.6 and Table 7.7; ING114467 Week 48 CSR Table 7.10 and Table 7.8. a. Baseline HIV-1 RNA: The lower ends of the 95% CIs for the treatment differences are above -10%. The test for evidence against homogeneity of the treatment difference across high and low Baseline HIV-1 RNA was not statistically significant. b. Background NNRTI: The lower ends of the 95% CIs for the treatment differences are above -10%. The test for evidence against homogeneity of the treatment different across NRTI backbones was not statistically significant. In this study, investigators chose the dual NRTI backbone of either ABC/3TC or TDF/FTC for each subject. Overall, 41% of subjects received ABC/3TC, and 59% of subjects received TDF/FTC (m5.3.5.1, ING113086 Week 48 CSR Table 6.26).

Among subjects with low viral load (100,000 c/mL) receiving ABC/3TC, response rates were similar between the DTG and RAL treatment groups (DTG 87%, RAL 88%) (Table 62). Among subjects with low viral load (100,000 c/mL) and receiving the TDF/FTC NRTI, response rates between the DTG and RAL treatment groups again were similar (DTG 92%, RAL 91%).

Among subjects with high viral load (>100,000 c/mL) receiving ABC/3TC, response rates were similar between the DTG and RAL treatment groups (DTG 81%, RAL 82%). For subjects with viral load >100,000 c/mL receiving TDF/FTC, response rates were more disparate (DTG 83%, RAL 71%).

93 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 62 Proportion of Subjects Responding based on HIV-1 RNA <50 c/mL at Week 48 by Baseline HIV-1 RNA and Backbone Dual NRTI (ITT-E Population): ING113086

DTG 50 mg RAL 400 mg Difference in once daily + 2 NRTI BID + 2 NRTI Proportion N=411 N=411 (95% CI) n/N (%) n/N (%) (DTG – RAL) Response <50 c/mL at Week 48 100,000 c/mL, ABC/3TC 115/132 (87) 110/125 (88) -0.9 (-8.9, 7.2) 100,000 c/mL, TDF/FTC 152/165 (92) 154/170 (91) 1.5 (-4.5, 7.5)

>100,000 c/mL, ABC/3TC 30/37 (81) 32/39 (82) -1.0 (-18.4, 16.5) >100,000 c/mL, TDF/FTC 64/77 (83) 55/77 (71) 11.7 (-1.4, 24.8) Data Source: ING113086 Week 48 CSR Table 7.7

3.3.2. ART-Experienced, INI-Naïve Subjects

Higher response rates in DTG vs. RAL were consistent across subgroups defined by almost all clinical characteristics. The exceptions were age (50 years) and the use of boosted darunavir for which RAL response increased to a similar rate as DTG.

These are discussed in detail below.

3.3.2.1. Principal Efficacy by Age, Gender and Race

Virologic suppression (HIV-1 RNA <50 c/mL) treatment differences based on the Snapshot (MSDF) algorithm were comparable across the Baseline characteristics of gender, race, and HIV-1 subtype, and generally consistent across other subgroups explored with the exception of age (<50 vs. 50) (Data Source: ING111762 Week 24 CSR Table 7.8 and Figure 7.9).

The Snapshot (MSDF) response rate for subjects in the DTG arm was similar regardless of age (80% for <50 years vs. 78% for 50 years); whereas the response rate was lower in the RAL arm for subjects <50 years of age (67%) than those 50 years of age (80%). The test for treatment by age interaction was marginally significant based on a supplemental logistic regression analysis (p=0.063, although above the pre-specified 5% Type I error cut-off) (Data Source: ING111762 Week 24 Table 7.45). Additional summary tables by age, Baseline HIV-1 RNA and DRV/RTV use are provided in the Data Source: ING111762 Week 24 Table 7.44, ING111762 Week 24 CSR Post-hoc Table 7.46, Table 7.47, and Table 7.48.

A post-hoc logistic regression analysis was performed to assess the age by treatment interaction within a larger model that also included interaction terms for treatment by Baseline HIV-1 RNA and treatment by DRV/RTV use. Despite this additional adjustment, there was still some evidence of a treatment by age interaction (p=0.083) (Data Source: ING111762 Week 24 CSR Table 7.54). However, since the treatment differences by age were caused by an improvement in RAL response in older patients

94 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

(rather than a decrease in DTG response), the clinical importance of this interaction is uncertain.

Treatment differences in favor of DTG using the Snapshot (MSDF)algorithm were observed across all pre-specified levels of adherence (though not always statistically significant) with the exception of subjects with adherence <70% (ING111762 Week 24 CSR Section 6.1.2.4).

Table 63 Primary Efficacy by Age, Gender, and Race in ING111762 at Week 24 (mITT-E, Snapshot [MSDF])

Subgroup of Interest ING111762 DTG 50 mg once daily + BR RAL400 mg BID + BR N=354 N=361 n/N (%) n/N (%) Age <50 years 215/269 (80) 185/277 (67) 50 years 66/85 (78) 67/84 (80) Gender Females 89/107 (83) 85/123 (69) Males 192/247 (78) 167/238 (70) Race White 140/178 (79) 121/175 (69) Non-White 140/175 (80) 131/185 (71) Resistance 2-class 151/185 (82) 132/179 (74) 3 or more-class 130/169 (77) 120/182 (66) Clade B 192/241 (80) 176/245 (72) C 42/55 (76) 30/48 (63) Other 46/57 (81) 46/68 (68) Data Source: ING111762 Week 24 CSR Table 7.8

3.3.2.2. Plasma HIV-1 RNA <50 c/mL at Week 24 by Strata Related to Randomization

Results were summarized by Baseline HIV-1 RNA ( and >50 000 c/mL), DRV/RTV use in the presence of primary mutations or no DRV/RTV use vs. DRV/RTV use in the absence of primary mutations, and by the number of fully active background agents as measured by PSS at Baseline (2 and <2) (Table 64).The response rates in the DTG and RAL arms were lower for those subjects whose Baseline HIV-1 RNA was >50 000 c/mL compared with subjects whose Baseline was 50 000 c/mL. The test for evidence against homogeneity of the treatment difference across high and low Baseline HIV-1 RNA was not statistically significant (p=0.148); therefore, the treatment difference between DTG and RAL were maintained across this stratification factor.

The response rate for subjects in the DTG and RAL arms were similar regardless of the number (2 or <2) of fully active background agents (80% vs. 79%, respectively). The test for evidence against homogeneity of the treatment difference across PSS=2 and PSS <2 was not statistically significant (p=0.734).

95 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

The response rate for subjects in the DTG arm was similar for subjects who used DRV/RTV with no primary PI mutations compared to subjects who did not use DRV/RTV or used DRV/RTV but had primary PI mutations (Table 64). In the RAL arm, response rates were higher in subjects who used DRV/RTV without primary PI mutations than in those who either did not use DRV/RTV or did use DRV/RTV, but had primary PI mutations. The test for evidence against homogeneity of the treatment difference across the strata for DRV/RTV use without primary PI mutations (yes/no) was statistically significant (p=0.087) according to the pre-specified 10% type I error cut-off. The treatment difference was not statistically significant from 0 for subjects receiving DRV/RTV without primary PI mutations, but was statistically different in favor of DTG in subjects either not receiving DRV/RTV or receiving DRV/RTV with primary PI mutations. An additional pre-specified analysis within this latter group is described in ING111762 Week 24 CSR Section 6.1.2.2.1.

Table 64 Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 24 by Strata - Snapshot (MSDF) Analysis (mITT-E Population)

ING111762 DTG 50 mg RAL 400 mg Difference in once daily + BR BID + BR Proportion N=354 N=361 (95% CI) n/N (%) n/N (%) (DTG-RAL)a Response <50 c/mL at Week 24 Baseline Plasma HIV-1 RNA 50,000 c/mL 207 / 249 (83) 195 / 254 (77) 6.4 (-0.6, 13.3) >50,000 c/mL 74 / 105 (70) 57 / 107 (53) 17.2 (4.3, 30.1) p-valueb -- -- 0.148 PSS = 2 198 / 249 (80) 185 / 267 (69) 10.2 (2.8, 17.7) PSS <2 83 / 105 (79) 67 / 94 (71) 7.8 (-4.2, 19.8) p-valueb -- -- 0.734 DRV/RTV with no primary PI Mutations Yes 57 / 71 (80) 63 / 78 (81) -0.5 (-13.2, 12.2) No 224 / 283 (79) 189 / 283 (67) 12.4 (5.1, 19.6) p-valueb -- -- 0.087 Data Source: ING111762 Week 24 CSR Table 7.5 a. Difference: Proportion on DTG - Proportion on RAL (unadjusted). b. One-sided p-value from weighted least squares chi-squared statistic. A p-value 0.10 will be used to indicate statistically significant evidence of heterogeneity in the difference in proportions across levels of each analysis strata.

3.3.2.3. Plasma HIV-1 RNA <50 c/mL at Week 24 by Selected Baseline Background Regimen and Resistance Subgroups

The proportion of subjects with plasma HIV-1 RNA <50 c/mL was consistently higher in subjects receiving DTG compared to subjects receiving RAL (Table 65), although the difference was not always statistically significant.

96 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 65 Proportion of Subjects Responding with HIV-1 RNA <50 c/mL at Week 24 by Selected Baseline Treatment and Resistance Subgroups - Snapshot (MSDF) Analysis (mITT-E Population)

ING111762 DTG 50 mg RAL 400 mg Difference in once daily + BR BID + BR Proportion N=354 N=361 (95% CI) n/N (%) n/N (%) (DTG-RAL) Response <50 c/mL at Week 24 Baseline resistance: 2 class resistance 151 / 185 (82) 132 / 179 (74) 7.9 (-0.6, 16.4) Baseline resistance: 3 or more class resistance 130 / 169 (77) 120 / 182 (66) 11.0 (1.6, 20.4) Recently Approved ARTa in background regimen: No 145 / 189 (77) 119 / 186 (64) 12.7 (3.6, 21.9) Recently Approved ARTa in background regimen: Yes 136 / 165 (82) 133 / 175 (76) 6.4 (-2.2, 15.0) DRV/RTV in background regimen No 164 / 214 (77) 131 / 209 (63) 14.0 (5.3, 22.6) Yes, with Primary PI Mutations 60 / 69 (87) 58 / 74 (78) 8.6 (-3.7, 20.9) Yes, without Primary PI Mutations 57 / 71 (80) 63 / 78 (81) -0.5 (-13.2, 12.2) Use of moderate to strong inducers in background 19 / 27 (70) 16 / 26 (62) 8.8 (-16.6, 34.3) regimen Data Source: ING111762 Week 24 CSR Table 7.8 and Post hoc Table 7.49 a. For analysis purposes, darunavir/ritonavir, etravirine, enfuvirtide, and maraviroc were included as recently approved ART.

3.3.3. Studies in ART-Experienced, INI-resistant Subjects

3.3.3.1. Functional Monotherapy Phase

Good short-term responses were seen across sub-groups related to HIV disease factors (i.e., HIV-1 RNA, CD4+ cell count), Baseline INI resistance, and activity of the failing background regimen in both studies. In both studies, Baseline CD4+ cell count, IN mutational pathway, and DTG FC were associated with differences in short-term response rates. Limited Baseline HIV-1 RNA subgroups were examined in ING112961 Cohort II due to the limited sample size; however, in ING112574, higher Baseline HIV-1 RNA was associated with larger declines in HIV-1 RNA at Day 8. Additionally, the phenotypic susceptibility of the failing background regimen was associated with larger declines in HIV-1 RNA in ING112961 but not in ING112574. This difference may be related to the greater treatment experience of the patient population enrolled in ING112574 versus that enrolled in ING112961 Cohort II (Table 66). Response rates were higher in subjects without primary IN mutations detected at Screening and without INI drug pressure during Screening.

97 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 66 Change from Baseline in Plasma HIV-1 RNA log10 c/mL at Day 11 and Day 8: Subgroup Analysis in INI-resistant Subjects (LOCDBF, ITT-E)

Factorsa ING112961 ING112574 Cohort II ITT-E DTG 50 mg BID DTG 50 mg BID N=24 N=183 n Mean [SD] n Mean [SD] Baseline viral load (c/mL) <10,000 c/mL 7 -1.71 [0.21] - - 10,000 c/mL 17 -1.77 [0.63] - - <1000 - 21 -0.92 [0.32] 1000 to <10,000 - 49 -1.51 [0.49] 10,000 to <50,000 - 52 -1.47 [0.66] 50,000 to <100,000 - 20 -1.41 [0.59] 100,000 to 500,000 - 34 -1.63 [0.65] >500,000 - 6 -1.17 [0.75] Baseline CD4+ cell count <50 cells/mm3 7 -1.58 [0.65] 50 cells/mm3 17 -1.83 [0.48] <50 - 49 -1.26 [0.68] 50 to <200 - 60 -1.53 [0.67] 200 to <350 - 34 -1.55 [0.38] 350 to <500 - 24 -1.52 [0.43] 500 - 15 -1.20 [0.62] Baseline IN Mutation pathway Q148 + 2d 2 -1.34 [0.63] 20 -0.98 [0.81] Q148 + 1 8 -1.65 [0.49] 32 -1.13 [0.51] Mixturea or ≥2 primary mutations 1 -1.35 [0] 8 -1.45 [0.76] N155 6 -1.57 [0.56] 33 -1.43 [0.51] Y143 6 -2.10 [0.14] 28 -1.70 [0.42] Otherb IN mutations 1 -2.92 [0] 1 -1.85 [0] Primary integrase mutation detected - 122 -1.34 [0.62] Primary not detected - 60 -1.62 [0.55] Baseline PSSf to failing regimen 0 15 -1.57 [0.50] 96 -1.44 [0.52] 1 6 -1.89 [0.35] 67 -1.47 [0.71] 2 3 -2.43 [0.47] 11 -1.22 [0.50] >2 0 8 -1.26 [0.73] Receipt of prohibited medication(s) in functional monotherapy phasec No 22 -1.77 [0.55] 176 -1.44 [0.60] Yes 2 -1.64 [0.47] 6 -1.31 [0.74] RAL/EVG treatment Ongoing at Screening - 100 -1.35 [0.63] Discontinued prior to Screening - 82 -1.54 [0.57] Data Source: ING112961 Cohort II Week 48 CSR Table 7.7, Table 7.31, Table 7.100 and Table 7.101; ING112574 Week 24 CSR Table 7.6. a. Mixtures: Q148H + G140S/Y143H (n=1); Q148H,+ E138A+G140S/Y143H (n=2) b. Others: ING112961 E92Q (n=1); none (screen; G140G/S, Q148H/Q) (n=1); ING112574 T66 (n=1) c. Receipt of ETR without DRV/RTV or LPV/RTV (n=2), FPV plus RAL (n=1),TPV/RTV (n=1), EFV (n=1) and glucocorticoid (n=1) potentially impacting DTG exposure. d. Q148+2

98 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Within the category of Primary Integrase mutations detected, there was no difference in viral response at Day 8 based on whether or not drug pressure from RAL/EVG was present before DTG was started. Additionally, for subjects with historical integrase inhibitor resistance, viral responses at Day 8 were comparable based on whether or not RAL/EVG was ongoing during screening.

Table 67 ING112574: Primary IN Mutations and INI Drug Pressure at Baseline

Primary IN mutation at Baseline RAL/EVG Status n Mean SD Detected Discontinued prior to Screening 32 -1.39 0.509 Ongoing at Screening 90a -1.33 0.653 Not detected Discontinued prior to Screening 50 -1.63 0.583 Ongoing at Screening 10 -1.52 0.305 Data Source: ING112574 Week 24 CSR Table 7.100 and Table 7.101 a. 91 subjects had primary IN mutation with RAL/EVG ongoing at Screening, but only 90 subjects with Day 8 viral load data

Linear Regression Analyses for Functional Monotherapy

A key secondary objective in ING112574 was to explore the impact of Day 1 covariates (e.g. demographics, HIV RNA, resistance to DTG, overall susceptibility score of background ART) and PK on treatment response (e.g. antiviral activity, development of resistance, and/or AEs) using multivariate analysis.

A number of factors were included in the model building in Step 1 that would be considered highly correlated: IN genotypic pathway and/or number of IN mutations with FC in half-maximal inhibitory concentration (IC50); DTG pre-dose concentration (C0) and FC with phenotypic inhibitory quotient (PIQ); OSS/PSS and GSS. As the initial results indicated Baseline DTG resistance (represented by DTG FC in susceptibility) to have the strongest impact on the Day 8 HIV-1 RNA change from Baseline, further regression analyses were conducted to determine which of the Baseline resistance factors would be individually impactful when assessed in separate linear regression models adjusting for other factors identified from the model building process.

Of all factors examined, Baseline IN resistance and Baseline HIV-1 RNA were strongly associated with the Day 8 response (ING112574 Week 24 CSR Section 6.2.1.2). Table 68 shows the effects of each parameter, with Baseline resistance represented by genotypic resistance pathway.

99 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 68 ING112574: Summary Results of Multivariate Linear Regression Analyses for Change from Baseline in Plasma HIV-1 RNA (log 10 c/mL) at Day 8 against Baseline Characteristics (LOCFDB, VO) including IN Mutation Category

Baseline factors N Effect of Estimated S.E. 95% CI for P-value effect estimated effect IN mutation category: 143 vs Y143 Q148+2 0.72 0.155 (0.41 ,1.02) <0.0001 Q148+1 0.48 0.147 (0.19, 0.77) 0.0014 N155 0.10 0.149 (-0.19, 0.04) 0.4952 Primary not detected 0.06 0.130 (-0.20, 0.32) 0.6451

Baseline HIV-1 RNA (c/mL) 10-fold -0.12 0.050 (-0.22, -0.02) 0.0164 increase

DTG PK exposure – Day 8 1 unit -0.05 0.023 (-0.09,- 0.00) 0.0355 C0g/mL increase

PSSf of Day 1 to 8 ART vs 0 >2 0.53 0.246 (0.05, 1.02) 0.0323 2 0.43 0.199 (0.04, 0.83) 0.0306 1 -0.05 0.093 (-0.24, 0.13) 0.5680 Data Source: ING112574 Week 24 CSR Table 7.37

When compared to the response with the Y143 pathway virus (-1.7 log10 c/mL reduction; Data Source: ING112574 Week 24 CSR Section 6.2.1.1) subjects with virus exhibiting the mutation category Q148+2 showed a reduced response, with a 0.72 log10c/mL lower response compared to that of the Y143 genotypic category. Other representations of Baseline resistance are explored in the CSR (Data Source: ING112574 Week 24 CSR, Section 9).

3.3.3.2. Optimized Phase

Table 68 summarizes the longer term response rates in INI-resistant subjects based on subgroups, including Baseline HIV-1 RNA, CD4+ cell count, activity of the OBR (PSS), and IN mutational pathway. There was no multivariate analysis of predictors conducted based on Cohort II data due to the small number of subjects. Factors that impact virologic response in ING112574 from multivariate analyses included Baseline HIV-1 RNA, CD4+ cell count, DTG FC and IN categories(Data Source: ING112574 Week 24 CSR, Table 7.34). Increasing activity of the OBR had no impact on response at Week 24 in ING112574. This may be due, in part, to the weaker activity of the additional active agents (beyond 1) in ING112574; in many instances, these 2nd and 3rd active agents were NRTIs (Data Source: ING112574 Week 24 CSR, Section 6.3.2.2). DTG is efficacious (sustained viral load suppression) in a population of patients with current or historical clinically-relevant integrase mutations and DTG FC.

100 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 69 Proportion of Subjects with Plasma HIV-1 RNA <50 c/mL: Subgroup Analysis for INI-Resistant Subjects

Baseline factors ING112961 ING112574 Week 48/TLOVR Week 24/Snapshot (MSDF) Cohort II Week 24 ITT-E DTG 50 mg BID + BR DTG 50 mg BID + BR N=24 N=114 Viral load, n (%) <10,000 c/mL 6/7 (86) N/A 10,000 c/mL 11/17 (65) N/A

<1000 c/mL - 11/12 (92) 1000 to <10,000 c/mL - 23/30 (77) 10,000 to <50,000 c/mL - 21/ 29 (72) 50,000 to <100,000 c/mL - 8/ 13 (62) 100,000 to 500,000 c/mL - 8/ 24 (33) >500,000 c/mL - 1/ 6 (17) CD4+ cell count, n (%) <50 cells/mm3 4/7 (57) 11/ 36 (31) 50 cells/mm3 13/17 (76) 61/78 (78) PSSf to OBR at Day 11/8a, n (%) 0 1/1 (100) 4/ 5 (80) 1 6/9 (67) 27/ 41 (66) 2 8/11 (73) 29/ 47 (62) >2 2/3 (67) 12/ 21 (57) IN Mutation, n (%) Q 148+2 1/2 (50) 0/ 12 Q148+1 4/8 (50) 10/ 20 (50) Mixture or 2 Primary Mutations 1/1 (100) 3/5 (60) N155 6/6 (100) 18/ 21 (86) Y143 4/6 (67) 10/ 15 (67) Other 1/1 (100) N/A FC in IC50 to DTG Missing - 4/ 4 (100) 0 to 2.5 - 58/ 78 (74) >2.5 to 4 - 2/ 8 (25) >4 to 8 - 5/ 11 (45) >8 to 10 - 1/ 4 (25) >10 to 15 - 1/ 5 (20) >15 to 20 - 1/ 3 (33) >20 to 25 - 0/0 >25 - 0/ 1 <2 7/9 (78) - ≥2 10/15 (67) - Data Source: ING112961 Cohort II Week 48 Table 7.16; ING112574 Week 24 CSR Table 7.31 Note: PSSf: Phenotypic susceptibility score on fully active agents. a. Day 11 for ING112961 and Day 8 for ING112574

101 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Regression Analyses for Week 24

Aligned with the objective to explore the impact of Day 1 covariates (e.g. demographics, HIV RNA, resistance to DTG, overall susceptibility score of background ART) and PK on treatment response, logistic regression analyses were conducted for predictive factors for the Week 24 response.

As with the multivariate analyses conducted on Day 8 response, a number of factors were included that would be considered highly correlated: IN genotypic pathway and/or number of IN mutations with FC in IC50; DTG C0 and FC with PIQ; OSS/PSS and GSS. Similar to the Day 8 analyses, further models were conducted to determine whether genotypic and phenotypic resistance were individually significant predictors of response adjusting for potential confounding factors identified from the model building process (Data Source: ING112574 Week 24 CSR, Section 6.3.2.2).

As both DTG FC and the number of IN resistance mutations remained in the second step of the regression analyses (Data Source: ING112574 Week 24 Table 7.34) three additional models were conducted to evaluate the individual contributions of FC, mutation category and number of IN mutations (Data Source: ING112574 Week 24 CSR Table 7.39, Table 70, and Table 7.41).

In these further analyses, similar to Baseline FC in susceptibility to DTG, Baseline IN mutation category was strongly predictive of outcome (p<0.001). After adjusting for the covariates Baseline HIV-1 RNA and CD4+cell count, DTG exposure, OBR susceptibility (full PSS score), subjects with a higher Baseline DTG FC, or whose virus exhibited the Q148+2 or Q148+1 pathways or who had a larger number of IN resistance mutations at Baseline were all less likely to respond at Week 24 with their HIV-1 RNA suppressed to <50 c/mL. The Odds Ratio for response was particularly low at 0.005 for those harbouring virus with Q148+2 secondary mutations at Baseline when compared to the response rate in those with Y143 virus.

102 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 70 ING1112574: Summary Results of Multivariate Logistic Regression Analyses for Proportion of Subjects with Plasma HIV-1 RNA <50 c/mL at Week 24 against Baseline Factors (Snapshot [MSDF], VO) including IN Mutation Category

Baseline Factors n Effect of Odds Ratio 95% CI for Odds P-value Ratio IN mutation category: 100 vs Y143 Q148+2 0.005 (0.000, 0.130) 0.001 Q148+1 0.124 (0.014, 1.084) 0.059 N155 0.524 (0.054, 5.119) 0.579 Primary not detected 1.600 (0.276, 9.266) 0.600

HIV-1 RNA (c/mL) 10-fold 0.195 (0.057, 0.662) 0.009 increase

CD4+ (cell/mm3) 50-unit 1.619 (1.098, 2.386) 0.015 increase

DTG exposure: C0-average 1 unit 1.049 (0.681, 1.616) 0.829 (g/mL) increase

PSSf to OBR: vs 1 >2 0.785 (0.175, 3.516) 0.751 2 0.512 (0.084, 3.122) 0.468 Data Source: ING112574 Week 24 CSR Table 7.40

3.3.3.3. Antiviral Activity of DTG by Baseline Resistance in INI-resistant Subjects in ING112574

As per the FDA Guidance for Industry and the European Medicines Agency (EMA) guideline, analyses of antiviral activity of DTG observed in Study ING112574 were conducted according to genotypic and/or phenotypic resistance [FDA, 2007; EMA, 2009]. In this analysis no precise phenotypic FC cut-off could be defined to effectively predict antiviral activity at both Day 8 and Week 24. Three integrase mutation groups could be derived and were found to correlate with antiviral response: ‘No Q148 mutation’ (Y143, N155H, T66, and E92Q mutations or historical evidence of INI resistance), ‘Q148+1’ (Q148H/K/R with one mutation [G140A/C/S, L74I, E138A/K/T]), and ‘Q148+2’ (Q148H/K/R with two or three mutations [G140A/C/S, L74I, E138A/K/T]).

More than 90% of subjects achieved full response (>1 log10 c/mL decline or <50 c/mL plasma HIV-1 RNA) at Day 8 in the group of subjects with 155/143/66/92/no primary mutation detected. In subjects with Q148 mutations, virologic response at Day 8 decreased with increasing number of secondary mutations, however approximately half of subjects with Q148+2 still achieved full response at Day 8 (Table 71).

103 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 71 ING112574: Virologic Response (Plasma HIV-1 RNA) at Day 8 by Derived Baseline IN Resistance Mutation Group (Day 8 Virologic Outcome Population, N=177)

INI Mutations at Baseline Number of Mean CFB (SD)c at Day 8 % >1 log10 Decline or Subjects <50 c/mL at Day 8 No Q148H/K/R mutationsa 122 -1.59 (0.51) 92% Q148 + 1 secondary mutationb 35 -1.18 (0.52) 71% Q148 + 2 secondary mutationsb 20 -0.92 (0.81) 45% Data Source: m5.3.5.4 ING112574 Annex B Virology Report Table 12.106 and Table 12.110 a. CFB: Change from Baseline; SD: Standard deviation. b. Includes Baseline primary IN resistance mutations N155H, Y143C/H/R, T66A, E92Q and primary mutation not detected at Baseline. c. G140A/C/S, E138A/K/T, L74I.

After the monotherapy phase (i.e., Day 8 visit), subjects were to optimize their background regimen. Of the 114 subjects who completed 24 weeks on study or discontinued before data cutoff, 72 (63%) had <50 c/mL RNA at Week 24 (Snapshot [MSDF]). In subjects with Q148 mutations, virologic response at Week 24 decreased with increasing number of secondary mutations (Table 72). Background overall susceptibility score (OSS) was not associated with Week 24 response (Table 72), highlighting the independent activity of DTG in driving sustained virologic responses in this INI-resistant population.

Table 72 Number and % of Subjects with HIV-1 RNA <50 c/mL at Week 24 by OSS of OBR and Derived IN Resistance Mutation Group (Snapshot [MSDF]) (Week 24 Virologic Outcome Population, N=101)

Derived IN Mutation Group OSS=0 OSS=1 OSS=2 OSS>2 Total No Q148H/K/R mutationsa 2/2 (100%) 24/29 (83%) 21/28 (75%) 10/13 (77%) 57 (79%) Q148 + 1 secondary mutationb 2/2 (100%) 3/7 (43%) 4/11 (36%) - 9 (45%) Q148 + 2 secondary mutationsb 1/2 (50%) 0/7 - - 1 (11%) Data Source: ING112574 Annex B Virology Report Table 12.107 a. Includes Baseline primary IN resistance mutations N155H, Y143C/H/R, T66A, and primary mutation not detected. b. G140A/C/S, E138A/K/T, L74I.

3.3.4. Virologic Response Rates in Historical Studies

As ING112574 did not include a comparator agent in the study design, a summary of virologic outcomes from historical studies for antiretroviral agents addressing in-class resistance is presented below. As ING112574 required use of at least 1 fully active drug in the background regimen, the most relevant comparison is to response rates for regimens including investigational agent and an OBR with PSS 1. Week 24 DTG virologic response rates in ING112574 are comparable or better than those observed in these historical studies, keeping in mind the limitations of cross-study comparisons and different analyses applied to the virologic endpoints.

104 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Table 73 Studies of Agents Addressing In-class Resistance

Active Comparator Study Endpoint / Time Comparison Incl. Criteria OBR Activity response response Reference point n/N (%) n/N (%) 0 (# active) 21/45 (47) 4/46 (9) Failing ART, ≥1 1 62/105 (59) 23/95 (24) DUET-1 ETR vs. PBO NNRTI and ≥3 PI <50 c/mL at Week 24 2 45/66 (68) 57/93 (61) Madruga, 2007 mutations 3+ 40/61 (66) 32/49 (65) Any 170/304 (56) 119/308 (39) 0 (# active) 19/43 (44) 3/45 (7) Failing ART, ≥1 1 58/94 (62) 40/116 (34) DUET-2 ETR vs. PBO NNRTI and ≥3 PI <50 c/mL at Week 24 2 67/82 (82) 45/64 (70) Lazzarin, 2007 mutations 3+ 39/49 (80) 37/51 (73) Any 183/295 (62) 129/296 (44) 0 (#active) 5/25 (20) 0/18 3 class experience, ≥1 1 17/34 (50) 1/ 40 (3) POWER-1 and -2 DRV vs. CPI <50 c/mL at Week 48 Clotet, 2007 primary PI mutation 2+ 27/ 48 (56) 10/ 60 (17) Any 50/110 (45) 12/120 (10) ENF-naïve 24/53 (45) N/A 3 class experience, DRV (no ENF reused 13/49 (27) N/A POWER-3 ≥1 primary PI <50 c/mL at Week 24 Molina, 2007 comparator) mutation ENF not used 61/144 (42) N/A Any 98/246 (40) N/A <50 c/mL at Week 24 Any 139/582 (24) 54/577 (9) 3+ mos 3 class experience, incl ≥2 0 (# GT susc) 11.6-21.1% 0-13.2% Gathe, 2006; RESIST-1 and -2 TPV vs. CPI >1 log10 c/mL drop PI regimens , ≥1 3+ 54.7-57.6% 29.8-41% Cahn, 2006 primary PI mutation at Week 24 Any 240/582 (41) 109/577 (19) CPI, control protease inhibitor; DRV, darunavir; EFN, enfuvirtide; ETR, etravirine; PBO, placebo; TPV, tipranavir

105 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

4. ANALYSIS OF CLINICAL INFORMATION RELEVANT TO DOSING RECOMMENDATIONS

This section describes the data relevant to dose selection decisions made with DTG, and concludes with the data and subsequent decisions regarding the selected dose in treatment-naive adults, treatment-experienced and INI-naive adults and adolescents (of 12 to <18 years old and at least 40 kg of weight), and INI-resistant adults with HIV-1 infection.

Clinical pharmacology data to support dose recommendations in various patient populations and with concomitant medications are detailed in m2.7.2.

4.1. Dose Selection for ART-Naïve Adult Subjects

Dolutegravir 50 mg once daily in combination with other ART is recommended for treatment-naive adults with HIV-1 infection. The selection of the 50 mg once daily dose for evaluation in the Phase III program was based upon data from the Phase IIb dose- ranging study ING112276 comparing DTG 10 mg, 25 mg, and 50 mg once daily dose in treatment-naive adults. Two Phase III studies, ING113086 and ING114467, were performed to demonstrate the non-inferiority of DTG 50 mg once daily against the selected comparator drug in combination with NRTIs in ART-naive adult subjects. An additional large ongoing Phase IIb study, ING114915, in treatment-naive subjects is also administering DTG 50 mg once daily.

4.1.1. Phase IIb Study ING112276

Study ING112276 assessed durability of response (through 96 weeks) and safety profiles across DTG doses at 10 mg, 25 mg, and 50 mg once daily in combination with NRTIs in HIV-1infected, treatment-naïve adult subjects (Section 1.7.2.2 for study design). A fourth cohort of subjects received EFV with NRTIs as a control arm. A sustained antiviral response without genotypic or phenotypic evidence of INI or NRTI resistance through Week 96 was observed at the 50 mg DTG dose and no apparent relationship between DTG dose and antiviral response was observed (Section 2.2.2; ING112276 Week 96 CSR). DTG was well tolerated at all doses evaluated. The maximum tested dose, 50 mg once daily, was selected for the evaluation in Phase III program in treatment-naive adult subjects and treatment-experienced (INI-naive) adult subjects to accommodate potential reductions in DTG exposure by intrinsic or extrinsic factors, e.g. drug-drug interaction, imperfect adherence, or other causes (Section 1.6.1).

4.1.2. Pivotal Phase III ART-Naive Studies

In the pivotal Phase III Study ING113086, the efficacy of DTG 50 mg once daily + 2 NRTIs for the management of HIV-1 infection in ART-naive adult subjects was demonstrated to be non-inferior to RAL 400 mg BID + 2 NRTIs through Week 48 based on the 10% non-inferiority margin (see Section 2.1.1). Few subjects experienced protocol-defined virologic failure (5% on DTG arm and 7% on RAL arm), and while one and four subjects on RAL had INI and/or NRTI mutations at failure, respectively, there

106 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

were no subjects on DTG who had INI or NRTI mutations detected (See Section 3.2.3). The safety profile for DTG was similar to RAL (m2.7.4).

In the pivotal Phase III study ING114467, the efficacy of DTG +ABC/3TC 50 mg/600 mg/300 mg once daily was demonstrated to be superior to Atripla (See Section 2.1.2). Subjects receiving the DTG-containing regimen had fewer withdrawals due to AEs when compared to the EFV-containing regimen, which led to greater overall treatment success with the DTG-containing regimen (See Section 2.1.2). As observed in ING113086, no subjects who received DTG+ ABC/3TC had primary INI or NRTI mutations; in contrast, four subjects treated with EFV/TDF/FTC developed primary NNRTI mutations, and one developed primary mutations to the NRTI backbone (See Section 3.2.3). The DTG-containing regimen (DTG+ABC/3TC) in ING114467 had a safety profile that was generally favourable when compared with the EFV-containing regimen (EFV/TDF/3TC) (See m2.7.4 for details).

In ING113086 and ING114467, virologic response rate differences between DTG and RAL and DTG/ABC/3TC and Atripla, respectively, were maintained across demographic subgroups including age, gender and race (See Section 3.3.1.1), with comparable and adequate response rates noted for each treatment group within each sub-group. Therefore the same dose of DTG may be administered regardless of demographic characteristic.

The Week 48 response rates for subjects receiving DTG 50 mg once daily in combination with backbone NRTI was consistent with the Week 48 response rate for RAL 400 mg twice daily (86%) and EFV 600 mg once daily (82%) observed in the STARTMRK study, and with the Week 48 response rates observed for tenofovir/emtricitabine/ cobicistat/elvitegravir and Atripla (88% and 84%, respectively) in naive subjects [Lennox, 2009; Sax, 2012]. Therefore, the DTG response rates (HIV-1 RNA <50 c/mL) assessed at Week 48 in both studies were similar to those observed with standard of care third agents in contemporary studies in treatment-naive populations.

The antiviral efficacy of the DTG 50 mg once daily dose has thus been demonstrated in two well-controlled studies against standard of care comparators and has shown comparable efficacy across key demographic sub-groups. Thus, DTG 50 mg once daily is the recommended dose for all treatment-naive, HIV-infected adults.

4.1.3. ART-Naïve Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis

DTG C0 was estimated at 1.18 g/mL (geometric mean), which is 18 times higher than the in vitro PA-IC90 (0.064 g/mL), based on sparse PK sampling in Study ING113086 (see m2.7.2 for details). Based on a population PK analysis using pooled data (ING111521, ING112276, and ING113086), neither demographic characteristics (e.g., gender, race, age, weight), co-infection status (e.g., hepatitis C), smoking status, nor other lab parameters (e.g., bilirubin, alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine clearance [CRCL]) were determined to cause clinically significant differences in DTG exposure requiring dose adjustment (see m2.7.2 for details).

107 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

In Study ING112276, no exposure-response relationship was identified for efficacy endpoints (See m2.7.2, Section 2.3.4). The lack of DTG exposure-antiviral activity and DTG exposure-immunologic response relationship was consistent with the high response rates and low virologic failure rate observed in this study, as would be expected given that all three doses achieved exposures on the plateau of the dose-response curve defined in Study ING111521.

4.1.3.1. Supportive Study ING111521

Study ING111521 was a Phase IIa, randomized, double-blind, dose-ranging study. In this study, INI-naive, HIV-1-infected adults currently off antiretroviral therapy were randomized to receive DTG (2, 10, or 50 mg) or placebo once daily for 10 days in an eight active and two placebo randomization scheme per DTG dose. Placebo patients were pooled for the purpose of analysis.

Significant reductions in plasma HIV-1 RNA from Baseline to Day 11 were observed for all DTG dose groups compared with placebo (p<0.001), with a mean decrease of 1.51 to 2.46 log10 c/mL. In addition, a well characterized dose-response relationship was observed for viral load decrease. Most patients (7/10, 70%) receiving DTG 50 mg achieved plasma HIV-1 RNA less than 50 c/mL. The pharmacokinetic variability was low (coefficient of variation, range 25 to 50%). Plasma HIV-1 RNA reduction was best predicted by Cτ using an Emax model (Figure 7; see m2.7.2, Section 2.3.3). Based on data from this study, doses were selected for evaluation in ING112276, the Phase IIb, dose-ranging, therapeutic study in treatment-naïve, HIV-infected subjects.

4.2. Dose Selection for ART-Experienced, INI-Naive Adult Subjects

Dolutegravir 50 mg once daily is recommended for treatment-experienced, INI-naive adults with HIV-1 infection. The selection of the 50 mg once daily dose for evaluation in the Phase III program was based upon data from ING112276. One Phase III study, ING111762, was performed to demonstrate the non-inferiority of DTG 50 mg once daily against the selected comparator drug, RAL, both in combination with an investigator selected background regimen in treatment-experienced, INI-naive adult subjects.

4.2.1. Principle of Dose Selection

In addition to the dose selection strategy discussed in Section 4, special consideration of dose selection was given for Study ING111762 in terms of effect of background therapy and potential impact of drug-drug interactions between DTG with concomitant antiviral therapy.

4.2.1.1. Impact of Background Therapy and Predicted Durability of DTG on Selected Dose

As subjects evaluated in ING111762 have various background antiviral therapy components with variable activity and Baseline resistance, the selected dose of DTG needed to deliver high drug pressure (e.g., exposure), especially in patients with less than 2 fully active anti-retroviral agents in their background therapy in order to achieve long-

108 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

term durability. To ensure durability of response in the setting of a treatment- experienced subject, the highest once daily (50 mg) dose of DTG assessed in ING112276 was also evaluated in ING111762. Similar to the rationale for ART-naïve subjects, the 50 mg dose provides high exposures that compensate, in part, for any deficiencies of partially active background therapy and for any drug interactions decreasing DTG exposures.

4.2.2. Pivotal Phase III Study ING111762 (ART-Experienced, INI-Naive)

The efficacy of DTG once daily in ART-experienced, INI-naive subjects was confirmed by the Week 24 results of Study ING111762. At Week 24, virologic suppression (HIV-1 RNA <50 c/mL) in the DTG arm (79%) was statistically significantly greater than in the RAL arm (70%) based on the pre-specified analysis of outcomes of the FDA Snapshot (MSDF) algorithm (adjusted treatment difference and 95% CI 9.7 [3.4, 12.3], p=0.003). This result was supported by the Per-Protocol analysis, where 81% and 72% of DTG and RAL subjects, respectively, achieved plasma HIV 1 RNA <50 c/mL at Week 24 adjusted treatment difference and 95% CI: 9.3 [3.0, 15.7]. Other pre-specified sensitivity analyses confirmed these results. Virologic response rate treatment differences were comparable across key subgroups including gender, race and HIV-1 subtype. Virologic response rate treatment differences were also consistent across the number of active agents in the background regimen and Baseline resistance. More subjects on DTG than on RAL achieved virologic suppression with a Baseline background regimen of <2 active agents (PSSf<2, DTG: 79%; RAL: 71%; PSSp=1, DTG: 77%; RAL: 64%; GSS<2, DTG: 79%; RAL 68%) and with 2-class (DTG: 82%; RAL: 74%) and 3-class (DTG: 77%; RAL: 66%) resistance.

4.2.2.1. Comparison to Historical Studies

In the BENCHMRK studies in a treatment-experienced, INI-naïve patient population, RAL subjects who suppressed had done so by Week 4, remained suppressed at Week 16 and 24, and in general, had durable suppression at Week 48 [Steigbigel, 2008].

Therefore, the Week 24 response was a good predictor of longer term response at Week 48 (HIV-1 RNA <50 c/mL: 60% (BENCHMRK-1) and 65% (BENCHMRK-2) at Week 24 with a combined response rate of 63% at Week 48) [Steigbigel, 2008].

The performance of RAL in ING111762 is comparable to historical studies with RAL in this patient population. As the BENCHMRK studies included subjects with 3 active and <1 active background agent, consideration should be given for the sub-group analysis for phenotypic susceptibility score (PSS) and a similar population to that enrolled in ING111762. Using an observed-failure approach, response rates for RAL in BENCHMRK-1 and -2 were 61% and 71% for PSS of 1 and 2, respectively, at Week 48 [Cooper, 2008]. RAL response rates in ING111762 were comparable to the response rates observed in BENCHMRK-1 and -2 for PSS of 1-2. In a more recent study in treatment-experienced, integrase-naïve subjects, response rates for EVG versus RAL were 59% and 58% of subjects, respectively, for HIV-1 RNA <50 c/mL (TLOVR algorithm) at Week 48 [Molina, 2012]. The RAL response rate at Week 24 in ING111762 was numerically higher than the response rate for RAL at Week 24 seen in this study versus EVG with a similar design and patient population.

109 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Based on comparison to these studies, the DTG response rate at Week 24 is expected to be predictive of Week 48 efficacy in ING111762. As the response rates on RAL are comparable to or better than those observed in historical studies, the statistically significant treatment difference in favor of DTG was not attributable to the under- performance of RAL.

4.2.2.2. ING111762 Pharmacokinetics and Pharmacokinetics/ Pharmacodynamics

Plasma DTG pre-dose concentrations, C0, were similar across visits (Week 4 and 24). C0_avg was calculated for each subject as the average of Week 4 and Week 24 C0 for the purpose of this report. The overall geometric mean C0_avg was 0.856 g/mL (with a between-subject coefficient of variation [CVb%] of 140%), which is lower than that observed in treatment-naïve subjects (Section 4.1.3), likely due to drug interactions with concomitant medications, including antiretrovirals, and less optimal compliance (based on non-detectable DTG concentrations). Plasma DTG C0_avg was lower in virologic non-responders than responders, was lower in PDVF subjects when compared to non- PDVF subjects. In a multivariate regression analysis, DTG C0_avg was a significant predictor of virologic response based on the Snapshot (MSDF) analysis (p=0.002) [ING111762 Week 24 CSR, Section 9].

The pharmacokinetics and pharmacodynamics of DTG was further investigated for subjects receiving concomitant ART that were considered metabolic inducers. Subjects on moderate to strong metabolic inducers including tipranavir/ritonavir and efavirenz in their background therapy (n=16) showed lower DTG C0 geometric mean (CV%) at 0.169 (209) μg/mL than for subjects not on these inducers, as well as a lower antiviral response (69% based on Snapshot) compared to non-users (83%). Subjects receiving milder inducers such as fosamprenavir/ritonavir and darunavir/ritonavir were noted to have DTG C0 (CV%) of 0.266 (149%) g/mL and 0.760 (105%) g/mL, respectively, which was within the exposures observed in ING112276 with the 10 mg or 25 mg dose; responses for recipients of fosamprenavir/ritonavir were comparable to the overall population [ING111762 Week 24 CSR, Section 9 and Section 11].

A repeat PK/PD analysis was subsequently performed, excluding subjects on moderate to strong inducers (i.e., tipranavir/ritonavir, efavirenz) and suspected non-compliant subjects (e.g., those with at least one non-detectable DTG concentration at Week 4 or Week 24); this analysis found that average DTG trough concentrations were no longer correlated with virologic efficacy (m2.7.2). Therefore, for patients not receiving strong metabolic inducers (e.g., tipranavir/ritonavir, efavirenz) who had measurable DTG exposures, PK was not a significant predictor for antiviral response.

In summary, the Week 24 interim analysis of ING111762 supports the recommended dose of DTG 50 mg once daily for ART-experienced, INI-naïve HIV-infected adults as shown by a statistically greater virologic response rates versus raltegravir. Plasma DTG C0_avg was associated with virologic response when non-compliant subjects and subjects receiving moderate to strong inducers were included. For subjects receiving efavirenz and tipranavir/ritonavir, low DTG exposures and lower virologic responses support use of a higher DTG dose in the small number of subjects who wish to use

110 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

tipranavir/ritonavir or efavirenz together with DTG. Additionally, etravirine, as currently advised in all clinical studies, should be co-administered with a boosted protease inhibitor (e.g., darunavir/ritonavir, lopinavir/ritonavir or atazanavir/ritonavir) with DTG 50mg once daily. When excluding these subjects receiving efavirenz, tipranavir/ritonavir and etravirine alone (no PI) along with non-compliant subjects, the effect of DTG PK on virologic endpoints was no longer present, suggesting that a sufficiently high DTG exposure was achieved for robust virologic responses for the rest of the population. Therefore, the recommended DTG dose for ART-experienced, INI-naïve HIV-infected adults is 50 mg once daily.

4.3. Dose Selection for ART-Experienced, INI-Resistant Adult Subjects

Dolutegravir 50 mg twice daily is recommended for treatment-experienced, INI-resistant adults with HIV-1 infection. The selection of the 50 mg twice daily dose for evaluation in the Phase III program was based upon data from the Phase IIb dose-ranging study ING112961, with sequential cohorts receiving DTG 50 mg once daily and 50 mg twice daily doses in RAL-resistant adults (Section 1.6.2). One Phase III study, ING112574, was performed to demonstrate the efficacy and safety of DTG 50 mg twice daily dose in combination with OBR in treatment-experienced, INI-resistant adult subjects.

4.3.1. Pivotal Phase III Study ING112574

The efficacy of DTG BID in ART-experienced subjects with INI resistance was confirmed by the Day 8 and Week 24 results of Study ING112574 (Section 1.7.1.4 and Section 2.1.4). The majority of subjects with RAL and/or EVG resistance (historic or current) showed a good and rapid response to DTG 50 mg BID administered with failing background therapy to Day 8 and with an optimized background thereafter. At Day 8, 82% (150/183) of subjects in the ITT-E population had greater than 1 log10 c/mL decline in HIV-1 RNA (See Section 2.1.4, Table 15). At Week 24, 63% (72/114) of subjects had plasma HIV-1 RNA <50 c/mL (See Section 2.1.4). When considering subjects without Q148 plus two or more secondary mutations in IN (who represent the majority of the INI- resistant patient population), 66/92 (72%) of subjects in the virologic outcome population were fully suppressed at Week 24 (See Section 3.3.3.2, Table 69).

4.3.1.1. Correlation between Baseline Factors and Efficacy

In analyses of Day 8 antiviral response adjusting for Baseline covariates, Baseline resistance (reflected by either DTG FC or Baseline IN mutation pathway) was the major driver of response. The presence of the Q148+2 and Q148+1 mutations reduced the Day 8 response by 0.72 log10 c/mL (p<0.0001) and 0.48 log10 c/mL, (p=0.0014) respectively, compared to that of the Y143 mutation category. A doubling of the DTG FC reduced the response by 0.18 log10 c/mL (p<0.001). DTG exposure (Day 8 C0 g/mL) was also associated with Day 8 response in one of the 3 models, but the estimated effect was very small in all models: for every 1g/mL increase in DTG Day 8 C0, a further decrease in plasma HIV-1 RNA at Day 8 of 0.05 log10 c/mL was observed (See Section 3.3.3).

111 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Multivariate analyses of factors impacting response indicated Baseline resistance to be the strongest predictor of response at Week 24, with higher FC in susceptibility to DTG, and the presence of virus with Q148+ 2 secondary integrase inhibitor resistance mutations reducing the proportion of subjects with HIV RNA <50 c/mL. However, HIV-1 infected adults harboring viruses with Q148+ 2 secondary integrase inhibitor resistance mutations and/or high level of DTG FC in IC50 represent a very small sub- population of adults with HIV-1 INI-resistant virus. In the Screening population of ING112574, 26/269 (10%) of subjects harbored viruses with Q148+ 2 secondary integrase inhibitor resistance mutations, and 15/274 (5.5%) had DTG FC in excess of 10 (ING112574 Week 24 CSR, Table 96 and Table 97). In a separate analysis of approximately 700 unrelated clinical isolates with raltegravir resistance, viruses with Q148+ 2 secondary integrase inhibitor resistance mutations represented only 13% of the population and those with DTG FC >10 represented only 6% of the population (m2.7.2.4, Section 4.1.12.3.2). Considering the strong influence of Baseline resistance on response and the relatively narrow range of exposures, DTG exposure was not associated with Week 24 response.

Finally, the activity of the OBR co-administered with DTG from Day 8 was not clearly associated with Week 24 response, indicating that the longterm antiviral activity was predominantly driven by DTG.

4.3.1.2. Comparison to Historical Studies

Recognizing the limitations of cross-study comparisons, it is notable that the study population enrolled in ING112574 had similarly advanced disease but higher-treatment experience and Baseline resistance when compared to the study population enrolled in the Phase III ETR DUET studies [Madruga, 2007; Lazzarin, 2007]; the ING112574 population also had more advanced disease and was more highly treatment-experienced with more Baseline resistance than the study populations in prior Phase III studies in ART-experienced subjects for DRV/RTV in the POWER studies [Clotet, 2007], RAL in the BENCHMRK studies [Steigbigel, 2008] and EVG in the GS-US-183-0145 Study [Molina, 2012]. A combined analysis of the POWER 1 and 2 study data showed DRV/RTV to induce HIV-1 RNA suppression to <50 c/mL at Week 24 (ITT-TLOVR) in 45% of subjects with 3-class ART experience [Clotet, 2007]. A similar analysis of the combined BENCHMRK studies, where first-in-class RAL was used in INI-naïve subjects, showed approximately 60% of subjects had plasma HIV-1 RNA <50 c/mL at Week 24 [Steigbigel, 2008]. Thus, DTG responses in INI-resistant subjects in ING112574 were similar in magnitude to responses achieved by RAL in integrase naïve subjects.

4.3.1.3. Pharmacokinetics

The overall geometric mean plasma DTG pre-dose concentration (C0_avg) for 50 mg BID was 2.35 g/mL. Despite the fact that subjects in ING112574 were receiving multiple ART and non-ART co-medication, the exposure of DTG 50 mg BID was approximately twice that observed with 50 mg once daily in ART-naive subjects. In the multivariate analyses, plasma DTG C0_average was not statistically predictive of Day 8 or Week 24 antiviral response (See m2.7.2 for details).

112 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

A small sub-set of subjects harbouring viruses with higher levels of resistance to DTG (such as those with more advanced genotypes in the Q148 pathway) could theoretically benefit from a higher dose such as DTG 100 mg BID. However, overall efficacy in this population is robust and better than 2nd generation protease inhibitors (tipranavir, darunavir) or NNRTIs (etravirine) that were designed to overcome in-class resistance (See Section 3.3.3). There was no correlation between DTG exposure and Week 24 efficacy in ING112574, suggesting that higher exposures may not be able to overcome some viruses with higher Baseline resistance. Finally, data from healthy subjects in ING114005 demonstrated that plasma DTG area under the curve (AUC) increased less than dose proportionally from 50 mg to 100 mg. Indeed, one-third of subjects did not have any appreciable increase in C between 50 mg and 100 mg doses. Therefore, increases in exposures with increasing dose are not predictable (See m5.3.3.4 ING114005 CPSR). Accordingly, the 50 mg twice daily dose appears to be appropriate for the vast majority of ART-experienced, INI-resistant patients.

In summary the Day 8 and Week 24 primary analysis of ING112574 supports the recommended dose of DTG 50 mg BID for ART-experienced, INI-resistant HIV-infected adults as shown by the high short term and sustained antiviral activity through 24 weeks in this heavily pre-treated population. Baseline resistance is the strongest predictor of response at both Day 8 and Week 24, whereas OBR activity was not clearly associated with Week 24 response indicating that the antiviral activity was predominantly driven by DTG. Plasma DTG C0_avg was not associated with Day 8 or Week 24 antiviral response, suggesting that a sufficiently high exposure was achieved for the population as a whole. The efficacy of DTG 50 mg twice daily is favorable, and thus, DTG 50 mg twice daily is the recommended dose for treatment-experienced, INI-resistant patients.

4.3.2. Supportive Phase II Study ING112961

The dose of DTG 50 mg twice daily was selected for study in ING112574 based on data from the Phase IIb study, ING112961. Virologic responses from functional monotherapy (Day 11), Week 24 and Week 48 data from this study demonstrated better efficacy with 50 mg BID than with 50 mg once daily dosing (Table 18), in addition to comparable safety of the twice daily dose compared to DTG 50 mg once daily. A high response rate was observed at Week 48 in subjects treated with 50 mg BID with 71% (17/24) of subjects having suppression of HIV-1 RNA to <50 c/mL by TLOVR algorithm (See Section 2.2.3

The higher efficacy of DTG 50 mg BID compared to once daily is consistent with the higher DTG exposure achieved with the BID dose. The DTG PK data from Cohort I and II demonstrated that DTG 50 mg BID geometric means of C and AUC(0-) were 2 to 3 times higher than that for DTG 50 mg once daily (See m2.7.2 for details).

In light of the efficacy, safety, and PK data, DTG 50 mg BID was selected as the dose to be assessed in ING112574.

113 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

4.4. Dose Selection for Adolescent Subjects

Dolutegravir 50 mg once daily is recommended for INI-naïve adolescents (12 to <18 years old and weighing at least 40 kg of weight) with HIV-1 infection. The selection of the 50 mg once daily dose was based upon PK and safety data from the Phase I/II dose- finding study, ING112578 (P1093). Based on the data from 10 adolescent subjects enrolled and providing intensive PK samples, DTG 50 mg once daily dose provided similar drug exposure in adolescents to adults (see m2.7.2 for details) and was well tolerated in combination with OBT through Week 24 (see m2.7.4 for details).

Although HIV-infected children are different from adults in some aspects of the natural history of the disease due to acute HIV infection occurring in an immature immune system, the virological and immunological principles underlying the use of ART are similar. With the use of antiretroviral agents, the course of HIV infection is similar in children compared to adults [Gortmaker, 2001; Doerholt, 2006] with similar therapeutic outcomes sought. Therefore, efficacy data and exposure-response relationship from adult studies should be relevant for the prediction of antiviral response in HIV infected children. Additionally as HIV integrase is a viral target, not a host target, it is expected that the PK/PD relationship between DTG drug exposure and antiviral activity is similar between adults and pediatric populations. The guiding principles of disease management in children is similar to adults with the same goals of therapy, i.e., complete suppression of viral replication as measured by plasma HIV-1 RNA and restoration of the immune system.

Therefore, the PK data from ING112578 in adolescents aged 12 to <18 years are sufficiently similar to adults to permit extrapolation of efficacy data from pharmacokinetic correlation, which is in line with the International Conference on Harmonization guidance for medicinal products in the pediatric population [EMA, 2011]. 5. PERSISTENCE OF EFFICACY AND/OR TOLERANCE EFFECTS

5.1. Treatment-Naïve Subjects

Although Week 48 efficacy data (ITT-E, Snapshot [MSDF]) are available for pivotal studies, ING113086 and ING114467, ING112276 is the first study to have long-term (96- week) data with DTG in treatment-naive subjects with HIV-1. Through 96 weeks, high response rates for all three DTG arms were generally well sustained. The proportion of subjects with HIV-1 RNA <50 c/mL at 96 weeks was 88% with DTG 50 mg, the dose selected for Phase III evaluation. For the other DTG doses (10 mg and 25 mg once daily) the response rates at Week 96 were 79% and 78%, respectively, and remained numerically better and statistically similar to the response rate for EFV (72%). The response rate in the EFV arm was consistent with previously published response rates [Lennox, 2010].

In ING112276, no subjects receiving the Phase III selected dose of DTG 50 mg once daily had a confirmed protocol-defined virologic failure (PDVF, 400 c/mL), and no virologic resistance was observed in this treatment group. A low rate of confirmed protocol-defined virologic failure was observed in the DTG 10 mg and 25 mg treatment

114 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

groups and the EFV treatment group. No subjects demonstrated integrase or NNRTI resistance at PDVF. The only demonstrated virologic resistance mutations were a M184V, consistent with lamivudine/emtricitabine resistance, in a subject receiving TDF/FTC and DTG 10 mg once daily (See m2.7.2.4). The absence of integrase resistance across DTG doses at Week 96 is clinically of interest, as 3 of 6 subjects with PDVF in a similar study of raltegravir developed integrase resistance by the Week 96 timepoint [Markowitz, 2009].

PDVF rates in ING113086 and ING114467 were low and consistent for DTG and the DTG-containing regimen (5% and 4%, respectively) despite stringent PDVF criteria (confirmed HIV-1 RNA 50 c/mL after Week 24). In ING113086, none of the 8 subjects in the DTG treatment arm with Baseline and PDVF IN genotypic data had treatment- emergent INI resistance mutations while 1/18 (6%) of the subjects on the RAL treatment arm had treatment-emergent INI resistance mutations. None of the 12 subjects with Baseline and PDVF RT and PR genotypic data in the DTG treatment arm had treatment- emergent NRTI resistance mutations, while 4/19 (21%) of the subjects on the RAL treatment arm had treatment emergent NRTI resistance mutations (See Section 3.2.3). In ING114467, none of the 7 subjects in the DTG + ABC/3TC treatment group had treatment-emergent primary INI resistance mutations, while 4/17 (24%) subjects in the Atripla treatment group had treatment-emergent NNRTI resistance mutations. No treatment-emergent NRTI resistance mutations were observed in any of the subjects with PDVF in the DTG + ABC/3TC treatment group, while 1/17 (6%) subject in the EFV/TDF/FTC treatment group had the treatment emergent NRTI resistance mutation K65K/R (See Section 3.2.3).

A detailed resistance profile for DTG is discussed in m2.7.2.4.

The only limitation to the description of the DTG resistance profile described to date in treatment-naive subjects was the strict PDVF criteria employed in ING113086 and ING114467 (confirmed HIV-1 RNA 50 c/mL at or after Week 24). The majority of subjects on DTG in both studies who had confirmed PDVF tended to have low plasma HIV-1 RNA (<400 c/mL), which may have limited the ability to detect clinically-relevant genotypic or phenotypic changes, nevertheless even in the three DTG subjects with PDVF who had HIV-1 RNA >400 c/mL, no resistance could be detected (See Section 4.2.2.1.1 and Section 4.2.2.1.2, m2.7.2.4). In accordance with changes in treatment guidelines [DHHS, 2012], the PDVF was adjusted after Week 48 in both studies to confirmed plasma HIV-1 RNA >200 c/mL and thus may afford a greater opportunity to detect resistance to DTG or the nucleoside backbone, if it were to develop.

In conclusion, persistence of efficacy was demonstrated between Week 48 and Week 96 in ING112276, and when considering all treatment-naive studies (ING112276, ING113086, ING114467), the rate of protocol defined virologic failure was low. The lack of development of DTG resistance in ING113086 and ING114467 is in accordance with the lack of significant resistance to DTG observed from in vitro passage data (See Section 4.1.11.1, m2.7.2.4), and with the PK observed for DTG 50 mg in ING113086, which was 18-fold higher than the PA-IC90 (See Section 4.1.3). In contrast to RAL and EFV (where selection of a single resistance mutation is sufficient to confer high-level phenotypic resistance), single mutations do not confer high level resistance to DTG.

115 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Clinical data suggest that DTG has a higher barrier to resistance in vivo, which suggests a high likelihood for persistence of efficacy over time.

5.2. Treatment-Experienced, INI-Naïve Subjects

Twenty-four week data is available in treatment-experienced, INI-naïve subjects from ING111762, and at Week 24, there was a statistically significant difference in favor of DTG using the Snapshot (MSDF) algorithm of the proportion of subjects with plasma HIV-1 RNA <50 c/mL. As described in Section 4.2.2.1, based on historical studies with INIs, the Week 24 response is likely predictive of longer term responses (e.g., Week 48) in this patient population. Therefore, DTG 50 mg once daily is an appropriate dose for the treatment-experienced (integrase naïve) population for longer term use. These interim findings will be assessed definitively in the primary Week 48 analysis.

Subjects receiving DTG were also less likely to develop virologic failure with resistance. Virologic failure through Week 24 occurred earlier and more frequently in the RAL arm (m2.7.2.4, Section 4.2.1.2.1). At Week 16 there were 10 (3%) confirmed virologic failures for the DTG arm and 21 (6%) for the RAL arm. At Week 24 there were 14 (4%) and 34 (9%) virologic failures for DTG and RAL, respectively. The difference through Week 24 was driven by a greater proportion of virologic non-response in the RAL arm (13/21 PDVFs) compared with greater proportion of virologic rebound in the DTG arm (13/14 PDVFs). In a pre-specified analysis, there was a statistically significant difference in favor of DTG for the proportion of subjects who failed therapy with evidence of INI Resistance through Week 24 (DTG 2/354 (0.6%); RAL 10/361(2.8%); p=0.016). In addition, few cases of emergent resistance to the background regimen were seen in both treatment arms (RAL [6/351] vs. DTG [3/354]).

Unlike the studies in treatment-naïve subjects and consistent with clinical practice in treatment-experienced patients, the protocol-defined virologic failure criteria in ING111762 was set with a higher HIV viral load (400 c/mL), thus allowing sufficient ability at failure to detect resistance if present.

In conclusion, DTG may be more efficacious than current standard of care in treatment- experienced patients (INI-naïve), and persistence of efficacy in this patient population is expected based on prior experience with other INIs. In addition, subjects receiving DTG were less likely than those on RAL to develop virologic failure with INI resistance in ING111762. The integrase substitution that was observed for DTG subjects conferred maximum fold change of <2 in susceptibility to DTG and RAL. The infrequent occurrence and small shift in DTG susceptibility in ING111762 is in accordance with the low level resistance to DTG observed from in vitro passage data (m2.7.2.4).

5.3. Treatment-Experienced, INI-Resistant Subjects

Within Study ING112961, at Day 11 the proportion of subjects receiving DTG 50 mg twice daily (Cohort II) achieving plasma HIV-1 RNA <400 c/mL was 54% (13/24). The proportions at Week 24 and Week 48 were 83% (20/24) and 75% (18/24), respectively.

In Cohort II, 5/24 subjects met the definition for protocol defined virological failure (PDVF) through Week 24, no new PDVFs were identified through Week 48, except for

116 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy one subject with unconfirmed suspected failure at Week 40 (after having been <50 c/mL through Week 32) who subsequently withdrew from the study . One additional subject was classified as a non-responder between Week 24 and Week 48 for death (unrelated to study drug) while virologically suppressed. Of the 5 subjects with PDVF, no subjects harboring viruses with the Y143 (n=1) or N155 (n=1) pathway at baseline had treatment- emergent resistance or development of phenotypic resistance to DTG. The remaining 3 subjects harboring virus with Q148 +1 additional IN resistance associated mutations at Baseline had treatment emergent mutation resistance at PDVF.

Within Study ING112574, the PDVF rate through Week 24 was similar to ING112961 (26/114, 23%). For these 26 subjects, 16 (62%) had Q148 plus associated mutations detected in the Baseline IN genotype. Of the remaining 10 subjects, 2 subjects had N155H and 8 subjects did not have primary resistance detected at Baseline. Twenty-five of the 26 subjects with PDVF had paired Baseline and PDVF genotypic data, and 13/25 (52%) had treatment-emergent IN resistance at the time point of virological failure. For 11/13 subjects with treatment-emergent IN resistance detected at PDVF, a mutation at Q148, along with associated mutations, was seen at Baseline or was present on historical testing. The only mutations that were detected have been previously described for the integrase class and viruses at PDVF had multiple INI resistance-associated mutation supporting the high barrier to resistance of DTG (m2.7.2.4).

Persistence of efficacy was demonstrated between Week 24 and Week 48 in ING112961 and when considering both studies (ING112961 and ING112574) conducted in this highly treatment-experienced INI-resistant subjects, the rate of protocol defined virologic failure was relatively low. Treatment-emergent mutations further reducing DTG susceptibility occurred in viruses with multiple IN resistance associated mutations already present at Baseline, supporting DTG high barrier to resistance.

6. EFFICACY SUMMARY

The results from four pivotal studies (Studies ING113086, ING112574, ING111762, and ING114467) provide substantial evidence of effectiveness for dolutegravir as a treatment for HIV-1 infection in combination with other antiretroviral agents.

DTG with two NRTIs was highly effective in ART-naïve subjects. High rates of virologic suppression [HIV-1 RNA <50 c/mL]) were observed in both studies of ART-naïve subjects; consistent responses were demonstrated in important subgroups as defined by Baseline HIV-1 RNA, NRTI backbone, CD4+ cell count, gender, race, and age. DTG + NRTI backbone demonstrated comparable efficacy to RAL + NRTI backbone at Week 48. DTG + ABC/3TC achieved a statistically superior response through 48 weeks against a preferred fixed dose combination tablet Atripla (tenofovir/emtricitabine/ efavirenz), a result that was driven in large part by improved tolerability of the DTG- containing regimen.

Interim results from ING111762 showed that a significantly higher proportion of treatment-experienced patients treated with DTG plus BR achieved virologic suppression when compared to RAL plus BR; these differences were driven by better overall virologic efficacy with DTG.

117 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

DTG 50 mg twice daily was effective for patients with resistance to INIs and associated extensive antiretroviral resistance to other agents, with efficacy rates comparable to or better than other antiretroviral agents utilized for treatment of within class resistant virus in historical studies. Virologic responses in ING112574 were not clearly associated with the activity of the background antiviral agents but were best correlated with baseline DTG resistance (as determined by baseline genotype).

DTG-based regimens had a higher barrier to resistance in INI-naïve patients, as demonstrated in ING111762 where significantly fewer virologic failures with INI resistance were observed when compared with RAL. Data from ING113086 and ING114467 were also supportive, as no subjects on the DTG regimen developed resistance to either the INI or the background NRTIs, whereas resistance to both the third agent and the background NRTIs was observed in both the RAL and EFV-based comparator arms.

In the setting of INI-resistance, DTG had efficacy across a broad range of mutational patterns, with virologic responses across the viral populations which represent the majority of INI-resistant viruses. Additionally, the most prevalent treatment- emergent mutations detected were IN resistance-associated secondary mutations that were added to a viral genotype with IN primary mutations present. All treatment-emergent mutations detected in the setting of previous INI resistance were well characterized RAL and/or EVG resistance associated mutations.

Dolutegravir offers once-daily dosing in patients without INI resistance, no requirement for pharmacokinetic boosters and few dose adjustments for drug interactions. DTG can also be dosed without regard to meals, as there is no significant food effect. DTG also exhibits less PK variability, with more predictable exposures and lower risk of achieving inadequate or toxic exposures.

Finally, DTG represents a new option for therapy of adolescents with HIV infection. The PK data from ING112578 in adolescents aged 12 to <18 years are sufficiently similar to adults to permit extrapolation of efficacy data from pharmacokinetic correlation. Therefore, INI-naïve pediatric subjects can take the adult dose of 50 mg once daily.

6.1. Efficacy Conclusions

 Data support the use of DTG 50 mg once daily for the treatment of HIV infection in combination with other antiretroviral therapy in treatment-naïve adults;  Data support the use of DTG 50 mg once daily for the treatment of HIV infection in combination with other antiretroviral therapy in INI-naïve, treatment-experienced adults;  Data support the use of DTG 50 mg twice daily for the treatment HIV infection in combination with other antiretroviral therapy in INI-resistant (current and historical) treatment-experienced adults;  DTG-based regimens had a higher barrier to resistance in INI-naïve patients, as demonstrated in ING111762 where significantly fewer virologic failures with INI resistance were observed when compared with RAL. Data from ING113086 and

118 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

ING114467 were also supportive, as no subjects on the DTG regimen developed resistance to either the INI or the background NRTIs, whereas resistance to both the third agent and the background NRTIs was observed in both the RAL and EFV- based comparator arms;  Increases in CD4+ cell counts were observed for subjects receiving DTG-containing regimens across all patient populations evaluated;  Data support the use of DTG 50 mg once daily for INI-naïve adolescents (12 to <18 years old and weighing at least 40 kg of weight) with HIV infection (m2.7.2);  Data support the efficacy of DTG across a broad range of Clades and against both HIV-1 and HIV-2 (m2.7.2.4).

7. REFERENCES

Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial. Clin Infect Dis 2006; 43:1347–56.

Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169- 78.*

Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 Infection. N Engl J Med 2008; 359:355-65.*

DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429–2438.

Department of Health and Human Services (DHHS), Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Updated 27 March 2012. Available online at: http://aidsinfo.nih.gov/guidelines. Date accessed: April 1, 2012.

Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, Novelli V, Riordan A, Dunn D, Walker AS, Gibb DM. Outcomes for human immunodeficiency virus-1- infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Ped Infect Dis J 2006; 25:420-426.*

European AIDS Clinical Society (EACS). Guidelines version 6.1. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines- v6.1-English-Nov2012.pdf. Date Accessed: November 8, 2012.

119 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of HIV infection, Doc. Ref. EMEA/CHMP/EWP/9147/2008-corr*. London, adopted 22 October 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/ WC500017055.pdf. Date accessed: October 30, 2012.

European Medicines Agency (EMA ICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population, Doc. Ref. CPMP/ICH/2711/99*. January 2011. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500002926.pdf. Date Accessed: September 9, 2012.

Food and Drug Administration (FDA). Antiretroviral Drugs Using Plasma HIV RNA Measurements — Clinical Considerations for Accelerated and Traditional Approval. Maryland, 2002. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/ucm070968.pdf. Date accessed: September 9, 2012.

FDA Guidance for Industry: Role of HIV Resistance Testing in Antiretroviral Drug Development, October 2007, available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM071173.pdf. Date accessed: August 18, 2012.

FDA ad comm. Briefing Information for the Antiviral Drugs Advisory Committee (AVDAC) Meeting, May 11, 2012 available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Antiviral DrugsAdvisoryCommittee/ucm303394.htm. Date accessed: September 9, 2012.

Gathe J, Cooper DA, Farthing C, et al. Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial. Clin Infect Dis 2006; 43:1337–46.*

German P, Warren D, West S, Hui J, Kearney B. Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV. J Acquir Immune Defic Syndr 2010:55:323–329.

Good Clinical Practice (GCP) for Trials on Medicinal Products in the European Community (1996). Found at http://ec.europa.eu/health/files/eudralex/vol- 10/3cc1aen_en.pdf. Date accessed: September 9, 2012.

Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345(21):1522-1528.*

Hazuda DJ, Miller MD, Nguyen BY, and Zhao J. Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis of Protocol 005, a Phase 2 Study in Patients with Triple-

120 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Class Resistant HIV-1 Infection. XVI International HIV Drug Resistance Workshop, Abstract #8. Antiviral Therapy 2007:12:S10.

Hill A and Sabin, C. Designing and Interpreting Noninferiority Trials in Naïve and Experienced Patients. AIDS 2008;22(8):913-921.*

International AIDS Society (IAS) Guidelines – Update of the Drug Resistance Mutations in HIV-1: Topics in HIV Medicine. December 2009; 17(5). Available at: https://www.iasusa.org/sites/default/files/tam/17-5-138.pdf. Date accessed: November 8, 2012.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2001. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/UCM073139.pdf. Date Accessed: September 9, 2012.

Lazzarin A, Campbell T, Clotet B, Johnson M, et al. Efficacy and Safety Of Tmc125 (Etravirine) In Treatment-Experienced HIV-1-Infected Patients In DUET-2: 24-Week Results From a Randomized, Double-Blind, Placebo-Controlled Trial. Lancet 2007 Jul 7; 370(9581):39-48.*

Lennox J, DeJesus E, Lazzarin A, et. al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multi-centre, double-blind randomised controlled trial. Lancet 2009;374:796-806.*

Lennox JL, DeJesus E, Berger DS, et al. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. JAIDS 2010;55(1):39-48.*

Madruga JV, Cahn P, Grinsztejn B, Haubrich R, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370 (9581):29 - 38.*

Markowitz M, Nguyen B, Gotuzzo E, Mendo F, et al. Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naïve Patients With HIV-1 Infection. J Acquir Immune Defic Syndr 2009; 52(3):350-356.*

McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first-generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Program and abstracts of the 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Barbados, West Indies. 2007. Abstract 9.

Molina J, Cohen C, Katlama C, et al. Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients : 24-Week Results of POWER 3. JAIDS 2007;46:24–31.*

121 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Molina J, LaMarca A, Andrade-Villanueva J, Clotet B, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12: 27–35.

Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439–2448.

Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with Optimized Background Therapy for Resistant HIV-1 infection. N Engl J Med 2008; 359(4):339-354.*

UNAIDS (Joint United Nations Programme on HIV/AIDS). Report on the global AIDS epidemic. December 2010. Available at: http://www.unaids.org/globalreport/. Date accessed: September 9, 2012.

UNAIDS 2012a. Fact Sheet: The Global AIDS Epidemic; 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201 207_FactSheet_Global_en.pdf. Date Accessed: September 9, 2012.

UNAIDS 2012b. Core Slides: Global Summary of the AIDS Epidemic; July 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201 207_epi_core_en.pdf. Date Accessed: September 9, 2012.

World Medical Association (WMA). The Declaration of Helsinki: ethical principles for medical research involving human subjects. 7th revision, adopted by the 59th WMA General Assembly, Seoul, Korea, October, 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/. Date Accessed: September 9, 2012.

122 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

8. APPENDIX

Appendix Table 1 Description of Clinical Efficacy and Safety Studies

DTG 50 mg using 25 mg/200 mg compression; 25 mg; tablet; oral; single

123 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Part B: DTG 50 mg using 25 mg/150 mg compression; 25 mg; tablet; oral; single dose; low fat meal

DTG 50 mg using 25 mg/150 mg compression; 25 mg; tablet; oral; single dose; moderate fat meal

DTG 50 mg using 25 mg/150 mg compression; 25 mg; tablet; oral; single

124 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

DTG 50 mg; granule with purified water; oral; single dose

DTG 50 mg; granule with mineral water; oral; single dose

DTG 50 mg; granule with baby formula; oral; single dose

125 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Treatment C: DTG 50 mg; (formulation code BC) plus EPZICOM™; tablet; oral; single dose

126 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment Pharmacokinetic Studies ING111207 GSK 1 US Start 13 To assess Double-Blind, 18-55yrs, DTG 2 to 25 Enrolled, 20/5; DTG safety Completed Nov 2007; safety, Randomized, Healthy 100 mg; oral 13 31.8yrs parameters CPSR Completed tolerability and Placebo- subjects, suspension; Completed (19-54) 5.3.3.1 18 Feb PK of single Controlled male/ single dose; AUC(0-t), 2008; doses of DTG female fasted AUC(0-), 25/20 Cmax, tmax, C24, and t½ following single dose administration ING111322 GSK 1 US Start 27 Part 1: Part 1: Double- 18-50yrs, Part 1: Part 1: Part 1: Part 1: Completed Feb 2008; To assess Blind, Healthy DTG 10 to 32* (includes 27/5; DTG safety CPSR Completed safety, Randomized, subjects, 50 mg; oral 5 placebo) 31.7yrs parameters 5.3.3.1 12 Jun tolerability and Placebo- male/ suspension; Enrolled, 31 (18-50) from predose 2008; Part Pharmacokineti Controlled female once daily; 10 Completed values 1: 32/32, cs (PK) of days; fasted Part 2: Part 2: repeat doses of Part 2: Part 2: 12/0; DTG PK 12/12 DTG Randomized, 3- Part 2: 12 Enrolled, 30.8yrs parameters Period, DTG 20 mg; 12 (18-50) following single Part 2: Balanced, oral Completed dose To assess Crossover suspension; administration safety, singe dose; *1 subject on Day 1: tolerability and fasted assigned to AUC(0-) and PK of single placebo AUC(0-24), doses of DTG DTG 10 mg x2 received a Cmax, tmax, suspension and (20 mg); single dose C24, t1/2, tlag, single doses of tablet; oral; of DTG in and CL/F; and

127 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

128 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

AUC(0-t), AUC(0-∞), Cmax, tmax, λz, tlag, CL/F, Vz/F, and t½ of DTG in plasma following oral suspension [14C]-DTG dosing

Collection of samples for use in a separate study for characterizatio n and quantification of DTG-related metabolites in

129 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

130 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Accumulation of ratio of DTG in BP, SF, RF,

131 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

SF: BP, RT:BP, and RF: RT DTG AUC ratios ING113125 1 US Start 28 To evaluate the Single dose, 18-70yrs, DTG 50 mg; Renal: Renal: Plasma DTG Completed ViiV Healthcare Jun 2011; single dose PK open-label, Severe tablet; oral; 8 Enrolled, 5/3; tlag, tmax, CPSR Completed and safety of parallel group, renal single dose 8 Completed 56.8yrs Cmax, AUC(0- 5.3.3.3 20 April DTG in healthy two-part study impairment (47-65) t), 2012; subjects and in subjects Healthy: AUC(0-∞), 16/16 subjects with and 8 Enrolled, Healthy: %AUCex, severe renal matched, 8 Completed 5/3; t½, CL/F and impairment healthy 56.1yrs Vz/F control (43-68) subjects with normal renal function, male / female

132 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment ING113097 ViiV 1 US Start 19 To evaluate the Single dose, 18-70yrs, DTG 50 mg; Hepatic Hepatic Plasma DTG Completed Healthcare Nov 2010; single dose PK open-label, Subjects tablet; oral; Impaired: Impaire AUC(0-t), CPSR Completed and safety of parallel group, with mild or single dose 8 Enrolled, d: 5/3; AUC(0-∞), 5.3.3.3 04 Jun DTG in healthy two-part, moderate 8 Completed 55.5yrs Cmax, C24, 2011; subjects and in adaptive study hepatic (50-61) apparent 16/16 subjects with impairment Healthy t½, apparent mild or and Controls: Healthy clearance moderate matched, 8 Enrolled, Controls (CL/F), and hepatic healthy 8 Completed : 5/3; Vz/F impairment control 57.0yrs based on Child- subjects (42-67) Pugh category with normal hepatic function, male / female ING115381 ViiV 1 US Start 20 To assess Open label, 20-55yrs, DTG 50 mg; 10 Enrolled, 6/4; Plasma DTG Completed Healthcare Apr 2011; safety, single dose Healthy tablet; oral; 10 33.4yrs following single CPSR Completed tolerability and study Japanese single dose Completed (22-52) dose 5.3.3.3 27 May PK of single subjects, administration: 2011; doses of DTG in male / AUC(0-t), 10/10 healthy female AUC(0-∞), Japanese Cmax, and subjects C24

133 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

DTG 50 mg; tablet; oral; once daily for 7 days then DTG 50 mg; tablet; oral BID+ RIFABUT 300 mg; capsule; oral; once daily; 14 days

134 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment ING115696 1 US Start 01 To investigate Open-label, 18-65yrs, DTG 50 mg; 12 Enrolled, 5/7; DTG PK Completed ViiV Healthcare Sep 2011; the effects of repeat dose, Healthy tablet; oral; 12 28.5yrs parameters on CPSR Completed prednisone on two-period, subjects, once daily; 5 Completed (23-38) Day 5 and Day 5.3.3.4 17 Oct the steady-state single-sequence male / days 10: AUC(0-), 2011; PK of DTG female Cmax, C0, C, 12/12 DTG 50 mg; Cmin, CL/F, tablet; oral; and t½ once daily; Days 1-10 + prednisone; tablet; oral; once daily (60 mg Days 1-5; 50 mg Day 6; 40 mg Day 7; 30 mg Day 8; 20 mg Day 9; 10 mg Day 10) ING115697 1 US Start 13 To assess the Randomized, 18-65yrs, DTG 50 mg; DTG + BCV 19/13; Plasma steady- Completed ViiV Healthcare Mar 2012; potential for a open-label, two- Healthy tablet; oral; 16 Enrolled, 42.5yrs state DTG CPSR Completed drug interaction period, single- subjects, once daily; 5 13 (19-65) AUC(0-), 5.3.3.4 23 May between DTG sequence, two male / days Completed Cmax, Cmin, 2012; and telaprevir cohort study female C, following 32/32 (TLV) and DTG 50 mg; DTG + TLV administration between DTG tablet; oral; 16 Enrolled, of DTG 50 mg and bocepravir once daily + 15 once daily (BCV) TLV 750 mg; Completed (q24h) for 5 tablet; oral; days and

135 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment q8h; 10 days following co- administration DTG 50 mg; with BCV 800 tablet; oral; mg q8h for 10 once daily + days or TVR BCV 800 mg; 750 mg q8h for capsule; oral; 10 days q8h; 10 days ING115698 1 Canada Start 02 To assess the Open-label, 18-65yrs, Stable 11 Enrolled, 6/5; Steady-state Completed ViiV Healthcare Dec 2011; potential for a repeat dose, Healthy methadone 10 34.5yrs total and R- CPSR Completed drug interaction two-period, subjects dose; oral Completed (24-44) Methadone PK 5.3.3.4 30 Dec between DTG single-sequence enrolled in solution; once parameters: 2011; and methadone a daily; 3 days AUC(0-τ), 11/12 methadone Cmax, and Cτ maintenanc Stable e program, methadone male / dose; oral female solution + DTG 50 mg; tablet; oral; BID; 5 days ING111405 GSK 1 US Start 09 To assess the Randomized, 18-50yrs, DTG 30 mg; 31 Enrolled, 31/0; Plasma DTG Completed Oct 2008; potential for a open-label, two- Healthy tablet; oral; 30 29.4yrs steady-state CPSR Completed drug interaction period, single- subjects, once daily; 5 Completed (18-50) AUC(0-τ), 5.3.3.4 12 Dec between DTG sequence, two male / days Cmax, Cτ, 2008; and lopinavir cohort study female Cmin, CL/F, t½ 31/30 (LPV)/ ritonavir DTG 30 mg; and t1/2 (RTV) and tablet; oral; following

136 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

137 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

DTG 50 mg; tablet; oral; single dose + Maalox Advanced Maximum Strength; 20mL suspension; single dose

DTG 50 mg; tablet; oral; single dose 2 hrs prior to Maalox Advanced

138 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment Maximum Strength 20mL; suspension; single dose ING111603 1 US Start 16 To assess the Open-label, 18-65yrs, DTG 50 mg; 16 Enrolled, 16/0; Plasma DTG Completed GSK Oct 2008; potential for a repeat dose, Healthy tablet; oral; 15 41.5yrs steady-state CPSR Completed drug interaction two-period, subjects, once daily; 5 Completed (19-64) AUC(0-τ), 5.3.3.4 12 Dec between DTG single-sequence male/ days Cmax, Cτ, 2008; and etravirine study female Cmin, CL/F, 16/16 (ETR) DTG 50 mg; t½ following tablet; oral; administration once daily + of DTG 50mg ETR 200 mg; q24h for 5 days tablet; oral; and following q12h; 14 days co- administration with ETR 200mg q12h for 14 days ING111604 1 US Start 11 To assess the Open-label, 18-65yrs, DTG 50 mg; 16 Enrolled, 15/1; Plasma DTG Completed GSK Aug 2008; potential for a repeat-dose, Healthy tablet; oral; 15 38.6yrs steady-state CPSR Completed drug interaction single-sequence, subjects, once daily; 5 Completed (20-58) AUC[0-], 5.3.3.4 01 Oct between DTG three-period male/ days Cmax and C 2008; and tenofovir study female following 16/16 (TDF) TDF 300 mg; administration tablet; oral; of DTG 50 mg once daily; 7 q24h for 5 days

139 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment days and following co- DTG 50 mg; administration tablet; oral; with TDF 300 once daily + mg q24h for 5 TDF 300 mg; days tablet; oral; once daily; 5 days ING111854 1 US Start 07 To assess the Randomized, 18-65yrs, Period 1: 24 Enrolled, 21/3; Plasma DTG Completed GSK Apr 2009; potential for a open-label, Healthy DTG 30 mg; 24 37.2yrs steady-state CPSR Completed drug interaction repeat dose, subjects, tablet; oral; Completed (18-61) AUC(0-τ), 5.3.3.4 09 Jun between DTG two-period, male / once daily; 5 Cmax, C0, Cτ, 2009; and atazanavir single-sequence, female days; fed and Cmin 24/24 (ATV) and two-cohort study following between DTG Period 2: administration and ATV/RTV DTG 30 mg; of DTG 30mg tablet; oral; q24h for 5 days once daily + and following ATV/RTV co- 300/100 mg; administration capsule; once with ATV/RTV daily; 14 days 300/100mg q24h or ATV DTG 30 mg; 400mg q24h tablet; oral; for 14 days once daily + ATV 400mg;

140 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

EE / NGM; tablet; oral; once daily days 1-21 ING112934 1 US Start 02 To assess the Randomized, 18-65yrs, DTG 50 mg; 17 Enrolled, 17/0; Plasma DTG Completed GSK Apr 2009; potential for a open-label, Healthy tablet; oral; 17 37.6yrs steady-state CPSR Completed drug interaction repeat dose, subjects, once daily; 5 Completed (20 -61) AUC(0-τ), 5.3.3.4 20 May between DTG, three-period, male / days Cmax, C0, Cτ, 2009; ETR, and single-sequence, female and Cmin 17/18 LPV/RTV or two-cohort DTG 50 mg; following DRV/RTV adaptive study tablet; oral; administration once daily + of DTG 50 mg ETR/LPV/RTV q24h for 5 200/400/100 days, and

141 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment mg; tablet; following co- oral; q12h; 14 administration days of DTG 50 mg q24h (and DTG 50 mg; 50 mg q12h if tablet; oral; appropriate) once daily + with ETR (tablet) ETR/LPV/RTV DRV (tablet) 200/400/100 m /RTV g q12h or (capsule) ETR/DRV/RTV 200/600/100 200/600/100 m mg; oral; once g q12h, each daily; 14 days for 14 days ING112941 1 US Start 23 To evaluate the Part 1: 18-65yrs, Part 1: Part 1: Part 1: Plasma DTG Completed GSK Jul 2009; effect of a high Randomized, healthy DTG 50 mg; 14 Enrolled, 12/2; following a CPSR Completed fat meal and open-label, two subjects, tablet; oral; 12 40.6yrs single dose of 5.3.3.4 28 Sep omeprazole on sequence, three male / single dose; Completed (23-55) 50 mg under 2009; DTG PK and to treatment female fasted fasted Part 1: evaluate the crossover Part 2: Part 2: conditions with 14/14, safety and PK DTG 50 mg; 10 Enrolled 9/1; and without Part 2: of a 250 mg Part 2: tablet; oral; (includes 2 38.4yrs OMP 40 mg: 10/10 dose of DTG Randomized, single dose; placebo), (21-54) AUC(0-t), double-blind, within 30 10 AUC(0-∞), single dose PK minutes after Completed Cmax, tmax, study the start of a C24, tlag high fat meal Plasma DTG

142 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

143 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment ING113068 1 US Start 09 To investigate Part A: Open- 18-65yrs, Part A: Part A: Part A: Part A: Completed ViiV Healthcare Sep 2010; the effects of label, repeat Healthy DTG 50 mg; 12 Enrolled 10/2; Plasma DTG CPSR Completed fosamprenavir dose, two- subjects, tablet; oral; 12, 33.4yrs steady-state 5.3.3.4 04 Nov (FPV)/ RTV on period, single- male / once daily; 5 Completed (24-55) AUC(0-), 2010; the steady-state sequence female days Cmax, C0, C, Part A: PK of DTG and Part B: Part B: and Cmin 12/12, to evaluate Part B: Open- DTG 50 mg; 15 Enrolled, 4/11; following Part B: relative label, single tablet; oral; 15 34.7yrs administration 15/15 bioavailability of dose, once daily + Completed (20-60) of DTG 50 mg tablets with randomized, FPV 700 mg; q24h for 5 days varying particle three-period, tablet / RTV and following size cross over study 100 mg; co-administrati capsule; oral; on with q12h; 10 days FPV/RTV 700/100 mg Part B: q12h for 10 DTG 50 mg days using 25 mg tablets with Part B: micronized Plasma DTG drug AUC(0-), substance; AUC(0-t), and oral; single Cmax following dose a single dose of DTG 50 mg DTG 50 mg using 25 mg tablets with

144 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

DTG 50 mg using 25 mg tablets with intermediate particle size drug substance; oral; single dose

145 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment ING113096 1 US Start 15 To assess the Randomized, 18-55yrs, DTG 50 mg; 18 Enrolled, 14/4; Plasma DTG Completed GSK Feb 2010; safety, open-label, Healthy tablet; oral; 13 29.3yrs steady-state CPSR Completed tolerability and repeat dose, subjects, once daily; 5 Completed (19-45) AUC(0-), 5.3.3.4 05 Apr PK of repeat three-period male / days Cmax, C0, C, 2010; dose co- single-sequence, female and Cmin 18/18 administration study TPV / RTV following of DTG alone, 500/200 mg; administration tipranavir capsule; oral; of DTG 50 mg (TPV)/RTV BID; 7 days once daily for 5 alone, and DTG days and in combination DTG 50 mg; following co- with TPV/RTV tablet; oral; administration once daily and with TPV/RTV TPV / RTV 500/200 mg 500/200 mg; BID for 5 days capsule; oral; BID; 5 days ING114005 1 US Start 16 To evaluate PK Open label, 18-65yrs, DTG 100 mg; 12 Enrolled, 12/0; Plasma DTG Completed ViiV Healthcare Mar 2010; of DTG 100 mg repeat dose, Healthy tablet; oral; 12 38.7yrs AUC(0-24), CPSR Completed versus 50 mg three period subjects, single dose Completed (20-65) Cmax, and 5.3.3.4 26 May and the effect of single-sequence male / C24, and dose- 2010; efavirenz (EFV) female DTG 50 mg; normalized 12/12 on the PK, tablet; oral; AUC(0-24), safety and once daily; 5 Cmax, and tolerability of days C24 following DTG 50 mg single dose DTG 50 mg; administration tablet; oral; of 100 mg and

146 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

147 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment LAI116181 1 US Start 07 To assess the Open label, 18-55yrs Cohort 1: Cohort 1: 24/4; Plasma DTG Completed ViiV Healthcare Nov 2011; potential for a repeat dose, Healthy Treatment A = 16 Enrolled, 31.4yrs AUC(0-τ), CPSR Completed drug interaction single-sequence, subjects, DTG 50 mg; 16 (18-50) Cmax, and 5.3.4.4 20 Feb between DTG 3-period study male / tablet; oral; Completed tmax, and Cτ, 2012; and rilpivirine female q24h; 5 days following 50 Cohort 1: (RPV) Cohort 2: mg q24h 16/16, Treatment B = 12 Enrolled, administration Cohort 2: RPV 25 mg; 11 with and 12/12 tablet; oral; Completed without RPV 25 q24h; 11 days mg q24h Treatment C = RPV 25 mg; Plasma tablet; oral; GSK1265744 q24h + DTG steady-state 50 mg; tablet; AUC(0-τ), oral; q24h; 5 Cmax, tmax, days and Cτ following Cohort 2: GSK1265744 Treatment D = 30 mg q24h GSK1265744 administration 30 mg; tablet; with and oral; q24h;12 without RPV 25 days mg q24h

Treatment B = Plasma RPV RPV 25 mg; steady-state

148 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment tablet; oral; AUC(0-τ), q24h; 12 days Cmax, tmax, and Cτ Treatment E = following RPV RPV 25 mg; 25 mg q24h tablet; oral; administration q24h + with and GSK1265744 without DTG 30 mg; tablet; 50 mg q24h or oral; q24h; 12 GSK1265744 days 30 mg q24h Human Pharmacodynamic Studies ING111856 1 US Start 28 To evaluate the Randomized, 18-55yrs, DTG 250 mg; 42 Enrolled, 17/25; Change from Completed GSK Sep 2009; effect of DTG partial-blind, Healthy oral 38 34.5yrs Baseline in CPSR Completed on cardiac single dose, subjects, suspension; Completed (18-55) QTcF for DTG 5.3.4.1 29 Dec conduction as three-period, male / single dose 2009; assessed by cross-over study female 42/42 12-lead Placebo; oral electrocardiogra suspension; m compared to single dose placebo and moxifloxacin Moxifloxacin (Thorough QTc 400 mg; study of DTG) tablet; oral; single dose ING114819 1 US Start 05 To evaluate the Open-label, 18-65yrs, DTG 50 mg; 38 Enrolled, 28/10; GFR as Completed ViiV Healthcare Oct 2010; effect of DTG randomized, Healthy tablet; oral; 34 31.8yrs measured by CPSR Completed on glomerular three-arm, subjects, once daily; 14 Completed (19-59) iohexol plasma 5.3.4.1

149 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Aminohippurat e Sodium 2 g/10ml (20%) of Loading Dose : 8 mg/kg, Maintenance Dose: 12 mg/min; solution; IV

150 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Safety and tolerability parameters ING116070 3 US Start 24 To determine Phase IIIb 18yrs, DTG 50 mg; 13 Enrolled, ITT-E: Proportion of Completed ViiV Healthcare Jan 2012; plasma (total single-arm, HIV- tablet; oral; 12 Ongoing 13/0; subjects with Week 2 Ongoing; and unbound) open-label, infected, once daily + 40.2yrs plasma HIV-1 Synoptic 14/14 DTG multicenter study ART-naïve ABC/3TC (28-52) RNA <50 c/mL Clinical

151 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Incidence of disease progression HIV-associated conditions, AIDS and death

152 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment Efficacy and Safety Studies: Controlled Clinical Studies Pertinent to the Claimed Indication ING112276 34 centres: Start 30 To select a Phase IIb, 18yrs, DTG 10 mg; DTG 10 mg: 177/28; Proportion of Completed: 6 France, Jul 2009; once daily oral Randomized, HIV- tablet; oral + 53 37.2yrs subjects with ViiV Healthcare 4 Germany, Ongoing; dose of DTG multicentre, infected, ABC/3TC Randomized, (20-79) HIV-1 RNA (Week 16 3 Russia, 205/200 administered parallel group, ART-naïve 600mg/300 47 <50 c/mL Synoptic 4 Italy, with either dose-ranging subjects, mg or Completed (c/mL) through CSR) 5 Spain, ABC/3TC or male / TDF/FTC Week 16 using 12 US TDF/ female 300mg/200mg DTG 25 mg: the Time to (Week 24 emtricitabine ; tablet; oral; 51 Loss of Full CSR) (FTC) and to once daily; 96 Randomized, Virological evaluate weeks 45 Response (Week 48 antiviral activity, Completed (TLOVR) Abbreviated safety and PK DTG 25 mg; algorithm. CSR) over time tablet; oral + DTG 50 mg: Dose selection ABC/3TC 51 will be based (Week 96 600mg/300mg Randomized, primarily on Full CSR) or TDF/FTC 46 antiviral activity 300mg/200mg Completed and tolerability 5.3.5.1 ; oral; once in conjunction daily; 96 EFV 600 mg: with weeks 50 immunologic, Randomized, safety and PK DTG 50 mg; 39 measures will tablet; oral + Completed also be ABC/3TC considered 600mg/300mg DTG 50 mg or TDF/FTC Open label: 300mg/200mg 138 Enrolled,

153 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

EFV 600 mg + ABC/3TC 600mg/300mg or TDF/FTC 300mg/200 mg; oral; once daily; 96 weeks ING113086 100 centres: Start 19 To assess Phase III, 18yrs, DTG 50 mg; DTG: 411 703/119 The proportion Completed: ViiV Healthcare 27 Spain Oct 2010; safety and multicentre HIV- tablet; oral; Randomized, ; of subjects with Week 48 19 US,12 Ongoing; efficacy of DTG randomized, infected, once daily or 359 Ongoing. 37.0yrs HIV-1 RNA <50 Full CSR France, 822/788 50 mg once double blind, ART-naïve RAL 400 mg; (18-75) c/mL through 5.3.5.1 11 Russia, daily to RAL double-dummy, subjects, tablet; oral; RAL: Week 48 using 10 Germany, 400 mg BID active-controlled, male / once daily + 411 a Missing, 7 Canada, both parallel group, female ABC/3TC Randomized, Switch or 7 Italy, administered fully-powered 600mg/300mg 345 Ongoing Discontinuation 4 Australia, with fixed-dose non-inferiority or TDF/ FTC = Failure 3 UK dual nucleoside study 300mg/200mg (MSDF) reverse ; tablet; oral; algorithm transcriptase once daily; 96 inhibitor therapy weeks ING114467 136 centres: Start 01 To assess Phase III, 18yrs, DTG 50 mg; DTG: 414 703/130 The proportion Completed: ViiV Healthcare 4 Australia, Feb 2011; safety and randomized, HIV- tablet; oral; Randomized, ; of subjects with Week 48 4 Belgium, Ongoing; efficacy of DTG double-blind, infected, once daily + 363 Ongoing. 36.4yrs plasma HIV-1 Full CSR

154 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

ING111762 185 centres: Start 26 To evaluate Phase III, 18yrs, DTG 50 mg; DTG 485/230 The proportion Completed: ViiV Healthcare 4 Belgium, Oct 2010; safety and multicentre HIV- tablet; oral; 354 ; of subjects with Week 24 12 France, Ongoing; efficacy of DTG randomized, infected, once daily or Randomized 42.5yrs HIV-1 Full CSR 4 Greece, 719/688 50 mg once double-blind, ART- RAL 400 mg; 305 Ongoing (18-73) RNA <50 c/mL 5.3.5.1 1 Hungary, daily vs. active-controlled, experience tablet; oral; 1 Completed through 7 Italy, raltegravir parallel group, d subjects, BID + Week 48 using 2 (RAL) 400 mg non-inferiority integrase Investigator- RAL MSDF Netherlands, BID, both study inhibitor selected 361 algorithm as 3 Romania, administered naïve background Randomized codified by the 24 Spain, with an regimen, regimen; 48 189 Ongoing FDA’s 4 UK, investigator- male / weeks 111 “snapshot 6 Canada, selected female Completed algorithm. The 72 USA, background proportion of 6 Argentina, regimen subjects with 2 Australia, plasma HIV-1 9 Brazil, RNA <50 c/mL

155 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment 5 Chile, will also be 4 Mexico, assessed at 12 Russia, Week 24 3 South Africa, 5 Taiwan ING112961 16 centres:a Start 31 To assess the Phase IIb, 18yrs, Cohort I: Cohort I: Cohort The proportion Completed: ViiV Healthcare 7 France, Aug 2009; antiviral activity multicentre, HIV- DTG 50 mg; 27 I: 25/2; of subjects with 1 Italy, Ongoing; of DTG open-label, infected, tablet; oral; Randomized, 46.7yrs Day 11 plasma (Week 24 1 Spain, Cohort I: containing single-arm, ART- once daily; 96 12 Ongoing (19-61) HIV-1 RNA Cohort 1 Full 6 US 27/30, regimen sequential experience weeks <400 c/mL or CSR) 1 Canada Cohort II: cohort, pilot d subjects, Cohort II: Cohort at least 0.7 24/50 study raltegravir Cohort II: 24 II: 18/6; log10 c/mL (Week 72 resistance, DTG 50 mg; Randomized, 47.4yrs below their Cohort I/ male / tablet; oral; 17 Ongoing (33-68) Baseline value Week 24 female BID; 48 weeks (sample for Cohort II Full evaluation of CSR) plasma HIV-1 RNA to be (Week 96 taken prior to Cohort I/ Day 11 Week 48 background Cohort II treatment Abbreviated optimization) CSR)

5.3.5.2 ING112574 78 centres: Start 6 To assess the Phase III, 18yrs, DTG 50 mg; 183 141/42; Mean change Completed: ViiV Healthcare 1 Belgium, May 2011; antiviral activity multicentre, HIV- tablet; oral; Randomized, 47.0yrs from baseline Week 24

156 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment 3 Canada, Ongoing; of DTG single-arm, infected, BID; 24 weeks 155 Ongoing (19- 67) in plasma HIV- Full CSR 15 France, 183/175 administered open-label study ART- 1 RNA (log10 5.3.5.2 6 Italy, with failing experience c/mL) at Day 8 4 Portugal, background d subjects, 8 Spain, therapy to Day integrase 41 US 8 and thereafter inhibitor with optimized regimen, background male / ART female ING112578 1 US Start 16 To select a Phase I/II, 6wks- DTG once-a- Cohort 1 Cohort Toxicity Completed: March DTG dose for multicenter, <18yrs, day doses (Stage 1): 10 1: through week Week 24 2011; chronic dosing open-label, non- HIV-1 with target Enrolled, 10 (Stage 24 Full CSR Ongoing; in infants, comparative infected dose of ~1 Ongoing 1) 3/7; All AEs or lab 22/168 children and intensive PK and subjects, mg/kg and 14.0yrs (10 subjects toxicities of adolescents safety study male / with 4 weight Cohort 1 (12–17) [Stage 1] Grade 3 or that achieves female bands, and (Stage 2): 12 from higher severity similar maximum Enrolled, 12 Cohort Cohort 1 exposure to the dose of 50 Ongoing 1 (Stage through 24 Adverse events DTG adult dose mg; 48 weeks 2): no weeks) or lab toxicities selected from data of grade 3 or the Phase IIb availabl 5.3.5.2 higher severity clinical trial in e judged to be at ART-naïve adult least possibly subjects attributable to (ING112276), to the study evaluate safety, medication tolerability, and steady-state PK

157 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

PK: AUC(0-24) Reports of Analyses of Data from More Than One Study ING116265 NA NA To evaluate the Meta-analysis of Healthy DTG 50 mg; 89 subjects 78/11; NA Completed: ViiV Healthcare effects of UGT PGx and PK adult tablet; oral; included in 36.9yrs Meta- and CYP data from 9 subjects once daily; 5 the analysis (19-64) analysis polymorphisms Phase II studies days Report on the PK of 5.3.5.3 DTG Other Clinical Studies ING114915 65 centres: Start 31 To demonstrate Phase IIIb, 18yrs, DTG 50 mg; DTG: 239 412/71; The proportion Completed: ViiV Healthcare 32 US, Oct 2011; the non-inferior randomized, HIV- tablet; oral; Randomized, 36.0yrs of subjects with Brief Study 3 Puerto Ongoing; antiviral activity open-label, infected, once daily; 96 236 Ongoing (18-67) Day 11 plasma Summary Rico, 483/468 of DTG multicenter study ART-naïve weeks HIV-1 RNA <50 5.3.5.4 6 France, compared to subjects, DRV/RTV: c/mL through 3 Germany, DRV/RTV male / DRV/RTV 244 Week 48 using 5 Italy, female 800mg/100mg Randomized, the snapshot 5 Spain, ; tablet; oral; 238 Ongoing (MSDF) 3 once daily; 96 algorithm

158 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

159 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Protocol No./ No. Study Study Study Study Design Diagnosis; Treatment No. of Gender Primary Study Sponsor Centres Start; Objectives Key Details (Drug; Subjects by M/F; Endpoint(S) Reporting Location(s) Enrolment Inclusion Dose; Form; Group Mean Status s Status Criteria Route; Entered/ Age (Type of and Date; Frequency; Completed (Range) Report) / Total Duration) Location of Enrolment Report /Target Enrolment 3 Spain, resistance who 4 UK have no available treatment alternatives and/or limited treatment options ING116529 26 US Start 18 To quantify the Phase III, 18yrs, DTG 50 mg; 4 No data The mean Completed: ViiV Healthcare Apr 2012; antiviral activity randomized, HIV- tablet; oral; Randomized; availabl change from Brief Study Ongoing; of DTG multicentre, infected, BID or 4 Ongoing e baseline in Summary 4/30 compared to placebo- ART- Placebo; plasma HIV-1 5.3.5.4 placebo (PCB) controlled, experience tablet oral; RNA (log10 when double-blind d subjects, BID + current c/mL) at Day 8, administered followed by an integrase failing using a last with failing open inhibitor regimen; 7 observation background label phase regimen, days carried forward therapy for 7 male / with days female discontinuation equals baseline ING114580 1 US Planned To evaluate the Phase I, 18-65yrs, Part A: 0/0 No data Plasma DTG, Completed: ViiV Healthcare Start 19 bioequivalence randomized, two Healthy Treatment A = availabl ABC and 3TC Brief Study Jun 2012; between a part, open-label, subjects, DTG 50 e AUC(0-∞), Summary Ongoing; single FDC crossover, male / mg/ABC 600 AUC(0-t), and 5.3.5.4 0/66 tablet single center female mg/3TC 300 Cmax formulation of study mg; FDC DTG 50mg, tablet; oral;

160 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Part B: Treatment C = DTG 50 mg/ABC 600 mg/3TC 300mg; FDC tablet; oral; single dose; high fat meal a. The total number of centres that enrolled subjects includes one Canadian site reflected here, which was added after publishing of m5.3.5.3 Integrated Summary of Efficacy.

161 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Appendix Table 2 Results of Efficacy Studies

ING114467 DTG 50 mg + 422 Rand. 364/414 (88) 414 4.670 370 -3.035 Median time to viral The study demonstrated ABC/3TC once daily (3.06, 6.46) (-4.62, -0.12) suppression (<50 c/mL) and superiority of DTG compared 363 95% CI: 28 days [28, 29] to Atripla. At 48 weeks, the Ongoing Adjusted change from difference in the primary Baseline in CD4+ cell count endpoint and 95% CI was at Week 48 and SE: 267 7.4% (+2.5% to +12.3%). (9.05) Statistical superiority was concluded as part of a subsequent, pre-specified testing procedure p=0.003.

162 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Treatment Arm No. Primary Efficacy Variable Secondary Efficacy Other Comments Enrolled/ Plasma HIV-1 Plasma HIV-1 RNA Endpoints Completed RNA (log10 copies/mL) (copies/mL) <50 Baseline Change from Baseline n/N (%) n Median n Median [Range] [Range] EFV/TDF/FTC 422 Rand. 338/419 (81) 419 4.696 343 -3.093 Median time to viral Hazard ratio of time to viral once daily (2.48, 6.35) (-4.66, 0.35) suppression (<50 c/mL) and suppression (<50c/mL) and 363 95% CI: 84 days [83,84] 95% CI: 2.32 [2.00, 2.68] Ongoing Adjusted change from p<0.0001 significant at the Baseline in CD4+ cell count pre-specified threshold of at Week 48 and SE:208 0.01. (9.31) Adjusted difference in change from Baseline in CD4+ cell count at Week 48 and 95% CI: 58.9 [33.4, 84.4] p<0.001 significant at the pre-specified threshold of 0.04. ING111762d DTG 50 mg 360 Rand. 281/354 (79) 354 4.171 325 -2.436 Proportion of Subjects with In a predetermined analysis, once daily + BR (1.59,6.79) (-4.67,0.81) Detectable Virus that has there was a statistically 305 Treatment Emergent significant difference in favor Ongoing Genotypic or Phenotypic of DTG for the proportion of Evidence of INI Resistance subjects who failed therapy by Week 24: 2/354 (0.6%) with evidence of INI Resistance through Week 24.

Adjusted treatment difference and 95% CI: -2.3% (-4.2, -0.4); p=0.016.

163 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Treatment Arm No. Primary Efficacy Variable Secondary Efficacy Other Comments Enrolled/ Plasma HIV-1 Plasma HIV-1 RNA Endpoints Completed RNA (log10 copies/mL) (copies/mL) <50 Baseline Change from Baseline n/N (%) n Median n Median [Range] [Range] RAL 400 mg BID + 364 Rand. 252/361 (70) 361 4.209 326 -2.274 Proportion of Subjects with BR (1.59, 6.54) (-4.98,1.68) Detectable Virus that has 189 Treatment Emergent Ongoing Genotypic or Phenotypic Evidence of INI Resistance by Week 24: 10/361 (2.8%) ING112574 DTG 50 mg 183 Rand. 72 /114 (63) 183 4.384 182 -1.502 Day 8 response by Baseline The mean reduction at Day 8 Twice Daily (Week 24) (1.59, 7.37) (-3.37, 0.44) characteristics showed that was statistically significant 155 (Day 8) the Q148+2 and Q148+1 versus the hypothesis of no Ongoing mutations reduced the Day 8 change from Baseline. response by 0.72 (p<0.0001) Suppression to <50 c/mL was 114a and 0.48 log10 c/mL rapid with 52% (59/114) (p=0.0014) respectively, vs. already achieving this level of that of the Y143. A doubling suppression by Week 4. At of the FC to DTG reduced Week 24, 63% (72/114) of the response by subjects had<50 c/mL by the 0.18 log10 c/mL (p<0.001) Snapshot (MSDF) algorithm. while for each additional IN mutation, the response was lowered by 0.09 log10 c/mL (p=0.0054). At Week 24, the Q148+2, doubling DTG FC, and increasing number of pre-specified mutations also significantly reduced Week 24 response.

164 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Treatment Arm No. Primary Efficacy Variable Secondary Efficacy Other Comments Enrolled/ Plasma HIV-1 Plasma HIV-1 RNA Endpoints Completed RNA (log10 copies/mL) (copies/mL) <50 Baseline Change from Baseline n/N (%) n Median n Median [Range] [Range] Supportive Efficacy Studies ING112961 Cohort I DTG 50 mg 27 Enrolled 9/27 (33) 27 4.475 27 -1.614 The proportion of subjects More subjects in Cohort II once daily 13 Ongoing (Week 48) (2.64-6.06) (-2.54, -0.13) with Day 11 plasma HIV-1 compared to Cohort I (Day 11) RNA <400 c/mL or at least achieved the primary endpoint Cohort II DTG 50 mg 24 Enrolled 17/24 (71) 24 4.263 24 -1.833 0.7 log10 c/mL below their at Day 11. In the linear Twice Daily 19 Ongoing (Week 48) (3.32-5.84) (-2.92, -0.46) Baseline value is the primary regression model at Day 11, (Day 11) endpoint: Cohort II (96%) accounting for differences in compared to Cohort I (78%). Baseline factors, the mean Adjusted mean difference of change from Baseline in CFB in plasma HIV-1 RNA at plasma HIV-1 RNA was Day 11 was -0.32 log10 c/mL significantly greater for Cohort (Cohort II-I). II. At Week 48 a much greater proportion of subjects in Cohort II achieved <50 c/mL plasma HIV-1 RNA than Cohort I: 71% vs 33% by TLOVR for Cohort II and I, respectively. ING112276 DTG 10 mg 53 Rand. 51/53 (96) 53 4.496 52 -2.190 % <50 c/mL at Comparable efficacy and once daily + 2 NRTI 47 Ongoing (3.25, 6.17) (-4.48, -1.56) Week 24: 96% tolerability across all DTG Week 48: 91% doses; 50 mg selected for Week 96: 79% study in Phase III. DTG 25 mg 51 Rand. 47/51 (92) 51 4.487 49 -2.235 % <50 c/mL: once daily + 2 NRTI 45 Ongoing (2.91, 5.59) (-3.90, -1.22) Week 24: 90% Week 48: 88% Week 96: 78%

165 CONFIDENTIAL Module 2.7.3 Summary of Clinical Efficacy

Study Treatment Arm No. Primary Efficacy Variable Secondary Efficacy Other Comments Enrolled/ Plasma HIV-1 Plasma HIV-1 RNA Endpoints Completed RNA (log10 copies/mL) (copies/mL) <50 Baseline Change from Baseline n/N (%) n Median n Median [Range] [Range] DTG 50 mg 51 Rand. 46/51 (90) 51 4.640 49 -2.357 % <50 c/mL: once daily + 2 NRTI 46 Ongoing (2.93, 5.99) (-4.30, -1.24) Week 24: 92% Week 48: 90% Week 96: 88% EFV 600 mg 50 Rand. 30/60 50 4.462 45 -2.109 % <50 c/mL: once daily (60) (3.21, 6.00) (-3.84, -1.30) Week 24: 78% 41 Week 48: 82% Completed Week 96: 72% ING111521 DTG 2 mg 9 Rand. 1/9 (11)b 9 4.40 (0.27)c 9 -1.51 (0.58)c Median (range) change from A clear dose response once daily 9 Baseline to in CD4+ Cell relationship was noted. Completed (cells/mm3): 15 (-286, 222) DTG 10 mg 9 Rand. 0/9 9 4.58 (0.39) 9 -2.03 (0.49) Median (range) change from once daily 9 Baseline to in CD4+ Cell Completed (cells/mm3) :106 (-39, 142) DTG 50 mg 10 Rand. 4/10 (40) 10 4.47 (0.42) 10 -2.46 (0.35) Median (range) change from once daily 10 Baseline to in CD4+ Cell Completed (cells/mm3): 64 (-155, 523) a. 114 subjects had the chance to complete the Week 24 visit. b. 10 day monotherapy, secondary endpoint c. Mean (SD) d. The definitive primary endpoint for ING111762 is Week 48. The results presented here are for Week 24, which are secondary endpoints for the study. This Week 24 interim analysis was done to support regulatory submissions globally.

166